{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "3296e4dd",
   "metadata": {},
   "source": [
    "# PDF Summarization Midterm Project"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "adde303b",
   "metadata": {},
   "source": [
    "## By Mandy Liu, Mt. San Antonio College, CISB63 Fall 2023"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "89465a24",
   "metadata": {},
   "source": [
    "<img src =\"Reishi_Banner.jpg\" style=\"width:800px;heightt:40px\" align=\"left\"/>"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "ca1ad1ac",
   "metadata": {},
   "source": [
    "## Introduction"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "0e18c57b",
   "metadata": {},
   "source": [
    "Summarizing PDF documents using Natural Language Processing (NLP) is an important tool for gaining insight into the content. NLP-powered summarization can quickly extract the most important information from lengthy PDF documents, saving time compared to manual reading and summarizing, which can be time-consuming, especially for large files. Summaries make it easier to locate and retrieve key information from a document. NLP can be applied to documents in various languages, enabling multilingual summarization, which is valuable for global businesses and international research. In some cases, NLP-generated summaries can serve as a starting point for content generation, such as creating abstracts for research papers."
   ]
  },
  {
   "cell_type": "markdown",
   "id": "9fd97670",
   "metadata": {},
   "source": [
    "## Summary and Conclusion"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "05213788",
   "metadata": {},
   "source": [
    "In this project, I summarized one of my publications titled 'Inhibitory activity of the medicinal mushroom Ganoderma lucidum on colorectal cancer by attenuating inflammation.' In this PDF document, there are a total of 15 pages, comprising 8,235 words and 560 sentences. The text was tokenized into sentences and subsequently split into words. These words were converted to lowercase and cleaned by removing punctuation and stopwords. Subsequently, the words were rejoined into a string with space separators for further analysis. Term Frequency-Inverse Document Frequency (TF-IDF) scores were then calculated to identify the top three sentences in the document. Additionally, a summary and a frequency distribution plot were generated based on the top three sentences with the highest TF-IDF scores. Named Entity Recognition (NER) was also utilized to identify and classify the named entities in the text, with visualization being achieved using the spaCy displaCy module. Cosine similarity was employed to compare this document with another of my publications titled 'The medicinal mushroom Ganoderma lucidum attenuates UV-induced skin carcinogenesis and immunosuppression.' Both of these publications explore different forms of cancer, namely colon and skin cancers, through the use of the medicinal mushroom Ganoderma lucidum. A WordCloud was generated to provide a visual summarization of the PDF file.\n",
    "\n",
    "The techniques applied in this project are invaluable for summarizing a text document, offering a quick overview of the paper's content. I also attempted to translate the first sentence of the abstract into Chinese, which yielded satisfactory results. However, when I attempted to translate the entire text, certain sections were missing, and not all the text was processed or translated. Furthermore, there are some inaccurately labeled entities in the NER that require correction. This can potentially be improved by experimenting with different NER models or libraries. It's worth noting that the choice of the NER model can significantly impact the accuracy of entity recognition. Manually correcting all the mislabeled entities can be time-consuming. If labeled data is available, it can be used to annotate mislabeled entities and retrain the NER model. The Cosine similarity score obtained was 0.848. This suggests that 84.8% of the terms or words in the two texts share similarity or have overlapping word usage. I concur with this score, as the two papers revolve around a similar topic, meaning that the introduction, background information, discussion, and summary may contain similar words. Additionally, they also share some similar in vitro and in vivo techniques involving cells and mice.\n",
    "\n",
    "In summary, this project serves as an effective means of summarizing a PDF document. While it excels at summarizing multiple publications, the utility of NLP becomes more apparent when applied to a broader range of documents rather than just a few. Research articles are often well-organized, and one can typically find a summary in the abstract. However, techniques such as NER and cosine similarity prove extremely useful in labeling, extracting valuable information, and identifying similar articles for review."
   ]
  },
  {
   "cell_type": "markdown",
   "id": "6e36f35a",
   "metadata": {},
   "source": [
    "## Reference Links"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "1b9a0086",
   "metadata": {},
   "source": [
    "https://pubmed.ncbi.nlm.nih.gov/35692861/"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "c10c873a",
   "metadata": {},
   "source": [
    "https://pubmed.ncbi.nlm.nih.gov/35312729/"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "4d1f9628",
   "metadata": {},
   "source": [
    "My github: https://github.com/mandyliu-1/CISB63"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "1c038e87",
   "metadata": {},
   "source": [
    "## Import Libraries"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "33d9011a",
   "metadata": {},
   "outputs": [],
   "source": [
    "import nltk                                                      # NLTK\n",
    "from nltk.corpus import stopwords                                # Stopwords\n",
    "from nltk.tokenize import sent_tokenize, word_tokenize           # Tokenize\n",
    "from nltk.probability import FreqDist                            # Frequency distribution analysis\n",
    "\n",
    "from textblob import TextBlob                                    # TextBlob                 \n",
    "\n",
    "from sklearn.feature_extraction.text import TfidfVectorizer      # TF-IDF vectorizer\n",
    "from sklearn.feature_extraction.text import CountVectorizer      # Count vectorizer\n",
    "from sklearn.metrics.pairwise import cosine_similarity           # Cosine similarity\n",
    "\n",
    "import spacy                                                     # Named Entity Recognition\n",
    "from spacy import displacy                                       # Displacy\n",
    "\n",
    "import numpy as np                                               # NumPy\n",
    "\n",
    "import re                                                        # Regular expressions\n",
    "\n",
    "import PyPDF2                                                    # Read PDF files\n",
    "\n",
    "import string                                                    # String manipulation\n",
    "\n",
    "import matplotlib.pyplot as plt                                  # Matplotlib\n",
    "\n",
    "from wordcloud import WordCloud                                  # WordCloud\n",
    "\n",
    "from PIL import Image                                            # Image module"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "3535fd03",
   "metadata": {},
   "source": [
    "## Read the File"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "8c34da5b",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Precision Clinical Medicine , 4(4), 2021, 231–245\n",
      "https://doi.org/10.1093/pcmedi/pbab023\n",
      "Advance Access Publication Date: 28 August 2021Research Article\n",
      "RESEARCH ARTICLE\n",
      "Inhibitory activity of medicinal mushroom\n",
      "Ganoderma lucidum on colorectal cancer by\n",
      "attenuating inflammation\n",
      "Mandy M. Liu1,§, Tiantian Liu2,§, Steven Yeung1, Zhijun Wang3,\n",
      "Bradley Andresen1, Cyrus Parsa4,5, Robert Orlando4,5, Bingsen Zhou6,\n",
      "Wei Wu6,X i aL i6, Yilong Zhang6, Charles Wang2,*and Ying Huang1,*\n",
      "1Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences,\n",
      "Pomona, CA 91766, USA\n",
      "2Center for Genomics & Department of Basic Sciences, School of Medicine, Loma Linda University, Loma\n",
      "Linda, CA 92350, USA\n",
      "3Department of Pharmaceutical Sciences, College of Pharmacy, Marshall B. Ketchum University, Fullerton, CA\n",
      "92831, USA\n",
      "4College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766, USA\n",
      "5Department of Pathology, Beverly Hospital, Montebello, California, CA 90640, USA\n",
      "6Beijing Tong Ren Tang Chinese Medicine Co., Ltd., New Territories, Hong Kong 999077, China\n",
      "∗Correspondence: Charles Wang, chwang@llu.edu ; Ying Huang, yhuang@westernu.edu\n",
      "Charles Wang, http://orcid.org/0000-0001-8861-2121\n",
      "§Mandy M. Liu and Tiantian Liu contributed equally to this work.\n",
      "Abstract\n",
      "The medicinal mushroom Ganoderma lucidum (GL, Reishi or Lingzhi) exhibits an inhibitory effect on cancers.\n",
      "However, the underlying mechanism of the antitumor activity of GL is not fully understood. In this study, we\n",
      "characterized the gene networks regulated by a commercial product of GL containing a mixture of spores andfruitingbodiesnamely“GLSF”,incolorectalcarcinoma.Wefoundthat invitroco-administrationofGLSFextract\n",
      "at non-toxic concentrations significantly potentiated growth inhibition and apoptosis induced by paclitaxel in\n",
      "CT26 and HCT-15 cells. GLSF inhibited NF- κB promoter activity in HEK-293 cells but did not affect the function\n",
      "of P-glycoprotein in K562/DOX cells. Furthermore, we found that when mice were fed a modified diet contain-\n",
      "ing GLSF for 1 month prior to the CT26 tumor cell inoculation, GLSF alone or combined with Nab-paclitaxel\n",
      "markedly suppressed tumor growth and induced apoptosis. RNA-seq analysis of tumor tissues derived fromGLSF-treated mice identified 53 differentially expressed genes compared to normal tissues. Many of the GLSF-\n",
      "down-regulatedgeneswereinvolvedinNF- κB-regulatedinflammationpathways,suchasIL-1 β,IL-11andCox-2.\n",
      "Received: 2 June 2021; Revised: 16 August 2021; Accepted: 23 August 2021\n",
      "C/circlecopyrtThe Author(s) 2021. Published by Oxford University Press on behalf of the West China School of Medicine & West China Hospital of Sichuan University.\n",
      "This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/ ),\n",
      "which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\n",
      "231232Mandy M. Liu et al.\n",
      "Pathwayenrichmentanalysissuggestedthatseveralinflammatorypathwaysinvolvingleukocytemigrationand\n",
      "adhesion were most affected by the treatment. Upstream analysis predicted activation of multiple tumor sup-pressorssuchas α-cateninandTP53andinhibitionofcriticalinflammatorymediators.“Cancer” wasthemajor\n",
      "significantly inhibited biological effect of GLSF treatment. These results demonstrate that GLSF can improve\n",
      "the therapeutic outcome for colorectal cancer through a mechanism involving suppression of NF- κB-regulated\n",
      "inflammation and carcinogenesis.\n",
      "Key words: Ganoderma lucidum ; colorectal carcinoma; RNA-seq; NF- κB; inflammation\n",
      "Introduction\n",
      "Colorectal cancer is the third most common type of can-\n",
      "cer and also the third most common cause of cancer-related death in both men and women in the UnitedStates.\n",
      "1Currently, surgery and chemotherapy are the\n",
      "main treatment options for colorectal cancer, depend-ing on the stage, grade, and tumor location at diagnosis.Chemotherapy is used for patients with metastatic col-orectal cancer as primary therapy, and for patients withearly-stage colorectal cancer before or after surgery asadjuvant therapy. However, chemoresistance is a com-mon obstacle that occurs in almost all cases of col-orectal cancer. In addition, because chemotherapy non-selectively affects all cells that are active in the cellgrowth cycle, it causes toxicity in normal organs suchasthebonemarrow,gastrointestinaltract,andhairfolli-cles. Therefore, the common clinical practice is to use acombination of several anticancer agents with differentmechanisms of actions or toxicity profiles to overcomedrug resistance and reduce toxic reactions.\n",
      "Globally, it has become more and more popular for\n",
      "cancer patients to use complementary and alterna-tive medicine derived from natural sources during orafter the course of conventional anticancer therapies. Anationwide survey conducted in Japan revealed a preva-lence of herbal use in 44.6% of cancer patients and in25.5% of non-cancer patients with benign tumors, andthe most frequently used herbal products were mush-rooms.\n",
      "2One of the most well-known medicinal mush-\n",
      "rooms is Ganoderma lucidum (GL), also commonly named\n",
      "asReishiorLingzhi,whichhasbeenusedforcenturiesinEastAsiatotreatavarietyofdisorders,includinginflam-mation and cancer, without any obvious toxicity.\n",
      "3,4GL\n",
      "and related products are referred to as ‘The Mushroomof Immortality’ because of beneficial effects on healthand longevity. The spores of GL are the reproductivecells of the fungus, which are ejected from the cap afterthe fruiting bodies become mature. The major bioactivecomponents identified in GL spores and fruiting bod-ies are polysaccharides, which are known to stimulatethe immune system, as well as triterpenes, which maydirectly inhibit proliferating cancer cells.\n",
      "5\n",
      "Anticanceractivityhasbeeninvestigatedusingdiffer-\n",
      "entpartsoftheGLmushroom,thespores,fruitingbodiesor mycelia (the early harvest), in human and preclinicalanimalmodels.Theevidencerelatedtocolorectalcancercan be summarized into three types of studies. First, GLhasshownefficacy incertainpreclinical modelsofcoloncancerprevention,thatisprophylaxis.Inseveralreports,\n",
      "the water extracts of the mycelia culture media of GLprevented chemical carcinogen-induced colorectal car-cinogenesisinmiceorrats.\n",
      "6–8Thetriterpeneextractpre-\n",
      "vented colitis-associated colon carcinogenesis in mice.9\n",
      "Feeding water extract of GL powder to rats with a high-fat diet reduced fecal secondary bile acids and intestinalbacteria known to be related to colon carcinogenesis.\n",
      "10\n",
      "GL polysaccharide consumption reduced 30% of mor-tality, specific bacteria and expression of cancer-relatedgenes in mice with colon cancer induced by chemi-cal carcinogens.\n",
      "11Second, GL has shown some clinical\n",
      "evidence of preventing development of colon cancer ormodulating some biomarkers related to immunomodu-lation or carcinogenesis. For example, the same myceliaextract mentioned above suppressed the number andsizeofprecancerouscolorectaladenomasinhumansub-jects who took the mycelia extract at 1.5 g/day for 12months.\n",
      "12In patients with advanced colorectal cancer,\n",
      "taking oral GL at 5.4 g/day for 12 weeks induced somechanges in immune-related parameters such as IL-1 andTNF-α, although the effects were not statistically sig-\n",
      "nificant.\n",
      "13Third, GL has shown some antitumor effi-\n",
      "cacy in a few preclinical studies of human colon can-cer cell lines in vitro. For example, the effect of enzy-\n",
      "matically hydrolyzed GL polysaccharide has been exam-ined in human colon cancer cell lines, indicating inhibi-tion of apoptosis via up-regulation of BCL-2 associatedX protein (Bax) and down-regulation of COX-2.\n",
      "14How-\n",
      "ever, besides reports of the prophylactic efficacy for GL,few studies have reported the therapeutic effects of GLproducts as a single therapy or combined with conven-tional chemotherapies for already diagnosed colorectalcancer both in vitro andin vivo. Therefore, it is largely\n",
      "unknown whether colorectal cancer patients could ben-efit from treatment with GL products.\n",
      "The present study aimed to determine the effect of\n",
      "GL on colorectal cancer in vitro andin vivo. A com-\n",
      "mercial GL product containing a mixture of sporesand fruiting bodies, namely “GLSF”, was used. Wefirstly evaluated whether the GLSF extracts preparedin several methods including the use of artificial gas-trointestinal juice (to simulate in vivo digestion) have\n",
      "any direct anticancer effects on cancer cells in cul-ture. As colorectal cancers are commonly resistantto taxanes, we next evaluated whether artificial gas-trointestinal juice digested GLSF has any chemosen-sitizing effect in combination with paclitaxel in vitro.Antitumor activity of Ganoderma lucidum 233\n",
      "Furthermore,weevaluatedwhetheraGLSFmodifieddiet\n",
      "wasabletoinhibittumorgrowthinamousemodelbear-ing murine colorectal carcinoma CT26, which is one ofthemostextensivelyusedsyngeneicmousetumormod-els.\n",
      "15Tumor samples dissected from GLSF-treated and\n",
      "control diet-treated tumor-bearing mice were analyzedby RNA sequencing (RNA-seq). Potential mechanisms ofthe anticancer and chemosensitization effect of GLSFin colorectal carcinoma were further explored throughbioinformatics analysis.\n",
      "Materials and methods\n",
      "Compounds and reagents\n",
      "Paclitaxel (T7402) purchased from Sigma Aldrich (StLouis, MO) was used in vitro. Abraxane\n",
      "R/circlecopyrtfor injectable\n",
      "suspension(Celgene,Summit,NJ)wasused invivo.Asin-\n",
      "gle batch of a commercial product manufactured by Bei-jing Tong Ren Tang Chinese Medicine Co. (Hong Kong,China), named as GLSF, contains a mixture of the sporesand fruiting bodies of GL at a 30:8 ratio, was usedthroughout the present study.\n",
      "Preparation of GLSF extracts and quantification of\n",
      "the major components\n",
      "As there is no standardized preparation approach for\n",
      "GL and related products, several reagents were used toextract GLSF including ethanol, methanol, hot water, aswell as artificial gastric and intestinal (GI) juice. For theethanol/methanol extract, 0.5 g of GLSF was extractedwith 12.5 ml solvent in a round bottom flask attached toa reflux condenser at 80\n",
      "◦C for 2 hours. The mixture was\n",
      "centrifuged at 4500 g for 10 minutes. The supernatantwas collected, and the pellet was extracted by repeat-ingthestepsabove.Thesupernatantcollectedwascom-bined and filtered using Whatman filter paper. The sol-vent was removed using a rotary evaporator.\n",
      "For the hot water extract, 10 g of GLSF was extracted\n",
      "with 200 ml of nanopure water at 85\n",
      "◦C for 15 minutes\n",
      "under stirring. The mixture was then centrifuged for 15minutes at 4500 g. The supernatant was filtered usingWhatman filter paper and filtrate lyophilized. The pow-der obtained was weighed and stored at −20\n",
      "◦Cb e f o r e\n",
      "analysis.\n",
      "The extracts of GLSF were prepared in the artificial\n",
      "gastrointestinal juice, which was prepared according toreported methods.\n",
      "16,17In brief, 5 g of GLSF powder was\n",
      "mixedin50mlofartificialgastricjuiceat37◦Cwithshak-\n",
      "ing for 1 hour, then 50 ml of artificial intestinal juice wasadded and incubated at 37\n",
      "◦C with shaking for an addi-\n",
      "tional5hours.Themixturewascentrifugedatroomtem-perature for 15 minutes at 4500 g, and the supernatantwascollected.TheextractwasthenneutralizedtopH7.0using 0.2 M NaOH, filtered using Whatman filter paper,lyophilized, and stored at −20\n",
      "◦C.\n",
      "The major active components were determined using\n",
      "avalidatedHPLC-DADmethod(unpublished),whichwasable to quantify 13 major components in GLSF includingganoderenicAcidC,ganodericAcidC2,ganodericAcidG,\n",
      "ganoderic Acid B, ganoderenic Acid B, ganoderic Acid A,ganoderic Acid H, ganoderenic Acid D, ganoderic Acid D,ganoderic Acid F, ganoderic Acid DM, ganoderol A, andergosterol. The individual contents in the extracts werequantified and used as a fingerprint for GL products. Allthe extractions and fingerprint analysis were conductedin triplicate.\n",
      "Cell lines and cell culture\n",
      "CT26, HCT-15, HT-29, and HEK-293 cells were purchasedfromATCC(Manassas,VA).K562/DOXcellline(agiftfromJ.P.Marie,INSERM,E9912,UniversityofParis,France)wasobtained by in vitro passaging of K562 in progressively\n",
      "increasing doses of daunorubicin.\n",
      "18These cells were\n",
      "maintained in RPMI-1640 or DMEM supplemented with10% fetal bovine serum and 1% penicillin-streptomycin.Cells were incubated at 37\n",
      "◦Cw i t h5 %C O 2/95% air.\n",
      "SRB cell proliferation assay\n",
      "Plates (96-well) were seeded with 3000 cells per well andthe cells were allowed to attach overnight. Cells weretreated with drugs for 72 hours and incubated at 37\n",
      "◦C\n",
      "in 5% CO 2/95% air. Cell viability was determined using\n",
      "a Sigma sulforhodamine B (SRB) assay according to themanufacturer’s protocol.\n",
      "Apoptosis analysis\n",
      "Flow cytometry was used to assess apoptosis by FITC-labeledannexin-V(Sigma)andpropidiumiodide,respec-tively,aspreviouslydescribed.\n",
      "19Briefly,1 ×105cellswere\n",
      "seeded per well in six-well tissue culture plates for 24hours. The cells were then incubated with drugs for 72hours. Cells were collected and washed twice with coldPBS. Approximately 5 ×10\n",
      "5cells were mixed with bind-\n",
      "ing buffer with or without Annexin V or PI. FluorescencewasdetectedinfluorescencechannelsFL1andFL3.Dataacquisition and analysis were performed using AccuriC6 Flow Cytometer (BD Biosciences, Franklin Lakes, NJ).Analysis was based on acquisition of data from 10000cells.EarlyapoptoticcellsareAnnexin-VpositiveandPI-negative, whereas late apoptotic cells are both Annexin-V and PI-positive.\n",
      "Intracellular daunorubicin (DNR) accumulation\n",
      "assay\n",
      "The capacity of a compound to inhibit P-glycoprotein-\n",
      "mediated efflux from K562/DOX cells, was measured byflow cytometry as described previously.\n",
      "20Briefly, the cell\n",
      "pellet was resuspended in culture media at a concentra-tion of 6000000 cells/ml. Aliquots (50 μl) of the cell sus-\n",
      "pension were transferred to tubes containing 1.95 ml ofmedia in the presence or absence of test drugs in mediaand 5 μM of DNR for 50 minutes at 37\n",
      "◦C. After cen-\n",
      "trifugation and removal of supernatant, cold PBS wasadded to each tube, and cell suspension was transferred234Mandy M. Liu et al.\n",
      "to FACS tubes, which were placed on ice until analysis.\n",
      "Flow cytometry was performed with an Accuri C6 FlowCytometer. PSC833 (10 μM) served as a positive control.\n",
      "Luciferase reporter gene assay\n",
      "Dual luciferase assay for NF- κB has been described in\n",
      "previous work.21In brief, HEK-293 cells were transfected\n",
      "with pRL-TK-Luc Renillaluciferase (Promega, Madison,\n",
      "WI) and pGL4.22-NF- κB (Promega) plasmids at a ratio\n",
      "of 1:30 using FuGENE HD Transfection Reagent (RocheApplied Science, Indianapolis, IN). Twenty-four hourslater the cells were exposed to TNF- α(10 ng/ml) and\n",
      "incubated in fresh growth medium containing drugs foran additional 5 hours. Cell lysates were analyzed by thedualluciferasereportergeneassay(Promega)with Renilla\n",
      "luciferase serving as a normalization factor.\n",
      "Rodent diet preparation\n",
      "Forin vivostudies, 1.25% of GLSF powder was incorpo-\n",
      "ratedintomousedietsfororaladministration.Themodi-fiedanimaldietwasorderedthroughNewcoDistributors,Inc (Rancho Cucamonga, CA). The formulation included98.45% Laboratory Rodent Diet #5001, 1.25% GLSF, and\n",
      "0.3% color dye. The calculation of the drug was based on\n",
      "anaveragedailyintakeof4gpermouse.Foodconsump-tion for each group was monitored during the study andi tw a sc o n fi r m e dt h a tt h ed o s eo fG L S Fw a s ∼2.0 g/kg.\n",
      "Animal experiment\n",
      "All animal studies were carried out in strict accordance\n",
      "with the recommendations in the Guide for the Careand Use of Laboratory Animals of the National Institutesof Health and approved by the Western University ofHealthSciencesInstitutionalAnimalCareandUseCom-mittees.Apilotstudywasconductedusingfivemaleandsix female BALB/c mice. CT26 cells (3 ×10\n",
      "6) in 100 μl\n",
      "serum free media were injected subcutaneously into theright and left flanks of 6-week-old mice (Charles River,Burlington, MA). At 12 days after implantation, treat-ments began. The dose of GLSF (2 g/kg) was given by oralgavaging once a day, M-F, for a total of nine oral doses.Mice were treated with vehicle control or GLSF 2.0 g/kg(n=3–4).\n",
      "For a rodent diet-based drug regimen study, 4-week-\n",
      "oldmicewererandomlydividedintofourgroups.Groups1a n d3( n =8) were fed with standard diet while groups\n",
      "2 and 4 were fed with diet containing GLSF (n =4) for\n",
      "4 weeks before cell inoculation. When the mice were 8weeks old, 5 ×10\n",
      "5cells in 100 μl serum free media were\n",
      "injected subcutaneously into the right and left flanks ofmice.ThedoseforGLSFobtainedfromdietconsumptionwasestimatedtobe2.0g/kg,asforthepilotstudy.Groups3and4weretreatedwithasinglei.v .doseofabraxane(20mg/kg) (on Day 13 after tumor inoculation). The tumorvolumewascalculatedaccordingtotheformulation:Vol-ume=(width)\n",
      "2×length/2.RNA extraction, library preparation, and\n",
      "next-generation sequencing\n",
      "Tumors from the rodent diet-based drug regimen study\n",
      "were dissected, snap frozen, and stored at −80◦C. The\n",
      "total RNA was extracted from the tumor tissues usingTRIzol reagent (Invitrogen, Grand Island, NY) and aRNeasy Mini Kit (Qiagen, Germantown, MD). The qual-ityofRNAsampleswasdeterminedwithanAgilent2100Bioanalyzer. A total of eight RNA samples (four sam-ples per treatment, two groups) were sent to FulgentGenetics (Temple City, CA) for library preparation andsequencing. Briefly, the library was constructed usingthe NEBNext\n",
      "R/circlecopyrtPoly(A) mRNA Magnetic Isolation Mod-\n",
      "ule+NEBNext R/circlecopyrtUltraII Directional RNA Library Prep\n",
      "Kit (New England Biolabs, Ipswich, MA). The RNA-seqlibraries were sequenced using an Illumina HiSeq 4000with 150 bp, paired-end, at a minimum depth of total 60million reads per sample.\n",
      "Computational RNA-seq data analysis\n",
      "Raw data were converted into fastq files by Illu-mina bcl2fastq2 v2.20. Read quality was assessed usingFastQC. The sequence reads were mapped to mouse ref-erence genome GRCm38 using the Edico Genome Dra-gen aligner with default settings. Duplicate reads, asmarked by the Dragen aligner, were removed before cov-erage analysis. The aligned bam files were processed byHTSeq for gene quantification. Only genes with countsper million (CPM) values above 0.5 in at least two sam-ples were included in the differential expression anal-ysis. Differentially expressed genes were identified byR package EdgeR (version 3.24.3). Briefly, read countswere fitted into negative binomial distribution. The dif-ferential analysis was carried out using quasi-likelihoodF-test. Genes with Pvalues <0.05 and absolute log\n",
      "2-fold change above 1 were considered to be signif-icantly differentially expressed. Pathway analysis andprediction based on significant DEGs were performedusing Ingenuity Pathway Analyses (IPA; Ingenuity\n",
      "R/circlecopyrt\n",
      "Systems, www.ingenuity.com ). Global MDS, hierarchical\n",
      "clustering heat map, and volcano plot were generatedusing plotMDS, heatmap.2, and plotMD functions in R,respectively.\n",
      "Statistical analysis\n",
      "Dataareexpressedasmean ±standarddeviationunless\n",
      "stated otherwise. All plots were made using GraphPadPrism version 7.0 (GraphPad Software, Inc, La Jolla, CA),and statistical analysis was conducted using NCSS 2007(NCSS, LLC, Kaysville, UT). The specific tests are detailedin the text and figure legends. For all the statistical anal-ysis, means were indicated to be statistically differentwhenP<0.05.Antitumor activity of Ganoderma lucidum 235\n",
      "Figure 1. Effects of GLSF gastrointestinal (GI) juice extract on the growth inhibitory effects of paclitaxel in colorectal cancer cells. (A) SRB\n",
      "cytotoxicity assay was used to determine the effects of paclitaxel, GLSF, alone or in combination in the mouse colon cancer CT26 cells. (B) Thecytotoxicity of paclitaxel, GLSF, alone or in combination in human colon cancer HCT-15 cells. (C) The effects of paclitaxel, GLSF alone or in\n",
      "combination in human colon cancer HT-29 cells.\n",
      "∗:P<0.05,∗∗∗:P<0.001, comparing groups treated with paclitaxel alone with other groups,\n",
      "as determined by ttest.\n",
      "Results\n",
      "Identification of optimal extraction methods for\n",
      "GLSF\n",
      "As there is no standardized preparation approach for GL\n",
      "andrelatedproducts,wetriedseveralmethodsforprepa-ration of GLSF extracts, including the use of ethanol,methanol, hot water, as well as artificial gastrointesti-naljuice.Tocomparethepharmacologicactivityoftheseextracts, we examined their ability to inhibit cancer cellgrowthin vitro. The extracts were examined on a panel\n",
      "of cancerous and non-cancerous cell lines derived fromdifferenttissuesoforigin(PC3,MDA-MB-231,A375,H460,HT-29, HepG2, NCI-N87 and NHDF) using a sulforho-damine B (SRB) colorimetric assay. Comparison of thecytotoxicity datafor thefour extracts in melanoma A375or breast cancer MDA-MB-231 indicated that the gas-trointestinal juice and hot water extracts exhibited rel-atively higher potencies of cancer cell growth inhibition(Supplementary Figs. S1 and S2). The viability data andIC\n",
      "50values in these cell lines for gastrointestinal juice\n",
      "and hot water extracts are summarized in Supplemen-tary Table S1. Additionally, our previous study showedhigher contents of triterpenes from GLSF in the gas-trointestinal juice extract compared to the chloroformextract.\n",
      "22As the gastrointestinal juice extract showed\n",
      "thehighestpotencyonthemajorityofcancercelllines,itwasselectedforchemicalfingerprintanalysisandexam-ined for in vitroanticancer effects.\n",
      "Chemical fingerprint analysis of gastrointestinal\n",
      "juice extract of GLSF by HPLC\n",
      "Based on a literature search for components of GL\n",
      "products, 13 compounds were selected as chemicalmarkers for GLSF. A HPLC-DAD fingerprint method has\n",
      "been developed22and was used to quantify these mark-\n",
      "ers in the extract of GLSF. The contents of 13 com-pounds are shown in Supplementary Table S2. Amongthe 13 assessed compounds, only ganoderol A wasnot detectable; the other 12 compounds were identi-fied with substantial amounts. The inter-batch varia-tion was below 16.5% for all these compounds. Althoughthe chemical markers mainly consisted of triterpenes(polysaccharidesnotincluded),theresultsindicatedthatat least for selected active components GLSF was effi-ciently and consistently extracted.\n",
      "Effects of GLSF extract on chemosensitivity of\n",
      "colorectal cancer\n",
      "Paclitaxel (taxol) exhibited a modest inhibitory effect on\n",
      "CT26 cells (IC 50was 0.45 ±0.02μM), while GLSF did\n",
      "not cause cytotoxicity in CT26 at concentration up to3 mg/ml. However, the cells that were co-treated withtaxol (0.125 μM) and GLSF (0.3 mg/ml) showed signifi-\n",
      "cantly increased cytotoxic effects compared to the taxoltreatment alone ( P<0.05) (Fig. 1a). We observed a dose-\n",
      "dependent chemosensitizing effect of GLSF, where ahigher concentration (3.0 mg/ml) showed an increasedchemosensitizing effect compared to GLSF at 0.3 mg/ml(P<0.001). Similar effects were observed for combined\n",
      "treatment of GLSF (0.3 or 3.0 mg/ml) with a higher con-centration of taxol (0.5 μM). To confirm the nature of the\n",
      "interaction between GLSF and taxol, combination anal-yses were performed with the Combination Index (CI)method,\n",
      "23,24using drug combinations at various ratios.\n",
      "A synergistic interaction was produced (CI =0.04) when\n",
      "taxol 0.125 μM was combined with GLSF at 3.0 mg/ml\n",
      "(CI values <1 indicate synergistic activity). To confirm236Mandy M. Liu et al.\n",
      "Figure2. EffectsofGLSFGIjuiceextractonapoptosisinducedbypaclitaxelinmousecolorectalcancerCT26cells.(A)Cellapoptosiswasassessed\n",
      "by Annexin V/PI double staining which was detected by flow cytometry FACS analysis; Annexin-V-FITC staining in y axis (FL1) and PI in x axis\n",
      "(FL3). (B) The Annexin V/PI assay was performed three times and the average percentage of viable, early apoptosis, late apoptosis, and necrosis\n",
      "populations of cells were plotted.∗∗:P<0.01,∗∗∗:P<0.001, compared with vehicle control group, as determined by ttest.\n",
      "these results in human colorectal cancer cell lines, SRB\n",
      "assayswereperformedonhumancolorectalcancerHCT-15 and HT-29 cells, treated with taxol and GLSF aloneor in combination. The IC\n",
      "50in HCT-15 treated with taxol\n",
      "was 0.40 ±0.002 μM and similar to the CT26 cells, GLSF\n",
      "did not cause any cytotoxicity in HCT-15 cells up to3 mg/ml concentration. The cells that were co-treatedwith taxol (0.25 μM) and GLSF (0.11–3 mg/ml) showed a\n",
      "dose-dependent increase in cytotoxic effects comparedto the taxol treatment alone ( P<0.05 for GLSF 0.11\n",
      "mg/ml;P<0.001 for GLSF 1.0 and 3.0 mg/ml) (Fig. 1b).\n",
      "Although HT-29 cells were much more sensitive to taxol(IC\n",
      "50=0.0035 ±0.001 μM) than CT26 and HCT-15 and\n",
      "GLSF at 3 mg/ml alone was also nontoxic, co-treatmentwith GLSF and taxol did not demonstrate increased ordecreased effect on cell viability (Fig. 1c). Therefore, the\n",
      "chemosensitizing effect for GLSF is variable in differentcancer cell lines.\n",
      "Effects of GLSF extract on taxol-induced\n",
      "apoptosis in CT26 cells\n",
      "ThedegreeofapoptosisinducedbyGLSF(3mg/ml),taxol\n",
      "(0.125 μM), or their combination was evaluated in CT26\n",
      "cells. The cells were incubated for 72 hours with com-binations of drugs and the level of apoptosis was quan-tified by an Annexin-V binding and PI staining assay.As shown in Fig. 2, GLSF treatment slightly increased\n",
      "the viable cells compared to vehicle control ( P>0.05).\n",
      "Taxol decreased the viable cell population to 60.1 ±6.2%\n",
      "(P>0.05). When the cells were exposed to a combina-\n",
      "tion of GLSF and taxol, there was a significant reductionof viable cells ( P<0.001) (53.7 ±1.6% of viable cells in\n",
      "control) and increase in the number of early apoptoticcells (P<0.01). This result is consistent with those data\n",
      "obtained by SRB in CT26 cells (Fig. 1a), indicating that\n",
      "the co-treatment with non-toxic concentration of GLSFincreased the anticancer potency of taxol via enhancingapoptosis in CT26 cells.\n",
      "Effects of GLSF extract on P-glycoprotein (MDR1)\n",
      "activity in K562/DOX cells\n",
      "Previous studies have shown that both CT2625and HCT-\n",
      "1526express the efflux transporter P-glycoprotein (P-gp\n",
      "or MDR1, ABCB1gene), which is part of the mechanism\n",
      "for their intrinsic resistance to taxanes and other P-gp substrate drugs such as daunorubicin (DNR). There-fore, we examined whether GLSF was able to inhibitP-gp-mediated drug efflux from the multi-drug resis-tantcelllineK562/DOX,whichoverexpressesP-gp,usingdaunorubicin (DNR) as a fluorescent substrate.\n",
      "20Few\n",
      "cells were positive for DNR accumulation without P-gp inhibitor (Fig. 3a). Co-treatment with a known P-gp\n",
      "inhibitor PSC833 (10 μM) as a positive control greatly\n",
      "increased DNR positive cells to nearly 100%. However,GLSF (1, 2 and 3 mg/ml) only slightly increased DNRaccumulation (Fig. 3b). Although the treatment effect\n",
      "of GLSF (2 mg/ml) was significant ( P<0.05), compared\n",
      "to the positive control PSC833, the degree of inhibitionwas negligible. This result suggests that the chemosen-sitizing activity of GLSF is not attributed to P-gpinhibition.Antitumor activity of Ganoderma lucidum 237\n",
      "Figure 3. Effects of GLSF GI juice extract on P-glycoprotein activity in K562/DOX cells and NF- κB activity in HEK-293 cells. (A) Flow cytometry\n",
      "analysisofDNRaccumulationincellsincubatedwithDNR,treatedwithorwithoutPSC833(10 μM)orGLSF.Representativeflowcytometrydata\n",
      "are shown. (B) Graphs showing percentage of cells that were positive for DNR in cell samples co-treated with GLSF and DNR in comparisonwith those co-treated with 10 μM PSC833 and DNR. The data are presented as the mean ±SD from 3–6 independent experiments.\n",
      "∗:P<0.05\n",
      "comparedtotheDNRonlygroup.(C)EffectsofGLSFonTNF- α-inducedNF- κBpromoteractivity.HEK-293cellstransfectedwithNF- κBluciferase\n",
      "reporter and Renillacontrol reporter were treated with vehicle, TNF- α(10 ng/mL), GLSF (0.3, 1.0, 2.0 mg/mL) combined with TNF- αfor 5 hours.\n",
      "Data are expressed as mean +/- SEM; n =3–6.∗:P<0.05 as per one-way ANOVA.\n",
      "Effects of GLSF extract on NF- κBp r o m o t e ra c t i v i t y\n",
      "in HEK-293 cells\n",
      "We next evaluated the effect of GLSF on TNF- αpro-\n",
      "moted NF- κB activation. The HEK-293 cells were trans-\n",
      "fectedwithNF- κB-lucfireflyluciferasereporterconstruct\n",
      "andaplasmidencodingthe Renillaluciferaseforthedual\n",
      "luciferase assay. The transfected cells were treated withvehicle (control) or GLSF extracts at 0, 0.3, 1.0, or 2.0mg/ml, followed by a 5-hour co-incubation with TNF- α\n",
      "(10 ng/ml). As expected, TNF- αstrongly stimulated NF-\n",
      "κBa c t i v i t y( F i g . 3c). The promoter activity stimulated\n",
      "by TNF- αwas inhibited significantly by the GI extract\n",
      "at 2.0 mg/ml in a dose-dependent manner (Fig. 3c).\n",
      "As NF- κB plays a role in promoting carcinogenesis ofvarious types of cancer\n",
      "27and conferring chemoresis-\n",
      "tance to paclitaxel,28inhibition of NF- κBb yG L S Fm i g h t\n",
      "partly explain the in vitrochemosensitizing activity and\n",
      "thein vivoactivity described below.\n",
      "Anticancer efficacy of GLSF oral administration to\n",
      "mice bearing murine colorectal cancer tumorCT26\n",
      "To evaluate the anticancer activity of GLSF invivo,as y n -\n",
      "geneic model of colorectal cancer-bearing BALB/c micewasused.Wefirstlyconductedapilotstudyusingasmallnumber of mice with two tumors (CT26) implanted ineach mouse (n =2 each gender specific group).238Mandy M. Liu et al.\n",
      "Figure 4. Effects of GLSF on tumor growth and apoptosis in a colorectal cancer syngeneic model. (A) The CT26 cells were subcutaneously\n",
      "implanted into the female BALB/c mice after the mice were fed with the control diet (groups 1 and 3) or diet containing GLSF (groups 2 and 4)for 4 weeks. Groups 3 and 4 mice were treated with a single dose of abraxane\n",
      "R/circlecopyrton Day 13. Tumor volumes were measured on Days 13 and 19\n",
      "(Day 0 was the day of tumor injection).∗:P<0.05 by Tukey-Kramer Multiple-Comparison test (n =8f o rG 1a n dG 2 ;n =4f o rG 3a n dG 4 ) .( B )\n",
      "RepresentativephotosofmiceincontrolandGLSFgroups.(C)TumortissueswerestainedwithH&EorimmunohistochemicalstainingofKi-67.(D) Western blot analysis of PARP, cleaved PARP, and β-actin. Representative gel images are shown. Bar graphs represent the ratios of cleaved\n",
      "PARP/total PARP.\n",
      "∗:P<0.05 as compared with the control group by ttest. PARP, poly (ADP-ribose) polymerase. Control n =5 tumors, GLSF n =4\n",
      "tumors.\n",
      "The treatment by oral gavage (2.0 g/kg, daily, Monday\n",
      "toFriday,ninedosesintotal)wasstartedonthe11thdayaftertumorimplantation.Althoughstatisticallyinsignif-icant, a trend of treatment effect was observed in tumorvolume in both males and females (Supplementary Fig.S3): the average tumor volumes in GLSF-treated micewere smaller than in untreated control. In addition, themicedidnotlosebodyweightcomparedtoinitialweight,indicating the treatment was not toxic.\n",
      "To explore the potential anticancer mechanism, the\n",
      "effect of GLSF treatment on mouse spleen lympho-cyte proliferation induced by concanavalin A (Con A) orlipopolysaccharides (LPS) in vitrowas determined using\n",
      "the spleen samples obtained from the CT26 tumor-bearing mice. Compared with non-tumor-bearing mice,proliferation of spleen T and B lymphocytes induced byCon A and LPS were strongly declined in tumor-bearingmice (Supplementary Fig. S3). However, treatment withGLSFofthesemiceincreasedspleenTandBlymphocyteproliferationinCT26-bearingmice,althoughthiswasnotstatistically significant. These data indicate a potentialimmunomodulatory activity of GLSF, consistent with a\n",
      "previous report.\n",
      "4\n",
      "To confirm the anticancer activity of GLSF, BALB/c\n",
      "mice were pre-treated with control diet (groups 1 and3) or modified diet containing GLSF (groups 2 and 4)\n",
      "1 month before tumor implantation. As GLSF showedantitumor effects in both genders in the pilot studyand the CT26 tumor was derived from female mice,\n",
      "15\n",
      "only females were included in this experiment. Abrax-ane treatment was given for groups 3 and 4 to observethe effects of combination treatments. Two tumors wereimplanted in each mouse. Consistent with the pilotstudy, GLSF treatment alone inhibited tumor growth(Fig.4a), although repeated measures ANOVA analysis\n",
      "did not show a statistically significant difference. At theendoftheexperiment,100%ofthemicehadtwotumorsin the control group, while only 63% of mice in the GLSFgroup had two tumors, and two of the eight mice (25%)in the GLSF group did not show any tumors (Fig. 4b). The\n",
      "Tukey-Kramer post hoc analysis showed that on Day 19\n",
      "aftertumorinoculation,co-treatmentwithabraxaneandGLSF significantly suppressed tumor growth comparedwith the control group (Fig. 4a). Furthermore, tumors in\n",
      "thecontrolgroup(group1)showedasignificantincreasewhen comparing tumor size on Day 13 and 19, whilegroups 2, 3 and 4 did not show time-dependent tumor\n",
      "size increase, confirming the treatment effect.\n",
      "Tumor tissues dissected from the control and GLSF\n",
      "groups were subjected to hematoxylin and eosin (H&E)Antitumor activity of Ganoderma lucidum 239\n",
      "Figure 5. RNA-seqanalysisofCT26syngeneictumorsinmicetreatedwithcontroldietorGLSF-modifieddiet.(a)Multi-dimensionalscalingplot\n",
      "of detected genes in GLSF treatment (T, red) and control group (C, green). The distances correspond to leading log2 fold-changes between eachpairofsamples.(b)Volcanoplotsofdifferentiallyexpressedgenesbetweentreatmentandcontrolgroups.Thereddotsindicateup-anddown-\n",
      "regulatedDEGswith P<0.05andabsolutelog2FC >1.(c)Heatmapoftop30significantlydifferentiallyexpressedgenesbetweentreatment(T)\n",
      "and control groups (C). (d) Genes that are up- and down-regulated in treatment group (compared to control) are displayed within red or greennodes, respectively. The predicted inhibited biology effects are presented in blue nodes. Blue (predicted to be inhibited) or gray (undetermined\n",
      "direction) dash lines represent relationships with causal consistency.\n",
      "staining.TheimageofH&Esectionsindicatedthattumor\n",
      "tissues from both groups consisted of a morphologicallysimilardifferentiatedadenocarcinoma.However,tumorsin the GLSF group showed a conspicuous increase ofnecrosisinallthefourtumorsamplessubmittedforH&Estaining (representative images are shown in Fig. 4c). Ki-\n",
      "67 staining showed that the tumors in the control groupconsisted entirely of one cell type with high prolifera-tive index, while the tumors in the GLSF group demon-strated nonspecific staining of necrotic/apoptotic cellsbutshowedfainterstainingoffewerKi-67positiveviablecells (Fig. 4c).\n",
      "Western blot analysis was used to examine the\n",
      "expression of the apoptosis marker PARP and cleavedPARP in tumor tissue lysates. The expression of cleavedPARP was markedly increased in the GLSF treatmentgroup compared with that in the control group (Fig. 4d),\n",
      "andthisdifferencewasstatisticallysignificant( P<0.05),\n",
      "confirming that GLSF treatment induced apoptosis intumor tissues in vivo.RNA-seq profiling of GLSF-treated tumors\n",
      "To explore the mechanism underlying the treatment\n",
      "effectsbyGLSF,RNA-seqanalysiswasperformedtocom-pare the gene expression profiles between tumors iso-lated from mice subjected to the control diet (n =4)\n",
      "or GLSF modified diet (n =4). On average, 40 million\n",
      "pair-end reads pairs per sample were generated, withall of their uniquely mapping rates above 91%. Over-all, RNA sequencing detected 25 051 genes across eightsamples, of which 13 790 genes had a CPM value above0.5 in at least two samples. A multi-dimensional scal-ing (MDS) plot showed a trend of clustering separationbetween treated group and control group (Fig. 5a). Out of\n",
      "the 13790 genes, 53 were identified as significant differ-entially expressed genes (DEGs) between the two groupswith a absolute log2 fold-change >1a n da Pvalue <0.05\n",
      "(SupplementaryTableS3).Thetop12up-regulatedgenesand top 10 down-regulated genes (selected based on thelowestPvalue) are presented in Tables 1and2.Al o g 2240Mandy M. Liu et al.\n",
      "Table 1. Top 12 up-regulated genes in tumors from mice treated with GLSF compared to control group.\n",
      "Gene ID Gene name Log FC Pvalue\n",
      "Itga10 Integrin, alpha 10 1.07 9.34E-05\n",
      "Zbtb16 Zinc finger and BTB domain containing 16 2.07 2.79E-04\n",
      "Gm807 Predicted gene 807 1.26 9.47E-04Lvrn Laeverin 1.17 1.07E-03\n",
      "Gm6093 Predicted gene 6093 1.63 1.49E-03Hrct1 Histidine rich carboxyl terminus 1 1.33 2.15E-03Aldh1a1 Aldehyde dehydrogenase family 1,\n",
      "subfamily A11.08 2.59E-03\n",
      "Inpp5j Inositol polyphosphate 5-phosphatase J 1.67 3.06E-03\n",
      "Rcan2 Regulator of calcineurin 2 1.00 3.39E-03\n",
      "Ifng Interferon gamma 1.09 3.52E-03\n",
      "Retnla Resistin like alpha 2.52 3.63E-03\n",
      "Fmo2 Flavin containing monooxygenase 2 1.35 7.23E-03\n",
      "∗Log FC (log2 Fold change) larger than 1 indicates higher expression in GLSF-treated tumors.\n",
      "Table 2. Top 10 down-regulated genes in tumors from mice treated with GLSF compared to control group.\n",
      "Gene ID Gene name Log FC Pvalue\n",
      "Il1b Interleukin 1 beta −1.31 9.57E-06\n",
      "Il11 Interleukin 11 −1.09 4.89E-04\n",
      "4930565N06Rik RIKEN cDNA 4930565N06 gene −1.06 6.84E-04\n",
      "Nppb Natriuretic peptide type B −1.44 7.72E-04\n",
      "Ptgs2 Prostaglandin-endoperoxide synthase 2 (Cox-2) −1.11 1.18E-03\n",
      "Mmp10 Matrix metallopeptidase 10 −1.51 1.31E-03\n",
      "Mmp13 Matrix metallopeptidase 13 −1.16 1.68E-03\n",
      "Stamos Signal transducing adaptor molecule (SH3 domain and\n",
      "ITAM motif) 1, opposite strand−1.13 1.82E-03\n",
      "Cxcl1 Chemokine (C-X-C motif) ligand 1 −1.56 2.07E-03\n",
      "Mmp12 Matrix metallopeptidase 12 −1.03 4.01E-03\n",
      "∗Log FC (log2 Fold change) smaller than −1 indicates lower expression in GLSF-treated tumors.\n",
      "fold-change lower than −1 indicated that the expression\n",
      "of the gene was decreased by GLSF treatment, whereasa log2 fold-change more than 1 suggested an increasedgene expression in tumor tissues derived from GLSFtreatment. A heat map of the top 30 significant DEGswas plotted with unsupervised hierarchical clustering(Fig.5b). A volcano plot was generated with the signifi-\n",
      "cant DEGs highlighted in red color based on their Pval-\n",
      "ues and fold changes (Fig. 5c). It is notable that many\n",
      "of these GLSF down-regulated genes are involved in NF-κB-regulated inflammation, such as IL-1 β(Il1b) and IL-11\n",
      "(Il11)( T a b l e 2,F i g .5b).\n",
      "To explore the possible biological functions linked\n",
      "with these DEGs, ingenuity pathway analysis (IPA) wasperformedtoidentifycanonicalpathways,upstreamreg-ulators, diseases and functions that are associated withGLSFtreatment.BasedontheratioofthenumberofDEGsin our dataset to the total number of reference genesin the specific pathways in the IPA knowledge bases, aFisher’s exact test was used to determine the canonicalpathways associated with the treatment effect. Using acutoffPvalue <0.05, a total of 58 canonical pathways\n",
      "were identified as being significantly enriched based onthe DEGs (Supplementary Table S4). The most affectedpathways were “Granulocyte adhesion and diapedesis”and “Agranulocyte adhesion and diapedesis”, which areknown immune/inflammatory pathways.Upstream analysis through IPA was used to predict\n",
      "the upstream regulators potentially causing changesin gene expression and regulation direction based onthe DEGs. Predicted significantly activated and inhib-ited regulators are listed in Supplementary Table S5 ( P\n",
      "value <0.05,|Z-score |>2).Thetwosignificantlyactivated\n",
      "upstream regulators were alpha-catenin and TP53, both\n",
      "of which are known tumor suppressors for colon cancer.On the other hand, the most inhibited upstream regula-tors were factors that play critical roles in inflammatoryresponse and tumorigenesis, including TNFSF12, KRT17,IL17RA, TNF, and IL17A.\n",
      "”Diseases and functions” in IPA was used to predict\n",
      "affected biology and its regulation direction associatedwith GLSF treatment. Using a cutoff of Pvalue <0.05,\n",
      "|Z-score |>2, there was no significantly activated biology\n",
      "effect identified, while the top five significantly inhib-ited biological effects are presented in Fig. 5d, which\n",
      "included “Cancer”, “Epithelia neoplasm”, “Carcinoma”,“Secondary tumor”, “Frequency of tumor”. The networkof the top five inhibited biology effects in the GLSF treat-ment group, compared to the control, and the contribut-ing DEGs were displayed in Fig. 5d. Quantitative RT-PCR\n",
      "analysis confirmed that GLSF inhibited the expressionof selected inflammatory genes, cyclooxygenase-2 ( Ptgs2\n",
      "orCox-2)(P<0.05), interleukin-1 β(Il1b)(P<0.01), and\n",
      "interleukin-6 ( Il6)(P<0.01) (Fig. 6).Antitumor activity of Ganoderma lucidum 241\n",
      "Figure 6. qRT-PCRresults fromtumor samplesofcontrol or GLSF groupsfor(A) COX-2,(B) IL-1 β,and(C)IL-6. β-actin wasused asnormalization\n",
      "control and data are expressed as mean with 95% CI. n =8 tumor samples from control group. n =10 tumor samples for GLSF.∗:P<0.05;∗∗:\n",
      "P<0.01 via a Mann-Whitney U approximation without correction for normality.\n",
      "Discussion\n",
      "The present study examined the in vitroandin vivoanti-\n",
      "cancer activity of GLSF, which contains a mixture of bro-ken spores and fruiting bodies of mushroom. As differ-entmethodsofextractionaffecttherelease,bioavailabil-ity and pharmacological activity of active components,extracts of GLSF were prepared in ethanol, methanol,hot water, or artificial gastrointestinal juice and wereexamined in a panel of cell lines. We found that extractsprepared using gastrointestinal juice had the highestpotencyofcellgrowthinhibitionandthereforewereusedin ourin vitrostudies. This extraction method is physi-\n",
      "ologically relevant to clinical application. Although themethod of extraction has been used for ginseng\n",
      "29and\n",
      "notoginseng (“San-Qi”),30to our knowledge, this is the\n",
      "firststudyusingartificialgastrointestinaljuicetoprepareGLextracts. Invitro,GLSFaloneshowedmodestcytotoxi-\n",
      "cityoncoloncancercells,whichisconsistentwithapre-viousstudyindicatingthatthedirectanticancereffectofGL is limited.\n",
      "3However, when GLSF was combined with\n",
      "taxol, it induced stronger tumor inhibition and apopto-sis, suggesting that GLSF may be used as a chemosen-sitizer (Fig. 1a and b). As GLSF is not a P-gp inhibitor\n",
      "(Fig.3aandb),itschemosensitizingmechanismremainstobedetermined.Onepossiblemechanismisthroughits\n",
      "inhibitory activity against NF- κB signaling, suggested by\n",
      "the dual luciferase assay (Fig. 3c). Consistently, previous\n",
      "studieshaveshownthattriterpeneganodericacidC1iso-latedfromGLinhibitedinflamedCrohn’sdiseasecolonicm u c o s aa sar e s u l to fb l o c k a g eo fN F - κB.\n",
      "31\n",
      "In vivo, GLSF alone or in combination with abrax-\n",
      "ane (nanoparticle albumin bound paclitaxel or nab-paclitaxel) induced tumor growth inhibition and apop-tosis (Fig. 4). The syngeneic tumor model used in the\n",
      "studywasmurinecolorectalcarcinomacelllineColorec-talTumor#26(CT26).\n",
      "15CT26cellswerederivedbyexpos-\n",
      "ing BALB/c mice to the chemical carcinogen N-nitroso-N-methylurethane, resulting in a rapid-growing grade IVcarcinoma that is easily implanted and readily metasta-sizes.\n",
      "32AsCT26tumorintheimmunocompetentBALB/c\n",
      "miceprovidesasyngeneicmodel,itisfrequentlyusedfordeveloping and testing immunotherapeutic agents.\n",
      "15,33\n",
      "Comparedwith invitrodata,alarge invivoeffectsuggests\n",
      "that an intact immune system or tumor microenviron-ment may be essential for the pharmacological action ofGLSF. One limitation for these in vivostudies was that a\n",
      "single dose was used (2.0 g/kg), which was derived frompublished data of GL.\n",
      "34–36Dose-response studies should\n",
      "be considered in the future. Although taxol or abraxane242Mandy M. Liu et al.\n",
      "are effective to many types of cancer such as breast or\n",
      "ovariancancer,theirapplicationincolorectalcancerhasbeenlimitedbecauseofintrinsicresistance.\n",
      "37Thus,GLSF\n",
      "may be used as a chemosensitizer for taxanes. The ratioof GLSF versus taxol or abraxane should be optimizedin future studies to identify the optimal combinationalregimen. Further studies comparing therapeutic effectsof GLSF in different tumor models and with other anti-cancer agents should be considered.\n",
      "To gain mechanistic insight, RNA-seq was performed\n",
      "to evaluate genome-wide transcriptome changes asso-ciated with GLSF treatment. Based on the differentiallyexpressedgenes(DEGs),expressionlevelsofIL-1 βandIL-\n",
      "11, genes encoding for cytokines in the tumor microen-vironment that promote colorectal cancer progression,were decreased by GLSF. These cytokines, also includ-ing Il-6 which was not picked up by RNA-seq analysisb e c a u s eo fl o wC P Mv a l u e s ,a r ep r o d u c e db ym y e l o i dand T-helper interleukin (IL)-17-producing (Th17) cellsthat are accumulated in the tumor microenvironment.\n",
      "38\n",
      "Because these cytokines directly or indirectly activateneoplastic epithelium, therapies that target their acti-vation, for example anti-IL-11 therapy, have been pro-posed to treat colorectal cancer.\n",
      "38In addition, the GLSF\n",
      "down-regulated Ptgs2,encoding for Cox-2, known to\n",
      "be an inflammatory mediator that promotes colorectalcancer.\n",
      "39RT-PCR results confirmed that in GLSF-treated\n",
      "mice the tumor cell expression of Cox-2, IL-1 β,a n dI L - 6\n",
      "was significantly down-regulated at mRNA level (Fig. 6).\n",
      "These results suggest that inflammation is a potentialtargetfortreatmentofsometypesofcolorectal cancer.\n",
      "40\n",
      "Consistent with the luciferase assay data (Fig. 3c), these\n",
      "GLSF-down-regulated genes are under the control of NF-κB transcription factor. Furthermore, CT26 cells harbor\n",
      "the constitutively activating mutant KRAS,\n",
      "15which has\n",
      "been shown to trigger the production of several inflam-matory mediators including IL-6,\n",
      "41IL-1β42and associ-\n",
      "ated with COX-2.43Interestingly, NF- κBi sa c t i v a t e di n\n",
      "KRAS-mutated cancer and has been suggested as a tar-\n",
      "get to treat KRAS-induced cancer.44,45In addition, a pre-\n",
      "vious study showed that CT26 cells not only secret IL-6 ,b u ta l s ot h eg r o w t ho fC T 2 6t u m o rd e p e n d so nI L -6.\n",
      "46,47Thus, these inflammatory factors, many of which\n",
      "a r eu n d e rt h er e g u l a t i o no fN F - κB, are very likely tar-\n",
      "gets of a GL-mediated anticancer effect. These resultsalso suggest that inflammation-associated cancers andKRAS-driven tumors might be more likely to respondto GLSF. As inhibiting KRAS directly is very challenging,approaches to disrupt downstream signaling pathwaysmay be a better approach to treat these types of highlyaggressive cancer.\n",
      "48\n",
      "Another down-regulated gene in the GLSF-treated\n",
      "group was the inflammatory chemokine Cxcl1, which\n",
      "is involved in enhanced metastatic potential of coloncancer by increasing cell migration, matrix metal-loproteinases (MMP) expression, and epithelial-to-mesenchymal transition and therefore has a negativeprognostic impact to the clinical outcome.\n",
      "49Probably\n",
      "associatedwith Cxcl1down-regulation,threeMMPgeneswere among the top 20 down-regulated genes: MMP10,\n",
      "MMP13,a n dMMP12. These genes and their products\n",
      "have been identified as negative prognostic markersin colon cancer patients.\n",
      "50,51GLSF down-regulated\n",
      "Nppb, encoding for natriuretic peptide B, which has\n",
      "been shown to be a key oncogene candidate for colontumors and suggested as one of the early biomarkers forprevention in the clinical setting.\n",
      "52\n",
      "The GLSF-up-regulated genes have various functions.\n",
      "Although most of these genes have not yet been asso-ciated with colon cancer, they may contribute to GLSF-inducedanti-canceractivity.Someofthemmaybetumorsuppressor genes, for example, Fmo2(flavin containing\n",
      "monooxygenase 2) plays a role as a tumor suppressor inlung cancer.\n",
      "53The lower level of Inpp5j, which encodes\n",
      "inositol polyphosphate-5-phosphatase J, has been asso-ciated with more aggressive tumors and poorer sur-vival of cutaneous squamous cell carcinoma,\n",
      "54and was\n",
      "found to be deficient in oropharyngeal squamous cellcarcinoma.\n",
      "55Itga10, a top DEG of the GLSF-up-regulated\n",
      "genes,encodesintegrinsubunit α10,whichbindstocol-\n",
      "lagen and plays a role in cell adhesion and cell-surfacemediated signaling. Although the activity of increasedexpression of Itga10by GLSF is unknown, the interac-\n",
      "tionofintegrinandcollagenmaymediateananti-tumorimmune response.\n",
      "56\n",
      "The canonical pathway analysis highlighted “Gran-\n",
      "ulocyte adhesion and diapedesis” and “Agranulocyteadhesion and diapedesis” as the most significantly reg-ulated pathways influenced by GLSF treatment. Bothpathways contain the same set of genes, mainly MMPs,and have been associated with immunity and inflam-mation,\n",
      "57as well as tumor invasion and metastasis.58\n",
      "These results support the notion that these two path-wayswereinvolvedininflammationassociatedwithcol-orectal cancer, as previously reported,\n",
      "59and may con-\n",
      "tain the molecular targets that underlie the anticancereffect of GLSF. Based on the DEGs between the treat-mentandcontrolgroups,IPApredictedtheupstreamreg-ulators and their activation states which might resultin these gene expression changes. Several inflamma-tory cytokines were at the top of the inhibition listsuch as TNFSF12, TNF, and IL17A. On the other hand,tumorsuppressorssuchasalpha-cateninandTP53wereactivated (activation z-score >2) according to the pre-\n",
      "diction. This prediction further implied that GLSF mayelicit anti-tumor activity through its anti-inflammatoryeffects.Morespecifically,onepossiblemechanismisthatGLSF treatment resulted in an inhibition of the NF-kBpathway, a shared target of the aforementioned pre-dicted upstream regulators, which eventually may leadtotumorsuppression.Furtherstudiesarerequiredtoval-idate this hypothesis. Based on the IPA prediction, therewasnosignificantlyactivatedbiologyeffectwhilethetopfive inhibited biology effects were all related to “Cancer”anddisplayedthenetworkoftumorsuppressioninducedby GL treatment (Fig. 5d). These results implied a pos-\n",
      "sible mechanism of GL’s anti-tumor effect as alleviatingthe immune suppression in colorectal tumor tissue byAntitumor activity of Ganoderma lucidum 243\n",
      "promoting the recruitment of anti-tumor immune cells,\n",
      "or by inhibiting immune suppressive cells such asmyeloid derived suppressor cells. This hypothesis alignwell with the observation that GLSF alone showed lit-tle cytotoxicity in vitrobecause of a lack of immune sys-\n",
      "tem. It is notable that the in vivostudies used GLSF pow-\n",
      "der while in vitro assays used extract. Identification of\n",
      "the active components that are responsible for theseobserved effects requires further investigation.\n",
      "In conclusion, this study evaluated the anticancer\n",
      "effects and possible underlying anticancer mechanismof GLSF using both human and murine colorectal can-cer cell lines, and examined GLSF alone or in combi-nation with a commonly used chemotherapeutic agentpaclitaxel. InvitrodatarevealedthatalthoughGLSFalone\n",
      "had little anticancer effect, it had a chemosensitiza-tion effect in certain colon cancer cells and that NF- κB\n",
      "played a major role in mediating the in vitroanticancer\n",
      "effectofGLSF.Immunocompetentmicecarryingthesyn-geneic tumor CT26 were used for investigating the in\n",
      "vivoanticancer activity of GL. RNA-seq and bioinformat-\n",
      "ics analysis, for the first time, indicated that GLSF tar-geted inflammation and carcinogenesis and confirmedt h er o l eo fN F - κB as the potential target. Advanced col-\n",
      "orectal cancer shows inherent resistance to paclitaxel orrelated chemotherapeutic agents. With the use of GLSF,a non-toxic natural product, the antitumor effects ofchemotherapy may be enhanced. GSLF alone also hadanticancer activity in vivothrough an inhibitory effect\n",
      "against inflammation, NF-kB, and/or KRAS activation.\n",
      "Supplementary data\n",
      "Supplementary data are available at PCMEDI online.\n",
      "Data and material availability\n",
      "All materials, data, and associated protocols are avail-\n",
      "able to readers without undue qualifications in materialtransfer agreements. The GLSF is available from the Bei-jing Tong Ren Tang Chinese Medicine Co., Ltd.\n",
      "Author contributions\n",
      "Y.H. conceived and designed the study. M.L. carriedout most in vitro andin vivo experiments and ana-\n",
      "lyzed the data; T.L. and C.W. analyzed the RNA-seqdata and revised the manuscript; B.A. conducted sta-tistical analysis; S.Y. and Z.W performed HPLC finger-print analysis; C.P. and R.O. performed the pathologyanalysis; B.Z., W.W., X.L., Y.Z. and Y.H. coordinated theexperiments, wrote and reviewed the manuscript. Allauthors read and approved the final manuscript. C.W.submitted the manuscript.\n",
      "Acknowledgements\n",
      "We would like to thank Lily Kong Lim, A.S.C.P. (H.T.),at the Beverly Hospital for preparing the formalin-fixedparaffin-embedded tissues and H&E staining. The GLSF\n",
      "is available from the Beijing Tong Ren Tang ChineseMedicine Co., Ltd. This study was funded by a con-tract grant (YH) from the Beijing Tong Ren Tang ChineseMedicineCo.,Ltd.Thisstudywasalsopartiallysupportedby Loma Linda University (LLU) GCAT grant (CW).\n",
      "Conflict of interests\n",
      "B.Zhou,W.Wu,X.LiandY.Zhangareemployeesorcon-sultants of the Beijing Tong Ren Tang Chinese MedicineCo., Ltd. The other author(s) declare no competing inter-ests. Besides, as an Editorial Board Member of Precision\n",
      "ClinicalMedicine ,thecorrespondingauthorCharlesWang\n",
      "wasblindedfromreviewingandmakingdecisiononthismanuscript.\n",
      "References\n",
      "1. SiegelRL,MillerKD,JemalA.Cancerstatistics,2016. CACan-\n",
      "cer J Clin 2016;66:7–30. doi:10.3322/caac.21332.\n",
      "2. Hyodo I, Amano N, Eguchi K, et al.Nationwide sur-\n",
      "vey on complementary and alternative medicine in\n",
      "cancer patients in Japan. J Clin Oncol 2005;23:2645–54.\n",
      "doi:10.1200/JCO.2005.04.126.\n",
      "3. Sanodiya BS, Thakur GS, Baghel RK, Ganoderma lucidum: a\n",
      "potent pharmacological macrofungus. Curr Pharm Biotechnol\n",
      "2009;10:717–42. doi: 10.2174/138920109789978757.\n",
      "4. Wang PY, Zhu XL, Lin ZB. Antitumor and Immunomod-\n",
      "ulatory Effects of Polysaccharides from Broken-Spore\n",
      "of Ganoderma lucidum. Front Pharmacol 2012;3:135.\n",
      "doi:10.3389/fphar.2012.00135.\n",
      "5. Sliva D. Ganoderma lucidum in cancer research. Leuk Res\n",
      "2006;30:767–8. doi:10.1016/j.leukres.2005.12.015.\n",
      "6. Lu H, Kyo E, Uesaka T, et al.Prevention of develop-\n",
      "ment of N,N’-dimethylhydrazine-induced colon tumors by a\n",
      "water-soluble extract from cultured medium of Ganoderma\n",
      "lucidum (Rei-shi) mycelia in male ICR mice. Int J Mol Med\n",
      "2002;9:113–7. doi:https://doi.org/10.3892/ijmm.9.2.113..\n",
      "7. LuH,KyoE,UesakaT, etal.Awater-solubleextractfromcul-\n",
      "turedmediumofGanodermalucidum(Rei-shi)myceliasup-presses azoxymethane-induction of colon cancers in male\n",
      "F344 rats. Oncol Rep 2003;10: 375–9.\n",
      "8. Lu H, Uesaka T, Katoh O, et al.Prevention of the devel-\n",
      "opment of preneoplastic lesions, aberrant crypt foci, bya water-soluble extract from cultured medium of Gano-\n",
      "dermalucidum (Rei-shi)myceliain maleF344rats. OncolRep\n",
      "2001;8:1341–5. doi: 10.3892/or.8.6.1341.\n",
      "9. Sliva D, Loganathan J, Jiang J, et al.Mushroom Ganoderma\n",
      "lucidum prevents colitis-associated carcinogenesis in mice.\n",
      "PLoS One 2012;7:e47873. doi:10.1371/journal.pone.0047873.\n",
      "10. Yang Y, Nirmagustina DE, Kumrungsee T, et al.Feeding of\n",
      "thewaterextractfromGanodermalingzhitoratsmodulates\n",
      "secondary bile acids, intestinal microflora, mucins, and pro-pionate important to colon cancer. Biosci Biotechnol Biochem\n",
      "2017;81:1796–804. doi:10.1080/09168451.2017.1343117.\n",
      "11. Luo J, Li T, Xie J, et al.Guar gum different from Gano-\n",
      "derma lucidum polysaccharide in alleviating colorectal can-cer based on omics analysis. Food Funct 2020;11:572–84.\n",
      "doi:10.1039/c9fo02786f.\n",
      "12. OkaS,TanakaS,YoshidaS, etal.Awater-solubleextractfrom\n",
      "culture medium of Ganoderma lucidum mycelia suppresses244Mandy M. Liu et al.\n",
      "thedevelopmentofcolorectaladenomas. Hir oshimaJMedSci\n",
      "2010;59:1–6.\n",
      "13. Chen X, Hu ZP, Yang XX, et al.Monitoring of immune\n",
      "responses to a herbal immuno-modulator in patients withadvancedcolorectalcancer. IntImmunopharmacol 2006;6:499–\n",
      "508. doi:10.1016/j.intimp.2005.08.026.\n",
      "14. Bai JH, Xu J, Zhao J, et al.Ganoderma lucidum polysaccha-\n",
      "rideenzymatichydrolysatesuppressesthegrowthofhuman\n",
      "colon cancer cells via inducing apoptosis. Cell Transplant\n",
      "2020;29: 963689720931435. doi:10.1177/0963689720931435.\n",
      "15. Castle JC, Loewer M, Boegel S, et al.Immunomic, genomic\n",
      "andtranscriptomiccharacterizationofCT26colorectalcarci-\n",
      "noma.BMC Genomics 2014;15:190. doi:10.1186/1471-2164-15-\n",
      "190.\n",
      "16. Chrubasik S, Sporer F, Dillmann-Marschner R, et al.Physico-\n",
      "chemical properties of harpagoside and its in vitro release\n",
      "from Harpagophytum procumbens extract tablets. Phy-\n",
      "tomedicine 2000;6:469–73. doi:10.1016/S0944-7113(00)80076-8.\n",
      "17. PandaV,KhambatP,KundnaniK, etal.Evaluationofantacid\n",
      "activity of garcinia indica fruit rind by a modified artifi-cial stomach model. Bull Environ Pharmacol Life Sci 2013;2:\n",
      "38–42.\n",
      "18. Marie JP, Faussat-Suberville AM, Zhou D, et al.Daunorubicin\n",
      "uptake by leukemic cells: correlations with treatment out-\n",
      "come and mdr1 expression. Leukemia 1993;7:825–31.\n",
      "19. Liu M, RavulaR, WangZ, etal.TraditionalChinesemedicinal\n",
      "formula Si-Wu-Tang prevents oxidative damage by activat-ing Nrf2-mediated detoxifying/antioxidant genes. Cell Biosci\n",
      "2014;4:8. doi:10.1186/2045-3701-4-8.\n",
      "20. Wang EJ, Casciano CN, Clement RP, et al.In vitro flow\n",
      "cytometry method to quantitatively assess inhibitors of P-\n",
      "glycoprotein. Drug Metab Dispos 2000;28:522–8.\n",
      "21. HuangKM,LiangS,YeungS, etal.Topicallyappliedcarvedilol\n",
      "attenuates solar ultraviolet radiation induced skin carcino-\n",
      "genesis. Cancer Prev Res 2017;10:598–606. doi:10.1158/1940-\n",
      "6207.CAPR-17-0132.\n",
      "22. Yeung S, Chen Q, Yu Y, et al.Quality evaluation of\n",
      "commercial products of Ganoderma lucidum made\n",
      "from its fruiting body and spore. Acta Chromatogr 2021.\n",
      "doi:10.1556/1326.2020.00825.\n",
      "23. ChouTC,TalalayP.Quantitativeanalysisofdose-effectrela-\n",
      "tionships:thecombinedeffectsofmultipledrugsorenzyme\n",
      "inhibitors. AdvEnzymeRegul 1984;\n",
      "22:27–55.doi:10.1016/0065-\n",
      "2571(84)90007-4.\n",
      "24. Chou TC, Motzer RJ, Tong Y, et al.Computerized quanti-\n",
      "tation of synergism and antagonism of taxol, topotecan,and cisplatin against human teratocarcinoma cell growth: a\n",
      "rationalapproachtoclinicalprotocoldesign. JNatlCancerInst\n",
      "1994;86:1517–24. doi: 10.1093/jnci/86.20.1517.\n",
      "25. Lin F, Hoogendijk L, Buil L, et al.Sildenafil is not a useful\n",
      "modulator of ABCB1 and ABCG2 mediated drug resistance\n",
      "in vivo.Eur J Cancer 2013;49:2059–64. doi:10.1016/j.ejca.2012.\n",
      "12.028.\n",
      "26. Naito M, Matsuba Y, Sato S, et al.MS-209, a quinoline-type\n",
      "reversalagent,potentiatesantitumorefficacyofdocetaxelin\n",
      "multidrug-resistant solid tumor xenograft models. Clin Can-\n",
      "cer Res2002;8:582–8.\n",
      "27. Hu M, Peluffo G, Chen H, et al.Role of COX-2 in epithelial-\n",
      "stromal cell interactions and progression of ductal carci-nomainsituofthebreast. ProcNatlAcadSci 2009;106:3372–7.\n",
      "doi:0813306106 [pii] 10.1073/pnas.0813306106.\n",
      "28. Chen X, Sun X, Guan J, et al.Rsf-1 influences the sensitiv-\n",
      "ity of non-small cell lung cancer to paclitaxel by regulating\n",
      "NF-kappaB pathway and its downstream proteins. Cell Phys-\n",
      "iol Biochem 2017;44:2322–36. doi:10.1159/000486116.29. Rimar S, Lee-Mengel M, Gillis CN Pulmonary protective and\n",
      "vasodilator effects of a standardized Panax ginseng prepa-\n",
      "ration following artificial gastric digestion. Pulm Pharmacol\n",
      "1996;9:205–9. doi: 10.1006/pulp.1996.0025.\n",
      "30. Wang JR, Yau LF, Zhang R, et al.Transformation of gin-\n",
      "senosides from notoginseng by artificial gastric juice can\n",
      "increase cytotoxicity toward cancer cells. J Agric Food Chem\n",
      "2014;62:2558–73. doi:10.1021/jf405482s.\n",
      "31. Liu C, Dunkin D, Lai J, et al. Anti-inflammatory\n",
      "effects of ganoderma lucidum triterpenoid in humancrohn’s disease associated with downregulation of NF-\n",
      "kappaB signaling. Inflamm Bowel Dis 2015;21:1918–25.\n",
      "doi:10.1097/MIB.0000000000000439.\n",
      "32. GriswoldDP,CorbettTH.Acolontumormodelforanticancer\n",
      "agent evaluation. Cancer1975;36:2441–4. doi: 10.1002/1097-\n",
      "0142(197512)36:6 <2441::aid-cncr2820360627 >3.0.co;2-p.\n",
      "33. Lechner MG, Karimi SS, Barry-Holson K, etal.Immunogenic-\n",
      "ity of murine solid tumor models as a defining feature of in\n",
      "vivobehaviorand responseto immunotherapy. JImmunother\n",
      "2013;36:477–89. doi:10.1097/01.cji.0000436722.46675.4a.\n",
      "34. Wang S, Wang X, Lin L, et al.Inhibitory effect of Lucid Gan-\n",
      "oderma spore on human hepatocarcinoma cell line HepG2\n",
      "and growth of transplanted tumor in nude mice. World\n",
      "Chinese J Digestol 2008;16:1114–8. doi:10.3969/j.issn.1009-\n",
      "3079.2008.10.017.\n",
      "35. Sun L, Zhao M, Huang Y, Influence of ganodema lucidum\n",
      "spore on dendritic cells from mice bone marrow andits antitumor effect. (In Chinese). Shanxi Med J 2006;35:\n",
      "698–700.\n",
      "36. Huang G, Zhong W. Inhibition of mouse transplanted hep-\n",
      "atoma growth and telomerase activities by germination-\n",
      "activating sporoderm-broken ganoderma spores (GSGS). (In\n",
      "Chinese). China Medical Engineering 2007;15:1–8.\n",
      "37. Wang Y, Zhang C, Zhang S, et al.Kanglaite sensitizes\n",
      "colorectal cancer cells to Taxol via NF-kappaBeta inhibi-\n",
      "tion and connexin 43 upregulation. Sci Rep 2017;7:1280.\n",
      "doi:10.1038/s41598-017-01480-2.\n",
      "38. Ernst M, Putoczki TL. Targeting IL-11 signaling in colon\n",
      "cancer. Oncotarget 2013;4:1860–1. doi:10.18632/oncotarget.\n",
      "1410.\n",
      "39. Janakiram NB, Rao CV. The role of inflammation in colon\n",
      "cancer.Adv Exp Med Biol 2014;816:25–52. doi:10.1007/978-3-\n",
      "0348-0837-8\n",
      "2.\n",
      "40. Ray AL, Berggren KL, Restrepo Cruz S, et al.Inhibition of\n",
      "MK2 suppresses IL-1beta, IL-6, and TNF-alpha-dependent\n",
      "colorectal cancer growth. Int J Cancer 2018;142:1702–11.\n",
      "doi:10.1002/ijc.31191.\n",
      "41. Ancrile B, Lim KH, Counter CM. Oncogenic Ras-induced\n",
      "secretion of IL6 is required for tumorigenesis. Genes Dev\n",
      "2007;21:1714–9. doi:10.1101/gad.1549407.\n",
      "42. Beaupre DM, Talpaz M, Marini FC, 3rd, et al.Autocrine\n",
      "interleukin-1beta production in leukemia: evidence for theinvolvement of mutated RAS. Cancer Res 1999;59:2971–80.\n",
      "4 3 .P a nY ,J i a n gY ,T a nL , et al.Deletion of cyclooxygenase-\n",
      "2 inhibits K-ras-induced lung carcinogenesis. Oncotarget\n",
      "2015;6:38816–26. doi:10.18632/oncotarget.5558.\n",
      "44. MizumotoY,KyoS,KiyonoT, etal.ActivationofNF-kappaBis\n",
      "a novel target of KRAS-induced endometrial carcinogenesis.\n",
      "Clin Cancer Res 2011;17:1341–50. doi:10.1158/1078-0432.CCR-\n",
      "10-2291.\n",
      "45. Ling J, Kang Y, Zhao R, et al. KrasG12D-induced\n",
      "IKK2/beta/NF-kappaB activation by IL-1alpha and p62feedforward loops is required for development of pancre-\n",
      "atic ductal adenocarcinoma. Cancer Cell 2012;21:105–20.\n",
      "doi:10.1016/j.ccr.2011.12.006.Antitumor activity of Ganoderma lucidum 245\n",
      "46. AlshamsanA.InductionoftolerogenicdendriticcellsbyIL-6-\n",
      "secreting CT26 colon carcinoma. Immunopharmacol Immuno-\n",
      "toxicol2012;34:465–9. doi:10.3109/08923973.2011.625034.\n",
      "47. Ohno Y, Toyoshima Y, Yurino H, et al.Lack of interleukin-6\n",
      "in the tumor microenvironment augments type-1 immunity\n",
      "and increases the efficacy of cancer immunotherapy. Cancer\n",
      "Sci2017;108:1959–66. doi:10.1111/cas.13330.\n",
      "48. Golay HG, Barbie DA. Targeting cytokine networks in KRAS-\n",
      "driventumorigenesis. ExpertRevAnticancerTher 2014;14:869–\n",
      "71. doi:10.1586/14737140.2014.928596.\n",
      "49. HsuYL,ChenYJ,ChangWA, etal.Interactionbetweentumor-\n",
      "associated dendritic cells and colon cancer cells contributes\n",
      "to tumor progression via CXCL1. Int J Mol Sci , 2018;19:2427.\n",
      "doi:10.3390/ijms19082427.\n",
      "50. Klupp F, Neumann L, Kahlert C, et al.Serum MMP7, MMP10\n",
      "and MMP12 level as negative prognostic markers in colon\n",
      "cancerpatients. BMCCancer 2016;16:494.doi:10.1186/s12885-\n",
      "016-2515-7.\n",
      "51. Leeman MF, McKay JA, Murray GI. Matrix metalloproteinase\n",
      "13 activity is associated with poor prognosis in colorectalcancer.JClinPathol 2002;55:758–62.doi:10.1136/jcp.55.10.758.\n",
      "52. ErtemFU,ZhangW,ChangK, etal.OncogenictargetsMmp7,\n",
      "S100a9, Nppb and Aldh1a3 from transcriptome profiling ofFAP and Pirc adenomas are downregulated in response to\n",
      "tumor suppression by Clotam. Int J Cancer 2017;140:460–8.\n",
      "doi:10.1002/ijc.30458.\n",
      "53. Hsu YL, Hung JY, Lee YL, et al.Identification of novel gene\n",
      "expressionsignatureinlungadenocarcinomabyusingnext-generation sequencing data and bioinformatics analysis.\n",
      "Oncotarget 2017;8:104831–54. doi:10.18632/oncotarget.21022.\n",
      "54. Maly CJ, Cumsky HJL, Costello CM, et al.Prognostic value\n",
      "of inositol polyphosphate-5-phosphatase expression inrecurrent and metastatic cutaneous squamous cell\n",
      "carcinoma. J Am Acad Dermatol , 2019. doi:10.1016/\n",
      "j.jaad.2019.08.027.\n",
      "55. Patel AB, Mangold AR, Costello CM, et al.Frequent loss\n",
      "of inositol polyphosphate-5-phosphatase in oropharyngeal\n",
      "squamous cell carcinoma. J Eur Acad Dermatol Venereol\n",
      "2018;32:e36–7. doi:10.1111/jdv.14462.\n",
      "56. Harjunpaa H, Llort Asens M, Guenther C, et al.Cell adhe-\n",
      "sionmoleculesandtheirrolesandregulationintheimmuneand tumor microenvironment. Front Immunol 2019;10:1078.\n",
      "doi:10.3389/fimmu.2019.01078.\n",
      "57. Grozdanov V, Bliederhaeuser C, Ruf WP, et al.Inflam-\n",
      "matory dysregulation of blood monocytes in Parkinson’sdisease patients. Acta Neuropathol (Berl) 2014;\n",
      "128:651–63.\n",
      "doi:10.1007/s00401-014-1345-4.\n",
      "58. Merdad A, Karim S, Schulten HJ, et al.Expression of matrix\n",
      "metalloproteinases (MMPs) in primary human breast can-\n",
      "cer: MMP-9 as a potential biomarker for cancer invasion and\n",
      "metastasis. Anticancer Res 2014;34:1355–66.\n",
      "59. Guo Y, Su ZY, Zhang C, et al.Mechanisms of colitis-\n",
      "accelerated colon carcinogenesis and its prevention with\n",
      "the combination of aspirin and curcumin: Transcriptomicanalysis using RNA-seq. Biochem Pharmacol 2017;135:22–34.\n",
      "doi:10.1016/j.bcp.2017.02.021.\n"
     ]
    }
   ],
   "source": [
    "# Open the PDF file\n",
    "with open('/Users/mmliu/Desktop/CISB63/CISB63_midterm_MandyLiu/data/Inhibitory activity of medicinal mushroom on colorectal cancer.pdf', 'rb') as pdf_file:\n",
    "    # Create a PDF reader object\n",
    "    pdf_reader = PyPDF2.PdfReader(pdf_file)\n",
    "\n",
    "    # Initialize a variable to store the text\n",
    "    text = \"\"\n",
    "\n",
    "    # Iterate through each page and extract text\n",
    "    for page in pdf_reader.pages:\n",
    "        text += page.extract_text()\n",
    "\n",
    "# Print or use the extracted text\n",
    "print(text)\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "753c3a44",
   "metadata": {},
   "source": [
    "## Preprocess the text"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "33582799",
   "metadata": {},
   "source": [
    "### Get number of pages"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "ed53e8f2",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number of pages in the PDF: 15\n"
     ]
    }
   ],
   "source": [
    "# Get the number of pages\n",
    "num_pages = len(pdf_reader.pages)\n",
    "\n",
    "# Print the number of pages\n",
    "print(f\"Number of pages in the PDF: {num_pages}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "ec7088db",
   "metadata": {},
   "source": [
    "### Tokenize the text into sentences"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "c2ba3fb9",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['Precision Clinical Medicine , 4(4), 2021, 231–245\\nhttps://doi.org/10.1093/pcmedi/pbab023\\nAdvance Access Publication Date: 28 August 2021Research Article\\nRESEARCH ARTICLE\\nInhibitory activity of medicinal mushroom\\nGanoderma lucidum on colorectal cancer by\\nattenuating inflammation\\nMandy M. Liu1,§, Tiantian Liu2,§, Steven Yeung1, Zhijun Wang3,\\nBradley Andresen1, Cyrus Parsa4,5, Robert Orlando4,5, Bingsen Zhou6,\\nWei Wu6,X i aL i6, Yilong Zhang6, Charles Wang2,*and Ying Huang1,*\\n1Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences,\\nPomona, CA 91766, USA\\n2Center for Genomics & Department of Basic Sciences, School of Medicine, Loma Linda University, Loma\\nLinda, CA 92350, USA\\n3Department of Pharmaceutical Sciences, College of Pharmacy, Marshall B. Ketchum University, Fullerton, CA\\n92831, USA\\n4College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766, USA\\n5Department of Pathology, Beverly Hospital, Montebello, California, CA 90640, USA\\n6Beijing Tong Ren Tang Chinese Medicine Co., Ltd., New Territories, Hong Kong 999077, China\\n∗Correspondence: Charles Wang, chwang@llu.edu ; Ying Huang, yhuang@westernu.edu\\nCharles Wang, http://orcid.org/0000-0001-8861-2121\\n§Mandy M. Liu and Tiantian Liu contributed equally to this work.', 'Abstract\\nThe medicinal mushroom Ganoderma lucidum (GL, Reishi or Lingzhi) exhibits an inhibitory effect on cancers.', 'However, the underlying mechanism of the antitumor activity of GL is not fully understood.', 'In this study, we\\ncharacterized the gene networks regulated by a commercial product of GL containing a mixture of spores andfruitingbodiesnamely“GLSF”,incolorectalcarcinoma.Wefoundthat invitroco-administrationofGLSFextract\\nat non-toxic concentrations significantly potentiated growth inhibition and apoptosis induced by paclitaxel in\\nCT26 and HCT-15 cells.', 'GLSF inhibited NF- κB promoter activity in HEK-293 cells but did not affect the function\\nof P-glycoprotein in K562/DOX cells.', 'Furthermore, we found that when mice were fed a modified diet contain-\\ning GLSF for 1 month prior to the CT26 tumor cell inoculation, GLSF alone or combined with Nab-paclitaxel\\nmarkedly suppressed tumor growth and induced apoptosis.', 'RNA-seq analysis of tumor tissues derived fromGLSF-treated mice identified 53 differentially expressed genes compared to normal tissues.', 'Many of the GLSF-\\ndown-regulatedgeneswereinvolvedinNF- κB-regulatedinflammationpathways,suchasIL-1 β,IL-11andCox-2.', 'Received: 2 June 2021; Revised: 16 August 2021; Accepted: 23 August 2021\\nC/circlecopyrtThe Author(s) 2021.', 'Published by Oxford University Press on behalf of the West China School of Medicine & West China Hospital of Sichuan University.', 'This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/ ),\\nwhich permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.', '231232Mandy M. Liu et al.', 'Pathwayenrichmentanalysissuggestedthatseveralinflammatorypathwaysinvolvingleukocytemigrationand\\nadhesion were most affected by the treatment.', 'Upstream analysis predicted activation of multiple tumor sup-pressorssuchas α-cateninandTP53andinhibitionofcriticalinflammatorymediators.“Cancer” wasthemajor\\nsignificantly inhibited biological effect of GLSF treatment.', 'These results demonstrate that GLSF can improve\\nthe therapeutic outcome for colorectal cancer through a mechanism involving suppression of NF- κB-regulated\\ninflammation and carcinogenesis.', 'Key words: Ganoderma lucidum ; colorectal carcinoma; RNA-seq; NF- κB; inflammation\\nIntroduction\\nColorectal cancer is the third most common type of can-\\ncer and also the third most common cause of cancer-related death in both men and women in the UnitedStates.', '1Currently, surgery and chemotherapy are the\\nmain treatment options for colorectal cancer, depend-ing on the stage, grade, and tumor location at diagnosis.Chemotherapy is used for patients with metastatic col-orectal cancer as primary therapy, and for patients withearly-stage colorectal cancer before or after surgery asadjuvant therapy.', 'However, chemoresistance is a com-mon obstacle that occurs in almost all cases of col-orectal cancer.', 'In addition, because chemotherapy non-selectively affects all cells that are active in the cellgrowth cycle, it causes toxicity in normal organs suchasthebonemarrow,gastrointestinaltract,andhairfolli-cles.', 'Therefore, the common clinical practice is to use acombination of several anticancer agents with differentmechanisms of actions or toxicity profiles to overcomedrug resistance and reduce toxic reactions.', 'Globally, it has become more and more popular for\\ncancer patients to use complementary and alterna-tive medicine derived from natural sources during orafter the course of conventional anticancer therapies.', 'Anationwide survey conducted in Japan revealed a preva-lence of herbal use in 44.6% of cancer patients and in25.5% of non-cancer patients with benign tumors, andthe most frequently used herbal products were mush-rooms.', '2One of the most well-known medicinal mush-\\nrooms is Ganoderma lucidum (GL), also commonly named\\nasReishiorLingzhi,whichhasbeenusedforcenturiesinEastAsiatotreatavarietyofdisorders,includinginflam-mation and cancer, without any obvious toxicity.', '3,4GL\\nand related products are referred to as ‘The Mushroomof Immortality’ because of beneficial effects on healthand longevity.', 'The spores of GL are the reproductivecells of the fungus, which are ejected from the cap afterthe fruiting bodies become mature.', 'The major bioactivecomponents identified in GL spores and fruiting bod-ies are polysaccharides, which are known to stimulatethe immune system, as well as triterpenes, which maydirectly inhibit proliferating cancer cells.', '5\\nAnticanceractivityhasbeeninvestigatedusingdiffer-\\nentpartsoftheGLmushroom,thespores,fruitingbodiesor mycelia (the early harvest), in human and preclinicalanimalmodels.Theevidencerelatedtocolorectalcancercan be summarized into three types of studies.', 'First, GLhasshownefficacy incertainpreclinical modelsofcoloncancerprevention,thatisprophylaxis.Inseveralreports,\\nthe water extracts of the mycelia culture media of GLprevented chemical carcinogen-induced colorectal car-cinogenesisinmiceorrats.', '6–8Thetriterpeneextractpre-\\nvented colitis-associated colon carcinogenesis in mice.9\\nFeeding water extract of GL powder to rats with a high-fat diet reduced fecal secondary bile acids and intestinalbacteria known to be related to colon carcinogenesis.', '10\\nGL polysaccharide consumption reduced 30% of mor-tality, specific bacteria and expression of cancer-relatedgenes in mice with colon cancer induced by chemi-cal carcinogens.', '11Second, GL has shown some clinical\\nevidence of preventing development of colon cancer ormodulating some biomarkers related to immunomodu-lation or carcinogenesis.', 'For example, the same myceliaextract mentioned above suppressed the number andsizeofprecancerouscolorectaladenomasinhumansub-jects who took the mycelia extract at 1.5 g/day for 12months.', '12In patients with advanced colorectal cancer,\\ntaking oral GL at 5.4 g/day for 12 weeks induced somechanges in immune-related parameters such as IL-1 andTNF-α, although the effects were not statistically sig-\\nnificant.', '13Third, GL has shown some antitumor effi-\\ncacy in a few preclinical studies of human colon can-cer cell lines in vitro.', 'For example, the effect of enzy-\\nmatically hydrolyzed GL polysaccharide has been exam-ined in human colon cancer cell lines, indicating inhibi-tion of apoptosis via up-regulation of BCL-2 associatedX protein (Bax) and down-regulation of COX-2.', '14How-\\never, besides reports of the prophylactic efficacy for GL,few studies have reported the therapeutic effects of GLproducts as a single therapy or combined with conven-tional chemotherapies for already diagnosed colorectalcancer both in vitro andin vivo.', 'Therefore, it is largely\\nunknown whether colorectal cancer patients could ben-efit from treatment with GL products.', 'The present study aimed to determine the effect of\\nGL on colorectal cancer in vitro andin vivo.', 'A com-\\nmercial GL product containing a mixture of sporesand fruiting bodies, namely “GLSF”, was used.', 'Wefirstly evaluated whether the GLSF extracts preparedin several methods including the use of artificial gas-trointestinal juice (to simulate in vivo digestion) have\\nany direct anticancer effects on cancer cells in cul-ture.', 'As colorectal cancers are commonly resistantto taxanes, we next evaluated whether artificial gas-trointestinal juice digested GLSF has any chemosen-sitizing effect in combination with paclitaxel in vitro.Antitumor activity of Ganoderma lucidum 233\\nFurthermore,weevaluatedwhetheraGLSFmodifieddiet\\nwasabletoinhibittumorgrowthinamousemodelbear-ing murine colorectal carcinoma CT26, which is one ofthemostextensivelyusedsyngeneicmousetumormod-els.', '15Tumor samples dissected from GLSF-treated and\\ncontrol diet-treated tumor-bearing mice were analyzedby RNA sequencing (RNA-seq).', 'Potential mechanisms ofthe anticancer and chemosensitization effect of GLSFin colorectal carcinoma were further explored throughbioinformatics analysis.', 'Materials and methods\\nCompounds and reagents\\nPaclitaxel (T7402) purchased from Sigma Aldrich (StLouis, MO) was used in vitro.', 'Abraxane\\nR/circlecopyrtfor injectable\\nsuspension(Celgene,Summit,NJ)wasused invivo.Asin-\\ngle batch of a commercial product manufactured by Bei-jing Tong Ren Tang Chinese Medicine Co. (Hong Kong,China), named as GLSF, contains a mixture of the sporesand fruiting bodies of GL at a 30:8 ratio, was usedthroughout the present study.', 'Preparation of GLSF extracts and quantification of\\nthe major components\\nAs there is no standardized preparation approach for\\nGL and related products, several reagents were used toextract GLSF including ethanol, methanol, hot water, aswell as artificial gastric and intestinal (GI) juice.', 'For theethanol/methanol extract, 0.5 g of GLSF was extractedwith 12.5 ml solvent in a round bottom flask attached toa reflux condenser at 80\\n◦C for 2 hours.', 'The mixture was\\ncentrifuged at 4500 g for 10 minutes.', 'The supernatantwas collected, and the pellet was extracted by repeat-ingthestepsabove.Thesupernatantcollectedwascom-bined and filtered using Whatman filter paper.', 'The sol-vent was removed using a rotary evaporator.', 'For the hot water extract, 10 g of GLSF was extracted\\nwith 200 ml of nanopure water at 85\\n◦C for 15 minutes\\nunder stirring.', 'The mixture was then centrifuged for 15minutes at 4500 g. The supernatant was filtered usingWhatman filter paper and filtrate lyophilized.', 'The pow-der obtained was weighed and stored at −20\\n◦Cb e f o r e\\nanalysis.', 'The extracts of GLSF were prepared in the artificial\\ngastrointestinal juice, which was prepared according toreported methods.', '16,17In brief, 5 g of GLSF powder was\\nmixedin50mlofartificialgastricjuiceat37◦Cwithshak-\\ning for 1 hour, then 50 ml of artificial intestinal juice wasadded and incubated at 37\\n◦C with shaking for an addi-\\ntional5hours.Themixturewascentrifugedatroomtem-perature for 15 minutes at 4500 g, and the supernatantwascollected.TheextractwasthenneutralizedtopH7.0using 0.2 M NaOH, filtered using Whatman filter paper,lyophilized, and stored at −20\\n◦C.', 'The major active components were determined using\\navalidatedHPLC-DADmethod(unpublished),whichwasable to quantify 13 major components in GLSF includingganoderenicAcidC,ganodericAcidC2,ganodericAcidG,\\nganoderic Acid B, ganoderenic Acid B, ganoderic Acid A,ganoderic Acid H, ganoderenic Acid D, ganoderic Acid D,ganoderic Acid F, ganoderic Acid DM, ganoderol A, andergosterol.', 'The individual contents in the extracts werequantified and used as a fingerprint for GL products.', 'Allthe extractions and fingerprint analysis were conductedin triplicate.', 'Cell lines and cell culture\\nCT26, HCT-15, HT-29, and HEK-293 cells were purchasedfromATCC(Manassas,VA).K562/DOXcellline(agiftfromJ.P.Marie,INSERM,E9912,UniversityofParis,France)wasobtained by in vitro passaging of K562 in progressively\\nincreasing doses of daunorubicin.', '18These cells were\\nmaintained in RPMI-1640 or DMEM supplemented with10% fetal bovine serum and 1% penicillin-streptomycin.Cells were incubated at 37\\n◦Cw i t h5 %C O 2/95% air.', 'SRB cell proliferation assay\\nPlates (96-well) were seeded with 3000 cells per well andthe cells were allowed to attach overnight.', 'Cells weretreated with drugs for 72 hours and incubated at 37\\n◦C\\nin 5% CO 2/95% air.', 'Cell viability was determined using\\na Sigma sulforhodamine B (SRB) assay according to themanufacturer’s protocol.', 'Apoptosis analysis\\nFlow cytometry was used to assess apoptosis by FITC-labeledannexin-V(Sigma)andpropidiumiodide,respec-tively,aspreviouslydescribed.', '19Briefly,1 ×105cellswere\\nseeded per well in six-well tissue culture plates for 24hours.', 'The cells were then incubated with drugs for 72hours.', 'Cells were collected and washed twice with coldPBS.', 'Approximately 5 ×10\\n5cells were mixed with bind-\\ning buffer with or without Annexin V or PI.', 'FluorescencewasdetectedinfluorescencechannelsFL1andFL3.Dataacquisition and analysis were performed using AccuriC6 Flow Cytometer (BD Biosciences, Franklin Lakes, NJ).Analysis was based on acquisition of data from 10000cells.EarlyapoptoticcellsareAnnexin-VpositiveandPI-negative, whereas late apoptotic cells are both Annexin-V and PI-positive.', 'Intracellular daunorubicin (DNR) accumulation\\nassay\\nThe capacity of a compound to inhibit P-glycoprotein-\\nmediated efflux from K562/DOX cells, was measured byflow cytometry as described previously.', '20Briefly, the cell\\npellet was resuspended in culture media at a concentra-tion of 6000000 cells/ml.', 'Aliquots (50 μl) of the cell sus-\\npension were transferred to tubes containing 1.95 ml ofmedia in the presence or absence of test drugs in mediaand 5 μM of DNR for 50 minutes at 37\\n◦C.', 'After cen-\\ntrifugation and removal of supernatant, cold PBS wasadded to each tube, and cell suspension was transferred234Mandy M. Liu et al.', 'to FACS tubes, which were placed on ice until analysis.', 'Flow cytometry was performed with an Accuri C6 FlowCytometer.', 'PSC833 (10 μM) served as a positive control.', 'Luciferase reporter gene assay\\nDual luciferase assay for NF- κB has been described in\\nprevious work.21In brief, HEK-293 cells were transfected\\nwith pRL-TK-Luc Renillaluciferase (Promega, Madison,\\nWI) and pGL4.22-NF- κB (Promega) plasmids at a ratio\\nof 1:30 using FuGENE HD Transfection Reagent (RocheApplied Science, Indianapolis, IN).', 'Twenty-four hourslater the cells were exposed to TNF- α(10 ng/ml) and\\nincubated in fresh growth medium containing drugs foran additional 5 hours.', 'Cell lysates were analyzed by thedualluciferasereportergeneassay(Promega)with Renilla\\nluciferase serving as a normalization factor.', 'Rodent diet preparation\\nForin vivostudies, 1.25% of GLSF powder was incorpo-\\nratedintomousedietsfororaladministration.Themodi-fiedanimaldietwasorderedthroughNewcoDistributors,Inc (Rancho Cucamonga, CA).', 'The formulation included98.45% Laboratory Rodent Diet #5001, 1.25% GLSF, and\\n0.3% color dye.', 'The calculation of the drug was based on\\nanaveragedailyintakeof4gpermouse.Foodconsump-tion for each group was monitored during the study andi tw a sc o n fi r m e dt h a tt h ed o s eo fG L S Fw a s ∼2.0 g/kg.', 'Animal experiment\\nAll animal studies were carried out in strict accordance\\nwith the recommendations in the Guide for the Careand Use of Laboratory Animals of the National Institutesof Health and approved by the Western University ofHealthSciencesInstitutionalAnimalCareandUseCom-mittees.Apilotstudywasconductedusingfivemaleandsix female BALB/c mice.', 'CT26 cells (3 ×10\\n6) in 100 μl\\nserum free media were injected subcutaneously into theright and left flanks of 6-week-old mice (Charles River,Burlington, MA).', 'At 12 days after implantation, treat-ments began.', 'The dose of GLSF (2 g/kg) was given by oralgavaging once a day, M-F, for a total of nine oral doses.Mice were treated with vehicle control or GLSF 2.0 g/kg(n=3–4).', 'For a rodent diet-based drug regimen study, 4-week-\\noldmicewererandomlydividedintofourgroups.Groups1a n d3( n =8) were fed with standard diet while groups\\n2 and 4 were fed with diet containing GLSF (n =4) for\\n4 weeks before cell inoculation.', 'When the mice were 8weeks old, 5 ×10\\n5cells in 100 μl serum free media were\\ninjected subcutaneously into the right and left flanks ofmice.ThedoseforGLSFobtainedfromdietconsumptionwasestimatedtobe2.0g/kg,asforthepilotstudy.Groups3and4weretreatedwithasinglei.v .doseofabraxane(20mg/kg) (on Day 13 after tumor inoculation).', 'The tumorvolumewascalculatedaccordingtotheformulation:Vol-ume=(width)\\n2×length/2.RNA extraction, library preparation, and\\nnext-generation sequencing\\nTumors from the rodent diet-based drug regimen study\\nwere dissected, snap frozen, and stored at −80◦C.', 'The\\ntotal RNA was extracted from the tumor tissues usingTRIzol reagent (Invitrogen, Grand Island, NY) and aRNeasy Mini Kit (Qiagen, Germantown, MD).', 'The qual-ityofRNAsampleswasdeterminedwithanAgilent2100Bioanalyzer.', 'A total of eight RNA samples (four sam-ples per treatment, two groups) were sent to FulgentGenetics (Temple City, CA) for library preparation andsequencing.', 'Briefly, the library was constructed usingthe NEBNext\\nR/circlecopyrtPoly(A) mRNA Magnetic Isolation Mod-\\nule+NEBNext R/circlecopyrtUltraII Directional RNA Library Prep\\nKit (New England Biolabs, Ipswich, MA).', 'The RNA-seqlibraries were sequenced using an Illumina HiSeq 4000with 150 bp, paired-end, at a minimum depth of total 60million reads per sample.', 'Computational RNA-seq data analysis\\nRaw data were converted into fastq files by Illu-mina bcl2fastq2 v2.20.', 'Read quality was assessed usingFastQC.', 'The sequence reads were mapped to mouse ref-erence genome GRCm38 using the Edico Genome Dra-gen aligner with default settings.', 'Duplicate reads, asmarked by the Dragen aligner, were removed before cov-erage analysis.', 'The aligned bam files were processed byHTSeq for gene quantification.', 'Only genes with countsper million (CPM) values above 0.5 in at least two sam-ples were included in the differential expression anal-ysis.', 'Differentially expressed genes were identified byR package EdgeR (version 3.24.3).', 'Briefly, read countswere fitted into negative binomial distribution.', 'The dif-ferential analysis was carried out using quasi-likelihoodF-test.', 'Genes with Pvalues <0.05 and absolute log\\n2-fold change above 1 were considered to be signif-icantly differentially expressed.', 'Pathway analysis andprediction based on significant DEGs were performedusing Ingenuity Pathway Analyses (IPA; Ingenuity\\nR/circlecopyrt\\nSystems, www.ingenuity.com ).', 'Global MDS, hierarchical\\nclustering heat map, and volcano plot were generatedusing plotMDS, heatmap.2, and plotMD functions in R,respectively.', 'Statistical analysis\\nDataareexpressedasmean ±standarddeviationunless\\nstated otherwise.', 'All plots were made using GraphPadPrism version 7.0 (GraphPad Software, Inc, La Jolla, CA),and statistical analysis was conducted using NCSS 2007(NCSS, LLC, Kaysville, UT).', 'The specific tests are detailedin the text and figure legends.', 'For all the statistical anal-ysis, means were indicated to be statistically differentwhenP<0.05.Antitumor activity of Ganoderma lucidum 235\\nFigure 1.', 'Effects of GLSF gastrointestinal (GI) juice extract on the growth inhibitory effects of paclitaxel in colorectal cancer cells.', '(A) SRB\\ncytotoxicity assay was used to determine the effects of paclitaxel, GLSF, alone or in combination in the mouse colon cancer CT26 cells.', '(B) Thecytotoxicity of paclitaxel, GLSF, alone or in combination in human colon cancer HCT-15 cells.', '(C) The effects of paclitaxel, GLSF alone or in\\ncombination in human colon cancer HT-29 cells.', '∗:P<0.05,∗∗∗:P<0.001, comparing groups treated with paclitaxel alone with other groups,\\nas determined by ttest.', 'Results\\nIdentification of optimal extraction methods for\\nGLSF\\nAs there is no standardized preparation approach for GL\\nandrelatedproducts,wetriedseveralmethodsforprepa-ration of GLSF extracts, including the use of ethanol,methanol, hot water, as well as artificial gastrointesti-naljuice.Tocomparethepharmacologicactivityoftheseextracts, we examined their ability to inhibit cancer cellgrowthin vitro.', 'The extracts were examined on a panel\\nof cancerous and non-cancerous cell lines derived fromdifferenttissuesoforigin(PC3,MDA-MB-231,A375,H460,HT-29, HepG2, NCI-N87 and NHDF) using a sulforho-damine B (SRB) colorimetric assay.', 'Comparison of thecytotoxicity datafor thefour extracts in melanoma A375or breast cancer MDA-MB-231 indicated that the gas-trointestinal juice and hot water extracts exhibited rel-atively higher potencies of cancer cell growth inhibition(Supplementary Figs.', 'S1 and S2).', 'The viability data andIC\\n50values in these cell lines for gastrointestinal juice\\nand hot water extracts are summarized in Supplemen-tary Table S1.', 'Additionally, our previous study showedhigher contents of triterpenes from GLSF in the gas-trointestinal juice extract compared to the chloroformextract.', '22As the gastrointestinal juice extract showed\\nthehighestpotencyonthemajorityofcancercelllines,itwasselectedforchemicalfingerprintanalysisandexam-ined for in vitroanticancer effects.', 'Chemical fingerprint analysis of gastrointestinal\\njuice extract of GLSF by HPLC\\nBased on a literature search for components of GL\\nproducts, 13 compounds were selected as chemicalmarkers for GLSF.', 'A HPLC-DAD fingerprint method has\\nbeen developed22and was used to quantify these mark-\\ners in the extract of GLSF.', 'The contents of 13 com-pounds are shown in Supplementary Table S2.', 'Amongthe 13 assessed compounds, only ganoderol A wasnot detectable; the other 12 compounds were identi-fied with substantial amounts.', 'The inter-batch varia-tion was below 16.5% for all these compounds.', 'Althoughthe chemical markers mainly consisted of triterpenes(polysaccharidesnotincluded),theresultsindicatedthatat least for selected active components GLSF was effi-ciently and consistently extracted.', 'Effects of GLSF extract on chemosensitivity of\\ncolorectal cancer\\nPaclitaxel (taxol) exhibited a modest inhibitory effect on\\nCT26 cells (IC 50was 0.45 ±0.02μM), while GLSF did\\nnot cause cytotoxicity in CT26 at concentration up to3 mg/ml.', 'However, the cells that were co-treated withtaxol (0.125 μM) and GLSF (0.3 mg/ml) showed signifi-\\ncantly increased cytotoxic effects compared to the taxoltreatment alone ( P<0.05) (Fig.', '1a).', 'We observed a dose-\\ndependent chemosensitizing effect of GLSF, where ahigher concentration (3.0 mg/ml) showed an increasedchemosensitizing effect compared to GLSF at 0.3 mg/ml(P<0.001).', 'Similar effects were observed for combined\\ntreatment of GLSF (0.3 or 3.0 mg/ml) with a higher con-centration of taxol (0.5 μM).', 'To confirm the nature of the\\ninteraction between GLSF and taxol, combination anal-yses were performed with the Combination Index (CI)method,\\n23,24using drug combinations at various ratios.', 'A synergistic interaction was produced (CI =0.04) when\\ntaxol 0.125 μM was combined with GLSF at 3.0 mg/ml\\n(CI values <1 indicate synergistic activity).', 'To confirm236Mandy M. Liu et al.', 'Figure2.', 'EffectsofGLSFGIjuiceextractonapoptosisinducedbypaclitaxelinmousecolorectalcancerCT26cells.', '(A)Cellapoptosiswasassessed\\nby Annexin V/PI double staining which was detected by flow cytometry FACS analysis; Annexin-V-FITC staining in y axis (FL1) and PI in x axis\\n(FL3).', '(B) The Annexin V/PI assay was performed three times and the average percentage of viable, early apoptosis, late apoptosis, and necrosis\\npopulations of cells were plotted.∗∗:P<0.01,∗∗∗:P<0.001, compared with vehicle control group, as determined by ttest.', 'these results in human colorectal cancer cell lines, SRB\\nassayswereperformedonhumancolorectalcancerHCT-15 and HT-29 cells, treated with taxol and GLSF aloneor in combination.', 'The IC\\n50in HCT-15 treated with taxol\\nwas 0.40 ±0.002 μM and similar to the CT26 cells, GLSF\\ndid not cause any cytotoxicity in HCT-15 cells up to3 mg/ml concentration.', 'The cells that were co-treatedwith taxol (0.25 μM) and GLSF (0.11–3 mg/ml) showed a\\ndose-dependent increase in cytotoxic effects comparedto the taxol treatment alone ( P<0.05 for GLSF 0.11\\nmg/ml;P<0.001 for GLSF 1.0 and 3.0 mg/ml) (Fig.', '1b).', 'Although HT-29 cells were much more sensitive to taxol(IC\\n50=0.0035 ±0.001 μM) than CT26 and HCT-15 and\\nGLSF at 3 mg/ml alone was also nontoxic, co-treatmentwith GLSF and taxol did not demonstrate increased ordecreased effect on cell viability (Fig.', '1c).', 'Therefore, the\\nchemosensitizing effect for GLSF is variable in differentcancer cell lines.', 'Effects of GLSF extract on taxol-induced\\napoptosis in CT26 cells\\nThedegreeofapoptosisinducedbyGLSF(3mg/ml),taxol\\n(0.125 μM), or their combination was evaluated in CT26\\ncells.', 'The cells were incubated for 72 hours with com-binations of drugs and the level of apoptosis was quan-tified by an Annexin-V binding and PI staining assay.As shown in Fig.', '2, GLSF treatment slightly increased\\nthe viable cells compared to vehicle control ( P>0.05).', 'Taxol decreased the viable cell population to 60.1 ±6.2%\\n(P>0.05).', 'When the cells were exposed to a combina-\\ntion of GLSF and taxol, there was a significant reductionof viable cells ( P<0.001) (53.7 ±1.6% of viable cells in\\ncontrol) and increase in the number of early apoptoticcells (P<0.01).', 'This result is consistent with those data\\nobtained by SRB in CT26 cells (Fig.', '1a), indicating that\\nthe co-treatment with non-toxic concentration of GLSFincreased the anticancer potency of taxol via enhancingapoptosis in CT26 cells.', 'Effects of GLSF extract on P-glycoprotein (MDR1)\\nactivity in K562/DOX cells\\nPrevious studies have shown that both CT2625and HCT-\\n1526express the efflux transporter P-glycoprotein (P-gp\\nor MDR1, ABCB1gene), which is part of the mechanism\\nfor their intrinsic resistance to taxanes and other P-gp substrate drugs such as daunorubicin (DNR).', 'There-fore, we examined whether GLSF was able to inhibitP-gp-mediated drug efflux from the multi-drug resis-tantcelllineK562/DOX,whichoverexpressesP-gp,usingdaunorubicin (DNR) as a fluorescent substrate.', '20Few\\ncells were positive for DNR accumulation without P-gp inhibitor (Fig.', '3a).', 'Co-treatment with a known P-gp\\ninhibitor PSC833 (10 μM) as a positive control greatly\\nincreased DNR positive cells to nearly 100%.', 'However,GLSF (1, 2 and 3 mg/ml) only slightly increased DNRaccumulation (Fig.', '3b).', 'Although the treatment effect\\nof GLSF (2 mg/ml) was significant ( P<0.05), compared\\nto the positive control PSC833, the degree of inhibitionwas negligible.', 'This result suggests that the chemosen-sitizing activity of GLSF is not attributed to P-gpinhibition.Antitumor activity of Ganoderma lucidum 237\\nFigure 3.', 'Effects of GLSF GI juice extract on P-glycoprotein activity in K562/DOX cells and NF- κB activity in HEK-293 cells.', '(A) Flow cytometry\\nanalysisofDNRaccumulationincellsincubatedwithDNR,treatedwithorwithoutPSC833(10 μM)orGLSF.Representativeflowcytometrydata\\nare shown.', '(B) Graphs showing percentage of cells that were positive for DNR in cell samples co-treated with GLSF and DNR in comparisonwith those co-treated with 10 μM PSC833 and DNR.', 'The data are presented as the mean ±SD from 3–6 independent experiments.', '∗:P<0.05\\ncomparedtotheDNRonlygroup.', '(C)EffectsofGLSFonTNF- α-inducedNF- κBpromoteractivity.HEK-293cellstransfectedwithNF- κBluciferase\\nreporter and Renillacontrol reporter were treated with vehicle, TNF- α(10 ng/mL), GLSF (0.3, 1.0, 2.0 mg/mL) combined with TNF- αfor 5 hours.', 'Data are expressed as mean +/- SEM; n =3–6.∗:P<0.05 as per one-way ANOVA.', 'Effects of GLSF extract on NF- κBp r o m o t e ra c t i v i t y\\nin HEK-293 cells\\nWe next evaluated the effect of GLSF on TNF- αpro-\\nmoted NF- κB activation.', 'The HEK-293 cells were trans-\\nfectedwithNF- κB-lucfireflyluciferasereporterconstruct\\nandaplasmidencodingthe Renillaluciferaseforthedual\\nluciferase assay.', 'The transfected cells were treated withvehicle (control) or GLSF extracts at 0, 0.3, 1.0, or 2.0mg/ml, followed by a 5-hour co-incubation with TNF- α\\n(10 ng/ml).', 'As expected, TNF- αstrongly stimulated NF-\\nκBa c t i v i t y( F i g .', '3c).', 'The promoter activity stimulated\\nby TNF- αwas inhibited significantly by the GI extract\\nat 2.0 mg/ml in a dose-dependent manner (Fig.', '3c).', 'As NF- κB plays a role in promoting carcinogenesis ofvarious types of cancer\\n27and conferring chemoresis-\\ntance to paclitaxel,28inhibition of NF- κBb yG L S Fm i g h t\\npartly explain the in vitrochemosensitizing activity and\\nthein vivoactivity described below.', 'Anticancer efficacy of GLSF oral administration to\\nmice bearing murine colorectal cancer tumorCT26\\nTo evaluate the anticancer activity of GLSF invivo,as y n -\\ngeneic model of colorectal cancer-bearing BALB/c micewasused.Wefirstlyconductedapilotstudyusingasmallnumber of mice with two tumors (CT26) implanted ineach mouse (n =2 each gender specific group).238Mandy M. Liu et al.', 'Figure 4.', 'Effects of GLSF on tumor growth and apoptosis in a colorectal cancer syngeneic model.', '(A) The CT26 cells were subcutaneously\\nimplanted into the female BALB/c mice after the mice were fed with the control diet (groups 1 and 3) or diet containing GLSF (groups 2 and 4)for 4 weeks.', 'Groups 3 and 4 mice were treated with a single dose of abraxane\\nR/circlecopyrton Day 13.', 'Tumor volumes were measured on Days 13 and 19\\n(Day 0 was the day of tumor injection).∗:P<0.05 by Tukey-Kramer Multiple-Comparison test (n =8f o rG 1a n dG 2 ;n =4f o rG 3a n dG 4 ) .', '( B )\\nRepresentativephotosofmiceincontrolandGLSFgroups.(C)TumortissueswerestainedwithH&EorimmunohistochemicalstainingofKi-67.', '(D) Western blot analysis of PARP, cleaved PARP, and β-actin.', 'Representative gel images are shown.', 'Bar graphs represent the ratios of cleaved\\nPARP/total PARP.', '∗:P<0.05 as compared with the control group by ttest.', 'PARP, poly (ADP-ribose) polymerase.', 'Control n =5 tumors, GLSF n =4\\ntumors.', 'The treatment by oral gavage (2.0 g/kg, daily, Monday\\ntoFriday,ninedosesintotal)wasstartedonthe11thdayaftertumorimplantation.Althoughstatisticallyinsignif-icant, a trend of treatment effect was observed in tumorvolume in both males and females (Supplementary Fig.S3): the average tumor volumes in GLSF-treated micewere smaller than in untreated control.', 'In addition, themicedidnotlosebodyweightcomparedtoinitialweight,indicating the treatment was not toxic.', 'To explore the potential anticancer mechanism, the\\neffect of GLSF treatment on mouse spleen lympho-cyte proliferation induced by concanavalin A (Con A) orlipopolysaccharides (LPS) in vitrowas determined using\\nthe spleen samples obtained from the CT26 tumor-bearing mice.', 'Compared with non-tumor-bearing mice,proliferation of spleen T and B lymphocytes induced byCon A and LPS were strongly declined in tumor-bearingmice (Supplementary Fig.', 'S3).', 'However, treatment withGLSFofthesemiceincreasedspleenTandBlymphocyteproliferationinCT26-bearingmice,althoughthiswasnotstatistically significant.', 'These data indicate a potentialimmunomodulatory activity of GLSF, consistent with a\\nprevious report.', '4\\nTo confirm the anticancer activity of GLSF, BALB/c\\nmice were pre-treated with control diet (groups 1 and3) or modified diet containing GLSF (groups 2 and 4)\\n1 month before tumor implantation.', 'As GLSF showedantitumor effects in both genders in the pilot studyand the CT26 tumor was derived from female mice,\\n15\\nonly females were included in this experiment.', 'Abrax-ane treatment was given for groups 3 and 4 to observethe effects of combination treatments.', 'Two tumors wereimplanted in each mouse.', 'Consistent with the pilotstudy, GLSF treatment alone inhibited tumor growth(Fig.4a), although repeated measures ANOVA analysis\\ndid not show a statistically significant difference.', 'At theendoftheexperiment,100%ofthemicehadtwotumorsin the control group, while only 63% of mice in the GLSFgroup had two tumors, and two of the eight mice (25%)in the GLSF group did not show any tumors (Fig.', '4b).', 'The\\nTukey-Kramer post hoc analysis showed that on Day 19\\naftertumorinoculation,co-treatmentwithabraxaneandGLSF significantly suppressed tumor growth comparedwith the control group (Fig.', '4a).', 'Furthermore, tumors in\\nthecontrolgroup(group1)showedasignificantincreasewhen comparing tumor size on Day 13 and 19, whilegroups 2, 3 and 4 did not show time-dependent tumor\\nsize increase, confirming the treatment effect.', 'Tumor tissues dissected from the control and GLSF\\ngroups were subjected to hematoxylin and eosin (H&E)Antitumor activity of Ganoderma lucidum 239\\nFigure 5.', 'RNA-seqanalysisofCT26syngeneictumorsinmicetreatedwithcontroldietorGLSF-modifieddiet.', '(a)Multi-dimensionalscalingplot\\nof detected genes in GLSF treatment (T, red) and control group (C, green).', 'The distances correspond to leading log2 fold-changes between eachpairofsamples.', '(b)Volcanoplotsofdifferentiallyexpressedgenesbetweentreatmentandcontrolgroups.Thereddotsindicateup-anddown-\\nregulatedDEGswith P<0.05andabsolutelog2FC >1.', '(c)Heatmapoftop30significantlydifferentiallyexpressedgenesbetweentreatment(T)\\nand control groups (C).', '(d) Genes that are up- and down-regulated in treatment group (compared to control) are displayed within red or greennodes, respectively.', 'The predicted inhibited biology effects are presented in blue nodes.', 'Blue (predicted to be inhibited) or gray (undetermined\\ndirection) dash lines represent relationships with causal consistency.', 'staining.TheimageofH&Esectionsindicatedthattumor\\ntissues from both groups consisted of a morphologicallysimilardifferentiatedadenocarcinoma.However,tumorsin the GLSF group showed a conspicuous increase ofnecrosisinallthefourtumorsamplessubmittedforH&Estaining (representative images are shown in Fig.', '4c).', 'Ki-\\n67 staining showed that the tumors in the control groupconsisted entirely of one cell type with high prolifera-tive index, while the tumors in the GLSF group demon-strated nonspecific staining of necrotic/apoptotic cellsbutshowedfainterstainingoffewerKi-67positiveviablecells (Fig.', '4c).', 'Western blot analysis was used to examine the\\nexpression of the apoptosis marker PARP and cleavedPARP in tumor tissue lysates.', 'The expression of cleavedPARP was markedly increased in the GLSF treatmentgroup compared with that in the control group (Fig.', '4d),\\nandthisdifferencewasstatisticallysignificant( P<0.05),\\nconfirming that GLSF treatment induced apoptosis intumor tissues in vivo.RNA-seq profiling of GLSF-treated tumors\\nTo explore the mechanism underlying the treatment\\neffectsbyGLSF,RNA-seqanalysiswasperformedtocom-pare the gene expression profiles between tumors iso-lated from mice subjected to the control diet (n =4)\\nor GLSF modified diet (n =4).', 'On average, 40 million\\npair-end reads pairs per sample were generated, withall of their uniquely mapping rates above 91%.', 'Over-all, RNA sequencing detected 25 051 genes across eightsamples, of which 13 790 genes had a CPM value above0.5 in at least two samples.', 'A multi-dimensional scal-ing (MDS) plot showed a trend of clustering separationbetween treated group and control group (Fig.', '5a).', 'Out of\\nthe 13790 genes, 53 were identified as significant differ-entially expressed genes (DEGs) between the two groupswith a absolute log2 fold-change >1a n da Pvalue <0.05\\n(SupplementaryTableS3).Thetop12up-regulatedgenesand top 10 down-regulated genes (selected based on thelowestPvalue) are presented in Tables 1and2.Al o g 2240Mandy M. Liu et al.', 'Table 1.', 'Top 12 up-regulated genes in tumors from mice treated with GLSF compared to control group.', 'Gene ID Gene name Log FC Pvalue\\nItga10 Integrin, alpha 10 1.07 9.34E-05\\nZbtb16 Zinc finger and BTB domain containing 16 2.07 2.79E-04\\nGm807 Predicted gene 807 1.26 9.47E-04Lvrn Laeverin 1.17 1.07E-03\\nGm6093 Predicted gene 6093 1.63 1.49E-03Hrct1 Histidine rich carboxyl terminus 1 1.33 2.15E-03Aldh1a1 Aldehyde dehydrogenase family 1,\\nsubfamily A11.08 2.59E-03\\nInpp5j Inositol polyphosphate 5-phosphatase J 1.67 3.06E-03\\nRcan2 Regulator of calcineurin 2 1.00 3.39E-03\\nIfng Interferon gamma 1.09 3.52E-03\\nRetnla Resistin like alpha 2.52 3.63E-03\\nFmo2 Flavin containing monooxygenase 2 1.35 7.23E-03\\n∗Log FC (log2 Fold change) larger than 1 indicates higher expression in GLSF-treated tumors.', 'Table 2.', 'Top 10 down-regulated genes in tumors from mice treated with GLSF compared to control group.', 'Gene ID Gene name Log FC Pvalue\\nIl1b Interleukin 1 beta −1.31 9.57E-06\\nIl11 Interleukin 11 −1.09 4.89E-04\\n4930565N06Rik RIKEN cDNA 4930565N06 gene −1.06 6.84E-04\\nNppb Natriuretic peptide type B −1.44 7.72E-04\\nPtgs2 Prostaglandin-endoperoxide synthase 2 (Cox-2) −1.11 1.18E-03\\nMmp10 Matrix metallopeptidase 10 −1.51 1.31E-03\\nMmp13 Matrix metallopeptidase 13 −1.16 1.68E-03\\nStamos Signal transducing adaptor molecule (SH3 domain and\\nITAM motif) 1, opposite strand−1.13 1.82E-03\\nCxcl1 Chemokine (C-X-C motif) ligand 1 −1.56 2.07E-03\\nMmp12 Matrix metallopeptidase 12 −1.03 4.01E-03\\n∗Log FC (log2 Fold change) smaller than −1 indicates lower expression in GLSF-treated tumors.', 'fold-change lower than −1 indicated that the expression\\nof the gene was decreased by GLSF treatment, whereasa log2 fold-change more than 1 suggested an increasedgene expression in tumor tissues derived from GLSFtreatment.', 'A heat map of the top 30 significant DEGswas plotted with unsupervised hierarchical clustering(Fig.5b).', 'A volcano plot was generated with the signifi-\\ncant DEGs highlighted in red color based on their Pval-\\nues and fold changes (Fig.', '5c).', 'It is notable that many\\nof these GLSF down-regulated genes are involved in NF-κB-regulated inflammation, such as IL-1 β(Il1b) and IL-11\\n(Il11)( T a b l e 2,F i g .5b).', 'To explore the possible biological functions linked\\nwith these DEGs, ingenuity pathway analysis (IPA) wasperformedtoidentifycanonicalpathways,upstreamreg-ulators, diseases and functions that are associated withGLSFtreatment.BasedontheratioofthenumberofDEGsin our dataset to the total number of reference genesin the specific pathways in the IPA knowledge bases, aFisher’s exact test was used to determine the canonicalpathways associated with the treatment effect.', 'Using acutoffPvalue <0.05, a total of 58 canonical pathways\\nwere identified as being significantly enriched based onthe DEGs (Supplementary Table S4).', 'The most affectedpathways were “Granulocyte adhesion and diapedesis”and “Agranulocyte adhesion and diapedesis”, which areknown immune/inflammatory pathways.Upstream analysis through IPA was used to predict\\nthe upstream regulators potentially causing changesin gene expression and regulation direction based onthe DEGs.', 'Predicted significantly activated and inhib-ited regulators are listed in Supplementary Table S5 ( P\\nvalue <0.05,|Z-score |>2).Thetwosignificantlyactivated\\nupstream regulators were alpha-catenin and TP53, both\\nof which are known tumor suppressors for colon cancer.On the other hand, the most inhibited upstream regula-tors were factors that play critical roles in inflammatoryresponse and tumorigenesis, including TNFSF12, KRT17,IL17RA, TNF, and IL17A.', '”Diseases and functions” in IPA was used to predict\\naffected biology and its regulation direction associatedwith GLSF treatment.', 'Using a cutoff of Pvalue <0.05,\\n|Z-score |>2, there was no significantly activated biology\\neffect identified, while the top five significantly inhib-ited biological effects are presented in Fig.', '5d, which\\nincluded “Cancer”, “Epithelia neoplasm”, “Carcinoma”,“Secondary tumor”, “Frequency of tumor”.', 'The networkof the top five inhibited biology effects in the GLSF treat-ment group, compared to the control, and the contribut-ing DEGs were displayed in Fig.', '5d.', 'Quantitative RT-PCR\\nanalysis confirmed that GLSF inhibited the expressionof selected inflammatory genes, cyclooxygenase-2 ( Ptgs2\\norCox-2)(P<0.05), interleukin-1 β(Il1b)(P<0.01), and\\ninterleukin-6 ( Il6)(P<0.01) (Fig.', '6).Antitumor activity of Ganoderma lucidum 241\\nFigure 6. qRT-PCRresults fromtumor samplesofcontrol or GLSF groupsfor(A) COX-2,(B) IL-1 β,and(C)IL-6.', 'β-actin wasused asnormalization\\ncontrol and data are expressed as mean with 95% CI.', 'n =8 tumor samples from control group.', 'n =10 tumor samples for GLSF.∗:P<0.05;∗∗:\\nP<0.01 via a Mann-Whitney U approximation without correction for normality.', 'Discussion\\nThe present study examined the in vitroandin vivoanti-\\ncancer activity of GLSF, which contains a mixture of bro-ken spores and fruiting bodies of mushroom.', 'As differ-entmethodsofextractionaffecttherelease,bioavailabil-ity and pharmacological activity of active components,extracts of GLSF were prepared in ethanol, methanol,hot water, or artificial gastrointestinal juice and wereexamined in a panel of cell lines.', 'We found that extractsprepared using gastrointestinal juice had the highestpotencyofcellgrowthinhibitionandthereforewereusedin ourin vitrostudies.', 'This extraction method is physi-\\nologically relevant to clinical application.', 'Although themethod of extraction has been used for ginseng\\n29and\\nnotoginseng (“San-Qi”),30to our knowledge, this is the\\nfirststudyusingartificialgastrointestinaljuicetoprepareGLextracts.', 'Invitro,GLSFaloneshowedmodestcytotoxi-\\ncityoncoloncancercells,whichisconsistentwithapre-viousstudyindicatingthatthedirectanticancereffectofGL is limited.', '3However, when GLSF was combined with\\ntaxol, it induced stronger tumor inhibition and apopto-sis, suggesting that GLSF may be used as a chemosen-sitizer (Fig.', '1a and b).', 'As GLSF is not a P-gp inhibitor\\n(Fig.3aandb),itschemosensitizingmechanismremainstobedetermined.Onepossiblemechanismisthroughits\\ninhibitory activity against NF- κB signaling, suggested by\\nthe dual luciferase assay (Fig.', '3c).', 'Consistently, previous\\nstudieshaveshownthattriterpeneganodericacidC1iso-latedfromGLinhibitedinflamedCrohn’sdiseasecolonicm u c o s aa sar e s u l to fb l o c k a g eo fN F - κB.', '31\\nIn vivo, GLSF alone or in combination with abrax-\\nane (nanoparticle albumin bound paclitaxel or nab-paclitaxel) induced tumor growth inhibition and apop-tosis (Fig.', '4).', 'The syngeneic tumor model used in the\\nstudywasmurinecolorectalcarcinomacelllineColorec-talTumor#26(CT26).', '15CT26cellswerederivedbyexpos-\\ning BALB/c mice to the chemical carcinogen N-nitroso-N-methylurethane, resulting in a rapid-growing grade IVcarcinoma that is easily implanted and readily metasta-sizes.', '32AsCT26tumorintheimmunocompetentBALB/c\\nmiceprovidesasyngeneicmodel,itisfrequentlyusedfordeveloping and testing immunotherapeutic agents.', '15,33\\nComparedwith invitrodata,alarge invivoeffectsuggests\\nthat an intact immune system or tumor microenviron-ment may be essential for the pharmacological action ofGLSF.', 'One limitation for these in vivostudies was that a\\nsingle dose was used (2.0 g/kg), which was derived frompublished data of GL.', '34–36Dose-response studies should\\nbe considered in the future.', 'Although taxol or abraxane242Mandy M. Liu et al.', 'are effective to many types of cancer such as breast or\\novariancancer,theirapplicationincolorectalcancerhasbeenlimitedbecauseofintrinsicresistance.', '37Thus,GLSF\\nmay be used as a chemosensitizer for taxanes.', 'The ratioof GLSF versus taxol or abraxane should be optimizedin future studies to identify the optimal combinationalregimen.', 'Further studies comparing therapeutic effectsof GLSF in different tumor models and with other anti-cancer agents should be considered.', 'To gain mechanistic insight, RNA-seq was performed\\nto evaluate genome-wide transcriptome changes asso-ciated with GLSF treatment.', 'Based on the differentiallyexpressedgenes(DEGs),expressionlevelsofIL-1 βandIL-\\n11, genes encoding for cytokines in the tumor microen-vironment that promote colorectal cancer progression,were decreased by GLSF.', 'These cytokines, also includ-ing Il-6 which was not picked up by RNA-seq analysisb e c a u s eo fl o wC P Mv a l u e s ,a r ep r o d u c e db ym y e l o i dand T-helper interleukin (IL)-17-producing (Th17) cellsthat are accumulated in the tumor microenvironment.', '38\\nBecause these cytokines directly or indirectly activateneoplastic epithelium, therapies that target their acti-vation, for example anti-IL-11 therapy, have been pro-posed to treat colorectal cancer.', '38In addition, the GLSF\\ndown-regulated Ptgs2,encoding for Cox-2, known to\\nbe an inflammatory mediator that promotes colorectalcancer.', '39RT-PCR results confirmed that in GLSF-treated\\nmice the tumor cell expression of Cox-2, IL-1 β,a n dI L - 6\\nwas significantly down-regulated at mRNA level (Fig.', '6).', 'These results suggest that inflammation is a potentialtargetfortreatmentofsometypesofcolorectal cancer.', '40\\nConsistent with the luciferase assay data (Fig.', '3c), these\\nGLSF-down-regulated genes are under the control of NF-κB transcription factor.', 'Furthermore, CT26 cells harbor\\nthe constitutively activating mutant KRAS,\\n15which has\\nbeen shown to trigger the production of several inflam-matory mediators including IL-6,\\n41IL-1β42and associ-\\nated with COX-2.43Interestingly, NF- κBi sa c t i v a t e di n\\nKRAS-mutated cancer and has been suggested as a tar-\\nget to treat KRAS-induced cancer.44,45In addition, a pre-\\nvious study showed that CT26 cells not only secret IL-6 ,b u ta l s ot h eg r o w t ho fC T 2 6t u m o rd e p e n d so nI L -6.', '46,47Thus, these inflammatory factors, many of which\\na r eu n d e rt h er e g u l a t i o no fN F - κB, are very likely tar-\\ngets of a GL-mediated anticancer effect.', 'These resultsalso suggest that inflammation-associated cancers andKRAS-driven tumors might be more likely to respondto GLSF.', 'As inhibiting KRAS directly is very challenging,approaches to disrupt downstream signaling pathwaysmay be a better approach to treat these types of highlyaggressive cancer.', '48\\nAnother down-regulated gene in the GLSF-treated\\ngroup was the inflammatory chemokine Cxcl1, which\\nis involved in enhanced metastatic potential of coloncancer by increasing cell migration, matrix metal-loproteinases (MMP) expression, and epithelial-to-mesenchymal transition and therefore has a negativeprognostic impact to the clinical outcome.', '49Probably\\nassociatedwith Cxcl1down-regulation,threeMMPgeneswere among the top 20 down-regulated genes: MMP10,\\nMMP13,a n dMMP12.', 'These genes and their products\\nhave been identified as negative prognostic markersin colon cancer patients.', '50,51GLSF down-regulated\\nNppb, encoding for natriuretic peptide B, which has\\nbeen shown to be a key oncogene candidate for colontumors and suggested as one of the early biomarkers forprevention in the clinical setting.', '52\\nThe GLSF-up-regulated genes have various functions.', 'Although most of these genes have not yet been asso-ciated with colon cancer, they may contribute to GLSF-inducedanti-canceractivity.Someofthemmaybetumorsuppressor genes, for example, Fmo2(flavin containing\\nmonooxygenase 2) plays a role as a tumor suppressor inlung cancer.', '53The lower level of Inpp5j, which encodes\\ninositol polyphosphate-5-phosphatase J, has been asso-ciated with more aggressive tumors and poorer sur-vival of cutaneous squamous cell carcinoma,\\n54and was\\nfound to be deficient in oropharyngeal squamous cellcarcinoma.', '55Itga10, a top DEG of the GLSF-up-regulated\\ngenes,encodesintegrinsubunit α10,whichbindstocol-\\nlagen and plays a role in cell adhesion and cell-surfacemediated signaling.', 'Although the activity of increasedexpression of Itga10by GLSF is unknown, the interac-\\ntionofintegrinandcollagenmaymediateananti-tumorimmune response.', '56\\nThe canonical pathway analysis highlighted “Gran-\\nulocyte adhesion and diapedesis” and “Agranulocyteadhesion and diapedesis” as the most significantly reg-ulated pathways influenced by GLSF treatment.', 'Bothpathways contain the same set of genes, mainly MMPs,and have been associated with immunity and inflam-mation,\\n57as well as tumor invasion and metastasis.58\\nThese results support the notion that these two path-wayswereinvolvedininflammationassociatedwithcol-orectal cancer, as previously reported,\\n59and may con-\\ntain the molecular targets that underlie the anticancereffect of GLSF.', 'Based on the DEGs between the treat-mentandcontrolgroups,IPApredictedtheupstreamreg-ulators and their activation states which might resultin these gene expression changes.', 'Several inflamma-tory cytokines were at the top of the inhibition listsuch as TNFSF12, TNF, and IL17A.', 'On the other hand,tumorsuppressorssuchasalpha-cateninandTP53wereactivated (activation z-score >2) according to the pre-\\ndiction.', 'This prediction further implied that GLSF mayelicit anti-tumor activity through its anti-inflammatoryeffects.Morespecifically,onepossiblemechanismisthatGLSF treatment resulted in an inhibition of the NF-kBpathway, a shared target of the aforementioned pre-dicted upstream regulators, which eventually may leadtotumorsuppression.Furtherstudiesarerequiredtoval-idate this hypothesis.', 'Based on the IPA prediction, therewasnosignificantlyactivatedbiologyeffectwhilethetopfive inhibited biology effects were all related to “Cancer”anddisplayedthenetworkoftumorsuppressioninducedby GL treatment (Fig.', '5d).', 'These results implied a pos-\\nsible mechanism of GL’s anti-tumor effect as alleviatingthe immune suppression in colorectal tumor tissue byAntitumor activity of Ganoderma lucidum 243\\npromoting the recruitment of anti-tumor immune cells,\\nor by inhibiting immune suppressive cells such asmyeloid derived suppressor cells.', 'This hypothesis alignwell with the observation that GLSF alone showed lit-tle cytotoxicity in vitrobecause of a lack of immune sys-\\ntem.', 'It is notable that the in vivostudies used GLSF pow-\\nder while in vitro assays used extract.', 'Identification of\\nthe active components that are responsible for theseobserved effects requires further investigation.', 'In conclusion, this study evaluated the anticancer\\neffects and possible underlying anticancer mechanismof GLSF using both human and murine colorectal can-cer cell lines, and examined GLSF alone or in combi-nation with a commonly used chemotherapeutic agentpaclitaxel.', 'InvitrodatarevealedthatalthoughGLSFalone\\nhad little anticancer effect, it had a chemosensitiza-tion effect in certain colon cancer cells and that NF- κB\\nplayed a major role in mediating the in vitroanticancer\\neffectofGLSF.Immunocompetentmicecarryingthesyn-geneic tumor CT26 were used for investigating the in\\nvivoanticancer activity of GL.', 'RNA-seq and bioinformat-\\nics analysis, for the first time, indicated that GLSF tar-geted inflammation and carcinogenesis and confirmedt h er o l eo fN F - κB as the potential target.', 'Advanced col-\\norectal cancer shows inherent resistance to paclitaxel orrelated chemotherapeutic agents.', 'With the use of GLSF,a non-toxic natural product, the antitumor effects ofchemotherapy may be enhanced.', 'GSLF alone also hadanticancer activity in vivothrough an inhibitory effect\\nagainst inflammation, NF-kB, and/or KRAS activation.', 'Supplementary data\\nSupplementary data are available at PCMEDI online.', 'Data and material availability\\nAll materials, data, and associated protocols are avail-\\nable to readers without undue qualifications in materialtransfer agreements.', 'The GLSF is available from the Bei-jing Tong Ren Tang Chinese Medicine Co., Ltd.', 'Author contributions\\nY.H.', 'conceived and designed the study.', 'M.L.', 'carriedout most in vitro andin vivo experiments and ana-\\nlyzed the data; T.L.', 'and C.W.', 'analyzed the RNA-seqdata and revised the manuscript; B.A.', 'conducted sta-tistical analysis; S.Y.', 'and Z.W performed HPLC finger-print analysis; C.P.', 'and R.O.', 'performed the pathologyanalysis; B.Z., W.W., X.L., Y.Z.', 'and Y.H.', 'coordinated theexperiments, wrote and reviewed the manuscript.', 'Allauthors read and approved the final manuscript.', 'C.W.submitted the manuscript.', 'Acknowledgements\\nWe would like to thank Lily Kong Lim, A.S.C.P.', '(H.T.', '),at the Beverly Hospital for preparing the formalin-fixedparaffin-embedded tissues and H&E staining.', 'The GLSF\\nis available from the Beijing Tong Ren Tang ChineseMedicine Co., Ltd.', 'This study was funded by a con-tract grant (YH) from the Beijing Tong Ren Tang ChineseMedicineCo.,Ltd.Thisstudywasalsopartiallysupportedby Loma Linda University (LLU) GCAT grant (CW).', 'Conflict of interests\\nB.Zhou,W.Wu,X.LiandY.Zhangareemployeesorcon-sultants of the Beijing Tong Ren Tang Chinese MedicineCo., Ltd.', 'The other author(s) declare no competing inter-ests.', 'Besides, as an Editorial Board Member of Precision\\nClinicalMedicine ,thecorrespondingauthorCharlesWang\\nwasblindedfromreviewingandmakingdecisiononthismanuscript.', 'References\\n1.', 'SiegelRL,MillerKD,JemalA.Cancerstatistics,2016.', 'CACan-\\ncer J Clin 2016;66:7–30.', 'doi:10.3322/caac.21332.', '2.', 'Hyodo I, Amano N, Eguchi K, et al.Nationwide sur-\\nvey on complementary and alternative medicine in\\ncancer patients in Japan.', 'J Clin Oncol 2005;23:2645–54.', 'doi:10.1200/JCO.2005.04.126.', '3.', 'Sanodiya BS, Thakur GS, Baghel RK, Ganoderma lucidum: a\\npotent pharmacological macrofungus.', 'Curr Pharm Biotechnol\\n2009;10:717–42.', 'doi: 10.2174/138920109789978757.', '4.', 'Wang PY, Zhu XL, Lin ZB.', 'Antitumor and Immunomod-\\nulatory Effects of Polysaccharides from Broken-Spore\\nof Ganoderma lucidum.', 'Front Pharmacol 2012;3:135.\\ndoi:10.3389/fphar.2012.00135.', '5.', 'Sliva D. Ganoderma lucidum in cancer research.', 'Leuk Res\\n2006;30:767–8.', 'doi:10.1016/j.leukres.2005.12.015.', '6.', 'Lu H, Kyo E, Uesaka T, et al.Prevention of develop-\\nment of N,N’-dimethylhydrazine-induced colon tumors by a\\nwater-soluble extract from cultured medium of Ganoderma\\nlucidum (Rei-shi) mycelia in male ICR mice.', 'Int J Mol Med\\n2002;9:113–7.', 'doi:https://doi.org/10.3892/ijmm.9.2.113..\\n7.', 'LuH,KyoE,UesakaT, etal.Awater-solubleextractfromcul-\\nturedmediumofGanodermalucidum(Rei-shi)myceliasup-presses azoxymethane-induction of colon cancers in male\\nF344 rats.', 'Oncol Rep 2003;10: 375–9.', '8.', 'Lu H, Uesaka T, Katoh O, et al.Prevention of the devel-\\nopment of preneoplastic lesions, aberrant crypt foci, bya water-soluble extract from cultured medium of Gano-\\ndermalucidum (Rei-shi)myceliain maleF344rats.', 'OncolRep\\n2001;8:1341–5.', 'doi: 10.3892/or.8.6.1341.', '9.', 'Sliva D, Loganathan J, Jiang J, et al.Mushroom Ganoderma\\nlucidum prevents colitis-associated carcinogenesis in mice.', 'PLoS One 2012;7:e47873.', 'doi:10.1371/journal.pone.0047873.', '10.', 'Yang Y, Nirmagustina DE, Kumrungsee T, et al.Feeding of\\nthewaterextractfromGanodermalingzhitoratsmodulates\\nsecondary bile acids, intestinal microflora, mucins, and pro-pionate important to colon cancer.', 'Biosci Biotechnol Biochem\\n2017;81:1796–804.', 'doi:10.1080/09168451.2017.1343117.', '11.', 'Luo J, Li T, Xie J, et al.Guar gum different from Gano-\\nderma lucidum polysaccharide in alleviating colorectal can-cer based on omics analysis.', 'Food Funct 2020;11:572–84.', 'doi:10.1039/c9fo02786f.', '12.', 'OkaS,TanakaS,YoshidaS, etal.Awater-solubleextractfrom\\nculture medium of Ganoderma lucidum mycelia suppresses244Mandy M. Liu et al.', 'thedevelopmentofcolorectaladenomas.', 'Hir oshimaJMedSci\\n2010;59:1–6.', '13.', 'Chen X, Hu ZP, Yang XX, et al.Monitoring of immune\\nresponses to a herbal immuno-modulator in patients withadvancedcolorectalcancer.', 'IntImmunopharmacol 2006;6:499–\\n508. doi:10.1016/j.intimp.2005.08.026.', '14.', 'Bai JH, Xu J, Zhao J, et al.Ganoderma lucidum polysaccha-\\nrideenzymatichydrolysatesuppressesthegrowthofhuman\\ncolon cancer cells via inducing apoptosis.', 'Cell Transplant\\n2020;29: 963689720931435. doi:10.1177/0963689720931435.', '15.', 'Castle JC, Loewer M, Boegel S, et al.Immunomic, genomic\\nandtranscriptomiccharacterizationofCT26colorectalcarci-\\nnoma.BMC Genomics 2014;15:190. doi:10.1186/1471-2164-15-\\n190.', '16.', 'Chrubasik S, Sporer F, Dillmann-Marschner R, et al.Physico-\\nchemical properties of harpagoside and its in vitro release\\nfrom Harpagophytum procumbens extract tablets.', 'Phy-\\ntomedicine 2000;6:469–73.', 'doi:10.1016/S0944-7113(00)80076-8.', '17.', 'PandaV,KhambatP,KundnaniK, etal.Evaluationofantacid\\nactivity of garcinia indica fruit rind by a modified artifi-cial stomach model.', 'Bull Environ Pharmacol Life Sci 2013;2:\\n38–42.', '18.', 'Marie JP, Faussat-Suberville AM, Zhou D, et al.Daunorubicin\\nuptake by leukemic cells: correlations with treatment out-\\ncome and mdr1 expression.', 'Leukemia 1993;7:825–31.', '19.', 'Liu M, RavulaR, WangZ, etal.TraditionalChinesemedicinal\\nformula Si-Wu-Tang prevents oxidative damage by activat-ing Nrf2-mediated detoxifying/antioxidant genes.', 'Cell Biosci\\n2014;4:8. doi:10.1186/2045-3701-4-8.', '20.', 'Wang EJ, Casciano CN, Clement RP, et al.In vitro flow\\ncytometry method to quantitatively assess inhibitors of P-\\nglycoprotein.', 'Drug Metab Dispos 2000;28:522–8.', '21.', 'HuangKM,LiangS,YeungS, etal.Topicallyappliedcarvedilol\\nattenuates solar ultraviolet radiation induced skin carcino-\\ngenesis.', 'Cancer Prev Res 2017;10:598–606.', 'doi:10.1158/1940-\\n6207.CAPR-17-0132.', '22.', 'Yeung S, Chen Q, Yu Y, et al.Quality evaluation of\\ncommercial products of Ganoderma lucidum made\\nfrom its fruiting body and spore.', 'Acta Chromatogr 2021.\\ndoi:10.1556/1326.2020.00825.', '23.', 'ChouTC,TalalayP.Quantitativeanalysisofdose-effectrela-\\ntionships:thecombinedeffectsofmultipledrugsorenzyme\\ninhibitors.', 'AdvEnzymeRegul 1984;\\n22:27–55.doi:10.1016/0065-\\n2571(84)90007-4.', '24.', 'Chou TC, Motzer RJ, Tong Y, et al.Computerized quanti-\\ntation of synergism and antagonism of taxol, topotecan,and cisplatin against human teratocarcinoma cell growth: a\\nrationalapproachtoclinicalprotocoldesign.', 'JNatlCancerInst\\n1994;86:1517–24.', 'doi: 10.1093/jnci/86.20.1517.', '25.', 'Lin F, Hoogendijk L, Buil L, et al.Sildenafil is not a useful\\nmodulator of ABCB1 and ABCG2 mediated drug resistance\\nin vivo.Eur J Cancer 2013;49:2059–64.', 'doi:10.1016/j.ejca.2012.', '12.028.', '26.', 'Naito M, Matsuba Y, Sato S, et al.MS-209, a quinoline-type\\nreversalagent,potentiatesantitumorefficacyofdocetaxelin\\nmultidrug-resistant solid tumor xenograft models.', 'Clin Can-\\ncer Res2002;8:582–8.', '27.', 'Hu M, Peluffo G, Chen H, et al.Role of COX-2 in epithelial-\\nstromal cell interactions and progression of ductal carci-nomainsituofthebreast.', 'ProcNatlAcadSci 2009;106:3372–7.', 'doi:0813306106 [pii] 10.1073/pnas.0813306106.', '28.', 'Chen X, Sun X, Guan J, et al.Rsf-1 influences the sensitiv-\\nity of non-small cell lung cancer to paclitaxel by regulating\\nNF-kappaB pathway and its downstream proteins.', 'Cell Phys-\\niol Biochem 2017;44:2322–36.', 'doi:10.1159/000486116.29.', 'Rimar S, Lee-Mengel M, Gillis CN Pulmonary protective and\\nvasodilator effects of a standardized Panax ginseng prepa-\\nration following artificial gastric digestion.', 'Pulm Pharmacol\\n1996;9:205–9.', 'doi: 10.1006/pulp.1996.0025.', '30.', 'Wang JR, Yau LF, Zhang R, et al.Transformation of gin-\\nsenosides from notoginseng by artificial gastric juice can\\nincrease cytotoxicity toward cancer cells.', 'J Agric Food Chem\\n2014;62:2558–73.', 'doi:10.1021/jf405482s.', '31.', 'Liu C, Dunkin D, Lai J, et al.', 'Anti-inflammatory\\neffects of ganoderma lucidum triterpenoid in humancrohn’s disease associated with downregulation of NF-\\nkappaB signaling.', 'Inflamm Bowel Dis 2015;21:1918–25.', 'doi:10.1097/MIB.0000000000000439.', '32.', 'GriswoldDP,CorbettTH.Acolontumormodelforanticancer\\nagent evaluation.', 'Cancer1975;36:2441–4.', 'doi: 10.1002/1097-\\n0142(197512)36:6 <2441::aid-cncr2820360627 >3.0.co;2-p.\\n33.', 'Lechner MG, Karimi SS, Barry-Holson K, etal.Immunogenic-\\nity of murine solid tumor models as a defining feature of in\\nvivobehaviorand responseto immunotherapy.', 'JImmunother\\n2013;36:477–89.', 'doi:10.1097/01.cji.0000436722.46675.4a.', '34.', 'Wang S, Wang X, Lin L, et al.Inhibitory effect of Lucid Gan-\\noderma spore on human hepatocarcinoma cell line HepG2\\nand growth of transplanted tumor in nude mice.', 'World\\nChinese J Digestol 2008;16:1114–8.', 'doi:10.3969/j.issn.1009-\\n3079.2008.10.017.', '35.', 'Sun L, Zhao M, Huang Y, Influence of ganodema lucidum\\nspore on dendritic cells from mice bone marrow andits antitumor effect.', '(In Chinese).', 'Shanxi Med J 2006;35:\\n698–700.', '36.', 'Huang G, Zhong W. Inhibition of mouse transplanted hep-\\natoma growth and telomerase activities by germination-\\nactivating sporoderm-broken ganoderma spores (GSGS).', '(In\\nChinese).', 'China Medical Engineering 2007;15:1–8.', '37.', 'Wang Y, Zhang C, Zhang S, et al.Kanglaite sensitizes\\ncolorectal cancer cells to Taxol via NF-kappaBeta inhibi-\\ntion and connexin 43 upregulation.', 'Sci Rep 2017;7:1280.\\ndoi:10.1038/s41598-017-01480-2.', '38.', 'Ernst M, Putoczki TL.', 'Targeting IL-11 signaling in colon\\ncancer.', 'Oncotarget 2013;4:1860–1.', 'doi:10.18632/oncotarget.', '1410.', '39.', 'Janakiram NB, Rao CV.', 'The role of inflammation in colon\\ncancer.Adv Exp Med Biol 2014;816:25–52.', 'doi:10.1007/978-3-\\n0348-0837-8\\n2.', '40.', 'Ray AL, Berggren KL, Restrepo Cruz S, et al.Inhibition of\\nMK2 suppresses IL-1beta, IL-6, and TNF-alpha-dependent\\ncolorectal cancer growth.', 'Int J Cancer 2018;142:1702–11.', 'doi:10.1002/ijc.31191.', '41.', 'Ancrile B, Lim KH, Counter CM.', 'Oncogenic Ras-induced\\nsecretion of IL6 is required for tumorigenesis.', 'Genes Dev\\n2007;21:1714–9.', 'doi:10.1101/gad.1549407.', '42.', 'Beaupre DM, Talpaz M, Marini FC, 3rd, et al.Autocrine\\ninterleukin-1beta production in leukemia: evidence for theinvolvement of mutated RAS.', 'Cancer Res 1999;59:2971–80.', '4 3 .P a nY ,J i a n gY ,T a nL , et al.Deletion of cyclooxygenase-\\n2 inhibits K-ras-induced lung carcinogenesis.', 'Oncotarget\\n2015;6:38816–26.', 'doi:10.18632/oncotarget.5558.', '44.', 'MizumotoY,KyoS,KiyonoT, etal.ActivationofNF-kappaBis\\na novel target of KRAS-induced endometrial carcinogenesis.', 'Clin Cancer Res 2011;17:1341–50.', 'doi:10.1158/1078-0432.CCR-\\n10-2291.', '45.', 'Ling J, Kang Y, Zhao R, et al.', 'KrasG12D-induced\\nIKK2/beta/NF-kappaB activation by IL-1alpha and p62feedforward loops is required for development of pancre-\\natic ductal adenocarcinoma.', 'Cancer Cell 2012;21:105–20.', 'doi:10.1016/j.ccr.2011.12.006.Antitumor activity of Ganoderma lucidum 245\\n46.', 'AlshamsanA.InductionoftolerogenicdendriticcellsbyIL-6-\\nsecreting CT26 colon carcinoma.', 'Immunopharmacol Immuno-\\ntoxicol2012;34:465–9.', 'doi:10.3109/08923973.2011.625034.', '47.', 'Ohno Y, Toyoshima Y, Yurino H, et al.Lack of interleukin-6\\nin the tumor microenvironment augments type-1 immunity\\nand increases the efficacy of cancer immunotherapy.', 'Cancer\\nSci2017;108:1959–66.', 'doi:10.1111/cas.13330.', '48.', 'Golay HG, Barbie DA.', 'Targeting cytokine networks in KRAS-\\ndriventumorigenesis.', 'ExpertRevAnticancerTher 2014;14:869–\\n71. doi:10.1586/14737140.2014.928596.', '49.', 'HsuYL,ChenYJ,ChangWA, etal.Interactionbetweentumor-\\nassociated dendritic cells and colon cancer cells contributes\\nto tumor progression via CXCL1.', 'Int J Mol Sci , 2018;19:2427.\\ndoi:10.3390/ijms19082427.', '50.', 'Klupp F, Neumann L, Kahlert C, et al.Serum MMP7, MMP10\\nand MMP12 level as negative prognostic markers in colon\\ncancerpatients.', 'BMCCancer 2016;16:494.doi:10.1186/s12885-\\n016-2515-7.', '51.', 'Leeman MF, McKay JA, Murray GI.', 'Matrix metalloproteinase\\n13 activity is associated with poor prognosis in colorectalcancer.JClinPathol 2002;55:758–62.doi:10.1136/jcp.55.10.758.', '52.', 'ErtemFU,ZhangW,ChangK, etal.OncogenictargetsMmp7,\\nS100a9, Nppb and Aldh1a3 from transcriptome profiling ofFAP and Pirc adenomas are downregulated in response to\\ntumor suppression by Clotam.', 'Int J Cancer 2017;140:460–8.', 'doi:10.1002/ijc.30458.', '53.', 'Hsu YL, Hung JY, Lee YL, et al.Identification of novel gene\\nexpressionsignatureinlungadenocarcinomabyusingnext-generation sequencing data and bioinformatics analysis.', 'Oncotarget 2017;8:104831–54.', 'doi:10.18632/oncotarget.21022.', '54.', 'Maly CJ, Cumsky HJL, Costello CM, et al.Prognostic value\\nof inositol polyphosphate-5-phosphatase expression inrecurrent and metastatic cutaneous squamous cell\\ncarcinoma.', 'J Am Acad Dermatol , 2019. doi:10.1016/\\nj.jaad.2019.08.027.', '55.', 'Patel AB, Mangold AR, Costello CM, et al.Frequent loss\\nof inositol polyphosphate-5-phosphatase in oropharyngeal\\nsquamous cell carcinoma.', 'J Eur Acad Dermatol Venereol\\n2018;32:e36–7.', 'doi:10.1111/jdv.14462.', '56.', 'Harjunpaa H, Llort Asens M, Guenther C, et al.Cell adhe-\\nsionmoleculesandtheirrolesandregulationintheimmuneand tumor microenvironment.', 'Front Immunol 2019;10:1078.\\ndoi:10.3389/fimmu.2019.01078.', '57.', 'Grozdanov V, Bliederhaeuser C, Ruf WP, et al.Inflam-\\nmatory dysregulation of blood monocytes in Parkinson’sdisease patients.', 'Acta Neuropathol (Berl) 2014;\\n128:651–63.', 'doi:10.1007/s00401-014-1345-4.', '58.', 'Merdad A, Karim S, Schulten HJ, et al.Expression of matrix\\nmetalloproteinases (MMPs) in primary human breast can-\\ncer: MMP-9 as a potential biomarker for cancer invasion and\\nmetastasis.', 'Anticancer Res 2014;34:1355–66.', '59.', 'Guo Y, Su ZY, Zhang C, et al.Mechanisms of colitis-\\naccelerated colon carcinogenesis and its prevention with\\nthe combination of aspirin and curcumin: Transcriptomicanalysis using RNA-seq.', 'Biochem Pharmacol 2017;135:22–34.', 'doi:10.1016/j.bcp.2017.02.021.']\n"
     ]
    }
   ],
   "source": [
    "sentences = sent_tokenize(text)\n",
    "print(sentences)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "0e5c91d3",
   "metadata": {},
   "source": [
    "### Print the first sentence of the abstract"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "67ec4a59",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Abstract\n",
      "The medicinal mushroom Ganoderma lucidum (GL, Reishi or Lingzhi) exhibits an inhibitory effect on cancers.\n"
     ]
    }
   ],
   "source": [
    "abstract_sent = sentences[1]\n",
    "print(abstract_sent)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "812ccf55",
   "metadata": {},
   "source": [
    "### Translate the frist sentence of the abstract to Chinese"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "3e5343e2",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "抽象的\n",
      "藥用蘑菇ganoderma lucidum（GL，Reishi或Lingzhi）對癌症表現出抑製作用。\n"
     ]
    }
   ],
   "source": [
    "# Create a TextBlob object with the text\n",
    "blob = TextBlob(abstract_sent)\n",
    "\n",
    "# Translate the text to Chinese\n",
    "translated_blob = blob.translate('en', 'zh-TW')\n",
    "\n",
    "# Print the translated text\n",
    "print(translated_blob)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "e34dc30a",
   "metadata": {},
   "source": [
    "### Split the text into words and count the number of words"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "8b12d34a",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Total number of words: 8235\n",
      "Total number of Sentences:  560\n"
     ]
    }
   ],
   "source": [
    "words = text.split()\n",
    "total_words = len(words)\n",
    "\n",
    "# Print the total number of words\n",
    "print(f\"Total number of words: {total_words}\")\n",
    "\n",
    "# Print the total number of sentences\n",
    "print(f\"Total number of Sentences: \", len(sentences)) "
   ]
  },
  {
   "cell_type": "markdown",
   "id": "8135b108",
   "metadata": {},
   "source": [
    "### Remove punctuation and stopwords"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "4b38cc10",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[nltk_data] Downloading package punkt to /Users/mmliu/nltk_data...\n",
      "[nltk_data]   Package punkt is already up-to-date!\n",
      "[nltk_data] Downloading package stopwords to /Users/mmliu/nltk_data...\n",
      "[nltk_data]   Package stopwords is already up-to-date!\n"
     ]
    }
   ],
   "source": [
    "nltk.download('punkt')\n",
    "nltk.download('stopwords')\n",
    "stop_words = set(stopwords.words('english'))"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "491502fa",
   "metadata": {},
   "source": [
    "### Convert words to lowercase, remove stop words and remove non-alphabetic characters and symbols"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "be6dbe67",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "precision clinical medicine 4 4 2021 https advance access publication date 28 august 2021research article research article inhibitory activity medicinal mushroom ganoderma lucidum colorectal cancer attenuating inflammation mandy liu1 tiantian liu2 steven yeung1 zhijun wang3 bradley andresen1 cyrus robert bingsen zhou6 wei wu6 x al i6 yilong zhang6 charles wang2 ying huang1 1department pharmaceutical sciences college pharmacy western university health sciences pomona ca 91766 usa 2center genomics department basic sciences school medicine loma linda university loma linda ca 92350 usa 3department pharmaceutical sciences college pharmacy marshall ketchum university fullerton ca 92831 usa 4college osteopathic medicine pacific western university health sciences pomona ca 91766 usa 5department pathology beverly hospital montebello california ca 90640 usa 6beijing tong ren tang chinese medicine new territories hong kong 999077 china charles wang chwang ying huang yhuang charles wang http liu tiantian liu contributed equally work abstract medicinal mushroom ganoderma lucidum gl reishi lingzhi exhibits inhibitory effect cancers however underlying mechanism antitumor activity gl fully understood study characterized gene networks regulated commercial product gl containing mixture spores andfruitingbodiesnamely glsf concentrations significantly potentiated growth inhibition apoptosis induced paclitaxel ct26 cells glsf inhibited κb promoter activity cells affect function cells furthermore found mice fed modified diet ing glsf 1 month prior ct26 tumor cell inoculation glsf alone combined markedly suppressed tumor growth induced apoptosis analysis tumor tissues derived mice identified 53 differentially expressed genes compared normal tissues many β received 2 june 2021 revised 16 august 2021 accepted 23 august 2021 author 2021 published oxford university press behalf west china school medicine west china hospital sichuan university open access article distributed terms creative commons attribution license https permits unrestricted reuse distribution reproduction medium provided original work properly cited 231232mandy liu et al pathwayenrichmentanalysissuggestedthatseveralinflammatorypathwaysinvolvingleukocytemigrationand adhesion affected treatment upstream analysis predicted activation multiple tumor cancer wasthemajor significantly inhibited biological effect glsf treatment results demonstrate glsf improve therapeutic outcome colorectal cancer mechanism involving suppression inflammation carcinogenesis key words ganoderma lucidum colorectal carcinoma κb inflammation introduction colorectal cancer third common type cer also third common cause death men women unitedstates 1currently surgery chemotherapy main treatment options colorectal cancer stage grade tumor location used patients metastatic cancer primary therapy patients colorectal cancer surgery asadjuvant therapy however chemoresistance obstacle occurs almost cases cancer addition chemotherapy affects cells active cellgrowth cycle causes toxicity normal organs suchasthebonemarrow gastrointestinaltract therefore common clinical practice use acombination several anticancer agents differentmechanisms actions toxicity profiles overcomedrug resistance reduce toxic reactions globally become popular cancer patients use complementary medicine derived natural sources orafter course conventional anticancer therapies anationwide survey conducted japan revealed herbal use cancer patients patients benign tumors andthe frequently used herbal products 2one medicinal rooms ganoderma lucidum gl also commonly named asreishiorlingzhi whichhasbeenusedforcenturiesineastasiatotreatavarietyofdisorders cancer without obvious toxicity related products referred mushroomof immortality beneficial effects healthand longevity spores gl reproductivecells fungus ejected cap afterthe fruiting bodies become mature major bioactivecomponents identified gl spores fruiting polysaccharides known stimulatethe immune system well triterpenes maydirectly inhibit proliferating cancer cells 5 entpartsoftheglmushroom thespores fruitingbodiesor mycelia early harvest human summarized three types studies first glhasshownefficacy incertainpreclinical modelsofcoloncancerprevention water extracts mycelia culture media glprevented chemical colorectal vented colon carcinogenesis feeding water extract gl powder rats diet reduced fecal secondary bile acids intestinalbacteria known related colon carcinogenesis 10 gl polysaccharide consumption reduced 30 specific bacteria expression mice colon cancer induced carcinogens 11second gl shown clinical evidence preventing development colon cancer ormodulating biomarkers related carcinogenesis example myceliaextract mentioned suppressed number took mycelia extract 12months 12in patients advanced colorectal cancer taking oral gl 12 weeks induced somechanges parameters although effects statistically nificant 13third gl shown antitumor cacy preclinical studies human colon cell lines vitro example effect matically hydrolyzed gl polysaccharide human colon cancer cell lines indicating apoptosis via associatedx protein bax ever besides reports prophylactic efficacy gl studies reported therapeutic effects glproducts single therapy combined chemotherapies already diagnosed colorectalcancer vitro andin vivo therefore largely unknown whether colorectal cancer patients could treatment gl products present study aimed determine effect gl colorectal cancer vitro andin vivo mercial gl product containing mixture sporesand fruiting bodies namely glsf used wefirstly evaluated whether glsf extracts preparedin several methods including use artificial juice simulate vivo digestion direct anticancer effects cancer cells colorectal cancers commonly resistantto taxanes next evaluated whether artificial juice digested glsf effect combination paclitaxel activity ganoderma lucidum 233 furthermore weevaluatedwhetheraglsfmodifieddiet murine colorectal carcinoma ct26 one 15tumor samples dissected control mice analyzedby rna sequencing potential mechanisms ofthe anticancer chemosensitization effect glsfin colorectal carcinoma explored throughbioinformatics analysis materials methods compounds reagents paclitaxel t7402 purchased sigma aldrich stlouis mo used vitro abraxane injectable suspension celgene summit nj wasused gle batch commercial product manufactured tong ren tang chinese medicine hong kong china named glsf contains mixture sporesand fruiting bodies gl ratio usedthroughout present study preparation glsf extracts quantification major components standardized preparation approach gl related products several reagents used toextract glsf including ethanol methanol hot water aswell artificial gastric intestinal gi juice extract g glsf extractedwith ml solvent round bottom flask attached toa reflux condenser 80 2 hours mixture centrifuged 4500 g 10 minutes supernatantwas collected pellet extracted filtered using whatman filter paper removed using rotary evaporator hot water extract 10 g glsf extracted 200 ml nanopure water 85 15 minutes stirring mixture centrifuged 15minutes 4500 supernatant filtered usingwhatman filter paper filtrate lyophilized obtained weighed stored e f r e analysis extracts glsf prepared artificial gastrointestinal juice prepared according toreported methods brief 5 g glsf powder ing 1 hour 50 ml artificial intestinal juice wasadded incubated 37 shaking 15 minutes 4500 g naoh filtered using whatman filter paper lyophilized stored major active components determined using unpublished whichwasable quantify 13 major components glsf includingganoderenicacidc ganodericacidc2 ganodericacidg ganoderic acid b ganoderenic acid b ganoderic acid ganoderic acid h ganoderenic acid ganoderic acid ganoderic acid f ganoderic acid dm ganoderol andergosterol individual contents extracts werequantified used fingerprint gl products allthe extractions fingerprint analysis conductedin triplicate cell lines cell culture ct26 cells purchasedfromatcc manassas va inserm e9912 universityofparis france wasobtained vitro passaging k562 progressively increasing doses daunorubicin 18these cells maintained dmem supplemented with10 fetal bovine serum 1 incubated 37 h5 c air srb cell proliferation assay plates seeded 3000 cells per well andthe cells allowed attach overnight cells weretreated drugs 72 hours incubated 37 5 co air cell viability determined using sigma sulforhodamine b srb assay according themanufacturer protocol apoptosis analysis flow cytometry used assess apoptosis sigma andpropidiumiodide aspreviouslydescribed seeded per well tissue culture plates 24hours cells incubated drugs 72hours cells collected washed twice coldpbs approximately 5 5cells mixed ing buffer without annexin v pi analysis performed using accuric6 flow cytometer bd biosciences franklin lakes nj based acquisition data whereas late apoptotic cells intracellular daunorubicin dnr accumulation assay capacity compound inhibit mediated efflux cells measured byflow cytometry described previously 20briefly cell pellet resuspended culture media 6000000 aliquots 50 μl cell pension transferred tubes containing ml ofmedia presence absence test drugs mediaand 5 μm dnr 50 minutes 37 trifugation removal supernatant cold pbs wasadded tube cell suspension transferred234mandy liu et al facs tubes placed ice analysis flow cytometry performed accuri c6 flowcytometer psc833 10 μm served positive control luciferase reporter gene assay dual luciferase assay κb described previous brief cells transfected renillaluciferase promega madison wi κb promega plasmids ratio using fugene hd transfection reagent rocheapplied science indianapolis hourslater cells exposed α 10 incubated fresh growth medium containing drugs foran additional 5 hours cell lysates analyzed thedualluciferasereportergeneassay promega renilla luciferase serving normalization factor rodent diet preparation forin vivostudies glsf powder inc rancho cucamonga ca formulation laboratory rodent diet 5001 glsf color dye calculation drug based group monitored study andi tw sc n fi r e dt h tt h ed eo fg l fw animal experiment animal studies carried strict accordance recommendations guide careand use laboratory animals national institutesof health approved western university female mice ct26 cells 3 6 100 μl serum free media injected subcutaneously theright left flanks mice charles river burlington 12 days implantation began dose glsf 2 given oralgavaging day total nine oral treated vehicle control glsf rodent drug regimen study n d3 n fed standard diet groups 2 4 fed diet containing glsf n 4 weeks cell inoculation mice 8weeks old 5 5cells 100 μl serum free media injected subcutaneously right left flanks day 13 tumor inoculation tumorvolumewascalculatedaccordingtotheformulation width extraction library preparation sequencing tumors rodent drug regimen study dissected snap frozen stored total rna extracted tumor tissues usingtrizol reagent invitrogen grand island ny arneasy mini kit qiagen germantown md total eight rna samples four per treatment two groups sent fulgentgenetics temple city ca library preparation andsequencing briefly library constructed usingthe nebnext mrna magnetic isolation directional rna library prep kit new england biolabs ipswich sequenced using illumina hiseq 4000with 150 bp minimum depth total 60million reads per sample computational data analysis raw data converted fastq files bcl2fastq2 read quality assessed usingfastqc sequence reads mapped mouse genome grcm38 using edico genome aligner default settings duplicate reads asmarked dragen aligner removed analysis aligned bam files processed byhtseq gene quantification genes countsper million cpm values least two included differential expression differentially expressed genes identified byr package edger version briefly read countswere fitted negative binomial distribution analysis carried using genes pvalues absolute log change 1 considered differentially expressed pathway analysis andprediction based significant degs performedusing ingenuity pathway analyses ipa ingenuity systems global mds hierarchical clustering heat map volcano plot generatedusing plotmds plotmd functions r respectively statistical analysis dataareexpressedasmean stated otherwise plots made using graphpadprism version graphpad software inc la jolla ca statistical analysis conducted using ncss 2007 ncss llc kaysville ut specific tests detailedin text figure legends statistical means indicated statistically differentwhenp activity ganoderma lucidum 235 figure 1 effects glsf gastrointestinal gi juice extract growth inhibitory effects paclitaxel colorectal cancer cells srb cytotoxicity assay used determine effects paclitaxel glsf alone combination mouse colon cancer ct26 cells b thecytotoxicity paclitaxel glsf alone combination human colon cancer cells c effects paclitaxel glsf alone combination human colon cancer cells p p comparing groups treated paclitaxel alone groups determined ttest results identification optimal extraction methods glsf standardized preparation approach gl andrelatedproducts glsf extracts including use ethanol methanol hot water well artificial examined ability inhibit cancer cellgrowthin vitro extracts examined panel cancerous cell lines derived fromdifferenttissuesoforigin pc3 a375 h460 hepg2 nhdf using b srb colorimetric assay comparison thecytotoxicity datafor thefour extracts melanoma a375or breast cancer indicated juice hot water extracts exhibited higher potencies cancer cell growth inhibition supplementary figs s1 s2 viability data andic 50values cell lines gastrointestinal juice hot water extracts summarized table s1 additionally previous study showedhigher contents triterpenes glsf juice extract compared chloroformextract 22as gastrointestinal juice extract showed thehighestpotencyonthemajorityofcancercelllines vitroanticancer effects chemical fingerprint analysis gastrointestinal juice extract glsf hplc based literature search components gl products 13 compounds selected chemicalmarkers glsf fingerprint method developed22and used quantify ers extract glsf contents 13 shown supplementary table s2 amongthe 13 assessed compounds ganoderol wasnot detectable 12 compounds substantial amounts compounds althoughthe chemical markers mainly consisted triterpenes polysaccharidesnotincluded theresultsindicatedthatat least selected active components glsf consistently extracted effects glsf extract chemosensitivity colorectal cancer paclitaxel taxol exhibited modest inhibitory effect ct26 cells ic 50was glsf cause cytotoxicity ct26 concentration to3 however cells withtaxol μm glsf showed cantly increased cytotoxic effects compared taxoltreatment alone p fig 1a observed dependent chemosensitizing effect glsf ahigher concentration showed increasedchemosensitizing effect compared glsf p similar effects observed combined treatment glsf higher taxol μm confirm nature interaction glsf taxol combination performed combination index ci method drug combinations various ratios synergistic interaction produced ci taxol μm combined glsf ci values 1 indicate synergistic activity confirm236mandy liu et al figure2 effectsofglsfgijuiceextractonapoptosisinducedbypaclitaxelinmousecolorectalcancerct26cells cellapoptosiswasassessed annexin double staining detected flow cytometry facs analysis staining axis fl1 pi x axis fl3 b annexin assay performed three times average percentage viable early apoptosis late apoptosis necrosis populations cells p p compared vehicle control group determined ttest results human colorectal cancer cell lines srb cells treated taxol glsf aloneor combination ic 50in treated taxol μm similar ct26 cells glsf cause cytotoxicity cells to3 concentration cells taxol μm glsf showed increase cytotoxic effects comparedto taxol treatment alone p glsf p glsf fig 1b although cells much sensitive taxol ic μm ct26 glsf 3 alone also nontoxic glsf taxol demonstrate increased ordecreased effect cell viability fig 1c therefore chemosensitizing effect glsf variable differentcancer cell lines effects glsf extract apoptosis ct26 cells thedegreeofapoptosisinducedbyglsf taxol μm combination evaluated ct26 cells cells incubated 72 hours drugs level apoptosis binding pi staining shown fig 2 glsf treatment slightly increased viable cells compared vehicle control p taxol decreased viable cell population p cells exposed tion glsf taxol significant reductionof viable cells p viable cells control increase number early apoptoticcells p result consistent data obtained srb ct26 cells fig 1a indicating concentration glsfincreased anticancer potency taxol via enhancingapoptosis ct26 cells effects glsf extract mdr1 activity cells previous studies shown ct2625and 1526express efflux transporter mdr1 abcb1gene part mechanism intrinsic resistance taxanes substrate drugs daunorubicin dnr examined whether glsf able drug efflux usingdaunorubicin dnr fluorescent substrate 20few cells positive dnr accumulation without inhibitor fig 3a known inhibitor psc833 10 μm positive control greatly increased dnr positive cells nearly 100 however glsf 1 2 3 slightly increased dnraccumulation fig 3b although treatment effect glsf 2 significant p compared positive control psc833 degree inhibitionwas negligible result suggests activity glsf attributed activity ganoderma lucidum 237 figure 3 effects glsf gi juice extract activity cells κb activity cells flow cytometry analysisofdnraccumulationincellsincubatedwithdnr treatedwithorwithoutpsc833 10 μm shown b graphs showing percentage cells positive dnr cell samples glsf dnr comparisonwith 10 μm psc833 dnr data presented mean independent experiments p comparedtothednronlygroup c κbluciferase reporter renillacontrol reporter treated vehicle α 10 glsf combined αfor 5 hours data expressed mean sem n p per anova effects glsf extract κbp r e ra c v cells next evaluated effect glsf moted κb activation cells andaplasmidencodingthe renillaluciferaseforthedual luciferase assay transfected cells treated withvehicle control glsf extracts 0 followed α 10 expected αstrongly stimulated κba c v f g 3c promoter activity stimulated αwas inhibited significantly gi extract manner fig 3c κb plays role promoting carcinogenesis ofvarious types cancer 27and conferring tance κbb yg l fm g h partly explain vitrochemosensitizing activity thein vivoactivity described anticancer efficacy glsf oral administration mice bearing murine colorectal cancer tumorct26 evaluate anticancer activity glsf invivo n geneic model colorectal mice two tumors ct26 implanted ineach mouse n gender specific group liu et al figure 4 effects glsf tumor growth apoptosis colorectal cancer syngeneic model ct26 cells subcutaneously implanted female mice mice fed control diet groups 1 3 diet containing glsf groups 2 4 4 weeks groups 3 4 mice treated single dose abraxane day 13 tumor volumes measured days 13 19 day 0 day tumor injection p test n rg 1a n dg 2 n rg 3a n dg 4 b c tumortissueswerestainedwithh western blot analysis parp cleaved parp representative gel images shown bar graphs represent ratios cleaved parp p compared control group ttest parp poly polymerase control n tumors glsf n tumors treatment oral gavage daily monday tofriday ninedosesintotal trend treatment effect observed tumorvolume males females supplementary average tumor volumes micewere smaller untreated control addition themicedidnotlosebodyweightcomparedtoinitialweight indicating treatment toxic explore potential anticancer mechanism effect glsf treatment mouse spleen proliferation induced concanavalin con orlipopolysaccharides lps vitrowas determined using spleen samples obtained ct26 mice compared mice proliferation spleen b lymphocytes induced bycon lps strongly declined supplementary fig s3 however treatment althoughthiswasnotstatistically significant data indicate potentialimmunomodulatory activity glsf consistent previous report 4 confirm anticancer activity glsf mice control diet groups 1 and3 modified diet containing glsf groups 2 4 1 month tumor implantation glsf showedantitumor effects genders pilot studyand ct26 tumor derived female mice 15 females included experiment treatment given groups 3 4 observethe effects combination treatments two tumors wereimplanted mouse consistent pilotstudy glsf treatment alone inhibited tumor growth although repeated measures anova analysis show statistically significant difference ofthemicehadtwotumorsin control group 63 mice glsfgroup two tumors two eight mice 25 glsf group show tumors fig 4b post hoc analysis showed day 19 aftertumorinoculation significantly suppressed tumor growth comparedwith control group fig 4a furthermore tumors thecontrolgroup group1 showedasignificantincreasewhen comparing tumor size day 13 19 whilegroups 2 3 4 show tumor size increase confirming treatment effect tumor tissues dissected control glsf groups subjected hematoxylin eosin h e antitumor activity ganoderma lucidum 239 figure 5 detected genes glsf treatment red control group c green distances correspond leading log2 eachpairofsamples b regulateddegswith p 1 c heatmapoftop30significantlydifferentiallyexpressedgenesbetweentreatment control groups c genes treatment group compared control displayed within red greennodes respectively predicted inhibited biology effects presented blue nodes blue predicted inhibited gray undetermined direction dash lines represent relationships causal consistency esectionsindicatedthattumor tissues groups consisted tumorsin glsf group showed conspicuous increase ofnecrosisinallthefourtumorsamplessubmittedforh estaining representative images shown fig 4c 67 staining showed tumors control groupconsisted entirely one cell type high index tumors glsf group nonspecific staining fig 4c western blot analysis used examine expression apoptosis marker parp cleavedparp tumor tissue lysates expression cleavedparp markedly increased glsf treatmentgroup compared control group fig 4d andthisdifferencewasstatisticallysignificant p confirming glsf treatment induced apoptosis intumor tissues profiling tumors explore mechanism underlying treatment effectsbyglsf gene expression profiles tumors mice subjected control diet n glsf modified diet n average 40 million reads pairs per sample generated withall uniquely mapping rates 91 rna sequencing detected 25 051 genes across eightsamples 13 790 genes cpm value least two samples mds plot showed trend clustering separationbetween treated group control group fig 5a 13790 genes 53 identified significant expressed genes degs two groupswith absolute log2 1a n da pvalue supplementarytables3 top 10 genes selected based thelowestpvalue presented tables g 2240mandy liu et al table 1 top 12 genes tumors mice treated glsf compared control group gene id gene name log fc pvalue itga10 integrin alpha 10 zbtb16 zinc finger btb domain containing 16 gm807 predicted gene 807 laeverin gm6093 predicted gene 6093 histidine rich carboxyl terminus 1 aldehyde dehydrogenase family 1 subfamily inpp5j inositol polyphosphate j rcan2 regulator calcineurin 2 ifng interferon gamma retnla resistin like alpha fmo2 flavin containing monooxygenase 2 fc log2 fold change larger 1 indicates higher expression tumors table 2 top 10 genes tumors mice treated glsf compared control group gene id gene name log fc pvalue il1b interleukin 1 beta il11 interleukin 11 4930565n06rik riken cdna 4930565n06 gene nppb natriuretic peptide type b ptgs2 synthase 2 mmp10 matrix metallopeptidase 10 mmp13 matrix metallopeptidase 13 stamos signal transducing adaptor molecule sh3 domain itam motif 1 opposite cxcl1 chemokine motif ligand 1 mmp12 matrix metallopeptidase 12 fc log2 fold change smaller indicates lower expression tumors lower indicated expression gene decreased glsf treatment whereasa log2 1 suggested increasedgene expression tumor tissues derived glsftreatment heat map top 30 significant degswas plotted unsupervised hierarchical clustering volcano plot generated cant degs highlighted red color based ues fold changes fig 5c notable many glsf genes involved inflammation β il1b il11 b l e 2 f g explore possible biological functions linked degs ingenuity pathway analysis ipa wasperformedtoidentifycanonicalpathways diseases functions associated dataset total number reference genesin specific pathways ipa knowledge bases afisher exact test used determine canonicalpathways associated treatment effect using acutoffpvalue total 58 canonical pathways identified significantly enriched based onthe degs supplementary table s4 affectedpathways granulocyte adhesion diapedesis agranulocyte adhesion diapedesis areknown analysis ipa used predict upstream regulators potentially causing changesin gene expression regulation direction based onthe degs predicted significantly activated regulators listed supplementary table s5 p value 2 upstream regulators tp53 known tumor suppressors colon hand inhibited upstream factors play critical roles inflammatoryresponse tumorigenesis including tnfsf12 krt17 il17ra tnf il17a diseases functions ipa used predict affected biology regulation direction associatedwith glsf treatment using cutoff pvalue 2 significantly activated biology effect identified top five significantly biological effects presented fig 5d included cancer epithelia neoplasm carcinoma secondary tumor frequency tumor networkof top five inhibited biology effects glsf group compared control degs displayed fig 5d quantitative analysis confirmed glsf inhibited expressionof selected inflammatory genes ptgs2 p β il1b p il6 p fig 6 activity ganoderma lucidum 241 figure fromtumor samplesofcontrol glsf groupsfor b β c wasused asnormalization control data expressed mean 95 ci n tumor samples control group n tumor samples p p via u approximation without correction normality discussion present study examined vitroandin cancer activity glsf contains mixture spores fruiting bodies mushroom pharmacological activity active components extracts glsf prepared ethanol methanol hot water artificial gastrointestinal juice wereexamined panel cell lines found extractsprepared using gastrointestinal juice highestpotencyofcellgrowthinhibitionandthereforewereusedin ourin vitrostudies extraction method ologically relevant clinical application although themethod extraction used ginseng 29and notoginseng knowledge firststudyusingartificialgastrointestinaljuicetoprepareglextracts invitro cityoncoloncancercells limited 3however glsf combined taxol induced stronger tumor inhibition suggesting glsf may used fig 1a b glsf inhibitor inhibitory activity κb signaling suggested dual luciferase assay fig 3c consistently previous sdiseasecolonicm u c aa sar e u l fb l c k g eo fn f κb 31 vivo glsf alone combination ane nanoparticle albumin bound paclitaxel induced tumor growth inhibition fig 4 syngeneic tumor model used 26 ct26 ing mice chemical carcinogen resulting grade ivcarcinoma easily implanted readily miceprovidesasyngeneicmodel itisfrequentlyusedfordeveloping testing immunotherapeutic agents comparedwith invitrodata alarge invivoeffectsuggests intact immune system tumor may essential pharmacological action ofglsf one limitation vivostudies single dose used derived frompublished data gl studies considered future although taxol abraxane242mandy liu et al effective many types cancer breast ovariancancer theirapplicationincolorectalcancerhasbeenlimitedbecauseofintrinsicresistance 37thus glsf may used chemosensitizer taxanes ratioof glsf versus taxol abraxane optimizedin future studies identify optimal combinationalregimen studies comparing therapeutic effectsof glsf different tumor models agents considered gain mechanistic insight performed evaluate transcriptome changes glsf treatment based differentiallyexpressedgenes degs 11 genes encoding cytokines tumor promote colorectal cancer progression decreased glsf cytokines also picked analysisb e c u eo fl wc p mv l u e r ep r u c e db ym e l dand interleukin il th17 cellsthat accumulated tumor microenvironment 38 cytokines directly indirectly activateneoplastic epithelium therapies target example therapy treat colorectal cancer 38in addition glsf ptgs2 encoding known inflammatory mediator promotes colorectalcancer results confirmed mice tumor cell expression β n di l 6 significantly mrna level fig 6 results suggest inflammation potentialtargetfortreatmentofsometypesofcolorectal cancer 40 consistent luciferase assay data fig 3c genes control transcription factor furthermore ct26 cells harbor constitutively activating mutant kras 15which shown trigger production several mediators including ated κbi sa c v e di n cancer suggested get treat addition vious study showed ct26 cells secret b u ta l ot h eg r w ho fc 2 6t u rd e p e n ni l inflammatory factors many r eu n e rt h er e g u l fn f κb likely gets anticancer effect resultsalso suggest cancers tumors might likely respondto glsf inhibiting kras directly challenging approaches disrupt downstream signaling pathwaysmay better approach treat types highlyaggressive cancer 48 another gene group inflammatory chemokine cxcl1 involved enhanced metastatic potential coloncancer increasing cell migration matrix mmp expression transition therefore negativeprognostic impact clinical outcome 49probably associatedwith threemmpgeneswere among top 20 genes mmp10 mmp13 n dmmp12 genes products identified negative prognostic markersin colon cancer patients nppb encoding natriuretic peptide b shown key oncogene candidate colontumors suggested one early biomarkers forprevention clinical setting 52 genes various functions although genes yet colon cancer may contribute genes example fmo2 flavin containing monooxygenase 2 plays role tumor suppressor inlung cancer 53the lower level inpp5j encodes inositol j aggressive tumors poorer cutaneous squamous cell carcinoma 54and found deficient oropharyngeal squamous cellcarcinoma 55itga10 top deg genes encodesintegrinsubunit α10 lagen plays role cell adhesion signaling although activity increasedexpression itga10by glsf unknown response 56 canonical pathway analysis highlighted ulocyte adhesion diapedesis agranulocyteadhesion diapedesis significantly pathways influenced glsf treatment bothpathways contain set genes mainly mmps associated immunity 57as well tumor invasion results support notion two cancer previously reported 59and may tain molecular targets underlie anticancereffect glsf based degs activation states might resultin gene expression changes several cytokines top inhibition listsuch tnfsf12 tnf il17a hand activation 2 according diction prediction implied glsf mayelicit activity onepossiblemechanismisthatglsf treatment resulted inhibition shared target aforementioned upstream regulators eventually may hypothesis based ipa prediction therewasnosignificantlyactivatedbiologyeffectwhilethetopfive inhibited biology effects related cancer anddisplayedthenetworkoftumorsuppressioninducedby gl treatment fig 5d results implied sible mechanism gl effect alleviatingthe immune suppression colorectal tumor tissue byantitumor activity ganoderma lucidum 243 promoting recruitment immune cells inhibiting immune suppressive cells asmyeloid derived suppressor cells hypothesis alignwell observation glsf alone showed cytotoxicity vitrobecause lack immune tem notable vivostudies used glsf der vitro assays used extract identification active components responsible theseobserved effects requires investigation conclusion study evaluated anticancer effects possible underlying anticancer mechanismof glsf using human murine colorectal cell lines examined glsf alone commonly used chemotherapeutic agentpaclitaxel invitrodatarevealedthatalthoughglsfalone little anticancer effect effect certain colon cancer cells κb played major role mediating vitroanticancer tumor ct26 used investigating vivoanticancer activity gl ics analysis first time indicated glsf inflammation carcinogenesis confirmedt h er l eo fn f κb potential target advanced orectal cancer shows inherent resistance paclitaxel orrelated chemotherapeutic agents use glsf natural product antitumor effects ofchemotherapy may enhanced gslf alone also hadanticancer activity vivothrough inhibitory effect inflammation kras activation supplementary data supplementary data available pcmedi online data material availability materials data associated protocols able readers without undue qualifications materialtransfer agreements glsf available tong ren tang chinese medicine ltd author contributions conceived designed study carriedout vitro andin vivo experiments lyzed data analyzed revised manuscript conducted analysis performed hplc analysis performed pathologyanalysis coordinated theexperiments wrote reviewed manuscript allauthors read approved final manuscript manuscript acknowledgements would like thank lily kong lim beverly hospital preparing tissues h e staining glsf available beijing tong ren tang chinesemedicine ltd study funded grant yh beijing tong ren tang loma linda university llu gcat grant cw conflict interests beijing tong ren tang chinese ltd author declare competing besides editorial board member precision clinicalmedicine thecorrespondingauthorcharleswang wasblindedfromreviewingandmakingdecisiononthismanuscript references 1 siegelrl millerkd cer j clin 2016 2 hyodo amano n eguchi k et vey complementary alternative medicine cancer patients japan j clin oncol 2005 3 sanodiya bs thakur gs baghel rk ganoderma lucidum potent pharmacological macrofungus curr pharm biotechnol 2009 doi 4 wang py zhu xl lin zb antitumor ulatory effects polysaccharides ganoderma lucidum front pharmacol 2012 5 sliva ganoderma lucidum cancer research leuk res 2006 6 lu h kyo e uesaka et ment n n colon tumors extract cultured medium ganoderma lucidum mycelia male icr mice int j mol med 2002 doi https 7 luh kyoe uesakat turedmediumofganodermalucidum colon cancers male f344 rats oncol rep 2003 10 8 lu h uesaka katoh et opment preneoplastic lesions aberrant crypt foci bya extract cultured medium dermalucidum myceliain malef344rats oncolrep 2001 doi 9 sliva loganathan j jiang j et ganoderma lucidum prevents carcinogenesis mice plos one 2012 7 e47873 10 yang nirmagustina de kumrungsee et thewaterextractfromganodermalingzhitoratsmodulates secondary bile acids intestinal microflora mucins important colon cancer biosci biotechnol biochem 2017 11 luo j li xie j et gum different derma lucidum polysaccharide alleviating colorectal based omics analysis food funct 2020 12 okas tanakas yoshidas culture medium ganoderma lucidum mycelia suppresses244mandy liu et al thedevelopmentofcolorectaladenomas hir oshimajmedsci 2010 13 chen x hu zp yang xx et immune responses herbal patients withadvancedcolorectalcancer intimmunopharmacol 2006 14 bai jh xu j zhao j et lucidum rideenzymatichydrolysatesuppressesthegrowthofhuman colon cancer cells via inducing apoptosis cell transplant 2020 29 15 castle jc loewer boegel et genomic genomics 2014 190 16 chrubasik sporer f r et chemical properties harpagoside vitro release harpagophytum procumbens extract tablets tomedicine 2000 00 17 pandav khambatp kundnanik activity garcinia indica fruit rind modified stomach model bull environ pharmacol life sci 2013 2 18 marie jp zhou et uptake leukemic cells correlations treatment come mdr1 expression leukemia 1993 19 liu ravular wangz formula prevents oxidative damage genes cell biosci 2014 20 wang ej casciano cn clement rp et vitro flow cytometry method quantitatively assess inhibitors glycoprotein drug metab dispos 2000 21 huangkm liangs yeungs attenuates solar ultraviolet radiation induced skin genesis cancer prev res 2017 22 yeung chen q yu et evaluation commercial products ganoderma lucidum made fruiting body spore acta chromatogr 23 choutc tionships thecombinedeffectsofmultipledrugsorenzyme inhibitors advenzymeregul 1984 2571 84 24 chou tc motzer rj tong et tation synergism antagonism taxol topotecan cisplatin human teratocarcinoma cell growth rationalapproachtoclinicalprotocoldesign jnatlcancerinst 1994 doi 25 lin f hoogendijk l buil l et useful modulator abcb1 abcg2 mediated drug resistance j cancer 2013 26 naito matsuba sato et reversalagent potentiatesantitumorefficacyofdocetaxelin solid tumor xenograft models clin cer res2002 27 hu peluffo g chen h et stromal cell interactions progression ductal procnatlacadsci 2009 pii 28 chen x sun x guan j et influences ity cell lung cancer paclitaxel regulating pathway downstream proteins cell iol biochem 2017 rimar gillis cn pulmonary protective vasodilator effects standardized panax ginseng ration following artificial gastric digestion pulm pharmacol 1996 doi 30 wang jr yau lf zhang r et senosides notoginseng artificial gastric juice increase cytotoxicity toward cancer cells j agric food chem 2014 31 liu c dunkin lai j et al effects ganoderma lucidum triterpenoid humancrohn disease associated downregulation kappab signaling inflamm bowel dis 2015 32 griswolddp agent evaluation cancer1975 doi 0142 197512 2441 33 lechner mg karimi ss k ity murine solid tumor models defining feature vivobehaviorand responseto immunotherapy jimmunother 2013 34 wang wang x lin l et effect lucid oderma spore human hepatocarcinoma cell line hepg2 growth transplanted tumor nude mice world chinese j digestol 2008 35 sun l zhao huang influence ganodema lucidum spore dendritic cells mice bone marrow andits antitumor effect chinese shanxi med j 2006 35 36 huang g zhong inhibition mouse transplanted atoma growth telomerase activities activating ganoderma spores gsgs chinese china medical engineering 2007 37 wang zhang c zhang et sensitizes colorectal cancer cells taxol via tion connexin 43 upregulation sci rep 2017 38 ernst putoczki tl targeting signaling colon cancer oncotarget 2013 1410 39 janakiram nb rao cv role inflammation colon exp med biol 2014 2 40 ray al berggren kl restrepo cruz et mk2 suppresses colorectal cancer growth int j cancer 2018 41 ancrile b lim kh counter cm oncogenic secretion il6 required tumorigenesis genes dev 2007 42 beaupre dm talpaz marini fc 3rd et production leukemia evidence theinvolvement mutated ras cancer res 1999 4 3 ny j n gy nl et 2 inhibits lung carcinogenesis oncotarget 2015 44 mizumotoy kyos kiyonot novel target endometrial carcinogenesis clin cancer res 2011 45 ling j kang zhao r et al activation p62feedforward loops required development atic ductal adenocarcinoma cancer cell 2012 activity ganoderma lucidum 245 46 secreting ct26 colon carcinoma immunopharmacol toxicol2012 47 ohno toyoshima yurino h et tumor microenvironment augments immunity increases efficacy cancer immunotherapy cancer sci2017 48 golay hg barbie da targeting cytokine networks driventumorigenesis expertrevanticancerther 2014 49 hsuyl chenyj changwa associated dendritic cells colon cancer cells contributes tumor progression via cxcl1 int j mol sci 2018 50 klupp f neumann l kahlert c et mmp7 mmp10 mmp12 level negative prognostic markers colon cancerpatients bmccancer 2016 51 leeman mf mckay ja murray gi matrix metalloproteinase 13 activity associated poor prognosis 2002 52 ertemfu zhangw changk s100a9 nppb aldh1a3 transcriptome profiling offap pirc adenomas downregulated response tumor suppression clotam int j cancer 2017 53 hsu yl hung jy lee yl et novel gene sequencing data bioinformatics analysis oncotarget 2017 54 maly cj cumsky hjl costello cm et value inositol expression inrecurrent metastatic cutaneous squamous cell carcinoma j acad dermatol 55 patel ab mangold ar costello cm et loss inositol oropharyngeal squamous cell carcinoma j eur acad dermatol venereol 2018 32 56 harjunpaa h llort asens guenther c et sionmoleculesandtheirrolesandregulationintheimmuneand tumor microenvironment front immunol 2019 57 grozdanov v bliederhaeuser c ruf wp et matory dysregulation blood monocytes parkinson sdisease patients acta neuropathol berl 2014 58 merdad karim schulten hj et matrix metalloproteinases mmps primary human breast cer potential biomarker cancer invasion metastasis anticancer res 2014 59 guo su zy zhang c et accelerated colon carcinogenesis prevention combination aspirin curcumin transcriptomicanalysis using biochem pharmacol 2017\n"
     ]
    }
   ],
   "source": [
    "def preprocess_text(text):\n",
    "    \n",
    "    # tokenize the input text into words and assign it to words variable\n",
    "    words = word_tokenize(text)\n",
    "    \n",
    "    # converts each word in the list to lowercase\n",
    "    # checks whether a word consists of alpha numeric characters; remove non-alphabetic characters and symbols\n",
    "    words = [word.lower() for word in words if word.isalnum()]\n",
    "    \n",
    "    # remove stop words\n",
    "    words = [word for word in words if word not in stop_words]\n",
    "    \n",
    "    # join the preprocessed words back together into a single string with space separators\n",
    "    return ' '.join(words)\n",
    "\n",
    "print(preprocess_text(text))"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "de29c311",
   "metadata": {},
   "source": [
    "### Process a list of sentences and store the preprocessed versions of those sentences in a new list"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "76fdc30f",
   "metadata": {},
   "outputs": [],
   "source": [
    "preprocessed_sentences = []\n",
    "for sentence in sentences:\n",
    "    preprocessed_sentence = preprocess_text(sentence)\n",
    "    preprocessed_sentences.append(preprocessed_sentence)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "c1d109b6",
   "metadata": {},
   "source": [
    "## Data Exploration and Visualization"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "28a35115",
   "metadata": {},
   "source": [
    "### Calculate the Term Frequency-Inverse Document Frequency (TF-IDF) scores"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "2640792b",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Calculate the overall importance of each sentence in the context of the entire document or corpus\n",
    "# Higher TF-IDF score means more important or distinctive \n",
    "tfidf = TfidfVectorizer()\n",
    "tfidf_matrix = tfidf.fit_transform(preprocessed_sentences)\n",
    "tfidf_scores = tfidf_matrix.sum(axis=1)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "5517b546",
   "metadata": {},
   "source": [
    "### Find the top 3 sentences (highest TF-IDF scores)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "1fc59b74",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Find the most important sentences based on TF-IDF scores\n",
    "top_sentence_indices = np.argsort(tfidf_scores, axis=0)[-3:]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "8efc73aa",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "matrix([[234],\n",
       "        [231],\n",
       "        [  0]])"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "top_sentence_indices"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "200e131a",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'gene id gene name log fc pvalue il1b interleukin 1 beta il11 interleukin 11 4930565n06rik riken cdna 4930565n06 gene nppb natriuretic peptide type b ptgs2 synthase 2 mmp10 matrix metallopeptidase 10 mmp13 matrix metallopeptidase 13 stamos signal transducing adaptor molecule sh3 domain itam motif 1 opposite cxcl1 chemokine motif ligand 1 mmp12 matrix metallopeptidase 12 fc log2 fold change smaller indicates lower expression tumors'"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Print one of the top sentences\n",
    "preprocessed_sentences[234]"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "36673641",
   "metadata": {},
   "source": [
    "### Generate a summary of the document based on the top sentences with the highest TF-IDF scores"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "ed189c3e",
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "0 precision clinical medicine 4 4 2021 https advance access publication date 28 august 2021research article research article inhibitory activity medicinal mushroom ganoderma lucidum colorectal cancer attenuating inflammation mandy liu1 tiantian liu2 steven yeung1 zhijun wang3 bradley andresen1 cyrus robert bingsen zhou6 wei wu6 x al i6 yilong zhang6 charles wang2 ying huang1 1department pharmaceutical sciences college pharmacy western university health sciences pomona ca 91766 usa 2center genomics department basic sciences school medicine loma linda university loma linda ca 92350 usa 3department pharmaceutical sciences college pharmacy marshall ketchum university fullerton ca 92831 usa 4college osteopathic medicine pacific western university health sciences pomona ca 91766 usa 5department pathology beverly hospital montebello california ca 90640 usa 6beijing tong ren tang chinese medicine new territories hong kong 999077 china charles wang chwang ying huang yhuang charles wang http liu tiantian liu contributed equally work\n",
      "precision clinical medicine 4 4 2021 https advance access publication date 28 august 2021research article research article inhibitory activity medicinal mushroom ganoderma lucidum colorectal cancer attenuating inflammation mandy liu1 tiantian liu2 steven yeung1 zhijun wang3 bradley andresen1 cyrus robert bingsen zhou6 wei wu6 x al i6 yilong zhang6 charles wang2 ying huang1 1department pharmaceutical sciences college pharmacy western university health sciences pomona ca 91766 usa 2center genomics department basic sciences school medicine loma linda university loma linda ca 92350 usa 3department pharmaceutical sciences college pharmacy marshall ketchum university fullerton ca 92831 usa 4college osteopathic medicine pacific western university health sciences pomona ca 91766 usa 5department pathology beverly hospital montebello california ca 90640 usa 6beijing tong ren tang chinese medicine new territories hong kong 999077 china charles wang chwang ying huang yhuang charles wang http liu tiantian liu contributed equally work.\n",
      "1 abstract medicinal mushroom ganoderma lucidum gl reishi lingzhi exhibits inhibitory effect cancers\n",
      "abstract medicinal mushroom ganoderma lucidum gl reishi lingzhi exhibits inhibitory effect cancers.\n",
      "2 however underlying mechanism antitumor activity gl fully understood\n",
      "however underlying mechanism antitumor activity gl fully understood.\n"
     ]
    }
   ],
   "source": [
    "top_sentences = []\n",
    "\n",
    "for index in range(len(top_sentence_indices)):\n",
    "    val = preprocessed_sentences[index]\n",
    "    print(index, val)\n",
    "    top_sentences.append(sentences[index])\n",
    "\n",
    "    # Join the top sentences to create the summary\n",
    "    summary = ''.join(val) +  '.'\n",
    "\n",
    "    print(summary)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "c0684a5a",
   "metadata": {},
   "source": [
    "### Plot Frequency Distribution of words from top sentences"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "f6911a74",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Plotting Frequency Distribution of words will not accept lists as an input (top_sentences = [])\n",
    "# Define top_sent_words; tokenize the top_sentences list and obtain a list of words\n",
    "top_sent_words = [word for sentence in top_sentences for word in word_tokenize(sentence)]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "77265648",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['precision', 'clinical', 'medicine', '', '4', '', '4', '', '', '2021', '', '', 'https', '', '', 'advance', 'access', 'publication', 'date', '', '28', 'august', '2021research', 'article', 'research', 'article', 'inhibitory', 'activity', '', 'medicinal', 'mushroom', 'ganoderma', 'lucidum', '', 'colorectal', 'cancer', '', 'attenuating', 'inflammation', 'mandy', '', 'liu1', '', '', '', 'tiantian', 'liu2', '', '', '', 'steven', 'yeung1', '', 'zhijun', 'wang3', '', 'bradley', 'andresen1', '', 'cyrus', '', '', 'robert', '', '', 'bingsen', 'zhou6', '', 'wei', 'wu6', '', 'x', '', 'al', 'i6', '', 'yilong', 'zhang6', '', 'charles', 'wang2', '', '', '', 'ying', 'huang1', '', '', '1department', '', 'pharmaceutical', 'sciences', '', 'college', '', 'pharmacy', '', 'western', 'university', '', 'health', 'sciences', '', 'pomona', '', 'ca', '91766', '', 'usa', '2center', '', 'genomics', '', 'department', '', 'basic', 'sciences', '', 'school', '', 'medicine', '', 'loma', 'linda', 'university', '', 'loma', 'linda', '', 'ca', '92350', '', 'usa', '3department', '', 'pharmaceutical', 'sciences', '', 'college', '', 'pharmacy', '', 'marshall', 'b', 'ketchum', 'university', '', 'fullerton', '', 'ca', '92831', '', 'usa', '4college', '', 'osteopathic', 'medicine', '', '', 'pacific', '', 'western', 'university', '', 'health', 'sciences', '', 'pomona', '', 'ca', '91766', '', 'usa', '5department', '', 'pathology', '', 'beverly', 'hospital', '', 'montebello', '', 'california', '', 'ca', '90640', '', 'usa', '6beijing', 'tong', 'ren', 'tang', 'chinese', 'medicine', 'co', '', 'ltd', '', 'new', 'territories', '', 'hong', 'kong', '999077', '', 'china', '', '', 'charles', 'wang', '', 'chwang', '', '', '', 'ying', 'huang', '', 'yhuang', '', '', 'charles', 'wang', '', 'http', '', '', '', '', 'liu', '', 'tiantian', 'liu', 'contributed', 'equally', '', '', 'work', '', 'abstract', '', 'medicinal', 'mushroom', 'ganoderma', 'lucidum', '', 'gl', '', 'reishi', '', 'lingzhi', '', 'exhibits', '', 'inhibitory', 'effect', '', 'cancers', '', 'however', '', '', 'underlying', 'mechanism', '', '', 'antitumor', 'activity', '', 'gl', '', '', 'fully', 'understood', '']\n"
     ]
    }
   ],
   "source": [
    "# Create a function to preprocess top_sentences_words\n",
    "def preprocess_text(top_sent_words):\n",
    "    cleaned_top_sent_words = []\n",
    "    \n",
    "    for sentence in top_sent_words:\n",
    "        # Tokenize each sentence into words\n",
    "        words = word_tokenize(sentence)\n",
    "        \n",
    "        # Converts each word in the list to lowercase, checks whether a word consists of alphanumeric characters, \n",
    "        # and removes non-alphabetic characters and symbols\n",
    "        words = [word.lower() for word in words if word.isalnum()]\n",
    "        \n",
    "        # Remove stop words\n",
    "        words = [word for word in words if word not in stopwords.words('english')]\n",
    "        \n",
    "        # Join the preprocessed words back together into a single string with space separators\n",
    "        cleaned_top_sent_words.append(' '.join(words))\n",
    "    \n",
    "    return cleaned_top_sent_words\n",
    "\n",
    "# Call the preprocess_text function\n",
    "cleaned_top_sent_words = preprocess_text(top_sent_words)\n",
    "\n",
    "# Print the preprocessed sentences\n",
    "print(cleaned_top_sent_words)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "5ae5ebfc",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1200x400 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "plt.figure(figsize=(12, 4))\n",
    "fdist = nltk.FreqDist(cleaned_top_sent_words)\n",
    "fdist.plot(30, cumulative=False)\n",
    "plt.show()\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d306fcc3",
   "metadata": {},
   "source": [
    "### Named Entity Recognition"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "66b1eb2b",
   "metadata": {},
   "outputs": [],
   "source": [
    "import spacy\n",
    "nlp = spacy.load('en_core_web_sm')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "4ef6f8e6",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Import the displaCy library\n",
    "from spacy import displacy"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "557c0bef",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Create a dococument object\n",
    "document = nlp(text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "098c22d0",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Clinical Medicine-People, including fictional\n",
      "4(4-Objects, vehicles, foods, etc. (not services)\n",
      "2021-Absolute or relative dates or periods\n",
      "231–245-Numerals that do not fall under another type\n",
      "Advance Access Publication Date-Companies, agencies, institutions, etc.\n",
      "28-Numerals that do not fall under another type\n",
      "Article\n",
      "RESEARCH ARTICLE-Named documents made into laws.\n",
      "Ganoderma lucidum-Non-GPE locations, mountain ranges, bodies of water\n",
      "Mandy M. Liu1,§-People, including fictional\n",
      "Tiantian-Nationalities or religious or political groups\n",
      "Steven Yeung1-People, including fictional\n",
      "Zhijun Wang3-People, including fictional\n",
      "Bradley-Companies, agencies, institutions, etc.\n",
      "Robert Orlando4,5-People, including fictional\n",
      "Bingsen Zhou6-People, including fictional\n",
      "Wei Wu6,X-People, including fictional\n",
      "Yilong Zhang6-People, including fictional\n",
      "Charles Wang2,*and Ying Huang1-People, including fictional\n",
      "1Department of Pharmaceutical Sciences-Monetary values, including unit\n",
      "College of Pharmacy-Companies, agencies, institutions, etc.\n",
      "Western University of Health Sciences-Companies, agencies, institutions, etc.\n",
      "Pomona-Countries, cities, states\n",
      "CA 91766-Buildings, airports, highways, bridges, etc.\n",
      "USA-Countries, cities, states\n",
      "2Center-Numerals that do not fall under another type\n",
      "Genomics & Department of Basic Sciences, School of Medicine-Companies, agencies, institutions, etc.\n",
      "Loma Linda University-Companies, agencies, institutions, etc.\n",
      "Loma-Countries, cities, states\n",
      "Linda-People, including fictional\n",
      "CA 92350-Buildings, airports, highways, bridges, etc.\n",
      "USA-Countries, cities, states\n",
      "3Department-Numerals that do not fall under another type\n",
      "Pharmaceutical Sciences-Companies, agencies, institutions, etc.\n",
      "College of Pharmacy-Companies, agencies, institutions, etc.\n",
      "Marshall B. Ketchum University-Companies, agencies, institutions, etc.\n",
      "Fullerton-Countries, cities, states\n",
      "CA-Companies, agencies, institutions, etc.\n",
      "92831-Countries, cities, states\n",
      "USA-Countries, cities, states\n",
      "Osteopathic Medicine of the Pacific-Companies, agencies, institutions, etc.\n",
      "Western University of Health Sciences-Companies, agencies, institutions, etc.\n",
      "Pomona-Countries, cities, states\n",
      "CA 91766-Buildings, airports, highways, bridges, etc.\n",
      "USA-Countries, cities, states\n",
      "5Department-Numerals that do not fall under another type\n",
      "Pathology-Countries, cities, states\n",
      "Beverly Hospital-Countries, cities, states\n",
      "Montebello-Countries, cities, states\n",
      "California-Countries, cities, states\n",
      "USA-Countries, cities, states\n",
      "6Beijing-Numerals that do not fall under another type\n",
      "Tong Ren Tang Chinese Medicine Co., Ltd.-People, including fictional\n",
      "New Territories-Countries, cities, states\n",
      "Hong Kong 999077-Countries, cities, states\n",
      "China-Countries, cities, states\n",
      "Charles Wang-People, including fictional\n",
      "Ying Huang-People, including fictional\n",
      "Charles Wang-People, including fictional\n",
      "Mandy M. Liu-People, including fictional\n",
      "Tiantian Liu-People, including fictional\n",
      "Ganoderma lucidum-People, including fictional\n",
      "GL-Companies, agencies, institutions, etc.\n",
      "Reishi-People, including fictional\n",
      "Lingzhi-Countries, cities, states\n",
      "GL-Companies, agencies, institutions, etc.\n",
      "GL-Companies, agencies, institutions, etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "K562/DOX-Non-GPE locations, mountain ranges, bodies of water\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "1 month-Absolute or relative dates or periods\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "53-Numerals that do not fall under another type\n",
      "suchasIL-1-People, including fictional\n",
      "2 June 2021-Absolute or relative dates or periods\n",
      "Revised-People, including fictional\n",
      "16 August 2021-Absolute or relative dates or periods\n",
      "23-Numerals that do not fall under another type\n",
      "August 2021-Absolute or relative dates or periods\n",
      "2021-Absolute or relative dates or periods\n",
      "Oxford University Press-Companies, agencies, institutions, etc.\n",
      "the West China School of Medicine & West China Hospital of Sichuan University-Companies, agencies, institutions, etc.\n",
      "Open Access-Companies, agencies, institutions, etc.\n",
      "the Creative Commons Attribution License-Companies, agencies, institutions, etc.\n",
      "https://creativecommons.org/licenses/by/4.0/-\"first\", \"second\", etc.\n",
      "231232Mandy M. Liu-People, including fictional\n",
      "al.-Countries, cities, states\n",
      "Pathwayenrichmentanalysissuggestedthatseveralinflammatorypathwaysinvolvingleukocytemigrationand-Countries, cities, states\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "Ganoderma lucidum-People, including fictional\n",
      "RNA-Companies, agencies, institutions, etc.\n",
      "third-\"first\", \"second\", etc.\n",
      "third-\"first\", \"second\", etc.\n",
      "UnitedStates-Companies, agencies, institutions, etc.\n",
      "1Currently-Numerals that do not fall under another type\n",
      "Chemotherapy-Companies, agencies, institutions, etc.\n",
      "Japan-Countries, cities, states\n",
      "44.6%-Percentage, including \"%\"\n",
      "in25.5%-Percentage, including \"%\"\n",
      "2One-Numerals that do not fall under another type\n",
      "Ganoderma lucidum-People, including fictional\n",
      "GL-Companies, agencies, institutions, etc.\n",
      "3,4GL-Numerals that do not fall under another type\n",
      "The Mushroomof Immortality-Titles of books, songs, etc.\n",
      "GL-Companies, agencies, institutions, etc.\n",
      "GL-Companies, agencies, institutions, etc.\n",
      "5-Numerals that do not fall under another type\n",
      "three-Numerals that do not fall under another type\n",
      "First-\"first\", \"second\", etc.\n",
      "GLhasshownefficacy-Companies, agencies, institutions, etc.\n",
      "GLprevented-Companies, agencies, institutions, etc.\n",
      "6–8Thetriterpeneextractpre--Numerals that do not fall under another type\n",
      "GL-Companies, agencies, institutions, etc.\n",
      "10-Numerals that do not fall under another type\n",
      "GL-Companies, agencies, institutions, etc.\n",
      "30%-Percentage, including \"%\"\n",
      "11Second-Numerals that do not fall under another type\n",
      "GL-Companies, agencies, institutions, etc.\n",
      "1.5-Numerals that do not fall under another type\n",
      "12months-Absolute or relative dates or periods\n",
      "12In-Numerals that do not fall under another type\n",
      "GL-Companies, agencies, institutions, etc.\n",
      "5.4-Numerals that do not fall under another type\n",
      "12 weeks-Absolute or relative dates or periods\n",
      "13Third-Absolute or relative dates or periods\n",
      "GL-Companies, agencies, institutions, etc.\n",
      "GL-Companies, agencies, institutions, etc.\n",
      "BCL-2-Nationalities or religious or political groups\n",
      "Bax-People, including fictional\n",
      "COX-2-Buildings, airports, highways, bridges, etc.\n",
      "14How--Numerals that do not fall under another type\n",
      "GL-Companies, agencies, institutions, etc.\n",
      "GLproducts-Companies, agencies, institutions, etc.\n",
      "GL-Companies, agencies, institutions, etc.\n",
      "GL-Companies, agencies, institutions, etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "Antitumor-Companies, agencies, institutions, etc.\n",
      "Ganoderma-Nationalities or religious or political groups\n",
      "233-Numerals that do not fall under another type\n",
      "one-Numerals that do not fall under another type\n",
      "15Tumor-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "RNA-Companies, agencies, institutions, etc.\n",
      "Paclitaxel-People, including fictional\n",
      "T7402-People, including fictional\n",
      "Sigma Aldrich-Companies, agencies, institutions, etc.\n",
      "StLouis-People, including fictional\n",
      "MO-Countries, cities, states\n",
      "Summit-Companies, agencies, institutions, etc.\n",
      "Tong Ren Tang Chinese Medicine Co.-People, including fictional\n",
      "Hong Kong-Countries, cities, states\n",
      "China-Countries, cities, states\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "GL-Companies, agencies, institutions, etc.\n",
      "30:8-Numerals that do not fall under another type\n",
      "GL-Companies, agencies, institutions, etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "GI-Companies, agencies, institutions, etc.\n",
      "0.5-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "12.5-Numerals that do not fall under another type\n",
      "80-Numerals that do not fall under another type\n",
      "2 hours-Times smaller than a day\n",
      "4500-Numerals that do not fall under another type\n",
      "10 minutes-Times smaller than a day\n",
      "Whatman-People, including fictional\n",
      "10-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "200 ml-Measurements, as of weight or distance\n",
      "85-Numerals that do not fall under another type\n",
      "15 minutes-Times smaller than a day\n",
      "4500-Absolute or relative dates or periods\n",
      "−20-Countries, cities, states\n",
      "Cb e f o r-People, including fictional\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "16,17In-Numerals that do not fall under another type\n",
      "5-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "Cwithshak--Objects, vehicles, foods, etc. (not services)\n",
      "1 hour-Times smaller than a day\n",
      "50 ml-Measurements, as of weight or distance\n",
      "37-Numerals that do not fall under another type\n",
      "15 minutes at-Times smaller than a day\n",
      "4500-Absolute or relative dates or periods\n",
      "0.2-Numerals that do not fall under another type\n",
      "Whatman-People, including fictional\n",
      "−20-Countries, cities, states\n",
      "avalidatedHPLC-DADmethod(unpublished),whichwasable-Objects, vehicles, foods, etc. (not services)\n",
      "13-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "ganodericAcidC2,ganodericAcidG-People, including fictional\n",
      "Acid B-People, including fictional\n",
      "Acid B-People, including fictional\n",
      "Acid A-People, including fictional\n",
      "Acid H-People, including fictional\n",
      "Acid D-People, including fictional\n",
      "Acid D-People, including fictional\n",
      "Acid F-People, including fictional\n",
      "Acid DM-Companies, agencies, institutions, etc.\n",
      "GL-Companies, agencies, institutions, etc.\n",
      "conductedin triplicate-People, including fictional\n",
      "HT-29-Objects, vehicles, foods, etc. (not services)\n",
      "INSERM-Companies, agencies, institutions, etc.\n",
      "K562-Objects, vehicles, foods, etc. (not services)\n",
      "18These-Numerals that do not fall under another type\n",
      "with10%-Percentage, including \"%\"\n",
      "1%-Percentage, including \"%\"\n",
      "37-Numerals that do not fall under another type\n",
      "2/95%-Percentage, including \"%\"\n",
      "SRB-Companies, agencies, institutions, etc.\n",
      "Plates-Countries, cities, states\n",
      "96-Numerals that do not fall under another type\n",
      "3000-Numerals that do not fall under another type\n",
      "overnight-Times smaller than a day\n",
      "72 hours-Times smaller than a day\n",
      "37-Numerals that do not fall under another type\n",
      "5%-Percentage, including \"%\"\n",
      "2/95%-Percentage, including \"%\"\n",
      "Sigma-Objects, vehicles, foods, etc. (not services)\n",
      "SRB-Companies, agencies, institutions, etc.\n",
      "19Briefly,1 ×105cellswere-Measurements, as of weight or distance\n",
      "six-Numerals that do not fall under another type\n",
      "72hours-Absolute or relative dates or periods\n",
      "Approximately 5-Numerals that do not fall under another type\n",
      "5cells-Numerals that do not fall under another type\n",
      "Annexin V-People, including fictional\n",
      "PI-Companies, agencies, institutions, etc.\n",
      "Franklin Lakes-People, including fictional\n",
      "10000cells-Numerals that do not fall under another type\n",
      "EarlyapoptoticcellsareAnnexin-People, including fictional\n",
      "Annexin-V-People, including fictional\n",
      "PI-Companies, agencies, institutions, etc.\n",
      "DNR-Companies, agencies, institutions, etc.\n",
      "K562/DOX-Companies, agencies, institutions, etc.\n",
      "20Briefly-Numerals that do not fall under another type\n",
      "6000000-Numerals that do not fall under another type\n",
      "50-Numerals that do not fall under another type\n",
      "1.95 ml-Measurements, as of weight or distance\n",
      "5-Numerals that do not fall under another type\n",
      "DNR-Companies, agencies, institutions, etc.\n",
      "50 minutes-Times smaller than a day\n",
      "37-Numerals that do not fall under another type\n",
      "PBS-Companies, agencies, institutions, etc.\n",
      "transferred234Mandy M. Liu et-People, including fictional\n",
      "al.-Countries, cities, states\n",
      "FACS-Companies, agencies, institutions, etc.\n",
      "Accuri-Countries, cities, states\n",
      "10-Numerals that do not fall under another type\n",
      "work.21In-Companies, agencies, institutions, etc.\n",
      "pRL-TK-Luc Renillaluciferase-Companies, agencies, institutions, etc.\n",
      "Promega-People, including fictional\n",
      "Madison-People, including fictional\n",
      "WI-Companies, agencies, institutions, etc.\n",
      "Promega-People, including fictional\n",
      "1:30-Times smaller than a day\n",
      "Indianapolis-Countries, cities, states\n",
      "Twenty-four-Numerals that do not fall under another type\n",
      "additional 5 hours-Times smaller than a day\n",
      "Forin-Nationalities or religious or political groups\n",
      "1.25%-Percentage, including \"%\"\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "Inc (Rancho Cucamonga-Companies, agencies, institutions, etc.\n",
      "CA-Companies, agencies, institutions, etc.\n",
      "5001-Monetary values, including unit\n",
      "1.25%-Percentage, including \"%\"\n",
      "0.3%-Percentage, including \"%\"\n",
      "fG L S-People, including fictional\n",
      "the Guide for the Careand Use of Laboratory Animals of the National Institutesof Health-Companies, agencies, institutions, etc.\n",
      "3-Numerals that do not fall under another type\n",
      "6-Numerals that do not fall under another type\n",
      "100-Numerals that do not fall under another type\n",
      "6-week-old-Absolute or relative dates or periods\n",
      "Charles River-Non-GPE locations, mountain ranges, bodies of water\n",
      "Burlington-Countries, cities, states\n",
      "MA-Countries, cities, states\n",
      "12 days-Absolute or relative dates or periods\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "2 g/kg-Measurements, as of weight or distance\n",
      "M-F-Objects, vehicles, foods, etc. (not services)\n",
      "nine-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "2.0-Numerals that do not fall under another type\n",
      "4-week--Absolute or relative dates or periods\n",
      "8)-Numerals that do not fall under another type\n",
      "fed-Companies, agencies, institutions, etc.\n",
      "2-Numerals that do not fall under another type\n",
      "fed-Companies, agencies, institutions, etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "4-Numerals that do not fall under another type\n",
      "4 weeks-Absolute or relative dates or periods\n",
      "8weeks-Numerals that do not fall under another type\n",
      "5-Numerals that do not fall under another type\n",
      "5cells-Numerals that do not fall under another type\n",
      "100-Numerals that do not fall under another type\n",
      "ThedoseforGLSFobtainedfromdietconsumptionwasestimatedtobe2.0g/kg-People, including fictional\n",
      ".doseofabraxane(20mg/kg-Companies, agencies, institutions, etc.\n",
      "Day 13-Absolute or relative dates or periods\n",
      "2×length/2.RNA-Numerals that do not fall under another type\n",
      "RNA-Companies, agencies, institutions, etc.\n",
      "usingTRIzol-Nationalities or religious or political groups\n",
      "Invitrogen-Companies, agencies, institutions, etc.\n",
      "Grand Island-Countries, cities, states\n",
      "NY-Companies, agencies, institutions, etc.\n",
      "Mini Kit-People, including fictional\n",
      "Qiagen-People, including fictional\n",
      "Germantown-Countries, cities, states\n",
      "MD-Countries, cities, states\n",
      "eight-Numerals that do not fall under another type\n",
      "RNA-Companies, agencies, institutions, etc.\n",
      "four-Numerals that do not fall under another type\n",
      "two-Numerals that do not fall under another type\n",
      "FulgentGenetics-Companies, agencies, institutions, etc.\n",
      "Temple City-Countries, cities, states\n",
      "CA-Companies, agencies, institutions, etc.\n",
      "Ipswich-Countries, cities, states\n",
      "MA-People, including fictional\n",
      "RNA-Companies, agencies, institutions, etc.\n",
      "150-Numerals that do not fall under another type\n",
      "Illu-mina bcl2fastq2 v2.20-Companies, agencies, institutions, etc.\n",
      "ref-Companies, agencies, institutions, etc.\n",
      "Dragen-Companies, agencies, institutions, etc.\n",
      "CPM-Companies, agencies, institutions, etc.\n",
      "0.5-Numerals that do not fall under another type\n",
      "at least two-Numerals that do not fall under another type\n",
      "3.24.3-Numerals that do not fall under another type\n",
      "Pvalues-Companies, agencies, institutions, etc.\n",
      "0.05-Numerals that do not fall under another type\n",
      "2-fold-Numerals that do not fall under another type\n",
      "1-Numerals that do not fall under another type\n",
      "Ingenuity Pathway Analyses-Companies, agencies, institutions, etc.\n",
      "IPA-Companies, agencies, institutions, etc.\n",
      "Ingenuity-Companies, agencies, institutions, etc.\n",
      "Dataareexpressedasmean ±standarddeviationunless-Companies, agencies, institutions, etc.\n",
      "7.0-Numerals that do not fall under another type\n",
      "GraphPad Software,-Companies, agencies, institutions, etc.\n",
      "Inc-Countries, cities, states\n",
      "La Jolla-Countries, cities, states\n",
      "NCSS 2007(NCSS-Companies, agencies, institutions, etc.\n",
      "LLC-Companies, agencies, institutions, etc.\n",
      "Kaysville-Countries, cities, states\n",
      "Ganoderma-Non-GPE locations, mountain ranges, bodies of water\n",
      "235-Numerals that do not fall under another type\n",
      "1-Numerals that do not fall under another type\n",
      "GI-Companies, agencies, institutions, etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "HT-29-Objects, vehicles, foods, etc. (not services)\n",
      "GL-Companies, agencies, institutions, etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "NCI-N87-Companies, agencies, institutions, etc.\n",
      "NHDF-Companies, agencies, institutions, etc.\n",
      "SRB-Companies, agencies, institutions, etc.\n",
      "A375or-People, including fictional\n",
      "Figs-People, including fictional\n",
      "S2-Numerals that do not fall under another type\n",
      "andIC-People, including fictional\n",
      "50values-Numerals that do not fall under another type\n",
      "Supplemen-Any named language\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "22As-Numerals that do not fall under another type\n",
      "Chemical-Companies, agencies, institutions, etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "HPLC-Countries, cities, states\n",
      "GL-Companies, agencies, institutions, etc.\n",
      "13-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "HPLC-Countries, cities, states\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "13-Numerals that do not fall under another type\n",
      "Supplementary-Countries, cities, states\n",
      "13-Numerals that do not fall under another type\n",
      "12-Numerals that do not fall under another type\n",
      "16.5%-Percentage, including \"%\"\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "Paclitaxel-People, including fictional\n",
      "50was 0.45-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "to3 mg/ml-Titles of books, songs, etc.\n",
      "0.125-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "0.3 mg/ml-Measurements, as of weight or distance\n",
      "Fig-People, including fictional\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "3.0 mg/ml-Measurements, as of weight or distance\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "0.3 mg/ml(P<0.001-Measurements, as of weight or distance\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "0.3-Numerals that do not fall under another type\n",
      "3.0 mg/ml-Measurements, as of weight or distance\n",
      "0.5-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "23,24using-Numerals that do not fall under another type\n",
      "CI-People, including fictional\n",
      "0.04-Numerals that do not fall under another type\n",
      "0.125-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "3.0 mg/ml-Measurements, as of weight or distance\n",
      "CI-People, including fictional\n",
      "1-Numerals that do not fall under another type\n",
      "confirm236Mandy M. Liu-People, including fictional\n",
      "Annexin V/PI-People, including fictional\n",
      "Annexin-V-FITC-Companies, agencies, institutions, etc.\n",
      "PI-Companies, agencies, institutions, etc.\n",
      "The Annexin V/PI-People, including fictional\n",
      "three-Numerals that do not fall under another type\n",
      "SRB-Companies, agencies, institutions, etc.\n",
      "HT-29-Objects, vehicles, foods, etc. (not services)\n",
      "GLSF-Objects, vehicles, foods, etc. (not services)\n",
      "50-Numerals that do not fall under another type\n",
      "0.40-Absolute or relative dates or periods\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "to3 mg/ml concentration-Titles of books, songs, etc.\n",
      "0.25-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "0.11–3 mg/ml-Measurements, as of weight or distance\n",
      "1.0-Numerals that do not fall under another type\n",
      "3.0 mg/ml-Measurements, as of weight or distance\n",
      "Fig-People, including fictional\n",
      "1b-Numerals that do not fall under another type\n",
      "HT-29-Objects, vehicles, foods, etc. (not services)\n",
      "50=0.0035-\"first\", \"second\", etc.\n",
      "3 mg/ml alone-Times smaller than a day\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "Fig-People, including fictional\n",
      "1c-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "ThedegreeofapoptosisinducedbyGLSF(3mg-Companies, agencies, institutions, etc.\n",
      "0.125-Numerals that do not fall under another type\n",
      "72 hours-Times smaller than a day\n",
      "PI-Companies, agencies, institutions, etc.\n",
      "Fig-People, including fictional\n",
      "2-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "P>0.05-Companies, agencies, institutions, etc.\n",
      "Taxol-People, including fictional\n",
      "60.1-Numerals that do not fall under another type\n",
      "P>0.05-Companies, agencies, institutions, etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "53.7 ±1.6%-Percentage, including \"%\"\n",
      "SRB-Companies, agencies, institutions, etc.\n",
      "Fig-People, including fictional\n",
      "GLSFincreased-Countries, cities, states\n",
      "K562/DOX-Non-GPE locations, mountain ranges, bodies of water\n",
      "1526express-Absolute or relative dates or periods\n",
      "DNR-Companies, agencies, institutions, etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "DNR-Companies, agencies, institutions, etc.\n",
      "20Few-Numerals that do not fall under another type\n",
      "DNR-Companies, agencies, institutions, etc.\n",
      "Fig-People, including fictional\n",
      "3a-Numerals that do not fall under another type\n",
      "10-Numerals that do not fall under another type\n",
      "DNR-Companies, agencies, institutions, etc.\n",
      "nearly 100%-Percentage, including \"%\"\n",
      "GLSF-People, including fictional\n",
      "1-Numerals that do not fall under another type\n",
      "2-Numerals that do not fall under another type\n",
      "3 mg/ml-Measurements, as of weight or distance\n",
      "Fig-People, including fictional\n",
      "3b-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "2 mg/ml-Measurements, as of weight or distance\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "Antitumor-Companies, agencies, institutions, etc.\n",
      "Ganoderma-Non-GPE locations, mountain ranges, bodies of water\n",
      "237-Numerals that do not fall under another type\n",
      "3-Numerals that do not fall under another type\n",
      "GLSF GI-Companies, agencies, institutions, etc.\n",
      "K562/DOX-Non-GPE locations, mountain ranges, bodies of water\n",
      "Graphs-People, including fictional\n",
      "DNR-Companies, agencies, institutions, etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "DNR-Companies, agencies, institutions, etc.\n",
      "10 μM PSC833-Measurements, as of weight or distance\n",
      "DNR-Companies, agencies, institutions, etc.\n",
      "3–6-Numerals that do not fall under another type\n",
      "κBpromoteractivity-Companies, agencies, institutions, etc.\n",
      "Renillacontrol-Companies, agencies, institutions, etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "0.3-Numerals that do not fall under another type\n",
      "1.0-Numerals that do not fall under another type\n",
      "2.0-Numerals that do not fall under another type\n",
      "5 hours-Times smaller than a day\n",
      "3–6.∗:P<0.05-Numerals that do not fall under another type\n",
      "one-Numerals that do not fall under another type\n",
      "Renillaluciferaseforthedual-Companies, agencies, institutions, etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "0-Numerals that do not fall under another type\n",
      "0.3-Absolute or relative dates or periods\n",
      "1.0-Numerals that do not fall under another type\n",
      "2.0mg/ml-Measurements, as of weight or distance\n",
      "5-hour-Times smaller than a day\n",
      "10 ng/ml-Measurements, as of weight or distance\n",
      "F-Companies, agencies, institutions, etc.\n",
      "3c-Numerals that do not fall under another type\n",
      "GI-Companies, agencies, institutions, etc.\n",
      "2.0 mg/ml-Measurements, as of weight or distance\n",
      "Fig-People, including fictional\n",
      "3c-Numerals that do not fall under another type\n",
      "27and-Numerals that do not fall under another type\n",
      "L S-Countries, cities, states\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "two-Numerals that do not fall under another type\n",
      "2-Numerals that do not fall under another type\n",
      "M. Liu-People, including fictional\n",
      "al.-Countries, cities, states\n",
      "4-Numerals that do not fall under another type\n",
      "1-Numerals that do not fall under another type\n",
      "GLSF-People, including fictional\n",
      "2-Numerals that do not fall under another type\n",
      "4 weeks-Absolute or relative dates or periods\n",
      "Groups 3 and 4 mice-Companies, agencies, institutions, etc.\n",
      "Days 13-Absolute or relative dates or periods\n",
      "19-Numerals that do not fall under another type\n",
      "the day-Absolute or relative dates or periods\n",
      "Tukey-Kramer Multiple-Comparison-Companies, agencies, institutions, etc.\n",
      "8f-Numerals that do not fall under another type\n",
      "1a-Numerals that do not fall under another type\n",
      "2-Numerals that do not fall under another type\n",
      "4f-Numerals that do not fall under another type\n",
      "3a-Numerals that do not fall under another type\n",
      "PARP-Companies, agencies, institutions, etc.\n",
      "Control n-Companies, agencies, institutions, etc.\n",
      "5-Numerals that do not fall under another type\n",
      "4-Numerals that do not fall under another type\n",
      "2.0 g/kg-Measurements, as of weight or distance\n",
      "daily-Absolute or relative dates or periods\n",
      "Monday-Absolute or relative dates or periods\n",
      "Althoughstatisticallyinsignif-People, including fictional\n",
      "Supplementary Fig-People, including fictional\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "Con A-People, including fictional\n",
      "LPS-Companies, agencies, institutions, etc.\n",
      "LPS-Companies, agencies, institutions, etc.\n",
      "Supplementary Fig-People, including fictional\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "4-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "GLSF-People, including fictional\n",
      "2-Numerals that do not fall under another type\n",
      "1 month-Absolute or relative dates or periods\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "15-Numerals that do not fall under another type\n",
      "3-Numerals that do not fall under another type\n",
      "Two-Numerals that do not fall under another type\n",
      "growth(Fig.4a-People, including fictional\n",
      "ANOVA-Companies, agencies, institutions, etc.\n",
      "only 63%-Percentage, including \"%\"\n",
      "GLSFgroup-Companies, agencies, institutions, etc.\n",
      "two-Numerals that do not fall under another type\n",
      "two-Numerals that do not fall under another type\n",
      "eight-Numerals that do not fall under another type\n",
      "25%)in-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "Fig-People, including fictional\n",
      "4b-Numerals that do not fall under another type\n",
      "Day 19-Absolute or relative dates or periods\n",
      "Fig-People, including fictional\n",
      "4a-Numerals that do not fall under another type\n",
      "Day 13-Absolute or relative dates or periods\n",
      "19-Absolute or relative dates or periods\n",
      "2-Numerals that do not fall under another type\n",
      "3-Numerals that do not fall under another type\n",
      "4-Numerals that do not fall under another type\n",
      "Tumor-Countries, cities, states\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "hematoxylin-Countries, cities, states\n",
      "Ganoderma-Nationalities or religious or political groups\n",
      "239-Numerals that do not fall under another type\n",
      "5-Numerals that do not fall under another type\n",
      "RNA-Companies, agencies, institutions, etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "Fig-People, including fictional\n",
      "4c-Numerals that do not fall under another type\n",
      "67-Numerals that do not fall under another type\n",
      "one-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "Fig-People, including fictional\n",
      "4c-Numerals that do not fall under another type\n",
      "PARP-Companies, agencies, institutions, etc.\n",
      "cleavedPARP-Companies, agencies, institutions, etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "Fig-People, including fictional\n",
      "4d-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "4-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "4-Numerals that do not fall under another type\n",
      "40 million-Numerals that do not fall under another type\n",
      "91%-Percentage, including \"%\"\n",
      "RNA-Companies, agencies, institutions, etc.\n",
      "25 051-Numerals that do not fall under another type\n",
      "13 790-Numerals that do not fall under another type\n",
      "CPM-Companies, agencies, institutions, etc.\n",
      "at least two-Numerals that do not fall under another type\n",
      "MDS-Companies, agencies, institutions, etc.\n",
      "Fig-People, including fictional\n",
      "5a-Numerals that do not fall under another type\n",
      "13790-Absolute or relative dates or periods\n",
      "53-Numerals that do not fall under another type\n",
      "two-Numerals that do not fall under another type\n",
      "1a-Numerals that do not fall under another type\n",
      "0.05-Numerals that do not fall under another type\n",
      "10-Numerals that do not fall under another type\n",
      "Tables-Companies, agencies, institutions, etc.\n",
      "al.-Countries, cities, states\n",
      "Table 1-Buildings, airports, highways, bridges, etc.\n",
      "12-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "Log FC Pvalue-People, including fictional\n",
      "Integrin-Any named language\n",
      "10-Numerals that do not fall under another type\n",
      "Zbtb16 Zinc-People, including fictional\n",
      "BTB-Companies, agencies, institutions, etc.\n",
      "16 2.07 2.79E-04-Measurements, as of weight or distance\n",
      "807 1.26-Numerals that do not fall under another type\n",
      "9.47E-04Lvrn-Numerals that do not fall under another type\n",
      "1.17-Numerals that do not fall under another type\n",
      "6093-Numerals that do not fall under another type\n",
      "1.63 1.49E-03Hrct1-Absolute or relative dates or periods\n",
      "1-Numerals that do not fall under another type\n",
      "Aldehyde-People, including fictional\n",
      "1-Numerals that do not fall under another type\n",
      "Inositol-Companies, agencies, institutions, etc.\n",
      "5-Numerals that do not fall under another type\n",
      "J 1.67-Objects, vehicles, foods, etc. (not services)\n",
      "Rcan2 Regulator-Objects, vehicles, foods, etc. (not services)\n",
      "2 1.00-Absolute or relative dates or periods\n",
      "Ifng Interferon-Non-GPE locations, mountain ranges, bodies of water\n",
      "1.09-Numerals that do not fall under another type\n",
      "Retnla Resistin-People, including fictional\n",
      "2.52-Numerals that do not fall under another type\n",
      "Fmo2 Flavin-Objects, vehicles, foods, etc. (not services)\n",
      "2 1.35-Numerals that do not fall under another type\n",
      "FC-Titles of books, songs, etc.\n",
      "1-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "Table 2-Buildings, airports, highways, bridges, etc.\n",
      "10-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "Log FC Pvalue\n",
      "Il1b-People, including fictional\n",
      "RIKEN-Companies, agencies, institutions, etc.\n",
      "4930565N06-Numerals that do not fall under another type\n",
      "−1.06-Numerals that do not fall under another type\n",
      "Nppb Natriuretic-Companies, agencies, institutions, etc.\n",
      "Ptgs2 Prostaglandin-People, including fictional\n",
      "2-Numerals that do not fall under another type\n",
      "Mmp10 Matrix-Companies, agencies, institutions, etc.\n",
      "10 −1.51 1.31E-03-Measurements, as of weight or distance\n",
      "13-Numerals that do not fall under another type\n",
      "Stamos Signal-People, including fictional\n",
      "1-Numerals that do not fall under another type\n",
      "1-Numerals that do not fall under another type\n",
      "12-Numerals that do not fall under another type\n",
      "FC-Titles of books, songs, etc.\n",
      "−1-Countries, cities, states\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "−1-Countries, cities, states\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "more than 1-Numerals that do not fall under another type\n",
      "GLSFtreatment-Companies, agencies, institutions, etc.\n",
      "30-Numerals that do not fall under another type\n",
      "DEGswas-Companies, agencies, institutions, etc.\n",
      "clustering(Fig.5b-Companies, agencies, institutions, etc.\n",
      "Fig-People, including fictional\n",
      "5c-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "NF-κB-Companies, agencies, institutions, etc.\n",
      "IL-1-Companies, agencies, institutions, etc.\n",
      "IPA-Companies, agencies, institutions, etc.\n",
      "BasedontheratioofthenumberofDEGsin-Countries, cities, states\n",
      "IPA-Companies, agencies, institutions, etc.\n",
      "aFisher-Companies, agencies, institutions, etc.\n",
      "58-Numerals that do not fall under another type\n",
      "Supplementary Table S4-Titles of books, songs, etc.\n",
      "Agranulocyte-Companies, agencies, institutions, etc.\n",
      "IPA-Companies, agencies, institutions, etc.\n",
      "Supplementary Table S5-Titles of books, songs, etc.\n",
      "TNFSF12-Numerals that do not fall under another type\n",
      "KRT17,IL17RA-Companies, agencies, institutions, etc.\n",
      "TNF-Companies, agencies, institutions, etc.\n",
      "IPA-Companies, agencies, institutions, etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "Pvalue <0.05-Companies, agencies, institutions, etc.\n",
      "|>2-Countries, cities, states\n",
      "five-Numerals that do not fall under another type\n",
      "Fig-People, including fictional\n",
      "5d-Numerals that do not fall under another type\n",
      "five-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "Fig-People, including fictional\n",
      "5d-Numerals that do not fall under another type\n",
      "RT-PCR-People, including fictional\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "Fig-People, including fictional\n",
      "Ganoderma-Nationalities or religious or political groups\n",
      "241-Numerals that do not fall under another type\n",
      "6-Numerals that do not fall under another type\n",
      "95%-Percentage, including \"%\"\n",
      "CI-Companies, agencies, institutions, etc.\n",
      "8-Numerals that do not fall under another type\n",
      "10-Numerals that do not fall under another type\n",
      "Mann-Whitney-Companies, agencies, institutions, etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "29and-Numerals that do not fall under another type\n",
      "3However-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "Fig-People, including fictional\n",
      "1a-Numerals that do not fall under another type\n",
      "GLSF-People, including fictional\n",
      "Fig-People, including fictional\n",
      "3c-Numerals that do not fall under another type\n",
      "F - κB.-People, including fictional\n",
      "31-Numerals that do not fall under another type\n",
      "Fig-People, including fictional\n",
      "15CT26cellswerederivedbyexpos--Absolute or relative dates or periods\n",
      "15,33-Numerals that do not fall under another type\n",
      "Comparedwith-Companies, agencies, institutions, etc.\n",
      "One-Numerals that do not fall under another type\n",
      "2.0 g/kg-Measurements, as of weight or distance\n",
      "GL-Companies, agencies, institutions, etc.\n",
      "abraxane242Mandy M. Liu-People, including fictional\n",
      "al.-Countries, cities, states\n",
      "37Thus-Numerals that do not fall under another type\n",
      "GLSF-Objects, vehicles, foods, etc. (not services)\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "11-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "db-Countries, cities, states\n",
      "38-Numerals that do not fall under another type\n",
      "38In-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "39RT-Numerals that do not fall under another type\n",
      "Cox-2-Countries, cities, states\n",
      "Fig-People, including fictional\n",
      "40-Numerals that do not fall under another type\n",
      "Fig-People, including fictional\n",
      "3c-Numerals that do not fall under another type\n",
      "NF-κB transcription-Companies, agencies, institutions, etc.\n",
      "KRAS-People, including fictional\n",
      "IL-6-Companies, agencies, institutions, etc.\n",
      "IL-6-Companies, agencies, institutions, etc.\n",
      "46,47Thus-Numerals that do not fall under another type\n",
      "g u l-Companies, agencies, institutions, etc.\n",
      "F - κB-Companies, agencies, institutions, etc.\n",
      "KRAS-Companies, agencies, institutions, etc.\n",
      "48-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "Cxcl1-Objects, vehicles, foods, etc. (not services)\n",
      "49Probably-Numerals that do not fall under another type\n",
      "20-Numerals that do not fall under another type\n",
      "MMP13,a-People, including fictional\n",
      "dMMP12-Objects, vehicles, foods, etc. (not services)\n",
      "50,51GLSF-Numerals that do not fall under another type\n",
      "Nppb-Companies, agencies, institutions, etc.\n",
      "one-Numerals that do not fall under another type\n",
      "52-Numerals that do not fall under another type\n",
      "Fmo2(flavin-People, including fictional\n",
      "2-Numerals that do not fall under another type\n",
      "54and-Numerals that do not fall under another type\n",
      "55Itga10-Absolute or relative dates or periods\n",
      "α10,whichbindstocol--Companies, agencies, institutions, etc.\n",
      "56-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "two-Numerals that do not fall under another type\n",
      "59and-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "TNF-Companies, agencies, institutions, etc.\n",
      "2-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "IPA-Companies, agencies, institutions, etc.\n",
      "Fig-People, including fictional\n",
      "5d-Numerals that do not fall under another type\n",
      "GL-Companies, agencies, institutions, etc.\n",
      "Ganoderma-Non-GPE locations, mountain ranges, bodies of water\n",
      "243-Numerals that do not fall under another type\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "assays-Absolute or relative dates or periods\n",
      "GLSF-People, including fictional\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "InvitrodatarevealedthatalthoughGLSFalone\n",
      "-People, including fictional\n",
      "effectofGLSF.Immunocompetentmicecarryingthesyn-geneic-Countries, cities, states\n",
      "GL-Companies, agencies, institutions, etc.\n",
      "first-\"first\", \"second\", etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "F - κB-Companies, agencies, institutions, etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "GSLF-Companies, agencies, institutions, etc.\n",
      "KRAS-Companies, agencies, institutions, etc.\n",
      "Supplementary-People, including fictional\n",
      "PCMEDI-Companies, agencies, institutions, etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "Tong Ren Tang Chinese Medicine Co.-People, including fictional\n",
      "Y.H.-Companies, agencies, institutions, etc.\n",
      "M.L.-People, including fictional\n",
      "T.L.-Companies, agencies, institutions, etc.\n",
      "C.W.-Companies, agencies, institutions, etc.\n",
      "RNA-Companies, agencies, institutions, etc.\n",
      "B.A.-Countries, cities, states\n",
      "S.Y.-Countries, cities, states\n",
      "Z.W-Countries, cities, states\n",
      "HPLC-Companies, agencies, institutions, etc.\n",
      "C.P.-Companies, agencies, institutions, etc.\n",
      "R.O.-Companies, agencies, institutions, etc.\n",
      "B.Z.-Countries, cities, states\n",
      "W.W.-Countries, cities, states\n",
      "X.L.-Countries, cities, states\n",
      "Y.Z.-Countries, cities, states\n",
      "Y.H.-Companies, agencies, institutions, etc.\n",
      "Lily Kong Lim-People, including fictional\n",
      "A.S.C.P.-Countries, cities, states\n",
      "the Beverly Hospital-Companies, agencies, institutions, etc.\n",
      "H&E-Companies, agencies, institutions, etc.\n",
      "GLSF-Companies, agencies, institutions, etc.\n",
      "the Beijing Tong Ren Tang ChineseMedicine Co.-Buildings, airports, highways, bridges, etc.\n",
      "YH-Companies, agencies, institutions, etc.\n",
      "the Beijing Tong Ren Tang-Buildings, airports, highways, bridges, etc.\n",
      "Thisstudywasalsopartiallysupportedby Loma-People, including fictional\n",
      "LLU-Companies, agencies, institutions, etc.\n",
      "B.Zhou-Countries, cities, states\n",
      "W.Wu-Countries, cities, states\n",
      "X.LiandY.Zhangareemployeesorcon-Companies, agencies, institutions, etc.\n",
      "the Beijing Tong Ren Tang-Buildings, airports, highways, bridges, etc.\n",
      "Editorial Board-Companies, agencies, institutions, etc.\n",
      "Precision\n",
      "ClinicalMedicine-Companies, agencies, institutions, etc.\n",
      "1-Numerals that do not fall under another type\n",
      "JemalA.Cancerstatistics,2016-Nationalities or religious or political groups\n",
      "J Clin-Objects, vehicles, foods, etc. (not services)\n",
      "doi:10.3322/caac.21332-Companies, agencies, institutions, etc.\n",
      "2-Numerals that do not fall under another type\n",
      "Amano N-People, including fictional\n",
      "Eguchi K-People, including fictional\n",
      "Japan-Countries, cities, states\n",
      "Oncol 2005;23:2645–54-Absolute or relative dates or periods\n",
      "3-Numerals that do not fall under another type\n",
      "Sanodiya BS-People, including fictional\n",
      "Thakur GS-People, including fictional\n",
      "Baghel RK-People, including fictional\n",
      "Ganoderma-Nationalities or religious or political groups\n",
      "Curr Pharm Biotechnol-People, including fictional\n",
      "2009;10:717–42-Absolute or relative dates or periods\n",
      "4-Numerals that do not fall under another type\n",
      "Wang PY-People, including fictional\n",
      "Zhu XL-People, including fictional\n",
      "Lin ZB-People, including fictional\n",
      "Antitumor-Companies, agencies, institutions, etc.\n",
      "Effects of Polysaccharides-Companies, agencies, institutions, etc.\n",
      "Ganoderma lucidum-Non-GPE locations, mountain ranges, bodies of water\n",
      "Front Pharmacol 2012;3:135-Companies, agencies, institutions, etc.\n",
      "5-Numerals that do not fall under another type\n",
      "Sliva D. Ganoderma-People, including fictional\n",
      "Leuk Res-People, including fictional\n",
      "doi:10.1016-People, including fictional\n",
      "6-Numerals that do not fall under another type\n",
      "Lu H-People, including fictional\n",
      "Uesaka-Nationalities or religious or political groups\n",
      "al.Prevention-Companies, agencies, institutions, etc.\n",
      "N-Countries, cities, states\n",
      "Ganoderma\n",
      "lucidum-Companies, agencies, institutions, etc.\n",
      "Rei-shi-Companies, agencies, institutions, etc.\n",
      "Int J Mol Med-People, including fictional\n",
      "2002;9:113–7-Absolute or relative dates or periods\n",
      "https://doi.org/10.3892-People, including fictional\n",
      "7-Numerals that do not fall under another type\n",
      "KyoE-Countries, cities, states\n",
      "UesakaT-Countries, cities, states\n",
      "Awater-solubleextractfromcul-\n",
      "turedmediumofGanodermalucidum(Rei-shi)myceliasup-presses azoxymethane-Non-GPE locations, mountain ranges, bodies of water\n",
      "F344-Objects, vehicles, foods, etc. (not services)\n",
      "Oncol Rep-People, including fictional\n",
      "2003;10-Numerals that do not fall under another type\n",
      "375–9-Numerals that do not fall under another type\n",
      "8-Numerals that do not fall under another type\n",
      "Lu H-People, including fictional\n",
      "Uesaka T-People, including fictional\n",
      "Katoh O-People, including fictional\n",
      "al.Prevention-Companies, agencies, institutions, etc.\n",
      "crypt foci-People, including fictional\n",
      "Rei-shi)myceliain maleF344rats-Companies, agencies, institutions, etc.\n",
      "OncolRep-Companies, agencies, institutions, etc.\n",
      "2001;8:1341–5-Numerals that do not fall under another type\n",
      "10.3892-Numerals that do not fall under another type\n",
      "9-Numerals that do not fall under another type\n",
      "Loganathan J-People, including fictional\n",
      "Jiang J-People, including fictional\n",
      "Mushroom Ganoderma-People, including fictional\n",
      "lucidum-People, including fictional\n",
      "PLoS One-People, including fictional\n",
      "doi:10.1371/journal.pone.0047873-Companies, agencies, institutions, etc.\n",
      "10-Numerals that do not fall under another type\n",
      "Yang Y-People, including fictional\n",
      "Nirmagustina DE-People, including fictional\n",
      "Kumrungsee-Countries, cities, states\n",
      "Biosci Biotechnol Biochem-Companies, agencies, institutions, etc.\n",
      "doi:10.1080/09168451.2017.1343117-People, including fictional\n",
      "11-Numerals that do not fall under another type\n",
      "Luo J-People, including fictional\n",
      "Xie J-People, including fictional\n",
      "derma lucidum-People, including fictional\n",
      "Food Funct-Companies, agencies, institutions, etc.\n",
      "12-Numerals that do not fall under another type\n",
      "Awater-solubleextractfrom-People, including fictional\n",
      "Ganoderma-Nationalities or religious or political groups\n",
      "suppresses244Mandy M. Liu-People, including fictional\n",
      "al.-Countries, cities, states\n",
      "2010;59:1–6-Numerals that do not fall under another type\n",
      "13-Numerals that do not fall under another type\n",
      "Chen X-People, including fictional\n",
      "Hu ZP-People, including fictional\n",
      "Yang XX-People, including fictional\n",
      "IntImmunopharmacol-Companies, agencies, institutions, etc.\n",
      "2006;6:499-Numerals that do not fall under another type\n",
      "508-Numerals that do not fall under another type\n",
      "doi:10.1016-Companies, agencies, institutions, etc.\n",
      "j.intimp.2005.08.026-Countries, cities, states\n",
      "14-Numerals that do not fall under another type\n",
      "Xu J-People, including fictional\n",
      "Zhao J-People, including fictional\n",
      "Ganoderma lucidum-People, including fictional\n",
      "rideenzymatichydrolysatesuppressesthegrowthofhuman\n",
      "colon-People, including fictional\n",
      "963689720931435-Numerals that do not fall under another type\n",
      "15-Numerals that do not fall under another type\n",
      "Castle JC-People, including fictional\n",
      "Boegel S-Companies, agencies, institutions, etc.\n",
      "BMC Genomics-Companies, agencies, institutions, etc.\n",
      "2014;15:190-Numerals that do not fall under another type\n",
      "2164-15--Absolute or relative dates or periods\n",
      "190-Numerals that do not fall under another type\n",
      "16-Numerals that do not fall under another type\n",
      "Sporer F-People, including fictional\n",
      "Harpagophytum-Companies, agencies, institutions, etc.\n",
      "2000;6:469–73-Numerals that do not fall under another type\n",
      "doi:10.1016-Companies, agencies, institutions, etc.\n",
      "17-Numerals that do not fall under another type\n",
      "KundnaniK-People, including fictional\n",
      "38–42-Numerals that do not fall under another type\n",
      "18-Numerals that do not fall under another type\n",
      "Marie JP-People, including fictional\n",
      "Faussat-Suberville AM-Companies, agencies, institutions, etc.\n",
      "Zhou D-People, including fictional\n",
      "19-Numerals that do not fall under another type\n",
      "Liu M-People, including fictional\n",
      "Si-Wu-Tang-People, including fictional\n",
      "Nrf2-Companies, agencies, institutions, etc.\n",
      "Biosci-Countries, cities, states\n",
      "2014;4:8-Absolute or relative dates or periods\n",
      "20-Numerals that do not fall under another type\n",
      "Wang EJ-People, including fictional\n",
      "Casciano CN-People, including fictional\n",
      "Clement RP-Companies, agencies, institutions, etc.\n",
      "Drug Metab Dispos-People, including fictional\n",
      "21-Numerals that do not fall under another type\n",
      "LiangS-Countries, cities, states\n",
      "YeungS-Absolute or relative dates or periods\n",
      "Cancer Prev Res-People, including fictional\n",
      "6207.CAPR-17-0132-Absolute or relative dates or periods\n",
      "22-Numerals that do not fall under another type\n",
      "Yeung S-People, including fictional\n",
      "Chen Q-People, including fictional\n",
      "Yu Y-People, including fictional\n",
      "Ganoderma-Nationalities or religious or political groups\n",
      "Acta Chromatogr-People, including fictional\n",
      "2021-Absolute or relative dates or periods\n",
      "23-Numerals that do not fall under another type\n",
      "ChouTC-Companies, agencies, institutions, etc.\n",
      "1984-Absolute or relative dates or periods\n",
      "22:27–55.doi:10.1016/0065--Numerals that do not fall under another type\n",
      "2571(84)90007-4-Absolute or relative dates or periods\n",
      "24-Numerals that do not fall under another type\n",
      "Chou TC-People, including fictional\n",
      "Motzer RJ-People, including fictional\n",
      "Tong Y-People, including fictional\n",
      "cisplatin-Companies, agencies, institutions, etc.\n",
      "1994;86:1517–24-Numerals that do not fall under another type\n",
      "10.1093-Numerals that do not fall under another type\n",
      "25-Numerals that do not fall under another type\n",
      "Lin F,-People, including fictional\n",
      "Hoogendijk L-People, including fictional\n",
      "Buil L-Companies, agencies, institutions, etc.\n",
      "ABCB1-Objects, vehicles, foods, etc. (not services)\n",
      "ABCG2-Companies, agencies, institutions, etc.\n",
      "doi:10.1016-Companies, agencies, institutions, etc.\n",
      "12.028-Numerals that do not fall under another type\n",
      "26-Numerals that do not fall under another type\n",
      "Naito M-Companies, agencies, institutions, etc.\n",
      "Matsuba-Countries, cities, states\n",
      "Y-Objects, vehicles, foods, etc. (not services)\n",
      "Sato S-People, including fictional\n",
      "Res2002;8:582–8-People, including fictional\n",
      "27-Numerals that do not fall under another type\n",
      "Hu M-People, including fictional\n",
      "Peluffo G-People, including fictional\n",
      "Chen H-People, including fictional\n",
      "COX-2-Titles of books, songs, etc.\n",
      "2009;106:3372–7-Numerals that do not fall under another type\n",
      "10.1073-Numerals that do not fall under another type\n",
      "28-Numerals that do not fall under another type\n",
      "Chen X-People, including fictional\n",
      "Guan J-People, including fictional\n",
      "2017;44:2322–36-Numerals that do not fall under another type\n",
      "Rimar S-People, including fictional\n",
      "Lee-Mengel M-Companies, agencies, institutions, etc.\n",
      "Gillis CN Pulmonary-People, including fictional\n",
      "1996;9:205–9-Absolute or relative dates or periods\n",
      "10.1006-Numerals that do not fall under another type\n",
      "30-Numerals that do not fall under another type\n",
      "Wang JR-People, including fictional\n",
      "Yau LF-People, including fictional\n",
      "Zhang R-People, including fictional\n",
      "2014;62:2558–73-Numerals that do not fall under another type\n",
      "31-Numerals that do not fall under another type\n",
      "Liu C-People, including fictional\n",
      "Dunkin D-People, including fictional\n",
      "Lai J-People, including fictional\n",
      "humancrohn-Countries, cities, states\n",
      "kappaB-People, including fictional\n",
      "2015;21:1918–25-Numerals that do not fall under another type\n",
      "32-Numerals that do not fall under another type\n",
      "GriswoldDP-Companies, agencies, institutions, etc.\n",
      "10.1002/1097--Numerals that do not fall under another type\n",
      "2441::aid-Numerals that do not fall under another type\n",
      "3.0.co;2-p.-Measurements, as of weight or distance\n",
      "33-Numerals that do not fall under another type\n",
      "Lechner MG-People, including fictional\n",
      "Karimi SS-People, including fictional\n",
      "Barry-Holson K-People, including fictional\n",
      "JImmunother\n",
      "2013;36:477–89-People, including fictional\n",
      "34-Numerals that do not fall under another type\n",
      "Wang S-People, including fictional\n",
      "Wang X-People, including fictional\n",
      "Lin L-People, including fictional\n",
      "Lucid-People, including fictional\n",
      "oderma-People, including fictional\n",
      "Chinese J Digestol-Companies, agencies, institutions, etc.\n",
      "3079.2008.10.017-Numerals that do not fall under another type\n",
      "35-Numerals that do not fall under another type\n",
      "Sun L-Companies, agencies, institutions, etc.\n",
      "Zhao M-People, including fictional\n",
      "Huang Y-People, including fictional\n",
      "ganodema lucidum-People, including fictional\n",
      "Chinese-Nationalities or religious or political groups\n",
      "Shanxi Med J-People, including fictional\n",
      "2006;35-Numerals that do not fall under another type\n",
      "698–700-Numerals that do not fall under another type\n",
      "36-Numerals that do not fall under another type\n",
      "Huang G-People, including fictional\n",
      "Zhong W. Inhibition-People, including fictional\n",
      "Chinese-Nationalities or religious or political groups\n",
      "China Medical Engineering-Companies, agencies, institutions, etc.\n",
      "2007;15:1–8-Numerals that do not fall under another type\n",
      "37-Numerals that do not fall under another type\n",
      "Wang Y-People, including fictional\n",
      "Zhang C-People, including fictional\n",
      "Zhang S-People, including fictional\n",
      "Taxol-People, including fictional\n",
      "43-Numerals that do not fall under another type\n",
      "Sci Rep 2017;7:1280-People, including fictional\n",
      "38-Numerals that do not fall under another type\n",
      "Ernst M-People, including fictional\n",
      "Putoczki TL-Companies, agencies, institutions, etc.\n",
      "1410-Absolute or relative dates or periods\n",
      "39-Numerals that do not fall under another type\n",
      "Janakiram NB-Companies, agencies, institutions, etc.\n",
      "Rao CV-People, including fictional\n",
      "Adv Exp Med Biol-People, including fictional\n",
      "0348-0837-8-Absolute or relative dates or periods\n",
      "2-Numerals that do not fall under another type\n",
      "40-Numerals that do not fall under another type\n",
      "Ray AL-People, including fictional\n",
      "Berggren KL-People, including fictional\n",
      "Restrepo Cruz S-People, including fictional\n",
      "IL-1beta-Nationalities or religious or political groups\n",
      "TNF-Companies, agencies, institutions, etc.\n",
      "Int J Cancer-People, including fictional\n",
      "41-Numerals that do not fall under another type\n",
      "Lim KH-People, including fictional\n",
      "Counter CM-People, including fictional\n",
      "Oncogenic Ras-induced-People, including fictional\n",
      "Genes Dev-People, including fictional\n",
      "2007;21:1714–9-Absolute or relative dates or periods\n",
      "42-Numerals that do not fall under another type\n",
      "Talpaz M-People, including fictional\n",
      "Marini-Nationalities or religious or political groups\n",
      "3rd-Countries, cities, states\n",
      "RAS-Companies, agencies, institutions, etc.\n",
      "Res 1999;59:2971–80-Absolute or relative dates or periods\n",
      "4 3-Numerals that do not fall under another type\n",
      "nL-Countries, cities, states\n",
      "2-Numerals that do not fall under another type\n",
      "K-ras-induced lung-Companies, agencies, institutions, etc.\n",
      "2015;6:38816–26-Numerals that do not fall under another type\n",
      "44-Numerals that do not fall under another type\n",
      "KyoS-People, including fictional\n",
      "Clin Cancer Res 2011;17:1341–50-People, including fictional\n",
      "10-2291-Absolute or relative dates or periods\n",
      "45-Numerals that do not fall under another type\n",
      "Kang Y-People, including fictional\n",
      "Zhao R-People, including fictional\n",
      "IKK2-Companies, agencies, institutions, etc.\n",
      "Cancer Cell-People, including fictional\n",
      "doi:10.1016-Companies, agencies, institutions, etc.\n",
      "Ganoderma-Companies, agencies, institutions, etc.\n",
      "245-Numerals that do not fall under another type\n",
      "46-Absolute or relative dates or periods\n",
      "47-Numerals that do not fall under another type\n",
      "Ohno Y-People, including fictional\n",
      "Toyoshima-Named hurricanes, battles, wars, sports events, etc.\n",
      "Yurino H-People, including fictional\n",
      "Sci2017;108:1959–66-Companies, agencies, institutions, etc.\n",
      "doi:10.1111/cas.13330-Companies, agencies, institutions, etc.\n",
      "48-Numerals that do not fall under another type\n",
      "HG-People, including fictional\n",
      "Barbie DA-People, including fictional\n",
      "2014;14:869-Numerals that do not fall under another type\n",
      "71-Numerals that do not fall under another type\n",
      "49-Absolute or relative dates or periods\n",
      "CXCL1-Objects, vehicles, foods, etc. (not services)\n",
      "Int J Mol Sci-People, including fictional\n",
      "2018;19:2427-Non-GPE locations, mountain ranges, bodies of water\n",
      "50-Numerals that do not fall under another type\n",
      "Klupp F,-People, including fictional\n",
      "Neumann L-Companies, agencies, institutions, etc.\n",
      "Kahlert C-Countries, cities, states\n",
      "BMCCancer 2016;16:494.doi:10.1186-People, including fictional\n",
      "016-2515-7-Absolute or relative dates or periods\n",
      "51-Numerals that do not fall under another type\n",
      "McKay JA-People, including fictional\n",
      "Murray GI-People, including fictional\n",
      "13-Numerals that do not fall under another type\n",
      "2002;55:758–62.doi:10.1136-Numerals that do not fall under another type\n",
      "52-Numerals that do not fall under another type\n",
      "S100a9-Numerals that do not fall under another type\n",
      "Nppb-Companies, agencies, institutions, etc.\n",
      "Aldh1a3-Absolute or relative dates or periods\n",
      "Clotam-People, including fictional\n",
      "Int J Cancer-People, including fictional\n",
      "53-Numerals that do not fall under another type\n",
      "Hsu YL-People, including fictional\n",
      "Hung JY-People, including fictional\n",
      "Lee YL-People, including fictional\n",
      "al-Companies, agencies, institutions, etc.\n",
      "54-Absolute or relative dates or periods\n",
      "Maly CJ-People, including fictional\n",
      "Cumsky HJL-Companies, agencies, institutions, etc.\n",
      "Costello CM-People, including fictional\n",
      "al-Companies, agencies, institutions, etc.\n",
      "2019-Absolute or relative dates or periods\n",
      "55-Numerals that do not fall under another type\n",
      "Patel AB-Companies, agencies, institutions, etc.\n",
      "Mangold AR-Companies, agencies, institutions, etc.\n",
      "Costello CM-People, including fictional\n",
      "al.-Companies, agencies, institutions, etc.\n",
      "doi:10.1111/jdv.14462-Companies, agencies, institutions, etc.\n",
      "56-Numerals that do not fall under another type\n",
      "Harjunpaa H-People, including fictional\n",
      "Llort Asens M-People, including fictional\n",
      "Front Immunol 2019;10:1078-Companies, agencies, institutions, etc.\n",
      "57-Numerals that do not fall under another type\n",
      "Grozdanov V-People, including fictional\n",
      "Bliederhaeuser C-Companies, agencies, institutions, etc.\n",
      "Ruf WP-People, including fictional\n",
      "al.-Companies, agencies, institutions, etc.\n",
      "Acta Neuropathol-People, including fictional\n",
      "2014-Absolute or relative dates or periods\n",
      "128:651–63-Numerals that do not fall under another type\n",
      "58-Numerals that do not fall under another type\n",
      "Merdad A-People, including fictional\n",
      "Schulten-People, including fictional\n",
      "MMP-9-People, including fictional\n",
      "59-Numerals that do not fall under another type\n",
      "Guo Y-People, including fictional\n",
      "Su ZY-People, including fictional\n",
      "2017;135:22–34-Numerals that do not fall under another type\n",
      "doi:10.1016/j.bcp.2017.02.021-Companies, agencies, institutions, etc.\n"
     ]
    }
   ],
   "source": [
    "# Define a function to display named entities along with their corresponding entity labels and explanations \n",
    "def show_ents(document):\n",
    "    if document.ents:\n",
    "        for ent in document.ents:\n",
    "            print(ent.text + '-' + str(spacy.explain(ent.label_)))\n",
    "show_ents(document)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "4f9b7453",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Precision \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Clinical Medicine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " , \n",
       "<mark class=\"entity\" style=\"background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    4(4\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PRODUCT</span>\n",
       "</mark>\n",
       "), \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2021\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    231–245\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>https://doi.org/10.1093/pcmedi/pbab023<br>\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Advance Access Publication Date\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ": \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    28\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " August 2021Research \n",
       "<mark class=\"entity\" style=\"background: #ff8197; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Article\n",
       "RESEARCH ARTICLE\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">LAW</span>\n",
       "</mark>\n",
       "<br>Inhibitory activity of medicinal mushroom<br>\n",
       "<mark class=\"entity\" style=\"background: #ff9561; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ganoderma lucidum\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">LOC</span>\n",
       "</mark>\n",
       " on colorectal cancer by<br>attenuating inflammation<br>\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Mandy M. Liu1,§\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Tiantian\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
       "</mark>\n",
       " Liu2,§, \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Steven Yeung1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Zhijun Wang3\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ",<br>\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Bradley\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " Andresen1, Cyrus Parsa4,5, \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Robert Orlando4,5\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Bingsen Zhou6\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ",<br>\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Wei Wu6,X\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " i aL i6, \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Yilong Zhang6\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Charles Wang2,*and Ying Huang1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ",*<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1Department of Pharmaceutical Sciences\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">MONEY</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    College of Pharmacy\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Western University of Health Sciences\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ",<br>\n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Pomona\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #9cc9cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CA 91766\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">FAC</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    USA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       "<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2Center\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " for \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Genomics &amp; Department of Basic Sciences, School of Medicine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Loma Linda University\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Loma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       "<br>\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Linda\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #9cc9cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CA 92350\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">FAC</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    USA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       "<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    3Department\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Pharmaceutical Sciences\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    College of Pharmacy\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Marshall B. Ketchum University\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Fullerton\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "<br>\n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    92831\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    USA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       "<br>4College of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Osteopathic Medicine of the Pacific\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Western University of Health Sciences\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Pomona\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #9cc9cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CA 91766\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">FAC</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    USA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       "<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    5Department\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Pathology\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Beverly Hospital\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Montebello\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    California\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ", CA 90640, \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    USA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       "<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    6Beijing\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Tong Ren Tang Chinese Medicine Co., Ltd.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    New Territories\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Hong Kong 999077\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    China\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       "<br>∗Correspondence: \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Charles Wang\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", chwang@llu.edu ; \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ying Huang\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", yhuang@westernu.edu<br>\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Charles Wang\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", http://orcid.org/0000-0001-8861-2121<br>§\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Mandy M. Liu\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Tiantian Liu\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " contributed equally to this work.<br>Abstract<br>The medicinal mushroom \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ganoderma lucidum\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Reishi\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " or \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Lingzhi\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ") exhibits an inhibitory effect on cancers.<br>However, the underlying mechanism of the antitumor activity of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " is not fully understood. In this study, we<br>characterized the gene networks regulated by a commercial product of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " containing a mixture of spores andfruitingbodiesnamely“GLSF”,incolorectalcarcinoma.Wefoundthat invitroco-administrationofGLSFextract<br>at non-toxic concentrations significantly potentiated growth inhibition and apoptosis induced by paclitaxel in<br>CT26 and HCT-15 cells. \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " inhibited NF- κB promoter activity in HEK-293 cells but did not affect the function<br>of P-glycoprotein in \n",
       "<mark class=\"entity\" style=\"background: #ff9561; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    K562/DOX\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">LOC</span>\n",
       "</mark>\n",
       " cells. Furthermore, we found that when mice were fed a modified diet contain-<br>ing \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " for \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1 month\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " prior to the CT26 tumor cell inoculation, \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " alone or combined with Nab-paclitaxel<br>markedly suppressed tumor growth and induced apoptosis. RNA-seq analysis of tumor tissues derived fromGLSF-treated mice identified \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    53\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " differentially expressed genes compared to normal tissues. Many of the GLSF-<br>down-regulatedgeneswereinvolvedinNF- κB-regulatedinflammationpathways,\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    suchasIL-1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " β,IL-11andCox-2.<br>Received: \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2 June 2021\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       "; \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Revised\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ": \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    16 August 2021\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       "; Accepted: \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    23\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    August 2021\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       "<br>C/circlecopyrtThe Author(s) \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2021\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ". Published by \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Oxford University Press\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " on behalf of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    the West China School of Medicine &amp; West China Hospital of Sichuan University\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ".<br>This is an \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Open Access\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " article distributed under the terms of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    the Creative Commons Attribution License\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " ( \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    https://creativecommons.org/licenses/by/4.0/\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORDINAL</span>\n",
       "</mark>\n",
       " ),<br>which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.<br>\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    231232Mandy M. Liu\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " et \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    al.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       "<br>\n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Pathwayenrichmentanalysissuggestedthatseveralinflammatorypathwaysinvolvingleukocytemigrationand\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       "<br>adhesion were most affected by the treatment. Upstream analysis predicted activation of multiple tumor sup-pressorssuchas α-cateninandTP53andinhibitionofcriticalinflammatorymediators.“Cancer” wasthemajor<br>significantly inhibited biological effect of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " treatment. These results demonstrate that \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " can improve<br>the therapeutic outcome for colorectal cancer through a mechanism involving suppression of NF- κB-regulated<br>inflammation and carcinogenesis.<br>Key words: \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ganoderma lucidum\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " ; colorectal carcinoma; \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    RNA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "-seq; NF- κB; inflammation<br>Introduction<br>Colorectal cancer is the \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    third\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORDINAL</span>\n",
       "</mark>\n",
       " most common type of can-<br>cer and also the \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    third\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORDINAL</span>\n",
       "</mark>\n",
       " most common cause of cancer-related death in both men and women in the \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    UnitedStates\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ".<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1Currently\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ", surgery and chemotherapy are the<br>main treatment options for colorectal cancer, depend-ing on the stage, grade, and tumor location at diagnosis.\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Chemotherapy\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " is used for patients with metastatic col-orectal cancer as primary therapy, and for patients withearly-stage colorectal cancer before or after surgery asadjuvant therapy. However, chemoresistance is a com-mon obstacle that occurs in almost all cases of col-orectal cancer. In addition, because chemotherapy non-selectively affects all cells that are active in the cellgrowth cycle, it causes toxicity in normal organs suchasthebonemarrow,gastrointestinaltract,andhairfolli-cles. Therefore, the common clinical practice is to use acombination of several anticancer agents with differentmechanisms of actions or toxicity profiles to overcomedrug resistance and reduce toxic reactions.<br>Globally, it has become more and more popular for<br>cancer patients to use complementary and alterna-tive medicine derived from natural sources during orafter the course of conventional anticancer therapies. Anationwide survey conducted in \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Japan\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " revealed a preva-lence of herbal use in \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    44.6%\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERCENT</span>\n",
       "</mark>\n",
       " of cancer patients and \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    in25.5%\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERCENT</span>\n",
       "</mark>\n",
       " of non-cancer patients with benign tumors, andthe most frequently used herbal products were mush-rooms.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2One\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " of the most well-known medicinal mush-<br>rooms is \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ganoderma lucidum\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "), also commonly named<br>asReishiorLingzhi,whichhasbeenusedforcenturiesinEastAsiatotreatavarietyofdisorders,includinginflam-mation and cancer, without any obvious toxicity.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    3,4GL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>and related products are referred to as ‘\n",
       "<mark class=\"entity\" style=\"background: #f0d0ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    The Mushroomof Immortality\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">WORK_OF_ART</span>\n",
       "</mark>\n",
       "’ because of beneficial effects on healthand longevity. The spores of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " are the reproductivecells of the fungus, which are ejected from the cap afterthe fruiting bodies become mature. The major bioactivecomponents identified in \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " spores and fruiting bod-ies are polysaccharides, which are known to stimulatethe immune system, as well as triterpenes, which maydirectly inhibit proliferating cancer cells.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    5\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>Anticanceractivityhasbeeninvestigatedusingdiffer-<br>entpartsoftheGLmushroom,thespores,fruitingbodiesor mycelia (the early harvest), in human and preclinicalanimalmodels.Theevidencerelatedtocolorectalcancercan be summarized into \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    three\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " types of studies. \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    First\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORDINAL</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLhasshownefficacy\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " incertainpreclinical modelsofcoloncancerprevention,thatisprophylaxis.Inseveralreports,<br>the water extracts of the mycelia culture media of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLprevented\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " chemical carcinogen-induced colorectal car-cinogenesisinmiceorrats.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    6–8Thetriterpeneextractpre-\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>vented colitis-associated colon carcinogenesis in mice.9<br>Feeding water extract of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " powder to rats with a high-fat diet reduced fecal secondary bile acids and intestinalbacteria known to be related to colon carcinogenesis.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    10\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " polysaccharide consumption reduced \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    30%\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERCENT</span>\n",
       "</mark>\n",
       " of mor-tality, specific bacteria and expression of cancer-relatedgenes in mice with colon cancer induced by chemi-cal carcinogens.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    11Second\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " has shown some clinical<br>evidence of preventing development of colon cancer ormodulating some biomarkers related to immunomodu-lation or carcinogenesis. For example, the same myceliaextract mentioned above suppressed the number andsizeofprecancerouscolorectaladenomasinhumansub-jects who took the mycelia extract at \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1.5\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " g/day for \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    12months\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ".<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    12In\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " patients with advanced colorectal cancer,<br>taking oral \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " at \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    5.4\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " g/day for \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    12 weeks\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " induced somechanges in immune-related parameters such as IL-1 andTNF-α, although the effects were not statistically sig-<br>nificant.<br>\n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    13Third\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " has shown some antitumor effi-<br>cacy in a few preclinical studies of human colon can-cer cell lines in vitro. For example, the effect of enzy-<br>matically hydrolyzed \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " polysaccharide has been exam-ined in human colon cancer cell lines, indicating inhibi-tion of apoptosis via up-regulation of \n",
       "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BCL-2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
       "</mark>\n",
       " associatedX protein (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Bax\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ") and down-regulation of \n",
       "<mark class=\"entity\" style=\"background: #9cc9cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COX-2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">FAC</span>\n",
       "</mark>\n",
       ".<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    14How-\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>ever, besides reports of the prophylactic efficacy for \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ",few studies have reported the therapeutic effects of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLproducts\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " as a single therapy or combined with conven-tional chemotherapies for already diagnosed colorectalcancer both in vitro andin vivo. Therefore, it is largely<br>unknown whether colorectal cancer patients could ben-efit from treatment with \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " products.<br>The present study aimed to determine the effect of<br>GL on colorectal cancer in vitro andin vivo. A com-<br>mercial \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " product containing a mixture of sporesand fruiting bodies, namely “GLSF”, was used. Wefirstly evaluated whether the \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " extracts preparedin several methods including the use of artificial gas-trointestinal juice (to simulate in vivo digestion) have<br>any direct anticancer effects on cancer cells in cul-ture. As colorectal cancers are commonly resistantto taxanes, we next evaluated whether artificial gas-trointestinal juice digested \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " has any chemosen-sitizing effect in combination with paclitaxel in vitro.\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Antitumor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " activity of \n",
       "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ganoderma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
       "</mark>\n",
       " lucidum \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    233\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>Furthermore,weevaluatedwhetheraGLSFmodifieddiet<br>wasabletoinhibittumorgrowthinamousemodelbear-ing murine colorectal carcinoma CT26, which is \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    one\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " ofthemostextensivelyusedsyngeneicmousetumormod-els.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    15Tumor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " samples dissected from \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "-treated and<br>control diet-treated tumor-bearing mice were analyzedby \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    RNA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " sequencing (RNA-seq). Potential mechanisms ofthe anticancer and chemosensitization effect of GLSFin colorectal carcinoma were further explored throughbioinformatics analysis.<br>Materials and methods<br>Compounds and reagents<br>\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Paclitaxel\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T7402\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ") purchased from \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Sigma Aldrich\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    StLouis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    MO\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ") was used in vitro. Abraxane<br>R/circlecopyrtfor injectable<br>suspension(Celgene,\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Summit\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ",NJ)wasused invivo.Asin-<br>gle batch of a commercial product manufactured by Bei-jing \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Tong Ren Tang Chinese Medicine Co.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Hong Kong\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ",\n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    China\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       "), named as \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", contains a mixture of the sporesand fruiting bodies of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " at a \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    30:8\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " ratio, was usedthroughout the present study.<br>Preparation of GLSF extracts and quantification of<br>the major components<br>As there is no standardized preparation approach for<br>\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " and related products, several reagents were used toextract \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " including ethanol, methanol, hot water, aswell as artificial gastric and intestinal (\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ") juice. For theethanol/methanol extract, \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    0.5\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " g of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " was extractedwith \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    12.5\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " ml solvent in a round bottom flask attached toa reflux condenser at \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    80\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>◦C for \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2 hours\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">TIME</span>\n",
       "</mark>\n",
       ". The mixture was<br>centrifuged at \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    4500\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " g for \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    10 minutes\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">TIME</span>\n",
       "</mark>\n",
       ". The supernatantwas collected, and the pellet was extracted by repeat-ingthestepsabove.Thesupernatantcollectedwascom-bined and filtered using \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Whatman\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " filter paper. The sol-vent was removed using a rotary evaporator.<br>For the hot water extract, \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    10\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " g of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " was extracted<br>with \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    200 ml\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">QUANTITY</span>\n",
       "</mark>\n",
       " of nanopure water at \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    85\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>◦C for \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    15 minutes\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">TIME</span>\n",
       "</mark>\n",
       "<br>under stirring. The mixture was then centrifuged for 15minutes at \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    4500\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " g. The supernatant was filtered usingWhatman filter paper and filtrate lyophilized. The pow-der obtained was weighed and stored at \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    −20\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       "<br>◦\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Cb e f o r\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " e<br>analysis.<br>The extracts of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " were prepared in the artificial<br>gastrointestinal juice, which was prepared according toreported methods.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    16,17In\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " brief, \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    5\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " g of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " powder was<br>mixedin50mlofartificialgastricjuiceat37◦\n",
       "<mark class=\"entity\" style=\"background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Cwithshak-\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PRODUCT</span>\n",
       "</mark>\n",
       "<br>ing for \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1 hour\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">TIME</span>\n",
       "</mark>\n",
       ", then \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    50 ml\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">QUANTITY</span>\n",
       "</mark>\n",
       " of artificial intestinal juice wasadded and incubated at \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    37\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>◦C with shaking for an addi-<br>tional5hours.Themixturewascentrifugedatroomtem-perature for \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    15 minutes at\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">TIME</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    4500\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " g, and the supernatantwascollected.TheextractwasthenneutralizedtopH7.0using \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    0.2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " M NaOH, filtered using \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Whatman\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " filter paper,lyophilized, and stored at \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    −20\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       "<br>◦C.<br>The major active components were determined using<br>\n",
       "<mark class=\"entity\" style=\"background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    avalidatedHPLC-DADmethod(unpublished),whichwasable\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PRODUCT</span>\n",
       "</mark>\n",
       " to quantify \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    13\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " major components in \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " includingganoderenicAcidC,\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ganodericAcidC2,ganodericAcidG\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ",<br>ganoderic \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Acid B\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", ganoderenic \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Acid B\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", ganoderic \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Acid A\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ",ganoderic \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Acid H\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", ganoderenic \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Acid D\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", ganoderic \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Acid D\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ",ganoderic \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Acid F\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", ganoderic \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Acid DM\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", ganoderol A, andergosterol. The individual contents in the extracts werequantified and used as a fingerprint for \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " products. Allthe extractions and fingerprint analysis were \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    conductedin triplicate\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ".<br>Cell lines and cell culture<br>CT26, HCT-15, \n",
       "<mark class=\"entity\" style=\"background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    HT-29\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PRODUCT</span>\n",
       "</mark>\n",
       ", and HEK-293 cells were purchasedfromATCC(Manassas,VA).K562/DOXcellline(agiftfromJ.P.Marie,\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    INSERM\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ",E9912,UniversityofParis,France)wasobtained by in vitro passaging of \n",
       "<mark class=\"entity\" style=\"background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    K562\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PRODUCT</span>\n",
       "</mark>\n",
       " in progressively<br>increasing doses of daunorubicin.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    18These\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " cells were<br>maintained in RPMI-1640 or DMEM supplemented \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    with10%\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERCENT</span>\n",
       "</mark>\n",
       " fetal bovine serum and \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1%\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERCENT</span>\n",
       "</mark>\n",
       " penicillin-streptomycin.Cells were incubated at \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    37\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>◦Cw i t h5 %C O \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2/95%\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERCENT</span>\n",
       "</mark>\n",
       " air.<br>\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SRB\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " cell proliferation assay<br>\n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Plates\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    96\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "-well) were seeded with \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    3000\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " cells per well andthe cells were allowed to attach \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    overnight\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">TIME</span>\n",
       "</mark>\n",
       ". Cells weretreated with drugs for \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    72 hours\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">TIME</span>\n",
       "</mark>\n",
       " and incubated at \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    37\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>◦C<br>in \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    5%\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERCENT</span>\n",
       "</mark>\n",
       " CO \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2/95%\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERCENT</span>\n",
       "</mark>\n",
       " air. Cell viability was determined using<br>a \n",
       "<mark class=\"entity\" style=\"background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Sigma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PRODUCT</span>\n",
       "</mark>\n",
       " sulforhodamine B (\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SRB\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ") assay according to themanufacturer’s protocol.<br>Apoptosis analysis<br>Flow cytometry was used to assess apoptosis by FITC-labeledannexin-V(Sigma)andpropidiumiodide,respec-tively,aspreviouslydescribed.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    19Briefly,1 ×105cellswere\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">QUANTITY</span>\n",
       "</mark>\n",
       "<br>seeded per well in \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    six\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "-well tissue culture plates for 24hours. The cells were then incubated with drugs for \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    72hours\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ". Cells were collected and washed twice with coldPBS. \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Approximately 5\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " ×10<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    5cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " were mixed with bind-<br>ing buffer with or without \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Annexin V\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " or \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ". FluorescencewasdetectedinfluorescencechannelsFL1andFL3.Dataacquisition and analysis were performed using AccuriC6 Flow Cytometer (BD Biosciences, \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Franklin Lakes\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", NJ).Analysis was based on acquisition of data from \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    10000cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ".\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    EarlyapoptoticcellsareAnnexin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       "-VpositiveandPI-negative, whereas late apoptotic cells are both \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Annexin-V\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "-positive.<br>Intracellular daunorubicin (\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    DNR\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ") accumulation<br>assay<br>The capacity of a compound to inhibit P-glycoprotein-<br>mediated efflux from \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    K562/DOX\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " cells, was measured byflow cytometry as described previously.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    20Briefly\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ", the cell<br>pellet was resuspended in culture media at a concentra-tion of \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    6000000\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " cells/ml. Aliquots (\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    50\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " μl) of the cell sus-<br>pension were transferred to tubes containing \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1.95 ml\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">QUANTITY</span>\n",
       "</mark>\n",
       " ofmedia in the presence or absence of test drugs in mediaand \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    5\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " μM of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    DNR\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " for \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    50 minutes\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">TIME</span>\n",
       "</mark>\n",
       " at \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    37\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>◦C. After cen-<br>trifugation and removal of supernatant, cold \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PBS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " wasadded to each tube, and cell suspension was \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    transferred234Mandy M. Liu et\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    al.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       "<br>to \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    FACS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " tubes, which were placed on ice until analysis.<br>Flow cytometry was performed with an \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Accuri\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " C6 FlowCytometer. PSC833 (\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    10\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " μM) served as a positive control.<br>Luciferase reporter gene assay<br>Dual luciferase assay for NF- κB has been described in<br>previous \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    work.21In\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " brief, HEK-293 cells were transfected<br>with \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pRL-TK-Luc Renillaluciferase\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Promega\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Madison\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ",<br>\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    WI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ") and pGL4.22-NF- κB (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Promega\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ") plasmids at a ratio<br>of \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1:30\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">TIME</span>\n",
       "</mark>\n",
       " using FuGENE HD Transfection Reagent (RocheApplied Science, \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Indianapolis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ", IN). \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Twenty-four\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " hourslater the cells were exposed to TNF- α(10 ng/ml) and<br>incubated in fresh growth medium containing drugs foran \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    additional 5 hours\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">TIME</span>\n",
       "</mark>\n",
       ". Cell lysates were analyzed by thedualluciferasereportergeneassay(Promega)with Renilla<br>luciferase serving as a normalization factor.<br>Rodent diet preparation<br>\n",
       "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Forin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
       "</mark>\n",
       " vivostudies, \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1.25%\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERCENT</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " powder was incorpo-<br>ratedintomousedietsfororaladministration.Themodi-fiedanimaldietwasorderedthroughNewcoDistributors,\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Inc (Rancho Cucamonga\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "). The formulation included98.45% Laboratory Rodent Diet #\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    5001\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">MONEY</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1.25%\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERCENT</span>\n",
       "</mark>\n",
       " GLSF, and<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    0.3%\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERCENT</span>\n",
       "</mark>\n",
       " color dye. The calculation of the drug was based on<br>anaveragedailyintakeof4gpermouse.Foodconsump-tion for each group was monitored during the study andi tw a sc o n fi r m e dt h a tt h ed o s eo \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    fG L S\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " Fw a s ∼2.0 g/kg.<br>Animal experiment<br>All animal studies were carried out in strict accordance<br>with the recommendations in \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    the Guide for the Careand Use of Laboratory Animals of the National Institutesof Health\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " and approved by the Western University ofHealthSciencesInstitutionalAnimalCareandUseCom-mittees.Apilotstudywasconductedusingfivemaleandsix female BALB/c mice. CT26 cells (\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    3\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " ×10<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    6\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ") in \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    100\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " μl<br>serum free media were injected subcutaneously into theright and left flanks of \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    6-week-old\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " mice (\n",
       "<mark class=\"entity\" style=\"background: #ff9561; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Charles River\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">LOC</span>\n",
       "</mark>\n",
       ",\n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Burlington\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    MA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       "). At \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    12 days\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " after implantation, treat-ments began. The dose of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2 g/kg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">QUANTITY</span>\n",
       "</mark>\n",
       ") was given by oralgavaging once a day, \n",
       "<mark class=\"entity\" style=\"background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    M-F\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PRODUCT</span>\n",
       "</mark>\n",
       ", for a total of \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    nine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " oral doses.Mice were treated with vehicle control or \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2.0\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " g/kg(n=3–4).<br>For a rodent diet-based drug regimen study, \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    4-week-\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       "<br>oldmicewererandomlydividedintofourgroups.Groups1a n d3( n =\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    8)\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " were \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    fed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " with standard diet while groups<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " and 4 were \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    fed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " with diet containing \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " (n =\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    4\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ") for<br>\n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    4 weeks\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " before cell inoculation. When the mice were \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    8weeks\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " old, \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    5\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " ×10<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    5cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    100\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " μl serum free media were<br>injected subcutaneously into the right and left flanks ofmice.\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ThedoseforGLSFobtainedfromdietconsumptionwasestimatedtobe2.0g/kg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ",asforthepilotstudy.Groups3and4weretreatedwithasinglei.v \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    .doseofabraxane(20mg/kg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ") (on \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Day 13\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " after tumor inoculation). The tumorvolumewascalculatedaccordingtotheformulation:Vol-ume=(width)<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2×length/2.RNA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " extraction, library preparation, and<br>next-generation sequencing<br>Tumors from the rodent diet-based drug regimen study<br>were dissected, snap frozen, and stored at −80◦C. The<br>total \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    RNA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " was extracted from the tumor tissues \n",
       "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    usingTRIzol\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
       "</mark>\n",
       " reagent (\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Invitrogen\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Grand Island\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    NY\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ") and aRNeasy \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Mini Kit\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Qiagen\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Germantown\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    MD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       "). The qual-ityofRNAsampleswasdeterminedwithanAgilent2100Bioanalyzer. A total of \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    eight\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    RNA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " samples (\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    four\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " sam-ples per treatment, \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    two\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " groups) were sent to \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    FulgentGenetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Temple City\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ") for library preparation andsequencing. Briefly, the library was constructed usingthe NEBNext<br>R/circlecopyrtPoly(A) mRNA Magnetic Isolation Mod-<br>ule+NEBNext R/circlecopyrtUltraII Directional RNA Library Prep<br>Kit (New England Biolabs, \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ipswich\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    MA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       "). The \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    RNA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "-seqlibraries were sequenced using an Illumina HiSeq 4000with \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    150\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " bp, paired-end, at a minimum depth of total 60million reads per sample.<br>Computational RNA-seq data analysis<br>Raw data were converted into fastq files by \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Illu-mina bcl2fastq2 v2.20\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ". Read quality was assessed usingFastQC. The sequence reads were mapped to mouse \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ref\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "-erence genome GRCm38 using the Edico Genome Dra-gen aligner with default settings. Duplicate reads, asmarked by the \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Dragen\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " aligner, were removed before cov-erage analysis. The aligned bam files were processed byHTSeq for gene quantification. Only genes with countsper million (\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CPM\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ") values above \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    0.5\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    at least two\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " sam-ples were included in the differential expression anal-ysis. Differentially expressed genes were identified byR package EdgeR (version \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    3.24.3\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "). Briefly, read countswere fitted into negative binomial distribution. The dif-ferential analysis was carried out using quasi-likelihoodF-test. Genes with \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Pvalues\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " &lt;\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    0.05\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " and absolute log<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2-fold\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " change above \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " were considered to be signif-icantly differentially expressed. Pathway analysis andprediction based on significant DEGs were performedusing \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ingenuity Pathway Analyses\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    IPA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "; \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ingenuity\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "<br>R/circlecopyrt<br>Systems, www.ingenuity.com ). Global MDS, hierarchical<br>clustering heat map, and volcano plot were generatedusing plotMDS, heatmap.2, and plotMD functions in R,respectively.<br>Statistical analysis<br>\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Dataareexpressedasmean ±standarddeviationunless\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "<br>stated otherwise. All plots were made using GraphPadPrism version \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    7.0\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GraphPad Software,\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Inc\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    La Jolla\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ", CA),and statistical analysis was conducted using \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    NCSS 2007(NCSS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    LLC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Kaysville\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ", UT). The specific tests are detailedin the text and figure legends. For all the statistical anal-ysis, means were indicated to be statistically differentwhenP&lt;0.05.Antitumor activity of \n",
       "<mark class=\"entity\" style=\"background: #ff9561; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ganoderma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">LOC</span>\n",
       "</mark>\n",
       " lucidum \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    235\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>Figure \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". Effects of GLSF gastrointestinal (\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ") juice extract on the growth inhibitory effects of paclitaxel in colorectal cancer cells. (A) SRB<br>cytotoxicity assay was used to determine the effects of paclitaxel, \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", alone or in combination in the mouse colon cancer CT26 cells. (B) Thecytotoxicity of paclitaxel, \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", alone or in combination in human colon cancer HCT-15 cells. (C) The effects of paclitaxel, \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " alone or in<br>combination in human colon cancer \n",
       "<mark class=\"entity\" style=\"background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    HT-29\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PRODUCT</span>\n",
       "</mark>\n",
       " cells.<br>∗:P&lt;0.05,∗∗∗:P&lt;0.001, comparing groups treated with paclitaxel alone with other groups,<br>as determined by ttest.<br>Results<br>Identification of optimal extraction methods for<br>GLSF<br>As there is no standardized preparation approach for \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "<br>andrelatedproducts,wetriedseveralmethodsforprepa-ration of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " extracts, including the use of ethanol,methanol, hot water, as well as artificial gastrointesti-naljuice.Tocomparethepharmacologicactivityoftheseextracts, we examined their ability to inhibit cancer cellgrowthin vitro. The extracts were examined on a panel<br>of cancerous and non-cancerous cell lines derived fromdifferenttissuesoforigin(PC3,MDA-MB-231,A375,H460,HT-29, HepG2, \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    NCI-N87\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    NHDF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ") using a sulforho-damine B (\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SRB\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ") colorimetric assay. Comparison of thecytotoxicity datafor thefour extracts in melanoma \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A375or\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " breast cancer MDA-MB-231 indicated that the gas-trointestinal juice and hot water extracts exhibited rel-atively higher potencies of cancer cell growth inhibition(Supplementary \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Figs\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". S1 and \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    S2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "). The viability data \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    andIC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       "<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    50values\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " in these cell lines for gastrointestinal juice<br>and hot water extracts are summarized in \n",
       "<mark class=\"entity\" style=\"background: #ff8197; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Supplemen\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">LANGUAGE</span>\n",
       "</mark>\n",
       "-tary Table S1. Additionally, our previous study showedhigher contents of triterpenes from \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " in the gas-trointestinal juice extract compared to the chloroformextract.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    22As\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " the gastrointestinal juice extract showed<br>thehighestpotencyonthemajorityofcancercelllines,itwasselectedforchemicalfingerprintanalysisandexam-ined for in vitroanticancer effects.<br>\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Chemical\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " fingerprint analysis of gastrointestinal<br>juice extract of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " by \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    HPLC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       "<br>Based on a literature search for components of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "<br>products, \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    13\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " compounds were selected as chemicalmarkers for \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ". A \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    HPLC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       "-DAD fingerprint method has<br>been developed22and was used to quantify these mark-<br>ers in the extract of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ". The contents of \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    13\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " com-pounds are shown in \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Supplementary\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " Table S2. Amongthe \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    13\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " assessed compounds, only ganoderol A wasnot detectable; the other \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    12\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " compounds were identi-fied with substantial amounts. The inter-batch varia-tion was below \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    16.5%\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERCENT</span>\n",
       "</mark>\n",
       " for all these compounds. Althoughthe chemical markers mainly consisted of triterpenes(polysaccharidesnotincluded),theresultsindicatedthatat least for selected active components \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " was effi-ciently and consistently extracted.<br>Effects of GLSF extract on chemosensitivity of<br>colorectal cancer<br>\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Paclitaxel\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " (taxol) exhibited a modest inhibitory effect on<br>CT26 cells (IC \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    50was 0.45\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " ±0.02μM), while \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " did<br>not cause cytotoxicity in CT26 at concentration up \n",
       "<mark class=\"entity\" style=\"background: #f0d0ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    to3 mg/ml\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">WORK_OF_ART</span>\n",
       "</mark>\n",
       ". However, the cells that were co-treated withtaxol (\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    0.125\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " μM) and \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    0.3 mg/ml\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">QUANTITY</span>\n",
       "</mark>\n",
       ") showed signifi-<br>cantly increased cytotoxic effects compared to the taxoltreatment alone ( P&lt;0.05) (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Fig\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". 1a). We observed a dose-<br>dependent chemosensitizing effect of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", where ahigher concentration (\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    3.0 mg/ml\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">QUANTITY</span>\n",
       "</mark>\n",
       ") showed an increasedchemosensitizing effect compared to \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " at \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    0.3 mg/ml(P&lt;0.001\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">QUANTITY</span>\n",
       "</mark>\n",
       "). Similar effects were observed for combined<br>treatment of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    0.3\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " or \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    3.0 mg/ml\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">QUANTITY</span>\n",
       "</mark>\n",
       ") with a higher con-centration of taxol (\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    0.5\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " μM). To confirm the nature of the<br>interaction between \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " and taxol, combination anal-yses were performed with the Combination Index (CI)method,<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    23,24using\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " drug combinations at various ratios.<br>A synergistic interaction was produced (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " =\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    0.04\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ") when<br>taxol \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    0.125\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " μM was combined with \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " at \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    3.0 mg/ml\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">QUANTITY</span>\n",
       "</mark>\n",
       "<br>(\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " values &lt;\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " indicate synergistic activity). To \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    confirm236Mandy M. Liu\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " et al.<br>Figure2. EffectsofGLSFGIjuiceextractonapoptosisinducedbypaclitaxelinmousecolorectalcancerCT26cells.(A)Cellapoptosiswasassessed<br>by \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Annexin V/PI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " double staining which was detected by flow cytometry FACS analysis; \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Annexin-V-FITC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " staining in y axis (FL1) and \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " in x axis<br>(FL3). (B) \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    The Annexin V/PI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " assay was performed \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    three\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " times and the average percentage of viable, early apoptosis, late apoptosis, and necrosis<br>populations of cells were plotted.∗∗:P&lt;0.01,∗∗∗:P&lt;0.001, compared with vehicle control group, as determined by ttest.<br>these results in human colorectal cancer cell lines, \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SRB\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "<br>assayswereperformedonhumancolorectalcancerHCT-15 and \n",
       "<mark class=\"entity\" style=\"background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    HT-29\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PRODUCT</span>\n",
       "</mark>\n",
       " cells, treated with taxol and \n",
       "<mark class=\"entity\" style=\"background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PRODUCT</span>\n",
       "</mark>\n",
       " aloneor in combination. The IC<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    50\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "in HCT-15 treated with taxol<br>was \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    0.40\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " ±0.002 μM and similar to the CT26 cells, \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "<br>did not cause any cytotoxicity in HCT-15 cells up \n",
       "<mark class=\"entity\" style=\"background: #f0d0ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    to3 mg/ml concentration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">WORK_OF_ART</span>\n",
       "</mark>\n",
       ". The cells that were co-treatedwith taxol (\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    0.25\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " μM) and \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    0.11–3 mg/ml\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">QUANTITY</span>\n",
       "</mark>\n",
       ") showed a<br>dose-dependent increase in cytotoxic effects comparedto the taxol treatment alone ( P&lt;0.05 for GLSF 0.11<br>mg/ml;P&lt;0.001 for GLSF \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1.0\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    3.0 mg/ml\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">QUANTITY</span>\n",
       "</mark>\n",
       ") (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Fig\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1b\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ").<br>Although \n",
       "<mark class=\"entity\" style=\"background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    HT-29\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PRODUCT</span>\n",
       "</mark>\n",
       " cells were much more sensitive to taxol(IC<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    50=0.0035\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORDINAL</span>\n",
       "</mark>\n",
       " ±0.001 μM) than CT26 and HCT-15 and<br>GLSF at \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    3 mg/ml alone\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">TIME</span>\n",
       "</mark>\n",
       " was also nontoxic, co-treatmentwith \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " and taxol did not demonstrate increased ordecreased effect on cell viability (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Fig\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1c\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "). Therefore, the<br>chemosensitizing effect for \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " is variable in differentcancer cell lines.<br>Effects of GLSF extract on taxol-induced<br>apoptosis in CT26 cells<br>\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ThedegreeofapoptosisinducedbyGLSF(3mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "/ml),taxol<br>(\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    0.125\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " μM), or their combination was evaluated in CT26<br>cells. The cells were incubated for \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    72 hours\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">TIME</span>\n",
       "</mark>\n",
       " with com-binations of drugs and the level of apoptosis was quan-tified by an Annexin-V binding and \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " staining assay.As shown in \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Fig\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " treatment slightly increased<br>the viable cells compared to vehicle control ( \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    P&gt;0.05\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ").<br>\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Taxol\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " decreased the viable cell population to \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    60.1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " ±6.2%<br>(\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    P&gt;0.05\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "). When the cells were exposed to a combina-<br>tion of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " and taxol, there was a significant reductionof viable cells ( P&lt;0.001) (\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    53.7 ±1.6%\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERCENT</span>\n",
       "</mark>\n",
       " of viable cells in<br>control) and increase in the number of early apoptoticcells (P&lt;0.01). This result is consistent with those data<br>obtained by \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SRB\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " in CT26 cells (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Fig\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". 1a), indicating that<br>the co-treatment with non-toxic concentration of \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSFincreased\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " the anticancer potency of taxol via enhancingapoptosis in CT26 cells.<br>Effects of GLSF extract on P-glycoprotein (MDR1)<br>activity in \n",
       "<mark class=\"entity\" style=\"background: #ff9561; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    K562/DOX\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">LOC</span>\n",
       "</mark>\n",
       " cells<br>Previous studies have shown that both CT2625and HCT-<br>\n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1526express\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " the efflux transporter P-glycoprotein (P-gp<br>or MDR1, ABCB1gene), which is part of the mechanism<br>for their intrinsic resistance to taxanes and other P-gp substrate drugs such as daunorubicin (\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    DNR\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "). There-fore, we examined whether \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " was able to inhibitP-gp-mediated drug efflux from the multi-drug resis-tantcelllineK562/DOX,whichoverexpressesP-gp,usingdaunorubicin (\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    DNR\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ") as a fluorescent substrate.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    20Few\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>cells were positive for \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    DNR\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " accumulation without P-gp inhibitor (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Fig\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    3a\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "). Co-treatment with a known P-gp<br>inhibitor PSC833 (\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    10\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " μM) as a positive control greatly<br>increased \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    DNR\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " positive cells to \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    nearly 100%\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERCENT</span>\n",
       "</mark>\n",
       ". However,\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    3 mg/ml\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">QUANTITY</span>\n",
       "</mark>\n",
       ") only slightly increased DNRaccumulation (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Fig\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    3b\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "). Although the treatment effect<br>of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2 mg/ml\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">QUANTITY</span>\n",
       "</mark>\n",
       ") was significant ( P&lt;0.05), compared<br>to the positive control PSC833, the degree of inhibitionwas negligible. This result suggests that the chemosen-sitizing activity of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " is not attributed to P-gpinhibition.\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Antitumor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " activity of \n",
       "<mark class=\"entity\" style=\"background: #ff9561; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ganoderma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">LOC</span>\n",
       "</mark>\n",
       " lucidum \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    237\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>Figure \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    3\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". Effects of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF GI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " juice extract on P-glycoprotein activity in \n",
       "<mark class=\"entity\" style=\"background: #ff9561; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    K562/DOX\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">LOC</span>\n",
       "</mark>\n",
       " cells and NF- κB activity in HEK-293 cells. (A) Flow cytometry<br>analysisofDNRaccumulationincellsincubatedwithDNR,treatedwithorwithoutPSC833(10 μM)orGLSF.Representativeflowcytometrydata<br>are shown. (B) \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Graphs\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " showing percentage of cells that were positive for \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    DNR\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " in cell samples co-treated with \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    DNR\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " in comparisonwith those co-treated with \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    10 μM PSC833\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">QUANTITY</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    DNR\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ". The data are presented as the mean ±SD from \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    3–6\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " independent experiments.<br>∗:P&lt;0.05<br>comparedtotheDNRonlygroup.(C)EffectsofGLSFonTNF- α-inducedNF- \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    κBpromoteractivity\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ".HEK-293cellstransfectedwithNF- κBluciferase<br>reporter and \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Renillacontrol\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " reporter were treated with vehicle, TNF- α(10 ng/mL), \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    0.3\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1.0\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2.0\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " mg/mL) combined with TNF- αfor \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    5 hours\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">TIME</span>\n",
       "</mark>\n",
       ".<br>Data are expressed as mean +/- SEM; n =\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    3–6.∗:P&lt;0.05\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " as per \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    one\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "-way ANOVA.<br>Effects of GLSF extract on NF- κBp r o m o t e ra c t i v i t y<br>in HEK-293 cells<br>We next evaluated the effect of GLSF on TNF- αpro-<br>moted NF- κB activation. The HEK-293 cells were trans-<br>fectedwithNF- κB-lucfireflyluciferasereporterconstruct<br>andaplasmidencodingthe \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Renillaluciferaseforthedual\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "<br>luciferase assay. The transfected cells were treated withvehicle (control) or \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " extracts at \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    0\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    0.3\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1.0\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ", or \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2.0mg/ml\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">QUANTITY</span>\n",
       "</mark>\n",
       ", followed by a \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    5-hour\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">TIME</span>\n",
       "</mark>\n",
       " co-incubation with TNF- α<br>(\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    10 ng/ml\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">QUANTITY</span>\n",
       "</mark>\n",
       "). As expected, TNF- αstrongly stimulated NF-<br>κBa c t i v i t y( \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    F\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " i g . \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    3c\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "). The promoter activity stimulated<br>by TNF- αwas inhibited significantly by the \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " extract<br>at \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2.0 mg/ml\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">QUANTITY</span>\n",
       "</mark>\n",
       " in a dose-dependent manner (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Fig\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    3c\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ").<br>As NF- κB plays a role in promoting carcinogenesis ofvarious types of cancer<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    27and\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " conferring chemoresis-<br>tance to paclitaxel,28inhibition of NF- κBb yG \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    L S\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " Fm i g h t<br>partly explain the in vitrochemosensitizing activity and<br>thein vivoactivity described below.<br>Anticancer efficacy of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " oral administration to<br>mice bearing murine colorectal cancer tumorCT26<br>To evaluate the anticancer activity of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " invivo,as y n -<br>geneic model of colorectal cancer-bearing BALB/c micewasused.Wefirstlyconductedapilotstudyusingasmallnumber of mice with \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    two\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " tumors (CT26) implanted ineach mouse (n =\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " each gender specific group).238Mandy \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    M. Liu\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " et \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    al.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       "<br>Figure \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    4\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". Effects of GLSF on tumor growth and apoptosis in a colorectal cancer syngeneic model. (A) The CT26 cells were subcutaneously<br>implanted into the female BALB/c mice after the mice were fed with the control diet (groups \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " and 3) or diet containing \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " (groups \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " and 4)for \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    4 weeks\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Groups 3 and 4 mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " were treated with a single dose of abraxane<br>R/circlecopyrton Day 13. Tumor volumes were measured on \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Days 13\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>(Day 0 was \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    the day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " of tumor injection).∗:P&lt;0.05 by \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Tukey-Kramer Multiple-Comparison\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " test (n =\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    8f\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " o rG \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1a\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " n dG \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " ;n =\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    4f\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " o rG \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    3a\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " n dG 4 ) .( B )<br>RepresentativephotosofmiceincontrolandGLSFgroups.(C)TumortissueswerestainedwithH&amp;EorimmunohistochemicalstainingofKi-67.(D) Western blot analysis of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PARP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", cleaved PARP, and β-actin. Representative gel images are shown. Bar graphs represent the ratios of cleaved<br>PARP/total PARP.<br>∗:P&lt;0.05 as compared with the control group by ttest. PARP, poly (ADP-ribose) polymerase. \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Control n\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " =\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    5\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " tumors, GLSF n =\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    4\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>tumors.<br>The treatment by oral gavage (\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2.0 g/kg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">QUANTITY</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Monday\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       "<br>toFriday,ninedosesintotal)wasstartedonthe11thdayaftertumorimplantation.\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Althoughstatisticallyinsignif\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       "-icant, a trend of treatment effect was observed in tumorvolume in both males and females (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Supplementary Fig\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ".S3): the average tumor volumes in GLSF-treated micewere smaller than in untreated control. In addition, themicedidnotlosebodyweightcomparedtoinitialweight,indicating the treatment was not toxic.<br>To explore the potential anticancer mechanism, the<br>effect of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " treatment on mouse spleen lympho-cyte proliferation induced by concanavalin A (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Con A\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ") orlipopolysaccharides (\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    LPS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ") in vitrowas determined using<br>the spleen samples obtained from the CT26 tumor-bearing mice. Compared with non-tumor-bearing mice,proliferation of spleen T and B lymphocytes induced byCon A and \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    LPS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " were strongly declined in tumor-bearingmice (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Supplementary Fig\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". S3). However, treatment withGLSFofthesemiceincreasedspleenTandBlymphocyteproliferationinCT26-bearingmice,althoughthiswasnotstatistically significant. These data indicate a potentialimmunomodulatory activity of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", consistent with a<br>previous report.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    4\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>To confirm the anticancer activity of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", BALB/c<br>mice were pre-treated with control diet (groups 1 and3) or modified diet containing \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " (groups \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " and 4)<br>\n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1 month\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " before tumor implantation. As \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " showedantitumor effects in both genders in the pilot studyand the CT26 tumor was derived from female mice,<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    15\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>only females were included in this experiment. Abrax-ane treatment was given for groups \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    3\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " and 4 to observethe effects of combination treatments. \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Two\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " tumors wereimplanted in each mouse. Consistent with the pilotstudy, GLSF treatment alone inhibited tumor \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    growth(Fig.4a\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       "), although repeated measures \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ANOVA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " analysis<br>did not show a statistically significant difference. At theendoftheexperiment,100%ofthemicehadtwotumorsin the control group, while \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    only 63%\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERCENT</span>\n",
       "</mark>\n",
       " of mice in the \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSFgroup\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " had \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    two\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " tumors, and \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    two\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " of the \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    eight\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " mice (\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    25%)in\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " the \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " group did not show any tumors (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Fig\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    4b\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "). The<br>Tukey-Kramer post hoc analysis showed that on \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Day 19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       "<br>aftertumorinoculation,co-treatmentwithabraxaneandGLSF significantly suppressed tumor growth comparedwith the control group (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Fig\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    4a\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "). Furthermore, tumors in<br>thecontrolgroup(group1)showedasignificantincreasewhen comparing tumor size on \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Day 13\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ", whilegroups \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    3\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    4\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " did not show time-dependent tumor<br>size increase, confirming the treatment effect.<br>\n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Tumor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " tissues dissected from the control and \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "<br>groups were subjected to \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hematoxylin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " and eosin (H&amp;E)Antitumor activity of \n",
       "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ganoderma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
       "</mark>\n",
       " lucidum \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    239\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>Figure \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    5\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    RNA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "-seqanalysisofCT26syngeneictumorsinmicetreatedwithcontroldietorGLSF-modifieddiet.(a)Multi-dimensionalscalingplot<br>of detected genes in \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " treatment (T, red) and control group (C, green). The distances correspond to leading log2 fold-changes between eachpairofsamples.(b)Volcanoplotsofdifferentiallyexpressedgenesbetweentreatmentandcontrolgroups.Thereddotsindicateup-anddown-<br>regulatedDEGswith P&lt;0.05andabsolutelog2FC &gt;1.(c)Heatmapoftop30significantlydifferentiallyexpressedgenesbetweentreatment(T)<br>and control groups (C). (d) Genes that are up- and down-regulated in treatment group (compared to control) are displayed within red or greennodes, respectively. The predicted inhibited biology effects are presented in blue nodes. Blue (predicted to be inhibited) or gray (undetermined<br>direction) dash lines represent relationships with causal consistency.<br>staining.TheimageofH&amp;Esectionsindicatedthattumor<br>tissues from both groups consisted of a morphologicallysimilardifferentiatedadenocarcinoma.However,tumorsin the \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " group showed a conspicuous increase ofnecrosisinallthefourtumorsamplessubmittedforH&amp;Estaining (representative images are shown in \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Fig\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    4c\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "). Ki-<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    67\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " staining showed that the tumors in the control groupconsisted entirely of \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    one\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " cell type with high prolifera-tive index, while the tumors in the \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " group demon-strated nonspecific staining of necrotic/apoptotic cellsbutshowedfainterstainingoffewerKi-67positiveviablecells (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Fig\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    4c\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ").<br>Western blot analysis was used to examine the<br>expression of the apoptosis marker \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PARP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " and cleavedPARP in tumor tissue lysates. The expression of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cleavedPARP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " was markedly increased in the \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " treatmentgroup compared with that in the control group (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Fig\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    4d\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "),<br>andthisdifferencewasstatisticallysignificant( P&lt;0.05),<br>confirming that \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " treatment induced apoptosis intumor tissues in vivo.RNA-seq profiling of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "-treated tumors<br>To explore the mechanism underlying the treatment<br>effectsbyGLSF,RNA-seqanalysiswasperformedtocom-pare the gene expression profiles between tumors iso-lated from mice subjected to the control diet (n =\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    4\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ")<br>or \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " modified diet (n =\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    4\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "). On average, \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    40 million\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>pair-end reads pairs per sample were generated, withall of their uniquely mapping rates above \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    91%\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERCENT</span>\n",
       "</mark>\n",
       ". Over-all, \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    RNA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " sequencing detected \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    25 051\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " genes across eightsamples, of which \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    13 790\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " genes had a \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CPM\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " value above0.5 in \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    at least two\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " samples. A multi-dimensional scal-ing (\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    MDS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ") plot showed a trend of clustering separationbetween treated group and control group (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Fig\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    5a\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "). Out of<br>the \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    13790\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " genes, \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    53\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " were identified as significant differ-entially expressed genes (DEGs) between the \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    two\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " groupswith a absolute log2 fold-change &gt;\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1a\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " n da Pvalue &lt;\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    0.05\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>(SupplementaryTableS3).Thetop12up-regulatedgenesand top \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    10\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " down-regulated genes (selected based on thelowestPvalue) are presented in \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Tables\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " 1and2.Al o g 2240Mandy M. Liu et \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    al.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       "<br>\n",
       "<mark class=\"entity\" style=\"background: #9cc9cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Table 1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">FAC</span>\n",
       "</mark>\n",
       ". Top \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    12\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " up-regulated genes in tumors from mice treated with \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " compared to control group.<br>Gene ID Gene name \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Log FC Pvalue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       "<br>Itga10 \n",
       "<mark class=\"entity\" style=\"background: #ff8197; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Integrin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">LANGUAGE</span>\n",
       "</mark>\n",
       ", alpha \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    10\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " 1.07 9.34E-05<br>\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Zbtb16 Zinc\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " finger and \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BTB\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " domain containing \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    16 2.07 2.79E-04\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">QUANTITY</span>\n",
       "</mark>\n",
       "<br>Gm807 Predicted gene \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    807 1.26\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    9.47E-04Lvrn\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " Laeverin \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1.17\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " 1.07E-03<br>Gm6093 Predicted gene \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    6093\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1.63 1.49E-03Hrct1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " Histidine rich carboxyl terminus \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " 1.33 2.15E-03Aldh1a1 \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Aldehyde\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " dehydrogenase family \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ",<br>subfamily A11.08 2.59E-03<br>Inpp5j \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Inositol\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " polyphosphate \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    5\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "-phosphatase \n",
       "<mark class=\"entity\" style=\"background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    J 1.67\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PRODUCT</span>\n",
       "</mark>\n",
       " 3.06E-03<br>\n",
       "<mark class=\"entity\" style=\"background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Rcan2 Regulator\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PRODUCT</span>\n",
       "</mark>\n",
       " of calcineurin \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2 1.00\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " 3.39E-03<br>\n",
       "<mark class=\"entity\" style=\"background: #ff9561; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ifng Interferon\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">LOC</span>\n",
       "</mark>\n",
       " gamma \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1.09\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " 3.52E-03<br>\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Retnla Resistin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " like alpha \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2.52\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " 3.63E-03<br>\n",
       "<mark class=\"entity\" style=\"background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Fmo2 Flavin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PRODUCT</span>\n",
       "</mark>\n",
       " containing monooxygenase \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2 1.35\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " 7.23E-03<br>∗Log \n",
       "<mark class=\"entity\" style=\"background: #f0d0ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    FC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">WORK_OF_ART</span>\n",
       "</mark>\n",
       " (log2 Fold change) larger than \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " indicates higher expression in \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "-treated tumors.<br>\n",
       "<mark class=\"entity\" style=\"background: #9cc9cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Table 2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">FAC</span>\n",
       "</mark>\n",
       ". Top \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    10\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " down-regulated genes in tumors from mice treated with \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " compared to control group.<br>Gene ID Gene name \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Log FC Pvalue\n",
       "Il1b\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " Interleukin 1 beta −1.31 9.57E-06<br>Il11 Interleukin 11 −1.09 4.89E-04<br>4930565N06Rik \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    RIKEN\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " cDNA \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    4930565N06\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " gene \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    −1.06\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " 6.84E-04<br>\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Nppb Natriuretic\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " peptide type B −1.44 7.72E-04<br>\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ptgs2 Prostaglandin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       "-endoperoxide synthase \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " (Cox-2) −1.11 1.18E-03<br>\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Mmp10 Matrix\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " metallopeptidase \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    10 −1.51 1.31E-03\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">QUANTITY</span>\n",
       "</mark>\n",
       "<br>Mmp13 Matrix metallopeptidase \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    13\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " −1.16 1.68E-03<br>\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Stamos Signal\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " transducing adaptor molecule (SH3 domain and<br>ITAM motif) \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ", opposite strand−1.13 1.82E-03<br>Cxcl1 Chemokine (C-X-C motif) ligand \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " −1.56 2.07E-03<br>Mmp12 Matrix metallopeptidase \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    12\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " −1.03 4.01E-03<br>∗Log \n",
       "<mark class=\"entity\" style=\"background: #f0d0ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    FC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">WORK_OF_ART</span>\n",
       "</mark>\n",
       " (log2 Fold change) smaller than \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    −1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " indicates lower expression in \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "-treated tumors.<br>fold-change lower than \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    −1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " indicated that the expression<br>of the gene was decreased by \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " treatment, whereasa log2 fold-change \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    more than 1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " suggested an increasedgene expression in tumor tissues derived from \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSFtreatment\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ". A heat map of the top \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    30\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " significant \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    DEGswas\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " plotted with unsupervised hierarchical \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    clustering(Fig.5b\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "). A volcano plot was generated with the signifi-<br>cant DEGs highlighted in red color based on their Pval-<br>ues and fold changes (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Fig\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    5c\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "). It is notable that many<br>of these \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " down-regulated genes are involved in \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    NF-κB\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "-regulated inflammation, such as \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    IL-1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " β(Il1b) and IL-11<br>(Il11)( T a b l e 2,F i g .5b).<br>To explore the possible biological functions linked<br>with these DEGs, ingenuity pathway analysis (\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    IPA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ") wasperformedtoidentifycanonicalpathways,upstreamreg-ulators, diseases and functions that are associated withGLSFtreatment.\n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BasedontheratioofthenumberofDEGsin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " our dataset to the total number of reference genesin the specific pathways in the \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    IPA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " knowledge bases, \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    aFisher\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "’s exact test was used to determine the canonicalpathways associated with the treatment effect. Using acutoffPvalue &lt;0.05, a total of \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    58\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " canonical pathways<br>were identified as being significantly enriched based onthe DEGs (\n",
       "<mark class=\"entity\" style=\"background: #f0d0ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Supplementary Table S4\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">WORK_OF_ART</span>\n",
       "</mark>\n",
       "). The most affectedpathways were “Granulocyte adhesion and diapedesis”and “\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Agranulocyte\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " adhesion and diapedesis”, which areknown immune/inflammatory pathways.Upstream analysis through \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    IPA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " was used to predict<br>the upstream regulators potentially causing changesin gene expression and regulation direction based onthe DEGs. Predicted significantly activated and inhib-ited regulators are listed in \n",
       "<mark class=\"entity\" style=\"background: #f0d0ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Supplementary Table S5\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">WORK_OF_ART</span>\n",
       "</mark>\n",
       " ( P<br>value &lt;0.05,|Z-score |&gt;2).Thetwosignificantlyactivated<br>upstream regulators were alpha-catenin and TP53, both<br>of which are known tumor suppressors for colon cancer.On the other hand, the most inhibited upstream regula-tors were factors that play critical roles in inflammatoryresponse and tumorigenesis, including \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    TNFSF12\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    KRT17,IL17RA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    TNF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", and IL17A.<br>”Diseases and functions” in \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    IPA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " was used to predict<br>affected biology and its regulation direction associatedwith \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " treatment. Using a cutoff of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Pvalue &lt;0.05\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ",<br>|Z-score \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    |&gt;2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ", there was no significantly activated biology<br>effect identified, while the top \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    five\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " significantly inhib-ited biological effects are presented in \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Fig\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    5d\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ", which<br>included “Cancer”, “Epithelia neoplasm”, “Carcinoma”,“Secondary tumor”, “Frequency of tumor”. The networkof the top \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    five\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " inhibited biology effects in the \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " treat-ment group, compared to the control, and the contribut-ing DEGs were displayed in \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Fig\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    5d\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". Quantitative \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    RT-PCR\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       "<br>analysis confirmed that \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " inhibited the expressionof selected inflammatory genes, cyclooxygenase-2 ( Ptgs2<br>orCox-2)(P&lt;0.05), interleukin-1 β(Il1b)(P&lt;0.01), and<br>interleukin-6 ( Il6)(P&lt;0.01) (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Fig\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". 6).Antitumor activity of \n",
       "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ganoderma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
       "</mark>\n",
       " lucidum \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    241\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>Figure \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    6\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". qRT-PCRresults fromtumor samplesofcontrol or GLSF groupsfor(A) COX-2,(B) IL-1 β,and(C)IL-6. β-actin wasused asnormalization<br>control and data are expressed as mean with \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    95%\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERCENT</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ". n =\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    8\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " tumor samples from control group. n =\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    10\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " tumor samples for GLSF.∗:P&lt;0.05;∗∗:<br>P&lt;0.01 via a \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Mann-Whitney\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " U approximation without correction for normality.<br>Discussion<br>The present study examined the in vitroandin vivoanti-<br>cancer activity of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", which contains a mixture of bro-ken spores and fruiting bodies of mushroom. As differ-entmethodsofextractionaffecttherelease,bioavailabil-ity and pharmacological activity of active components,extracts of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " were prepared in ethanol, methanol,hot water, or artificial gastrointestinal juice and wereexamined in a panel of cell lines. We found that extractsprepared using gastrointestinal juice had the highestpotencyofcellgrowthinhibitionandthereforewereusedin ourin vitrostudies. This extraction method is physi-<br>ologically relevant to clinical application. Although themethod of extraction has been used for ginseng<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    29and\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>notoginseng (“San-Qi”),30to our knowledge, this is the<br>firststudyusingartificialgastrointestinaljuicetoprepareGLextracts. Invitro,GLSFaloneshowedmodestcytotoxi-<br>cityoncoloncancercells,whichisconsistentwithapre-viousstudyindicatingthatthedirectanticancereffectofGL is limited.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    3However\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ", when \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " was combined with<br>taxol, it induced stronger tumor inhibition and apopto-sis, suggesting that \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " may be used as a chemosen-sitizer (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Fig\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1a\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " and b). As \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " is not a P-gp inhibitor<br>(Fig.3aandb),itschemosensitizingmechanismremainstobedetermined.Onepossiblemechanismisthroughits<br>inhibitory activity against NF- κB signaling, suggested by<br>the dual luciferase assay (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Fig\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    3c\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "). Consistently, previous<br>studieshaveshownthattriterpeneganodericacidC1iso-latedfromGLinhibitedinflamedCrohn’sdiseasecolonicm u c o s aa sar e s u l to fb l o c k a g eo fN \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    F - κB.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       "<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    31\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>In vivo, GLSF alone or in combination with abrax-<br>ane (nanoparticle albumin bound paclitaxel or nab-paclitaxel) induced tumor growth inhibition and apop-tosis (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Fig\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". 4). The syngeneic tumor model used in the<br>studywasmurinecolorectalcarcinomacelllineColorec-talTumor#26(CT26).<br>\n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    15CT26cellswerederivedbyexpos-\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       "<br>ing BALB/c mice to the chemical carcinogen N-nitroso-N-methylurethane, resulting in a rapid-growing grade IVcarcinoma that is easily implanted and readily metasta-sizes.<br>32AsCT26tumorintheimmunocompetentBALB/c<br>miceprovidesasyngeneicmodel,itisfrequentlyusedfordeveloping and testing immunotherapeutic agents.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    15,33\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Comparedwith\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " invitrodata,alarge invivoeffectsuggests<br>that an intact immune system or tumor microenviron-ment may be essential for the pharmacological action ofGLSF. \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    One\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " limitation for these in vivostudies was that a<br>single dose was used (\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2.0 g/kg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">QUANTITY</span>\n",
       "</mark>\n",
       "), which was derived frompublished data of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ".<br>34–36Dose-response studies should<br>be considered in the future. Although taxol or \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    abraxane242Mandy M. Liu\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " et \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    al.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       "<br>are effective to many types of cancer such as breast or<br>ovariancancer,theirapplicationincolorectalcancerhasbeenlimitedbecauseofintrinsicresistance.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    37Thus\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ",GLSF<br>may be used as a chemosensitizer for taxanes. The ratioof \n",
       "<mark class=\"entity\" style=\"background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PRODUCT</span>\n",
       "</mark>\n",
       " versus taxol or abraxane should be optimizedin future studies to identify the optimal combinationalregimen. Further studies comparing therapeutic effectsof GLSF in different tumor models and with other anti-cancer agents should be considered.<br>To gain mechanistic insight, RNA-seq was performed<br>to evaluate genome-wide transcriptome changes asso-ciated with \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " treatment. Based on the differentiallyexpressedgenes(DEGs),expressionlevelsofIL-1 βandIL-<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    11\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ", genes encoding for cytokines in the tumor microen-vironment that promote colorectal cancer progression,were decreased by \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ". These cytokines, also includ-ing Il-6 which was not picked up by RNA-seq analysisb e c a u s eo fl o wC P Mv a l u e s ,a r ep r o d u c e \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    db\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " ym y e l o i dand T-helper interleukin (IL)-17-producing (Th17) cellsthat are accumulated in the tumor microenvironment.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    38\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>Because these cytokines directly or indirectly activateneoplastic epithelium, therapies that target their acti-vation, for example anti-IL-11 therapy, have been pro-posed to treat colorectal cancer.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    38In\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " addition, the \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "<br>down-regulated Ptgs2,encoding for Cox-2, known to<br>be an inflammatory mediator that promotes colorectalcancer.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    39RT\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "-PCR results confirmed that in GLSF-treated<br>mice the tumor cell expression of \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Cox-2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ", IL-1 β,a n dI L - 6<br>was significantly down-regulated at mRNA level (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Fig\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". 6).<br>These results suggest that inflammation is a potentialtargetfortreatmentofsometypesofcolorectal cancer.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    40\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>Consistent with the luciferase assay data (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Fig\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    3c\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "), these<br>GLSF-down-regulated genes are under the control of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    NF-κB transcription\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " factor. Furthermore, CT26 cells harbor<br>the constitutively activating mutant \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    KRAS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ",<br>15which has<br>been shown to trigger the production of several inflam-matory mediators including \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    IL-6\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ",<br>41IL-1β42and associ-<br>ated with COX-2.43Interestingly, NF- κBi sa c t i v a t e di n<br>KRAS-mutated cancer and has been suggested as a tar-<br>get to treat KRAS-induced cancer.44,45In addition, a pre-<br>vious study showed that CT26 cells not only secret \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    IL-6\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " ,b u ta l s ot h eg r o w t ho fC T 2 6t u m o rd e p e n d so nI L -6.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    46,47Thus\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ", these inflammatory factors, many of which<br>a r eu n d e rt h er e \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    g u l\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " a t i o no fN \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    F - κB\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", are very likely tar-<br>gets of a GL-mediated anticancer effect. These resultsalso suggest that inflammation-associated cancers andKRAS-driven tumors might be more likely to respondto GLSF. As inhibiting \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    KRAS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " directly is very challenging,approaches to disrupt downstream signaling pathwaysmay be a better approach to treat these types of highlyaggressive cancer.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    48\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>Another down-regulated gene in the \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "-treated<br>group was the inflammatory chemokine \n",
       "<mark class=\"entity\" style=\"background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Cxcl1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PRODUCT</span>\n",
       "</mark>\n",
       ", which<br>is involved in enhanced metastatic potential of coloncancer by increasing cell migration, matrix metal-loproteinases (MMP) expression, and epithelial-to-mesenchymal transition and therefore has a negativeprognostic impact to the clinical outcome.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    49Probably\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>associatedwith Cxcl1down-regulation,threeMMPgeneswere among the top \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    20\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " down-regulated genes: MMP10,<br>\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    MMP13,a\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " n \n",
       "<mark class=\"entity\" style=\"background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    dMMP12\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PRODUCT</span>\n",
       "</mark>\n",
       ". These genes and their products<br>have been identified as negative prognostic markersin colon cancer patients.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    50,51GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " down-regulated<br>\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Nppb\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", encoding for natriuretic peptide B, which has<br>been shown to be a key oncogene candidate for colontumors and suggested as \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    one\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " of the early biomarkers forprevention in the clinical setting.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    52\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>The GLSF-up-regulated genes have various functions.<br>Although most of these genes have not yet been asso-ciated with colon cancer, they may contribute to GLSF-inducedanti-canceractivity.Someofthemmaybetumorsuppressor genes, for example, \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Fmo2(flavin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " containing<br>monooxygenase \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ") plays a role as a tumor suppressor inlung cancer.<br>53The lower level of Inpp5j, which encodes<br>inositol polyphosphate-5-phosphatase J, has been asso-ciated with more aggressive tumors and poorer sur-vival of cutaneous squamous cell carcinoma,<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    54and\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " was<br>found to be deficient in oropharyngeal squamous cellcarcinoma.<br>\n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    55Itga10\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ", a top DEG of the GLSF-up-regulated<br>genes,encodesintegrinsubunit \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    α10,whichbindstocol-\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "<br>lagen and plays a role in cell adhesion and cell-surfacemediated signaling. Although the activity of increasedexpression of Itga10by GLSF is unknown, the interac-<br>tionofintegrinandcollagenmaymediateananti-tumorimmune response.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    56\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>The canonical pathway analysis highlighted “Gran-<br>ulocyte adhesion and diapedesis” and “Agranulocyteadhesion and diapedesis” as the most significantly reg-ulated pathways influenced by \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " treatment. Bothpathways contain the same set of genes, mainly MMPs,and have been associated with immunity and inflam-mation,<br>57as well as tumor invasion and metastasis.58<br>These results support the notion that these \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    two\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " path-wayswereinvolvedininflammationassociatedwithcol-orectal cancer, as previously reported,<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    59and\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " may con-<br>tain the molecular targets that underlie the anticancereffect of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ". Based on the DEGs between the treat-mentandcontrolgroups,IPApredictedtheupstreamreg-ulators and their activation states which might resultin these gene expression changes. Several inflamma-tory cytokines were at the top of the inhibition listsuch as TNFSF12, \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    TNF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", and IL17A. On the other hand,tumorsuppressorssuchasalpha-cateninandTP53wereactivated (activation z-score &gt;\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ") according to the pre-<br>diction. This prediction further implied that \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " mayelicit anti-tumor activity through its anti-inflammatoryeffects.Morespecifically,onepossiblemechanismisthatGLSF treatment resulted in an inhibition of the NF-kBpathway, a shared target of the aforementioned pre-dicted upstream regulators, which eventually may leadtotumorsuppression.Furtherstudiesarerequiredtoval-idate this hypothesis. Based on the \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    IPA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " prediction, therewasnosignificantlyactivatedbiologyeffectwhilethetopfive inhibited biology effects were all related to “Cancer”anddisplayedthenetworkoftumorsuppressioninducedby GL treatment (\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Fig\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    5d\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "). These results implied a pos-<br>sible mechanism of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "’s anti-tumor effect as alleviatingthe immune suppression in colorectal tumor tissue byAntitumor activity of \n",
       "<mark class=\"entity\" style=\"background: #ff9561; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ganoderma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">LOC</span>\n",
       "</mark>\n",
       " lucidum \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    243\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>promoting the recruitment of anti-tumor immune cells,<br>or by inhibiting immune suppressive cells such asmyeloid derived suppressor cells. This hypothesis alignwell with the observation that \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " alone showed lit-tle cytotoxicity in vitrobecause of a lack of immune sys-<br>tem. It is notable that the in vivostudies used \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " pow-<br>der while in vitro \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    assays\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " used extract. Identification of<br>the active components that are responsible for theseobserved effects requires further investigation.<br>In conclusion, this study evaluated the anticancer<br>effects and possible underlying anticancer mechanismof \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " using both human and murine colorectal can-cer cell lines, and examined \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " alone or in combi-nation with a commonly used chemotherapeutic agentpaclitaxel. \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    InvitrodatarevealedthatalthoughGLSFalone\n",
       "\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       "had little anticancer effect, it had a chemosensitiza-tion effect in certain colon cancer cells and that NF- κB<br>played a major role in mediating the in vitroanticancer<br>\n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    effectofGLSF.Immunocompetentmicecarryingthesyn-geneic\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " tumor CT26 were used for investigating the in<br>vivoanticancer activity of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ". RNA-seq and bioinformat-<br>ics analysis, for the \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    first\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORDINAL</span>\n",
       "</mark>\n",
       " time, indicated that \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " tar-geted inflammation and carcinogenesis and confirmedt h er o l eo fN \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    F - κB\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " as the potential target. Advanced col-<br>orectal cancer shows inherent resistance to paclitaxel orrelated chemotherapeutic agents. With the use of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ",a non-toxic natural product, the antitumor effects ofchemotherapy may be enhanced. \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GSLF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " alone also hadanticancer activity in vivothrough an inhibitory effect<br>against inflammation, NF-kB, and/or \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    KRAS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " activation.<br>Supplementary data<br>\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Supplementary\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " data are available at \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PCMEDI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " online.<br>Data and material availability<br>All materials, data, and associated protocols are avail-<br>able to readers without undue qualifications in materialtransfer agreements. The \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " is available from the Bei-jing \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Tong Ren Tang Chinese Medicine Co.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", Ltd.<br>Author contributions<br>\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Y.H.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " conceived and designed the study. \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    M.L.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " carriedout most in vitro andin vivo experiments and ana-<br>lyzed the data; \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T.L.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    C.W.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " analyzed the \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    RNA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "-seqdata and revised the manuscript; \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    B.A.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " conducted sta-tistical analysis; \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    S.Y.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Z.W\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " performed \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    HPLC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " finger-print analysis; \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    C.P.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    R.O.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " performed the pathologyanalysis; \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    B.Z.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    W.W.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    X.L.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Y.Z.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Y.H.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " coordinated theexperiments, wrote and reviewed the manuscript. Allauthors read and approved the final manuscript. C.W.submitted the manuscript.<br>Acknowledgements<br>We would like to thank \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Lily Kong Lim\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A.S.C.P.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " (H.T.),at \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    the Beverly Hospital\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " for preparing the formalin-fixedparaffin-embedded tissues and \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    H&amp;E\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " staining. The \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GLSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "<br>is available from \n",
       "<mark class=\"entity\" style=\"background: #9cc9cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    the Beijing Tong Ren Tang ChineseMedicine Co.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">FAC</span>\n",
       "</mark>\n",
       ", Ltd. This study was funded by a con-tract grant (\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    YH\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ") from \n",
       "<mark class=\"entity\" style=\"background: #9cc9cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    the Beijing Tong Ren Tang\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">FAC</span>\n",
       "</mark>\n",
       " ChineseMedicineCo.,Ltd.\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Thisstudywasalsopartiallysupportedby Loma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " Linda University (\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    LLU\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ") GCAT grant (CW).<br>Conflict of interests<br>\n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    B.Zhou\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ",\n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    W.Wu\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ",\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    X.LiandY.Zhangareemployeesorcon\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "-sultants of \n",
       "<mark class=\"entity\" style=\"background: #9cc9cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    the Beijing Tong Ren Tang\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">FAC</span>\n",
       "</mark>\n",
       " Chinese MedicineCo., Ltd. The other author(s) declare no competing inter-ests. Besides, as an \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Editorial Board\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " Member of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Precision\n",
       "ClinicalMedicine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " ,thecorrespondingauthorCharlesWang<br>wasblindedfromreviewingandmakingdecisiononthismanuscript.<br>References<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". SiegelRL,MillerKD,\n",
       "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    JemalA.Cancerstatistics,2016\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
       "</mark>\n",
       ". CACan-<br>cer \n",
       "<mark class=\"entity\" style=\"background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    J Clin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PRODUCT</span>\n",
       "</mark>\n",
       " 2016;66:7–30. \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    doi:10.3322/caac.21332\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ".<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". Hyodo I, \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Amano N\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Eguchi K\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", et al.Nationwide sur-<br>vey on complementary and alternative medicine in<br>cancer patients in \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Japan\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ". J Clin \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Oncol 2005;23:2645–54\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ".<br>doi:10.1200/JCO.2005.04.126.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    3\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Sanodiya BS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Thakur GS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Baghel RK\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ganoderma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
       "</mark>\n",
       " lucidum: a<br>potent pharmacological macrofungus. \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Curr Pharm Biotechnol\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       "<br>\n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2009;10:717–42\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ". doi: 10.2174/138920109789978757.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    4\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Wang PY\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Zhu XL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Lin ZB\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Antitumor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " and Immunomod-<br>ulatory \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Effects of Polysaccharides\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " from Broken-Spore<br>of \n",
       "<mark class=\"entity\" style=\"background: #ff9561; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ganoderma lucidum\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">LOC</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Front Pharmacol 2012;3:135\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ".<br>doi:10.3389/fphar.2012.00135.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    5\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Sliva D. Ganoderma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " lucidum in cancer research. \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Leuk Res\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       "<br>2006;30:767–8. \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    doi:10.1016\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       "/j.leukres.2005.12.015.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    6\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Lu H\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", Kyo E, \n",
       "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Uesaka\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
       "</mark>\n",
       " T, et \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    al.Prevention\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " of develop-<br>ment of \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    N\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ",N’-dimethylhydrazine-induced colon tumors by a<br>water-soluble extract from cultured medium of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ganoderma\n",
       "lucidum\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Rei-shi\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ") mycelia in male ICR mice. \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Int J Mol Med\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       "<br>\n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2002;9:113–7\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ". doi:\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    https://doi.org/10.3892\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       "/ijmm.9.2.113..<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    7\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". LuH,\n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    KyoE\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ",\n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    UesakaT\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ", etal.\n",
       "<mark class=\"entity\" style=\"background: #ff9561; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Awater-solubleextractfromcul-\n",
       "turedmediumofGanodermalucidum(Rei-shi)myceliasup-presses azoxymethane\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">LOC</span>\n",
       "</mark>\n",
       "-induction of colon cancers in male<br>\n",
       "<mark class=\"entity\" style=\"background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    F344\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PRODUCT</span>\n",
       "</mark>\n",
       " rats. \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Oncol Rep\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2003;10\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ": \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    375–9\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ".<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    8\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Lu H\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Uesaka T\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Katoh O\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", et \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    al.Prevention\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " of the devel-<br>opment of preneoplastic lesions, aberrant \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    crypt foci\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", bya water-soluble extract from cultured medium of Gano-<br>dermalucidum (\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Rei-shi)myceliain maleF344rats\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    OncolRep\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2001;8:1341–5\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". doi: \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    10.3892\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "/or.8.6.1341.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    9\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". Sliva D, \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Loganathan J\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Jiang J\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", et al.\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Mushroom Ganoderma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       "<br>\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    lucidum\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " prevents colitis-associated carcinogenesis in mice.<br>\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PLoS One\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " 2012;7:e47873. \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    doi:10.1371/journal.pone.0047873\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ".<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    10\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Yang Y\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Nirmagustina DE\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Kumrungsee\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " T, et al.Feeding of<br>thewaterextractfromGanodermalingzhitoratsmodulates<br>secondary bile acids, intestinal microflora, mucins, and pro-pionate important to colon cancer. \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Biosci Biotechnol Biochem\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "<br>2017;81:1796–804. \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    doi:10.1080/09168451.2017.1343117\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ".<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    11\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Luo J\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", Li T, \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Xie J\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", et al.Guar gum different from Gano-<br>\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    derma lucidum\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " polysaccharide in alleviating colorectal can-cer based on omics analysis. \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Food Funct\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " 2020;11:572–84.<br>doi:10.1039/c9fo02786f.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    12\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". OkaS,TanakaS,YoshidaS, etal.\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Awater-solubleextractfrom\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       "<br>culture medium of \n",
       "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ganoderma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
       "</mark>\n",
       " lucidum mycelia \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    suppresses244Mandy M. Liu\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " et \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    al.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       "<br>thedevelopmentofcolorectaladenomas. Hir oshimaJMedSci<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2010;59:1–6\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ".<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    13\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Chen X\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Hu ZP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Yang XX\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", et al.Monitoring of immune<br>responses to a herbal immuno-modulator in patients withadvancedcolorectalcancer. \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    IntImmunopharmacol\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2006;6:499\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "–<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    508\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    doi:10.1016\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "/\n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    j.intimp.2005.08.026\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ".<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    14\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". Bai JH, \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Xu J\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Zhao J\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", et al.\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ganoderma lucidum\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " polysaccha-<br>\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    rideenzymatichydrolysatesuppressesthegrowthofhuman\n",
       "colon\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " cancer cells via inducing apoptosis. Cell Transplant<br>2020;29: \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    963689720931435\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". doi:10.1177/0963689720931435.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    15\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Castle JC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", Loewer M, \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Boegel S\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", et al.Immunomic, genomic<br>andtranscriptomiccharacterizationofCT26colorectalcarci-<br>noma.\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BMC Genomics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2014;15:190\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". doi:10.1186/1471-\n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2164-15-\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       "<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    190\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ".<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    16\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". Chrubasik S, \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Sporer F\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", Dillmann-Marschner R, et al.Physico-<br>chemical properties of harpagoside and its in vitro release<br>from \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Harpagophytum\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " procumbens extract tablets. Phy-<br>tomedicine \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2000;6:469–73\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    doi:10.1016\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "/S0944-7113(00)80076-8.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    17\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". PandaV,KhambatP,\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    KundnaniK\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", etal.Evaluationofantacid<br>activity of garcinia indica fruit rind by a modified artifi-cial stomach model. Bull Environ Pharmacol Life Sci 2013;2:<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    38–42\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ".<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    18\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Marie JP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Faussat-Suberville AM\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Zhou D\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", et al.Daunorubicin<br>uptake by leukemic cells: correlations with treatment out-<br>come and mdr1 expression. Leukemia 1993;7:825–31.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Liu M\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", RavulaR, WangZ, etal.TraditionalChinesemedicinal<br>formula \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Si-Wu-Tang\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " prevents oxidative damage by activat-ing \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Nrf2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "-mediated detoxifying/antioxidant genes. Cell \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Biosci\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       "<br>\n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2014;4:8\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ". doi:10.1186/2045-3701-4-8.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    20\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Wang EJ\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Casciano CN\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Clement RP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", et al.In vitro flow<br>cytometry method to quantitatively assess inhibitors of P-<br>glycoprotein. \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Drug Metab Dispos\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " 2000;28:522–8.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    21\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". HuangKM,\n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    LiangS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ",\n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    YeungS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ", etal.Topicallyappliedcarvedilol<br>attenuates solar ultraviolet radiation induced skin carcino-<br>genesis. \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Cancer Prev Res\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " 2017;10:598–606. doi:10.1158/1940-<br>\n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    6207.CAPR-17-0132\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ".<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    22\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Yeung S\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Chen Q\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Yu Y\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", et al.Quality evaluation of<br>commercial products of \n",
       "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ganoderma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
       "</mark>\n",
       " lucidum made<br>from its fruiting body and spore. \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Acta Chromatogr\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2021\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ".<br>doi:10.1556/1326.2020.00825.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    23\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ChouTC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ",TalalayP.Quantitativeanalysisofdose-effectrela-<br>tionships:thecombinedeffectsofmultipledrugsorenzyme<br>inhibitors. AdvEnzymeRegul \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1984\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ";<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    22:27–55.doi:10.1016/0065-\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>\n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2571(84)90007-4\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ".<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    24\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Chou TC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Motzer RJ\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Tong Y\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", et al.Computerized quanti-<br>tation of synergism and antagonism of taxol, topotecan,and \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cisplatin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " against human teratocarcinoma cell growth: a<br>rationalapproachtoclinicalprotocoldesign. JNatlCancerInst<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1994;86:1517–24\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". doi: \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    10.1093\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "/jnci/86.20.1517.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    25\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Lin F,\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Hoogendijk L\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Buil L\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", et al.Sildenafil is not a useful<br>modulator of \n",
       "<mark class=\"entity\" style=\"background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ABCB1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PRODUCT</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ABCG2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " mediated drug resistance<br>in vivo.Eur J Cancer 2013;49:2059–64. \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    doi:10.1016\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "/j.ejca.2012.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    12.028\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ".<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    26\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Naito M\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Matsuba\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Y\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PRODUCT</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Sato S\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", et al.MS-209, a quinoline-type<br>reversalagent,potentiatesantitumorefficacyofdocetaxelin<br>multidrug-resistant solid tumor xenograft models. Clin Can-<br>cer \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Res2002;8:582–8\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ".<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    27\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Hu M\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Peluffo G\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Chen H\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", et al.Role of \n",
       "<mark class=\"entity\" style=\"background: #f0d0ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COX-2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">WORK_OF_ART</span>\n",
       "</mark>\n",
       " in epithelial-<br>stromal cell interactions and progression of ductal carci-nomainsituofthebreast. ProcNatlAcadSci \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2009;106:3372–7\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ".<br>doi:0813306106 [pii] \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    10.1073\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "/pnas.0813306106.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    28\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Chen X\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", Sun X, \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Guan J\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", et al.Rsf-1 influences the sensitiv-<br>ity of non-small cell lung cancer to paclitaxel by regulating<br>NF-kappaB pathway and its downstream proteins. Cell Phys-<br>iol Biochem \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2017;44:2322–36\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". doi:10.1159/000486116.29. \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Rimar S\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Lee-Mengel M\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Gillis CN Pulmonary\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " protective and<br>vasodilator effects of a standardized Panax ginseng prepa-<br>ration following artificial gastric digestion. Pulm Pharmacol<br>\n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1996;9:205–9\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ". doi: \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    10.1006\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "/pulp.1996.0025.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    30\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Wang JR\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Yau LF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Zhang R\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", et al.Transformation of gin-<br>senosides from notoginseng by artificial gastric juice can<br>increase cytotoxicity toward cancer cells. J Agric Food Chem<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2014;62:2558–73\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". doi:10.1021/jf405482s.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    31\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Liu C\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Dunkin D\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Lai J\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", et al. Anti-inflammatory<br>effects of ganoderma lucidum triterpenoid in \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    humancrohn\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       "’s disease associated with downregulation of NF-<br>\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    kappaB\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " signaling. Inflamm Bowel Dis \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2015;21:1918–25\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ".<br>doi:10.1097/MIB.0000000000000439.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    32\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    GriswoldDP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ",CorbettTH.Acolontumormodelforanticancer<br>agent evaluation. Cancer1975;36:2441–4. doi: \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    10.1002/1097-\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>0142(197512)36:6 &lt;\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2441::aid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "-cncr2820360627 &gt;\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    3.0.co;2-p.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">QUANTITY</span>\n",
       "</mark>\n",
       "<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    33\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Lechner MG\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Karimi SS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Barry-Holson K\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", etal.Immunogenic-<br>ity of murine solid tumor models as a defining feature of in<br>vivobehaviorand responseto immunotherapy. \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    JImmunother\n",
       "2013;36:477–89\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". doi:10.1097/01.cji.0000436722.46675.4a.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    34\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Wang S\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Wang X\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Lin L\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", et al.Inhibitory effect of \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Lucid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " Gan-<br>\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    oderma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " spore on human hepatocarcinoma cell line HepG2<br>and growth of transplanted tumor in nude mice. World<br>\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Chinese J Digestol\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " 2008;16:1114–8. doi:10.3969/j.issn.1009-<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    3079.2008.10.017\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ".<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    35\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Sun L\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Zhao M\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Huang Y\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", Influence of \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ganodema lucidum\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       "<br>spore on dendritic cells from mice bone marrow andits antitumor effect. (In \n",
       "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Chinese\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
       "</mark>\n",
       "). \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Shanxi Med J\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2006;35\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ":<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    698–700\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ".<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    36\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Huang G\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Zhong W. Inhibition\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " of mouse transplanted hep-<br>atoma growth and telomerase activities by germination-<br>activating sporoderm-broken ganoderma spores (GSGS). (In<br>\n",
       "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Chinese\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
       "</mark>\n",
       "). \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    China Medical Engineering\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2007;15:1–8\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ".<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    37\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Wang Y\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Zhang C\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Zhang S\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", et al.Kanglaite sensitizes<br>colorectal cancer cells to \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Taxol\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " via NF-kappaBeta inhibi-<br>tion and connexin \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    43\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " upregulation. \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Sci Rep 2017;7:1280\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ".<br>doi:10.1038/s41598-017-01480-2.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    38\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ernst M\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Putoczki TL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ". Targeting IL-11 signaling in colon<br>cancer. Oncotarget 2013;4:1860–1. doi:10.18632/oncotarget.<br>\n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1410\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ".<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    39\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Janakiram NB\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Rao CV\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". The role of inflammation in colon<br>cancer.\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Adv Exp Med Biol\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " 2014;816:25–52. doi:10.1007/978-3-<br>\n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    0348-0837-8\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       "<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ".<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    40\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ray AL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Berggren KL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Restrepo Cruz S\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", et al.Inhibition of<br>MK2 suppresses \n",
       "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    IL-1beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
       "</mark>\n",
       ", IL-6, and \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    TNF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "-alpha-dependent<br>colorectal cancer growth. \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Int J Cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " 2018;142:1702–11.<br>doi:10.1002/ijc.31191.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    41\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". Ancrile B, \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Lim KH\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Counter CM\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Oncogenic Ras-induced\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       "<br>secretion of IL6 is required for tumorigenesis. \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Genes Dev\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       "<br>\n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2007;21:1714–9\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ". doi:10.1101/gad.1549407.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    42\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". Beaupre DM, \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Talpaz M\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Marini\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
       "</mark>\n",
       " FC, \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    3rd\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ", et al.Autocrine<br>interleukin-1beta production in leukemia: evidence for theinvolvement of mutated \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    RAS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ". Cancer \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Res 1999;59:2971–80\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ".<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    4 3\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " .P a nY ,J i a n gY ,T a \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    nL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " , et al.Deletion of cyclooxygenase-<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " inhibits \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    K-ras-induced lung\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " carcinogenesis. Oncotarget<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2015;6:38816–26\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". doi:10.18632/oncotarget.5558.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    44\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". MizumotoY,\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    KyoS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ",KiyonoT, etal.ActivationofNF-kappaBis<br>a novel target of KRAS-induced endometrial carcinogenesis.<br>\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Clin Cancer Res 2011;17:1341–50\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". doi:10.1158/1078-0432.CCR-<br>\n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    10-2291\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ".<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    45\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". Ling J, \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Kang Y\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Zhao R\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", et al. KrasG12D-induced<br>\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    IKK2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "/beta/NF-kappaB activation by IL-1alpha and p62feedforward loops is required for development of pancre-<br>atic ductal adenocarcinoma. \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Cancer Cell\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " 2012;21:105–20.<br>\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    doi:10.1016\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "/j.ccr.2011.12.006.Antitumor activity of \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ganoderma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " lucidum \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    245\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "<br>\n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    46\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ". AlshamsanA.InductionoftolerogenicdendriticcellsbyIL-6-<br>secreting CT26 colon carcinoma. Immunopharmacol Immuno-<br>toxicol2012;34:465–9. doi:10.3109/08923973.2011.625034.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    47\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ohno Y\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #ffeb80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Toyoshima\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">EVENT</span>\n",
       "</mark>\n",
       " Y, \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Yurino H\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", et al.Lack of interleukin-6<br>in the tumor microenvironment augments type-1 immunity<br>and increases the efficacy of cancer immunotherapy. Cancer<br>\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Sci2017;108:1959–66\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    doi:10.1111/cas.13330\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ".<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    48\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". Golay \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    HG\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Barbie DA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". Targeting cytokine networks in KRAS-<br>driventumorigenesis. ExpertRevAnticancerTher \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2014;14:869\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "–<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    71\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". doi:10.1586/14737140.2014.928596.<br>\n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    49\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ". HsuYL,ChenYJ,ChangWA, etal.Interactionbetweentumor-<br>associated dendritic cells and colon cancer cells contributes<br>to tumor progression via \n",
       "<mark class=\"entity\" style=\"background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CXCL1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PRODUCT</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Int J Mol Sci\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " , \n",
       "<mark class=\"entity\" style=\"background: #ff9561; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2018;19:2427\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">LOC</span>\n",
       "</mark>\n",
       ".<br>doi:10.3390/ijms19082427.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    50\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Klupp F,\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Neumann L\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Kahlert C\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       ", et al.Serum MMP7, MMP10<br>and MMP12 level as negative prognostic markers in colon<br>cancerpatients. \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BMCCancer 2016;16:494.doi:10.1186\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       "/s12885-<br>\n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    016-2515-7\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ".<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    51\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". Leeman MF, \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    McKay JA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Murray GI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". Matrix metalloproteinase<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    13\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " activity is associated with poor prognosis in colorectalcancer.JClinPathol \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2002;55:758–62.doi:10.1136\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       "/jcp.55.10.758.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    52\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". ErtemFU,ZhangW,ChangK, etal.OncogenictargetsMmp7,<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    S100a9\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Nppb\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Aldh1a3\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " from transcriptome profiling ofFAP and Pirc adenomas are downregulated in response to<br>tumor suppression by \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Clotam\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Int J Cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " 2017;140:460–8.<br>doi:10.1002/ijc.30458.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    53\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Hsu YL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Hung JY\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Lee YL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", et \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    al\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ".Identification of novel gene<br>expressionsignatureinlungadenocarcinomabyusingnext-generation sequencing data and bioinformatics analysis.<br>Oncotarget 2017;8:104831–54. doi:10.18632/oncotarget.21022.<br>\n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    54\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Maly CJ\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Cumsky HJL\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Costello CM\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", et \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    al\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ".Prognostic value<br>of inositol polyphosphate-5-phosphatase expression inrecurrent and metastatic cutaneous squamous cell<br>carcinoma. J Am Acad Dermatol , \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2019\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ". doi:10.1016/<br>j.jaad.2019.08.027.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    55\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Patel AB\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Mangold AR\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Costello CM\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", et \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    al.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "Frequent loss<br>of inositol polyphosphate-5-phosphatase in oropharyngeal<br>squamous cell carcinoma. J Eur Acad Dermatol Venereol<br>2018;32:e36–7. \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    doi:10.1111/jdv.14462\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ".<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    56\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Harjunpaa H\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Llort Asens M\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", Guenther C, et al.Cell adhe-<br>sionmoleculesandtheirrolesandregulationintheimmuneand tumor microenvironment. \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Front Immunol 2019;10:1078\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ".<br>doi:10.3389/fimmu.2019.01078.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    57\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Grozdanov V\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Bliederhaeuser C\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ruf WP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", et \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    al.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "Inflam-<br>matory dysregulation of blood monocytes in Parkinson’sdisease patients. \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Acta Neuropathol\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " (Berl) \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2014\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ";<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    128:651–63\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ".<br>doi:10.1007/s00401-014-1345-4.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    58\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Merdad A\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", Karim S, \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Schulten\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " HJ, et al.Expression of matrix<br>metalloproteinases (MMPs) in primary human breast can-<br>cer: \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    MMP-9\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " as a potential biomarker for cancer invasion and<br>metastasis. Anticancer Res 2014;34:1355–66.<br>\n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    59\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Guo Y\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Su ZY\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       ", Zhang C, et al.Mechanisms of colitis-<br>accelerated colon carcinogenesis and its prevention with<br>the combination of aspirin and curcumin: Transcriptomicanalysis using RNA-seq. Biochem Pharmacol \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2017;135:22–34\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       ".<br>\n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    doi:10.1016/j.bcp.2017.02.021\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       ".</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Visualize named entities in the text document using spaCy's displacy module\n",
    "displacy.render(document, style='ent', jupyter=True)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "9c62aa78",
   "metadata": {},
   "source": [
    "### Cosine Similarity"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "6f63491a",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "PLOS ONE\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "                                                      RESEARCH ARTICLE\n",
      "\n",
      "\n",
      "                                                      The medicinal mushroom Ganoderma lucidum\n",
      "\n",
      "\n",
      "                                                      attenuates UV-induced skin carcinogenesis\n",
      "\n",
      "\n",
      "                                                      and immunosuppression\n",
      "\n",
      "\n",
      "\n",
      "                                                      Ayaz Shahid 1*, Matthew Huang1, Mandy Liu1, Md Abdullah Shamim 1, Cyrus Parsa2,3, \n",
      "                                                      Robert Orlando2,3, Ying Huang1 *\n",
      "\n",
      "\n",
      "                                                      1 Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, \n",
      "                                                      Pomona, California, United States of America, 2 College of Osteopathic Medicine of the Pacific, Western \n",
      "                                                      University of Health Sciences, Pomona, California, United States of America, 3 Department of Pathology, \n",
      "                                                      Beverly Hospital, Montebello, California, United States of America\n",
      "\n",
      "\n",
      "                                                      * ashahid@westernu.edu (AS); yhuang@westernu.edu (YH)\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "                                                      Abstract\n",
      "\n",
      "\n",
      "                                                      The medicinal mushroom Ganoderma lucidum is traditionally used for treating multiple dis- \n",
      "\n",
      "    OPEN ACCESS                                       eases, including cancer. This study examined skin cancer preventive activity of a commer- \n",
      "                                                      cial product containing spore and fruiting body in 30:8 ratio (GLSF). Extracts of GLSF and \n",
      "Citation: Shahid A, Huang M, Liu M, Shamim MA, \n",
      "Parsa C, Orlando R, et al. (2022) The medicinal       spore component (GLS) were prepared using artificial gastrointestinal juice and examined \n",
      "mushroom Ganoderma lucidum attenuates UV-             on JB6 cells. GLSF and GLS dose-dependently inhibited epidermal growth factor-induced \n",
      "\n",
      "induced skin carcinogenesis and                       JB6 transformation at non-toxic concentrations. SKH-1 mice which were fed with diets con- \n",
      "immunosuppression. PLoS ONE 17(3): e0265615.          taining GLSF (1.25%), GLS (0.99%) or the fruiting body (GLF) (0.26%) were exposed to \n",
      "https://doi.org/10.1371/journal.pone.0265615\n",
      "                                                      chronic low-dose ultraviolet (UV) radiation to assess their effects on skin carcinogenesis. \n",
      "Editor: N. Rajendra Prasad, Annamalai University,     GLSF, but not GLS or GLF, reduced skin tumor incidence and multiplicity. In non-tumor skin \n",
      "INDIA\n",
      "                                                      tissues of mice, GLSF attenuated UV-induced epidermal thickening, expression of Ki-67, \n",
      "Received: July 30, 2021                               COX-2 and NF-κB, while in tumor tissues, GLSF increased expression of CD8 and Gran- \n",
      "Accepted: March 1, 2022                               zyme B. To examine the effects of GLSF on UV-induced immunosuppression, mice which \n",
      "\n",
      "Published: March 21, 2022                             were fed with GLSF were evaluated for the contact hypersensitivity (CHS) response to dini- \n",
      "\n",
      "Copyright: © 2022 Shahid et al. This is an open       trofluorobenzene (DNFB). GLSF significantly reversed UV-mediated suppression of DNFB- \n",
      "access article distributed under the terms of the     induced CHS by increasing CD8+ and decreasing CD4+ and FoxP3+ T-cells in mouse ears. \n",
      "\n",
      "Creative Commons Attribution License, which           Therefore, GLSF prevents skin cancer probably via attenuating UV-induced \n",
      "permits unrestricted use, distribution, and           immunosuppression.\n",
      "reproduction in any medium, provided the original \n",
      "author and source are credited.\n",
      "\n",
      "Data Availability Statement: All relevant data are \n",
      "within the paper and its Supporting information \n",
      "files.\n",
      "\n",
      "Funding: Research reported in the publication was     Introduction\n",
      "partly supported by Beijing Tong Ren Tang Chinese     Skin cancer is a major type of cancer with a well-known association with environmental fac- \n",
      "Medicine Co., Ltd. This work was also supported       tor–solar ultraviolet (UV) radiation. Overexposure to UV radiation, particularly in the mid- \n",
      "by Western University of Health Sciences              wavelength range (UVB, 280–320 nm), is the most significant risk factor for the development \n",
      "Intramural Student Funds as part of the Graduate \n",
      "Program. The funders had no role in study design,     of non-melanoma skin cancers (NMSC), including basal cell and squamous cell carcinomas \n",
      "data collection and analysis, decision to publish, or (BCC and SCC), which originate from keratinocytes. In contrast to many other tumor types, \n",
      "\n",
      "preparation of the manuscript.                        NMSC incidence is increasing at an alarming rate in the US—3 to 4 million cases of BCC and\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "PLOS ONE | https://doi.org/10.1371/journal.pone.0265615 March 21, 2022                                                                                                     1 / 18\n",
      "\f",
      "\n",
      "PLOS ONE                                                                     Ganoderma lucidum prevent UV-induced skin cancer and immunosuppression\n",
      "\n",
      "\n",
      "Competing interests: The authors have declared 1 million cases of SCC annually [1–3]. Chemoprevention, i.e., using a pharmacological \n",
      "that no competing interests exist.             approach to block or reverse the initiation, promotion and progression of cancer, represents a \n",
      "                                               very attractive strategy for the control of NMSC.\n",
      "                                                  UV radiation not only induces DNA damage and skin inflammation, but also creates an \n",
      "                                               immunosuppressive microenvironment in which premalignant cells are able to grow into \n",
      "                                               tumors [4]. Only when mutations and immunosuppression coexist, it is possible for skin \n",
      "                                               tumors to occur [5]. Supporting this notion, organ transplant recipients who receive long- \n",
      "                                               term immunosuppressant treatment are at increased risk for skin cancer [6]: for BCC, there is \n",
      "                                               a 10-fold increased risk in organ transplant recipients, while the risk of developing SCC is \n",
      "                                               increased by 65–250 times. UV-irradiated skin is unable to elicit sensitization to contact aller- \n",
      "                                               gens by development of immune tolerance to them [7]. UV-irradiated skin is also unable to \n",
      "                                               reject syngeneic UV-induced tumors, although the same tumors are strongly rejected when \n",
      "                                               transplanted into non-UV-exposed syngeneic mice [8]. Therefore, overcoming UV-induced \n",
      "                                               immunosuppression could be an important strategy for skin cancer prevention.\n",
      "                                                  Since the target population for cancer chemoprevention is healthy individuals, pharmaco- \n",
      "                                               logical agents that can be used for the preventive purposes should be both effective and safe. \n",
      "                                               Therefore, natural products have become a very attractive source for developing cancer pre- \n",
      "                                               ventive agents. Ganoderma lucidum (GL), commonly known as Reishi or Lingzhi, is a medici- \n",
      "                                               nal mushroom recorded in the American Herbal Pharmacopoeia (2000) as one of the most \n",
      "                                               popular and highly effective herbal medicines and is frequently used as an ingredient in dietary \n",
      "                                               supplements. It has been used for thousands of years for the prevention and treatment of \n",
      "                                               many diseases due to a wide spectrum of actions, including immunomodulatory, anti-inflam- \n",
      "                                               matory, antioxidant, and antitumor properties [9]. The most important and widely studied \n",
      "                                               pharmacologically active compounds in GL are polysaccharides and triterpenoids [10, 11].\n",
      "                                                  The present study examined the chemopreventive efficacy and potential mechanisms for \n",
      "                                               GL on skin carcinogenesis. GLS and GLF are commercial products derived from the broken \n",
      "                                               spore or fruiting body of GL, respectively. GLSF is a relatively new GLS-derived product con- \n",
      "                                               taining GLS and GLF in a 30:8 ratio. The present study demonstrated that GLSF has skin can- \n",
      "                                               cer chemopreventive activity both in vitro and in vivo. In a chronic UV induced skin \n",
      "                                               carcinogenesis mouse model, GLSF, but not GLS or GLF, prevented UV-induced skin carcino- \n",
      "                                               genesis in-vivo. To explore a possible mechanism of GLSF’s anticancer effects, an established \n",
      "                                               model of contact hypersensitivity (CHS) in mice was used to evaluate the effects of the dietary \n",
      "                                               GLSF on the immunosuppressive effects of UV. These results led us to conclude that this spe- \n",
      "                                               cific product derived from GL containing both spore and fruiting body may have a novel func- \n",
      "                                               tion in skin cancer prevention. Although this study used murine skin carcinogenesis models, \n",
      "                                               these data may support further clinical investigations of GLSF on other types of cancer.\n",
      "\n",
      "                                               Materials and methods \n",
      "                                               Preparation of GLSF extracts\n",
      "                                               A single batch of a commercial product manufactured by Beijing Tong Ren Tang Chinese \n",
      "                                               Medicine Co. (Hong Kong, China), named as GLSF, containing a mixture of the spore (GLS) \n",
      "                                               and fruiting body of GL (GLF) (30:8 ratio in weight), was used throughout the present study. \n",
      "                                               The artificial gastrointestinal juice was prepared according to reported methods [12, 13]. In \n",
      "                                               brief, the gastric extracts were prepared by mixing 5 grams of GLSF or GLS powder in 50 mL \n",
      "                                               of artificial gastric juice in 37˚C shaker for 1 hour, then 50 mL of artificial intestinal juice was \n",
      "                                               added and incubated at 37˚C shaker for additional 5 hours. The mixture was centrifuged at \n",
      "                                               room temperature for 15 minutes at 4,700 g, and the supernatant was collected. The solution \n",
      "                                               was then neutralized to pH 7.0 using 0.2 N NaOH. The extract was filtered using Whatman\n",
      "\n",
      "\n",
      "\n",
      "PLOS ONE | https://doi.org/10.1371/journal.pone.0265615 March 21, 2022                                                                             2 / 18\n",
      "\f",
      "\n",
      "PLOS ONE                             Ganoderma lucidum prevent UV-induced skin cancer and immunosuppression\n",
      "\n",
      "\n",
      "                      filter paper No. 42, lyophilized, and stored at -20˚C. An established HPLC-DAD fingerprint \n",
      "                      method based on 11 chemical markers has been used for identity determination of GLSF, GLS, \n",
      "                      and GLF [14].\n",
      "\n",
      "                      Cell line and cell culture\n",
      "                      The JB6 CI 41-5a (also named JB6 P+) is a mouse epidermal cell line purchased from Ameri- \n",
      "                      can Type Culture Collection (ATCC, Manassas, VA) sensitive to promotion by growth factors \n",
      "                      or environmental stressors, including EGF. The JB6 P+ cells were cultured in Eagle’s mini- \n",
      "                      mum essential medium (EMEM) containing 4% heat-inactivated fetal bovine serum and 1% \n",
      "                      penicillin/streptomycin and incubated at 37˚C in 5% CO2/95% air.\n",
      "\n",
      "                      UV light source\n",
      "                      UV lamps emitting UVC (100–280 nm; 2% of total energy), UVA (320–400 nm; 37% of total \n",
      "                      energy), UVB (280–320 nm; 54% of total energy), and visible light (400–450 nm; 7% of total \n",
      "                      energy; catalog nos., #95-0042-08 and #95-0043-13, UVP) were used to irradiate in both in \n",
      "                      vitro and in vivo experiments. UVX Radiometer (#97-0015-02, UVP) coupled with a sensor \n",
      "                      with a calibration point of 310 nm (UVX-31, #97-0016-04, UVP) was used to measure stable \n",
      "                      power output (mW/cm2). The exposure time was determined using the following formula: \n",
      "                      dose (mJ/cm2) = exposure time (s)*output intensity (mW/cm2). Quality control of the lamps \n",
      "                      and exposure time were calculated and monitored before using each of the lamps to account \n",
      "                      for power output changes.\n",
      "\n",
      "                      JB6 anchorage independent soft-agar assay\n",
      "                      The JB6 P+ cell line (neonatal BALB/c epidermal cells) is sensitive to transformation. The soft \n",
      "                      agar assay supports cells to grow in 3-dimension, mimicking in vivo cell growth. The process \n",
      "                      of this assay has been described previously [15]. In brief, In a 96-well tissue culture plate, 2x103 \n",
      "                      JB6 P+ cells were mixed with 0.33% agar and suspended on top of a solidified bottom layer \n",
      "                      containing 0.5% agar. Nobel Agar (Sigma-Aldrich) was prepared in PBS, autoclaved, and \n",
      "                      stored at 4˚C. EGF (10 ng/mL) was used to promote and stimulate the anchorage-independent \n",
      "                      growth of JB6 P+ cells. The GLSF or GLS extracts were mixed with EGF and added to both \n",
      "                      agar layers. Plates were incubated at 37˚C with 5% CO2/95% air for 10–14 days. Colonies \n",
      "                      larger than 10 cells were counted manually under a microscope. The anchorage-independent \n",
      "                      soft agar assay can be used to identify chemopreventive activities of GLSF or GLS extracts by \n",
      "                      accessing their ability to suppress cell transformation of JB6 P+ induced by EGF.\n",
      "\n",
      "                      Cell proliferation assay\n",
      "                      96-well plates were seeded with 3,000 to 4,000 cells per well and allowed to attach overnight. \n",
      "                      Cells were treated with test compounds for 72 hours and incubated at 37˚C in 5% CO2/95% \n",
      "                      air. According to the manufacturer’s protocol, cell viability was determined using Sulforhoda- \n",
      "                      mine B (SRB) assay (Sigma) according to manufacturer’s protocol.\n",
      "\n",
      "                      Rodent dietary supplement of GLS, GLF, and GLSF\n",
      "                      To evaluate the cancer preventive effects of GLSF in comparison with GLS and GLF in vivo, \n",
      "                      the test agents were homogeneously blended into the AIN 93G diet by Animal Specialties \n",
      "                      (Hubbard, OR). The formulations included 1.25% GLSF, 0.26% GLF, or 0.99% GLS. The drug \n",
      "                      dose calculation was based on an average daily intake of 4 grams per mouse. Food\n",
      "\n",
      "\n",
      "PLOS ONE | https://doi.org/10.1371/journal.pone.0265615 March 21, 2022 3 / 18\n",
      "\f",
      "\n",
      "PLOS ONE                             Ganoderma lucidum prevent UV-induced skin cancer and immunosuppression\n",
      "\n",
      "\n",
      "                      consumption for each group was monitored weekly during the course of the study and con- \n",
      "                      firmed that the dose of GLSF, GLF and GLS was approximately 2.0 g/kg, 0.42 and 1.58 g/kg, \n",
      "                      respectively.\n",
      "\n",
      "                      Skin carcinogenesis studies in mice\n",
      "                      All animal studies were carried out in accordance with the recommendations in the Guide for \n",
      "                      the Care and Use of Laboratory Animals of the National Institutes of Health and approved by \n",
      "                      the Western University of Health Sciences Institutional Animal Care and Use Committee \n",
      "                      (Pomona, CA). Five-week-old female SKH-1 mice (Charles River, Wilmington, MA) were ran- \n",
      "                      domly divided into five groups (n = 12). For a diet-based drug regimen study, Groups 1 and 2 \n",
      "                      were fed with the standard diet AIN 93G, while groups 3, 4 and 5 were fed with diet containing \n",
      "                      GLS, GLF and GLSF. Mice were switched to modified diet 1 week after arrival. 4 weeks after \n",
      "                      starting the modified diet, the mice were irradiated with gradually increasing levels of UV \n",
      "                      three times a week for 27 weeks with an initial dose of 50 mJ/cm2that is increased each week \n",
      "                      by 25 mJ/cm2to 150 mJ/cm2, which is continued for the duration of the experiment. During \n",
      "                      the UV exposure, mice roamed freely in acrylic cages on a rotating platform with rotational \n",
      "                      placement ensuring consistent and equal dorsal distribution of UV irradiation. Tumors of at \n",
      "                      least 1 mm in diameter were counted and measured with a caliper weekly. The tumor volume \n",
      "                      was calculated according to the formula: (width)2x length/2. At the end of the study, animals \n",
      "                      were anesthetized with isoflurane until respiration ceased, and all efforts were made to mini- \n",
      "                      mize suffering. Tumorous and non-tumorous skin samples were excised and fixed in 10% for- \n",
      "                      malin for pathological analysis.\n",
      "\n",
      "                      Contact hypersensitivity (CHS) assay\n",
      "                      The UV radiation-induced suppression of the immune system in mice was assessed using the \n",
      "                      CHS model, as described previously [16]. In brief, the SKH-1 hairless mice (females) from the \n",
      "                      breeding cohort were randomly distributed into 5 groups (6–8 weeks). The mice were pre- \n",
      "                      treated with a modified diet containing GLS, GLF, GLSF or control diet for 4 weeks. Mice \n",
      "                      were irradiated with a single dose of UV (336 mJ/cm2) on the back. During exposure, the ear \n",
      "                      skin of mice is protected by covering with black electric tape. 24 hours after UV exposure, the \n",
      "                      mice were sensitized with freshly prepared 2,4-dinitro-1-fluorobenzene (DNFB) (Sigma) (25 \n",
      "                      uL, 0.5% in acetone:olive oil 4:1, vol/vol) on UV treated back skin. Seven days later, the mice \n",
      "                      were challenged with DNFB (10 ul, 0.5%) on the right ear skin (dorsal side only) (the other ear \n",
      "                      treated with vehicle). 24 hours after the challenge, the mice were euthanized and 5 mm punch \n",
      "                      biopsies were obtained from the ears and weighed before fixation in 10% formalin. Previous \n",
      "                      studies have demonstrated that measurement of weights of ear punch biopsies correlated with \n",
      "                      measurement of ear thickness with calipers [16]. We prefer this method due to greater repro- \n",
      "                      ducibility in our data. Non-UV irradiated mice that received the same dose of DNFB serves as \n",
      "                      a positive control. Non-UV-irradiated mice that received only ear challenge serve as a negative \n",
      "                      control.\n",
      "\n",
      "                      Histopathological analysis and immunohistochemical staining for \n",
      "                      detection of NF-kB, COX-2, Ki-67, CD8, CD4, Granzyme B, and FoxP3\n",
      "                      For the carcinogenesis study, the non-tumorous and tumorous skin tissues, and the CHS \n",
      "                      study, the ears were excised, and all the tissues were fixed in 10% neutral formalin and embed- \n",
      "                      ded in paraffin. The paraffin-embedded tissues were then de-paraffinized using xylene and \n",
      "                      ethanol. To analyze histology, the de-paraffinized sections were stained with hematoxylin and \n",
      "                      eosin (H&E). In IHC, for antigen retrieval, sections were boiled in antigen retrieval Buffer (cat\n",
      "\n",
      "\n",
      "PLOS ONE | https://doi.org/10.1371/journal.pone.0265615 March 21, 2022 4 / 18\n",
      "\f",
      "\n",
      "PLOS ONE                             Ganoderma lucidum prevent UV-induced skin cancer and immunosuppression\n",
      "\n",
      "\n",
      "                      no. ab93678) for 20 minutes. Different expression of proteins in skin tissue was determined \n",
      "                      using the Vectastain Elite ABC universal plus kit (PK-8200). In brief, sections were incubated \n",
      "                      with bloxall endogenous enzyme blocking solution for 10 min to quenching of endogenous \n",
      "                      peroxidase activity and then rinsed three times (5 min each) with TBST (0.05% Tween-20). \n",
      "                      Blocking solution was applied for 20 minutes; then sections were incubated with diluted poly- \n",
      "                      clonal antibodies, anti-COX-2 (1:200, Cell Signaling Technology), anti- NF-kB (p65) (1:400, \n",
      "                      Cell Signaling Technology), Ki-67 (1:400, Cell Signaling Technology), CD8 (1:400, Cell Signal- \n",
      "                      ing Technology), CD4 (1:100, Cell Signaling Technology), Granzyme B (1:125, Cell Signaling \n",
      "                      Technology) and FoxP3 (1:400, Cell Signaling Technology) overnight at 4˚C in a humid cham- \n",
      "                      ber [For more information about antibodies see S1 Table]. Further processing was performed \n",
      "                      according to the instructions of the Detection System. Scoring the images from IHC analysis \n",
      "                      was carried out using a semi-quantitative scoring system. Ki-67 was scored by counting the \n",
      "                      positively stained cells in 4 to 5 fields at various locations along the skin section to obtain the \n",
      "                      average for each mouse skin (n = 3 mice for long-term UV study). To quantitate CD8, CD4, \n",
      "                      Granzyme B, FoxP3 COX-2, and NF-kB staining, an expression index was calculated by the \n",
      "                      extent of staining multiplied by the intensity of staining. For the extent of staining, the follow- \n",
      "                      ing system was used: 0, no staining, 1 is < 25% of cells positive, 2 is >25% and <50% of cells \n",
      "                      positive, and 3 is >50% of cells positive. For staining intensity, the following system was used: \n",
      "                      0 is no staining, 1 is faint staining, 2 is moderate staining, and 3 is strong staining. Skin sections \n",
      "                      were evaluated at 20x or 40x magnification using a Leica DM750 LED Biological Microscope.\n",
      "\n",
      "\n",
      "                      Statistical analysis\n",
      "                      Data are expressed as mean +/- standard error or standard deviation and was analyzed using \n",
      "                      GraphPad Prism software. One-way ANOVA analysis with Dunnett’s multiple comparison \n",
      "                      test or student t test was used. For all statistical analysis, mean was indicated to be statistically \n",
      "                      different when P < 0.05.\n",
      "\n",
      "\n",
      "                      Results\n",
      "                      Effects of GLSF and GLS extracts on EGF-induced neoplastic \n",
      "                      transformation of JB6 P+ cells\n",
      "                      Since signaling through EGF and its receptor EGFR promotes skin cancer, EGF was used to \n",
      "                      promote the transformation of mouse epidermal cells JB6 P+ (the tumor promoter sensitive \n",
      "                      subline). EGF (10 ng/mL) consistently induced anchorage-independent colony formation as \n",
      "                      expected [17]. As the colony formation in soft agar is dependent on cell viability, we first con- \n",
      "                      ducted a SRB cytotoxicity assay in JB6 P+ cells growing in a monolayer to evaluate the effects \n",
      "                      of these extracts on growth inhibition for this specific cell type. The GLSF and GLS extracts \n",
      "                      showed comparable in vitro effects on cell proliferation. For both extracts, SRB assay showed \n",
      "                      dose-dependent growth inhibitory activity (IC50was estimated as 1.0 mg/mL) (Fig 1A and \n",
      "                      1B). Next, the extracts at the dose range of 0.004 to 1.0 mg/mL were examined on EGF-\n",
      "                      induced JB6 P+ cell transformation. The data showed that both GLSF and GLS inhibited trans- \n",
      "                      formation (i.e., soft agar colony formation) in a dose-dependent manner (Fig 1C and 1D)\n",
      "                      (P < 0.0001 for all doses examined). The IC50for the transformation inhibitory activity of \n",
      "                      GLSF and GLS was estimated at 0.0085 and 0.0075 mg/mL, respectively. Thus, GLSF and GLS \n",
      "                      inhibited epidermal malignant transformation at non-toxic concentrations. Since transforma- \n",
      "                      tion of JB6 P+ is an assay predictive for in vivo cancer preventive activity [18], these data sug- \n",
      "                      gest that GL products, both GLSF and GLS, are able to prevent skin cancer.\n",
      "\n",
      "\n",
      "PLOS ONE | https://doi.org/10.1371/journal.pone.0265615 March 21, 2022 5 / 18\n",
      "\f",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# Load the second file for comparison\n",
    "# The second pdf file had to be converted to text file because of some file protection and did not load correctly\n",
    "# The second file was converted from pdf to text file using https://www.onlineocr.net/\n",
    "\n",
    "# import chardet to auto-detect the encoding of the text file\n",
    "import chardet\n",
    "\n",
    "# Detect the file's encoding\n",
    "with open('/Users/mmliu/Desktop/CISB63/CISB63_midterm_MandyLiu/data/The medicinal mushroom Ganoderma lucidum attenuates UV-induced skin carcinogenesis.txt', 'rb') as file:\n",
    "    rawdata = file.read()\n",
    "    result = chardet.detect(rawdata)\n",
    "\n",
    "# Open the file with the detected encoding\n",
    "with open('/Users/mmliu/Desktop/CISB63/CISB63_midterm_MandyLiu/data/The medicinal mushroom Ganoderma lucidum attenuates UV-induced skin carcinogenesis.txt', 'r', encoding=result['encoding']) as file:\n",
    "    text_file = file.read()\n",
    "\n",
    "print(text_file)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "936ab24d",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "plos one research article medicinal mushroom ganoderma lucidum attenuates skin carcinogenesis immunosuppression ayaz shahid 1 matthew huang1 mandy liu1 md abdullah shamim 1 cyrus robert ying huang1 1 department pharmaceutical sciences college pharmacy western university health sciences pomona california united states america 2 college osteopathic medicine pacific western university health sciences pomona california united states america 3 department pathology beverly hospital montebello california united states america ashahid yhuang yh abstract medicinal mushroom ganoderma lucidum traditionally used treating multiple open access eases including cancer study examined skin cancer preventive activity cial product containing spore fruiting body ratio glsf extracts glsf citation shahid huang liu shamim parsa c orlando r et al 2022 medicinal spore component gls prepared using artificial gastrointestinal juice examined mushroom ganoderma lucidum attenuates jb6 cells glsf gls inhibited epidermal growth induced skin carcinogenesis jb6 transformation concentrations mice fed diets immunosuppression plos one 17 3 e0265615 taining glsf gls fruiting body glf exposed https chronic ultraviolet uv radiation assess effects skin carcinogenesis editor rajendra prasad annamalai university glsf gls glf reduced skin tumor incidence multiplicity skin india tissues mice glsf attenuated epidermal thickening expression received july 30 2021 tumor tissues glsf increased expression cd8 accepted march 1 2022 zyme b examine effects glsf immunosuppression mice published march 21 2022 fed glsf evaluated contact hypersensitivity chs response copyright 2022 shahid et al open trofluorobenzene dnfb glsf significantly reversed suppression access article distributed terms induced chs increasing decreasing mouse ears creative commons attribution license therefore glsf prevents skin cancer probably via attenuating permits unrestricted use distribution immunosuppression reproduction medium provided original author source credited data availability statement relevant data within paper supporting information files funding research reported publication introduction partly supported beijing tong ren tang chinese skin cancer major type cancer association environmental medicine ltd work also supported ultraviolet uv radiation overexposure uv radiation particularly western university health sciences wavelength range uvb nm significant risk factor development intramural student funds part graduate program funders role study design skin cancers nmsc including basal cell squamous cell carcinomas data collection analysis decision publish bcc scc originate keratinocytes contrast many tumor types preparation manuscript nmsc incidence increasing alarming rate 4 million cases bcc plos one https march 21 2022 1 18 plos one ganoderma lucidum prevent skin cancer immunosuppression competing interests authors declared 1 million cases scc annually chemoprevention using pharmacological competing interests exist approach block reverse initiation promotion progression cancer represents attractive strategy control nmsc uv radiation induces dna damage skin inflammation also creates immunosuppressive microenvironment premalignant cells able grow tumors 4 mutations immunosuppression coexist possible skin tumors occur 5 supporting notion organ transplant recipients receive term immunosuppressant treatment increased risk skin cancer 6 bcc increased risk organ transplant recipients risk developing scc increased times skin unable elicit sensitization contact gens development immune tolerance 7 skin also unable reject syngeneic tumors although tumors strongly rejected transplanted syngeneic mice 8 therefore overcoming immunosuppression could important strategy skin cancer prevention since target population cancer chemoprevention healthy individuals logical agents used preventive purposes effective safe therefore natural products become attractive source developing cancer ventive agents ganoderma lucidum gl commonly known reishi lingzhi nal mushroom recorded american herbal pharmacopoeia 2000 one popular highly effective herbal medicines frequently used ingredient dietary supplements used thousands years prevention treatment many diseases due wide spectrum actions including immunomodulatory matory antioxidant antitumor properties 9 important widely studied pharmacologically active compounds gl polysaccharides triterpenoids 10 11 present study examined chemopreventive efficacy potential mechanisms gl skin carcinogenesis gls glf commercial products derived broken spore fruiting body gl respectively glsf relatively new product taining gls glf ratio present study demonstrated glsf skin cer chemopreventive activity vitro vivo chronic uv induced skin carcinogenesis mouse model glsf gls glf prevented skin genesis explore possible mechanism glsf anticancer effects established model contact hypersensitivity chs mice used evaluate effects dietary glsf immunosuppressive effects uv results led us conclude cific product derived gl containing spore fruiting body may novel tion skin cancer prevention although study used murine skin carcinogenesis models data may support clinical investigations glsf types cancer materials methods preparation glsf extracts single batch commercial product manufactured beijing tong ren tang chinese medicine hong kong china named glsf containing mixture spore gls fruiting body gl glf ratio weight used throughout present study artificial gastrointestinal juice prepared according reported methods 12 13 brief gastric extracts prepared mixing 5 grams glsf gls powder 50 ml artificial gastric juice shaker 1 hour 50 ml artificial intestinal juice added incubated shaker additional 5 hours mixture centrifuged room temperature 15 minutes g supernatant collected solution neutralized ph using n naoh extract filtered using whatman plos one https march 21 2022 2 18 plos one ganoderma lucidum prevent skin cancer immunosuppression filter paper 42 lyophilized stored established fingerprint method based 11 chemical markers used identity determination glsf gls glf 14 cell line cell culture jb6 ci also named jb6 mouse epidermal cell line purchased type culture collection atcc manassas va sensitive promotion growth factors environmental stressors including egf jb6 cells cultured eagle mum essential medium emem containing 4 fetal bovine serum 1 incubated 5 air uv light source uv lamps emitting uvc nm 2 total energy uva nm 37 total energy uvb nm 54 total energy visible light nm 7 total energy catalog uvp used irradiate vitro vivo experiments uvx radiometer uvp coupled sensor calibration point 310 nm uvp used measure stable power output exposure time determined using following formula dose exposure time output intensity quality control lamps exposure time calculated monitored using lamps account power output changes jb6 anchorage independent assay jb6 cell line neonatal epidermal cells sensitive transformation soft agar assay supports cells grow mimicking vivo cell growth process assay described previously 15 brief tissue culture plate 2x103 jb6 cells mixed agar suspended top solidified bottom layer containing agar nobel agar prepared pbs autoclaved stored egf 10 used promote stimulate growth jb6 cells glsf gls extracts mixed egf added agar layers plates incubated 5 air days colonies larger 10 cells counted manually microscope soft agar assay used identify chemopreventive activities glsf gls extracts accessing ability suppress cell transformation jb6 induced egf cell proliferation assay plates seeded cells per well allowed attach overnight cells treated test compounds 72 hours incubated 5 air according manufacturer protocol cell viability determined using mine b srb assay sigma according manufacturer protocol rodent dietary supplement gls glf glsf evaluate cancer preventive effects glsf comparison gls glf vivo test agents homogeneously blended 93g diet animal specialties hubbard formulations included glsf glf gls drug dose calculation based average daily intake 4 grams per mouse food plos one https march 21 2022 3 18 plos one ganoderma lucidum prevent skin cancer immunosuppression consumption group monitored weekly course study firmed dose glsf glf gls approximately respectively skin carcinogenesis studies mice animal studies carried accordance recommendations guide care use laboratory animals national institutes health approved western university health sciences institutional animal care use committee pomona ca female mice charles river wilmington domly divided five groups n 12 drug regimen study groups 1 2 fed standard diet 93g groups 3 4 5 fed diet containing gls glf glsf mice switched modified diet 1 week arrival 4 weeks starting modified diet mice irradiated gradually increasing levels uv three times week 27 weeks initial dose 50 increased week 25 150 continued duration experiment uv exposure mice roamed freely acrylic cages rotating platform rotational placement ensuring consistent equal dorsal distribution uv irradiation tumors least 1 mm diameter counted measured caliper weekly tumor volume calculated according formula width 2x end study animals anesthetized isoflurane respiration ceased efforts made mize suffering tumorous skin samples excised fixed 10 malin pathological analysis contact hypersensitivity chs assay uv suppression immune system mice assessed using chs model described previously 16 brief hairless mice females breeding cohort randomly distributed 5 groups weeks mice treated modified diet containing gls glf glsf control diet 4 weeks mice irradiated single dose uv 336 back exposure ear skin mice protected covering black electric tape 24 hours uv exposure mice sensitized freshly prepared dnfb sigma 25 ul acetone olive oil uv treated back skin seven days later mice challenged dnfb 10 ul right ear skin dorsal side ear treated vehicle 24 hours challenge mice euthanized 5 mm punch biopsies obtained ears weighed fixation 10 formalin previous studies demonstrated measurement weights ear punch biopsies correlated measurement ear thickness calipers 16 prefer method due greater ducibility data irradiated mice received dose dnfb serves positive control mice received ear challenge serve negative control histopathological analysis immunohistochemical staining detection cd8 cd4 granzyme b foxp3 carcinogenesis study tumorous skin tissues chs study ears excised tissues fixed 10 neutral formalin ded paraffin tissues using xylene ethanol analyze histology sections stained hematoxylin eosin h e ihc antigen retrieval sections boiled antigen retrieval buffer cat plos one https march 21 2022 4 18 plos one ganoderma lucidum prevent skin cancer immunosuppression ab93678 20 minutes different expression proteins skin tissue determined using vectastain elite abc universal plus kit brief sections incubated bloxall endogenous enzyme blocking solution 10 min quenching endogenous peroxidase activity rinsed three times 5 min tbst blocking solution applied 20 minutes sections incubated diluted clonal antibodies cell signaling technology p65 cell signaling technology cell signaling technology cd8 cell ing technology cd4 cell signaling technology granzyme b cell signaling technology foxp3 cell signaling technology overnight humid ber information antibodies see s1 table processing performed according instructions detection system scoring images ihc analysis carried using scoring system scored counting positively stained cells 4 5 fields various locations along skin section obtain average mouse skin n 3 mice uv study quantitate cd8 cd4 granzyme b foxp3 staining expression index calculated extent staining multiplied intensity staining extent staining ing system used 0 staining 1 25 cells positive 2 25 50 cells positive 3 50 cells positive staining intensity following system used 0 staining 1 faint staining 2 moderate staining 3 strong staining skin sections evaluated 20x 40x magnification using leica dm750 led biological microscope statistical analysis data expressed mean standard error standard deviation analyzed using graphpad prism software anova analysis dunnett multiple comparison test student test used statistical analysis mean indicated statistically different p results effects glsf gls extracts neoplastic transformation jb6 cells since signaling egf receptor egfr promotes skin cancer egf used promote transformation mouse epidermal cells jb6 tumor promoter sensitive subline egf 10 consistently induced colony formation expected 17 colony formation soft agar dependent cell viability first ducted srb cytotoxicity assay jb6 cells growing monolayer evaluate effects extracts growth inhibition specific cell type glsf gls extracts showed comparable vitro effects cell proliferation extracts srb assay showed growth inhibitory activity ic50was estimated fig 1a 1b next extracts dose range examined induced jb6 cell transformation data showed glsf gls inhibited formation soft agar colony formation manner fig 1c 1d p doses examined ic50for transformation inhibitory activity glsf gls estimated respectively thus glsf gls inhibited epidermal malignant transformation concentrations since tion jb6 assay predictive vivo cancer preventive activity 18 data gest gl products glsf gls able prevent skin cancer plos one https march 21 2022 5 18\n"
     ]
    }
   ],
   "source": [
    "# Convert words to lowercase, remove stop words and remove non-alphabetic characters and symbols in the text file\n",
    "def preprocess_text(text_file):\n",
    "    \n",
    "    # tokenize the input text into words and assign it to words variable\n",
    "    words = word_tokenize(text_file)\n",
    "    \n",
    "    # converts each word in the list to lowercase\n",
    "    # checks whether a word consists of alpha numeric characters; remove non-alphabetic characters and symbols\n",
    "    words = [word.lower() for word in words if word.isalnum()]\n",
    "    \n",
    "    # remove stop words\n",
    "    words = [word for word in words if word not in stop_words]\n",
    "    \n",
    "    # join the preprocessed words back together into a single string with space separators\n",
    "    return ' '.join(words)\n",
    "\n",
    "print(preprocess_text(text_file))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "a0b130ec",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Cosine Similarity Score: 0.847872119674535\n"
     ]
    }
   ],
   "source": [
    "# Create TF-IDF vectors\n",
    "vectorizer = TfidfVectorizer()\n",
    "tfidf_matrix = vectorizer.fit_transform([text, text_file])\n",
    "\n",
    "# Calculate cosine similarity\n",
    "cosine_sim = cosine_similarity(tfidf_matrix[0], tfidf_matrix[1])\n",
    "\n",
    "# Print the cosine similarity score\n",
    "print(\"Cosine Similarity Score:\", cosine_sim[0][0])\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "dda63988",
   "metadata": {},
   "source": [
    "### WordCloud"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "a6525264",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAxYAAAGVCAYAAABjBWf4AAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjcuMSwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy/bCgiHAAAACXBIWXMAAA9hAAAPYQGoP6dpAAEAAElEQVR4nOy9d3xcV3qf/9w2vQOD3gECYO+kWET1tiuttnib7XjtXTsbx7FjO92JE6fYidOcxHb8s52Nsy5bvH216hJVKYq9V/TeZgbTy62/PwaECBGdAEXt4vl8JAK4d849Z+bMvec97/t+X8GyLIs11lhjjTXWWGONNdZYY43bQPygO7DGGmusscYaa6yxxhprfPhZMyzWWGONNdZYY4011lhjjdtmzbBYY4011lhjjTXWWGONNW6bNcNijTXWWGONNdZYY4011rht1gyLNdZYY4011lhjjTXWWOO2WTMs1lhjjTXWWGONNdZYY43bZs2wWGONNdZYY4011lhjjTVumzXDYo011lhjjTXWWGONNda4bdYMizXWWGONNdZYY4011ljjtpFXo1HD0LEsC0mSEQRhluMGpmkgyzKC8J5tY1kWmq4iSwqCIGAYerGTsnLL6y3LnNH+jQLiN19P01VEQUIUxVn7scaPN5ZlYZkGlmmAWZwzWBYWFtyoNy+AgACCUJyLgoggigiiVPz5Lpk3t47FAsv8UI7lxwFT1zD1ApZpAiBIMpLiQBDX9mrWWGO1MU0Ty7LWnu1r3BFurB1me47OtvZcfLvF5/hSns+WaYAgAMJdO/dXxbDo7rtMMjXJ+tYduJzeW4739F+mo+sc+/c8gd9XMv13wzR4+fVvcs+uR3G7fJy9cISCmuO+/R+b8fqBoQ7GI4NsbN+D2+XDskwmExFsigOP2zd93rsnX6KmqonaqnW3GCc/CRimQT6fI5/Po8gKbrcHSZI+6G6tLpaFaeiYWh41M0lq4BKp/gukR7ooTA6jpqLo+TSmriIIAqLiQLI5UNwhbP4wjmAV7vIm3JXrcJU1oLgDSDYnomy7C8ZymVT/edKjU2NJvn8sdiSbE8UdxOYvwxGsxF3efHeM5ceMyMXD9L3y52THezEKGYKt+1n/+X+PI1T1QXdtjTU+lJimgWWBKIpYlokgiBiGgSiKiKKIaZqYpokoisTiUWKTUaoqqnE53QjC3bvIWuPDjWWa5OMjmIUcjlA1omIrGhmiBFjohQyiqCAqNgRBxDT04ly8sWlumcX5LMpTP1vTx/VsAjUVnWrXXjQyil8CBEEsGhEwbXiYhk56+Bo2Twi7vwyEu3M9t+KGhaarlIdrqCxvwGF3oesa+UJ22stgtzmxTAtd10hnEpiWicvhwWZzoKo59u1+HJ8niG5oWJioap5EMoYoiricXizLJBQspzRUidPhxjQNEskYp8+9QVm4hpbGzdjtTjRNZVP7XlxOD5IkY1kWmWwSwyh+UG6XF93QKBTyQNEAdDo9KB/wosswdDRNQ5bl2zaG4olJXnjlh3z/2W9RV9PAP/21f015WeUK9fTuwzR09GySRPcpxk4/S/TqEfRsYs7zLQuMQgajkEFNRcmMdsw4Ljk8BJp3UXf/Fwi1H1jt7s9geiw9pxk79SzRq28vYixZjEJ2aiydM45LDjeBpp3U3v/zlKw/uNrdv2OYWgHT0BAVO6J05zYPQu0HcVeuIz85Qsd3/+Mdu+4aP9nk8zkEUcSm2MgXcoiihE2xUSjkyWTTCIKI0+FEN3QKagEsC0VRcDk9KMrdvbk2ONyPpuuES8pIJCbxev0MDPXh8/qpqqghnphkbGKEULCUQiHHyOggkiji9wUI+IMfms1DyzLJF3Kk0vHbbsvrCeCwu9aMqlXC1DUKiTGSfecRZTuK208hmcEoZHEEq0AQGD3xAxyhaoKt9yAIItnxHgRBxFXePLW2iGAUcrgr15GL9GMUskh2F45QNXohg6HmEAQRPZdETU5gaio2XwmyK0A+Noyp5XCEahAlhexEL8meM/gbtmPzlSLwE2JYTESGOfzWd/B6Ajx476dIpmIcPfESuVyKglagobaNkmAFo+MDvH7k+6QzCTavv4c9Ox7m1Lk3eOvoM3zxp3+LQCCMpha41nmaSHQYWVbYv+cjKIrCq29+B1lSePSBzyGKIucvH+X85aP4PAEymSQb2/fQP3Sdl177Jg8e/AQb2/eiGzrPv/o1DEND1zV2b3+QeCLCmQtv4/cG0QyNe3Y8QmvLtpV+S5bEyOgw17uv0tLYSl1Nw221VRIs5Wc+/UXKSst56+jrK9K/uxVDzZMeusLA639J5NLrGIXM7beZT6MmI+/tGtwhVmcsmamx6CvQw7uHRO850sPXCLUfwF3edMeuKzvcyI4mHIFy5Fm8smussRocP30Uj9vLxvVbeOfYm5SESmlbt5E33n6Zi1fOYne42LVtL+ORUc5fPEM8EWP7lt3cd+BhaqvrP+juz8tb77xGPDlJS2MriWQcQRQxTYNkMsGDhx7nzPkT5PJZ7HYHG9u3MBmPMR4Zo7V5PSWh8Afd/UWjairHT7/C//v6f7rttr740/+C/Xs+giStSvDJTzy5SB+pwSto2SSy3Ulq6CqFxDj5yVECTTvwVK7D1FRExYEgSkQvvYFeyJAevk7dfT9HPj5K9PIblG19DCOfZvjotxAVO65wA0Yhi2izkxntwFlSTWasm/TwdSxdw1FSg2R3ko8Nk48NE2rbh5qMIio28pOjeGu1D/qtmZcVn41VFQ1s2bCPWHx8+m+SJHHPrkcpLank1be+i02x43J5ePzBn8YwdX704lfZseU+9u16jO6+y9OvEyWZupo2Hn3gc1y6eowLV97l8Qc/z7ZNBxka6QaKFvum9j2oWp7GuvW0NG4GYFP7Xnr7r2KzOQC41nkal8PNow98lslEhG9+7w/Zu+NhQoEwn/joL3Gt8wxXOk4vybAwTZPYZIR4YhJd1xFFkfraRmw2O7l8jpHRITRdxabYKQ9X4HK5yWTTjE+M4nA4SaWTKLJCaUkZbpeHeGKSY6fe5mrH5aKnJ5+jsqIaj9tLIhmnoBbQNJVMNo1pWjQ3tKAoNrLZDKPjw2i6ht3moCxcgdvlXvZnmM/nGJsYnfI25ZFEiXBpOcFAiGhsAsMwKKh5crkcTqeLmqo6LCwSiTixyQimZeL1+CgJhVFkheHRQdwuD8FACIChkQGcDhcej5eh4X5cTjfJdALTNCkPVxLwB5fUX0PNE736Nr0v/gmp/ou8l3Rw+zhLa3GVNa5YewthqHliV4/Q89KfkOq7wEqOxVFSg7u8ecXa+6CxTIPU4CWSvefwN27/oLuzxhqrTmwyQjqdpKaqloGhPkRJoru3g9ePvMLv/LPfx253oOkaNsXGuqZ2Xjz8I372M19atf7kcllGxoYJBUuWfN9+P4rdRri0nONnjvL4g09x8uy72G0OQqFSVE0lEhvHptgoC1cAEIlOYLfZCfiDmJaJNEtYyGQ8RiwepaayFrvdcVv9W+MnD1NXESUFV1k9plqY3qCTFDuSzYHs9KK4AyjuAIIoo6Un0XMp7N4SQEAQRXwN2/DWbkDLxFG8IezeMK7yJkwtj2RzggV6IYtlmjhD1SjuQDHyIB0rXsvmRFTs6IU0npI2nOG6O+qdXw53xMz1egLYHS4UxY5lGpimSdBfhiwryChoetH6st63iBJFCafDjSzJ2GwOCmpu9gsIFNdf86zBMtkkbre/6KJyesnmUoiSRChYjiCIyLINXV+aFTg0MsAzL3yHrp7rqJqGJIr801/7N5SVVfDK68/x5juH0XQVl8PNnp37efyhpzh/8Qz/609/n317DtHb34VhGDxw76M8fN8TnL1wghcPP8vI2BADQ734vH5+9jNfYvOG7bxz/E1OnTuGXbEzNjFCNpfl3/7z/0zAH+S5V37AuyfexjA03C4v+/bcy6MPfBSbzb6k8dzgxJl3eenwjxAEkUtXz5HPZ/mNv/8vOXDPfXz32W8yPDKAw+ZkeHSQxvoW/t4Xf51obJznXv4h1zouYVkWFWVVPPLAR2hr2cCffOUP2L1jHx//6GcA+D9/+Udsat/K/r338S//w2+yf88hhkYGSCbjbNm4k1/4mb+Hzba4kDTL0Il3n6T/lT8n1X9hWeOdC1Gx4yytwx68M+FjlqGT6DlF36t/Tqrv/Iq2LcorPxbLNNHzKQrxMYxCBss0ECQF2eHB7i+b3sm3LBMtE0dNTKBPeV9khwdHsBLJ4Z4WcMjFhlCTEbw168lFB9EyCcBCtruxB8pQXAEQBIxClnxijMLkKMnec+Sig6QGLmGoWQAUdxBnSU3xpg3kJ0dRUxE8Va1o2QSF+CimVkCQFOxTuSjFflqYWp785Ch6NoFlGog2B3ZfKYqnBHFtV3CNu4DegW4QBHoHuqmtaeD8pTPcf+BhHI7ifLcpdy6ct7uvk9//n7/D5z7583zkkY8t/IJ5qCyrwmF3MjkZpb11I3a7g46uK5SVVlBbXceubffQP9RLuKSMYKCE3Tv2UVALRKLjlIcrkKbGfzNvvnOYb37vq/zuv/oDGutbbqt/a/zkYfeXU0iMkx7uwFVah6e6DVG2oWUTKN4SBNmGzRsiN9GHs6SG4Lq9JPvOgyCgeILoagbb1LpUECUcwSoUlx/Z4cEoZNFySbTMJIX46HT+o2R3I4gy9kAFomRDL6SxeUrwN2wjNXgZNRVFkJWiUMtdyoo+KU3TJJNNEp0cI5GMEomNYJomwixvwc0hgQKgGzqR2DCZbJLxyBCCKGEYOtHJUXoHrhKbHKMiXEs6kyA6OUo8GSESG8Fms2NTHFiWyVhkkGAgjMcTIJWeJJmKEYmNUhKsoKqikbMX3mJgqINEKjbt2eA2PpxnX/oek/EYv/blf0ZtdT3JVAKvx0csHuHP//KP+P3f+UPa1m3g6rWL/Lf//Xu0tWxA01Wy+Sz37L6XX/7ib/CD5/6WsxdOcmDv/Tx03xOomsaVaxf46GOfoK1lw4zrXb1+iX/wi/+YXTvuQS0UcLlcDA4P8Jff+HP+27//E5oa1nHu4in+z1/9MW3rNrKuqW1Z43rupe8XDaGHP8bb777O9370De4/+AiarqKqBQYG+/i93/6fhEvDqKqKKIqcOnuc3v4u/smv/mv8vgBf/+5XefPoYcIlZfNeKxqboKaqjr/787/G2PgIX/6Nn+Xh+x+nubF1UX3NxYYZOfY9EotYiN9Y9IqKHUGSp5KjTCxTx9RVTL2AqeanQ5/s/grcFS13bEGZnxxm5Nj3SfSeW/Dc+ceiYer5mWMJlOOpXLdiY7FMg1x0kPGzLxC98hZ6JlFMSpNkPJUtVB/4PIHmnViWRS4ywNipZ5m8fhQtPVm86br9hLc8Qtn2J4qxooLIyLHvMXTk66z/3L9n+Nj3yEcHMXUV2eGhbOtjVO79BIonSD4+xuiJ7xPvPEFmtAtTV+l/9SuIU97JYOs+au/7OzhLagAYO/McQ29/gw0/+x+JXnmbRNcJ1HQcUVao2P0x6h74BSzLQs+liF5+g7HTz5GPDWGZBrLdja9xGxW7nsJT1Y54Sxz33XtzX+PHE5fTRcAfxOV0IQCyLJNX8x90t26be/c9CMDuHfsA2LxhGxvXb0FAQBRFdm7by46te6YTtasqqhfZ8o/zd/THeWwfPDZvCSUb7qNkw6HpDTBnuL64iT01D0s3PYhpGgiCiOLyF48LAAKeiveMWdnppXL307dcI9iye87rO8N1Uz8Vr+Uqa5y+7t3MyhoWlkl0cpR0JoGu64yM9REOVRIurcLp8CBLMlWVTfi9IVQ1P50o3VDXjmkadPddxucJMjo+gCwrlATLyWTidHSfx+3y0r5uJ/FEhEQiimVajI714fUEKA1VUhauZXC4k8HhLupr2xgc7kKWFOKJCMNjvWxo283IWB/Xus5iWRYPHPwEk/EJbIodQRDxegJUVTQsabw9fV3cs/sgZaXliKI47QoeGOrHYXfQtm4DkihRUV5FdWUNXb3X8Xn9lIbCbNu8E5vNRihYiqLYyOUXjqNvalhHfV0TiqygyAqWZTEw1Ifb5aa1ZT0AlRXVlIXL6e3rXLZhUVlRzdDIAGfPn2RouI/62sbpiawoNta3baKivLjL63TK0+7mcGk5lVM3+4baRs5eOEUkNjHd7g01BMMwZnintm7agSIrVJRXUVleRd9Az6IMC1PXiF19m3jHMZgnD8LmLcUZrsdVWosz3IDNG0JSnAiSVFRdUnNo2SRaJkYhMYGWnkTLxnFXNOOpWres93CpmLpG7No7TF5/d1FjcZbU4iprwOYJItlcCJKMaWiYah4tmyjugiTGp8aSwFXWgKdqccbaQliWhZaJM/jmXzN2+nlCbfsI7H4axelDTUWLC3JXUZ1Ny0wy9PbXiV5+k0DLbvz7dgAQ7zxB36tfwTQ0qg9+HtleDN3T0pP0vvT/4W/aSdm2xzG1PBPnX2bw7a9j84ep2PUUNl8pZdsex1e/heF3voWWjlF14DO4pnIsFFcAm7d0Rp/1bJKht76GaHNSsfeTyA4vhfgorrKGqfdfZbLjXXpe/N84glVUH/wciitAZqSDyKU3UJMRGh77ZTyVd2Y+3E2oyQh6IY2ztH7BB5qh5snHBlHTk9i8JTiCVRhqlnx0EEGScZbWIzuWH6a5FPRcCtHmuCVsQE1OoBeyuMJ3d87BXNTXNLJ9y276B3sRRYmN7Vt45oXvcP7Saew2B5UV1fi8/jvap9VY5wiCMCO86W5UfsrmsoyMDpIv5IubqEIx0qK1uX3OZHJRFCkJVrBlwz50XUM3NDS9mPt54/cbPxc383KYU7LWa9x5hClp1/d+F2+x50Txpnm6gpLjN5djWOm2V5MVNSxkSaahtp2G2vY5zzmw54lb/vboA58D4NC+W12pG9p2zfjd7wtRU3VrnPi2TQfYtuk95Z5t/oNs2zRT/Wb/7sdn/B4KlmMUsmQGL1Fdv4Xqyib0QhY1FUFx+lDcgTnHAeDz+olEJ8jmsjgcTlS1gCwr+L1+dF0nEp0gXFpGOpMilUoS9IcwTANRlLC/P0xpap0tSRK6YaDrtybZ2hQb4vturH5fAE1TicQmCAVKSKdTZDIZ/L7lx7vu3bmf//vXf4Ku6yiKwmc/8XOIUxNaEARsysy+K4qC0+FieGSAVDqJw+4gnowjCCIetxdZlsnmMqiaSqGQJzoZmQ5/AxgaGaS2poF0OkU6ncLvCyyqn/n4KPHu0xQS43Oe46lspWznRynb+giussZiTYd5sAwdNRMnN9EHgoAr3LCovtwuhcSNsYzNeY67ch3lO5+kbMsjuMoaEBbwPlimgZqenBoL04vo28YyyYx1M3b6eYLr9rDuk/8Cmyc066nJ3rNMXn+XYOs91D/8S9NhR+FND6Cmogwd+VvCmx5CutE3QcRTvZ7mp/4RoiRjmQaOkhqu/NU/I9l3jopdT6E4vSg161E8IWze17AMHU9VO766TXN32TIwdZXWn/pXyK7ALQsULR1j/PRzSLKdpid+FX/jNgAMLY/iDjDw5t8w2XEMV1nDqsW3atkk+clhjFwaBLD5woiyHcvQsPlKMdQ8CCDbPaQGL095owQ8VeuQHZ552zZ1dcpojk3/TfGGsPvKZvHCzERNRcjHR3GWLrwQz0UHGD/zPIaax9+4DZsnhJaOMXHhVQwtT/X+zyA77kyeT+z6u/jrt2APlM/4eyE5QSE5seqGhWXdvBhcmUVxTVUdLqcLSZKor20k4AvS0tRG27oNnDl/Aq/Hj8vlxuf14/cFaF+38bavuSCWxWQ8xpFjb5BKJfD7AjQ3thIuLUcQBApqgaHhfoZGBshk0kiyTGVZFc1NbThvCl/qH+yhu6+LbDaNItsoCZXSvm4jrql8wXwhT99ANwND/RiGTihYSmN9MyXBUgRBwLIsxiZG6eq5Pt2PZCrOSuapvZ9cLkNn9zUuXj2P1+PD5XQxPDrI3//Sb+Keo46XItvY0Lab5sZN5PNZ8oUMuXy2+HM+Q65Q/DefzxJPRjh74W0isZFV6b9pmqQzCeLJCKl0nEIhh66rUzVCJGyKHYfDhcftx+8rxe3yLjiPLctC1QokklGSqRjZbApVy2MYxlTYuYzD7sbrCVASKsd5UzjsXGRzabp6LpDOJvG4/dTXtOHzFnNrstkU0dgoydQkBTWHObXGcjrc+LwhwqVV2G3OZdaZMMnlMkwmJkim4+TzGXRdnZY9VmQ7drsTj9uPzxvC6/HPMDLmwzQNsrk00ckxUqnYlHGqI4oSDrtr6v2pxOX0TK+/FkLTVXr7rxKJjWC3OaitWke4tGrqesWIokh0hGQ6NqWIaiHLNhx2J15PkGAgPHW921Ob+okPGtYycYbf/Q6++i1AcXdusuNd/PVbFzQs7t33IG8ePcwLr/4Qvy+Iqham1Te2bd7JM89/m4ryKiLRCUpCYdpbN3Hp6vxhLuXhCkzD4Mi7rzM43M/2zbumk9Vmo6G2iQ1tW/jBc9+irLSC8cgo4dJyWlvWMxmPcenqec5fOsPQyABHjr3B+rZNNNY347DfGo96g9hkFIfTRVVFDS6Xm57+LsrL5u6Dy+mmrWU9PX2dPPP8d3C6XPT0dtLc2Ep1ZS0tTW1093byzAvfQZZk0ukk4tSNRBIlzpw7QTKVYCIyRnlZJeua5jZMbyYz2kF66Oqcxx2hGuof+buEtz4yHW+/EIIkY/eVYveVLnzyCpIZ7SI1eHnO445QNQ0PT43F7lpUm4IorcpYTK1AZuQ6giAQbNs3p1EBkB3vRU3H8NVtwu5/b4EnO30EmnYS7zpJNtKHo7QWAFGUCW9+aDpkSxAlFKcP2elByyZvq9/hrY8i2T2zPmD0fIrU4GXcFetmGCiS4sBduQ7F5SM30YeeS71vvCu3aDEKGfKRASY7jiHaHJSsP4SeS5IevkbZ9sdR4+MgyXgqWxl+51t4qtun8oBqFjQs1GSE0ePfY7Lj2PTfSjc/RMXujy34+eUnR6Y9QJZpUkiMkxnrKqa2GTq2QDnuihYK8TGil98kFx0i1LYfT8W66eTGUNuBYuzxTaSGrqImJjANFbsvjLdmA6nBy5i6ipZNYvOWoGeTuMobUVMRTDWPaWhIiqNogFa1ouczZMd7iomQDk8xdFGxkxvvYfTE91GTEzhL6/A3bkeyu8hN9FGIj2LzvxeiaWgF0sPX0NIxRNmGs7Qeu6+UXGyIwuQollU04NzljdMSkwsRjY1y+dqJ6Z1mu93J9i33Yl/kfWgudm2/Z/rnfbvvnf756Sc+XazzYJkoU4ZidWUt1ZW1t3W9xZDJpjl19hjXOi8TT8RQVZW9O/fz9Ec+QzAQIp/Pcvz0O5y7eBpd11A1FSz4O5/7JbZu3IGiKERjEf7vX/8JuXwWwyxq+YeCpdRW1+NyuVHVAhcvn+WHL3ybbDYLAoiCxKYNW3n8oacoKy0nNhnlh899izMXTmK32fH7giRTcXK57KqNvSQU5rGHniKZTrKhbTNVlTV84ztfnS6aNheiKOJ0uHE63MDcilax+DijY/3zGBbLu/9YlsVkYoK+gWt0916if6iD8YlB0pkE+UIW0zSRJQWXy1NcnJdUUVPVzJaN+2mq3zBrm4ZpkEpNMjTaw9BwNwNDHYyO9xObHCeTTRYLFosidpsTnzdEWbiapvqNtK/bTmPdBmRZmXPxPxkf57vP/hm9/Vepq2nl00//Cq1NWxgc7uLi1eN0dJ9jdKyfdCaOpusosoLfV0JleT3t63awecM9lIdrF62edaM8Qd/ANbr7LtM3cI3RiQGSydhU+QQdSZJwOjzFqJmSSirLG9jYtpvWlm23bL6+v+1cPkNv/xWudZ2lu/cyY+P9pDIJNE1FkRW8ngDlZXW0NG6irWU79bVtU3NlfgqFHIff/A7vnnqJgD/M0098iftLn6ag5hkc6uT85aN0dJ1jdLyfVCYOFjgcTjyeIOXhWrZvPsiOLffh9QQW9T7NxU+8YYEgIEhyMUFnpANJcWDq6oJGBcA9uw8iyzIXr5wtKlTYHViWhaLY+Ltf+DVefO1HdPd24vcH+NnPfIlQsITqyloePPTYdBs11XXs1u/B6y2GjrQ0tbFn536uXL9IT18nrc3FEKf62sZiLY+b1J4EQcDlcvF3v/BrvPLGc/T2dxIMlPL5T/4cAX+QkbFhBob6sNsdrG/bRDQ2QSQ6Tm11A8wx7yfjUfoGeqgIVzI8OoAF9PR14nV72LppJ5vat6JpM5PcRVFkfdtmLMvi1LljTCZibFq/jd079uFyuXnw0GMcefd1RseGqCir4mNPfJrW5nYUpXgjqa9rZGCoD13X+PIv/EN8voXd+Kahk5voJx8dmPOcil1PElp/76KNig+K6bFEBuc8p3zn1FgWaVSsJpZpoGXiCLIy76IUQFdzIAiINuctbtyblTS4sbsrCDMWfcU/CTOLBS0Tuy88pyvZMgz0QhbZ6bnFEyTZXEh2N0Yhg7mKseyOYCWOYCVqOorNW0pw3R4mLrxKITlBZqQLU8shO31Ypo6FSfn2x5FdPoRFeFBysSEil14j2feewIGrvAlTV+d9nZZNEL38JpLTi7duY1GJa+gKQ299jdJND6AmJ7BMg7oHfgE9nyyGTeWSFOKjaOE6HFbtnFHganKiqOuu5Rg79Sztn/t3jJ97CcnmJDvWg6OkBlPLk4v2k58sLqy0TBzFFSgWo5IVJJuTXHQAI58hG+mnbOujeGs3FL0SiQnysWEQBLx1m5CmXh+59AaKJ4SvdhOWaZCd6GXs1I9wBKswtQLZsW5CGw4Ru/o2qYEr+Oo2Fg3k5ARlO54oGjYLcP7yO3zt2/8D3SjeK0PBctrWbV/QsLAsE03XEAVxyXUZVDW/bMGOm8lkUzjszkUvwnL5HJZl8blP/hxul4cXDz/DuyeP0NSwjkP7H8Jhd7KxfSub1m+jLFxOPD7J7//P3+HYySO0NLYS8Afp7e/i5def4/d++3+yecNWUukk4xNj+KfCiyOxCV567VkkUeKXv/jrOJ0u3jjyCm++c5jycDmPPfgUZ86f4MSZoxy85wEePPQYicQkf/x//hv5wurnn1SWVzE8OshEZAyfN7DoHeYPAl3XGBzu4tjplzlz/i0mosOYs9xbVdNATeSJJyL0D17n7MW38XlDcxoWuVyasxfe4vDb32NkrHdWMRzTNNB1jUw2ychYL+cvvcO6pi089sDn2bJx/6LmfC6fYXxiEMs0ePn1v+Va5xlUrTDjHMPQyE9kGZsY4NLV43T3Xeajj/wc1VVNSAvsxhuGQSQ6zPEzr3Ly7GsMjXRjGLdGkJimgabFSKZiDI10c+7iEQAa6zfMaVhYlkUqPcnx06/yzonn6Ru4fst7bxjF2m8T0WGuXD/JhSvvcu/eJ9mx9T48bv+iPS+GoZHOxMkXsly9fopX3vw21zrP3PK5pDMa6UyS0bE+gv5SNq+/Z44WF89PvGEhiBKy3UN6+Dpjp57BW7NxKkZ84cWtTbGxf88h9u85dMuxyopqfv7zX77l7y1NbbTclPvQ1rJhRpK22+XhwUOPzTA+ADa2b2Fj+5Zb+y+I1NbU8ws/88u39qG8is9/6gsLjuNmBob6uHL9Ir/x93+L+tpGNF3j3/zeP6Z3oIdd2/dxYO99s77O6XCyc9tedm7be8ux6spaPvOJv3PL35OpBLqhs2v7viUk4hXRc6li2MgcSmE2X5hQ+wGURXyOHzRG/sZYZt9Zs/nChNr2o7jvkrGIIpLdjWUYGAvkBkmKA6yil+NGNd0b6Pk0WEZRPeqmm+VCoTnLZb4wOEGUkGxOjEK2qG5107mmlsfU8oiKY5aq5asf8+2r20xmrAtJcSA5b+SuxIl1vItsdxNq248w3w6ZaVCIj5Id71vytf0NW8lPDpMevjbj75LDTfWBz5IZ7WToyDfR82m81evR1seQXT4qdj+NIzi3l9MyjakiUUUPwNCRv8XSNRBEvDUbUJx+LMvEEaom3nUC2eXHXd5EIT5WNK5FiUJiDE/FumIFWh8k+86jJseRnfdQsv5eRk/+iPDWR/E3vHff9DduIx8bIjPWBRRDxNJD15AdHuru/wLp0U5GT/yQXKQfy7JwlTVQffCnGTv9LGpyAiOfWZRhceX66VkXawthGAbpTBKbYsezhO+BYej09F+mtnrdnLuN2WwKzdDweYLzLk46us/R3LBp0buWXo+PHVt3s7616OnbvX0f5y+eobu3k0P7H0KWFXxeHx1d17h09TyappLL54hEx6dDYktDYdY1t/P2u6+TziRpW7eRHVv3IEnF72E0NlE0RJraeP3tVwAYGRtiaLif3v5uLMuko+sqbreX3dvvoba6ntrqerZv3cN4dGZ4qWVZWFqe3PhV3DXbMfUC6uQAtkA1ojK34WfqanGTZBZDvqlhHS+++iMmomM01DUjidIdygdZ2jVM06B34CovHv46F68cI18oPnNsip1gsIygvwynw4UoSmhagXQmSSw+RiIZw+3ysWn9rc/3m0ml41NGhY7L6aEkVEkoEMbt8qEodkyrGHo1NNJNNDaKYehc7zpHQc1TUV5HZXn9wmFR2SQXLh9FNzQuXT2Oy+mlvraNULAch92JYRjEExEGhjpIpifR9GLdEJvi4LOf+Ae4Xb45PxvTNJmIDvHia1/nxOnDZKa85LKkEPCXEgqWTxVdltB1nUw2yWRigkQiiizLrG/dOaessWVZZLMp3nr3R7z65reZjE8gSTLh0mqqyhvwegJIkoyqFYgnJhga6SGVmqSr5yLJ1CQWFnt2PIzLOb93+ga6rhFPROjqvcRzr/4Nnd3ncTm91FS14PMEkBUbhq5PCyJlsika6tbjXoF1xpphISnITg+5SD/2QAXZsW6c4TqkeR7UP86EgiWUlpbx4uEf4XV7UXUVWVbYsnHHB921GWiZSdTkxJzHPTXrsc2zQ303oWXiFOYbS3U7dn/ZgvkhdwpRtuEub8YyNBI9pynd/OCcoTiucD2K2096+DpqKjYdlqUXMiT7ziPZXDhL65Y1NlGSEWS5qOa1wM77QsgOD56qNvKTI2RGOvFUF41/U1fJTvShZeI4QtUfSDE8m7cUU1fJjHZin1qsC9xIIlx4YaHn0mTHe9FztxdKdgNBlLB7SxFECUGQEGUb5hILLxbio0QuHMZV1ohkc2KquaLhCUh2F4JsK+76ikVPlSCI03ruks2BqevomTjxrpPFcKdwPYaaxTQMpiRbwDLAMqdFI+bGulW30LKQbE4kxY4gisXFpLg4r1k2l6Z34CqmtbSEW8syicRGGI8MUVXRgKYVmIxPkM2lCPhLKQtXMzTSQyabIugvfo/8vhJcTg+dPRcYGOokk0ni9QaL+YKGztBwF3a7k7LSavoGrzMRGWJd01ZCwTJS6TixyTGCgTBBf5iR8X5UNU9H13mqK5sWbVgosoLH7Zv+3eFwIcsyuXxx0+fK9Ys8/8oPKKgFQoESZFnGMPTiLvBUyFBdbSO/9HO/yjvH3uTNdw5z5N032LF1D08+9gnsdgeFQoHoZIRatZ7xSNFQkCSZfXvumzZosrkMdpt9WnYXIBgITYeG3YypZUn3HMVdU6x/Y5nGdF9m/WwMHS0+VJQXDdy6CXbpyjnKSsupqS6q+Nytz52xqcLE5y69g6YVEASB2qoWNq7fS31NGyWhCpwON5IooWoFUuk40dgII+P9yJJMuKRqzrbdLh9t67azfagTRbFTW91CRXkdJcEKPB4/NsWBaRqk0nH6B69z5NhzXOs6i6YV6Bu4xpnzb1H2YA2yPP97l8tnuHz9JJZlUVXewO4dD9HWsp1wSRUOhwtd15mMj3Ot8wxvvPMDRscHsCyTE2de5Z5dj9C+bue0wfp+Uuk4b7/7LEdPvEihkENAIFxaxab199BUv4HSkircLt+UYVH0vERjo4xNDKDpGnXV65DE2ZfVmqZy8eoxXnnj28QTEzgdbta37mTntgeoq27B5w0VDQu1QGxyjI7u8xw9+QKDw11MRIZ45Y1vURauobV5K/IivNSartLTf2XKyOqcCgnbR01VM35vCYpiwzB0UulJxiPDRGMjNDdumjeMa7H8xBsWoiQj2Vykh69Rsv5eJs6/CoK0OjIXHwKqKmp58tFP0NNXrLFhs9n4xJOfpaVpZRSFbsZuc/Cln/37+Ly+hU9+H0Y+PVXnYHZc4YYF487vFvR8Gi0Tn/O4K1x/V41FEGXclS0E1+0levktFHcIX/0WJLsLPZ/CKGTxVLXiqWrDW7eZQMtuJjuOIdmc+Bu2gVDcXU70nqVs++PYAxUL7lLNhmR3Y/eFmbz2DtHLb2LpKogiitOPs7QOaZ48ovejeIKUbXuM3pf/lL5Xv0J468PIDi/ZSB/jZ57HWVpHoHkn4lQtHj2Xxihk0LIJTK2YBJeLDmBhISlOFE9gWWOai2DLHhLdp6c9dIontGiPnJqaIDNyfcnXtCyTyMXXiXeeID85wviZFwm0TIlpLPL+aJkGqYHLxK4dITsliCAIEkwpi+n5FIKkoHhCMP1+zdX2zL9bpoWhZlGzCex6AcnuRroRCiQIOIJVRC6/SWase+rz9BC5cJjJrpOoiXHGz75IoHkXnqo2UgOXGTzyDYx8BpsnhLOkdir8aunPgYGhDtLp+JJfB+/Fqef8YbK5FBORIZxODx3d58nm0oxNDODzhhBEke6eSzTWr8dud3Lu0hECvhJUXSWbS3Ot4zRNDZtIpifJjPdNh1dksklEUSQ2OU7/0HVyuTQjY734faWYpoHT4S56WpYQuq/pGqn0e/fiXC6Lpms4ncXv37sn36ar5zqf/eQX2LNjP3abnWudV2YYe4IgcGDvfWzduIOrHZc4eeZdvvHdv6SxvpkdW/cgyzJl4XIO7L2fpx7/1Izr2xQbgiDidLpQ1cKM0Kd0OolhvGcMZgbPYWrZaeU9y9DIj19Hz8SmDQYjnyQ/0Ymp5ZGdfpRANVpylEz/KUTFgbNyE7ZADZL9vbDkWDxKS2MbNdX1SKKIIt99S6tCIcelayc4d/EImlYABFqbt/HgvZ9kQ9ueeROz84UshcIcdcSmEASBmspmnnzs53E63YQC5bMu4L2eAJXl9fh9JURiI4yO9wNw5uLbPHTfpxcMhzJNE1XNUx6u4YF7P8k9ux7F7Zq5hvD7QlRW1KPpKi+99o1iYrqa4+KVd2lp2owk3fps0HWN3v6rvHP8+emxVlU28tChT7Ft070E/KVzvj+qmidXyOKZwxtiWRaJVJRX3ywaFYpso7V5G089/gvU17TOeFa4XRAMhKmuasLhcPL8K3/DeGSIoZFuTp45THVFI35fybzvEYCh6wwOdRKJjrCpbTePPvh5GmrbUWapc9O+zqKg5pClufNclsLdN/vvMMWHWhA9k8BV1ljU1L9LdoY/CERRZPuW3WzfMre28kpht9tnDZFaDIaaxyjMHYZj95Uifki8ToaanzekyOYL31VjEQQBm7eU2gd/gZGj3yZ69S1i149O7WCLOEKV2H3FhES7v4yqe34KQZSY7DjG5PWjQHHBWbb1UaoPfHbZ8qOiYifUtp/MWDexK2+R6DpZ/Fv7Qcq9oSUZFqLiINS2vxiDf/Ew/Yf/L4IoFVWpQtVU7PoYnqqiF0NNxRg59l1Sg5cx1By56CCCKNH70v83lawcZN3H//mSrn8z/sYdSFM1OTyVrSCI2P1hKvZ8HHugHMnupnzHRxcVkgNFFaT08NINCyh6cgJNuzANFdnlK3qrKpqn85ZsvlLCWx6ezrVxlTciOb0zPDuizYG3ZgOu8qZi7RXZVjTkdnwEQ80i2Vw0PvbLSHYXJRvvxxGqQnEHi9KdNieyw4Nkc6C4Q9gD5YiygmWaIAhYukZ2og/R5qB8x0enJJWLCkzlu54iN9GHIClFY4ailnygeReWoSE7vYiyDVdZA2XbHqOQGMcRqMBV1oQ9WF6s5j61i+2pWY8zXLcoA/9qxxn0WWKyF0IQRHyeIHa7syhBqhXwuAM0N27iyLHnGB7twe3ysa5pCy6nh+sdZ9C0okJNKh2nJFBObVULToeb1498H7+vZCo0RCeTTePzhjBNg6qKRjp7zpPPZwkFy9F1jcn4ODVVzdTVtNLdd5mlWBapdJIz50+ya/s9uF0eTp49iq5rNE0VpCsU8lhWsf6GqhY4fuodevu6aG99T7Gqs+c6mUya8nAFjfUt5PM5vv/c3xJPThZrBZSUsaFtM8dPHmFj22YqK6rJ5rKk0knCpWWUhytpaWrjzPkTnDpzDJ/XTzqd4syFU2SyxXurnomSG7mEs7wNXb1hCBUXUfnx6zgr1iNINtT4IFpiGMVbgZoYwTI0RMVZrKchOxBl+y0eibLScvoGehibGEUURR44+Ah2+51YRyz+cxqPDHHp2gnSUxtyFWW1HNr3FFs3HcRum/9e4rC7cCwiv8/l8lLnWtirKwgC65q3UlvdQiQ2gq5rjIz1Fr/Xi0BR7LS37mTXtgduMSpuYLc52b39IY6ffpXUlKHf0391hqF5M+lMgrMX32IyUYweCPhLuWfXo+zd+eiC4Uc2mwPbPO+hrmtc7zo39d0qtr1/z+PU17TNuZB32F1s33yIy9dOEomNYpoG5y4e4b4DHy9uLiykzkVRnau6solH7v8sLY2b53yNIAiL+nwXy6oYFqfOHqOr5zo7t+2ltqbhjlYCXSqirOBv2IbiDuIIVlK+4yOLSoaEokvu8FvfZXwq6baxbj37dj2GfZkLijUWj2Vo84a/3Khe+WFg4bG4FpSWvdOIsoK3ZgO2R79MZqQTLR2brlTt8FfgrihKigqCgKe6nbr7f570aAdaKgoIKN4Q3ur12Lwl04Z86aYHcISqsHlnqqTYAxU0PP4Ppmtj3EAQBLw1G2h45Mtkx7rRC5miN6W8ccYCsKT9ADZ3EGe4Yc6ddkEQUDwhKvd8HG/NevKTw5h6cfHpKmvEVVo3bdyJNjue6vZpgYfw5odmvjeKA2EOV/tiuLneiLP0PVWfkvb35LRDbfsW1Zapq+Rjw+RjQ0vuhyCIBNftueXvisuPM1Tc3VXcAQLN70mCO4JVReWkG22IEp7KdbPW/7h5PDcINE2FXAbey8+4UehwLm6Erb0fb3U73uqZCnPBdbPHiE9f9+Z2b+rzYqVpLcvketdZDOPWxNWFKKh5RsZ66R+8TqGQQ5Zl3C5/MexBgFCgjNGJfi5cPkpZuIaAP8ylq8eZiA4jiTK6odPVexFFsREKljE02sNkfAKX04PL6cVhd5FOJ7jefQ67zYEkyUxERygP11JV0ch4ZGhKcjS/pF1Lvy9ISaiUb37vr4gnJikUcuzZeYDNG7YBRSWrvoEe/uZvv4LfH8Tr8VNbXY/H9d53dHRsmOdfLoZLiaKIhcXBfQ+weX2xjXBpOU8/8Wl+9OJ3+Yuv/SmSJCJJMvW1jTxy/0coD1eyY8tuunquc+T4G5w+f5ySUJjSUJiR0eLzWUuMItpcOKs2oSXHyI9fRZBkbMFapOFLxc9Pz1OYHEBNjiHIDoxcAsnhwxaqR/FVInvLsJc03PIe6LpBT38X+XwOWVE4eM8D2O+evaApKd5BeqcWtoIgsL51J+tbdy1oVKwWxdCqamTZhq5r5HJpdENbROhicUd/XdNWfN75xUNKQ5X4fSGGRkRM0yQ2OT5rTRDLskhnEly6enz6bzWVzeza9sCicxrmQ1XznLv4NoahTxnKlaxv3bXgOH3eEJXlDTgdJ4v5HPEJxsb7qSpvmNXz8H5cTg9t63bQ1LBxwWsNj/bi8wbx3JRj0T94ncqKhumac4tlVVYrl66e56tf/zMa6ppY37qZ3Tv2sXXTdvy++ZPGPggEUcIRqiomEQLemvWLfq2qFTh74S06e4pKK/lchl3bHlwzLO4AlmlgzbMrKMq2uzbO9f3cqJg9F5Jsm95xvZsQJRlnqHp6kTkXgiDM+I7Nha92I77aW3X3FXeAsm2Pzt4HxT4VdjV3qJ6nqm3a27BQP2/saM+H4vRRunF2EYO7DS2bIDPScds5KGssjsn4BGMTA8sqaCaJEqFAOZs37MPpcKMoNuw2J4rNzpYN+/B5QwT8pRimgdcdoCRYgdPpxmF3c9/+cux257Q6js8bQlPzZHIpbIoDt8uLYyp2vlhrKYTL6SGbS+N2+XA5PdMejXBpNR7P4uogVVfW8ut/759TFi5naGSQ5FT9iJamNgL+4qJv84btuF0ehkb6saziayRJQqCY+A3Q1rIeLItkOollmXjcXhrrW6al1u02O1s27SAULKFvoIdcPotNsVNRVklFefG+UhIK8/GPfIZN67eRSicI+EOUhysZGx8mXFIOmSGsKYNvzvutUMynkexu7MFaKGlAdoUoejas99Tr3sf61k2UhSvQNJWjJ98CrEUtkG+fxbWvankisWGS6UkAPO4AdTWt+H3zL8xXG5vNPl2by7KsWdWXZiPoD1NV0bjg+ytJEm6XD1GUME1zKln9Vi+PYRpEY6NEJ4v5Ow67i5qq5nlzShaLZVmoeoGunotAsY5JaUnVjAX8XAiCgN9Xgt3mIJNNYmExERlC19VFGRYed4Dmho2LUtu6fP0ErU1bZ/Tr3VMv85GHf/buMCw0TWN4dJDh0UHOXzrDW0dfpaG+mR1b9rB/zyHq65ruai/GGnc/lmXNqxVeNCruLiN2bqx5EweZpdLnGmssBi0VnbfWyxorS3fvJfL55dVNkGWF0pJKSksqbzlWVdEIgMftnyq8Vwz38nr83Lg53CgSN/Nna0b8trPqPU+iy+Wdcf7NISWLXRAH/EH27ip6nhqnQp/ej8vpYtP6rWxav3XOdsKl5YRLy+c8DkXjormxlebG2TcRBEGgsqKayvcpDDY3Fj1PhlJLpv80yauvwNTzQc8lyHS/izrZT6b/JI6yVmyhevTsJPlIF5Ldi2T3ILmCIIhkh85jmRqO8Dokx3shP16vD1mWi0pB6fSsBW4/SHK5DJPxiWmDNxgIEwqW33YhtLko1oFIMDLWz0RkiHgiQjafJl/IoWsquq6iGzqDw50UbpbwXqD+xw3cLi9B/9z1P25GuqlQoWHqs64bdF1lIjo0reTmdvuoKKtbtOTy/Fik0nHiyWjxWobOtY7T/PFXfmtRr47ERkhn3hPeSGcSGItUnHM6XJSVzr/xp6p5cvks4xNDhALleKc2FfKFLP2D12eVDV6IVTEsbr4npTMprnddpau3kzPnT/Lcy99nQ9tm9u+5jz079+PzLl6Xd4011lhjjcVhWRaFdHTZ+RVrLJ3rXeemEmNXj5sNhfcLBLw/Ifr9OxLvf9beev6PL5LdjW/d/VimhiApOCs2FpOxqzZiDzchKk4kpx9BtiMqTiyjeJ7o8CFINlzVW7CX1CPaPAjyzDinvv5u+gZ70HWDjeu3zCk5+kGhagWyudT0726nd0VCfN6PYRqMjvVx6twbdPVcmDIoMqhqDl3X0A0dyzSnizlaS1ROu4Gi2HE6l5ETMIfdYhjGDAECu82B17s4r91CmJZFOp2YNlpM02A8MsR4ZOnhqVD8LBf7vsmygmuBnJd4Msr5S+/Q2X2B0fF+Tp97Ayhuzra1bF9WBM6qGBb3H3wUTdd56+hhrly7QDZXrFQ4ERljIjJGZ/d13jn+JtWVdezdtZ8HDj5Kc2PrnBJga6yxxhprLA1TzZEb70NNxz7orvxEoOsa3X2X0dbCzu5abIFbQ1tswVurk9v8t54nu0PI7tlDh7xeH32DvcRiE9yz+14kUbyrDDXD0FHV9wxeRbEtObxlIfKFLOcvvcOrb32HkdFeMpnktORyMSTJT8AfxuFwYVMc2BQbYxODcxbomw9JkpFXsP+WZU7X9LjR/orlnlgWuXx6ZdriRrTG4s4VBBF5Aa+L3xti84Z9TESGqKtppbKiAQBREAkEwgsW9ZyNVTEs6msb+fwnv8BjD36U7r5Ojh5/i7eOHmZwuB/DMMjmMvQPZhgc7ufq9Ys888J3aW/dyCP3PcHBfQ/gdt090po/ThhagXx0gNTAZbLjPeQmh9HSk1NFwfTp2FKbtwR7sAJPZSve2k04QpUrKp15O5iGjp5LoSYnMPXV3RlcbUxDR8+nKCTGMVZ5l/NOYWoFcrHB4hwb6yY/OYKajmEWspjTc8yFzVOCPViJu7IFX+0mHKGqu1qNTS9kyE30kxntJBcZoJAYQ03HMPJpTE0tJq4rNkTZjqjYUdwB7IEK7IFyHMEq3OXNOALld0zG2jIMctFB4t2n5owLv1uxLJN4Ikpv/xUGh7uIxEZJpKIUCjl0Q0cSJRx2Fz5vkNJQJVWVjdMFshaqqrtaaLpKR9c5YvGxeUM011g9ilWN44xNDDA61s/YxACJVJRcLjMll1pMSpdlGafDg9tdDKcpDVVRVdlIVUUDzmUq1F26ep5D+x7E7wvw6hvPU9AKKIrtrjEuBEGYUQ3ctMwl11mZD11XuXz1BN979s8YjwxhmiZ2u5OWhs1s2bifmqom3C4fsqwgihKiICKIIi+8+jXeOfEChcLSwgeLvriVfW9vvndYlrWsPKnFtO1wuNmx5RB7dkyJftx8u5hK5ZkxtPcdLwlVLNHbNP/7ZLc7KQ/XcO++p/D7ShZdv2Y+VsWwkCQJn8+Pz+enqrKWbZt28tlP/B0uXD7Da2+9xLFT75BMJTBNk8lEjMlEjIGhPk6ePkrF31Rx6MBDPHTocVpb1t81X8wPK5Zlkp8cIXLhMNErb5Ed78UoZDC1YlExy9CKbjXLmtaYFyQZUbYVC0TZXXiq2wlve5Tw5odXtXCgZeio6ShqMlr8NxVFTUVQUzHUZAQ1FUHLxDG1fNG4mGcntvu5P6T/9a8uyyASFQdl2x+n/sEv3uZYYlP9j878LxlBTUfQ0lNjyadQU3OPpeeFP2bgzb9a5ljslG17jPqHfnHZY1kIyzIpxMem51hmvBsjny1WrNZVLEPHsox555i7qpXw5oco2/bYtJTpB42ez5Dsv0D00usk+85PGYD5YhVxXcW8MS6zGMuOMLVLKYjF8UkKomwrjtPuwuYvw1u7gUDTTvyN26clWm+H4u6VST42RHa0i8xYN9mxbrITfUXjJxWd87XjZ55nsvP4rJWEl4KvbhPrPvlbt11rxTB0zl16h1PnXqO3/yq5fBZVzaHpGoauTYVOFBNiRaGoCiQrNuyKA5fLS211C7u2PUD7up24FyF5uVxyuTQT0WFGxvoYGetjdKyP8cgwyXSMRHL273EiGeW//tGv3XbM9s995p/Q1LBx1WLjP2wYhs7YxCBXO05xpeM0Y+P95PIZNLWAqhWKhfhMA9N8L+ymuMiWphPZFdmGzebA6wnQ0riZ7VsO0dK4eVEJrzdIpYr1QXxeP4lkHMu8U8bl4q4jS8qMHXhVLaxoyN54ZIi3jv2IsYlBLMsi4C/l/gOfYN/ux/B6AthtDgThVi+Oy+meTt7+IBFFCYfjvdAqXddmeDBuB0EQcN4svy0IBHwlbGqfv4r5fO2txkbvYqqeL5ZV17C0KTZCwVKCgRJqquq4d/9DjI+PcOT4G7x4+FmudVxC14tuurGJUcYjY3T1dvC9H32T9nUbefzhpzl4z334fYHV7uodwVRz5MauUpjoAMvCXtqEu34VakZYFoXkBCPHv8fYqefITw5jFDLzKilhWViWjmXqU4v3YsJQLjbEZOdxht78G2rv/wLhLQ+v6O5yavAKnd//z+Qmh7B0raj4NKX6VPxZxzKm/l2ky7QQH6UQH11Wf0Sbc1b5ycWQGrpC5/f/C7lYUYFkegwf4Fj8DduX9doFsSzUVJSREz9g9OQz5GNDy59j0UHinccZfOtr1D3w85Rte+wD82Bo2QTRS28wcvz7pIevYRQyGGp+4Z1/y5xyURtFCWFmFpTKjPeQ7D3L6LHvoXhLKGk/QNW+z0xL8y4KyyI92klmpIPMaOfUf91Fz4muzvhvof5qmfi8hRkXi+zyLXouz8Xlayd44dWv0z94jWwuPW84kWVZGJaBYRrF2HFSTCYmGJsY5PK1E9TXtvHIfZ+hrWX7vNryi0HTVUbH+ujqvcTwaA/Do73EJseKSai6iq5raLo6law79yLPMHSGR3tvqy9QDDdZc4hAMjXJ+cvvcPLsawyNdJPLZaY8Wgsnmt5QHzIMfVpFC4pJskMjPZw69wbrmrfw0L0/RXPjpkVtbt5/76Mcefc1jhx7nX17DuF03B2bIzew2Ry4byqmmUzFSKbiK9K2aZpMREe4ev30lOEvsmn9Xu4/8PSC9RbyhdyKek6WiyTJM4rO5fIZYlMKUbeLIIj4/cWq2jfmXCw+sUKJ4StHKh3n1NnX6B/uxLgpYftzn/yHi1Kwupk7NjJBEHA4nDgcTkKBEhrrW/jUU5/netdVXjr8LC+99izR2MSUnnCKdCbF6PgIx0+/Q3m4kvsOPMzjDz9F+7qNH+pcDKOQQk9H8K9/DERp0TUzloKpq8S7TtL7wp+QHLhQrNZ7G08jS1fRUlHi6Uky4z1ELr5G81O/id1ftiL91TJxkv0XpheZH2a0TILUwMUVWbDdzZi6RqL3LD3P/yHJvgsYavb25pihoaUn0TIJrv3tv2Xiwqus+/g/xe6fXylmJTF1lWTvOXpf+XMS3aemQgRvb8E88wIGRiGLUciipmLYveEl1ycxDY2r3/htMiOdRePF0KclND+MZHNpfvjCX3Ds1EskU5NLjrW+GV1XSaaKIRl9/de478DTPHTopxZVpXYuUqlJ3jz6I44cexZ9ajF6O31cY/lYlkk0NsbREy9w8tzrTESHUQu5RSvkLNx+sfpwQc2ROBNlYKiTh+/7NAf3fnRB74Vh6AyNDjI6NkJddcMdkppdPG6Xj3Bp1fTiNjo5RiQ6hGHot73A1XWVeGJieoff5w1QV926qCJu0cmxZakOrTSKbKOqvAFZVtB1jXQmwdBID7quLclzNRdOh4eaqmb6Bq6h6xrR2AjxZJTAbdybVprX3/kBmlZgU/veGd4t2yILsd7MB2IyiaKI0+nC6XSxe/s+tm7cwa/84m/y9rHXef7lH/DuySMUCnl0XSOZSpBKJ+kb7OG7z3ydDW2beeqJT3HwngcIBe+eD2WxCIIEgoCWnkC0uRAVF6K8cuFFRiHL2Jnn6XrmvxfDIFZyN8Ay0VJRxk49Sy46QOun/iXemg0r0fCy1SHuOixr0dVDP6wYap6Jcy/R+YP/TCEVhZVcaFkmWmaS8bMvkosM0vbp38ZXt2nl2p8DLZdk9N3v0ffKn6FOFftbTSS7E3dly4LF32ZDyyZ+LIzwSHSEv/n2f+fK9VMU1NzCL1gkhmmQTE/ywqtfY2x8gM98/FcIBSuWtdAzTZNCIUcun1mx/q2xPEzTpLf/Ki8c/hq5fGZVc1l0Q2N4tIcfvfRVdEPngQMfn3cB/uY7h/nIw09TUV7NV7/+pxzYe98dyrFYXPuiKBIKlhMurWZ0rA9NK9DRfYFN6/dSUzW7TPBiMUyDQuE9yVib4sDpdC849rGJASYiQ4uuXbGaCIKAxxOgpqqZ3v6rGIbO4EgXnT0XaF+3vOiFm9u2KXbWr9tF38A1oGhQXbj0Dvfue2olur8iqGqeTe17aW3eOuOzW07Y5W0HVA0Od/Hy63+LYRhcuX6at999dklJL5Ik4XS6CAVLefLRT/I//9NXeOHb7/C7/+oPeOLhpykNhYsFRtQCsXiUI8ff4F/+h9/kc7/4JH/wv/8jnT3X0PXZtYnvRgRZQZTtFMY7yA2eR40Prki7lmWh5VIMHvkG1775b1CTEwsbFTfiwUWpGHYiSsWaCQvcrEy9QLzrFFe+9i+Jd5/+8TEK1pgXy7LQCxmGjv4tV772Lykkxhc2Kt43x4RFzjFLV0n2nePy3/xzJrtOrtocs6ZCBruf/Z90fP/3KSQnlmlULG0B4QhVU7L+3rs6YX21sCyLkbE+/vyv/h0Xrrw7r1ExHQ8vyciSgiwryJKCJMmIojRvAqemq5w4+xp/+bf/lUhsZNnPiLto45mf5II2oihRUV5HS+PmRX2WgiDeOnduzB9RXjCe3LIsorFR3jjyfc5cfHvea/q8PkbHR+gb6Kag5hkY6md0fPlzbvEsrn1BEKipamZD63vFPy9cPsrx06+STE0u2M8bycyz3YclUZ6Rn1BQc2SzqTnbtCwLXdc4/NZ3iE4uL8R3pblRiG7vjkem7yn9g9d5/cj3iU6OLfj8ufH+FN+jW8dttzvZt/ux6Voxk/Fx3j72LIPDXYtaL98I35ur/ZUgFChjMj5OJpvENI3p/5bDbXss3C4ffm+Q3v4r6Ia6KEt1NkzLRFULZLJpTp8/zrsn3+b8pdPEJt9LPrzRrq5rDAz28mdf/V/88Plv8dlP/BxPf+TTlIUr7v4wKUEEUcTUciCIKxLGYFkWhppl9Nj36PzBf5l3sSdMJZTaPCHcFS04QpXI7iCCJGPkUqjpSTJDV8nHRzDUHKamMuvNyzJJDV6m43v/ifbP/js81W3L3p0RRBnZ6V1S4pBl6Bja3HHvouJAlBWW8yCWbE7EZbj/AASpOJalsJpjEW0OxBWQzbMsC1MrMHrih3R89z8uMMdkRNmO4gkW1ZBKqlHcAQRJwcilUdMxMiPXyceGp+ZYgbnmWGa4g47v/C7rP/+7eGpWVszBsizU5ARdP/xvjBz/3qJeI4gyglT8T5yat5LDjSjbpnJG0hhTCljTuTXG++LvRQlXuJ5Ay/Jyq2S7B9npW/A8yzIw1cKcVYYFSUFU7LedsCfbF3/PtyyLSGyEv/7Wf6Wz58KcDy5FseN2eWmsX09L4xbKw7W4XT5sNjv5fIZkKsbQSA/Xus4yMtpLLp+ZdefTskzOX3qH77v9fObpX1lUeMaMsckKJaEKGmoXrtyezWeIRkcxZnm/JUmmsrx+QenHhXA43Ldt6Oi6TqGQR1YU7LbVE+NYaQRBoKy0hm2bD3L5+slbQmgkUUKaSsYOBcuprW6mpmodoUAZHrcPl9OLYepkc2mi0RE6ei5wvescyVRs3kTmweEuTp45TH31OsJzFBsLBUro6L6Gpmv4fUHOXDxJbXUd5eHlecpWg6A/zOb193Dl+ilGxnrRdJUXD3+ddCbJg/d+itKSCiRRmr4fWBS974ZpYhgq3X1XCPrD1FbP9HAoio2SYAUul49sNkkyNUlXz0W2bTpISajiph1vC8MwKBRyvPLGtzh64sUZno4PGqfDzab1ezl+5lV6+i5jGDqnzr6Oqub5yMN/h+qqpuKGxvT90sI0LUzLQNc1Boe7sNkc1Fa13FIVW0CgtKSSR+7/DM+8+P8wDJ3Ongv85Tf/C08/8UWaGjbe2va0saITjY1x7tIR6mpai7UlVkoK9yZy+QwvvvZ1fvjC/8Xp9EzPg1//8n9ZcjjpbRsWPm+QUKiCc5ffobqyica6xT/8b3gisrksvQNd/OiF7/HCK88Qi0emz7mRmxHwBwmXlJHNZRmfGCWXz6LrOqPjI/zhn/8XLl+/wN/9wq/Rvm4jsnx3JcXcjGUaWLoGooyoOJAWsUCYtz3LwjJ1Jq+/S9cz/23OBZ8gKdh8pZS0H6Bi99N4azfOreJiWWQj/UycfYnho98mPzlUTAad5bzUwEV6nv8j2j77b7D7FlcJ8/34Graw69e/vqRd6XjHcXpf+TOyY92zHm/6yK9SuulBxGWoWAmCgLRMhRtf/RZ2/sO/WdpYOk/Q+/KfzjmWxsd/hfCWh+/4WG5gWRZYJvHuk3R+7z/NM8dkbN5SQm37qNj9cXz1mxeYYwNMnH+FkXe/TS46MGVg3HIi6aFrdP3oD1j/07+7Ynk9lmWh55L0v/bVhY0KQUBUHNg8JfjqNxNsvQdf3RZc4Xokh+uWhbmeT5Od6CMz0kmi9yyJ7lMUEuOYWh5DK2DzlhBs278s9StRUtjyi3+IuYjwgXx0kN6X/4zY1bdnPV62/QlqD/0sNl/pkvsxo0+yHcm+uDmWy2d45oW/oLPn4qxGhShKlAQruHffkxza/zH83vmVswzDoLv/Moff/DYXrxwjk03OuqP3zvHnqa9p474DT2NT7EuoLF3Kxx7/Ih97fGGFuAuXj/J//+b3iCcjtxzz+0r4zb//B4uuFryanL90mq9+48+5d98D/NTHfvqD7s6SsNnsNNS209K4masdpxFFCbvNgccToKG2jc3r72F9225CgfCCIRz3H/wEmWySt489y6tvfItYfHzO3ePO7vNc6zpLacns0utjE6PEJqPT9/3Pf+oLd51sviAIrG/bxYP3fpIfvfRVkqkYqlbgtbe/y+nzb9DavJX62rYp41ukUMgSjY0yNNpDd+9l8oUMX/qZf3WLYSEIAiXBcja07uLUudewLIszF99GNzQO7X+aqooGJFEmk03SO3CVo8dfoLP3IgANte0MjXajqh+8gSEIAhVldTz9xBf5q7/9r8Qmx9ENjTMX3uJ61zmaGjbSVL+BYKAMWZJR1TyTiQmGR3vp6b9CPDHB0098icry+lsNC0HA5fRwaN/HGBnr4/S5N4oS1d3n+OOv/BZN9RtoadpMMFCOJMloWp5kMsZYZIi+wWuMTwyi6xo//anfYF3TllUZ/337n2bfrsdu+bvHHVhyW7e9ApckGZvNQSaTQNc0wiW3FpZ5P4ahk8lmiCcmOX76HX704vc4dfbdKWWNG+1KeD0+ysOV3Lv/QZ54+GO0rdtAbDLKW+8c5qXXnuXytQvEEzE0TePl157Dsiz+wS/+Y9Y1t8/QbL6bECQZyeHFVDNYpoa5ArHFueggHd/53WKS9ixINifB1nuoe+hLBBp3LJwwKgi4wvXUP/JLVOz9OF0//G+Mn30Ro3BrnLFl6MS7TzF89NvUP/QlxGUUrZEUB1Jo4XlzM5nRLgRx7nEo7gCOUDXSKlj28yEp9iWPJTveM6/kZ3EsVR+oDGs+Psa1b/7OnHNMtDkJNu+i7uFfJNi8e5FzrI76h75I5e6n6HrufzF++vlZcwcsUyfZd46ht79Ow2O/vKw5NqM9y8IydKKXXqP/8FfmPVeU7ThLawlvfYSK3R/HFa5HWODeIjs8+Go34qvdSOWepzENncxoF9HLrxO9/BaS3UWo/cDyOi8I2AMVizrVMrR5PW+yw409WIFjke3dLoah887x57l49fisCwlJlGlp2swXPvfPqSyvW1SbkiSxrnEztVXNvPHOD3jljW8RjY3Oalw88+Jf0LZuG7XV6xbUwLcsC9MyERCm5B3vjl3nNaCivJ5tmw4yPjFIRXkDu7bdz9ZNBwj6w0v6nARBwOP288h9n6G5YRNf/87/oHfg6qxzJzo5Rt/ANbZtOjirQo6i2KiurMHldCOIwl2n+HMDu83Bvt2PY5oGr739fSKxEXRdJZGMcuLMYU6cOTzna2VZmfPeV1pSyYE9jzM43Ml4ZBBNK3D6/JucPv8mkiiDwAyPotPhYd/uR7ln56N85W/+A2MTKxMSfrvIskL7up189uO/yo9e/Cqj4/2oWp5MNsmFy0e5cPnovK9fyPsb8JfyU0/9Mnabg1Pn3iCXT5PLZ7h07QSXrp2Yv29TIaCrdS9yu30IgoCua3g9AURRRFULCOLSr7cis9/rCdJUvxGvNzDnoC3LIl/Ik0jGGRzq440jr/DC4R8xPDIwY5fAYXcQCpZSX9vEYw89yQP3PkpZ6XvKMOGSMj751Od4/OGnOHbyCF//zlc5dfYY2VyGw2++yOYN26msqMbnXZo81p3CMnT0bByjkEFyeBFvY7FoWRammqP/1a+Qi87+xZTsbsq2PU7Do1/GVdaw5GvYfWHaPvtvke1uBo98Y9bQLS0dJXLxMMF1e5ct07rG3Ytl6vQf/gq5SP+sxyWbi9ItD9P4+N/HXd605PZtvjBtn/7XKA4fA2/+5ayeCy0TZ+Lia4TaDxBo3jVLK0sjFx2k65n/MW8ekuTwULL+ILX3/wL+hq0LGhRzIUoy3uo2vNVt1N7/82iZyTu2mL+bGB7t5cSZV5mMj89yVKClaQu//Av/Dt8CXorZcNhdPHjvp7BMixdf+wbxxMQt56QzCV5+/Vv8nU//I2w2xzzPKpNMNkUiEUFW7Pi8QRx214+RcbHSpcXuLE6Hm13bHqC1eSuVFY047Le34SJJMo116/nkk1/mL77+H+eUGR0d62ciMjSrYZFOJwmFSgn4gwgISHdsY3Ppn6Tb5eXBez9FdUUjbx59ht6Ba2RzKVQ1j36T6tmMWjE2Bz5vaE6PmywrrG/bxSef/DIvv/5NRscHKBSyaLqGaRoIooii2LFP1Qu5Z9dj3H/gaTzuAF5viPHI8F2Tq2m3Odix5RBlJVW8fuQHXOs8QzqbRFVz0+/PDVldSZKQ5eL743J6KA1VzlukUxCKIVGffvpXaKhbz7snX2IiMkS+kEXTVAzTwLLMYqSBKCPLCjabA4fdRU1VM7XVLciroCQKMDrez9HjL9A/1MFnP/4PCAbCHDv9CvfsfHTJhSNXxLAI+ks5sPcjsx4zDINUOsFEdJyLV85x+I0XOXbqCKn0zJ1Jvy9AuLScLRu28/jDH2Pvzv3Y5on/dDndPHDvo9TVNPDHX/nvvPLac2i6xtHjb3LvvgfuWsNClBRkdxBTnSrxblnThcOWQ2rw8pyhHIJsI9i6j/qHf3FZRsUNRNlG05O/Tma8m9jVI7OekxntYuL8y3hrN65qEb017jzpoWuMvPudWY8JkkKgZReNj355WUbFDURJofEjv0pmtIPIpddnPSc30cvYmefx1m2+rTlmGRqDb/41+cnhOc+RnT7Kd36U+od/aVnKTXMhKXakn0CjQtNVTpx5laGRnlmPl4Yq+OlP/cMl50DcjCLb2Lf7cQaGOzlx+tVZa2EcP/UKjz/4Oaor564domoqfQPXuN51DrvdSX1NGxvadvJhTJy2LItCIc/YxCipdBJZVpiMR7FuyvkxTZP+wV68Hh+6rhGbjKIbOsFAiIryKmRJpqPrKj6vn/KySqCY5zg2MYph6NTVNAKQz+cYj4yRTCUwDAMoLr5KS8oIl5ahrIBs5w1KQhWUhFbueyTLCvW1bRzc8xGeeemrsy5yo5NjTCYiNM7y+prqeo68+zoFtYDf62dD+5ZbwmHuJmRZYeP6vbQ0b2VgqJOungsMjXSTSE2SzxfXJopix+cJUlpSRW3NOtpbts9bz8Buc7Jr2/001q3nwpVjdPddJDY5jmFo2GxOfJ4gLpeHrRsPsK5py3SNmc3texEFEd3QkOaYIzbFTnVl03R4W7i0ZtFLprLSahrrN6DrGg67a1HeJEmSqa9r56ermhgbH+B61zkGh7uYTEyQy6cxTQNFtuNx+ykJVVBT2Uxr8xaCwfJ5DYsbeNx+7j/wcXZuvZ/O7vN0911mPDJIJpNC01VkWcbj9hMKVlBd2UhT/QbKSmsWnFOSKFEWrqGpYSMA1ZVNi87rOnH6VUpCFYxNDGIYBk6Hh/MX32H7pns/GMPi/dy4mUViE8WK2meOcvitl+jq6UDT3rvZK7JCSUmY6ooa9u46yKMPPklrc/uSHizNja08dOgxrly7QG9/N929HcQTk6sxrBXBKKTRs3H8Gx5HnRxET49DaRPLeWhZpk7/618t5mzMgqusgeoDn11aAa5ZEAQBye6m6SO/RrLvPHoudcs5Rj5Nsu8CmZGOOyIPusadwTR0Bt74arFA3Cw4S2upPvh53JXrbvtaomKn6aP/kHj36VlDooxCllT/RdJD1/A3LD/ONBcZYPTE9+fph4PSjfdT9+CXZjUqTF0t3qPE+d3SN/KfzHwKyRmY0+NxozK5IClwYzdMWli15sPEyGgfHV3nyGRv/VxFUeKxB3+ayoqG2/YK+H0hdm69n56+K4yM9d5yXNMLvHvyZT75ZGNR+nsWLMvC4XATDITJ5tJTC4UPn1EBRSPp1LnjfPO7f0kkNkEwEMLvC5BIxKfPKRQK/MH//j1aGluRZJkLl86STCfYv+cQP/e5X8Lr8fHbv/ePue/Aw/zyF38dgGQqyVe//mfEE5P853/7RxTUAqfPn+AHz36LeHKSeCLGwFAffl+QL3z+7/KRR55GuUs3+27gcftY37aLN975AYnUrRXUk6kYqXR81teGgiXU1NSTyaQpCZUiiuJdV8tiNuw2By2Nm2hpvL1n9g1VJEEs7sg/cPDjPHDw4zPO0XWNr333fzA00kND3fppw+JjT3yRjz0xfw5TuLSaX/zZ315W355+4ks8/cSXlvVaRbZRU9VMTdXtraFmQxAEfN4gO7bex46t961Im06nh0989Jf4xEd/acmv1XWNyvIGevuvAsXihbNVS18Mq2JYjIwNc/zUEY4ce4Njp44wERnnZlUUj9tLRXkVzY3rOHjPA9x/4GFKQqXLfpCua2qnprqe3v5u4on4XaU08H6Kqkx2CtE+zEIaUXEu21uRHe8lduWtWY9JNheBpp2EWu+5ne5OI4gi7sp1hNoOMH72hdn7M9FLouc03tqNd/0NdY3FkZvoI3rpzVlDhkTFgb9xO6H2gytyLUEQcFW0ULL+XsZOPzt7fyIDxLtO4KvfvOw5NnriB+i59BydEPFUt1N14DO4wrfG+VuWiZGdLOZKOQNTxsPU7qxkQxDEotCBqSMoTkwtS2bwNN7GA6A4wNSLss6WCYIEpoGensDU88jeciw1h2WZyK4glnCjbRNBtCFMqclZplmsfSNKH4rvmWWZXO04zejEwKzHy8tq2b7l3hVz8bc0bqa8rJaxif5Zk3HPXHiLpx7/Bey22Q0Lh91JuKSSRDKKzxuivKz2Q/E+z8bI6BDPvvQ9FEXhX/zGv0UUJb7zw68zNHLrZ/HGO4f51Mc+xz/5td+ecqSbiw4zmpgY49U3XsDlcvNb/+jfE09M8idf+QPKwuU8+dgn8LiXppT3QSAIIj5viJrqFhJXj99yPF/ITlU+v9VgOHvhJPt330tVZS1//tU/RNNUHPY7kd93d8jsZ7MpJmLDlAQr8HoCs54jCALVFU2EgmW3rY72k4xhGBTU3Lz1skRRwulcmpehtKSSSGyYeDJK3+A1uvsuEwqWIS3jvrwqn+7rb7/Ef/2j/0Aul53+myiKlITC1FbXs3nDdg7ecz/bt+7G5bj92FWPx4tr6k00TH1JdTRWlEUMQ7S5kd0hsv2nEO1uXNVbF/fCWRg7/SzGHDJ59mDFspWE5kKU7ZRtf3xOw0JLRUkPd2AUMnOrAa3xoWL87AsYheysx+y+MGXbHlvR0DdRkinf+eSchoWaiZEeurrsOabnM4yfe4m5HsiK20/pxvsINO2cvQHTxCikEBUnktNCS45i6gXMQgZ7aRNYFmpyBAEBe2kTouxEEKSi5KteQEuOovjK0bNxJLsHI5dAjQ8AApIrhFFIT90OAujpCEYhg6nlsAVqQBDQU+Po2Umc5W2IjttTlLtTZLJp+gavkUzeugsMsGvbA7hdvhVbvPu8QWqrmunoOksme6t3dXS8n0h0mOrKW0P3LMvCMHWcDjeb1+8lm0t/aGokzcZEZIyh4X4+9bGfYfOG7QCMjg/T2XPtlnNbm9s5tP8hqitrl3ydgponl89SWV6Fy+nCwsLvD5DL51DVAnwIDAsAp8NFebiWS7MYFoaho2kFTMtEep+3q7K8hoGhfqKxCH5f8Cdq4WxZFqMT/bz97nPct/9jcxoWkiTz0KFP3dnO/RiSTEY5df4NcnNtjlFUoTu0/2NLanfbpoOcOHMYm83O5WsnUGQ79x98GudNNUoWy6rM/lwuN21U2O0OqsqraW5qZceWPRzYex8Ndc3YbCsXfygKIuLUQ8lhd65ICfbFYBrGjIeOLCkLOh9MLYeWGkfxlYMgFOtZLOfaukrk4muzS38KIo5QNf6Gbctqey4ESZ6SqfWi5299YFumQT42RC4yiLemfUWvvcadx9RVIpffwJyt1oogYg9Wzr0AXy6CiLduE7LTO2vIHaZJfnKE7EQfvtqNS24+NXiJfGxojmsLuMKNhLc+OnfhOkHEyKewdBXZU0oh0oPk8FKYHER2l6Clx7EMDcVXeYsn0tTy5CNdSE4fanwA2Vk0Hm7UsxEEoagWZ2hYnjIKkwMIgJ6JIdpcWLqKlh5HT47iKG9d8tg/KEbGepmIDGPOUVyrrXn7isbfA5SX1eF0eGY1LCzLpKv30qyGRb6QZXSsb3pzaiI6jNPpJuC/PUnehcjm0kSiIxTUHE6nh4CvpJhAnowSCoQJBsqWpTRUUAuomkYo+F5CvNftw+u51SitKK9c9CLCwpqh8hMMhGhuWMf5S2f4wXPfoqAWSKWT7NmxH88s17pbkWUbHvfc/TWmknffH0ff2rKezu6rjE2MsKF9M4rtTlTdhtsJ0dM0lUhshInIMLl8BkmSCAXKqK5swj7lqbpy/SQBf5hMNklscgxRlAgFy6mvaUWSZLK5FNe7ztPZc56ungsEA2GGR3vxePzUVa+b/t70DVxjZKwP0zKpqWyisrzhlnyBfD5L/1AH8UQE0zRwOFxUVTRSVlqNaRokUzGGR/umJKVNvJ4gVRUN0zUWhka6UbUCoiASi4+jaSoet5/6mlZcLu/051G8znXiiejUddxUVTRQNlWjRFULjE0MMB4p5hr4vEEqy+un878M06C79xIelw/TshifGEDVCpSGKqmtWYdtlXNMxyKDPP/q38wpMgBQX9O6ZMMi4C/lvgMfZ8vG/ahqHp8vhN3mWJbC6qoYFoJQTMZurG9hfesmdm7by65tewmXli2rPPhC5NU8pmVhtzsoL6vE5Vy6hbUcUpn4jARB1yKKvFl6AUtXcdftRJBtxbjqZZCd6JtTCUp2uPFWty+5UNtCFHMtXLjKGkn2n5/1HDUVIR8bWjMsfgzIRfrJRQZmDYOSbE68NetXZ47ZHLjLm0n0np31HC0dIx8dXJZhEbv6zpyVtSWbC2/dRtzlc8fTWqaOZagYWh5TzWJZJoq/suiRsEwwDUTJXvzZsjDVDHoujp6OILmCCIKIOjmAWciAM4iFUIz1l6ypgnoaRj6JoWbAMpF9FQiyvSh7anOhpyOIdg+CeGc2T1aC0fF+JmdRaYLiw6wsXL3iz4XSUMWMasA3Y1nFomezoWkqiWQM5abFgSKvvhjFZHycqx2ni9K2okhd9TryhQzXOs6ysX03fl/JsgwLWZKRJInsTdEDmqbOyHW8QbGa+ewLVUVWZhSkM3SdWDw2bRAGAyE2tG/h3ZNHOHHmXcrLKrl334Ps3XkA212cxPx+RFHCNo9So2VZs3qwrnVcYtvmXYSCJTz/yg/RNBV5FaVBVwJVy3O98yydPRcwTB1dLxpNDx36FOuatiLLCs+/+jW8ngB2m7OoXKQW0A2NJx/7eZobNlIo5Ojuu0TfwDXiySg9fZeZiAwRLq2iJFg+bVhMRIe51nmGS1ePc8/OR3nk/s/MMCxUtcCR489x+doJZElBFCVkWcHaalFWWo1hGIyO9XPs1EtFpSlDRzd02tftYP+eJ3A5PZy79A7Xu84R9IfRdRVVK5DOJNi/5wl2brkPh8OFquZ5+/izXL52EuXGdRQbWIcoK61G01V6+i9z9MQLRU+bACDQUNvOnh0PEfCXYug6rx/5PoqsEAqWE50cI5/L0lDXTnlZ7aobFoVCblWicvoHOxgZ6yuuaW+a47u3PzhtaC6WVTEs2tZt5Auf/zK7tu2lvXXjrLsjK4nb6eGBg4/QVN9CuLSM6qqlu3KXw+BQJ9mbdsRKS6oWvPkLkoIgKeQnOhFlG5IrhD20OM32m0l0n5ozaVtyePBUr87CXpQUnOG6OQ0LLT1JITG3Jf1hJzd6BS05iiDKiDYn9tIWJKcfI5cgN3wBZ9UmJGcATJ1M/0k8jfuAohJRIdaHkY3jqtvxoUjMTfScnaNoHUh2F97aDatyXUGUcYbr5zYssgkK8dFltR3vPjWnYaF4ggSad80vK2sZSHYvpl6sFm4LVCEqLmRvGaLdi93hRY32YBbSYFlFw8NThmUZxYr3wVr0bBzZXYLsCYMooacjyM4ggigVPROmDpaF4i1Hcvim87LUySEUbxmWoRXzs2xO7vakYsuyiERHSM6SDAvFmgTKEgrWLRa3yzeP59piIjK718rj9rGxffe0YVFQ83NWB19p7DYHLpeXbDaFKIpUlNWTzaYpDVXOMHSWQiAQpCRYypnzJ9jYtgVRErl8/SJjE0v7/lRV1HCt4zIjY0PYFDsXr5yjq/s67a1F417XDSYiY/h8fn7ty/+M6sqVU1K7kwiCgCQtYOTOEhk3Hhmlu6+DTDbN9a4rHNi7Msm4q4lNcdBQ1059beu0V+Kb3/8jrnacpqaqZTqkqaPrHJ9++ldoadpMPBHhm9/7Q06cOUxzw0YC/lKefPQLnLvwNi/mvsGTj36B+trWYlHRmzYLdm17gG2bDvJnf/k7s/alp/8yL732Te4/8DTbt9yH0+EilY7jchbDXSVJIlxazb7djxEuqcY0TY4cf45rnWdY17SF+to2AEbH+miobWPPjoeRJZlnX/4rzlx4i7aWbTgcLnr6r/Di4W/w0L2fYvuWe3HYZ14nkYxx8uxriKLMk499HrvdyfmLRzh3+SjBQJjd2x+c7nP/UCctjVuKReUEEbBw2Fd/Uzs/lYe30py9+Da5XJpgoGyGl2I5oaCrYljs2bGP3dv3rWi403yES8v4+Ec/c0eudYPo5BjnLx+dfmDabMUv6UJhWIIgIdk9SA4PRi6FkY3BMgyL1OCVuXdeFceKSmTOQBBR5qnEqOfTaJn46lz7LiDTdwIjn8Re0kgh2o2p5nDV7kBPR0hceh7TKOBtOYSlqyQuvTBtWBhqlmTHG5iFNPbSRmR3yQc8koVJD1+dtW4JTBWOK1n6vF0MgiCgeIJzHjfyGdT00pXf9HyG3ETfjN2Ym1FcfrwLeEFExYmz8j2DSnYVQ0wkx3ueG7lm29Q1BBR3CUrze8Xw7KXN2KdkOAEkpx97SeP0wlqakTdxQzO++F5oyTEUTxlGIbVswYc7TaGQI5GMzllZtyRUvirx6Habs1iYaw5mq44NxR1ry7IYmxhkaKQbw9ApL6ulrvr2Vc8WQtc1srk0FeV1VIRryeZvLUi6VKoqajh4z/28/Prz/Plf/hF+X4BkKoHXszRP42MPPclX/vqP+cpf/W+cDif5fI7Kiurp46ZlYhgGQ8MDfPsHf43L6cFut9Pc2Mqm9Vvx+wK3PZa7mQ1tmxkdGyE2GaWhtgmbcqdCoZaf/yNJEg6Hm8HhTrr7rqDrGvl8hkQqNiMSo66mlc0b7sFhd+FyeqitXjdtmAuCWPQwTHlnJElGnrOAqcBcGyEXrxzD6XRz776npvOtboQ43biOzeZA13UuXj2GquaJREfIF7JkbwqZLQ1Vsr51J1UVDQA01W/g2KmX0bXic+zC5aO4XV4O7XsKp9Nzy3WSqRhXrp+iqqKRM+ffBCAWHyMSHWJsvH/GIruqvJ7Wlm2ES9/7HtwJCoXsqngsfN4QoijidnmRZHn6k/rACuS9n7tZv3kuDMMgm0thmsa8WuqmZTI61s/bx57l6vVTqFM7uutbd1EerkFcaCdalBAUB6auYgkg2ZeX5JwZ7ZrTsBAV+6Kr8y4VQRSR5tE0NrQ8eiH9oZDaWy7Oqi34Wu4l3Xuc/EQHjrLiokPxV5IdPIe7dueMEDfrRkhMchRHWSv58U48jXe/YZEZ68a6KY76ZkTZhj1YuToXFoR5E7MNLY+eTy15juUnh+dMREcQUbwlOAIrMSZhzoV/sb/C+35fHPbSpmJIldOH7C75UHi9Upn4rBKzNxga6ea5l/9q2Tvyc5HLZ+YoxFckm5078VHVCkSiwwwMd5JOxxFEgdqqllW/n/m8IRrq2igtqULXNfqHOhgd7ycYCBMMlqEso+K81+PjwUOP4fMGGBjuw+P2sn/PIQ7tf3C6JoWiyDzxyNOUBEvnVIE6cM99mKZB32AvoiDQWN/CR3wBorFIMXl3bJi+gW7qaxvJ5XPk83nSmRTnLp5C01QO7X9oWbHay8UwdHK5DKlMnFwuTS6fRVVzaLqGrqsYho5hGBjmzH8LhRw9/ZeXfL3NG7YTLiknk01TWVGN/Y4oQt0e/UOdHD/1MqpWwOcNFUOPLAvTMGZsvpQEK6bXNQJCMSxujg2n5ZJMxfD7SlDk2Q2yVHqSd46/wOBI95QHzzZdqO7mRbbH45/hNZBlpVh0juI5ianryLMYfpZloWkqqXQc09RJT22Q2hQ7m9ffQ33tzCgQr7eYg3CnKRRWx2NhGDqJZBRRFGeEc1nmXeKx+DCi6SrXu85x7uLbVJTVU1paScBbgtPpRhQldF0jlY4zPNZLR9c5rnWemda0Li2p5P4DT0+XRJ8NyzKLNSzSEYxCGjXag6A4sfmWbgBYhk4+PjJn1WA1GaHv1f+DuIwH0cLX1kj2XZj7BNPA1FQsU192/siHAdPUMLUsgmQryodS3H0WTZ382DWcFetvOllHSwwjuYLYgnXkx6/hbth9Vy8MLUOnEB+b03jVMjH6D39ldeaYaZDqvzjfCZhaYclzLB+bu7qrqNhxBCoR75Dww3IQFQe24IcrxCSXS5Ofy5gDunou0tUzz2e9SsxWPO8GkihRWlKJJMmMjvfjca1+/QWfN4QkyXjcgeIzRACvJ0hDXTteT3DZtbIFQaAkFOaxh56c8xxZVnj8oafmbcduc/Dw/bMXwS0U8py9cIrrXVf51V/6J9RU1wECg8N9/On/+19c77zC/j2H5i14e7vohkY8HmFkvI+JyDCx+BipVJx0Nkk+nyafz6FqeXRdQzf06STs6X9NA8MwME1jWaFvgiDM8ODcOZZv7F7rOM3gSDf3H/g4G1p3oSh2hka6b1nDLCa3p/gaa0bhxaXg8QToH+pENzRsluOWPkzGJzh59jV2bDnEvfuewuX0cPTkSxw79fKM80RRmve56nUHGRzuQte1WY0YWZII+kvZ0LaH/bsfm3lMVmacL4rLq/Fwu+RXyWNRKGTx+0qprmzCpjimp9aycrtWuG8fWkzTYCIyxNvHnsXpcOP3leJx+7DbnYiChGFoZHJpopOjpNOJ6QVKaaiSxx74PK3NW+fXYbcsLC2PkU8gSjKKv6ooQ7mM+DUtl8JU51aTUlMRBt/4qyW3u1JYhl7c6f4xNSyyg6dR4wNYhoa7dgeSw4eRTYBl4mncR/L6a9hLG7nhpjb1AvmxDpzlbcjuEHoujpGZRPbcvV4LPZfCmGeOaZn4BzvHTANLX9ocU5PjMMcNWZRt2P3hWY8tBj2XQLK7ARFTzyEqt8poW5YFpo5l6sX6NT8B5AtTcqN3GeYcnjgoVhx2OjzEzDHsNie2VcgBeT9eT2CGTKci26itbqG2umVVr7sSWBQTwrPZNIapIwgC+XyO/sFecrkMHo93VbwVlmWRziTo6btMV+9Fhkd7icRGiMcjpDLxGapVa9zKjSRdu82Bpqtc6zzD8Ggv1RWz1RafG0EQsCn2qVC4bkqC5YiihN3mmOGJLHoNLMxZzI9N7fdw4vSrvHX0R+zYeh8Om5N0Nlk02MrrMU0DTVex2RyIgkj/UAdXO07NGWI5F5s33MPxM6/y9rs/Yvvme7G/7zo+Xwn1tW1cuX6S+ppWSkIVFAo5srkUAX8pwUDZkq63GqyWxyIYKGNkrJeh4e4ZxkRDbfuSo5DWDIspbiRtWZZFNpcmO49GMBQfPuuatrB/9+Ns3XQQp8Mz/8NHEJEcPuzvWwgJy9jx1TLxeYujfOBY5t3dv9tEdgYRFQd6IYPkChaLlQFYoPgqkZwB8uOdWNwIg8qSHT6PLVtDPtKDkUuQj3ThuYsNCy2bmNNbcVdgmVjW0vqnZRJz3pAFSb4ld0hLjqElR5C9ZejpCUTFNR329n5ywxdxVW9GkGwY2Tiiz1EsgDez05haHlPL/8QYFrqurnjYxEow33bODRnOVCZOMBDG4/5gKkabpokgsCjPpmVZxfoKU95TTVNJZxJ4PP5bQqh0XWN0vB9ZVgiXVt8inbpUbIqNTRu2cuX6Bf7f1/5sKqTGxDQNNm3Yxt6dB1dcAj6TTXGt8wznLr5N78A1xiND5FcgJ+UnidamrYyO9fPqm9/G7fbjdvkIl1bhdC4tPFsQBMpKq2lu3MS7p17i8vWT1FY1s2PrfZSHaxkc7uLshbcYmxikp+8KI2P9xGKjBIPlPHzopwgGwjQ1bOCR+z/Llesn6eq9iCRK2O0utm7cT2V5PQF/mE3tezl78W16+6/icLqRJYVwSdWS+trUsJFHH/gsV66foqP7PJIo4bC72HLjOr5S9u95gndPvsSLh7+OIApIokx5WS07t95/VxgW+VVShWpp2jydm3IzywnBXBXDorPnOleuFcNlNq7fSlP98nZdVLVAT183E9Ex3G4PTfUtq5YEZlPsrG/dxcce/yK9A1eZiAyRSseLbifDQJJlHHYXoUAZVZWNNDdspqlhA1UVjYuKsxMEAUFxICq3H5NnqNk5E1DXWH1sJY24a7YyeeEZ1Ggvivs9jXtBEPE2H2Ty3HenJEcN1MkBJIcfT+M+LFNHdfrJT3Tgqd991ybhGmrux26OFWvGzD4mQZCQ3iczaaqZopJXIYOeiaD4KshHutGSY9h85cjeMgqRbky9gBrrw1HeijrRBRQVnSzTINN/EiywBauRHH5yo5eRXSFEmwt1sh8jn0KQbNhDdRhqGjU+hOIuxRas+bEwPm6EmnyYMEydZCrGeGQYwzBxzpNTtuxrGDq5fAbDMLDbHTjsLrK5FKpawO3yYWHR3XcZWZKpqWrGYXcRT0YRBRGP20dBzaGpKqZl4veFSGeSXL52gubGTZQEyymoOVLpOB63H8syyebS5HIZvJ4AimKbqgVgEQqW37ZhIYoijfUt/Mynv1j0UuRziKKI3xegvraRstLyFXrXisbW2MQAbx97lnMXjzAeGZxVOvcnh+Xfo+vr2nnE7iISG8ayikIKNwQP3FPG9Ece/llcTs+0YSjJCnt3PXpLcbZQsJyHDv0UI2N96LpGwFcyHULocftpqF9PuLSaje17gOJ6yG53TsuY2m0ODu79CPW1rSSSsWLV96n6ElAsenn/wY8zNNKNpql4PQE8ngCGoROYSr7etukArc1bKQm9F17e2ryNQCBMwBeevs69ez9KfU0byVTxOk6Hm6opL42i2Giq34jPG2RsYghVzSPLCsFAmFCwOI9lWeaBg5/ENuXZvNMUCrlZawKtRLuhYPkMz2lv/5W7RxXqzLnj/J+/+mMAfvmLv7FswyKby3L4rRd44dVnqK6s5Wc/8yX27zm0kl2dRpJkqioaeOS+TxNPRsnm0qhqHt3QppJERWRZwWl34fUE8PtKsNlujQW8E1i6yu3cUNa4fSSnD1ftdtJdb6MEqmbshNsC1UhOP3o6gmXo5Mau4q7fibtuB5ZpIjk8pDrfQstEUTyrW3hruZjv07L+caA4ptmPCYJwa76GIIJlYeQSU/8mi8aJZZEbvYI4OYBocyM7gxQEERCQ7B4Kk31YmGixIUw1i6OsFcnhRRDlokcjl0ByBdFS48iuAKZeIDNwClG2Yxo6+VxXschleO56Gh8WrOn/fXiQRAlZUshmkwiA3xda8DVLJZGKcb3zLLKsYLM5KA/XMhEdIptNURKsoCxczchoLy6nl8ryBgaGOpmMjxOJjbBlw366ei/idHgYHu3mvv1Pk8ul6e67Qk1Vcc7kC1mGRnsoCZWD4CCdSdA7cA2Py8/G9t1IkoymqStWVdxus9PUsI6mhtVTzzJNg/7BDp575a+5fP0EmczcogA3I4kSHk+QgK8Et9s3pVjlxKY4UBQbimJHkW3TCcEd3ec5f+mdVRvH3YLd5qC+trUoDzsH7et2zPhdEiXqa249X5YVKsrqqCi7VSkw4C9dVIFJp9NDa/O2WY9Jkky4pGpeD0XVLCFc4dIqwqUzX+N0emhrmf06UDQuKssbqCxvmPW4KEq0NG6a8/WrTb6QXZWIkCvXT9LavG2GYXH05Es8+egX7o5QqGQqSf9gLwCp9OK+/HORz+e53nmFeHySrp7rq2ZYQHHCeKYs4buaD9mD+scJX/vDUzvJAo5wC5LNjewpBQSk9Y8g2lwIokRgw0cwCikEScHXcmhaRlQQReyhBqSNvmUrgt2Mlk0yfvYFREkh0LKbXKSfQmICLBN/03YsyyLRdRKbtxRfwzZs88i4/vgjLJDr+P4vljXjX0PNIAkeZFcIyRlET08gecPYAlVkh4qJfZLTD1EDLNAyUSRXCFugmNRpGRqS3YOeiYBlIogSiq8SPR2hMN6B7AkjuUIIkjJDvvbDjCRK88bX79/zBA217ctKELwd5vMyy1P5DS6nB0WxEbiN3Ju5UNU8BTVHuKSKycQEo+N9mIZBwB8mm09jGAZOh5tgIIzD7pxSqEpQUPPkCzkisRF2bXuQ0fF+svk0LpcPp8NFaagSKIZvmKZRTFTOZRgZ7WV4pGfGbu776X/t/6GmItQc/GkcofcWY+PnX2Hk3W+z4Wd+H+UDCguzLIuRsX6eefEvuHjl2LQa42wIgkh5WS3NDRupq15HWWkNLpcXm82BIivIkjJVDLA4N2/+N5tLUSjkfiIMi5XEKGRQY70Ish1H+O7PC/ows9Iei4KaJ5dLMx4ZJhSsmF7/5vNZBoe7lpWrdFfnWMiyTDBQXAhlc2lGx4c/4B7dHQiywpwrJEHEEawk2Lb/jvbpZvzNOxHv8ELhTmHzv/fAFWU79pKG6d+LybtFFF85CkXXqS04s2CjaHNhs61MIZ2J8y/jrmhBtrsZPf4DFE8IR0kVomxj7PTz2P3lmLpGLjqIZeiEtz6yqHZFSZl7ES4I2P3lhNbfuyJjWA6Bph1LVh2b73zLMjH1W2+gguJEVBwYuXix0J2WQ40PovirsAVrKcR6URMjmHoeI5+kEO2lEO3FFujCFqgh1fE6ZiGF4qtEVOxkRy5iaXlExQUICKJclNd1lyAqTtT4IDZfVfHvPwbIsjKv0VBbvY69Ox/BdodlG+fzNJumTjQ2SlfvRVwuH4Zh4HH7V9w7nUrH6em/gsvpoTxcy9BINxPRYSrK63E5vUiSzMhYL2Wl1YRLqkgkY4iigMvpKYZcegI4nW5M00SRFQxDp6v3Eq3NW4nGRhkc7sTr8VMSrCQSG6UwVVgrm0sxOlashu71BKisaEASJTKjneSjg8VQ25soTA4Tu3a06PH7gEgko7x19Jl5jQpJlGhu3MzenY/QWNeOzxvC5fJitzkQhMUp+BiGftuhYXeWuyOUVpTt2AK1cAclhX9SyReyK5q8nUhEOHPhLTq6zjE00j3tsZBEiY1tu5dcdRvucsNCkiQ8U1W7VVUllbo978ePC5LimDc231lSQ/NH/+Ed7NFMJJtzWUnpayydfHSIkg2HEGU7+fgIiieIs6QWLItCYmxKRrUC2eXH7l98rHMxF2iuh4SAI1Dxgc4x0eZYsjSspDiY60FsmSZGYWbyp+KvQnaVgChiGXrRoDcNTF1FlO0Isg3FWwZYWJZVLHzpDOKs2IBo9yAqDnxtDyGIYtHLJYh4m4vG2I1cK1F2INqcRa+GIGJqeQTZhqSsfgXXO4HD7sJmm/vBpKp5FMU2Z/2EDwJN1yioeURRJh6PTD1oiwUPVxKvO8DmDfcUx+9wE/CXomkFHA43imJjQ9suVLWAy+Wl3tlGuKQKy7LweoMc2PMEDruTbZsO4nC4kESZBw5+YsqQk6iuaiLgL8XhcGFT7Hi2P4iua9hsDuw2J1s27kPXNdwu38K1lz5gdF2jb+Aa7xx/fk6jwuFwc3DPRzi470nKwzXYbc4f2zpKdxtGLkG67zhachxXzVZcVZsoRPvIjV5Gz8YQZQeWoRbvcaKMkY2jpcZQvOVoyVHc9buQnUHS/ScIbH4SAYHJC8/gqd+DqWbJDJwqqmoaGvaydXib9qGlo2QHTqPGh5Ccfty1O2Zs8i2H4uaShigpCHMYSDdCBxeaW8WFv7Dic9Aw9BUNYQQIBMLs3v4QiWSUhrr1VFc2ASAKAh5PAPs89++5uKsNC0EQkOViF3VDJ5ufWw/9JwnFE5pbKcQyMQ0Nm7d0zi/HGj8+hNbfy9BbX0NyeAg07SwuTCUJyzCweYK4SuuI957FXdaIYwkF7ZT/n723DpPrPPO070PFXF3N3OoWtZjRsswQQ2wnjsM0geHZzc4OLwzt7O5MZuebJDMTjhMnseOYSbYsWbKYuVutZuZiOvD9Ua22ZHVLDdVS29F9XYlbdeg9VQfe532f5/dzeBHGG7kzdDQ19YG7xhSHZ9z7xtDTqLHgZZ+JshnkK7X3xUteLqI0EkALmf97vziDPFJDc/EFM5Z4gyDJMFKoLZrsl63/QcdmdWKxjB8kRaOhWVfcbTZZ8Xly6ehqRFFMo+lF2cRuc1FeOm9UZUYQBGS7Mvr3xXVs1veutUvznC+6BV+aD33pvqwW+2VF5xdlPy/u2+XMft3ITBGOBjl8YifhEcOy96PIJjav+wh33fo4HncO4jRmHAzDQJuBwtiZ48bnRYtmB9a8eRhqEj2VGZzR1QQYOoojBy0ZQ3YE0FNx1EQI2eZBcQbQ1STmQBWpoVYEUUGN9GUCCECN9GGoSbREiFSwi5xVnyId6iTWdQZLYA7JgWYMLY1n0f3EO0+S6DuPbPdPK4U0FR5g4Mw7+GrWY/GN/a4cbjiIZLbhKr16jcVQ/V4URw6Owuqs+lWlUkm0LD8vTYoZnzeXTes+gsvhxW53TXufszqwUFWNYHAYGIkUL4nSkgPNBM++QaK/AXQdQZRxVK7HOWczss1DpOUgyb7zuObdOWsLZMcjMdxN37E3cJUvwV2+hPZ3nsTiL8ZbvQbJZEWxexCvkjqgqym0ZATZevULZKLR97XQdZ14PIamabhcNyYH92okB9tQ3PmZ9J4PGa7SWmyBMhAyI/KGoY90Xg1KtnweUVZwVy5HEOUrVI+uhmJzX/UaM7QUajKCco1rbDZhcuWOO1Wvp1MkhnsmtJ/L7pdL/lZVFUmSEAQBwzBoaKyjML8Yu/3atTS6rmdmPaQPUhrGtXE6vdht418jPX1tqOrskaNVVZV0OonPm8+6VXcjCsKMiHTYbS6sFvtl+x3rGNdaPt66k1k224lEhzl1dt+4y+fPXcm6VXfh9QSm3YnTdPWmbO0kEUQJ0WxHlC9/X4iKdVS0IiNmMgCaimR2gsmOlo4h230kogNXmv1e7JuIMoojF9kZQFcTCKKYmfEYbifWeYrUcBt6OonZX46hTS1VT9fSxPtaiPY0ko4Mo2tptFSceH8ruprGnj8HyWQhPtiBoaso9qvUKRoGweZjaKnkSGCf3fsuOUOF2wB5geKsPSdmdWCRSMS40FQHgCIr2KzvjcCYPMX4Vz1BpHkfyf4mHOVrseTOQRgZYdTTCbREGCapdT9dhkNDDAz0oY9hgy7LEn5vDq5rSOYamko6HkJXM9O+6XgIJfWeKYogili8hSQGO8d039bTSZLBvqsGFqfOHmf/oXdZs3IDtfOXTOIMr0TTNcKREKqmXjOw+NkzP2T1ivVUlVfz7e/9I488+Elyc/Jm9MUXrt+OZ/EDiLYPX+GyKMkoIwXZ7/8ORVsmkLo4Sj6Z71gQRazeAuK9TWP6WehqmuRwz7QDi+HhQaLxjOxmcWEpBgYXGuvJzcnD4XQxNDRAMpnAZDKTG5i8S/2lWLwF43Y8dDVJcqgTQ9fGnKmJx2MEQ8Pouo7X48NkMtPa3owkSeTnFpBIJnjh1WeYV72AJbUr0TSVcCSENDLjmkqlaOtowef147A7GBoeJJlKYrPacNidHD5+gP6BXtat2kQgJ4++gR6i0SiBnDzstuzLnV4vzCYLXncOZrOVZPJKw8WW9vpZJRcaDA1Q13CUooJKnE4PvhnSrc8UC8++2b5gywkOf/OTl90DWio+okR4/VHVNL197QwH+8dcbjZbqalaQknhnKyMDF+UAb5JFhCEjLLexf8BYIz8bYz8XhnHbkE2oSczMvqGoZEOdY/uQ5DlUTd6EDKponY/tqLFuObdNrJLabTvNxkMTSXcfpbuA7/GUbyAcPtpfPM2MFi3h0hHHYrNTaTjHPmrHkQQJUItJ9BSCaz+8V3WRdlMpLMOPZ3MZAlc4Wc0dZKpBPoM9WlTqSTnzh+mu7cNTX+v3nDrxkewWif3DppyYHFxtHusXK9LfRUNw5iSmUcqneLoyUO88uYLANjtDgoLikeXC5KMJDkyDreSaSSn+cbn6X7/yW/z9HNPkkpd+SAO5OTy9S/+EQ/c8+gE9nTJ96vrV0h/OormEWw6iqFd+d1qiSiRzjrs+WPLVRqGQWd3O60dzSypXc7xU4c5W3+K7p5OFs5fgiSKdPV00N3TxdpVG1kwdzE/f/bHIMCWDbeTSMRRNW20g5QXKGDPgZ0sXphRITp0dC+d3R3kBfLZuO5W8nPfK3guKSylo7MVmyWjnjSThXJqtJ/gmQNE24+hxgYRZDOBtZ+nb+93Caz/MkMnnkM02XGUryFY9ybueXcSqttOKtiBbHVngtX8+bN7tE8QrjkmMtX22wtrGGo4OGZgoSVjRDrO4SiYnrzkq2++iNvt4fjpI3zp07/Nu/t24HK6eWfvW9yx5T627XgFn8dPKBLi4w9/CutV0mquhS23HEmxoMbHqNUyDFLRIaK9zTjGuG9OnT1OS1sTkViY+TW1VFXUEI6G2LF7Gx+566O4XB76+nuZW7UgIz4liBw8so+C/GI8bi/b33mDRCJKMBRk/erN7Du0G4vFiiRJ3H7LPYTCQaLRKIIg0NrezInTRzCbLTgdzg90YCEIAoGcItxOP73J9iuWDwf7GRjqwefNnVYKS7aw2RyYTGbe3v0sZosNm8VOVUUttfPW3OimXRcsvkLylt6N6RIlrKH6/fQd33ZD2pNWU/T2d4ybU54XKKG4sCpr104qlWRouC8r+7o+3Nh3k2EYpIOdDJ98kXS4B0E2oyXDyFbPSNuE92Z1RwMNAYyLy0BARHHlIdt99L7zLUSLA9l5SUA/+v7K1CyIigVLbg2Rxnfp2/M9QMBRvhp72epJt1/X0kTaz5KzYAu2vApSwT5SkQFSwV4CS27H0DQi7WdJDHZgDZSiOHxXH6wWBBxFc4n2Ns6IwWwiFZsRczyAt955huFgP129LRQVVNDV00JebumUCsWnHFjouk5ndzuHj105RXnm3InRv0+eOcYLrz494f0ahkHfQB+nz51g5+5tJFOZUXu/L8DCeYun2tzrgq7r7D+4i2BobIffeDyGOobyzPuRFDOGmkZLRNGSMeID7Zjflx/vKq2lU5IxxnC1VRMRwu3nyF12z5idylg8RiwWxefx09vXTTSe+XvLxjt5/pWn0XWd+dULuPeOh/m3H/wz5xvr8Lg95PjzePHVZ/j8J7/Gt7//TXL8Ab74qa+jqipV5TUMB4cwmcwIgsjdtz1AXcMZLjSdvyywWLZkNb9+6ee0tjezaMFS7PZrOJZPA9nux7P4IyT7LuBf+UQm310QESQTejKCFhvGUFPo6SRoGoneekRZJn/L75LoOUei5yyyM4DiyL7c5AcBZ/ECRFlBTyeuWKYlY4RbT5O34v5p/X7JdIK1KzeSTCaIRiN09nRw2y13k1bTdHa3YzaZ2bDmFo6cOEgsFptWYCFICvaCOSTD/WPO9KWjw4Rajo8ZWKiqSkFeIYrJhKFn0pzaOprp6u4gnU7j8/jxef2UlVUiSzK6qONyuVDVNOl0ivoLZ/C6fbjdHlLpFC6nm+VLVnOh+TwIkOPPxWKx4vX4cbs8tHW0cLb+FBWlVfh9H+zrr6SwihxfPr39VwYWYHDkxA5Ki6uxmG03PIi/6MI7p6IWWTZhszombGJ5zRHzD4AvjNmZQ2DpXdjz3rsHtFSCvpNv3ZD2aJpKODw07nKH3Y3T4c3KdWMYBpFokNb289Pe128SiruQwIYvv/fB1X6LKzQQBKx5C0AQ8K/+1OXrjsxsWAsXAZksFdPSR0f3713yUUZrTATh/TueIAKirKClExi6hqGlM7MfkoKeSmIYOoahI0hKJgVJ19E1DUPTQBxbaUwQJQRBzKpy00WSifiM1aRFYyFWLN3C6bqDrF1xBzm+Qn78i39AHaOPeS2mHFioapqjJw7yJ//jD6663kuvP8tLrz871cMAYDZbWDhvMauWrZvWfmaa5tZGOns6pn1BmZw52PKq6DrwHD2HXwZRQra5uXRs2lu9Fkkxo6euTC9QExEi7WfQU7HLJFAvcqGpnv6BPpwOJ/UXziHLMsWFpTgdLjIKNzoeTyZlQ9M10qk0TrsLh93OQ/d9HF3XcTicKLKCruuomkoqnUJVUxn9dasNt8uDJElXfBcOuwPdMGhsOs/WzXdhMc+kzKTw3steFDM3O2D2lRPvPodosoEokxpqQXHlYaRiyPZAJmfU5ADJhJYI/cYGFp45q5FMNtR4+IplWipOqO10pjBvGs7EFrMVWZZHR++XLVrFr174Gaqmcf9dH6W9sxVZljGbzAji9DoPgiDgqV7NUMOBMWf60uFBhur3k7/ygSvlkgU4U3+KZCrJupWbSKYSqKqG3eYYratQFBPv7HmL++58mL7+XhoazyMKInfd/hHWrdzE6XPHsdsceDxezGYLiqJgMpkQBRFZkmhpbaQgtxCvx0c8ESeZSpCaVprQNXw7rlNHtyCvnLzcEuouHBtTE33foW3ctvkxLOYbr4QlCAImxXzZiP1EURTTuB1cwzCu6r0wmxAE4TJRhhsZ7BmGcdWOzUWVq2yQSiXo6GokMk6R+Ozkxgaro9fGRNN9xrqUrrqP955hmXSosevbpoqomHBXLqfptW8RbD4OhobFW4AoK3QdeA7JZMFVuhjF7mHw3G6GGvYjKhZMTj+ussVIyvjpVzNx3yRS8RmbsbjYVzJ0nVB4CJfTOyJRfR2dtwVBxGF3UpBXRDwRI5FMkEols3rSGXULGyuWruYLn/waFsuNT3W6GkeO7yeZzMLLQxAoWP0gBasfHHcVizcfR/EChur3XtlBMHRifc0MnH2X3CV3XHEDDgcHWTh/EWtWbuS1bS/Q3duJ2WxBFAScDhearmEymQABt9vDXbfdxzPPP0UylUQSZXr7u1lSuxyX082Od7eRFyjgyPH9WC0Z4zirxYokiVgtVsxjBA7zqxegptOZzuIMv7QEMlOvWjyEKJkRLQ5MvjKCp1/FUbUePRkm3nka97zbUWNDJAebUePDqNEBDF1Dtn746jImisWTh6N4Pqlw/5XTuoZOYqCNgTM7yVt2z5Qf8o9/9DMA3HP7AwAUF5ayevnaUe+Dxx78JABbN981xbO4HN/cDbS88e9jdnB1NUmk4xzh1lO4K5ZetkyWZZYvWcWyRasyHS9BYO3KDSN/Zx7ITzz6udEC7tLiMv7iG38zuv2alRtYtWIdAgKiKFJaVA5AUUHG42TpopUsWrAMyMhs37LhNm7deMf0irkFAfEqfhiGrmXSLGcYRTFRM2cpZ+sP093besXyUHiQPQde4+7bnhjxHJjFqYdXwWZxjFs3Yehaxin6N3OMYsqIonjVwEHXNXR98gZe78cwDAaGejhw5M1p7+smHxwEQcQWKGfBp/4Xhq6NDijZAmW4y5diGMboZzkLt5CzcMtV96enk2jpBGo8jNmTR7ZT1VKpRFbN8S6lZs5SbFYH82tWsG3HL4jGwhTmlyNPUtYdphFYmEwmbtlwOwvnL+HYyUMcOX6AU2eP093TyXBoiFgsUwBls9qxWCY3Ki0IIrIs43Z62LD2Fj7xyGcpGXkRTxrDuGTUXBjZf/ZfXIZhcPj4gdHUretB/qoHGG44OGY6VDLYQ9/JN/HN23DFiPLm9beN/n3vnQ9dtuyJRz9/2b9/50v/GYA//PqfoGnaqPzv+1m+5Mr8xkuPcymrV2xg9YoNYy7LOoKAvXQloXPbEM02fMs/jslbhK7GsORWo0YGiHefw+QrRbL7SIe6GTz8SySzC1vpcmT7B0eWcSbIX3Efw+cPXGGaBZAK99N3/A38C26Z1qzFpQiCMKMuzK6ShVgDpUQ6zo25PD7QRs+Rl3EUzb1MRau8pBJBuLzgdqy87vHuD0EQkK4xqndpEKFM4WF+xTElGekqswBaKj4qEDHTzJ2zjOKiOfT2d4w5lf/aWz9lTkUt8+euRGRiZmazDZvNOW6uf1pN0955gcryhde5VR9sRFG6qvxlPB4hFotM6xiGYZBMxjnXcIS6hqPT2tdNPpgIgpCR/b70M1GadFgQ6b7AYN0e0pGBjBltlp9jiWRsxlKhlix8z1S5qKCSaCxEIKcIZQqeZNN6g0uSRF4gn7u23s9dW+8nkUzQ2HyeHz31b7z42rMYhsGtm+5k/erNE96nIGRSn/zeHKoqasjxj63KoacTaPEgarQfPRkmHepGtrqRLK7RC0RPxUkOtqAmMsWaksmG4i5kJgqeYvEoZ+pOkh6jaHumyF18B02v/H8kBq/MXdbTSYKNR+g7sY285fdN2kzs/VzqKfJBw1WzBVfNlvc+kM0U3vVnmT9tPiy51SN/e/Esuv8GtHD2krPoNixvfIdo94UrlulqimDzMXqPvZpJH/oAmCIKkkz+6odoeO4fxqyz0BIRBs7txlO1kpxFW0cligM5EzcXnC2IkoxkGV/qNhUZJB27Ms1tJvC6AyxduJHWtvoxay2SqTi/+PX/44uf/gtKCudkPbg0DINkKoFh6DNWy+F0erGMSkxePoucSiU413CU9avvmdII4PXA4s04vovvU9dRHD6cxfOvTA+8DkiSjNuVw1jfKcDAUA+9/e1UVy2ZksrWxVSr+sbjvPrmk1k1Hrs+fPAC8A8zrpIFuEoWzNj+k8mZS4XSNJVQeJBUOoXXE8Dp8JJIRpElZdLPy6w+KSxmC/NrallSu4I3d7xGLB5lSe1yPvqRx7N5GADSkX7CDe+QGmzB0DXCDTvRkxEc5WuQrC4kiwtEkeDZ99QszDkV+JY/hiBlvwN0pu4UweDwZYpYM41kcVC88XEaXvzHMTtJ8f42Onb/HGtOCa7SxdMOLq5GtjwxbpI9dE3F0NIT8q9IR4dJhfoRFTNmT95okCBbHBRt/ATnn/uHMSUnE4NddOx6CltOGa7ypR+Iayxv2T20vf1DksPdYy6P9TTR/s6TmN25OEtqZ/ScZhJRNqPYPeMuj/e3khzuwtBrr4vR4dLaDZxvPEYwNEByjNqw9q5GvvfkX/OJj/4+pcU12G2uaf3WhmGQVlNEoyFC4QEaW85it7lYvuQW5BnoJJsUMyWFVXT1NF/hzZFWU9Q3HKOh6SQ1VUtnpdRsxd1fH/Pz/BX3k7/ixgy4KLKJ/NwS7DYn0diVam5Dw300NJ9i4fw1eN2BSV0vmbqXBA2NJ3nu5f+gf6Arm02/yU2yTiawmJkZi46uJg4efYvW9no+9tDv4PPksvfQG6xfdXdGxGISZP3pKggCfm+AHH+A1vaZ04M2e4sxr3pi3OX24iXYi6fnzzAZjp08RPwGOIPnr/0oXYdeJNpZN8ZSg3DbKZrf+A5lt38ZV+miSZmkXQvDMNDVFKlwP1oiguLwY3Z9sMwIP8ykwv3Eui/gm3fttLNYbzNd+59Fsjgo2fJZLJ73RujzVz9M14HnCbeeHGNLg3BnHU2vf4uyO76Cu2zxVdNvJothGBhamlSoHzURRnH4MLuml6hududStPFxml75l7ElAQ2d4cYjNL32Lcpu/zLO0oXIY4ggTBXD0NHTyUwNz1VmFKaLZLZh9ZcgiDLGGHnoicFOgs3H8VStxOT0z1g7LmK3u9i07gF6+jo433h8zDqX9s4LfPfJv2bLhgepnb8GnycPu8056hx9NXRdJ62mSCRjxGJhItEgff0dnG88welzB+gf7ObOWz/OskWbYIaUbaurlnD01O4xTf+GQ/28+PoPeeyBr1OYX4HJNHnd/d80BEHAYXNTUTafU2f3X7HcMHROnz1AYV4561ffg8PuvmZwkZHA1xgY6qH+wjFefuNHdPe2zdQpzDAftBmWm0yHZCoxYzMWh4/vwO8roLuvDU3TsFjsnD67n5VLttz4wALA78sh4M+jtb15JnY/69A0lROnj1z3wEIQBEx2LxV3fZ26X/4V6THULHQ1xeDZ3aixMEUbH8dTuRyzOw9xAi/qsTAMAz2dIB0ZJBnqJ9bbxND5/aQigxSufTRTLH6T64ZhGCQGO0gG+xBEAZMzB4u3gHR0mKG6vQzW70WyODA5fFj8xaQjQySGOtHTSSSzFYu/GMXqwl2xlHRsmEhn/RXHkC0OKu7+Omd/9mekI4NXtkFNMVi/DzUepmjjE3iqVmD25F9VMeNa55S5xoZIhfuJ9jYzfH4/yWAPBWseIW/5PVPa7yiCSMGajzJwagfB5mNjt0FLM3huN+l4kKJ1j+GZs3qa56SjJaKkwgMkhrtJDHZgcvqvWQw4HUTZhMVbgNmTR2KwY4xG6fSfehtn0TxyFt+OfB1UmSrLFrBlw0NEo0E6uhvHfEkODffy/CvfY9+hN1i0YC0lhdX4fXmYzTZkSR5JkxJGCnc1VC3jlh2LRwiFB+nr76C9q5HW9vOEwgMz9iIei4XzVuPd8UsS8egVs9eaplLfcIyfPftNbln/IEUFlTjsbswmy6ifj27oaJqGpqUzUsVqinQ6lVGUMgxKiqtHHH1/c3DY3SxesI5z54+ijjFrOjDUzfZdvyKZirNo/lp83jzsNheSJI8GGYZhoKopoiMBZ09vG4dP7OToiZ0kLjFuVBQzLqeXaDREIpm997lhGBiGgaal0XQNTVMzv7Oe+a+uqZnPLi4b+W8wNDDmTM1FunpaOd94AllWkCQZSZSRJAlJlBElafRvScp8Ll66/CqzZm0d57N6/jfJDj397WhTkH+dCJqmkp9bQlPLGQDiiSiCMLV6t5kLLHJmxrF0NtI30EtzayPp9Mz84FdDECVyarcQan2Ejl1PjVlka+gawaYjxAda8c3dgG/+Rmy55ZicOSh2L5LJMqYGu2Ho6KkEaiKS+V88TDoySHygnUhnHeG2M0S6zmOoSWz5VWOmY91kZtESETr3PjM6Ki2IEsWbP0liuJtQ6yliPY0Mnd+Po3AuFn8xyWAPQw0HUGMh0tEh8pbdg7d6zVWLzARBwL9gM4XrH6N950/Qxnrh6BqhlhPEBzrwzVuPf/5GbLmVmJx+FIcXSbGOmW4zeo0lo2gj11hq5BqLdtYRbj876mJqDZRhMP1rTBAEzM4cyu/+OnW/+G8khjrHXM/QNUJNx4j3teKbux7fvA3Y86owuXJQ7B4kk3VMl27D0NGScbRkBDUeyaSZhfuJ97UQbj9DsOXESBD2+IwGFgAmVwBX2aKxAwsg1nOB9l0/wzB0vNVrMLkCE8qlNwwDQ1fRUwkQhAnPvAiCwMqlt5JIRNi282m6elrGnNrXDZ2unha6eloQRRGnw4vHnYPFbMNstiIIAul0inQ6STIVJxwJEo4MjTlTcD0J+AtZuWwrr7355JjysqqW5vyF47S1n6e4aA6F+eW4XX5MshmEjIx7Kp0kmYwRi0eJxcNEoyHC0WEU2cRXP/c/KC4c2/j0w4rFYmN+zSoqSudzvvH4mOv09nfw8rafcPLsfqorFpGfV4bN6sx4yhgaqpomGgvT09tGR1cjDU0nr+g4y7LCnIpFLFu0iUPHtlN/YexjTQXd0Ont6+Dc+cOkUglSqcSInHRGTTM58lkqnXjv71SCRDJGODI87n537nmeQ8ffxmyyYFIsmC79r8mMSTFnlpneW+ZwuKksW0B+bum4+33x9R/S1tGQtfO/SXYIhYdmTLY6L1BMT187g8O9NDSdpK7hGIGcwuurCnU1/L4A61ZvRhBEykoqZ+IQs4pTZ44Tjow/qjDTiIqF0i2fIxUeoPfoqxnDtzFIhfrpPvg8A2d2Ysurwl4wB1ugDMXuRZTNo7nkhp4ZQTHUNOnYEMlgH6lgL8nhbmJ9LaTC/dfz9G5yFWJ9zQyd30/F3V9HjYfpO7GNVLAPZ/EC1CVhdDVF+R2/BWQ6vIrdjatsEYIBnft+RWK4+0rPojEQRDlzjYX66Tn88pimeQDpyAA9h15k4Mw72POrsOePXGMOL6JsuewaMzQVXUujRodJhvpIXnqNhcZxv83SzL8gyXir11Ky5bO0vPkfV72m05FBeg6/xMDpHdjz52AvrMGaU4LJkYNkto6KRRialulsq0lS4UFSI+cU72sh1teClnwvNVS2OrNzItfA4snDN3c9g+feHdOPBCDYdIRkqBf/gs24y5diduchmW2jdTaGoWNoaXQ1hZ5OoafjaKkEajyCloxgzSkjd+mdE26TJElsWHMfkiTz9u5f09JeP2Za1EV0XScYGiAYGpjcyd8gNq65l4bGE5ytPzyup1EiGaOh8QQNjSfGXD4WXk/ujJhuzXYEQSDHl88t6x9gaLiH/sGxa6NSqcQl36mASTEhKyY0TSWVSly1MFuWFCrLFnLnrY9TVlxNT19bVgMLTVWpazjCj3/xD1nbJ0AsHiEWn5wqlscd4OH7vnTVwGJgsHtMaeibfHhZvHA9R068g8vpobn1LIrJwqa192GZQhrwjAQWToeLh+79GPfd+TAmZfYrxUyX46ePEI1OT/JuOgiCgMkVoOKur4Fh0Hdi29ijyiOko8MEGw8TbDx8cQeIsnm0/kJXU+hqakwZ25vMLvR0Ai0ZJdrdgCAIeGvWXqYEZBgahmEgCAJaIsrQ+QPE+1qw+Aoz/hRamjHsUK9AEAQUhzdT4GkY9B57/bKO8vtRY0GCjUcINh65uIPLrzEt00md9DWWRW0AUTFTsPYR1GSUzj2/HLeY+yJqIkKw+dh76VOChGS2IskZz5eL56SrKWZL7rNktuGuWIZnzir6T709rileYqCdjl0/o/vgi1h9hSh2D6JiASETMOlqEi0ZQ0vGUBNh1HgEPZ1ANFnJX/nApAILyIwOr199Dw6Hh937XuZM3UHiiZmrybuIcB1UdAL+Qh68+wvE4hGaW8/O+PF+E7BYbCxasI5gaIA333mGoeHea2yRMSScyOiuIpuYW72M22/5GIsXrCOdTlJUUIkoSjNWKHuTm8w23C4/m9c9wPLFm0mnUzidXkzK1LzGZiSwEAQBk8k0YrL24SaRiHOu/tQNKdy+FEEUseaUUnH3byNbnfQef4NU8FoP3xFGctrHG4W+yezFlluJp2oVZlcuiCKSyYbZk0lDlEwWDDVNz5FXsOdVYnbnokaDGLqObPOMzlQZuk644wyh5hPEB9sZqt+Lb+56TM6c9znwili8RVTcM3KNHXv9mp3xUbJ1jWWxvy4IArLVSfHmTyGZrHTte5Zo9/lJtEVDS0SY7V0Pa04pBaseIjHQQWRMkYf30BLha66TLURRYmntRnJziigpmsPJs/toaa27qtPy1BDwegIUF1Qyp3LRdVFkqpmzlAfv/gJv736WM3UHUa8yI3OTieFyelm3+m4EUWTfwddp77wwbbMwl9PH0tqNbFx7H3MqFmUGUBQzAX8BHpefwWsGMDe5yYeDnr427DY3Lqdv2sqLH0xjgllES3sz3b1daNqN714IooQ1UEr5Hb+F1V9Mz5FXCbefuS4zD4IgXWEwc5OZR3F4KVj9EJHOc8BFF+iMM7TVX0JO7a2oiQi6mkK2uXFXLifSWYehpvDN3YCzOKO5raeTmD15KHY3giCOqCVd2YsXRBGLr4iyO34Li7+Y3iOvEGo9dd2usYu+Etnbp4Bic1O4/mOY3Xl0H3ye4QuHrjob80FDMlnxzl1HKjpE29s/ItbbeKObdBmF+RXce8enqa5czNn6w1xoPkVHVxOh8JVCARNFkmQ87gABfwEFeWWUFc+lomw+hfkV45rYZZsltRvweXMpzC/nfNNJ2joaSKWmFliLgojD7ppR88gPAl53gFvWPUBuTjFHju+koekk/YNdk55ZcDm9VJQuoHb+GpYt2ozf954KniAIuJw+CvMrbgYWN/mN4eSZfcypWITdNnfa+/rNfkplgVNnjhEO37j6ivcjCCJmTz6F6z+OvaCG/lPbGazbQ7yvZWxpzWkdTERxeHGV1OKtWYs9vzq7+7/JNREEEVfZIlxli65YZnL6yVt+72Wfjbeup2oFnqoVEz6m2RWgaN1jOAqqM9fYuT3Eeptm4BoTUOxenCUL8VavwVFYk939MxJcWJ3kLrkTW14F/Se3M3huN+GOc+hj+C1M+3iijNmTj9VfkvV9j4dic5O75E5ExUzXvmcJNR+/bq7bE0GRTcyvWcmcysW0ttfT0dVIV08L/QNdDA73EokME4tHSKUTaKqKQSZ4UGQFWTZhtdhwODw4HR7cTh9+Xz4BfxE5/sIRHwTXdfeOEASBkqJqAv5CmtrO0dxyls6eFgYGuxkK9hGLhUmnk6TVFLquIYoSsqRgNluxWGzYba7R8/F5csnLLcV9HWSBAdR4mM69z2AvrME7ZzWCJJMM9tB75BVKt34BLRVn6Pz+91IdydQtucoWT0uQwDAMUqFe2t/5aeYDUUS2ODIzs3NWoVid2GxOltZuoLSomgvNp2lpP0dPbxv9g92EI0Mkk3FS6SS6riOKEoqsYLU6sNtd+Ny5BHIKKCmqprx0PiWFVWMGmn5vPls3PULNnKWXfV5TtQRJmnxgKkkSFaXz+ej9X5nK15JVLGYb5SXzbnQzbjLLCIYGSSbjTCQ1+lrcDCymgWEYnDp7nFAkeKObcgWyxY5v7nochdV4a9YSbDpKqPk40a4G0rHhqe9YlLB48rHllmPPn4OjaB6OornYAuUzqsl/k9mHZLbhrV6LvaAab/Uagk2Z+oNoVwPp6NDUdzwSHNtzy7HlV+Eomo+zaC623IoZvcZExYSzeAHWnBI8c1YRbD5GqPk4kfazJIM90wuaRAmLOw9bXiXOkoW4SmtxltZmr/ETwOT0k7f0bqz+EgbO7GTo/AGinfVjKslNCEFEsbkwTdNXZHR3goBJMTOnYhFV5QuJJ6IMDfeNSG6GiSeipNPJkdlhY0RCU0aWFSxmKzarC4fdhcPuxunwIsuTd4zNNoIgYLU6mF+9gprKJQyH+hka7icUHhg5nxSqmkY3dERRRJaUjJKP2YrV6sBhc+FweHBd5/NRExG6DvwaszsPZ/ECFLuHZLCX9l0/o3TrF9DTCYYbDjJ84TA5tVsy5yrJowX/0yEV6qdt508ov+MrCLKMGg/Te/QVtESE/FUPAJmgMpBTiN+XT+38NQwN9zIU7CMaDZJMJUirKYyRwEKWFcxmGzarA4/Lj9eTi9Phuep3abe7WLZ4E8sWb5r2+Vxsb1nJXMpKpj8afJObzAQFeaVcaD5FMhXHZnOO1qOVldQgT/K+nvWBRSwW5UzdSXr7usnPK2L5klU3ukmjDAcHaW69QCKR/VHNbCCIImZ3HoFFt+OpWkmsp4l4XzOxvhZi/a0kh7pIhQdIx0Lo6Ti6mkYABNmEKJsQFTOyxYHJ6cfkCmB2B7D4irH4CrF4CjB7CzA5fWNK1c40joJqKu7++pjeHQDuiuUTks2cDdjz51B+19fGPRdP1YqspwBlC0HMzF7kLLoNT9VKoj1NGRWk3mbiA60kRq4xNRZES8XRNRXBMBBkJaNEppiQzQ4Upx+zK4DJHcB68RrzFmD2FGBy+a/bNZaZvXDhrV6Dq3QR8YVbRlWd4v2tJAY7SYX7SUeHMylm6VRG5lcQECQFceS8ZKsTxeHH5PRh9uRhzSnF4inA4i3AmlNyVUfsmUQy2/BUrcSeX4V//mYinXXEehqJ9beRGOpAjYXQU3G0dAJD1xFEEVEyIVnsyBYHit2TeRa4cjF7C7D6CrEXzMl6OwVBxGZ1YrM6KSr44CsLCoKALCvk+ArI8RXc6OZMCMlkASDUchzfvI1XLBclBWfJAkpv++LIJ8KEA5+BM7vQ0gl8NWvfqwkM9VOw5qMjx7ZSvOUzSIqZxFAX7bt+ymD9vtHAYrQNojgSTLooKcr+dXiTm/ymIMsmevvbCYWHRiW9AQryyz98gcVwaIjnX/klh48fZOPaLbMqsDjfWEf/YN9VZexmA4IoYnL4MDl8uMuXoibCpCIDpKPBTPFpKp5RgRoZkRVEKdNJkuSR4MKJbM38T7F7sjIqNV0svkIsvsIb3YysYPFmOpwfZARBRLF78VR6cZcvQY1HRq6x4ateY4IkI40EsKPXmM2LeIPV5ARBQLbYcRbNw1E4Fz0VJx0dIhUdRo2H0ZIx9HQCQ1NHJEAFBFHMjNqKMqLJimyxI1kcKDYXit03KrV7oxEEIfM8qF6Nq3zxiM9G5rfSU5kBBkNLYxh6JmASM88BUbEgmW2X/E7uUZWvm3z4MDSN/JUfofvgi3iqVo65TibwnPx1HW4/jRqP4K5YyvCFQ/Qee53cZXdfLhaRGeZC19LoahqzOzszYze5yU2upKy4Br8v/4rPTVMwhZ31gUUymaSptZGmlgZqqmZXXuCZcycYDk4j5eMGIEgSit1zw0ZMb/LhRxAlFLsbxe6+0U3JCoIgIJltSGYbFl/RjW5OVpEUC5InH4vnyhfKTX6z0bU0ztJaBuv2EGw6doX3ipZO0n96J8lgxnPG5PARWHwHvnnrJ7R/QZIYqt/LwJld5C65E//8zQgjQYoaD3H6J99AEMWRoCKP3GX3XmOPN7nJTaZKXm4JeddebULM+sBC0zVi8dlnLa9pGufOnyEUGr7RTbnJTaZMMpmgqfUCp8+doLG5gaHhASLRCLIkYbc5cDndlJdVMnfOAmrmLMBitmT1+NFYhPqGc5ytP0VLayPB8DDRWARJlLBarLjdXgryiigvrWJe9QJyA/k3PG8+26TVNP39vbR3ttLb30Nffw/9g31Eo2GSySSJZIJ0OoUgCphNZsxmCxazFZ/XT14gn7zcQgrziygpLkeZJbMiHzaSyQR9A710dLXR0dVOd08HoXCQeDxOIhknkYij6xqmS34fm81GwJ9Lbk4+uYH8kd+qAOWD4u1kGIiyiYI1D9O+6ylKbv3MZYtFScYWKCd36d1AJn3JmjNxQYJ4bzP9p94mZ+EWvDVrL5sJFxULecvvRZBk0uFBwh1nGTy7C0d+1U31QUDXVCKddZidfkzuvA/dM/Em15/WjvN4XDm4nN7Rzy40n6K0qGbSz6xZf4dqmkY8PnukH1OpJL39PZytO0Xd+TOk0qkb3aSb3GTSxOIxjp44yGtvvci5+lMMDvUTjoRJJhOkVRVRFJAlBcWk4LQ7cbu8FBWUcNstd7Nl0x143b5pHX9oeICd777Jmztfo72jleHgEJFomNRIMasgCEiSjEkxYbPacDhcBPwBFsxdxNbNd7N44TLMWQ5yrhe6rjM0PMiJ00c4U3+Khgvn6O7tIhqNkEjGiSfiJJMJVDWNpmlouoauZ9KtJElEEiUkScZsMmOxWLFabdisdnL8AebOWcCCeYtYtGAZBXkfjlTBG0U4EuZc/SkOHdvPmXMn6OvvIRqPEotFiSdipFKpzO+jqWiahoGBKIpIkoQkysiyjMVswWKxYrFYsVlteNw+qiqqqamaT82cBZSVVGCz2m70qV4VV/kShHd/Sbj19GWfC6KELVB6uTniJGqhNDWFf8EthFpOEutpxFW2eHR7UTaRs3ALosmClogiSDLdh18if/WDmLMkFvCBRhBIR4eJdV8gdyQAu8lNpsPZukPMnbPsssBi36E3yM0p/vAFFrqmEb8BMxaGYRCPx+jsbqe5tZHm1gs0tzXR3tlKMDREJBKmr79nUvscGh7k3374zzzzwk9nqNVXpyCviEceeIL1qzfP+LFee/MFfvnckySSEy9sz/Hn8s2//Y/rLgs5UZ5/5Wmef+UZEldxNb8UAYGiwlL+4b//f9M+tqqq/I9/+K80NI1vXmY2Wdi6+S4+/fEvXXVfre3NPPP8z9j+zmt0dneMae6oaZmgPplKEImE6erp5HxjHafrTvDaWy/w6Y99iQ1rt0x6pEzXdfYf2s1Pn/kBp8+doH+gF1W90jzMMAx0PUU6nSIai9A30Etz6wXO1J3i3f07Wbd6M4888MSsS48cD8MwiCdiHDt5mN373ub4ycP0DfQSjoSIRiOk1Yn4gBioqo6KCiSJxaNwiSCdKIocOX4Ap8NFICePxQuXccuG21lSuxy77YOr2JZR3zvG3/3TX05o/UcfeII7t96Pw+689srvQ9d1uro7ePWtF9izfyddPZ0MBweJRMITMrnLBBoakBlwCkculyIXRZHDx/fjsDtx2p3k5RawpHYFa1ZuZH7Nwim1eaaRFAuF6x7hwov/eOVCQUCYoi+IxVdEweqHsHgLaHrtX6n+6J9iC5SPLjcMA0PXSUeHiXadR5JNyObZHYTNFGoiymDdu8T72/BWr8VRWIPJ7iXe0wSGQSo8SM/RV5AUC545q4j1tZAc7kEQBDxVK9C1NMMNBzF78nFXLMfk8F77oDf5jSCZihOLR+gf7MI/WIDD4QEgnojS2dWENgVzz1kfWFyPVChd1wlHQrS0NdLYcoGmlvM0tVygq7uDSDRMIpEYme5OkEolp+z2mVbTtLY309renN0TmCBDpYNsHZ666dRk6O3v4fjpI8RiE59tKswvntWF8N29XRw/fXgS5yQQzJLHiW7o1DWc5cTpI+Ouo8gKdrtj3MDCMAxOnD7C95/8NnsP7iISCWNMwspa01S6ezrpH+ilo7ONB+/7GJ99/MuYTBMr7kokE/zy1z/hVy8+RVPLBdKTnO0zDININExDUz2dPR00NNbx6Y9/iY1rb0WWZ+ejzDAM4sk4b+98g+dffZrG5nqCoSDRWCTr17qu64TCQULhIJ3d7Zy/cI7t77xOddU8HrjnUTauvRWH/YMZYITDIY6eODShdRcvXM7GdVsn1UnXdZ2ung5efO1XvLXzNdo7WwmFQ5M2XpvIcSKRMJFImG6gsaWBE6eP8vwrT1OQX8THH/4Md229f9Zdz+6KZSg2z7jKdVNBVCzINhf5Kz+ClozS8Nz/Yt7jfw1AOjrE4X96HEQJSTZjDZRScuvnECcpFqDrIwIEM5Aq1N7Ryi+f+wn33P4g82oWzmg6kmSyYC+oRk/FCTYfwZpTjCArIIBh6PQefx132RJExUz3gecwuXOx5ZSBKNJ95BXMrlwEUSYx0A6GQWDx7dNuk8lkYcXiW7hr6yeycIazg3Q6TXNbI0eOH6CxpYHOrnbC4dDoAKnZbMFhdxDIyaMwv5jK8moWzltEbk7+lPxNJsvrb/+cI8d3ksyiv9LwcD+Hj++g7vxRWtrP47C5gIxE8uKF67FYJh/MT+rplXmxR9h/aBfhSJjqqnksnLf4ihtqODjE4FD/pBszFm3tzVkNLAzDoG+glwuNdVxobqCxuZ7GlgZ6ertIJhMkU0mSqSSpVBI1rU6q43WTm9xI0mqa9o5W4ok4VsvlL2DDMDh++gjf+f432XdwF8nU1M3RVFWlsaWBnz39AzRN44uf+jqKcvXc/ng8xo9/8V1++euf0N3bOZLaMzUMwyAajXDwyF6GQ8Ok0ilu23z3dXmwTwZN03jrndf46dM/4EJTHcHQ8JizMzOBYRhEYxGisQg9vV2cOnucRQuW8rGHPsXalZswmyev9PFBYXh4aFIS4PF4jLfeeY0fPfXvtLQ1EYlGRpS+Zh5N00aDwUg0zHBwcFZcxyZXgMVf/hZmT6acU1QszHvir9HVzGCAbHVRvOUzMMX7uHD9x8HQkW1uREmmaMPj5C67G8XhQbG5WPMnL42uK4gSktmGYvdMWnb6n779tzx078eoLK/Oesc/mUrQ1dM5qVn5qRJqPUWs+wKS2YaWzEhBj2IYJIO9WJYWZf4O9WP25GHxF6KnkqRD/cgmG2ZvAYqtFIs3OymSsiQTCBR9KLw5Eok4ew/u4pfPPUn9hbPEYzGSqSTpdApN1zD0TD9QEGMMDAbp6OrhzLlzmEy7sFqslJVUsHHtrdy2+S4K8otn7B4O+AuQspz25vPlsXHtfcQTUSrLF1JcWAVkREtsVidm0+RTjifVwkg0zF//nz/jnT1voes6+XmFfO6Jr/LwfR+7bL1Xtz3Pt7//T5NuzFik1fSUpmLG4q13Xuc7P/gmfX3dpNJp0ukUaTWNmk6jZdsx+CY3uQFEYxHa2pupmTP/ss8bGuv48c//gz0HdpJOTyTt5uoYhkFPXxdPP/ckNquNzzz+5XHXTaVTPPn093nqmR/S29+dtZH6tJqmrv403/vJt7DbHGxYc0tW9psNevu6+adv/x07dm8jHA7d0OdLWk3T19/Drj3bOVN3krtve4AnHv0cJUVlN6xNM8lwcJBkMnHN9QzDYHBogG997x95+Y1fE46EphXwTpeC/GKKC8tmRSGuKMmXFWILgnCZcpggSpgcU6+zen8qzkUJYwAksOdXTXnfFwmGhjl24jC3bb572vsai9KSCv70j/4ndpt9xn8zXU0R62tBkGQEUSQ53MXA2V2E289iy6vEP38TrW99D9nqwjtnJVoqAaIEApjcASz+IoLNx7DnVWHxZkcBThQlbNbZl7o3GQzDoH+gl3/69t/z9q7XiUTDVx38MXQDXddR1fRlgxed3R0cO3mYF159hn/93z8kf4bq28wma9ZTxRXZhOL0sWnt/Tjsbmy26f+mkwoskskkb+96YzRvNBaP8s67b10RWMTiMfoGeqfduGzT0dnG+QvnJvTSuclNPogkk4mMNPMlgcXAYD+vbHuOt3a+mpWg4iKGYdDV08ELr/6KeTW1rF6+bsz13tj+Ms+9/MusBhUX0XSN02eP8+uXfk5+XiFV5dVZ3f9UeHXb8/y/f/8HOrraJ53uNZOk1TTdPZ089cwPOHH6CF/69G+zYe0WTNNUKdKSUbR4EJNndhSLDwUHrzmKbBgGbZ0t/Plf/xHHTx0mlbrxv1NZcTmVZdPvUM8W+vp7eGXbc7yx/WX6B/sI+PP4xCOfZcvGO7DbHfynP/8qq1ds4MDhdzlx+ij5eYX8l9//K2rnLQEyAg///qN/4Z0925EkiTu23MMnH/sCfl+A17e/xK692ynML+atna+hGzqPfOQT3H/XR7HbHXz7+//Ea9teoKOrja/90WdGZ1Sf/tFr5Obkk0wm+M73v8m2na+iaxqbN9zGFz/92+Tm5GEYBhea6vnhU//O4WP7MdCpnbeEJx79PMuXrCYUDvKd73+TN3e+imEY/P1f/T9WLF0zet66rvPjX3yXF1/9FUPD/eTmFvDg3Y/wiUc/P+Xv0l2+FEfRXARByqR2ySasgXIMXUVSLCCIOAoyzz5RNmEYBqKsYBgGpTmlCKKEr2YdgighTsGXYCwkUcJm/WCmVkLmGTA0PMCf/s8/ZP/hd6f1rNY0lUg0zIK5i2ZUVMRstiFOsabpWuT4C7MWIE8qsBBFAY/bO5qbrcgKDsfVL6xMQ6fTWCNrnRHd0Gd1Dv9NbjJdEskEF5rPj/47rabZd2gXP3/2JzPSeTIMg7qG0zz1zA+oqqjG7825bNnREwd5+rknaWppmLF7T9M13tz5GrXzl1CYX4R1Ejmhuq4RjYWRJHlaL0nDMEgkE/zb97/JU8/+iFA4eO2NbhDJVJKjJw7y3/7XH/OlT/82D9zzKC6ne9IvlczvaZAOdRFrP453yUOAAIIAhjHyp5hJKzIyixi9BkY+EEQEQRhZxxj5XLzMKG2yDA0PkkiMP3ik6zr1F87wh3/6FVramq9b2tPVMCkmykurKCyYuFzrbMekmKiunMe86loK8ot4e9cb/PrlX1CQX8SyxasIhUN8/8lv8Qdf+6/87m99g5//6kf85d/8Z37+/ZdQ0yr//qN/oanlAv/w3/6FeDLOr154im9//5v88e//N5LJJLv37uCOW+/lr//s/3K2/hQvvvYsXo+Pe25/gK9+7ve5/ZZ7+LP/+Yf8l9//SxYvXA4Ioymi//ajf+HgsX383V/+M6Io8ItfP8k//PN/5+/+8psMDQ/y8hvPIQjwrf/zIzRNHQmMcgFwOlz8/tf+K7dvuYdvfufvrxBe2Pnum7z46jP8xTf+jvxAAa2dzUiTTOF6P6KsjCo/XbxPxUtTYgwDweK4bDmM9LwubjfiEZKtzqMoSdg/oDMWhmGQTCX57k/+lT0Hdl42UymKIh63j0ULljKvegGBnDzMJjPJVJKh4UHaOlqobzhLe2cr8UQMXc/0KyVJ5u7bP4LT4ZqxdlvM2Z+xuEg29zupwMLpcPEnf/Q/+Y8f/QvDwSGWLVrJZz/xlatus6R2BXMqa6bcwMGhft7ete1mQHCTm0yAZDLBhabzo/fLhaZ6nn/laYaDM1e0r6oqJ04f5c23X+FjD3969MU1HBzixdee5fDxAzN+/yaTCV7f/hKLFi5n+eJVY748dV3HwMh0ZHUdUZRIphK8u/8Vevvb+MzH/3hKx9YNnZ7eLv7+m/+Nnbu3Tat+5XphGAa9fd3847f+lu6eTj752BfIzyuc1MvF0NIkeusJndtGariTdLgHa/48LHnziXeewuQpwpo/n3jHCdKRfhRXHvHOM2iJIHoqiuzIxVN7L5LVTfjCHuLtxzB0FXNOJZ7a+6ccXAwNDxJPxDEM44rrQNd16s6f5re/8Tm6ejqntP+ZoLCghDmVc2etIt5UcLk8rFy+jnQ6ha4brFq2lu273iB0iaDF5vW3sXblJjxuL7/zW9/gpUfXc+jofspLq3hzx6v87V/+EwvnL8EwDFQ1zXd//K8cP3UYgPKySm7ddCfzamqpLK/mTN1JTp09zqpl68gN5GMxWxBFMeMpYn0vXSmZTPDMc0/yt3/1TRYtWAoYfOqxz/NXf//HHDi8h8qKGlLpFIIgYrVY8Xp8VJTPQRwJDgQh4ydjMVuRxhg9TiYzAi+KouBye1geWD3mepPlqgGBIFxz+Dbb6VqSKGclbeZG0dPbxZO//N5lQYXb5eEjdz/CFz71dfICmZSxzNcmkBnkvrimQW9fD0dPHGT7rjc4eGQvNXPmUVE2Z0ZrpMxm64zNWGSTSQUWimLi1o13cOvGOya0vtls4aH7HuPjD3/m2iuPw8nTR9l7YBfxSRTj3eQmv6mk0inaOlpIpTL1QwcO7+Hd/Ttn/LhdPR3s3reDrZvvJpCTi6Zp7Hz3TXbv25G1GqlrceL0UU6dOcb8mtoxvQE6uhpJJKNYLHYGB3uYO2cZVoudlctu5bW3fjalY+q6TkdXK//9f/0J+w+/izoh2djZQyIR5wc/+w6RaIQvfOprlBSVTbhzK8omrAULQRSJNu0nsC6T6mEYOsmBRtLhHiy51aRCPSiOHGSbHy0ZwlW9BUtuNX17v09qqB05nSDacpCcNZ9CEBX69/2A1FAbZv/UakAi0TCxWBTD0BGE917Cuq7T2HyeP/jT35pVQQVASVEZcyrnzor6imwxHBri7V1v8PauN+jt6yaZTNDR1Y6uqzAiipKXm48iKwiCgMPuxO8N0N7ZitViRdd1ykoqR1WdHHYXdruT7r4uAJx2Jx63N9PRN1vwevz0jniNXI3u3i6SqSRV5TWjGRVWqx2fN4eO7nbWrtrE1k138q3v/xO/818+z9bNd3PHlnsoL62ckJ7/lo13cOjYPn7vv36RFUvW8PB9H2fpohVYZ7lfyWTJRo2FqqlIojSp615V06hqGkUxT7kTr+s6O3dvuyw12Gy2sGXjHXzjd/9iHKVDgUubmZ9XyD13PMg9dzxI/0Af8USMHH/ujN7DZpN1NMCdzcxoC21WG2bz5OTh3o8oSR+6G/Im2cXQNdR4kHS4j3SkDzU2hK6mfmNnuaKxCG0dzbS2N/H69pfGLUhVZGXEXduD2+XF6XBhMpm59tjXlRiGQf2Fs+w5sBPDMGhpb2LH7m20d7ZcdTuTYsJud+B2efC432vDVLjokdHeMfYx393/MoNDvfz0l/+Xnr42TpzZM6XjXHq8to4W/u4f/5KDR/ZkLagQRQmzyYzd5sDpcI1+N26XB5fTjcPuwGK2IGdJHcQwDJ5+/qf86Kl/p72zdWqF5oYxmuYkCCImdxEIMvGu00gmK7IjBwQByezIyGQCktWLnoqhRvvQYgMMHnmawSO/QLK4gOmlJw0FBy6bOTIMg46uNv7kf/wBbeNcHzcKSZIoKSqjrLjiRjclaxiGwVs7XuWVbc9zz+0P8sNv/Yp//Jt/Y8HcRZetl0q+95zWdR1VU1FkJSO3KzDa8cv42ujomjZ63auaNnrPGYaOpmmIgnjNjpciywiCMJoaahhGZns1jSTJSJLEiqVr+Ke/+Te+8rnf59TZ4/z9P/83Dh7dN6Fzt1gs/Pl//hu+849PkuML8Fd//w1+8svvTvzL+4AgiiL2ac5YnL9wfMK+UBdpbj3Ha9t/xsBg15SPa2DQcEnKMIDX7WXzuq1Tev/k+AOUFJVNu17tWsxkjUU2mVGxbKvFhmUKUlWXIkkSNqudwaGBabdHEqXMD5+FDqdhGKiaOunOqyTJSDdoultRTB+qqfaLaPEgg0d+SaLvApLFgWT1YC9fja1wMaLJ9qEaBZwI8XiMU+dOkE4lR9MGLiIIAjabnRxfLlUV1cytXkBuTj4mk4lgcJizdSc5XXeSzu72SUl2AnT1dHLyzDHuuPVeDh3dx5ETB8dcTxAEnA4Xfl+AedULmFM5jxxfDiaTmaHgIOfqT3P85GF6+rsn3Ybjp47Q3tk6ZlqJpmssmr+Ws+ePMKdiMS3t5ya170sxDIPO7g7+8V//hj0H3iE1jcI/QcjkftvtThx2Bzn+XIoKSinIK8Tt9mKz2FBMCqqqkkzGCYdDdPV20dXVTkd3O9FYhFgsSiQannIwbRg6v/j1j5Flmc898RXycyeWFpUZ75UwdJV0pA/RZEMyO1A8RaTDPcQ6TmAtWoziykeNDqIlQqiRfkSTHS02iFy4EMmRg8lTjKf2PgTFAoaBbM+55rGvxtDQIMlkcrTeZnB4gH/4f/+dc+dPTeo7EhCQFQWL2YLZZEZWFBRZQRQlRFEYrSHRRjq9mq6RSqVIpZIkk4kJXRc5/gBzKmuwWGank3xyuId0fGw/HslkxeovvuJzXdfp7e8lxxegdt5iZEmipa2JYGjosvWaWhsIRYJYrVY6utoJhYNUls+hIK8It9PDydNHCeTkoes63b2dpNIpigtLaWxuYGh4gM6uduZWLyQSCdHb302OPxenI9PZNSlmRFEiEo2gqmkEIeOKnptbQF4gn6MnDmbc6QWB7t4uwtEwFaWVmfsslcBsMnPr5jspK6ngP378L5ypOzkhc9lYPAoIVJRW8Xtf/WMK8ot4+vmf8Vuf/b3L1jMMHS0VJx0dRk8lAANRNiHb3MgWx5SNB68XkiRjnUBdWjIZJxYPj85OOBweREEkGguz493nuE16FL83D68ngKqmicZCeD2ZWe9QZBCHzY0gikQiw6TVFOHI8KgyUyQaRJFNmM1WEokYqpbGYrYhy1eXP8fgimtRkmQczpmrj8gGF9P7ZjszG1hYbZin+bDMFFXas9KespJybt10Z1ZGFsOREKfOHGf4fRfn1TCbLdRUzaO4sHTax58KgZw88nMLbsixZxpBMeNb+lFsJcuJdRwnVL8dUTZjK1wE0jUeMh8ywpEQr7zxHLF4dMQFOIMsyxTmF3PbLXfz4L2PUVVeM6YRV/2Fc/zoqX9n+zuvMRyc+PWdTqdobGlg974dHDq6d0xnepNioqy0kvvufJj77nyIgryiK6azdV2jqaWR7z35Ld7a+eqkCqEHhwe40FTPquXrxiyiE0Rx9MGcKeBLEAwNkEzGCYUHcdjdExoRGg4O8aOn/o290/AEkSQZj9tDUX4JixYuY82KDSycv5i8QMGEp/iDoWFOnjnGkeMH2HdoN109HQwM9E3QyftydF3nqV/9kBxfgI899CncI2kmV0UQkB0+ZLuf4VMvYy2sxVG2ClFSEBUrgmJBsjgR5cwooKhYiXWdIdZ5CsVThOIpQjI7cMzZROj8DjB0BMmEb9mjTGdCfXB4YFT9LxqL8oOffoc9+9+ZkI+IKIrYrDZcLg8+j5+iwlKqK+dSWlJBXk4+Of4ADrsLs9mMSTGRSqeIxqJEY2HC4RDtna00tzbS3NZIW3sLofAw4UiISCQ85u9SkFdM9Sx2kG985Z/p2v8chv7+707AW72a5b/3kyu2kSSJ/LxCztaf4uDRfQRy8ti9bwcD7xsgPFt/mh27tlFSXMYb219iwdxF1M5fQlpVefDex3jh1V8hihJpNcXufTtGCmoX0tjcQF9/L3sOvIMsKzQ2n2dwaIDbt9yD1+MHwO/PoaS4jHf37cjIriomli1aiaKY+PTHv8wLrzyN1WJDlER27H6ThfMWs3jhcoaCgxw8uhcREbfbQ3PrBUCgMD8TQAVDw/QP9NLYcp5INEJLayNul4fcnHw8bi+Hjx9gYKCP3Jx8NF2jvuEsS2qXX3behmGQDg/Se/wNug48R7S7AUNTsfqLCCy5k/yVD2DLLZ/VwYUsK1gm4IR+tv4wx069i25ouBweNqy5D6vFzqFjb9PcepZ39ryA3ebkwXu/RFdPC2/v+hVf+vRfEo2FeP6V77F18yMosom33nkGTVNRVRWz2cJwqJ+z5w+T4y9g8YL1nK47SDDUz9Lajfi8eddsl912eVCUSMZpaW1EX3PLrJ0VyMxY/IYGFl6Pj+qqecypqMHrnp51fEbSLDupUJvX38bm9bdlZV/1DWf4i7/9BsOnJ97xcjvdPP7Rz/LRjzyelTbc5EpExYyjfBXJgSYSvecx+ysQRBk1Oph5MQoCit2PaHGhJ8JoyTAmTxGQ0QrX4kOIinUkHeODSSQaZtfe7Zd9Jssyc+cs4LOf+Ap3bLkHi2X8FMWaqnn82X/6a9xON08//1Mi0fCEj93UfJ6f/vL7Y6abmE0WVq9Yx1c//wcsWrBsXFM9UZSoLJ/DN373L3C73Pz82R9PaubiTN1JBgb7rggscnOKEUWRvEAxFosNt9PPcLCfhqaTiKJIQ+NJFsxbjeUa6ZuxWJTnX32GN3e8Oiq9PRlEQcTlcjO/ppatm+9i66a7KMgvmtLMmtvlYePaLWxYcwuf/+RX2b3vbV5+/decrjtJb1/3pH0ZVFXl+z/9Nvl5hdxx631YzJZrtktxBPAte2T037qaRIsHUSP9KM48FEfu6DJRsWIvX43Zd3n9hK1gIbaChZNq69UYGs6kQqmqyvZ3XuP5V54eGUkeH0mS8Hn8lBSXs3jhMlavWM+iBcvI8QWuup3VasPt8oz+e/mS1cB7SmGnz53g+MnDnDhzlLaOZgYG+xkaHiCdTiMKIkUFJbNCJjnbbFxzC+FwiLd2vorZYuXOW+/DbDaPdPwz19Stm+6gqfUCb7+7jYA/l2/87l+MpCPJmfekAc+/8ktEUWT1yo3cf+fDo4MhleVz8PsCvPT6sxgY3HvnQ6xYsmb0erVabHz241/muVd+yY9//h/4PH7mVy9EUUw8eN9jpNMpXnjtGXRdY/mS1Xz0/k8gyzKiIBIMDrP3wDvE4zG8Xj+3bLidjWu3AFDXcIZXtz2fqQWxWnnj7ZfZtfdtHrrvY6PyzQeP7qOntxNFVphXU8vHH/70Zd+NlorRd/ItGl74P2iJyOjn0e4LxPq+i5aIUnb7l0cNCmcboiBitdgn1MmNxkLkBoqorlyCzxvA7fQjywpbN32UU2f3cf9dnyU/NzPYeuWTxkBNp+jr70CSFD756B9y6uwBjpx4B783j2gszOBQL/F4hKHhXvzefDzuq9+vkJklnlNxubHfcHCYbTteYeWytVSWV2OeYkruTGKZgeLtoeE+TCYLdpuTYGgAq8WOaZqZRjMSWGxav5XqqvnYbLZpj5DLsozb5cFitkyocOomNwEBk7uQeM9ZDDVFOtpJpOUgRjqBoaso7kK8ix8kOdhMqO5tcjd9BUE2kw51E6rbjqN8VaYo9UOCIAiUlVTymce/zD23f+Ta08Rk6qO+9sU/pLW9mR3vbrts5uNqdPd20d17Ze6rJEqsXLaW3/2t/8LCeYuu+XAUhIy09ROPfp4LTfXs2vv2hI4PGSWs4eDwFZ/fsSXjt3PXrZ8AoDC//LJ/TwRN0zhwZA/Pv/xLunsnXwCsyArlZVXceet9PHjvY1kzqbuYXnb3bQ+wYfUtvLHjFZ598efUnT9NLD65HOZgaJjv/OCfKSwoZmntyjFnta6GnowQ6zyNnoxgK16KZMmkpoiyGcWVj6i8F7hpyRiJwU5M7gCGro+4K08/dXFweJBkKkF9wxl++NS/MTjUP+66mWvNx/y5tWzZcAe3bLiN0uLyabfhYorbyqVrWLl0Daqq0t7Zwr5Du9l/6F0aWxpIJBNUVdSMjrJ/mMgN5PPZT3yZz37iPfPMe25/4LJ1/L5cHnvgCez2K1NqXE43n/vkV/jcJ8dWnrRZ7dx9+0eYO2fBuG1YsmgFSxatuOJzk2Liicc+zxOPXekt4ffl8IlHPssnHvnsmPtcvXw9q5evH/eYa1ZsYM2KDeMuh0x6Wd/Jty4LKi5iaGkG6/bgW7B59gYWojhhqdmlizZS13CME2f2IIkSa1feORpI6IYxUuOSUXATRXE0xVzXNRLJWCa9MJ0ckQMXUBQTVosNQRApzC+nqeUsJ8/uw2qxkxsomlCwI4oiq1esw25zEI1lfgNNUzlx6gj/+1/+B48//BkWzFtMbk7elGv+ZoKZKN7ed+gNigsrWbRgHXsPvs6iBWspKqic1j5nJLAI+HNHNZ+ni9PhZPOG2yjIL7qi8Os3BT2dAEHKuG5e1Hwfie31RAjR4prwy9gYLbD8kNcdiNKI8IiBZPNiL12BIClosWEGDj2Fd8lDmP3lCLKJRF8D1ry5qJE+DC2F2T+9m2q24XZ5uPPW+7j9lnsmFFRcxOlw8aXP/A4nzx6jt697Wm0oL6viUx//IvNqFk54xEUQBHJz8vno/Y9z+NiBa444X6S9q42h4QF0Xcv66E5HVxvPv/IMDU31k97WZDKzfPFqnnjsc2zZcMe4MzbTQRAEXC4PD937GPOra/nxL/6Dd/a8NamUNoCmlgZ+/PPvUvyHpeTlFkzqeSHb/bjn3jrG5z6cczZd9lmo9RRD9Xvxzl1HKtRPYMmdMEmVmLEYHOyjvaOV17e/RFPzhXFnbi7O5N12y93cf9dHZ9SNXJZlykurKC+t4oF7HuXMuZNcaD5PTdX8a298kw8VajxMtPvCuMvjg+2kQn1jSibPBgRRmpDUrGEYRKJBbFYn8+Ys48CRtwiGBsjPLUUQBOw2Jy1t54jFwpSVzsPh8JJKJam/cIx4IkosFkFRTHjcAc5fOEH9hWN09TSTSmXSHPMCJXT3tHLm/CEWL1hPIKdoYu0XBKoq5rJ1812ZGa+RflEylWTvgV3UnT/LxrVb2LTuVqqr5lOYX4TD7rzhv4ViMl/uX5IFovEwyZHvs6O7kaqK6Q+qzmiNRTbwevw8MQ3Hyg8ahq5i6HpGw90wQBBQowOIJjuSxYWhq6SCXchWN6LFSbzrDLaSpRgIiIoFQ9fQ1QSiZAZBBEMDQQJDz+wrPgxaGsnmQ5Q/nDNAhmGMFIjaQBCItZ9AjwcRZDOGrqKriYwUpWLBXrqMWNthFFceycFWLIE5iKbpKZnNJkRRZP7cRdy59X5stsnXKi2pXc7alRt56fVnJ51WcxGrxcZ9dz7EkoXLUSYR2ACYzWZq5sxn/txaDh/bP6Ft4vEYXT2dJJKJrNVnQSYF6o23X+bw8f2TrtMymcxsWHMLX/7M77Bs8aqstWk8ZFlhwbxF/M6X/zNul4dXtj3HwOD4o/Zj8fY7r7N6+Xoee+iTM5YWEG47jTVQjpqIEumsI7DotsygwDTp6evmF7/+CafOHCOeGHvGxmqxsn7NLTz+8GdYv+aW65q7bLPaWblsLSuXrb1ux5xtrFmxnsqyOUiTnBEDKC4sYcXSNbgc7hlo2cxjaGm0xPgDJXoqga7eeDf48RBFEZttYunCff2dNDafBkGgunIReYGMCaQgiKxZcQctbfUEQ4MUF1bh8+SycN5qzp0/itViZ/mSW3A6vPi9+fSXdlB/4TgWs42aOUsxjxRpKyYzdqsTt9OHaRKu4maTmS988mu0djRz8vTRy95vg0P9vPDqM+zYvY3FtctZu2ID8+cuoqykgkBO3oyrP42HJEoZ5UZByJrqpWHoRKJBBod6SSYThMLDDA71ji53u/2T9mGZ9YHFbxpqdAg10odocYKhI1ncqLFhFFEGDPR0gmjrQWz5CzGbHaRD3aSG29GSUax581EjfWjJCIJsQrZ50RLhzH+TESSzg2R/I3oqhq1oyYcysDC0NKlgB8nBZmyFi0EQiFx4F//qT2EJVJPsbyBU9xYAgqhg9lcSbTtKovc8aqQXR+X4U9wfRJwOF8sWraS6cu61Vx4DQRB46N6P8dqbL5DSp/aimztnPquXr8fr8U1pe4/bx8qlayccWAB093QQj8eyGlicPneCt3e9MWZR+tWQZZkVS1bz21/6Tyyctzhr7bkWgiBQXFjKZx7PpKI8/8ovLzMnuxaqpvKTX/wHy5esYl71whnpeNvzq4gPtKEmIpicOQhZmK2ATDrXznffHHe51Wrjvjse4kuf+W3KSj5cM5QfFL70md+Z8rbLl6werWX5ICKIEuJVOqeibEaUlCkIf18fRFGakNSsIAjUzl9D7fw1Yy5fWruRpbUbL/vsts2PjLnupnUfuezfsXiEC82n6ehqJC9QMuHZiouIokhVZQ1/+LU/4UdP/TtHjh8gGBq+bJ1QOMjuvW+z/+BuSorLWbl0DUsXrWR+TS2lJeUjKVnX91eymGyIgohmTEEWfAxMipmWtjpi8QjxRIT6C8fo6WsbXX7rxoexWib3Hr0ZWMwy1NggyYEmBElBNFmx5M1DT4bQFAuy3YcwMg0mWlwXLSEBgdRQGyZXAYneekyeYtLDnRhqEjU2hCApqOFuRKUio4ojmxGV2SltOFUMTSPefQYtESYd7kFxBLDmz0cy2VFcBSR7G1Aj/aixQYQRhRpBEJAsTqx584i2HMgUmjqvXfj1QaIgr4iVy9ZOyw10yaIV5Abyae9snfS2kiSxesV6KsvnTPn4DoeTudULkCRpwrUeXT2dWTXVDIWD7Nq7nXPnT09qO0EQqSyr5suf+d3rGlS8d3yBooISHnvoUwwND7Lt7ZcnpWLV2t7ML379Y/70D//n6EhZNrHlViCZbWipOIrNDddh1kCRFR64+1G+9sU/HHXXnW3ouoZBpkj2eqW5apo2akZ3I1I+DEPH0FQESZmx4xu6BoKY6bDfwLQWyWzD6i8mOTx2iqnZV4DJ6b+hbbwaojB9D4vpklZTDAf7sNtcVFXUTqk9iqywculacnPyefmNX7PnwE7qzp+9Iu02raZpbD5PY/N5tu14hSW1K1i7ciMrl62lqrz6qmIo2cZisWUyWqbiNzQG82tW0tndDMCKJVemsE7lXvyNCSzaOlooyC/KmqnUTCEIIqLZgRrpRbJ6EEQZPZ1EjfShOAOIZieibEFPx0ZTpUzeUtLBLgwtjSDKGFoq8/AUZdA1UoMtGLqKIMmIshU1ncys8yEJLgTFgrVgIenhdvRUFJOvDGv+fGS7H0EUcc3dSnKgES0exJxTgUe6G2GkAEqQzCjuQtS67bjn3Tn6+YcBQRDIyytgXvX0ciatFivLFq2cUmAR8Ocxr3ohnmmowymyQm5OHl63j/7Bvglt0z/QO2kPjKtxpu4kB4/uJRabWJ3HRRx2B0889nnWrtp47ZVnCEEQqCybwyMPfIKOrjaOjuMvMh5vbH+ZRx/4JLXzl2S9baHWE/jnb0K2uuja/2scRfNBmtmO7dbNd/HVL/zBrA0qAFramtF1jaLCUizmiT2nU+kU5+pPsaT2ymLliXC+8RxWi43C/KLrLpRi6BrR1sOIihVzTgWS+dr+CFMh2deA7MzNvFtn5AgTw+QK4Ju7jlDrqUwN5SWIigVf9Vrs+VMfjJlpMjMWN1Y50e30sWLJlmnvR5Ikyksr+eKnvs6q5evZs38HR08cov7C2StmMACGhgfZsXsbh4/tZ9niVWzddCe3bLid3EDedZGpNZuzW8BdU7WEmqrsPttndy87S+i6zg9/9m/8/lf/GJdzdudkynY/gmJBdvhR7IFMx9c5Ugg/cjGZA+89cCx5cxFECZOvFMnqwZw7By02jOLKRXEXgChl0qFMdgTJNOKAK2JMMV9+NiKZbDgr14273Jo/D2v+JTrxBbUjfxgYego13IPiysec8+FxvoVMukdpcfm0OvUXWbJoBS++/uykt6uqqKG4qGxaAVumyM9BQX7xhAOLoeDgtEzrLiUcDnLg8B7qL0zOUE8URTat28p9dz50w4v+JEmidv4S7rn9Ado7WukbmHg613BwiJ8/+2P+x5/872nNfI1FMthHpLMexekn0llP3vLs5A2PR+38JXzl878/a4OKeDzGUHCQ46cOY7PayfHnYug6/YN9OOxOXE43kiQxFBxE1zTCkdBIwblAa3sznd0dLKldQVpNE41GcDpcI7K3cWRJRhQlhoYHQBDweXwoioloNMJQcJAjxw9QUlhGwJ876cDC0DUMNYmupUDXkCwuBElB19LoiRCIcsZ1XZTQUjHQVPR0AsnmASAd6iLStAdb4WLMvjIMQ0dPRtFTMSS7D1FSMDQVPRUbkQ0XEU1WjHRi5H2mjszy2zG0FFo8hKhYEE12BFFES0bRUxHi3WexiQqS1ZP1324yKDY3gSV3kRjuZah+L8nhHgx0zO48fDVrKVjzMBbv7PWcytRYTHyGwNA00vEQksmCNAtrGAVBwGq1sXr5OmrnL6bu/BmOnjzEydPHOFN3gs7uDjTtch+XcCTEO3veou78GeovnOPxj36GirI5V1XRu+jyjiBMOTiwmEdmLLLEwFAPkijhdHiRJInBoV4amk6i6zrzqpfhdvkm/f6ekcDixOmjtLQ1smjBUgoLSm5YoctFUqkkO999k69+4Q9uaDsmgmz3Idt9QMnoZ9aCy+X0rHlzR5WhrPkZRZGLuvCi2Y7iyh+9EER/prN8sWMjOnORHR+udJ+pYOgayYEmYu3H0eJBHFUbLpPB/DDgcrioLJ2TlU7tVGc9yksrKcifXO7rWFgsVnJzJi69GAwOkZqicd37aWxu4OiJg5OerfC4vHzuia/gsN/YlIGLOOxONqzZwtETh3jtrRcmVfz39q43aHriK8yZYq3OeHiqVpAY6iIVHsBVvhhByk6NxVg4HW6+8KmvU10574YHemMRT8Q5dvIwfQM9NLc2UlJYSjwe4+iJQ6TSSUKhYTas2UJebgG/fvHnFOQXIwgChQXFiIJIb1/3aP1PPB7jbP0pCvOLMJnMNDY3UFk+h96+Hto6WjAMnbKSSspLKzl0dB+JRJzmlsZrenaMh56Kkeg7j56OIyAg2byYcypJDjShxYMYWhqzrwzFXUSs9QgAgmzGOtLJTIe6ESQZ2Z6DYLKiRgeId55GsjgxhlqxlywjHe0n1noExZmLbPehJWTSw+0YWhpdTaK48lHchaSDnehqEiMVx5I/H9FkJdZ2BNFkJx3qwhgdWLpxCKKEPa+S8ju/gm/uOpLBXsDA7MoFXwmauwDNgEhwKOPlZbNnPaifDqIoYbdmZiwMXUNLRNHUVMY53GJHTUTR00lkmwtBlEhHh0hHhzG785BMVlKRQQRRQrY4MHQdQ0uTjgUxuwJZUYWbKhcHsZYvWc3C+Uvo7GrjTN0pTp89ztGTmVmM978Hevq6ePbFpwhHQvzub32DooKScevRUqkkzW2NmE0WykunVttlyfKMxelzB/C6c5hfs5JUWmXvwdeIJSIj7uT93LL+QSyWyXnJzUhgcfzUYZ58+vtUV85lfk0tS2pXsGDuIjxub9YKAJtbL3C27tSE1o0lYhOWqvygMF4Embkhhff9e6x1ftMREGQzsiMHS+4cLHmz1/l2qtjtTkqKyrOyr9KSiknVOEDGEK+ooPgy87CpYjaZ8XonrvUfCodIpyfvPv1+VFXl3PnT1DWcmfS2WzbdMeskskuKSlm3ehPHTh6iq6djwtsFQ0O8vv2lrAcWzpJaTK4AeiqOlorPaE753bd/hPVrbplVHbRL6e3rpr2zlbzcfHzeTBpnc1sjew++g81m50JTPTk5efi8fo6dPEzt/KX4/QEkSUZAIC+3gJdHZhUVWUHTNA4f209VRQ0Xms+Tl1vAgcPv0tvfQzKVZGh4gEQiTk9vF3Mq5+JyuhGm6HZuaCnU2CCSyY4gKiOBgolE91n0dAItEcHQdWR7DsmhViw5lZg8hYiyGQOQbX4ksyszy24YJHrrMoGGI4dYxwnU6AB6MkI63IO1aBGS2ZkRLUnFwNDQkzG0RAg9FSM50IwgyaRDPZkZC9mEloxh9lciSNmXeJ4ouq4RiUZIppKj/lyC3Y9UtopcuwOLxUo4EqK+4QxytI1KxcTg0AA2mx2bzU40FsVsNpNOp5AlhVQ6STwexzB0/L5AVsUVNq29n4Xzxi64BrBZHfh9mVm/VHiQgbPvAAZmdx62QDmGrhLprMPiK8JROBctGSM+0I5ktpEK9ZEKD5CKDOKuWIahpQk1H8fk9GcEHLJ2FtPDbDJTUTaHspJK1q3eRMOFOo6fPsKe/Ts5eebYqP8FQCKZYNvbL1NZXs2nPvaFcQeTtJHZx1QqNeXAwmy2ZvW37uvvGDXea245x8BQD2tW3IHD7uaZF77F2pV3zo7AIpVK0drWRGtbEweP7KGkqJyqihoWL1zGiqVrqCibM235wmMnD/OTX34Xu9VxzXdRWlUvuwhuchNBFDF7SzB7S6698gcUu81OQX5hVvblsDnwuH0MTDAVCcDn9RPIyZu0xOxYKCYT7kmkMSaScdJqeto68L393Zw+d2LSPhAmk5mPP/yZ6yphOhEUxcSKJaupnb9kUoGFruu88fYrfO4Tv4U9CzMwaiKCGg+RCg+Sjg5hGDrDDQexF9QgSNn/zvIC+Tzykcdx2ByzdmAlnoghKzJFBSXEYlE0XScUDuL3BaiqqGZp7QrKSiuRpMwIdnXVvMuU1nwe/2iO98UZvsPH9mG3OcjNyUMAFEVhwdxF5Aby8bi9DAcHsdnsFBWUEMjJnZa3iiCZkGw+BFFCT8XQkxEE2YzJmY9kdmTSnkRp1CjR5MnMZAqAZHEiKhbkkdQoLRHBklOFbPMhKhb0VBwEKZPuO/LMTg23IZkzKb6aFM74FCXCiGYnJlcelkA1sjOX1FAbstWF7MhBtLhv2O8fiUZ4/a2X0A2NQE4e+bmFRKNRBob68Lp9FBYU09nVRkNTPQF/LqXF5XR2t+P1+PB5fBw7eYj5NQtpbmsiP7eQI8f3EwoHcbs81FTNp7oqe4Nj61bdjX6V4mBBEDGN1P5o6Tjx/lZMDj+6LUW0pxEwCLefwzAMnMULUeyezKxGIkK0pxGLtyCTNTDcBYKImojgKlucUYXL2llkB1EU8Xn8rF6xngXzFrFm+Xp27dvOi689S2t78+jMbyKZ4NkXn+KOLfdiKxvblVwSRTRVZdvbL9Pc0oAkSVSWV7Nx7ZVF0+NhMduyWgsqiiK6rpNOJzl+ajdlJTWUFFZhszlJpZLoxuTT5memxuKSKyMUDnH63AnOnT/N/sPv8vr2l5k7Zz4rRtxIfd6cKb18g6Fh8gIFPHjPo9fMB43GovzdP/3lpI9xk5t8kLGYrQT803duveiIGvDnTiqw8PsCWXMUVmRlUh1aXddJJhPouj6tEeqmlgZOnTs+ac3wpbUrsvqizybFhaXULljK/sPvEgoHJ7xde0cLB4/uY8vGO6bfCEFEEETC7WcxuXIQZRNqIsqIq2XWuePW+6gomzNrZysAcnPyMpLGu7cxNDxAZVk1NVXz6O3rpqu7E4vZwvyaRUiSjHTJO9MwDAYG+3h79zbaOlrYtWc7y5euxuvxYbM5OHX2BJ945LM4HE7ycwtp62hB13W8Hj+V5TU0Np/nzZ2v0tzaOK37VU9GiUdOI0omJKsHk7cELRlGiw9jaClkhz8zYyAIV5+ZEkQsOZXEO0+RGu5ATyeQnQHUcO+42wkABiiuPNLh3lH1P5O3GLOvlPCF3eiamjFBzZL+/2RJq2k6u9txuzyIgkjd+TMMDvUjSXLGe0lTSSYT5OUWIEsykiShqirxRBxN1+nsbqeirIqe3i6cDiedXe2k1TSF+cW0dbZk9XljNk88LVgQRCSTFcXuQbY6SQx1oiYiI7NUGoIoIplto/L2it1LcriHVKgXR34VuqZicgUwuXOzWjswEzjsThbXLqe4qBS/L8APfvodWtubR5e3d7Zytv4kJUVlmExX9ktlWWFO5Vzu1HVMJhOiIJIzSTNpi9mW1SLxsuK5nDp3gDN1BxEEgZXLbsNisRNPRBFEAWEKod6MBBYb1txCOBxk36Hd1F84RzweQ9M0enq76Ont4tSZY7y7fwfFhWUsXbSCtSs3sWjBEmR54jJziqIwt3oBt2+595ovi0QiwT9/5++zcWozRjKV5I3tL3Hk+EFsNhtFBSVs2XgHiUScl954jrtv+whzKmrYve9tbFY7i2szZmO/fvkXKLLCR+4eW/v5Jr+ZSKKEy+nGbs+Suoog4PflTGoTn9eXlcJxAEmSsVknNx0bT8TQdG3KnUlVVWlta6a5pXHS295750OYFNOsHB03mczUzl9CeWkVJ04fmfB2qXSS7e+8npXAQjJZEGUFz5yVmEZktEVRQhCy3/G32ezcseWeKRlEXk/cbi9rV2xgYGgAXdfx+3LIDeSjKAqhUBBBEEbP4YlHP3/ZvW2z2lm0YClFBSUUFRSjyCY8HjN3bb2fcCSUcU8XBZYvWU1hfjEIAjm+AD6vn41rtxKJhlm0YBkFeYWYzFPLJhAVSyagcOUjWVxINi+W/HlosUzbJXNmYMBRvgbJdvlzQbK6cVSsHzFHFDD5yjK59ogIihnJZANHLo6y97wrTN5SGCnkNnQVQZAQZDOKIzfj5SQIiIoVwerGXroSMDC581HcN6ZwXxQELGYrLqcbl9NDLBbF5XQzODSA3WbH5/Vz/kId3T0dlBSXEYmE6e7tJNWeJC+QSY87dHQf9RfOUlpcjslkxmy2kOPLpaun/YacE4DJ6Sew5E4kxYJosmDxFWYMACuXo9i9mYAuHsEwNARRwlm8gHRkEFugDEtOCYauYXbnZt1ReibxeXO45/YHOXXmOL39PaMKhIZh0NBYz9ZN6TEDC0mSyM8twGa1EYvHyM8tnHSga7HYslpjMbd6GVabk3B4iEBOIfm5paOzGLesfwDLJD0sYIYCizkVc/n041/mzq3309h8noNH9rHv0G46utrQNJV4IkZTywWaWho5dfYY23a8QnlpFRvXbmHDmi3k515bDWHLxjtJp1MTmu0wmUxs2XjnjLnHZgNNU+nsasfldLF5/W1s2/Eqp84cx+V0cfrMMexWO3mBfNram3G5PNQuWEo6nebIsQMoisLdtz+QlZSTDwpDwwMcOnaAhsZzqGpGrWHrprtYOP/6ewXMRhRFwePJXk2TgIDTMTl5QZfTM+ltxkMSxUnfv6l0elrqZ0PDAzS1XhjXuXk8bFYb61ZtmnVpUJdSUzWPitLKSQUWmqpx+PgB4vE4Vuv0hA4EQUSQROL9bQyceQdDTYGu465aOeU8//FYvng1JcXlk3aPvd5IokRRYSmFBRediTNBaXlp1agr8EWPiYWXSP9eDDjGElgoLS6/7N+5gfzREdKL+6ooq5q2BwYIiCYbijMPk69sdD+KPQfZ5h9Zg4w8uudKMQdRsWDyFr+3N9mM2V8JGKNpH5LZjmR+r5MjW8dOjZTMdmQjABfHWgUBs788C+c4PRx2J/fc8QAmkxmrxUppSTm6rhONRXA73VitdtwuD5FIGLfLg9PpZv3qzWiais/jZ/ni1QRDQ9TMmU9RQclo7Zrb5SE/78YpSEkmK/a8S+oFHL7LvutksI9oTwMWTwFmdx6y1YlsdY4uB8A68fdEZ3c7b2x/Gb8v54YOqLpdHqqr5uHc67xM2nw4NHSZi/elaJpGY8t5fvXCz8nLzefWDXfQ2t7MpvVbJ3xdmk3WrM7s2G0u5lYtxTB0RFEcvd8sZiuLF6zHNIV+84wEFrIs4/fm4PfmUFVezcqla3nkgcc5fe4E7+7fyaGj+0b0gQ2GhgcZGh6kobGe4ycP86sXnmJJ7Qpu2XAbS2tXjGs8UjgJpRlRFPnip76G3TYz2tjZQpZlSorKmVMxl9fefJFEMo7L5Wb+3FqOnz7MLRtuuyy6PXHmaGb0CThbd5LFC5ePu++Wtkbe3rWN7p5ObDY7WzbeweKFyzh3/jS7975N30AvxYWl3HP7A+T4c3nrndc4eGQfDrsDXde5+/YHqJlFqR1n605xoamO2vlLR+XdcnImN6X4YUZRTLhd2ZktAEAA2yTvH5fThdORHUUkUZJQxhgBuhq6pk4r7aGnt4sLTfWT3q52/lJ8kyg0v8jg0ACHju6lsaWB8tIqVi5dQ0NjPWfqTpKbm8/GNVvo7G5HFESqKqo5evIQhXnFFBWWTLqz5PX4KS+twulwEY5MzI3bwGBwsJ+z50+xfPGqSZ/fWDiL5mH1F2NoKr1HX81484z482SL9as343S4ZuXs0ViM1c5sBqlj7Wu6341kcWLNn48gXTlLN9V9v1+IZHLbZv8cp4uimK4I9AzDIHBJoGfJK4K899p66fp2GJ0BFoTLB3qyNYCTLS79rmWbC0fh3MyM1ogK2HR+i1gsSn3DWYoKb3x9pCiKVwyEXM2NO5GM09nVTn5eAYZuEI1H6R3oQdNU5AkODNttTjwu/1UHzZyOyb37M8+Ey89DkmT2HnqDFUtumX3O22azhfy8QvJyC6iqmMumdVvp7u3i0JG97Hj3Tc6cO0FaTaOqabp6Oujq6eD8hXO8vet1SorK2LR+K5vWbqW8tHJaF2M2JC9nmmgswvZdb/DmzldZMHcRyxavorevC5fTzZyKGk6ePUYkFsE98nDZvvM1btlwO2k1xdu7tl01sGhoqqezu407b70fvy8HvzdAKBzk3f07KcgvZsvGO3j2pV9w+txJqiqqefPtV3n4/o+T4w/wF3/7n1i/5pbr9TVMCFXTyM3JZ/XydaPR+2zOn77eKIoJTxbUmC4iAOZJduztdic2a3bSTwRBQJrkVLmqadMLLPq6aWxpmPR2q1esR5lEWidkpEb3HHiHSDTEHbfei81qp62jhabWBhYtWMqJM0czKRBF5fz82R/z8P0fY9ee7XzpM78z6fYBo0WDebkFEw4sIJOyefDI3qwFFoIoI8gKIJAM9WX8ECQ5awWcZrOF2gVLsE5S1WQmMAwDQ0tjaKkZM4C7UQiSgnQDFZc+qEw2CLvRwdFUkBQzkjJ7s0Wmiq7rNLVeIBS5vE4tL5A/bl9ElhQsFitNLRcwKyZOnjk2MlMw8b5LYX4FX/zUX6Bp46seKln6vo8c30Ht/DWzL7C4SEYf2D6iVFNETdU87rvrYZpbL7Dz3Td5e9c2OrszeYKRaJhINEx7Zxunz53gmed+xsJ5i7n/rofZsHbLVY/T0tbEufOn6entYu3KjVSWV5NMJpAkCbPZMqtvTIvFyub1twEGkiRlcvQEAQO4ddNd/OqFn2E2WygqKCGZTLDv0G5a2hrRdZ1gOEgqlRx32mpBzSIGBvp47a0XqSit4rZb7iYWj1J3/jSHj+1n/+F36evvoWbOfNram7FYrFRVVOPz5pAbKJg131tzayN7D+6ivbOV3v5uevq6RkZxBFYvX0dVRc2NbuKsQJZlHFmaLcggTHhEBTIjIFaLdUrTqGMfXbisYHUi6LqGMcViYFVT6R/so6+/d9LbLlqwFOkqJklj0dXdQSweZV71QirL5gACh47ux+vxM7d6AYlkgo7ONuZUzGVezUK++Z3/xWMPPoHDPnWVo+KiUnL8ARoa6ya8TVpNcerssSkdbyyi3Q3E+1owdJ2chbcgZjmds6q8mpwsS3FOFMPQSfTUYc2bO2JuamCk4+jp+IwGFoZhoCWjhFtPE2o9QbSnieRwD2oijKGpiIoJxebB7C3AUVCNu2IpttxKJNM4Dt83OIVMTyeJ9jYRbj1FtPsCyeEuUpFBtGQcQ1dHvBMcmNy5WHNKcRbNw1W6CMXhm/XFwDeZItPsjvT197Dj3TfZsuF2ApPwR7qUd/fv4NiJQyQS7zmny7LM4tpl4woKmUwm5lUvJJFI0NhcT24gj0Xzl07q+WQ2WykquD5mvvFEdErpxDekWuZiYanL6SY/r5BFC5bxuU98lRNnjvD27m3sOfAOg4P9aJo6kio1RGt7E4IojBtYxBNxfvXCz3j2xZ/T299NOq3idfsoLS7nqWd/RCgc5Cuf+71ZnQ4liRJut5c1Kzbws6d/QN35M6PFeh63l/lzF/HS67+mqqKGI8cPsGjBMr70md8mnU7zk198l2OnjrB6+dgO1IGcPO6+7QHWr7mF517+JXsP7mLj2lvx+wJsWn8bK5euxdA1HHYnA0MDDA0PkFYzqST9AzdOSeP9mE1mfB4/bpebeeoCJFkayZ0WMI/3YvwNRJbkrM0WXGQyHXuzyYLVYs1aQCpMwanU0I0piwxFImG6ezqvcFu9FmaThcqy6knn88cTMQRBwOFwjaZxJJJx7HYHiqJgtzvo6GrDMHQ8bi89vV24nJ5pyQ4W5hfh907OEE1VVZpaLpBOp6clTXoRV+kiHEXzAANRNo+oRWVvEKOqogab1T66z1jXadRIH1oijKNsNYJkItp6CDAw+ysRzXZi7UeRLG4UdwFqpB81PoRs82HJqSI13EayvxmzvwKzv4xEXwPpUA+KMxdzTgWxjpOosUHspasAg+CZ11HDvZhyKpEsLqKtBzG5i5AdOaSG24l1nkJxBFCcuaRDPajRISSbB2vBfORJukMbhk4q1E/X/mfpO/EmiaFu9HQcXU1haOpIByGTZiaIUsapWjZlcuQLqslbfh+BRVtR7JcfVzJZp92RmyyGrpMY6qTn8IsMnNlFfKAdPZ1AV1OZFEddBd1473wEEUGSM5K3ihnZ5sJduZz85ffjrlx23dye23f9lI49T6Mlp+ebFVi0leLNn8bqL75iWU9vF7/49U/Yd2g34UgQnzfAIx95nAfueRSAUDjIr158ird2vkYsFmPh/MU8+pFPsGTRCjq729mxexstbU10dLVRWFDCnIoa3t2/E5Ni4quf/32qKmr4m3/8c2oq59HW2creA+8giRIfufsRPvHo5xBFEVVNc+78aZ55/mfUnT9DKp2kumo+D933Mdau3AhkbAd+8ovvIkkSAX8eL73xLD29XaxZsZ5Pf/zLFBZkzu3AkT38/Nkf09hUj88X4P47H+bB+x5DEiUMw2BwqJ+fPv0Ddu99G6vNzoK5taN1lVMlGAryzW//HT948tusXLaWtas2sWzRyglltgRDw7y58zWeeuaHnG+s49KXzIolayjKH98gD8Buc7BmxXqWLV6JKIqTdrnPNn0DnYTCY8upT7a+8CI3vAxfkRU8bi9ul4fcQD4b195KJBrmxKmjvLPnLQ4c3kNHdxvJVPKqzrc7dm/jrZ2vsnXz3dy2+S7+5v/+Oal0CgOoKK3iP378L3z+ia/M6sDiIoUFxVRWVHOm7hSFBSNa34LA3Vvv54VXn0HT1Iw6y6Y7KCwoRtc01q7cwM7d28YMLAzDYO/Bd3j6uZ8iiCIup5s1Kzbg9/nZvP423tzxCtvfeR0Mg6987veoqpjL4trl/M3//XO8Hh+iKMyaGYvcQD5bNt7OkeMHOXXuBKuWraWirIqjJw7ybz/8JjVzFozWifwmI0kS1kmqKF2TSVwDJrMZ0w0O9KYTCodCw5PyebhIeWklNtvkv3evx4emqXT3dDJnZNbN780hEg0RjUXp7unE4/YgiCJ79u/k97/yx7zw2jPMqagZtw7tWricHgI5eZhM5km5lEeiYdo6W0ZmVqZGMthLfKCdobo9pOMhLv5ahqYRWHwHvrljD5BMlvKSysu+HzXci+zIxVpQS7h+B46q9ajxQby1D6ClosQ7TyCabOjpBNHm/Zi8pVjz5qOGe0kNd2bUigyDdLgH0ewgHerCkr8Ak6cIQZSx5s8n0XeBeNdpnNWbkWxebGUrESUzhqFjchejxYdRo0OkBtuxl65CjfYTbT2K4szFWjCfdLCTdLBrUoGFrqboPvQirW99l8RQF1oqAePpzxtGJtDQVPRUHDUWJBXqI9R0jO6Dz1N+51fxVK0YlQeVrS6uV2RhGAbp6DCtb32P7sMvocaGr34uF8/H0DB0DdJJtESYVLifxEA7/SfexF25grLbv4yrbBHiDKdrpWNB4v0taInpBRbJUD/GGKkuw6Eh/vs//DHRaJTHHvokxYWldHS2UzBSaxmNRnj6uSd5ffvLfOKRz+Hz+Ni9fwff/v43+crnfw+fN4czdacIR4IsrV3Juwd20trWyJaNd/Lamy9w9MRBCvOL6evvYfvO1/noA5/gj377z7nQVMf3fvqv5OUWcPuWe7g4gx3IyWPrprswMNj+zhs8+YvvkRvIp7JsDoZhMDQ8wPZdb7B5/VY+ev/jmBTTqA8LwOlzJ/inf/1btm6+i8cf/jTdvV38x4//FU3XeOzBTxKNRXjh1Wd4e/cbfPLRz+P1+Nm+63UOHNlDWcnUR+11Q2d4eIjBoQE6utt5fftLWK028nMLqSqvpqykAq/Xj93mQJYk4ok4A4N9NDTWc7ruBF3dHURj0cu8PmxWO5//5FfxeXPG7S/FE3FOnjkKwJoVGzh3/jQNF+q4766Hb1gf68TpvZw8u3fMZWaTeUrStjc8sLiIIAiYTCZMJhMOuxNhkUAoEiQcCRGJhgmGh6+6/Zm6k8ypmseD9z5CUUEpZst7nZqC/CIGBvvRtKkrxMw0VouNT37si5lcclHigXseRdczVfqGYaAoCqIg8p1//AkmxcQD9zyKSTEjCiKiLLJ1811sWn/buPtfs3IjSxetBEAUpdELZtWydSxZuBxtZLrLarEiSRKffPTzPPbgpxAFgb/+xz+/Lt/BRJAkCUmS6Orp4MixffT397B21UaGhgfYsulOWtub6exuvxlYSBKWSWiRZxtFVrIyoj0dpvOYDoaDdE8hsCgpKss4IU/yJZGfW0hxYSnbdrzCG2+/xNJFK1lSu5zX33qJf/52Rir7M5/4LXbufpOli1ayaOEyjp06xMGje9mwZsuUUn1EUSTHl4Pd5phUYJFOpbjQeH5agYXJmYPi8BLraaRg3aOjKjGGqtK+68msBRZFhaWYzZcEuIaOaLIgWRxoqSgCIpLZiWiyoqdjGc8Eew6S041s82JoSSSzHTUikhxoQosNIEgjI4yGiqjYkEx2RNlMrPMUaqgHyeZGjSZHZgVkRMWSkdHV0giSjGHoGLqKoaWRLC602BCGmkBUzEg2L+lwT6aTPAEMw0BLxzn/q7+h+9BL6KkEUwmpDV1DTYQZajhApLOeinu+TsHqh5EtDhS7B2EkJXemGTz3Luef/Rvi/W3oampa+9LVFLqaYuD0DoJNRyje/ClKb/0Cstk2ow7vM8mOXdtobW/hf/7Z/2HB3MXIkszS2hWjM5fB8DAvvf5rPvbwp7jvrocQBZHc3Hy+++N/Zfs7b/Dog08AMG/OQh6+/2NcaK4nNyeP22+5hzPnTjA0PEgimUBAoLysigfveZSCvEKWL1nFyTPHeOb5n3L7lnuQJInqyrmUl1ReliL7i1//hI7OtsueDTm+ALdtvpuli1eO6HQZiCM1CL964WfMq6nlofs+hs+bg6qp1J0/wzMv/IzHHvwkwdAw7+zZzq2b7uSBex/LSPZarDRNofZtPFKpJKlUklA4SF9fD2fOnUCUJMQRvxUBAcMw0A0dTdPQxhAFMZss/N5X/gvLl6weFZMZC01TCYdDuN0eIDMDHEtk7Biutt1Msmnd/axbdde4yyfrug2zILC49AcLhYZ5a+drbNvxCkdPHiKVSqHr2mVSe+OhqmnMihmzOZN+cemakUgYRTHN6meJIAhYLnkBjieteVH94eLSzAVuoCimcafUBEHIdPRGHgCXKTbI8pgXtNlsGW1DJgi53JDp0n2///PrEXnnBvK567aPYLXaUFWVtKpitdiwWrJrHvNBRRTFMXW0rxeXXm83iul0hKKxCP2D/ZPerqiwBHkKeuyiKLJu9WZWLV+HqmYUQhRZ4bc++7uk02lEUUJRFCrKqhAQRpTufntUMnSq+H0BHHYnQ8MDE94mraZp62ia8jEBhBE1ldyldyGZbQgj96yhaLgrxxehmCw5vhxM7wtwo837iYoStuIlI2lBmd9LtLgw+8uJtR9HcRUgKlbSoW6SA03Idj+KOx813IueTiDIpkzdhChd1klVowNoqehITYWAyV3A8MmXsBYtRkAg2nIwYxZn8yHbvQyffA7Z5sPsLxtNAxMEaUK/qWEYqIkwp3/0DQbO7oRpSCuPomukIwOcf/bvSUeClGz5DCaHb+R8Zg5dS9O248c0vfr/TTuN6P0YukY6MkTza98i3HqKuR//75jdmbz62TITP1EamuopzC8mP7do1CfnYqGwrusMDPYTigSZX1OLaaQ/kOPPJT+3gK6eDiKxMGaTGZvNjtVqR5EVnCN+RyaTGVVTR0fhy0sqcNgdSCMeM/OqF/LUr36YOZah09bZyi9//ROOnjjE0PAAsXiMHF/gikGKosISCvIKr3gfXPR8OPn/s/fWcZZd153v9+BlLmZqZu5Wg9RSi8FiNGOSsZNxnpM3kEwySQYyyUsydmYcO3GMsWxLtizJYpa61cwM1cVMl+nQ++NWV0NVdRe2uuX6ftxWVd1z9t7n3AN77bXWbx07wEuvPzf0XeiGjs/jR9c1stks3b1d1FXPGTqeYCCPosLhIUuWZWEY+vn5oiggifKIz0hREFEUJSdJfoE3zLRMTN0EffTE6AuRJImSojJ+9wtf59Yb78J1hZw3p8NFYUERP/nFv3L42AHC4QEqy6uvmvBM5+4XOPPC36CnE3hK51J91+/jr1uNLOXERgxDv6jStiiI106BvLFgGAaaliWVSbH3wE5efv3XvLv1zWExXedCOvJDBSy8QLv7Uqor63j7/dc4fHQ/q5avG2o/Fovw0uvPsXDekilLJL2msCxiLUfwVl6hfoNloqdiIAgozpH1vy/kXFyuqDr4sz++tLighZFJYWQT2LznPQNavB8jk8CRVzGBAxkfqqqyZ/8OMloGLAvdMMhqWXr7upk3e+G093+tIwri0IP4o2A0g/V6IZVODUpij4+SotIJvyQkUUJURNRBRY9zFc/PqWEJgoB4gSTgVJzfYCAP9ziLKOqGTnff+JPaR0KyX9K3IBKYtXZK2nY6XDid7kvyUEQ8dZuQvUVDxfi8c28d7FrGXjgPe+HcXLhTtBNBFLEVzEKyD4YDWeagIZF72dryaodadhQvwFE0Fy4o8ueZtRlMYygBOhisvGiMjtJzz+3zL29nxYoxHZ+hpTjx9J/Sd+y9y4cKQc57IsogikOrxpZl5bwnhj5sf8vQaHj1W4iKmqtRMI0TcENL0/DyN2l578eY2hU8Z+dyKYTzevsWFlhmTlHMMBhtScEyDXqPvEMm0sPiL/4jtsDU134QZRuy3TM4hNw5xjIH/3vJzxNY+rhgGW/YZ5ZloWsaIGCa1oUfYFomsiyjyOolE+2cKMb538/vl8uxPN+MOVhFG6C3t5v/9rf/GbvdwX/9j39DZXk1u/dt58c//+dh41JkZUQxC8uyyGoZHrjnMZ569Au4LwhTv/i5x0UiHKIwspDHQLibnz33TU6e3o/N5qC4sJKbNz3M3FnLURXbRRP+qooa/v6/f5dnn/839h/aQ0bLYOg5o8Q0TUzLHDz2wcVShAuexxKSLJMfKsyFcD34acpKKsa0yCOKIvPnLOYbX/0TmloayAsVUFlefdUM3MKV95K/5DZaP/g3+k9sA9PkyIkdqIqdmsr5/PiZ/4+zjUeGFmfLSut46qGv43Zdec54IVf1zW+aJtlsZqhA3lvvv8prb/2G9s62i6xGYdDd5XF7mTd7IXffdj8b1m4m4A+O2vbmjbdx/ORh/tf//q+Ul1VypuEU+uvP8fzLzxBLRPmr//x3U57MOhnOSQ8a2XTugpRVwMLUsjlllMFqopZpIA4m2RnZNJZlICkOBFHCyCQwDZ2OXc/hKV+AkUmCICAq9lxb2XTud1nF1DWy0V4kmxPZ4c0ZDnoWQZQQFdvQiuE5uve/SrT5MDV3/X4ubCAdB8jF3QoiWqwPQ0ujevKxDA1TyxBvO0Em2n1VDIvF85dRUliGhYXb5SaRTHD42AFqK2dRWz1r2vu/1hE+4qQwQRCv6QJxl8OyLNLpFLFLZATHQjCQNymP2UgvmOl86Xjcnos8pWPBMHT6psiwmKqaByPh8XhRlIvD0hRfEaLqGtErcOFkCwFE1YnkzkOUbeeNk8tUBhcEAYQRXqmX9WBN7HhNQ6P5jX+h9/BblzEqhJwClDuIu3g23srFOEKlSKoT09TR4gOkepuJtRwl2duMnoxgalmGJpeWRcPL36R47UM542MaMLQMzW/8M60f/PQyRoWAqNpRnD6c+VV4KhbgCJXnQrREESOTIhPtIdFxmljrMTKRboxMYtQxx1qOcOSHf8iiL/4jNk/elB5PyQ2PEJq3ES0+gJYMoyUG/yXD6Ikw2WQEPREhm+gnG+lBT41d6hmgpmoW7257k/bONgL+ILKkYJgGWBaqaqOwoBifx8eR4weZP3cRkijS1dNJd08XleXVYy4yamHR1NxANBbB7fagaRrHTh0Zyv9KZ1I0tzby7774DWqrZpHNZujp7WIgPHIS8EhXuSiKzK6bT3tnG4osEwwEQRDQdR2B8+Hx+aFCztSfJL0pjSiI9Pb30NHVTlVF7bA27XYnn3z0Gyyat5Zd+9/ipdd/gCKrzKlbepFcuSzLbN54Gzdt2EIkGubgkX0cP3WEtvYWOrraGYj0kcmkyWQyWJaF3e7A7fYM5mDMZvGCpSxZuGKorshYOedhys8rnLAa1WQQBAFJHawnMvi8O3n6AOWldchyLurlkU/8HhWlszFNk3/6wX9B08YfkjjthoVlWWSzGeLJOD29Xeza+yGvv/MSR44dIHOJy8ym2vC4vRQWFrN5w63ccuNdzKmbN6aXTX6ogD/4nf/AogXLeX/bm4OKAwILFyzj4fuepLZ61jVV58DUMkQbD9B3/ANE1Y6/ZiWWZRA+vRNnQQ2y00cm3ImWGMAeLMFdMo9Iwz70VBRf1VJsgRI69zyP4vRjmSbJnkY697yIpDoJzFqDKKv0HHoD1ZuPr3oplmkRadiPr3opqjePgVPbibUew5lfSaBuDar3/APWMk0S3Q1Yho6RTWEBre/9GFFR8VUvx5FfQc+Rd3AWVuPIqyDadJBw/R4sy8IRvDr1QvYf3sOLr/4qdy4Ng6yW4ZFPPMW61ZuuSv/XOqIgfqQeg8mG6HyUGIZBIhknkxl73sE5vF4/onj9HLfT6UK1jc+Ta+gGvX090zSiqUNVVMRLDAFH0bwx7y87A8jOKSwyOVVYFuH6vbRu/enoeQiihN1fRN6imylb/ziuorpRvQ6maZBoP0n7jl/Rd/Qd0v0dOdUlcp7rtq1PT89hGDo9B16j5YOf5hbFRkCQWCMLowABAABJREFUFBx55RQsuZ2iVfdd0Xuip2IMnN5F+45niTTsR0uERzS8Ig0HOPPcXzPn0T9HHqdG/+VQHF6UMVSRzsYHaH3/xzS88o/jav+mDbfy5nuv8O3v/R1333Y/hQXF9A/04rC7uOXGO/B5/dxz+4O8/MavsdsdBHwBdu7dRlbLcvOm0ePoL0VAoLmtgede+jnLFq3ibNNpDh3dx3/8+l8AuZyCkuJydu/7kJLiUlrbWnj5jV8PCzu8Eo984kn+29/+CT98+rvcsHoTsizT0dlGIBDi9pvvwef1c+MNt/Di67+iML+YUDCPHXu20nuFhQ273cnGtffQ3HqK46f2UFZSi9cz/F4WBBG/L8iN67dw4/ot4xr7SBjZNFoyjKTY0VJRJNWB7PCQjfYiiCKqJ29IFCGX1xRHT8UuMoIFSUZxBcZ8XRrZFFoijKQ60FJRZJsLSXWQjfcjSgqKO3hZGW9RFNENDcPQ2bjmHvJCxbhdPtLpxITlmqdt5qFpGvFEjIFwP8dOHubdrW+wffcH9A9cHLcsSRIetxefN8DSRSu4bfPdrFu9cUIFjfy+AA/e8xgP3vPYVB3GtGFkk+iZBK7iWcgOD4rLj+zMuduTXfVkoj048yvJX3wLnXt+Q+eeFyhYdgfukjk0vPItZIeH0LwbceSVcfpX/4O+Y+9jD5Qi290MnN6Bv2YlssNL2YYnANCSUTKRLox0nFRfK0Y2RcHSO3EVDldWyES6wTSwBYoJ1+9FVFScBVUULr8LyL1svNVLSPU0kY33kepvo3D53aT6WsiEu67K+Vu6aCWzauZiYRGNhtm5d9vUqyBdzwiMW551KhEHJSA/SiY6vc9qGeKJ2IT29Xl815WnxulwDYVejRXDNBiI9GNZ1pQaj3omgaSOXrV2vCiyinAdGXljRU8naHr9O+jJUTxqooS7qI7KW79C4fK7rjg5EEUJT9l8Zj84l76562l84ztEmw6PqEo0lSS66ml84zto8f4RP5dUB4HZa6m+86t4KxaNqU3Z4SF/8S0EZq+lY8eztG79GamexuHJ8JZJ94HX8FQspGzjU4gTyIv6KAj4g/zn/+evePb5n/Lcb35BMpUgFMznoftySdkul5tH7n8Ku93Ba2+9QDKVZM6s+Xzhk7/LwnlL6OhqoyC/KKf2KIgUFhQT8IcQBYHC/CJ8Xv/Qyv6WG+9A1zS++6NvIQoCn3/qd7lpfS5sMBjI48uf+Ro/+cX3+Ntv/SW1VbO5/eZ7iMVjQ/WTBEEgP68Qh8M5ag2kRfOX8ad/9N959oWn+ecffQsBgYry6qEkc5fTzT13PEQsEePF136J2+VhzYr1PPbAp674vhcEgbKSOs6cPUQ2m77stlNFrOUoZ1/6B/yzVtNz4DVsgVJK1j1E81vfA8ui5t4/JDh7LZZpkuprpWP7Lxmo34WejJKN9WLqWTxlC6i67XcIzd84pj7D9Xuo/80/kL9wM137XsZdNo/g3PW0ffBTFJef6ju+iq966aj7l5XUcrbxKG6nj6LCClLpBLF4mCPHd1CYVzau+lXnmJa7qa+/lyPHD7Jzz1be3/42TS1nh+kOu11uAv48yssqWb/mJm7eeDuV5VUTfqkkU8lcEbwRXH2WZdHX30MgEBq3vvx0ITu8CKLMwKkd5C3cjKln6DvyTi4EygIsC8nmHHrRiooNI5MkE+lClG2IigMjHUNPRnPKI7INy9SR7E5C8zZhGdqgTGDOMjYy8dyLyDKHdMr1ZJhsrA/Z4RmyogEGzuxCcQdRXD7CZ/cQnHMDlqGTDnciqU7AQosPoKdimIOhXFoqiqllrlpBItM00QcTrBwOF4ZhkEqnrkrf1wMCwkxxqAliGAZadmKKNC6XZ9oMqkQywcBALwX5xaiqSktbI35fMKeiN8Hnpt3umJB6l67rGIY+oZcOgKlruZW6CyZ8A6d35BYvLhNuNB4keWxJ0NcbPYffINZ6bGTlKEHAESqn6vbfHVoIGiuCKJK3cDOy08fp5/4HseYjY1anGi9GJknzuz8k1dfKSPkCoqwSWnATsx76T9h94w8Zke0uym/8NKonj4ZX/y+JrvphngtTS9Py7o8IzFqDp3TuRA/lqlNSVMbvf+WPR/3c4/by5MOf5cmHPzvss+LCUr78ma8N/f7vvviHQz9/6YK/A8iyypc+8zV8Xv+wdlRVZd2qjaxbNfrkV1VVPvPEly9zJDkWzFvCglHyZwVBIC+Uz9e+/Ed87ct/dMW2ho1BUTEmUSh1IqT6WvHVrKD23j/kyA+/gWXqVN/5Ndq2PU3X7hcIzl6LkUnSd/RdBs7spObuf48zv4K2bb8g2nyIyi1fHp8qngWp3mYkm4vKLV/i1LN/BZZJ5ZYv0rnreXoPv3VZw2LJwvWkM0ne2/4CkiihKCqJZAyX08sdtzyB0zn+QrvTYli8/s5L/H//+FckkvGL/q6qNkKBEIUFxSxZuIKN625m+ZJV2G2TL6S1a9+HYMGyxSvxes4XmcpmMzQ0n+XXL/2c3/vCHw6pKl2KaRpkMqlcst6g/v50rrgamQR6KobNm48WHwBBRHb60NMxFKcHwR0YjCGVsAWK8dWuJNFxmkTHaQKzVmEPlNJ94DXSkS68ZfMJzdtA96E3MdIJBJ+AaHdjGwxvMvUs6YFOMtEeLEPHXTwb2eYi2nwEPRnFU7kop/wxiKVnKVxxD6onhJ6M4ateTvv2Zxg4uR1XYQ2Sw0OqtwVLz2BoGRyhCiL1e5FsThx55dN2zi6kqeUsO/dsA3KKYMlUEpfz2smh+cgRcl6DGcaPaZpoY1QFuZic+tpYFX0isX46OhvxeYMUFlQMFYTq7eugb6CTgL+AUKBwaPLe0dXG089+n8ce+DQF+UV85wff5NH7P8mi+csmMNYc8qDiy3ixLJNMNjNhwyId7iDacABTzw49Z/tObqNg6R3D8r0mijAoFflxQs8k6Nr7Uk6IYwRku5uiVfdRsOyOCffhr1lO+U2f5czz/4vMQMeE27kcA2d2Ez69CzM7wmKQIOIpX0DdJ74xIaPifDsChcvvQkuEaXj922Qjw8NnspEuWt79IXMe/XOkcXruPv5cG0VxJ4plWfSHu3E53BNS6psopqFRuPxOXEWzsAdK8FYsxFeznFjLUcJndgGgp6IkOutx5FUQnL0WBAFv1RLi7SfIxsavRohlUrzmAQwtjT1YirdiEb6aFUSbj5CNX17xz25zcuMNn2D54hvp6+8kq2Vwu3zk55WgyBPL05yWs51MJoaMClEU8Xn9FBWUUFczh9UrbuCGVZsoLCie0pyHsw2n+WDQO3LThlzhuGgswv6Du3n2hX8jk8kMyZBdiqZlaes4S1vHWbyeABVls0ml4hQVVo64/VSgJQawTJ2C5XeTCXcgyCr5i27J5Q1eYtAULrsTAF/FopyixGD8esXNnx/UWQYEgYrNnwPLHHoxuwprgJxL2V+zHP8FMo6OvHKCpjlifyXrHh76ufymTwNQueVLI7YNuRvYV71sMHnx6rzIg4EQJcVldPd0YrfZWbd6E7Nrxx4//XHnXPLbbzMTfS2apoGmjd+wkGV5zJe/aRocOb6T7/3kL1mz4laefOjreD0BDEPnnW3P8ca7P+fWGx/l9pufwOcNAVBXPZvZtfPYuvM9ZEmmsryGubMWTOp7zklJjn8BxTQtstksrglGH5rZNI68CmSXb+iZomeTv/XX7JWINh0i0XFmKAfiIgQRV1Edpesfm/SiWMGSW+k9/BY9B1+fdD2JSzGyKbr3vZwLuR0B2eml8tav4AhNwSKVIFC89kEijQfo3v8qpn5x3pSpZ+k/+SGx1qP4q6dO5vh659wK/6X1Gq4XdF2jt7+DhubjLJyzGvsU5tFcCQEhFy0iCEh2J6onlIs6kVXMwVyKc6I5WnyAbGIA2eYaVO2UkGwTeKgKIrLTixnNIDncyC5/TkBFUob6vBIetx+P2z/+vkdgesw4IRe7W1RYTEVZNYsXLGfdqg3MqZs/bXHw99z+AKIo8t6Hb9HU0sDaVRs4deY4u/Z9yKzauTz50Gdxu0Z26UTjA2zb9TKiIGKz2ZEkmcbmE9x166emZawANl8hrsIaEp1nsPnycZfMuXLoyiUJsZdun5vYj91YG0+ozOXavpoGxTmy2SwDA3309OZyOgRRxO8NUFY6/YpUM3y8MU0TfQLx5bIkMd7MDkWxkdUy9PZ34PUEiMb6SSZjKLJtxAn/Xbc9wJ/9zz+it7eL//nn35q08pckTUy9y7KsCamFnMNZWIMgiBjZFNloD6ahDyYYz4TvjYpl0Xfsg8FK5cORbE4Klt+FzZs/6a5EWaV4zf0MnNpONjb2GidjId5+kljrMUxthLh3QcBfs4K8BTdOWX+S6qB0/eOE6/eQ7h9e9FJLhOna/SK+yiVT5i273skpHgU/UmXBiWAYOg3Nx9B1jYbm43hcfubNXol9IpP1iXJRfqGAKF4wzR401GSnD3/NClq3/pTW936MI6+cSOMhnPkVuIvHr2p5ofyyMKzPiR7IxJkWw6K6opaH73uC5UvXsGzRSvJCBdOe0FiQX8RTj3yOkuIyvv29v+ft91/FNE0+88SXefj+p/C6faOuhmlaBssyWbf6LvYdem9wojytw0VSHXgrF1+5/sQMI9LYXA+CwO98/uuAxXMv/pzm1oYZw2KGISZ1C0/oYTz+Hl0OD5Io0dffSU3lfPrD3YiCiMftZ6TFQtM0CPiDZDNpdF3DwppUuM/Eg4WsSa1mnkuWjTQeINl9Fsu0MNIx/LUrEbh2jYuxFgGdjmKhRiZJrPnwqApKisuf83pPEb6aFdgCxWTj/Yx4MU6Q/pPbyURHVhUTRDnncZniCb63eimeioVkIl3DZGjNbJrw2b1kwl3YgyVT2u/1yuee/J2PegjjRlXtVJXPo7ntFKfOHqQwv4xlizaSHyq55jyhkmrHWVSH6s0nXL+XbKwXZ0ENofmbpsZT9xEzLYbF+rU3sX7NjdjGqY8+GUzTpKOrnZ7eLvJC+eTnFZBIJojFY7S0NDJn1oJRkxQVWUVVHJyqP0h3byt+Xx5ez+g1M2b46JFlhWw2Q2t7E1iQ1bPIE0hCHR/Xp1t4hvEhitKErqWcl2N814jL5UGWFfr6c7Hs/QPdSLI8aFhcUrTMsnj/w7eoKq8hL5jPm+++wlOPfB5VtU34xalfUKl2PAjC1NRJiTUfwVVci5FJkYj1DBUQu5oTAcuycuE+lpnTd78M6f42RMU+lL82GtHmI3jL509ZIjpAsqcxNyEfQT5VECXcxbOnVO5btrnwVS0j0X56WAjRRDEySWItR0dVtLL5C/HXrpqSvi5EFCXyF93MwIkP0Y1L81MssrE+wmf3UjRjWFy3uF0+br3p0Y96GGPCsiyykW60eD+Vt36Z0Nz1VyXqw7IsLFPPhUeZJqahYRp6roDmFPY/LYbFWIuwTCWHju7nhVeepb2zhdUrbmDTuls4cfoor7/zEo0tZ7ll0+3cdvM9I47N5fIxd9YyTtUfxOFwI4oSc2qXXvVjmGHslBaX09Xdzt79OwCBgC9ISeH01tAwrcmt0s5wfSCK4oSS1gzdwDStcU2MXU4fToeH/nAPmWyagXA3iqzi9QSGXWuNLWc5evIwj3ziKfxeP//jH/6MY6eOsHTh2Co1jzhmw5igYZErXjVZPOXzcRXPYuDENkTVOeiBmV60ZBQt3ofs9KG4AujJKLHWo7kchcJabN48DC2Tk0EVRVR3EFFW0ZK5hEt7sGRoG8vQ0JNRRMWOMpgvkg53Em87jqdsLlgiRiaZ06xPRXOy4nY3pq6hJQYwsqmc1r3Td8Xk4Xj7KYx0YsTPBEnGX7tyyicn3qoldOx6DqbIsEj2NpMJd46qNuWvXXVF426i+OtWI9mc6Onhie9GOkGkYT9FK++dlr5nmOFiLCws9FSMvmPvkug8k6tf4fTjKZ+PM79yyr1254znZHcjkbP7SPW30n3gVRIdp/FULMRbsWjKarpcH+LNY2DfwV0kknEevf9TrF5+A263h1l1c6murOOl15/j58/9mI3rbh7RsLCpdubMWo7fn086ncDjDuB0XrnIzQwfHaFgHqFgAXsP7MC0LMqKK6bdn2BOcBI2w0fDRK8HSZRQJqB2ZGENSSCPFbvNgd+XR29fB109LURi/TidnhGT6LRslps33kZxYSlOh5NP3PkIljm5FX7d0HOVe8eJOEWGhSO/kkTHGTKxvsGiitMrEWvqWboPvIrqCeXinKuXkYn2MHBqB4o7iGxzoXpCaPF+Yq3H0NNxHKEy/LUr0VNRsrG+IW9Fur+VWMsxRNmGlugnb+FmVG8BmYHOQWlvwDSItRwh1duC7PRhahnyl2wh3d9GpOFA7pglmbyFN8MVDItkTxPGSCpK5EKIPOULpvp04S6ZhSBO3TQh2XUWbbT6G4C/ZsW0rdzaA8XYA8Ujen0MLU2i4wyGlplRh5phwtj8RZRtfArJlpugF6/6BO7y+QiijLdyEZLdBVbOQxZvO4HNV4iWiKCn4oCFlowQ7zhF6Q2P4giVjalPR17ZkMiOZHNRtOpeXMWzcqI9tStxFeeqpVuGjp6MoqeiuIrrcBXXAaAlwxjp+Iie0InysTEsVi1fy8YbNlNdUTskgSgKIosXLKO0uIy33nttVE9KMhXn4JGthCO9Q9KLpcU1LJq/9qqNf4bxcebsKU6ePkpxUSkgYpFL6J5ODMPANKZH132GawdJkrCNsxr1ORKpBJZlIowxBEYQRHyeEAPhHs42HkPTsgSK8hkID49Bn113serZxnWbJzTGC8kM5mqMF1mWkaXJhx5GGw8iiNKQyty0h0BZFuEzu/HXrcLmLwIEJNWObPdgDxRjCxQDOQNEiw8QaztBNtqLr2YFisuPlhggE+nGU76AbLSXVE8T/llribYcJj3QieIOYQ+VEXnznynbZIAokuxpIhvtwVU8i55Db+CvWU66r410Xyv2UBmZgU7EMUxmMwPtmNrIngNBlHBeoNQ3VThCZZet2jteUn2tuUnMKLhL50xZX5ciCCKuktlEW45iGZdMoiwz992GO3HmT58a5LVIz6G3UFx+vJWLLqpndSGWZRGu34MA+OumPlTtcujpBLGWI8gOD56y+Ve17/HiCJVSddtXhn4v2/jk0M/+2pX4a1diGjrx1uP0HX2P0g1P4KtZhiBKWLpG176XCNfvIdnTOGbDwllQTfUd/w7IyU2Xrn986LPg3PVDP9v8hRcpfk4n17xhkUolOXXmOD193RTkF7F4wcia7QvnLQVGfjGFgvk8eO/jo8rbxhMRjp3czeIFNyAP3lgjlX+f4dohHOnH7XJz55b7h77XiU4Gx0pudXfGY3G9MNEpqqKouJzuwRbG5/eIRiOYpsV4tCp83pz6ytnGIzjsLgK+yav6jJVkKjlug1wURTxu75QIcmTj/fiqlmIPFOUUoaZZFUqUVYpWfQItGSFSvw9v+QJkhwfFHUD15GHz5qElo6T6WpDsLuyBolxIgmUh292DoQLnryx7qAxnQSWJjmJMI5enYfPmIVygmy9KMu6SOdiDpShOP6aeRbJ7ME0d2e7GmV+JeAUjzTJNMtHeXB8jINlyspZTjWRzIzu8ZEdJth4vmUg3+ijJ54Io4whdOZw1lU5x8vRRDhzey0C4/yIFtyULV7B25Qa8Ht+I+zrzKhFEEWuE9SFDS5Pub/utMyx6j76DI78Sd+ncUQ0LYEoNzAsxdY3+E1sJzLlhRG9RzqunTKnn7KPFwsim0RLh8wpSlkU23k863IEoq8h290c9yElxzX9T4egAz730c/Yd2s36NTeOalhcaFDkwlUunhCI4uWnGW6Xj5VLN0+oWNQMV4+unk5OnDrCmYZT9PZ1s3XnO7icbgRgdu28QQ/G1KPrOlo2izlNlWhnuHaQJAmXy43Dbh93NfdINDzucDmvN4iq2jlyfAcL567B77+ahkWCbHZ88fOSJBMKTs0Y7f4iEp1nSPe3AgIFS2+f0oTnS9FSUfR0DCMdI9p6BABBUpDsLgZOfoggiNjzykn3tZKJ9YFlIjv9mHqGZHcDsdYTpMNdOAqqsAx9UOLx/LtFT8WItR4jE+6i79j7+OtW5voYPCYLQBQRRJFEZz2irBJwrc61dZkiXkY2lQuDGjHHS0DxBIeUtqYSQRBQ3UGS3Q2TDpWwLBM9GRnV6yI7vUiq87JeK13XOXR0Hz9/7sc4HE4K84o4eeYoh48eYOXytaxfcxPSZd7hNn/BqMarqWfJRidQnOxjwJUWYQRBwFe1dFr6TvU00n3gVXw1y0c0LCSb86IaXNc7gijjKp6Fv3YF3fteovfoO2CaWKaBIErkLboFZ8HUex+vJte8YZFOpznTcIrT9Seoqay7zHYpdu7dxt4DO+kP948YsvIf//AvRqy8LQgCA5Fennvpn/H78hAQKCqsZP6clVN6LKNh6pnB4nNy7uKSlGGJO3oyjCirCIp90sWPjEwCLBNRdeZccJYJCNecJNtIZLMZ+gd6cTpcFOQVEo2GyWTSCEAmO4Iu+hSRzqRJZ6av/RmuHQRBwGF34PX4x21Y9A/0jtv4dDm9eFw+BiK9yIqK33d5xaGpJB6Pjvu6liRpygwLb9WSXGEoyyLRcXpK2rwcgqRg8xVg8xbgLp0LgKTY8FUuyXkknF4Uhwd/3SoykW4EUUJxBxFECdnhJX/xLQiSgmxzIhXVYg+VI9vdBGatQXZ6EVU7qjePips/hz1YjKjY8dUsR5RtyHY3efM3Iggiqd5m8hfdjGRzke5rI5NXgX0wDGsk9HQMa7TaKgIoTv80nK0csjNX7GuySWymlhl694yE6g5eMb8iFo+ye992IpEBPvXoF6mpquPQ0X38S/r/MLtmHovnL8PlGn21V3EFRn3PWbqWW0W+Rom3n6T/+DZS/W0IgkBg1hpCC25EkBS0ZISuvS+R6mlEsrkIzF5LYNZq9GSUSOMBUn2tZCPdOAa9Men+dvIX3TyUl5Pqb6PlvR+hxfpw5FdSsPQOVG8egiCQ7u+gY9evyMb68NesoHDF3UNjSvY207nr13jK5hM+sxtEiUDdSgKzb0BS7WSjvfSf3kGs5SimlsURKiF/yW3Yg2WYWoauvS/Rf2Ir0ebD1L/wd4iKjdC8jYTmb8Q0dBLtp+ja/zKWZRKcsz6nnjSIqWvE2o7Tf2IbWmIAR17FkFyrIAi0vPdjbP4iUt0NpMOd2HwFFK36BDZ/4aTnUJNBEAQcoTLKb/oMia76oeefZHNiDxTjLKjKFdi7jrnmDQvDNEilRnadXsi+Q7t4+pc/IJvNUlRYwvY9HzB31nws0+LoiUM8eO8TSKOs6DjtLubNXoGmZVBVGyAgy1fv1Oixbkw9g+T0Y6ajSHYfgqRgnZv8CyJGOorg8CMoYGTiOQUVwwBMBElBT/Qjqk5ExYFlZLH0DJZpIDtyrnczm0BUHAiyiplNAAKi6sTUs2R6ziDINtRAGZgGgmzLGRuWiSCp15TBkR8q4IY1N9LX34um5b5rgM6ujsHvbnpIZ1LTarjMMPVMZh7ksDvxef109XSMa7/O7vZxJ0PLkozfl0coUITPE7yqxZwGwv0kkqPHvI9EzrCYnPGjp2JoyQjZWN9gnQSTaPNh8pfehsD0eSxkmxNf1TLAGlq8EUQJW6A4l3Mh5GLxnYW1uVXDC4qSOkJlo8Y9u4pqh372lM7DU3o+H0bOrxr62V0yh2y8H8swMDKpXFiU4kBSLy/NbmoZrFE9YQKybfoqC0uqYwJBgcMxtPRlqwBLl4SZjUQqnaS3rxufN0BNVR0+r5/ysir8viCpdBL9ClWGc0m1oxgWpoGRvfJc46Mg0XmG1g/+DdWTj7dqCZahnT9flknLuz9AT0Tw164gmxiga+9vBiew5YTr96AlBlA9+XTvz3kGstEeBs7sHsrLSXScxlVYg91fRN+JrSCIFK+6D9nhQbI78VYupm3rz4g0HbrIsNBi/bRvf5bCFffgLptPqq+FnsNvI9u9+OtWYlkGkmzDPZhA3HfsfQTZRtGKe5FsTlzFdSQ6z6D0NuOrWYZkcw3VEhEEEcUdxFVYQ8/ht0l4Cy4yLGJtx+na9xKq04+3fCGxthN073uFwpX34AiW0n/yQyxDI7TgJrxVS+g9/BaCKFG26VNXvN+mG1FWcBZU4Syo+kjHMV1c84aFaRgkx2BYHD52AJfTw+MPPkht9WzaO1u59/aHqKuZw/OvPJMzFEaRCnU4PSxZuJ6+/i4UWSYYKBzVCJkOjGwKM5tEVJ0YmQRaPKeQYqRj2PLqULyFaNGOXIl2m4t010ls+XVkeuqx5VWjRTsxswmMTBJXxTK0SCfZaDu2UA2CpJIdaMbU0qiBcmRZRU8O5DTbHV4sUycbaUN2BMBXQqa3AcVbQDbSgeorQXIFmfZqgePAbndgtzto72glFo+yZFBq8/DRA2BZlBSNLeFpvCQScZLJkaUeZ/j44XK5yQvlc6r++Lj2a+9oxRhDgr8oisybtZziggrcLj+z65bxKV8+QX+umOhN6+9HEAScDs9ED2FM9A30kUiMz7CQJYXiSUo7C6KEKCvE205iCxQhyg7MCVQ7n1jfw1crc0VRhVF/n0pkh4fAnLVoiTCCICI73MiOkXMCzmHp2mVDkS4XGz9ZpirEyjL0yxhHXDHPBMDt8lBSXM7JM69z4PBelixcxrETh+nv72Hl0jU4HJc3ykXFNur3allmrp7JNUjfsQ+wLIv8xVtwFc86HzojyWSjPXTteZGFn/vfeMrmko31o8UH6Nr7MlW3fQVBlHDkVeApX0gm3Im7ZA6y3Y2WCA8VW3TmVxKafxP2QDGmodF3/APyFmzK5R85fQTnbqD/xLYR51CS6sBXtZS8hZtJdJ6m7cNfkOg6g79uJYorQGD2WgRZRRBEMpEu0v1t6OkYisuHr2oJqd5mkj0N5C24CcXlH2pXEEXsgSICs9cRbT56UZ+GliHaeAAjHafoxs+g+vKx+Qtp//AZEh1nBuu5WNiDZeQt3IzNV4iejDJwavtgcvNHa1h83LnmDQvDNEilr2xYRCJhSovLWDBvCfmhAoK+IC6Xm+qqOm7bfDf/4x/+jKce+TxO5/CVnVQqzr6D79HaXk9pcTV11Yvp6mlhzYpbp+OQRseyAAEzk0Dx5GFZJtYF+uGWqeeSCN15ZHpOk+1vwV40h3TXSUSbK/dgHNRWl1Q3ijsPBCnn0RhoRbK5kF0hBEEYKpAiyjZExY7kCiLIaq7t/iayA23YgpVcS0YF5ELeTpw+ystv/JpkMklLWxO6oVPfcJpbb7pr2vqNxiLE4tFpa3+GawuvxzehyXNrezO6fvlVU8itxoWCRYSCRQCoqg2/93zybXnp6GGfU0lffw/xcRoWqqJQXVl75Q0vg6jaUWWVwNx1KE5/ztCQ5DGraV3PiJKC3V+E3V805n0sK6d7P3qj0xjaIcpMyXvAsris32MMhpzb5Wbjups523Cav/s/f0V+XiGyrLB6xXo2rtuMeqWijWOsmH6tkexpxBEoweYvzBl6F9wmmXAnhpbBUzYvF7Ln9OLMryRcvwfLMnJheA4fkmxDdQdRnOeT8c/VE7EHS1FcfkRZwVVYQ8euX2NqYzOyZIcHV/EsRFlBsrmQVAeGlvPu66kY/Se2EW0+gqlnSHSewZFXMWodk7FiZpNkY33IDh82fxGCKOLIq8A0dLR4/1BxUXfxLBSnH1GSsfkK0DPJYYVHdV3jbONRdu9/m96BThRFpbZyIXNnLefEmX0cPrZ9WP8b1tzN8sWbiCei7Dn4DvUNRwCBxfPXsmLpZuy2XC0WyzJpaa/nw10v093TTihYyAN3fQmnc+ILRrlw8C6MyyzEKIqNgvzpWWQdC9e+YWGMLRTK4XCQTqfRBm+GYCif1vZmUqkkDoeTgYG+UZMqk8kYHV1NLJi7iubW06TScfoGuqb0OC6HZHOhRTvIhluw+csQVQeC4kDK+eUx01H0aDdGKoLk8KH4ikk070V2BRElFcVXghZtR7L7EBV77iVt9yAqDsxsClPPYGaT6KkoqpZGi/WgJ/qQ7F5UfxkIEtlwG4o7D9mdR7L9MJLDiyBPvKLvdKEoKiVFZVSV19Ld20lxYSmCILBgzmJqq2dPW7+RaJhobMawuJ6YzJXr8wYoKR7/g7mx+SzpTPqqV4+eCLF4lN7e7nGH+Kk2G9UVkzMsBEEEScTSdSTFhiirSDbHtbaOMYyBcDeyrA7VGenr7+TAka0sXbSRUKBw2voVJAnhMidnshO1y/Y9Rd+JIMmXjW23rhDGBLkK2sZg7ZUN627m5o234bA7yc8rJBAIXvGeswxt1MgFQRDG5DX5KBAVG6aeHdHjI9vdWLqGqWVz95BpYmTTiIp9UGltUHlIYLjy2uC5yLWdO/9GNo0kq2NWaBNE8QLFKCH3z8pdk90HXiPWejznNfAX0rX3N4O1WC78DsZ/gQmSgiirGOkElqkjiGpOFEAAQVaG2hQU9byHUhCGffe6oXH05G5eev1HzKpZzLqVt2OYOVEGnzfIwrmrKS2q5vTZgzS2nGTBnFWUFFVTmF+GJCm0tJ/BMi3WrrwNw9B5+4NfEgwUMrt2CaIo0dXTxjPP/x8WL7iBxQvW47S7Jh2y3dndxLMvfJtwZHShgeKiKn73c385qX4mw7gMC8uySCTi7D6wnXg8Rm31bObNXjjsZo5EwwwM9E3JAFvbm0mmrhyCUlVRy669H9Lb10NJURlLFiznly8+TUdnG81tjQT9IWR55NUw0zIRgLxgCc2tp7Gsq7tyoXgKEG1uLENDVB1gMSitNphULUq4a3Ml3yWbG0QZ76ybEGQVRBlnySLM/FoEUUFUnajB83J5gqxiC1aieApzRoes4ixdNNiXCwQRZ+ni3O+KY+jmsxfOQZAm7l4XhPE/LsYSmy5JEnmhAjatv4VUOklZSQUCArKsTGtezEC4n0g0PG3tz3Bt4Xa5KCwoRlHUocWKsZBIxmlqOUthftGo8tbXCl3dHfT194zrWSeKIkX5xXhGkfMcD5ZpEms5guoOIIgS/Sd34CyoRVSuvQWNcxw7tQe/N48Fc1cDkNUydPe2kZ3m/CtRki/rlbAmUItkrJi6xuQzLHKemstVEzay6TH109PbRXdvJ5s33sqyxSvHpeRoXk4BTRARr+Tx+Ijw1yynfccv8TYdRJm7HtMw0GJ92EOl2ALFuEpm077955Ssf5xUXysDp3cSmLXmssbohYTr9xCan0sE7zv2Po78yvFVYR7hfrVMg/RAO4Io4R1MEs9G+4ZNDBSnl0ykBz0VQ3b6sEzjiuF3kurEWVhDb9dbhOv34q1czMCpHUiKDUewbMzPj3Q6xdvvP0tl+Wxu2/wYTocHyzIxTAOb6sDnDVJcWEUqnSAS7aeqYh511YuG2q+rWkhN5XwcdheWZbFjz2t0dDVSW7UAUZT4cNfLlBbXcsOqO3HYXVPyXIvFw7R2nGUg3D3qNlMhBT4ZxjUTSyTj/K9v/lfe+/AtTMOguKiMTz/+Re65/cGLtnvt7d/wLz/6xykZYDabGVNowdqVG1gwdzEF+Tn38k3rt9DQVM/7299ClVW+8Ol/N6hNPxyH3Y3L5eOFV/+V/nA3yVScpQs3TMn4x0JO7jCnAjDahSe7gqP+Lij23OpErgEE5Xz8oCBKiKoLUT1/UZ/r6xySzT00ucgOtGDLq0F2hSa1VCWK0rilezVtbC9HURQpKSrFshgyJk6eOYbb5aG0uHzcYx0LPb2d9PWPfiPPcO0xmamQKErkBfMpLiyhubVxXPseP3mYFUtWX/OGRVtHC70D46tPIMsKs2rnTcmLK9p0kN4j7xBrPY6oqKhOP8JVOmemaXC28Sg7972JgEAmm2bR/LWsXLqZjq4mPtj+IpFoP26XlxVLN1NaVM3h4zt4/8MXURSVvQffY9O6e7DZHKTTSV57+2fohobL6eG+2z/HL3/zHR67/6u8+d4zyLLCulV38Ma7P+PmjQ/z1vvPEo70YLM5WbZoI0WFFZyuP0h+qIS6msWcOXuY7t5WZtcuJS+UU4oSVcdlJuUWWmr6vKmjycOOF8nmvGwhQD0VHdNNGwzkIUkyf/PNv+Tb3/t7JEki4A9x4/ot3LnlPgoLRlfX0lKR0T0Wkow8zTlNEyU4dyNaMkb7jl/R8Nq3EUSZguV3Ubr+MUTFTt39f0zLOz+ge/+riKoT/6zVFK95AHMMBq8gKbgK6+jY+SsSnfWoniCVt3wRxZ2r5dX89r8ycGYXsdbjCECypxlf9dKLCsGN3K5MoG41bdt+weF//QPsgWIUdzDnVbkAX81yPKVzOfLDP0RS7JTd+CkKltyGlozS9MZ3iDYdItnTiKQ6iTTsJ2/hZopX309g9lqMTJKWd3+Yi8bwF1K08r4xF1m0LItItJe2zgbuveNz+Lwj14HJpVvlRBxEQbjo2edynZ9LZbNporEBfN7Q0NznyPGdzJm1jH/6/p9iYbFo/jpu3vAgyiQM2Ew2NSyc61pjXIZFOp3m9XdeJhIdAHKeiXe3vjHMsIjForS0NU3dKMdAKJhPKJg/NHl2u7187qnf4dEHPokoiPh8gaGK3JficfvYvOEB2joaSCSjlBZXkx8quZrDn5wle4V9x9L2uW1UXzEggChNakySJI17YpVKJy8fR0xOd38g3D/s7wcO7aGmata0GBbxeIyuns4xiQjM8PGhsKCY2urZ4zYsdu3bzmMPfmZaVcqmgoamejq72se1j6qoLF8yNZV33aXzKNv4JPZQGaKsDq5oy1fNW5FKJejsauYLn/wTuntb2brjZeqqF5EXLOK2zY9jWRb7Dr3P6bOHqK1ayOL562huPUUoWMzKpTfhcLjp6+8gGu/n5g0PUVZSyy9+/Y90djeTSEVJpRO0dzWiyArpdIJUOoXH42fLjY9gWRan6g9w9MQu5tQtxQJa2s5QW72I1o56FNmGz3t+8UhxeEcP07Es9MTAtJ0nLRWZEg++IIgoTh+irI6YJJ2N9Q2qEVqjvtNO1R/n6Wd/QMgf4s4v3IvD6ULXNU6fOcGLr/4Sh8PJA3c/Ouq9N9THCIiSgnLJAt61gmxzUrTibvIW3JjzIAkg2z1DIUje0vnMfvA/YmgZBEFCtruQ7G4sh0HZxqcQRDFnQBTVIakO3CWzc6qRdjc1d/0+giBgGTqmnkGQbShO31BBuuI1D1Kw7K6hUClBlBEHz6+nbB6LvvAtFHduUm4PllB165cRRAlBEPHPWoO7bB6mriFKck5kQBCQLlC+k2wu6j7xDfRMMhd94Mx5Q2W7i4qbP4+pn1NEE3LG3+C+itNP4bI7Cc3bgGUYuRxRh2dIyGDu43+FpNqHjNnQ3A34qpYi23PGo2WZxBM5Q3Mq5ntvf/Ar/L58qsrnDon/dPe2UVZSy5OPfJ1YbIDX3/k5HpefG1bfMeF+0pnUuGslXW3GZVgIooDT6RwyLERRvGZenpeuoAmCgMftHbFuxaVksmn6+rtyD3jLQtOztLTXY1kmFWWzUaZRceNaQ5iiGFNJksetrKXrGrFYlIB/9If73gM7+eHT36XoksTalrYmnnjw0xMa65Xo6ukc9wRshuuf4sJS6mrm8M4Hr49rvz0HdpJMJXA6Ll/s66MknojR2HyWcGR8E1JVVVm1fN2UjEFS7SguP6orQKz1GIaeJVC7atrUmC5FEHMJ9D5vCF3P4nC46BvoIhobYNvOlzBMg67uFirKZyOKAna7C5vNgdPhumB1UyAUKCQULMTvy8Pl8pLOJCkvqaO+8QiKrCIKIs1tZygtqqK/v5u3PngWXdcIR3pxOt1IkkJhXhmt7fXUNxxBFCTyQsXIF7x3BFlFsrtzce8jTIyz0b4rFtmbKFpsYNRV/nEhCKjePKRBmfNLMbU02Vgvkq1ixACebDbDsZOHae1o5ve/8scsWbgid39ZcLbuFPUNp+jp6SKdTo86L0n3t41uWMg2bN6rV5xyXAxOxqXRpKglCdUzXAJakGRE5/k50LkCdBd6jtRBz8RoKC4/yihRUaJiw+Y7n1skSjLiBcpOkmJDUi5/TgVBQHEFUFwXj0MQpctWkxeucE5s3ovPx/BtBWyqA9OySKUSo3osxsL23a9y/NRe7rvz8/j9uQVuy7KQJIlNN9xHUX4FPk+QuupF1DccnpRhkRkhAf1aY1xPIY/Lwze++qd89wffJBwdYNmilXzy0S9cdp/5cxdRVT7xKoLhSD8f7vrgitvpupaTYxXFYS9zy7IwTXPEzwD6B7r5/tP/nbKSGm684X4sy+Ldbb8m4M+nr7+L1ctvmfD4f1tRFfXKCh2XYFkW3b2dlzUsCvOLeezBT7Nh7U0X/f3t918bCoObSizLormtgaaWs1Pe9gzTy2Snp16Pj+qKWnxe/7jyaxKJGHv2b+e2m+9BukZVjuobTtPUcnbc+RW11bMpyJu6+6zv2AcE522g78Q29GQEX9VSROHq1M4xTYPe/g4MwyCTTROLhVFkhYamY/h9+Wxcdw/vb3+ReCIytIhumgb6YPKwOJjcKkkKgiAOhUtYWFRXzOOD7b9hwdzVZLIpDh7ZyrrVd1DfeARVsXPfHZ9j36H3OXlmPwBlJbX0D3Sxc98bzKlbRnlp3UXnQBAE7P6iXBJvdnjRRtPIkhpox5lXMaXnyMimycb7mIocC8jVApEcbrRkeMTPz6kGjYQsK/g8fvr6enj97ZewTAubzUZXTwdvvPsKLW1N3HvXw7jdI4czWZZForMeRsnlk2wOHPlTe/5muHYRBIGAPx+X08OREzspLCjj0rfGFcUALIt9B99j5943ueOWJ6ksmz30XAAIBYpIDeUI59oSJxnu+bHzWCiKyh233Mttm+/CYtBivEwcvc1m4+H7nuSR+z854QEeOXaAfQf3kM5cvgLu//rmX1BcWMJjD34G5yVa1oeP7uf/fO/v+Os//xZ+33DrXBRFKsvmsHHdvZw5e4iaqvlUls2mpKiaSGzkJHRxAqFCpmmSuVzy2EeEYejoho4syUPHpRsahq6jKOrQS3M8uJxuXCNI+14Oy7I423iGOXXzR91mVu1c6mrmIIpiLsnKMNANg1XL1+GwT31hMdM0aWw+S9M4w2FmuP4RBIHK8mpm181j977hkoOX4/mXn+GWTXcgKuO/d6YbyzI5fOwAp+pPjGs/WZZZv+amKU4MtGh9/yeUbfokfcfeY6omsGNBEAQMQ+dff/rfyGRTLFu4kZKiaqLRfvYdfp+2zrOYhkFt9aJBJ4pAZflcdux+jcNHt3PHlqdwOtxDXgkg97MoUVE6mx/94m946N7fIRLrY9uul6mumEdHZyPb97zGT3/5D4iCQEFeTnlMVe243D4kScbl9OIYIXHWHipFUuwjGhaWaZBoOznlhkWqt2X0it8TwJlfjeLwkaZ1xM+jTQfJW7iZkZYFBEFg5bK1fPXL3+BXv/k5/+kv/z2ZbAaf18/8OQv5D1//C1YtW3vZytrx9lMjKmgJooTNmz9s1XyGjy+CIOCwu9m49l7efPcXiILInFnLsCyLbDZNWUkt6hUK6R08uo13P3yezevvp7x0FrquYZgG6qBHaO3K23j17X+jsKCMWCzMsVN72LTu3kmNO5NOYn6cPBZDCSxjfLE47E4cdifyJNyziqLidDqvaFgYhoFhmoz0YrLZHbS0NWGMImcnSwp+Xz6iIJBKJ+jt68A0TUzLGFVVQVFUJGl8L1jDNMZd5fZqcPTkbt549xdsXHsPSxduQFVt7Nr7Jm+89wyffvQbVJbPHb9h4XLjco2cLD8almVx6sxx7txy32W3yWpZNC3LQLif/Yd2s3vfdiLRME8+/DnWrd44rj6vRHtnCydOHSWdvvz1N8O1x1RMUeuqZ7NkwXL27t85rof5tp3v0dnVQXlZ5ZU3vsp093Zx9MRB+gdGlyscCYfdyR23TO6leCkl6x4hE+nGHiolNH8Tonx1vBUAoiBSWlzDJx/5fy76+8L5a1k4f+2I+yxfvInlizdd9LeH7/vdoZ8fvf+rQz//9X95BoD8vBL+7I++D0BN1QL+8Hf/7qL9TTPnMUkkIoQCRRQXVox4DlxFdUg2J9oI+RSmoRNp3E/+kqmtvRRvPX7ZatnjxVUyG5s3n9gotbwHTu7AutNEGOHdei68+e7bHuDu2x4Yd9+RpgMY6diIn0l2F96qJdfcIsAM04OpaxiZBFgmG1beisPu5P3tL/LSGz/CbnOwZO4a8jY/gmD3INkcKLKK3eYcFt697+B7tLad4ae//Ieha6ekqJovffq/4HJ62bzhARLJGN/65/+ATXVww+o7hz0/xks6k7psoclrgWmtY+FwOLHZJlfhUJIkHA4XjCBfaxgG6UwKTcuSyWZIp1NEomGyF3gFLMuivuHUoDE08kNDVW2YpsGrbz9NYUEZZ5uO4XS4aWg8RlHhyBMDRVHGrXpkGAaJxMgPtqlG1zWyWhpZVslk0thUWy4kzDIxDB3TNFEVG6pqZ/H8dbR1nL1oxf+G1Xdytuk4kjixS8Tt8uB2jU9hw7Is9h/aNRS2NhIdXW28/s7LHD1+EEmSMAyD9Wtv5N47HpqUATvyeExOnj7OkWMHprTdGa4fvF4/8+csoqS4jNb25jHvp+s6T//qh/zR1/7kmir6Zpom+w/t4dCR/ePaTxAEli1eRWV59ZSOJ9XXSsfO58hfcit6KoarsBaLq1MDRFFsuJxXzsGbKJZloaeiSDbXkHymZVlgmRcpPPUNdLNjz+v0h7tYu+I2/L6RY9LdxbNHVS2yDJ1w/R5MQ5uyWgyWZRFu2Ic1hdWoZbsLV9lcwo370JPDlaxircdJ97fizK+asj4hdyx9xz4YlLQdaVwefNXLp7TPGa5doi2HOfubfyDV00zppqfYuOVLbBz0JGjJKD0HX+PE976GqNio3PIlliy6hSUL1w9r5/NP/efL9qMoNh64+0s8cPeXpmzsmczHzGMxXpx2J/YpMCwuDW06RzQW4b0P3+TAoT3sP7Qbu81OY3P9RValrmscP32UFUtWY7ONnNDl84Z45BO/h2kZSKKMYRh0djcTjvRQWT53xH1cTjfKKCpTo5HVsvT09VyV4lkdXU3sP/wBtVUL2LXvLRbOW4uuZ0ilE/T0tZPJpikvqWPZoo34fcOTviZLMBAi4B9fMpRlWZw8c4z+gV7yQgUjbtPc2sjOPVtZMGcxa1dt4Mjxg5imiaZlEQdzbKaKaCzC4WP7aZzJr/itZs6s+Sycv5S2jpZx5SQ8//IveOrhz1FWeu3Ebff197Bjz1Yams+Maz9Zkrn3EvW/qaD/1HZ8VUswtQyxtuOE5q7P1eeZZkRRYnbdUmbXLZ2+TiyTjl3PUbD0duz+YizLwkjHyUS7cRWeLzCYHyrm3ts/c8Xm7MFS7KFSEp1nhheTs0ySPc3Emo/iq146JcM3MgnCZ/cO1rGYOoKz19F76M0RDQvT0Ojc+Wuq7/79yxbTGy9aMkzf0XdHls4VROz+InxVS6asvxmubfzVy1nyle9w8pm/GPaZ4vRSsu4RXEV1dOz69dUf3BX4rfVYeD1eKsqqqBpMfJwMkiiPalg4nS5qq2bT3dOFemQfhmmQyWQQpfMPXZuqcs9tD/DgvY/jdIwe8y8IApKQOx2SJFFaXE1p8eirc26XB4fdMZT9PxYy6TTNLQ2kUkmc48w/GC+5HAQLw8jlSTS3nsTrySVFlxbXUF5Sx8FjH9LR1TRthkUomDeu8wOQSqV5671XeWwUhad1qzaycO4Sjp44xM692zhdf4LiolI+9AVYvGA5+aMYJOPFMA0OHT3AB9vfueYTpWYYmaky3SvKqlm+eBU7dm8lHBkudTwa0ViEHzz9Xf7oa38yac/tVKBpWXbt+5Aduz8Yt3xoaXE5m26YehELmyePbLwfPZ3IFXmbpMz1R4GWjGCZJorTC4JAqrcVR6gULREmNHcjiiuIZZnoqRiRs/uINh+m5IZHURzenAphMpyT50RAdnoxdQ09FQPLRHZ6ke3u3OeiSGDWWiL1+0YMhzIyCTp3P4+nfMEFlZAnTt+xD8hGupnqvBdf9VKchTUke5qG529YJh27n6fkhkexB6dG8t0yDbr2vEg63MlIxyLbXYQW3jS64tJ1jqlnc/dYMoplmUiqA5s3H8nmxNAyaLE+9HT8/Gf+QkQ5V6Qy3nEG1RNEi/dj6jqy3YktUDLkgTMNHS3en7sHDB1JdaB683LVwC0LPRVDi/dh6llE1YHNk5erySII6OkEejKCqNjQEmFMPYvqDqL6Csb0DDC0DFq8Hz0Vw7JMZLsL1ZOPpNqxLBMtPoCWCGOZOpLNjc1XMFj9/fp6vlxKOpv67fRY3Lj+VmbXzcfpdFFcOLmHgyzLeD1+VNU2rA6FTbWxaP5SFs1fSiaTJj9UwH13PTKqITKVSJKE3x9EUdSLQq8uh4VFODpAfeNpFs1fOq3js6kOJEmit7+TkqIqzjYdQxAEND1LtLmfnt52HA73tBgVkIvHLsgvwuV0Ex9H+JemZ3nlzee5546HRk3+9ni8rF21gbWrNpBKJ6lvOMWe/TvJCxZMiWFhWRa9fT1s3fEOJ88cm3R7M1zfyLLM6uU3sGP3B7yz9Y0xT8oNw+CFV59l4w2b2bh280daDdU0Tc42nuG1t39DU0vDuPYVBZEnHv4cLtfUL4YE520g0nAAPRmmaOU9CB9xxdiJEG08RLL7LIUr7gHg7Mv/m7mP/jkDp3fQ+v5PmfvEX+DIqyDZ3UjPoTfJRLpRPSH8davJRnvp2vMiruI6RNWJr3Ixye4GYq3HAAtnYS2hBTdiG5QSDc1dT/uHv0BLhLl0kmxqGXqPvkvRqvvwVS2dlGyvlojQses59FFyEiaDpDooWHoHsZajpPvbhn2eiXTT/Pa/UnPP18dX/XkkBpWgOnb8KmesXYogYA+UULB04vKf1zKmniXWeozOPS/mEvF1DVdRLcVrHsRTPp/MQAede14k1nw4V2tCUSm/+fP4q5cjyAqHv/dVCpffTaLjFFoyimRzUH3H1/BWLMA0dJJduXOb7GnE0LI4Q2UUrXkAf81ytPgAPYfeoP/UdoxMEtnupnDF3QRnr0OyOYm1HKH9w2dwFdcRbz9JNtZH/qJbKNv0SbhC+KihZYg07KN7/6uk+9uxDB1P+XyK1z6Eq7CGzEAnHbufJ9ZyFFPLoLgDlG18Ck/5gmmRZL6aZDLJa36xc1rOcEF+IQX5hVfecAy4XG5uWL2JYCB02cn44gXLcDpdV7XabXFhKU6Hc8yGBcBAuI+9B3ayYO7iaZ1o2O1OHHYXPX1tLJy7hvaOBoL+AhTVjllkUFU+F5vNgcftpz/cTSw2QJ+9i4FwN35/PtFoH4lklJ6+dtxuPwF//rgt/bKSCooKSzhz9uSY9zFNk2Mnj/DB9ne4/ea7r9inw+5k4bylLJy3dFxjuxypdJKtO97htbdevOZv4BlGZyrXWWurZ7Nm5XoOHt1HX//Yk54TiRjf/t7fU1ZcQW31rCkc0dixLIv+gV5efesFtu18b9z7l5dVcdetn2DqfEDnx5XoOENg9lok1UHfsfdw5FeBKFxXq4q+6mX0HnsXLRkh2nyY4Kw1CLJK/pLbGTi9E8gVX3OXzCZ/yRaS3U2UbXwKgN6+VmSnh5J1DyM7vLkJViJMwdI7cBZU0fzOD0h1Nw4ZFq7CWnw1y0n1tmBqw/MFstEemt/6HrMe+hPsgYnJAuvpOJ27f0208eDwkKspIm/BjfQcep1stGdYTQvL0OjY/Ws85QsoWHr7xD0JlkV6oIOmN75LovvsiPU/JNVJwbI7cOZfeyILU0Em0kXX3pcQBJG5T/wlisOHkUkgKjkPquIOUrTqE5Tf9BkEQeD0c3/NwMntuItqc3UxLIt4+0lmP/ynyDYnJ5/9Szp2/QpvxQL0ZITO3S+gpaLMefTPUNwhjHQCUVawLIuBUzuINOyn9IZH8VUtpX3HL+k59Cb2QAmesnkAxLvO4CyqYfbDf4qkOnMJ1WMIgUv1NNG9/xVUTx7Vd/0+kurAzKSQ7E4sy6Jzzwtkwl3U3P3vcQSLOfvKP9L+4S+o+8QfXVRn43rDskwymfQ1X8fiml8eCgXy+OyTX+F//tk3eeqRz4+63Y3rt7Bq2TpsV7FgX2V59biVjwYG+vlw53vjmpxMBLvNSWlxLfmhEgrySqmpWkBl+RyqyuegaVkOHd3O2cajRGP9tLXXYwHhSB9tnQ0kk7FcArvTQ2d3M+1djUxkmlZVXjOhStjJZIJ/+8W/0NE5fDVruslk0uw9sJNfvfg0XT2dV73/GaaOqZyayrLMulWbWLFkDbI89vUY0zQ5fvIw3/7Xv6Oto2UKRzQ2LMsiGovw2tu/4dcv/YJkMnHlnS5AUVSefPiz+H3+KZ/sa/F+wvW7iTUfIdZ6jFjL0WmbyE4nssONzZtPuq+V8Omd+GpXjJJALQAClnWB3KkoIdk9yI5cErmpZXPKi4qKqNiwTP1iVSZBoHj1/dh8BYx0hZt6lv5T22l55wek+trGHfKmJcJ0H3id5nd/OOgVmR5kh4fSGx7P1awY4brSkzHOvvxNug++TnYUyffLYRo6ia6zNL35z/QefQdzpKRtQcRTNo/itQ9P5BCuC7LRPjLhLvIWbsbuK0RS7aie0JAnSJQVLFMn0XGaWNtxRFnGSMcx9fPXXOGyu1A9QUTVgbdyMZmBDgD0VIxEx2nyl9yKPVCCpNhQPUFkhwfL0El0n0VLhtHiAwyc2Y1l6KR7W9Di58NJRVGmYMltKK7A0NjG8pxJ97dhZNME523E5gkh25yo3hCS6sDSs0SbjyCIAsnuswyc2YNscxFtPjxiYcbrCU3X0KdQ/nm6uL59QuOgo7ONgvyiKfVo1FTNGlNl7wsxTIMzDad4671XefDex6atcrksK8ydtYy5s5YBkJ93vlJ1afHFBQsL88tZNP/iarprVtzKmhWTky4sLSmnsrwaRVHRtLHf0IZpcOzkEX7yzPf40qe/dtmCeVNJOpPmwOE9/Pjn32Pfwd1Xpc8Zrh9qq2dz6+a7OH32JA1NY09+zmpZ3tn6Bj5vgE8//qUpV1YajXNGxetvv8TTv/whnd0d425jxZLV3HXrJ4bJLE4F2VgfppYh3nYCQVHxVi6+qnKzU0lw7ga69r0EgojqDmGZxmB4Rz+JjjO52HNPrup0JtxNrOXYBTkE54/X5i9EbD9JrPUE6XAXiiswrKKyr2oZeQtvpm3bz0b0WuipGO07nsXIJilafT+uoloUh3fU0CjLsjAyCZLdjfSf/JC2rT8bDFGa3poigdlrKFp1H83v/OCiyebgqEj3t1P/wt+S7Gkib8FNOPMrkZ2+y14fpqGRjfYQaztB587n6Du+NbcKPgL2QDEVN38Bu39qoiuuRSzTwDL1IQ/FRZ9ZJuH6vfSf2IZlGoiyQrzjDM7Cai787hW3H0HI5WwKojTkxbcsE9PQkEZq29SxDI1UTxM9h94cCj+y51eguM+/zyWHB0FSxn3PW4YOloU4gtCDaWhYpkGs5RhaIjoUXnnu+XI9k7kOErfht8SwME2Tnzzzr/zO5/7gIkPANA3i8ciI+yiKLSdzexmqKmoozC/mdP0JDGPkap4j0dXTwQuvPENt9SxWLF3zkcZeTycup5v5cxZRVFBMS1vTuPZNphI8/9IzFOQVcd+dDxMMjE9hajxYlkUimWDnnq387Fc/nFC4yAzXHlM9LRJFkfVrb+Lo8UP09nUTiw9XtRmNZDLB8y8/Qyab5omHPsucunnDcsamEsM06Ont5vW3f8PTv/whjc31424jP1TA5z/5e/h9wWmZ7LtLZoN1F3omCeNcWb/WcJfOYeD0DgKz1uRWTQ2NZHcDzoJqsvEBMpEebP5iHPkV2PyFJDrPIDu92H2FWKXnVyBt3nzcZfOItRwl1dOIr3opjryLvb6CKFK26SmizYeJNOwfMcRHT0Xp2PkrYq3HyFt0C57SOTnDxu5CEGUs08TUMxiZJNlYH8nuBvpPbCXSePCiAnyi6sBbvpBIw74RC8tNBkGUKF3/OOmBDjp3PY+RTV6yhZXLt3jzXxg4uZ3gvA24S2ajenLJwaJiA0HAMgxMLYWWiJAZ6CDSfIi+Yx/kjKNRQkZkh4fS9Y8PFuObHEY2jZFNYRlZTD03oTYNDUvXMI0spqFj6dpFf9eSYeJtoxeoTPe10nPkHez+E4iyjCApiJKSm4TL536WESUFUR78u6Qgyiqywz2kqCU7PMhOH/HW43hK5yAqdgwtjSDkxAB6j76DAFTc8kVkh4f63/z98Inr4L1/6RNAUu3Y/IVEm4/grVycC0fSMoCAqNqw+Yvw162hbNNTuAprMA0dM5uakiR5xR1AkGQSHadxFdYgSgqGlkGUZCTViSNYirdiIcVrH8LmLchd69n0qHLN1wuZTApziu/D6eC3wrDIZjO89taLfPbJr1xkWGSyafYefBfTMslm05imiaLYMAyNyvI5zJ+z6rLtupxuFsxdzIHDe4hEw2Mej2maHD91hB8+/V1kWWHBvMWoyvVtSY/G4gXLqKuZQ2t787jd8v3hPr7/038inUlz55Z7qSirnvIJjq7rtLY18d6Hb/HCK89y7OThKW1/ho8XAV+Qu267n/qm0+zY/QGaNna3dCIZ56XXf01PbxcP3vsEK5asIS80cs2CiWJZFplsmuOnjvLaW7/hlTd+TXdv17jbURWV++9+jGWLV44r9Gu8JHua0FOxwVVFYcqkUq82oqRQecsXL/pb0crhxQTt/iIqb744pNddOuf8L4KAt3wB3vIFl+3PmV9J5S1f5PSv/yepnpEXbUw9S7TpELHWY9i8BTjyK1DdQQRZxTJ0jEwCLREh1deSCze6ZBIuiBL5i2+hbMOTHPj2FzEyl078J4/i8lN5yxcxsim6972CqQ/PVzT1XKJupPEAqjuII688ZyTZnAiiOKSilQl3kuprHdVDcQ7J5qR47UOUbfrklIgFhOv3EGnYh5aMYGq5CayppTG0NGb2/H9NbfDv536+jIxvpGE/0eYjiIodSbUhKjYkxY54wT9JsV3wee5vNm8epesfH5pA2/yF+GtXEq7fg2Voue1tTryVi7GHSrEHikl2NdB7+G0EWUWLD6CMkoNw6dtbcfoJzdtE75F3aP/wGSTVgaja8ZQvwF08K5fAHeule/+r2HwFWKaO4g4RqFuF6pncQqGzoApP2XwiZ/ehJyMIsori8OKrWYY9UEL+klvpPfIuXXt+g+zwYBoa9mAJwTk3IIkS/ad2kO5vJ9XThJFN0bX/FRyhcrwVC8kmBog2HCTacphkd8OQt8ddMgdHqGxS454smetAEQquY8Oio6uN5tZGykoqKC0u53T9iQtimC+u6plMJUmlhz8UBUFEtTlIJKM0NJ+gpnI+qmKjJ9pLR1fTFQ0LgBtWb+KVN18Yl2EBubCbbbveI51N8/C9T7Jq+TqCgbHFF15PlJVWsmThCg4c3stAePyxst09nfzw6e/Q0trIrZvvYvGC5QT8k1tBtSwL0zRobm3iwOE9fLjrfT748C0isZG9VzPMcCHz5yzi4XufpKeni1P1x8eV4J9Op9i28z2aWxu55cY7WLdyI3NnLyQYCE5Kt9+yLLLZLPWNp9izfwfvbXuTPft3kB1HCOI5BEFg0w238NB9T1xWonsqSPe345+1Gru/KJe0OYW1Cz7u5C3cTCbSRePr/0QmPHo+mGXopAfaSQ+0j71xQSQ4dwNVW76MI78K2embFsMCwJFXTvUdv4coyXTte3n0fiyTbKyXbGzi+YmKO0jRyvuouu13pkxeduDUdtq2/Wxk1alJYBkahqGNWi18JGyBYgqX3z1kWCgOL3kLb0Z2eEi0n8KMD+DIr0CQVURJIX/RFgZsO8hEu1E9eRStvBdBlJBsufu+eO1D2APFIAgICHhK5w7lD0mqg9C8TUiqg1jrcbTEQE6KdjDcyFVUhyDKhOv3kA53IooS9kAJwuD+Nn8RBUtuH8ovGg+qO0TB0tsJe0IkOuuxTH1QljnXtr92JaJiJ9JwgPRAO6JiQ7bPGXrGZmO9ZKPd+GqWIwgi6YGOXLggYOkamUgXAsJQ+FQm3IUjNP580akm57GYMSymjfqG07z8xq/ZctOdlBaX8/YHr/H+h2/jdLqGTTq1bJZEIj6sDbvNwfrVd9LV00JfXye3bX4cQRA4eWYfjS2nxjSO+XMWMXfWfNo6WsalDgW5ScaO3Vvp6u5gw9GbWL5kNXNnzacgr2hCuve5CbNJKpUgnkwQT8SIx2PEElFisSh5oXwWzlsy7ZOFC1FkhU3rbmbH7q3s3Lt13F4LgHBkgBdf+xVHTxxi3epNLJ6/lLraOZQUleN0OMdsZKTSSbp7OmlqaeT02RMcPX6IfYd20TWG2HObzU5pcTmxeJSeCawAz3D1mS4TXZIkNt5wMz19XXzvJ/933CIDhmHQ2HyWn/ziX9mxeyvLl6xm/pxF1FbPorS4Ap/XP+ZcsEwmTVtHK82tDRw/dYRDR/ex7+BuopMwkhcvWM5nn/wKJcVl0x6mafMXkeg4TWagHRByoSnXUKXyqcAyDbLhdlLth3MTOtmGLVSN6i8FQSAb6SDVeQxMEwQBUXVhL6hDcedjGRqZ3rNkw21Ypo7qL8WWX5erMyCKFK99CMs0aHnvR6N6LsaLKKsE522i6tYv4SyqRZQUXAXVZAZGrgMxFTjzq6i646so7hCdu18gEx5/PtCVcBXPpmjVfZSsfRjFFfjYLeKNiCCgugMULLkNltw27GNnQRXOgqpRd6+69csXtJVTQPNVLxtqW3a4yVu4ecSQMkGUcBXV4iqqHfYZ5LxuE1bjEgRsvgIKl9818seihK9qyahFD4sGpaFHwuYroHT9YxMb1zSTyc6EQk0r5aUV3Lh+C5VluUTI7p4uSovLWbPihmGJhslUkhOnj47aliTK6IbGBzt+g02109XTMlRM7ko4HE7u3PIJDhzeQ0fXOFaEBjEMnTNnT9Lc0sDW7e8wu24eZSWVlBSVEfAHcThy1ctlRQEsTMNE1zWyWpZMNkMmnSaVSZFKJUkkE6RSCRLJBIlk/LxhEY8SjUfZsOZGqsprr6phAVBXM5uN6zZT33hqwpNyTcty8swxzjad4Z3CUupq5lBeVklhQTGhQD5ejxeH3TkYtiGgGzq6rpFMJojGI0QiYbp7O+ns7qC5pYGzTWdIp1NX7BdyK7hLFi7nvjsf5u33XuPtD16b0DHM8PHBYXdw55ZP0NvXwy9+/WP6B8bvjctk0hw9cYgTp49RkFdIdWUtZaWVFBeUEAzm4fcFcDlcqKqKJCuYpoGmaWSyGaLRMAPhfrp7O2lta6aptYGGxjMT8lBcSE1lHZ994svMn7sYZRpzQM7hqViAHg9jWSap3qmZGF9zWCbZgRYSLXtxV61Bi/eixbpwV61FDZShhdtItR3KGQyK46JdU10nSLUfQ1QdiLKaS9a+IBRClNVcsT2Xn45dzxE+vWtSyjc2fzH5i27OVR4umTW0Ou0unUv/qR3TmgvjCJZQueWLOPMr6d7/KuH63RjZsT2jL4fqySM4Zx35S24jNG/jUIG2GWa43shk0r+9oVDNrQ2cacit+M+qmUt56cSs0qyWpa29hf5wL067i7LSSjzunIuvsryGyvLz6kZOh5OF85Zw350PD1vtS6VTfO8n/2fUfjxuP8sWbaSts4F0JkkoWERd9aIxj3Ptqg2sXLqW1995mcxIsnZjIKtlOdNwijMNp5BlhYAviM/rw253DBYHPFfp0kA3DDRdQ9OyZDJpMpkM6UyKVCpFNpvBGmVVKTp/6UdyUSqKypbNd3Hk+EHe/uA1MpmJnSPIGRhNrQ00tTYgiiJulwe/L4Db5cFmsw+dJ8Mw0HWNVDpFIhEnGo+QSMQn5DGpKKvmvjsf5vab7+Fsw2lU1TZu79QMV5/pTgcOBkI88omn0LQsz77wNJHo8GrIY8EwdDq62ujoynk+7HYHXo8Pr8eHw+5AUVQkScIyTTRDJ5vNEI/HiEQjxOKRCV3TI1FVUcunn/gy69fchMPuuPIOk0BPJ9DTMYxMEl1LgWmS6G7MKc9Ma88fEaKI6ivBO3cLeryP+NltJJr2oAZyMduKtwhP3UZkh39oFzObItl6CMVTgLtmHaLixDI0hAsMPkEQkBQbhcvvwpFfQf+x9+k7vo142/FxTcpVbz6+6uWE5m8iNG9DrkqxeP496i6Zc2mE8bSgOLwUr35gMBl+JwOndhJrOTJuyVlBlLCHyvBWLiZQt5rArDU4QmXXfXG0GX67SWd/i0Oh9h7YxQ9/9l0AvvipfzdhwyKVSvLOB6/x1vuvUVJUyqMPfJpVy9aOuO3tN9+D1+sf0XVvU23ceMOWUWtc2GwOZtUsxun0gGVRXFiJqo79xepxe3n8oc9y/PRR6htOTfpFr+saPX1d9PR9fEJuyksqePDex2lqbeDEySNTYuCYpkk0FplU2MeVCPpD3LnlPm684RbcLg9FhSX4PD56+rqnrc8Zrh9Kist44uHPYZomz774U2KxsStFjUY6nSKdTtF9FeuoVJXX8Jknvswdt9yL230VlFMEwLKINR9BdvkRZWVQcvT6Voe6EoIgIruCqMEK4me3D3kXsgPNhI+8hCjbUDyFOIoXYOoZLD2D4ivByMSJ1W/FTMfxzttykQECuYm0t2IxroIa/LPWkmg/SaztBMnuRjLhTrREOKdcZBqIkoJkd6F6QtiDpbiKanGXzsVTNh9HXgWSMvw9GZi1hjmP/PnFCd6D4ShTfIIQJAlP+UJcRbMIzl5HvPMMiY4zJLsbSPe1ko33oadimFoGy7IQJRlRdaK4fNi8BdjzynAV1uAqrMVVVIc9WIo4jd63/MW34iyoviZqJEg2F7LT91EPY4ZpYjpVoc7NW6fCmzcthkX/QB8nTx8DYCB8qT712LEsi3BkgH0Hd9HWUcyyRatGNSwWXqYqtyiKfOaJL48aApRMxth/+ANa2+spKqxAVe309nWwdNGGMY918YKlfPKRL/B3//e/E42Fx7zfbwuCILBi6RqeevizfPtf/zet7dd+2IPP6+eOLfdx/92PEgrm1HuKC0vw+4MzhsUMQ5QWl/HUo5/H4XDy9LM/YCAy8WfeR8GcWfN56uHPc+vmu/B6Ll8nYKqQFAeiR8VbtSRXFEtSchKYvwXJ24IoIci2XKG8wWJ5oupC9Zchqk5kuy/3eSaW21aSERUHsiNApHE37tob4BLDAnLPWNnhwV+7El/VEjLRHrLRHrRkBCOTzEmeWiaCKCHKNmSHG8UVwOYrQHb6EC+zmm8PllC24fHpOiUjHot0TmGodG5O9SnSg5boR0/HcypLhg5Yg8ejIKlOZIcXxRMcrBlydUKefNVLr1s1sxmuLyaSvK0bOl3dLZxpOIzXEyA/VEJndzPxRISAP5/qinnEExHaOhqorV5I0D/5xYJr2i8oSzJ+Xy7XIZGM09E98UrMlytKlVOFOk5l+Rx6etsoyCulvatxXIaFLCvcseVeuno6+P6/fZv0JMJ9Pq447A623HQX0ViU7//0n67qiux4cbs8bLnpTp569PNUlFUNvaCKC0uHrskZrm2uZkhNaXE5Tzz0GfJDBXz3h9+is6t91JDEawVRFFmzYj2PP/QZ1q7cgMftvWqx54IoIogiqjtA37EP0NNxXEU1XN1v7aPBMjTMdAxRUhGknIKO7ArhLFtySShUHMvM1T+QHV4cRXOJ1X9wxfYFQUCQVRzBUhzB0ituf60jiBKKyz+qDOoMM/y2MJHkbVEQkAdz9AxdI6tlSKXiBP0F9Ie7cTm99PV3cfrsQYoKygn48if9Hriml4ckScLjyUmAZbMZotGJh7wcOX5w1OrPxuAXVV5SBwzmp00gnMnn9fPEw5/lqUe+8LGtSzFZvB4f9931MF/57B9QVFBy5R0+AoL+EA/c8xif/+TvUVVec9FNVlRUSsAf+AhHN8O1Sl6ogHvueIg/+cZ/Y+niFdd0gqjH7eW+Ox/mq1/6BhvX3XzVPBWX0n9yO468cvzVy4g1H81V7L3Oi+VdDss0yAw0k+o6gb1w7kV5DJciOQKIqptMXwNGKop1HSRtzjDDDNNHJjP+OhaiKOFyugn483G7/aiKjWQqTltHA7quIYkSyVQMm+ogHOkjk5m8YMI17bEQRAFFycVG6rpOMjUxHW3TNPjmd/6av/7zfyTgH77abLc5cTm9vPHuz+npa0fXNebULZtQX/mhAj7zxJfw+fx8+3t/P2L9jN92gv4Q99z+AD6vn3/+4bc4ffbENZOQVFpSwVOPfI47b7mPgoIixEtCM/xeP3nBAhRFHdVQneHa4KOYnrpdbjau20xpcTnPv/wMP3vuh6RSk39QTxWCIDC7bh4P3fskN63fQlFhydAz9qMgE+3BXToPmy8/V5/g42pTmAapzhN0b/0Ogihjy6vGVbF86ON0z2m0nb25/AdnAHfVWmyhStxVa4g1bKd354+wLDMnMyvNLFrNML289vbT9A1cuxEFv62cqj9IdoICQRfidHgIBQspyC8jEuklmYyhqnYaW45TVFCB3T65Gi/XtGFhGMZQMqRlWRNesUmlU9Q3nEY39BE/97j9rF9zF82tp0kko5SV1FJSVDXRYZOfV8ij93+SkqIyvvvDb3HqzLEJt/VxxevxcfOm26mqqOEnP/8XXnnzBTIfodKS3eZg9YobeOKhz7Bs8Sp8Xv+I20mSTHFRKV63l76BiRdqmuHji6KozK6bx+c/+bssXbySnz77fXbt/fAjX4nPC+Zz6+a7ufu2+5ldNw+3y/ORe1XyFtxE5Oxe9HSc4NwNCJL08QuGEiUcJYtQvIW5PBJJRnL4kexuAOxFc8lz5w0pYgmyiuTMeUXVQDk+mxszGwfLQlAcwxK3Z5hhqjlwZCuNzSc+6mHMcAmansUYZR47Grqu0dndysnT+wkFiygtrsHpcFOYX04wUMiZs4cpLa6hvGwW23e/Riabzj2LJvFuuKYNi3Q6xdnG00Auh8FxgRV16Og+Ptz1/pjbicVHV2sRRYm8YBF+bx6maQzKO07u1Hg9PrbceAezaubwwivP8vzLz9Db3zOpNj9uOOwO5s1eyNd/7z+x5aY7+dHP/oVd+z68qmMQRZHqilqefOTz3Lj+FvJDBaijqIedo7S4HK/XP2NYXOdYpkGqvw1TzyLbXGiJMO6S2RiZBImuswiihLOgGsswsEwNxeXH1LIYmSSS3Y2kjl7EUhAEQsF8blq/hTl18zlweDfP/Prf2Hdo91U3MEKBPG658Q7u2HIfs2rn4vcGhmSZP2q0RJjA7BsQJBnF6Rusvv3xMi0EQUR2eEetMCzZ3Eg298j7SjKKJx/In8YRzjDDxWSzadLTVGl9hquLJEmUFlcT8OUhywqqaseyTFTFjiAILJy3BllWsKkONq27B7tt8nXOro23ywhoWpajJw/z+jsvA+ByuigqPB+Tf/TEIX7x3E/weX1XVBIxDJ3UZYqh9Q90sWvfW9y55SkAmlpO0t7ZyLpVt094/IIgYLPZqauZw5c+/VXu2HIvr731G95492WaWhom3O5EkCSZgvwiqqtmYZ9ARe/pRBRFCvKL2LjuFubPXczBw3v5zWu/YtvO96Y1AV6SJJYuWsm9tz/IulUbyQsV4BhjFe+SojL8o3g0Zrh2uNI3aWRTtG9/FkeghIH63fhrlmNkk9g8+aT72khHuoi1HidQt5p4+yncJbNI9bVimSb+muXA5e8lQRBQVRsVZVUUFhSxfMkajp08xGtvvcSOPR9MSjHvSiiKSl31bG658Q7Wr7mRirJqvB4v8lUoejceYi1HcRVWo7hm8pZmmOEc2Ug7oqQiu0LjNrRNLU023II9rzZnqM/wW40giDjsLhz2kQ0Gt+u8PPFYC0NfiQkbFoZp0NPbxbGTh4d9Vt9wcujn0/UnxlWp2LIs+vp6OHbqCG+//yr9g6vCAX+QObPmD22XzWbZsPYmvvSZr41an+Ic0ViUL/7+6FJ5hqETiw8M9R+Lh+npnbgC1YWIoojX62e+x0tVRS2PPfgpjp04zAfb32HfwV00tTZgGFOnSyyKIsFAiMryGuqqZzN/7mLmzppPYX4xTqcbl/PqVt0eK6qqUlRQQmhTPqtXrKe7p5Ode7exfc8HHDi8l0hkYsXHLkSSJObPWcSaFRvYsO4m6qrn4HK6sNns43L7zZuzkG/+9ffIZq+cYzFVK8OKrPCPf/N9tDH0CaAoCv4R8okmiizL/M7n/j2fevSLY97e4x55hXYiSJLEzZtu561f7x7zPj6fH/tlCr1ZpomZTeGvW0W88wyOvAqysT5svkK0ZIREx2kcwTJsgSKizYdIdNaTjfdj9xchjWNVRxAE7DYHZSUVFBYUs2bFBrp7Otmzfwc7933I4aP76OzqmLSKlMvhYv7cxSxbvJLVK9Yzp24eDocTu80xrGjotYIgyTS8+m0UdwBBlKi4+fMjyp6uWLpmXN89gKwoBHwzBssM1xd6KkKiaQ9mNoGjeD6qv5x071m0aCeKpxB74SySLfsx0jGcZUuQHH7i9R9gGjruytXoyX5ip99FK1uKLb8W1Vv8UR/SDL9lTHjWo2sa+w7s5s/+5x8N+yx7QVLr8688yytvvjCOli1M00TX9aF2ZEmmtmo2q5ffMLSVqtooLCimtLh8xKJ4F+L3BUec4GlaliMndvL6Oz+jvbOBY6f2YJomToeLDWvvGceYL48gCAiChNvlweV0U5hfwvq1N5HJZOjp6+bM2ZPUN5ykubWR7t4uevt6iETDpDMpspkMpmkiyzKqakNVbdhtdrweH6FgPvl5BeSHCijIL6KirIrysir83gCSJCFLMrIsI8kyoiB+5PHUVyK3wqsSUIL4fQGqK2t58N7HSaWStHe2cvL0ceqbTtHR2U5Pbyd9/b3EEzEymUwukVoAu82Ow+HC6XCRF8yjrLSSyvIaqipqWDBnET5fAFVRUdWJh7upikpeaPJaz5ahk2w7hJEcwDv3lstuKwgC+Vfo07JMsuE24mfeJ7TqqYs+M/U0iabdxM5+iCjZ8My6EVd5TqDA1NJEjr6Cs2wptryRZZkFQcDn9Y+aezJWsgMtCIoN2RlEEM+f/3NjM7UMJbf98Yj9OxxOHI7JJZUNR0CyuxAVFUFSyIQbMdJx7MESVG8e6f7cyqHqDhFtPoJkd2ELFCNc4ZkzYk+CgKqoKF4Fr8dHZUUN9931MKlUktb2Fk6dOUZTawPNrY10dLYRjg6QTCZJp5NomoaiqthtDhwOB26Xh5LCUspKKykvraS2ahazaufhcDhQZAVFUa+ZcKfLkb/kNsx0fGhVdiSVpHPe35Lisint2zJN0pFOog0HiDYfJtFxBi0xgJ6KYWhpJNWJ6g7gyKskULeKwKw1E/7up27QFvHOM4TP7iPWdIhkTxPZaDdGNg2WiWRzoXhCOPMr8ZQvwF+zAnfJ7MuqT12NMacHOgjX7ybSeJBEZz2ZaA9GOo4giEh2N4rLi81XhK9qCb7aFXhK513dMVsWeiZJtOkQkbP7iLWfIN3fjp4IY+pZBFFEcnix+QpxF9XirVyMv24VqjdvymuvSHYPsjsP0VaJvWgelq6hxTpxlixA8ZWSbD2AZeoovhKip94mtPJJnGXLSPfUk+4+OZjPU4KrYiWCdG15KGf47WDibx5BQBAFsloumcQ0zRFjh7PZDNlJJOVKksS8uYv44qe/etEK6MOfeHLMCSaKovD4Q5/BeUmmuywrLJ6/jqKCcrbvfp07tzwJCIiCOG0hA4KQU7pSFAWnw4XfH6CuehameRemZQ0lqZ+TvD13RoUL/i/3H2HQYBEQh34WEcVr34C4EueOy2azY7PZcbs85IUKWDhvKaZlYg1ea5Zl5VZ5c/8bdo4EQUAQRURBRBQFxMEX1YXnp6evnb/9xz8gEuu7oBHO/3zh3y7gC0/9Z1Ytu7wxkLsfrAuq1QowaOBZlgWCgKNk4cj7WSYXHZgw+JIdamvwyhAuePlaoHiLCCx9aNgYtFgPWqwHT+0mXOVLEURl6HNBUvAtuHPYS2j4OHK1By76+wXHNTSIoeeABVwQM2+ZJFoOoPpLkVQPyOLQdewsX47sK6Z32/cu6T83fkGULjif1tB5HP3cm+w9+D7vbn2Ots6zuF0+Nq67lxtv+ASqYhvaVxBlBIRcITJBRFLsWKZB175XEGUFZ2EtAJ7yBfSf/BDJ5sSZVzFqv2Nh6PpWbdhUGy6nm1Awn0Xzz1/f5uCxj3R9CwgwdN/nru3r8d63LItMuAtXYTWiYiPafBh7sCx3rNN0HJZlYRk6A6d30rb1p/Sf3I5laIPPFHPoejtHslsg0rCfzr0v5q6R3Bcw2BjDnw2XPEMkm5MlX/ku3srh9/kYB4xlWeiZBD0HX6d9xy+Jt53E1HKGxPkxX0BPI9GG/XTufgFRseEunkXJ2ofJW3wLitM/dM9NaDimQaRhPwe+fbHn0l06j1n3/79DheIsy8IydaJNh2nb9jT9Jz5ES0bANC54fpxj8JwKAt0HXkOQZFwF1ZTd+CkKlt6OZHNN/fUw+G61TIN0fxtt235G94HXyUa7sUwDyxx+LTDQSaLjNAMnPwRRRLa7Cc65gbINT+KpWICo5EIjJztWQRBz15ooIwgSFhqS4kRUnIiyiqmlEEQFUbHjqd1EsuUARjqC7AygJwcGiypKIEkzoVAzfCRM2LBQFZVbb7qLxQuWsWvfh+zcs42DR/bS3dNFVsug67nMdVmSx++GH3xpupxuNq3fwhc++btUV9ZddMMq45j4C4LA55/63WE3vCAISJJMKFjMxilKWhkPgiDkXlSSyIWnaCpLq38UjHX8Y91uyICahpVCy7LIZFPj1m4eU/iaZRJr+JD46VxRK8nhI7DsIVRvEUYqTPzshyRa9uEomkdw2cNDu2UHmonVb0WLdJANt6G48wmtegrR7qZ/788RJRU9OYCppQmtegJbXi2WoZFo2EGsYTuirFJ089dzjZk6qc5jRI69gZ7oQVQcZHrP4KndgC1UTbavkdjZraQ7jxNa/SkcRfOGxqEn+ggfegEt1ollmnhrN+CZfRNmNkHk6Cuku0+CKGELVeNfeA+CKBFv3Emy5QCCpGAkwzjKl+Ct2wRArH4rsbNbESUb0VNv4SxdjLt2A5LqGnqRXnT6tDTxxp3oqQECi+8HUyfetJtMXwOhFY9fbFRdwonT+/n1y/9MW8dZAMKRXp7+5f/G5wmyctnNSIKE7PBQd/83AIHae74OCPjrVoFlUrjqE4PGhpCbhJgGjoIqHKFyBHlq5T6n8/qeKizLwjB0slpmyPupKCqCIKDpGpZloSo2TMvENAxEUcIwdQxdByEnkKHIypBxD7lCcdHGA6juALLDQ9+Rd3EXzUJURw9fm9QxmAaZcBenfvXf6Tn8Foyl0JRl5Spkm8bEAtUEcvtPAMuyMLUM/cc/oOH1fyLedhxrLIow58aMgWFoRBr2E206jGf7M1Ru+RKheRsQlfGFf17UvGlgXJLYm432kOxtwle9FMs0yUZ7aN32NG1bf4YWv1Iu0aDlbFlYmFiGRqz1GCd+9qe0bX2aOQ//Ke7yBZetDD6u8Z9bbEmEafvg32h6+wcY6ThX1joeNPYtE0zQ4v107f0N3QffoGjl3VTe8iUc+ZVw7rkxCWR3HunOE5jZJLZgVW7RZ7BNZ9kSoiffxsjEsQUrQRTRE31YhoaoOhEkFdHmJnriLZylS1B9M6FQM1xdJnynCoKALMuUFpfzwN2P8cDdj5FKpzh15jg/ePo7vDoY/nTzpttZtXzd2NtFwO6wkx8qZM6sBRTmF41pP9M0h1bzLr2pr1QjQZYUXE4vkWgflmUOriY6cDhGVuoY63jSmSTOy7RxbtUduGhSoWkZRFEa8pqc82II11g402jj1w0NLAtFuXzuSyaTRFUdQ8dkDq6+iVfRBS4gIEm51eqpLkBlmTqJpj0Elj2UewEIwtDkWXYG8M69FVF1occvVgtLtuxH9RYTXP4IkaOvItm9yO48LD1DNtxKYPH9uMqXE2/cSez0u9jyahBlFXftehRfMeHD50MPBUnBWboE2Rkk0bIfW6gaZ+mioc9tedUo3kJ6d/2YC1+slmXRv/9Z7Pm15K35FIgyDE5qRMWBd87N+BbcgR7vI9G0m3T3aRxFczFSUQTFRmj5oxjpKImm3WT6m3GWLMS/4C705AD2vDqc5UsR5ctfH4Jix5ZXQ+rQ85haEjObRE/0YQtVXzFM4vTZg0SifZd+Ixw8so3li29EGnr5n7ufLrivBAnpgvaTPY30HHoTe6AYb8WiEe/Bc/fCOSNhPJzzvOUWba9N48KyLHbseZ0XXvs+RQXleFwBNt1wL0UFFbyz9Tm6elr5zGN/TGd3M6fqD1BTtYCDR7Zx4MhW/L4QwUARmzc8QGXZnKHzE206RLh+D4nOM4iyiqt4FuIF3qQpHb9pEK7fw4mn/4RkTzOjTyKFoRX94SvrVw/LMtHi/TS//QPatz+Dlphcjpll6kQbD3Dy5/+F0g1PUrrhCVRPcMquNz0VJdXbgmWaJHsaaXrzn+nc/fzYDKHRxmzoRJsOceSH/w91n/gj8hbdMjXGhWWS7G7g+E//hEjDvsk3p2fo2PEroo0HmfXgf8JftypXb2QS17E9rxZbsGrwWhQHlcFyyA4/waUPYpnGkEfCVb7sooUZ7+ybwTRznosZZrjKTGkQrsPuYPGCZaxYsoZ3P3iDdCbFymVr+eSjX5jKbkakq7sDwzTIzysclszd3tFCJpuhsrxmxLjjSLSX51/5VxqajxOLh3G7fKxevoV7bvv0hMfTN9DJ8y//C5994j8iSTLmoAvYMA1kSUEURdKZJJFoH7Ks4PfmIUkyhmlw9ORuAr58qirmYpomsfgA8UQEnzeE0+EBLCwrN5k3TANREHPtYyEKub8psgpY6Eaukq0iKwiD25mmiWmZiKJ0wQTrPJZloRsapmEgX7DKaFkmmpYdMno0LcNApAcQCAYKkKVc2fj6hiOYpsn8OSsxDANBYHDinjOQRFFC1zW27XqF1cu34HH7MU2T/nAX6XSSgrxSFMWGYehDeRCmaSIMrnxOJapqY07dcrp7W0km42haJrfqOhgakdUyuWqXY1ndvARBlPFUryF8+EUcJQtxlixE8VzZUBZEBcvQMFJRsEwE+fxqlWTzYAtV5mQovUUkmseX0Dp2TLL9TQSXPwKinLtGZCW3ippNEKvfhhbpACwMLYkSKM+NXVZRvUXIrlBuYibKWPrECgkKgoDk8KKGKkl3HEW0+zBSEdxVa664bzqdHNGrlEjGxp0k7SyoonLLxaEfuftARBy8fwxDJxLrx+cNIV9h8mOaBrqho8jq4ATWJJGMI4gCbufUJbxPNZIksXr5Fh6464vUNx7l9bef5q5bP40iq6TTCY6e3E0wcD4PyOFwc+tNj3HDqjv41UvfpaXtDCWF1UNyzv7alSguP45Q+WDIlzUtoRuWZRFvPc6Jn//ZyEaFICLbXUg2N7LDg+r2I8gqRiaJlgjnci7SCQwtNTzs6KJ2cgsHgiQjSjKCpCA7PIjj9HBZlkm6v4PG1/4vXXtfwsiOLvuZK5h3PuTFMg0sQ8cytBG3z8b6aH7n+xiZBOWbP4vNVzglhpyejpPuayXd30brez+ic9fzWOalRoUwdG449xw3TUwje1kDJNXbzNlX/hHVm4+veumkjCHLNIi3neDw979Oqqdx9A1FCVFScgsYF3gtc2FzI78LEp31HPvJf2DuY/+V0LyNMHh/T5QrLZ5c9Llw8TNHEASYMSpm+IiY8uy+nH57HvmhfFram6e6+VF5+c3naWyu51OPfYnZtXMv+mzbzvd5872X+Zu/+L/4R1AJSQ+GwXzpU/+FI8d3Ulk+h+7e1kmN5+CRbZimRVPrSSrL5tDV00I8GSOVihP0F1BUWEFr2xmOnNiF3xtizqzlFBdW0tffAQi4BicYmUySg0c/pH+gk9KiGhbMW0MiEcE0TfLzSmhuPUVeqJjOrubcirsgoGUzVFfOwzB02joaME2D4sJKAv4Cevs66BvowjB18oMl5OeVjmhYtLSepj/cjc8TpKZ6IVgWbR1n6enrwOP2U105j66eFvYceBeX08ucuqVUlM0mEu0nk0kRCuXcr+FID4ah4/fnE4sPoGsaAX8BbR1n8fvyh7wyyWSMD3e9CljUVS+mrnoRHV1NBIOFqLJK30AnbqcPr3fqlI4AfN4QX/70nw0et0k2myGRjJJIxkgmY5w4s48Pdrw0+L2ME0HEVbEae+F8Eo076Nv7cwJLH8QeGjlB+hz2wtlET79LuvcssjuELVSDpDrQtfRg1d0LX6zTVBPBAkFSsbTcvXFhfkO2v5l090kKb/oDjGQ/0dPvDe0miBKWeOlj5cIxCoxnzJLqxpZXS6JxJ/aCOYiyetHq3Wj4fXmoqo1UOn7R34sKK4ZVU78Uy7LIZtOkMklkScZhd6HrGulMEknK5Uedrj+Ex+2nIK8M1WYnGhtgINyDx+0nkUlhtzsRBZFEIord7iSRjAICToeLcKSX5rYzzKlbis3mQNOyDES6cdrdOO1uMpkkWS2DqubCVXRdQzd0VMWG3eb8yEOmJEmmqKCCyoq5nD57EI/bTyhYRFPrKZyO8+GklmkSiw3Q2HISTcvgdvmGhcXq6QSmoRGu34ORTVOw5FYsptYzq8UHOP3cX5PqaeLSa09U7LiLZ1Ow4i7y5t+EI7/iolVxPZ0g0X6S7kNv0HvknZzc8AiGsuIOYA+UYg+W5P4FSnAES7AHy3AV1Y55rJZlkYn00Pz2v9C17+URjQpRsaG4AiguP+6SOdh8BcgOD5ZpoCXCpAc6SHSeyRlFyciwibCRjtO+/Rkku4vyTZ9CcfnHPL5Rx23oJHuaaNv2czp2v3CRUSHKNmSnF9WTh7OgEpuvCMWd61NPxUl2N5DsbkSL96ElIoz0fEh2naX5zX9h7uN/gerNm9gYLYt4Zz3HfvL/jmxUDBqYijuIzV+Eq7AGxRVEUmwYehot1k+yu4F0fzvZxABGJjHM0MxGezj5i//Kws/9Hb7q5ZcN15xhho8r0yIbEgrkkZdXeFUNi/7+XnzewIj1BWbXzeMHT39n1IqFoihht+USu7Nahlh8gFQqMeGxGKbByTMH2LTuHg4c3kpJUTXHT++lp7eduupF7Nz3BrdvfgLTzK3eu1y+of4dNhfNrScRBYH8vJKh2Gab6sDjCSBJMk2tp9B1jWCwkENHP2TJghvYsfs16moWsXPvmyxZuJ5EMoogCAyEe3C7fHR0NbF+zV2cOL2P5rZTzJ+zCkmSR3yBm6ZB/0A3hqnz7Iv/xL//nb8lmYzxypv/xoZ192AYOgLCYIiZgNvlHQobs6l2evraicb6KSuuIZ1J0tB8nNrKBZw6e5C8YDEBfz5ul4833/sFVRVzcdhdmJaJYeh43AE8bj+WZdI/0ElHVyNVFXM5cGQr61ffPeHvZCwIgojN5sBmcxAMFAKQ1dLsPfgelwbVjAnLItPXiDgY0mOkIpjpXKFGU8+gx3sx0hGMTBwt1o1kcyOqTox0DNkVwp5fh+wMIMoq1hVyOizTQI/3oCf6MPUMWrQLUXUi2T2X3c9IR9ET/ZjZFHqiHy3ei+zwI0gyzpIFJJr34SwzcvkGsh15MPlTVP5/9v47yq77Pu+FP7ud3tv03ge9d4K9iRRJVavYllvc4tfOde51bhzflBsned9lxyuJ7ViJbMuWLckSVVgkkmIFQaL3PoPpvZ/e99n7/eMMDnAwM8DMYAYEy7OWxMGuv13O/n3r85hQYxNkw6NkoxMYPDWLuiWy2YWaCJIJDSFbvUhGO4IokY1NosYm0XJZMpExRMWMbHYiSHI++5FTSU/3zpZx3d7obGnazPlLR0ilE2QyaWRZwe0KsGPzw7fNeuVyKiPjfZy/dASrxU5b8xZmguMMDHcR8FXg91VwqfMEBsVIW/MWqioaudpzlnQmRUVZHRcuH6G2ug27zcXhE6+yZcMDHDn5M7LZNGtatxOJznDizNuATk1lM4lUnO7eC9RVt2EwGOnsPsvUzBh+Txk6OtFokGQqjtPpY+PaPYWgwwcJURQxKEbSmRRmkxWvpxST0cKVq6exWvLvXDqT5PLVU5y+cJANa/bQWLduDhNb8OpRcuk4ifFeUsERfGvvv22J3FKgaxpjJ14gNtoxx8AWFSP+9Q/T+Ol/iclTPu/+ssmKs34zjtoNeFr20P/G/yLUfXJORsC//hHqn/wdDI7AHTlFuVSM0WM/Yvz0q3nD9UYIAkZnCe6m7ZRtfxZn3WbEG0pJb7zmTGya6QvvMHb8RaJDl1BT0aJt1GSU0SM/xOyppGTzk4i3KVtdDCJ9eXatguMliBhsHlyN2whsegJ303YUq3ve+5OOTDF+8mVGj/6A2GjXnP4XPZclOnyJqYvvULbzs8u6x5noFF0/+i/ExrrnrBMVI9bSRnzrHqJk0+OY/bXzll1papb4eDfjJ19m6vzbJKb65zia6fA4nT/8L6z/lf+RZxG7h8qXP8EnuBtYHcfC47stNeZKQ9M1RP3Gmukboc82GM6/r8lkoba6FYPBiK5pXLl6mvqatvk3XgSmZ8bIZFJMzYwxPNJNJpvGZLTQ3rKV8pI6QuEpstk0LqcPn7eM8tLaQgmBw+HBbnMXKA0tFjsedwnZTJqqiiaMhmtNd/mLueYsSZJMW/NW+oc6KS+to6f/IiajhXXtO9F16Om/SCg8haIYqatuZ/P6/QuOP5mKoek5stl0viRK0xibGKC+tp01LdsK2zmdPnzeUkpLagj4KgCwWh24nL6CamdpoJrO7rOMTQyQTMax21wYDCb8vnKMRkvhaTnsbryeUtxOP1UVjei6TlVlE2+9+wPcLj+iIOFc4WzFqkPPER88me87kCQUZzmmQAsAaiJIrPcwamwaXVOJ9R7BXL4Wg6sCTU2Ri08Ti02DnkM0WnG2PopoMGNwVxbYm0TFhMFZOXuqLNHew+QSQUTFTLT7PUz+RiyVGwAQZCOy1YtoKCYoSE31kBq7AoJAarwTLR3HVrcLyezA2f4Ekc63iFx5AwBLxQYU2xYMnmoURznhK28gGW1YytchmRwgiEhmN6IhP9EKkoJi8xU5N5aqjcS63yPaeQBz+RosFRsQRIl43zHU+BSyxUX06rsYvXXYavPvmmS0objKSU/1YvTVL+rW11Q289Sjv8jxM28xMTWM0+5h17bHqalquW3EX9d1bFYnTfXrGZsYoKPrNDariw1r9lBRls829Q9coaqikdrqNgRBoKF2LecuHULTclSWN3D+0mECvkrcrgCiKNDcsJHxiQFGx/toqF1HXXUbm9btQxQl4okoweAEqXSCoZFuZElm/66nOXHmbSanR6irbmPLxvs5cOhFEsnYB+5Y5Eu3osyExqmrbiOTyX/L7DY3FzuOU13RCIDJZGXfzqewWRwMj/YQjQWxWZ1FhpbR6SfUfYKy7c8x03mIxTiNS0E2HmTi9KtkE5HiFYKAo3odzZ/514uKgAuihLdtb95pj4eJDV8uWj9+8if41j6At23fspv7tZzKTOdhJk79lGz0plCGIGIta6L2kV/Hv+5BJOPCtMuCKGJ0+Cnb9TnczTsYeOtvGTv5MmoiXLRdamaY8ZM/wVrWhL1qzR0bwLqWu+4QCCKWQB2Ve79EyZanMNxGeMvo8FH9wNdwNW6l43v/nkjf2TnbpMOTzFx5n8Cmx5FNS+t/1LJpBg98i1DPyTlOi2Sw4G3fT+1jv4m9snWBI+Qhygr2ilZs5c24G7fT/8b/Jtx7Gu0m5yI6cJ6hg9+m/lO/my9l/QSf4GOEVXIs/Gxct5VwJERJ4O4wEgT8pVy4dIbe/i5cTjcGQ/7jHo1FOHbqMCX+kgXZqZx2Dzu3Poquazx432eJRGaKaoWXirMX32fn1kcoL60jEplmYLADEJBuKhGRZBld05icGp7tn7ARi4eJRGeQJJlYPILFbMNoNDMTHGdicpDKikYsFgf9A1cYGx8oalAVRLFQf2pQjFjMNkYnBpBFGV3XMZusiyqj6B/sZGxikPXtu3DY3AgC2G1uItFTDI32IEsyAV8FkighihKTUyN4XAEcdjfxRJRQeIp0JkUkGsRmdeB2+enpu4TfV47T4UVVs4QiUySSUSanR7BaHRgUE2aTlamZESamhgn4KjAZrTgcHi5eOc76NYsnAFhpLHe6FSQF75YvzrvO4CgtYoK6hnRwEDU2ia1hL+bSNrRMgqmjf08uFUZxlBQdz+CqyPdAkG909mx4bsGxKPYAin3uO22t3Ii1cuO8+0gmO+71z8xdbrTj2fTZefYAW83Wwt+y2Yl9lhGqMGZnOZ7NX5izn2vtwtkoXcshIGD01iEZb52BuREtTZtoadq06O2vIRoLcuHyUbLZNLKkIM32ZYWj05hNVmw2J4rBSCQWIhKdwWi0EI7OEIuHicZClJbU8N7RnxKKTPPYAz/HuYvvEwxP4bTn+07y3yGd6ZkxbDYXiUSUcHQGi2rDYrah5lQmp0fRdA1FNmA0WgplUR8kdF0nFJrkas95Rsf70HWoq1lDx9VTiIJIaaAKn6eU0fEB2m8IQLQ0baZv8Aq9A5fxuksxGq+zPnnb7yc5PYimqZj9Nfm69hW8znDfGdKh8TlN2KJiovrBX15yWY2nZTehruMkJvvQMteZ5HLpOOMnX8ZZuwGDfXmlOunQGFPn3yQ20jlnnTVQR+PTv4+nZdeiswuCIGD2VVP94C+jazlGj/5wjgEc7DpG8OpRLIHaJRvrt4LZW0X1A1+jZOvTyLdwgm6GvbKdxk//n5z/29+d41zpuSyJyX5iI53kle8Xj8jgRcZPvFj0zCD/jfa07aXps/8ak6tk0ccTBBFv+30gSnS/9KdEBy/NeceGD3+Psh3PLakU7sMEURRxuwKUBRaXrf4Ed47RiX6Cocll9XzeTayKY+F0uPjy536Jzz/7lUKj3mpj0/ptnDhzlOdf+jZjEyP4PH5yWo6ung5eef3HfOrR526pwgv5j4Xd5iKXU5maGaNqNvK2ZOiwYe1eTEYzoigyNjGA112C1WKfjdZXYDCYUBQDTqeX4ZEe3K4AhtJaJqaGQYBEMkooPInJaKY0UM3waA/9Q50E/JVUlTfQ03eBnv6L+LzlWCx2qioaUWQDleX12K1OqioasdtcXLxyHFlWKA1U43R4cbsCt2U/CvgrGRrpZmCok4ryBiRJpqy0BofDw5XOk1jMdnyeMkxGM35vOVd7zuKa9GK1OJgJjpPOJNFyOaZnRjGbLNRWtTI+OURpoBqbzUU6nWRopBunw8vY+AABfyUGxUhNVQuHjr9C/8CVvGNhMlNV0cShY69SU9myvGfxIYMoGRBEmWxkHASBXDKMZHYhGlZu0v+wQNdUsrEp0lM9qMkw9oa9d+W8BoMJt8tPJDqDyWgh4KsgnUkzNt6PlstRXdlMZVkDQyPdTE7nnepweApJkglHpvF5ymhu2EA8EcFstuFxl5LJZmY1WZxYLQ583nIGR7qoLG8kHg+TyaRQFANuVwBN0+jpv4TPU4rXXYrd5kIUJUoD1RgNprtyD26GIIDL6UcURc5cOIjD7uWxB79UKINSFCMeV4D17bvoH+zAZnFQ6q/CaLLMlpNtJRKdIZmKFzkWsZEO4qNXZylM47jqtyKwcj0kkf7zqDf12QAYHQE8rUt/nySDGUfNBkwXD5AYLy6pmblyiEwsiGLzLtk50nIqoa7jBK8em2OgymYHFfu/iqthy7JKlkzeSkq2Pk106BKR/nPF582mmLl8EHfTDhzVy9TauAmy2U5g8xMENj+xJKcC8nOwo3Y9pZs/xeCBv5+zPhsPkhjvWZJjkcumGDn0T2TmZIEELIFa6h7/7SU5FTfC07yL6IbHSM2MzKHVVeNhRg4/T9Nzf7CsY98K6UwSg2JEVVUEUSSTTpJVs4iiiNlkXTUdrhthNJjZsflhPv/Mb6/6uT5BHt9/4S94+70fkUwtv1T/bmBVHIu8uJkRo/HuOBUA69o28NyTX+Dln/2If/je3yBJIllVxaAY2LF1L8986vOYjMWTsqpmGZuY2wcyOHyVSDS4bMfikfuvR2SrKpqoqmgqWr9x7Z7C32tat9Pekp9MRVGkqX49TfXri7Z3Obw8sOfZWdanPAvNkw9/NV/+NfvvEn+elWfvjuLIb2mg5oYoKTQ3bLjt+AO+Ch65/4uIYr607Nok+fB9n0fTcgUmHICm+vU01K1BIC9AV1PVQk1VsRPgchp57IGfK/zbYraxce1eNq4tntj93nKefuxrQJ5lZ3JqhHg8zIY1u1GUldUOuFch23wYffWkJrvIjQVnG8C3IC+iYfmjBl3LkQ2PkQ2PYi5pxTjLPLXasFmdbFizu8C8dg1N9esLDGcOu5uKsroCBfS1npxr2LRuX+Hv1qbNNDduLKKw3bRuX4EhDV8FdTXthXWlgep5qWu3bnxgWdeTF4XLkkvH0bJptJwKCIiSjKgY8wJkC/RbXYMgiLS3bKW9ZeucdWtatxf+bm/ZVshWlJZcj2S2NW+Z97iRvjNYSurR1QyxkZlZ0bfFCZ8uBonxHnI3RakB7FXtSMt00iyBGgwO7xzHIhsPkpwewhKoXbLicSYySajnFKmZ4Tnr3M078bTsRjYvPlt3IwRBwFbWhLd9P9GhS3MYmCID50lM9GCraEG8Y6VmAXvVWvzrH0YxL69kT5QUApufYOi9b88Zq5oIk5jsX9LxYsMdhLpPomWLhXpF2UDptmewVy6/7FkQRQKbHmfqwluE48Gbmrl1Js+9Tt3jv7XsZ7cQevuvUF/bzuTUMGaTlVgszMDwVXzeMqormu6KYyGKEuYVvq6VgKqq6LqGJMkfONHFSsNoNN9VOv7lYlUciw8CkiTz4P7HaG1eQ1d3BzOhaSRJoqK8mvbmtZjNljmTVTIV5633foDfW1G0fGp6ZJbWdfUhCuKiKBZvfpkEQURa1H7L+2HNVzZ2TVBwzjJhZV6jG4+VzWYIR2bQdVjXfnt60dXEKvEuzQtBlDCXthUJ1X1cIcpGrFUbsVZtvOvnzjsMN43npt/SYj/w+ff65t+vgLAAY8xytDBuhq7r5NIJklMDJKeHSIfHyUQmUVOxgoElKkZkswOjw4/RGcDkrcTsq0IyzP1WrhZs5S3YKlqZufI+omzMOxUrdGxd18gmwvNQmQpYfMsv3zDYvcjG+TOIqenB/PmWaKDHR7uI9M/tKxANZrzt+zG5FqfntBBkixNbRStGZ8kc50VNRokOd+Bu2Y1xmWVc1yCZrDjrNmGvuANjXRCx+GsxOktJzRSzM+YySTLRqVlq4sW9KVMX3ppXB8Rg91G69allj/MazL5qbBWtxIavzHFi0+EJIoMX8DSvbClvV+85JEmkp+8STfXrcTq8TM6MUFvddteCcKIo3VKnaynIZDNksxks5oVV1jVNI5PNl/LdHCS+EaPjw/T0ddHWspaAb3mZqHsVxnuAFXAx+Mg4FpA30ivLq6ksr17kHjro+cbLG2E0mEnd46mmjzoUxUDrMurjP8En+LhDUzPERjqZ6ThEuOck0cFLZKJTC/LvC6KEwRnAXtmOq34znpbdebG6FVYYnw9GZwm5dAJraSOK1UW45xS2ilYMtrm04EuFlk2jZVPM1a0A+Q4MIlE2LZiRUJOxgmjoYqGpGeITPSQm+uass/hrsJbm6abvBIIgYHKVYPHXzJsViY92ko3O3LFjYfZU4KhZh3gnEXMhr3dhCdTOcSx0LYeWSeUz54sQy1NTcUI9p1Bvns8FEUftBkzu+dnAljZcAXvVGibPvTHHsdC1HKGu4yvuWOi6TjQWIpGMAjp2uxubxYHb6butMO1KQZIkLJY7D8BmMmkudZwnEg1TV91AZUU1up7vj43FY/i9AWRZZiY4zdWeKxgUA3U1jbhdHpKpBKFQEMVgwOVwoygKWTXLwcNv4nS4PnKOhemTjMUHB13X5mWAujkSaDJauW/X09RWFzNBeFx+gqGpOxqDpmkEQ5OEI1NEonmBu0w2japmZkuT5HxjpsmM3erG5cz3P5hNC3vsK4lcLkc4MsXE1DDhyDTxRJTsbCRTlg0YDEYcNjcedwC/r/IGNqqVg65rhCNBwpEpwtEZorEQmUyKbDaDpuXF+WRZwWgwYbO5cDq8eFwBrBbHXW1k/YQscC40LUcsHp6lFg4Sj0fIZFOoahZN15FmRRSNBjMWix3bLFuY0+5Flle2Qfdeha7rJJJRJqaGiUTyzd3pzLV7lEMSJSQp/35bLHasFgcuhxen04dhmQrUuUySmcvvMXz4+wSvHp3TrDrvOLUc6eAo6eAoMx2HCHWdoHz35/G07l12udBiEe49jWx1YXT4yESnkLNpwj0n8a9/+I6Prc+Kks6/cvl5yHyP2vz7C6K45O9FJpbXR8g7QcWwlbcsuxn8ZihWN8YFMh/JqUHUZGTedUuB0V2GrfzO++EEQVzQudRyWbRMCnERzmF8vIdMeGJO34ogiribd97xOK/B4q+d1/nTtRzRoUsrdp5rkESJlsbNs2WDH0wEe6UyFvFEnOOnDs9mIwTKSiuZmpng6MlD2Kw2rvbI7Niyh9HxYY6dfB+/rwS73YHT6WJicpzu3g6isQgtTWtoa15LfU0jPu+d0T7fqzAazB/vjEUmkzdS71bzdjqT5sLlM1zuuEAkEiY3T3Tul7/6W1gt1+k2FcVAbXUrqpolErueKhUEkZLA0uu5dV1ncnqEkdFeRsZ6GRnvJxiaIByZvm40qxl0TUOWFRTFgMlkxWH34Hb6KS2ppqayhYa6tbMUq0t7gXRdY3pmnPeP/bSwzGpx0tq0icryPDNFTssxMTlER9dpevsvFcaYNwzThftiNJhw2D34PGVUlNXT0riJ5oYNRY2Xy4Gu6wRDEwyP9TI61sfoeD8zwXFCkWki0by4XjabySuUy3KBFcdhd+N2+gn4K6mpbKa+dg0BX+WH4ke2EFKpBF295+nuu1C03O+roK15C27nyvRVTEwNce7iIeKJ61z2giDQ3rKN+pr2JUVA8qKLPVztOcfQaA8Tk4OEw9NE46HrRrOmzTrOCkajBZvVgd3mwu0K4PeWU+KvpLK8gZJAdUF9eqmYnB7hUsdxQuGlBQB2bHmEEn/lqk/G4xODdHafYWD4KmMTA4TD00Riwfz7rWZm79F158tqmb1HTj8+bxkBfyWVZfWUltRgMi6uNElTM8x0HKL31b8oMmYEUUI221HsXmSTrVBHr6kZ1FSMTHQKNRkDXUPLJJm6+DbpyASCIOJp27uqmQs1FUW2Opm88BaZ4DjNX/h/GDn0/RVxLETFOP/Y9bwxv1zkUrF5nQDIG+8s8ZuUiUyRnBqcd53ZV4VicS55jPNBMlmRrfMfKx2eyEf1l1BidDMEUcJg92J0rMB3SxAQF2j81jUVLTdXpHA+xEc6UG/WA2GWqKWyfZ49lgeDwz9/FkvX8j0hd3Bf50Nj/XoUxUBZSS1mkxVJlKivXXPXshVwzbG484yFwWDEZLbgdLqpqa5D1zVOnjlKKpWkvqaRg0feoq66AZPRhN3mpKy0Et+snEEqnSQYCnL6/HEEQaS16c5pk+9lGI1mxA+B6OKqOBa5XI5Dx97lUsd52prXsrZtA16Pb0kGTCqd5MTpo1zuOI8kyTTUNbF/z8KTzcXLZ/mH7/01U9OTOB0uzp4/SW1NA7qu093bycP7n1iQDSmeiHLkxGv5CSebJptN09ywkQ03NFnfClk1y9BIF1e7z9LTf4mRsV7GJwYLhvp8yGTTZLJp4oko0zNj9AKyrODzlNHatJntmx+mvnbNklhgdF1namaUH//0G4VlHlfec68sbyCVTtLZdZrDJ16j4+ppQpGpeSN66XSSdDpJJBpkaKSb85cOc7HjOJvW7uW+3U/jWobBe61R/mrPOXr6LjI02s34xCDJVIKFon/Z2brLRDJGMDRB/2AHkijhdgVoaljPtk0P0dq4qSDO96GDACNjvfz09W8VvStlJbWz0WvfHX8kVTVLV895fvST/00ieZ0dx+3y4/OWU1+zuMlV13XiiQhHTvyM85cO0ztwmWgsdIvzZlDVDMlUnFB4srBckhTcLj8VpbU01K3jgb3PYVvA2LkVJqdGeOf9H9M3cGVJ+9VUthDwVazkHF+EdCbJqbMHOHP+Pa72nCN4w7XfDFXV8oreqUQRbbQkyTjsHspLaqmvbWfvzqcKOjELQdc1UsERBt7864JTISombBVtuBq2YPHXYLB7kYxWRElGB3Q1i5qOkYlOk5zsJ9R9gthIB1o2TXTwIv1vfgNLaSNm3+o5Ys76zaiJMM7q9aj+CMHOI1gCt1amXyxEScHo9CPKhptoVnViY13LPm4qNDarED0XRlcpwhzl+VsjGw+RDo7Ou85g999Ss2IpEGUDkjL/fJJLx8mlE+i6tmDvz+0gGSwYnYEVEduDvKMyL3QWnXG6mRa4AFHC7F05MgjZZFlwvGo8jJZNI65g9u8aCUt5aW1h2c0l3asNSZSwrsDca7VYcTs9mEwmKkor0XSdyakJNqzdTGV5NQ6bk2g8is/jx+32EvAF8Li8TM9MMTY+gtPhxOfJM9atJPHDvYiPdcYiGJrmwPtv8PJrP6SyvIbnnvoin3r0Obyexad0NU1jcLiPr3/zvyOKIju37Zt1UOY3ak+dO042m+Xzz3yF5sY2/vhP/w3PfeqLVFfW8tJrP6SqoqaIleVGKIqBirIG0HWyaoaRsT4mp0cWPdZodIafvfUdLlw5RiweYbntvteM7+ngOGMTAzzx8Fdpa9p8R1GIeCLK1PQI6XSS85cO89rb36V/4ArqTcqxt0JOy9E3cJnJqWEisSBPP/Y1nA7vksdx8MjLHDv1JpHo9Kxq99KR03JMzYwSikwxNj5A8v44W9bvv+NMyq2wWs3bRoOZ6spmykvr6Bu8biBPTg/TP9hBU/26O44IRWMhegcuFzkVkDewK8saFuXs67pOJDrDT9/4B46dfJ1QZPq2+yyEXC7L1PQIU9MjaJrGnu1PgvX2+30YkEhEefv9H/PekZcYnxxacq39NeRyKsHQBMHQBOlMis3r7wNu41ioWWY6DhPuPQ3kKUr9Gx+jbNunsZW3IFucC064uq6TjYfwtu9n7MRLTJ59DTUZJdx7mpmO9yl3f3bJom951WgdaYEm52tw1m4kE51CsXlB14gOXV4xxwLAXtHGzJVDc/QbYsNXSE4PY/be+r7eDF3XiQ5dIhWa6wgYnQFMnoqFDeIFoKaic6lQZzF57mfEx7tYiYJMPacSHby4wEodLZPMa8Yss4ZbNJpRrPeWiGkqODaHDQrymhi9r/yPRRGnLAZaNkUmMn8QQddy5DKJFXUs7gWI4sr0WACU+Es5eORtBAT273mI9pZ1HDt1mMHhARKJOOUlFQiCgCiIHDp2EFGUcNicDAz1kc1myWaziIJIMpWgq6eTnr4ujAYTAX8pAd/CGmYfNnysWaFGxoYZGOonFo/R0XWJUCSELC/tVEaDiebGdnJajngiRv9AD53dV9i1gGMRDE5TV93Azm37CPhK8Lp9+LwBNq7biqZr/Pn//hM++/SXMJvnRn8sZhsb1uwG8hOH1XJqSZFQk9FCMpWY5Rae35gwGc3Y7R6MBhOSJJNOJ4nGQsRvVoQFstk0nd1n8pFLm5uaqpZle+GZbIrpmTEuXDnKz975J3r6LhZlbhTZMMutb0eUJDKZNMHwJOn03ChPPBHh0PFXsVqdPP3oLy6J0s5oMJLNpkkmYws6FYqc1/UwGswosoFMNjUrGDiX0UNVs/QNdvDmgeexW12sbdv+gdWaLheCIFBaUkNz40b6Bju49u6oaparPefYsGb3HOrepWI6OEZndzHbjEExUlfTTsC/OKNK1zVee+s7HDj0IulZRfUbIUkydqsLq8WBrCjoukY6kyIej5BIRNEWyBSuX7Mbi2V5ES9FMWK3uTGbbWTSyXlLH+8mdF3j4JGXefPd5wmGJrn5O3BNI8dmdaLMGunpbJJEIkosHllQ8Ki5YQNu9+0bEDU1w9SFt9C1HKJswNW4jdqHfw1LoPa2+wqCgMHmxtOyC5O7jGw8yMzlg/ljnn+L0i1PLbkcKjPTj66pWCrW33I7UTYUNdAuVfjsdnA17WD48PNzWIGy8SAjh79P/ZO/syRDOjHRS6jr+FxlbMBZvwWD1bWkb/U19q75tDYAZq68z8yV9xd9vDuBlsuX6S4XoqQgrWKAZ6nQdY1sPIg2TxBNz6kMvfsPd2sk5LJpPmr625IkrVi1QHNjG8lUErvNgShKrG3bgDZLGdtY14Tb5UFVVTas3czQyABWsw2Px8u2TbsIhYPo6FSUVc1me5088fCnsVptmIwfvLDoSuKaNtq9jlVxLCanJxifzEd03E4P9TWN2G1L47SWJAmfx091ZS2dXZcJR4J0915l17Z9825vMBjIZrPkcvkJ2uP2Mjo+RDKVxO30MDE5tqDxEYkGOXrydSAfEQ8GJ/B5F0/vZ7HY2bbpIXr6LxbKQxTZQFVlE7VVrZQEqnA5fAXhGlEUUdUsiWSU4dE+zl8+TP9gB7kbaBE1TaOz6wznLx3G5y1bVrkI5Ceunv6LTAfH6B/qLDgVfm85bc1bqK9ZM2vMmxAEkVxOJRYP0z/Uycmz7zA5NVwUeU0l4xw7+TqtTZtoa5qfm34+mExW1rfv5srV04yO9wEgSwqlJTXUVrdQVlI725htn71HMrlclmQqzvjEEBevHKWz5xzqDZFHXdfoH+rgzIX3qCirm6MlsFJYzc+S3eairroNjyvATGi8sLxv4DIjY31UzgoULgeZTIqR2T6WGxHwV1Fd2YxxkUwzlztP8v6xnxY5FYIg4Hb6Wb9mN7XVrTjtXgwGE5Ikoes6ai5bcJ6npkcYGu1hcLiLUHgKTcsR8FXQULcWwwKlGbdDWUk1Tz36C0SiQbJqhkw6RSqdIJlKkErHGZ8corPrzCxryuqju+8i7x97Zbbn4/rvxWpxsHHtXhpq1+By+jEaTYXnqapZMpkU0XiY6ZlRhkd7GRzpYmZmHDWXxe0KUF+7Btsiauw1TSU2chUA2eIisPHRRTkVN8MSqCWw8XEi/efIRCaJjXYuyCY17zjUNOnpPqLd76GraTKhYcylbRg9NaRn+klNXEXLJlEcJZjL16FlEiRHLqBreZ0No7sSS9WWFTMGbOXNOOs2kA6NFfVF6DmVseMvYPHXULL16UUxDKWCo4we/SGh7hNz7olktBLY9MSS9QqusRzpS8ggrxbyTsXy87PCrC7KvQItm8mXQd1Bo/6KQAfuwGG7FyEIAkaDqRAkuVM4HS727ry/cGyLxcqOLXvyzsWs468oCjVVdVRX1gJ5+u/W5jVzNH/qahqoq/loqp3n6WY/phmLcCRIKJRvjisvqyTgK1mWl2UymqitaqCz6zLxRJyx8bk0eddQVVnL2fMnmQlOUVZSzprW9bxx4FUikTCDI/047M4FS6FEUbwhcioQ8FUUmp0Xi/VrdvPu4RewWhy0NW+lrWkzXk8pLqcPq9U5L8uLpmm0NcdobdrEe0d/wokzbxdlCrJqhtPnD7Juza5lOxYAM6GJvAz8bARgTcs29u58irrqNpyOuSw9mq7R2rSZ9uYtvPDK39B9Q5ZDR2cmOMHREz+jpWHTkp5rc8MGaiqb0fQcjXXraGvagt9Xgdvpx2ZzYZqNdt04Fl3XSaUTtDRt4vipN3n3yEskbyjryeVUrlw9ybr2navmWKwmJFGiqqKR+tp2Zs5cdyxi8TBdvedpbtyId5nXFYkGudpztsD2dQ01Vc1UVTQu2nh77+hPivopBEGkrKSGZ5/8Vepr2gvv0M3QdZ1cTiWRjBGJzhCOTDM82kNn9xkqyhrwupf3XYC8iF1zw8bCeTQth6pmyapZVDVLZ/dpRsf67ppjcfLMO0xODxdlA+02Nz/33O/QWL8et9M/L7/8tbEnU3Ei0SDhyDSj4/1c7TmL0+GlorRucWl8TSso/8omK/aqdcu+FkfNWmSTlUxkkmwsuGBv2nwQBAnZ6kEyO9FzWUz+RiSzEzUZJjl6AcnsxOCpJDl0DsnkQJAUEoOncLQ+gsEpEel8G6OvAdly53SzkFfKLt/1BcK9Z0jeJKyWCo7S97O/IjHRR2DjY1grWuadtNVUjEjfWcZP/oSpSwfmKCwD+Dc8grN245JLxnQtN6dM68MKQZRWQGBv5aCp6SU5xauLD9i5WWEIgojZbF/RbMDNc8HC+j/Cgv/+qMNkMC+Z1OeDwKo4FslEgngiz8Tg95XgcCzPKFYUAyWBfOYgnUkRCs8tibmG7Zt3U1/TSHlpvrzjvt0P0dXbyZvvvoYgwJc++zUslvmLuSVJpsRXlW+EEgR0XSMUnmZopIfSkmrkRUSz7DYnn3/mtwABjyuAy+krqPIuBFEUsVkdNNWvx2SykkjGOX3uQNE2QyPdzMyMU1XetOw6QV3X86rdosTatp186pGfp7aqZcHeDVEQcTq82G0uFMXEX33zj4rYdzLZNL39l5meGcV/m6bSG2Gx2Hni4a+QziRxOf24nX6k2yr+CphNVuqqW7Fa7KQySQ68/wI3fqgnJocZnxhEVbN3RXF0peH3VtBQu5bzl46QvqHR8MrVU2zb9OCyHAtd1wmGJ+m4erpoud3mpraqFdcie2SSyTidXWeKslYWs5X7dn2ajWv33lKMSRAEZFnBYXfPKlXXU1+7hvXtuzEaTVgty1Pmne88kiQjSXKh18Zucy8707NUpNIJevovzSkf3LfzKbZufPCWzHjXxm6zOrFZnZSV1FBf087ath1IooTDvsiadUFAMpjQsikEUUK5g9pn2WSDWQM7H4Fe/MQtSDKy1Yts8+Udi0ATAKmpbnRNxeCuxuipJjMzSDY6jmIPIBjMGL21iEYb0e73UKOTK+ZYADhq1lO55+fofe0vUW90NHWNxEQfQ+99m5kr7+UFAr1VKFYngqygZdOzje0DJKcHSc0Mk5unFNDVuJ2KPT+HweFdupGja+j6vWL8rgDuISPvlnTDn+COIIoi1hXqr/gEi4fRaPr4lkJl1ExBIdFiti6J2ehGSJKEdTaToKoqyXnq/q+hrKSC0kB5wfj2eQP8ws/9Gk88/AySJFFdWYthASMoEp3hJ6//HZUVjWzZ8ABaTuXwidew21zU165lbev2RY23vmbtsjxoSZKpLKtnw5pd9A9eYSZ4PXKdVTOMjvfT0rT5jn/IlWX17N3xJHXVbYsywEVRorFuLds2PcQbB753w0daJ5aIMDTSvSTHAqCyvHFZ90gUJfzecjat3UtH12nGbijvUXNZJqZGiMZCuF0rQ9F6N6EoBmoqm6kor6en73pz5fjkIANDndRUtWA2La3DOZ1OMjDUyfQN7xJARVkdNVUtiza6w5Hp2d6h6zAaLaxt275khddrTuJSr+VeRywWJpGMzjFiNq3ft6x7ZDSaCRiX9rsSRAmjq5xsPISua6jpBMstSlGTMfTZklKTuxxhyROZkC8/0bQCzaYom9HVbKHkJ5eOoRhLQZDQ0vG8zoCuo6VjiHcoBnczJMVI6Y7PkE2EGXj7mzdRxeqoiTCRgfNEhy4jGS15cTdBRNc1tGw6L3q2QOTbWb+Z2kd/HXvVmuVF6wVxQRYmUTHhqFmH0RlY+nGXAYu/dtmN2/ciBFFacJ5RrC48rYtjfbxTSEbrgtS5H1asFNXsJ1gaZNnwoQieropjIQoioiiiaTk0TVtSKv1G6LpetO+tTNGbo/mCIFBWUkFZye0n6FwuhyTKVFc009VzjoqyeixmG35vRZGRfzvciScpywq11W1UlNXPOWcoMkU2mwKW/0M2GEy0t2xlTcu2Jb2YkiSza+tjvPnu80WRtXQ6yfBYL5vW37ekcdzJPZIkmbLSWhpq1xY5FgCxeJBkKo6bD59jIQgClRWN1Nesobf/UsFAzeVULneeYG3bDsylS2PKicSCXO48WdQUnC+7alpSmV8yFUO/KY0vCiKmj9hEeSdIpRPzNl/fTQdKlBTczTuJDV8il04QH72KdZnsStGhy+Qy+ci8u3kHorRE5wiQrV7i/ceYOv4P2Gp3YvTWorgqifUeJtr1HqJiwuitQ1dTCIJI6MJP870XzjJk+8qXNBpsbqru/0UMzgB9r/4lmehc/RNdUxctEicqJkq3fIry3V/AVtmGtMzeAkGUEBb4HouKkdJtz+Bt3busYy8VstW5oKL4hxGibCxk3m6GbHbS8On/8+6In4oiinnx2dnkzDDRgYtYSxuwli69VyAbDzJ18R28bfdhsC+NvXGx+KhmLHQtR3qmn8xUL47Whxa9XyY0jGiw5Ms7l+ica5kEieHzIIjYarfdcltBEDDMlkMtRIpyL2BVHAujwYjRYERVs8QTMVLp+cWEbgdNyxGL5VPXsqxgMt3emBkeHaSru4PJ6XFMJjPVlbW0NLZjNC6cNZElhYC/ioCvksHhLhz2EIZZxeDwEgW47gQ+T9m8ZS+JZAz1hsbu5cDvLaexbh2mZRg7FWV1WC32ojp7NacWce/fLTjsbspKauYsT80K660G7kYy3WpxUFfdhtddxtTMdarjzu5zTEwOURqoXnTTlqbnVd87uorLoHzecuqq25bkFBiNFoSbpt+smmZwpAuvZ/EEBx9lGAymeUWLegcuU75Eh3C5EBUjJZseY/ToD8jGg0yefR1f+/2IS8yYqKkYE2deJRsPIZvslGx8fMnHQBAwl7ZhcFeCriMZ7QiSgrVyY740SsshyAYkk4NMcBDJ7MDWsAdRNiIoplUzbg12L2Xbn8NRvY7+17/O5Lk3lnwMyWTD3bidkq1P4arfgsHhX1Tj90IQRAnJYEGQlDkN3FomhWy0YvKUL7D3J7gVRMWQV8MWhDkN3Ll0HJO77J6sz8+X4E1hcpcta3/JZMfbdh/yCpWazgdRWDmq2XsKgojBWYZsWRptcmLoDEZfwyy99tIcC13LkUuGFy2saTJZ8lnk3MfMsbBYrFitNuKJGKNjw8wEl2eAptIpegd7ADAoBuy2hV/kWDzG8y/8Iy+88jxTU+MIgoCma8iSTHvren7/t/+QuprGeSPmsqyQSEZ54ZVv4HB4OHdxDIvFTjqdWDH148XAbLZiseQbom4sq0ink2i5O6vDDfgrqalqXdaHVJYVXE5/kWNxreH0bsNoMGO3Oufco2w2vSRtjnsNoihSV91KTVVzkWORSEbp6DpNXXU7Tufiok+pVJyu3vOzmirXUV5aR31N+5LeAb+3HLPJWvSsY/EIbx78Qb5Xw7l4bZqPKtyuwLy/21ff+g6tTZvxeZZnICwJgoi1rInaR/4ZXS/+KTNX3qf/jf9F1f2/uGimokxkir6ffZ3g1aPoapbqR38Ta1nTsrj+RcWEeBPjl2gwz1vmVGj4vo3mxUpANllJh8aI9J8rHoMko1jds6VPCdBBMpqRzXYMdi+WkgYcVWuwV6/D7KtCNjsQl6kaX3ReQUAyWpDN9jlN4ZqaL8O6E22JjzMEQcRg8yBKypwGeTUdR8umkVZRW6Lv9a8jiBLpmVFkqxNRMVG+8zOMHH6edHgSo7uUsm3PoOdUJs+9TnysG7OvCrO/lnRojOHBiwy9923cTTvwrXmA8TOvkhjrRk2Gqdj75QIdNLpGNhGi8r6fxxKoZeTw94mPdlH3xD/H5C4jPt7D2LEXUFNRLIE6DA4fycl+culkobk9sOlxHNWLF9jLZyxWznGJdr9HfOAkee0bB56tX0QyWNGyaeJDp4n3HgVdQ3GW4mx7FNnqRY3PEOs7Smq8E/QclsoNWGt3IBltZELDRLsOkI1MIFtcONseR3YEEAQRNRUhfO4lsrFxQMJWvwtb7XZymTjx/hMkhs9icJTh2fz5wviuMd2psUkE2YC9fg/msjVo2STR7veJdr9HYugsktmBpWI91tqdCJJCZrqf0OVXQM0i23w41zyJbHGRS8eI9x8nMXQGyZS/jwbP3IDpfLhGOXuHJuGqYlUcC7+vhNJAOROTY/QP9dA30M22TTtvmTW4GZqmMTU9wYVLZwCw2+wFmrH58MY7P+XVN19iz/b7eOyhp/F5/eRyOS53XOAb3/pz/vx//wn/4V//yby0ty6nl899+jfJqhkMihE1pzI+MUAwNEFj3a152FcSoiCiKEYkSSmiVdU0bU45ylKP63b4cLuWX6t780dE03Lzal2sNgRBQFYMKIqRTOZ6JuxOSu7uFQT8ldRWt3LxyjFSNzSJnrt0hB1bHl20YxGLhblw+Sg35lrMJivVlc34fUuLfsqyQnvLNt4/9krh/uZyKh1XT/H1v/u3fOqRn6e9ZduHggJvtSBLMs316xkcvlrkgI2O9fLfv/5/8enHf4lN6+9b1WbyvIFqpWznZ9GBvlf/kv63/oaZjkP41z2Es35L3iC2OBAlZbZ/IEMmOp3XZug5ydSFt0lM9KKrWWof/Q3K93wByWRb1aiuwV2Je/MXVryvYiEMHPh7+l/7qyJBOsXmoebBX6Zk26cRZnsrYJadbrYHQpBkRNlQ6L9YyXuimB0YHP552aZSoTHUZAzlDlgBP84weSoQFdNc5i0tR3ysG0f1mlU7dyY6g3/dQ4wMXca/8TFGj/6Q6NBlBEmm5pFfI9xzivFTP8XkLieXTVP/1O8hSgqpmRGigxfxtu/HEqhh8twbpEKjlG75FHpOJdR9gkjvGYyecjLhCRqf/b+IT/QwduJFmp77V3jb788LA2oq6Drp8ARqKkb1Q7+CYnES6j6JbHGCIKJYHKTDk+QW0FFZCKIorWgplLmkFXP5GkAgfOlnJAZPY2/YSy4dJTF8BtfaTyHb8kEs0ZivukjP9JPLxHBv/AyS0YogKYiKGS2byrPLeetwtj1OcvQCke53cbU/jmRyEDz9PIqjFOe6TwFCocdJVMxYq7cgiBKp8Y6i8ck2P641T4Aokxq9RCY0jOIoRbYHcDTtJzMzgKViHaaSVsTZDCSaSvDcj/Fu+zIIIsmhM0Su/Az3ps+RCQ6SHL2Ee9MX0FIhol0HF32vjEbLPa/ZtSozXXlpJZUV1Zy7eIpMJsMb77zChrWbWde+adHHCEdC/PClfyISDQPgcnpoqm9dcPvOrsu0N6/l889+laqKmsKHvzRQhizL/Kf/+kekM+l5uxREUUKWDUxOjWAwGCgNVGOuaqW+Zs1dV2wUV3jSAjCbbbjdgTvsAZn7qiwk6rXayDd/370f1t1KlouiRH3tGirK6+nuvVBYPjrez8DQVcpKa29LhKBpOWZCE3T1ni9aXhKooql+3ZIdAEEQeHj/5zl2+s0iRy6bzdDZdYahkR4a69fxwN7naG3ajOEe4rFfKiID5+n4/n/A5CpDNtvwrX0A//pHbrufIAjs2v44J88dKHIsNE1jaLSbv/n2f6L63ed58L7PsmHNnmWTWdwKeYG8d4hP9BAbvIgoK2TjIUI9p4gMXECQ5DxLnSghiBK6ruWjlbqeZ8/JqWi5DOg6osHC9JWDTF86gJqKomUzt3Xave330f6V/7zkcQuijGS8O+xdo8depO/V/0k2doNTYXXT/Ll/g3/9IyuSgVgOFJsbs7uM+EjHnHWJiV6y8eAnjsUyYQ3UIRktc3pndF0j0n9mVR0LAKPDh6gYMTr9aGqa2EgHUxfeITHWgyBJWMuayWWTGJ0BFKs7P7fJCga7F6OrBKOzBD2noiYiDF/5HpnoJNnYDIrdh9Fditlfg2J1YXKVko0FEQQRyWguKs+zljWRGO+l9yf/HU/LLiSTDXnWOFesrgXFGW+Flc5YpGcGiPUdQRBEstFxREN+fKLBjNFZQfDcj7DV7cZSuRFBzF+bYg+QHDlP+NJPsdfvwRjIZ1fV6ASCIKI4y5AsbswVG4n1/hVaNoVotJIcvYh702eRjMXjFwQRUTYhKnODHLlkiFjPYbLRcbRMPH9cdV3+m2qwzGq4WJBM9kIpZzoySnqqm4n3v4FA/p0zeqrQc1lyyRCS2YHBVUYuaUZxLT7gZzZa7nlmqFX5oldWVLNh7RbeP/IO4UiIY6cO8bf/+Ff85i//C+prGxEXYGvIN2vrRGMR/umHf8fzL/4jkBdGaahruqVjYjAaMRqNmM2WItaha0qMVrN1Tq34NYTCU7z21ncYm+inurKF1sZN9A918vhDX76j+3CtLOLadeno+Ykc/YZgsn7jn0UieSsFk8mC3bY0Rdi7icL9ueEeXVs+u0XxPVJV7iYv+N06kyAI1Fe3U1vZSm/fpUJzlq5rnLnwHm3Nm/F5y2/5HBPJOOcvHS7KeAmCmC+Dql3eJFpV0cRTj/4iP/7pN4qcSU3XiMVDnL3wHpeuHKOstJadWx9j49q9+Dylhd/5vfrezYWAraKVls/9Uf5fS3DCykpqefzBL/ODl79OJHo98qzrOslUnM7uM3T3XcTrKWHnlkfZuvEBSgJVSKJ0W1rqxUBNRrnwzX8xS1+q51mWAHQtz4K0hCpBLZMgOnCNnWxxb7+aCC9twHcZyekh+l798yKnQlSMVOz7MiWbnvhAS42MzhIsJQ1w8Z056+IjHWSiU5j9NR+i39G9A3v1WmSznXRorGi5rmkEO49SsffLq3tfBQEQ8sxokoIlUIe7JU31/V+bLZ3UmL70LqmZUXQ1gy6KoGmzjFbXjcfoYF5EsmL3Fwj3nycx0Zc/vCRfPwd5shs9pxb912B1UbbjWRw16wj1nCQ72Y81UDdrDV3btxiSrCDfQpPFYFg5uvBsbIrQxZ/g3/1ryFYPoQsvc+27IyoWHG2PYancRLTnfRIj53BveA6DoxTFWYZn0+dJT/cS7XqX5GQXjuYHZve8bu0JN/bY6Pn5dCEmtvmQyySID55CUIz4d/8KybHLpKd6btpKYM63UtORbX7KHv79QjmpgICuqbO2zbV7L4KweFPcaLz3tSxWjRVqx5bdHD3xHu+89zqapvHKGy/S1dPJ55/9Cg/sexSnw4Uozk6oet5IyWaznL1win/43jd4/+h1PYeqihqefOQZDIaFX/TN67fz2lsvceHSWbZs3I4syejopNNpfvjSd9m94z40XSOeyHvnAkJB1yKVTpDNpnnmiV/l1LkDMNufsVxomoaay6KqGRLJGCNjvYyM9jE1M0osHiGeCJNIRElnUmSzaTLZDNlsOv8/NbviJT2ypCxb4Xi1oOkaOVVFzWVJpROMTwwwNNrDxMQQsUSEeDxMPBElnUnm71EmnVdYzqZR1QzaR0zJ9BqMRjON9Wu50HGU8YnBwvKLHceYmhnD6yld8KOo6zrxRISzFw8VLfe4A3mtlGUyOYmiyBMPf4VcLstrb3+XdDpZ1Eug6zqZbJr+wQ76Bzt4+bVv0ta8lV3bHqOhdi0Wiw1ZUj4chpGm5csmBAFREBAW2YgnCAL7dj2Npud48dW/JRyZLnpHdV1HVTOMTwzywit/zatvfZumuvXs3v4ErU2bsVkdSLJyZxNGUQnPXTaU7/FSuNFjPyIdmSxaJhktVO778gfev6DY3FjLmpDNjjmR9djIVaKDF7FVtCF/xGia7wYsJfWYfdX5Er8bg3a6RrDzMMnJ/mUp1C8GksE8m0HIl64oNg+Omg1EBy/R+fx/xGDz4Fv/IPbqtSQm+rj8nT/E7KvBVt58ndFKEBAVE9ayJqYvvUf/m3+DbLIhm22zpT/5eV0QRSSDhdT0MANvf5PY8BX0XA5P215E2cDIkecRRAl7RRu28mZAQMhlESQFSTEiSHLhmy4IAr/5tf+3KDh1M0RRWnRp7u2gq+k8cYMoomWTpCY6MJfNCnzONjZLVje22h3EB06ixiYxOErRsym0bAqDtwZrZiuZ8AhaOopiD6DrKtnoOLLNR2L4HAZ3FYJsBEHEHGgh1nMIW/01umEdyWjLl4eqqbyDp+VmNYFk0PKBTFE2omsqmdAQaqJYU000WMilouTSMUSjFUFUMLjK8qVoE10YfHWg59C0HJLJgWR2kkuGUKMT5FIRspFRjIvtsbjWvH0PY1UcC0EQaGls59NPfI7hkQGu9nSgaRpXe67wn/7rH/Fn//M/01DbRIm/DJvNTiaTIRwJ0tF1memZ4o+/x+3lsQef4v69j9zSMNF1nYGhPv7tf/mXlJdU4vMFyGYz9PR1EYtH2bZ5F3/8p/+m8OOx2ez88R/+V+AaPa5MPBElk0mRSieWVQ+taTlSqQTjU8Ocu/A+p86/y+Dw1Q9cpEeS5CXz6a8WNE0jnUkyNT3KxY5jnDn/Hj39F1eF0SmbzZDTVDQtl+9dEWXSmbxRbDCYEAQhX96j53sJ7oV7JAgCDXXrqCyrZ3xiiGtRkEwmxflLh6ksb8Buc827by6nMjLWy/BocTSlxF9Fc/2GOzLsZUnh6cd+ibraNbz4079mZKyvcC9vRjwR4cSZtzh17h2qKprYu+NTrGvfOas+PVeB/l6BrqlEBs7R8U//DoPDh3/9I7gatix6f0EQuH/Pc9RUtfLDl75OT/8lkqn4vIGCdDrJhStHudhxjBJ/Fbu3P8Hm9ffh85ShKMYlp7pF2YBv7QNL2mclsZTGzw8C4Z4zN+lXgGx2YLB/8OQDgiBgLW3AXr2WYMehm9bqTF54G1fjNmwVrfd8bfW9BkEQ8K25n0jfmaK+GgA1k2T40PdoePpfrIpieMNTvwdA82f/EICm5/4VAPVP/k7RdplMhtL9X8NsLg78xGJR0jpUPfyrSKKEt23fgucy+6pp+eK/R9d1Gj/zr4tKuLPZLPVV67CY845pPgAVIxINo1hseNfcjyiKJBJxFIMBRVZuqQeVy+UIR4L5wMkK+OQGVzlGfxPTx/8RQTJgLltbcJhy6Sgzp59HS0UQZAOmQDMmf150Mz3dR6TjDbRMEsFgxl6/G9legigpOFoeItLxFtHu95BMTpxrn8yXKQkCnq1fJHjmR0y8+xcIooytbhe2+l2o8RlC51/KG/uZBNMn/wlr5UYslesx+RqIdh0kOXYFxR5AcZYVBSRsdTsIXXyF2MBxbDXbCs3bvp2/SPDci+gX04iKCXvTfiwV6zG6q8kGWpg6+nco9hJkszPvTC4CJoPl45mxuIYH9j5KNBbhW//0DXr7u8hm8/n4ZDLBhctnuXD57IL7CoKAz+Pn8Yc/zS995TdvWxs+PTNJwFdCwHedrtVkNLFh7eZ5t5dvOJ7V6qAkUMnr7/wT8WQEHZ1dWx9fyqWSTicZGu3hrYM/4NipN2/p7c+Ha30D+rVShhVE3nH64COKmUyKsYlBDh55mSMnXiMWX1r5xLWyGn02nXk7dHafYWxykHg8Qn1NG6WBGg6feJVcLkdb8xa8nlIOHn4Zm9VBfe0aGmrvDePI5ymjtqqNK1dPE09cj2CeufA+e3Y8iW2WFetmpNIJzpwvbgIzGsxUlTdSOg9F71IhSTLr23bRWLOWQ8df5dDxV5icGiGVipObp99G07RCFqOyvIH79zzL+vZduF2B2yqufxAQRBln3WZav/jv7+g4ddVt/N5v/AlHT73BWwd/wMTkEIlkbN4yR13XGZsY4Icvf533jrzM3h2fYsvGB/B5y1CWUPMvm+2s/7W/vKNxf5SRTYTQb8pyatk02djMqnH9LwXW0gbc9VsId5+Y02gc7DzC5Pm3MDpLUWzue+53c6/Dt/ZBRg59j0xspoh2VlczjB37Md72+3A3bv9AosBqTuVy5wWCoWnu35vv58rlcmSzGQ4eeRtFVti+ZTdWi41MNo0sKciyjKbl0HXIZNMosoIsK6hqlpGxYVQ1S0VZFUajCU3T6OrtYGCoj8cefApN10glk7z4yvNc7rzII/c/yeb12zAYjLz57musX7ORmqr6wtgymQwGRSkEWrPZLKHwDD98+bs89uBT1NU0rsBdEPBsfG7eNbLFTcl9vznvOnNZO+ay9nnXGZzl+LZ/df5jmt34d/3ynOWKzYd/1y8tcK41mMsWLiU2eusoue+35lleS+kD/585yyWTHWfbIzjbbt/DdzNMJss9Yc/dCqvqWBgMBj7z1M9R4i/luz/4ey52nCMSCZFKpxY0nhVZwWa1U15WyTNPfoEvPvfztyyBuobPPP1zfObpn1vWOC1mO/t2Pc2a1u0kk3H8vnJsS2iWiyeiHD/1Bi+8+jeE5tW9EDAajBgMJhTZgCQrSKKEKOYNfkmUUQwGjIqJyekRJqaGl3Ud9zKSqTjnLh7ipde+ychY77zP36DM3iPFgCwpiKKEKEmIgljIuhgVE5FYkKGR7tueMx4PU+KrpH5LOz95/VsMDF3FanHgdZdy9sL77Nv1NKqa5ZH7v3jL49ztaVwQBFqaNnL24vtFTdij4330D3bg91XMaZLWdZ1YPMz5y0eLlns9pbQ2b16xZi9BELBaHTy8//Ps2PIwJ88e4OTZdxgd7ycej5DOzM8UNjTSzbd/8Gecu3iYRx/4Io116wpZo48irglLbtmwn9Pn3uXIyTcYHukmFg+TSieZr3dhYmqYH/30G5y7fIRH7/8ia1q2YTavLivTxwWKxYkgigV6TcgLifW/8Q0q7/sqssVRKAnJM8Xc3Xsum2y4mnZg7zhEuOdk8UpdY+jdf8DsqcC37iFks31FxqdrGrlMElGSET/EpAu3g9Hpp2TrUySmBlEToaJ1mdgMPS/9V1q//MdYAnV3pElyI/ScipqOI5sdt3xWoVCQUHgG/2xANJdTGRzuZ3B4gMGhPqoqa8nlcvQP9jA0MoDNaqelqZ3pmWmCwSlmQtOYzVa2btzOxNQ4L7zyfcwmC1s2bGfT+m1EY2Emp8YpDeSbgzPpNFd7OhgZHaairJLa6nosFivdvZ2YzZZCVkNVs3T3XmVkfBiPy0Nbyzq0XI4z508QioRIxO8+1fwnyONjywp1I0RRZN+uB9m4biuHj73Le0cP0N3TQTQWIauq5HI5BFFAlmSMBiOV5VVs2biTxx58itKSuyMMlMmmmJ4Zp7y0dsn7pjMp3j38Ij99/VtzIvCSJONy+nA7/VRVNFFRVoffW47T6cNqtmM2WzEazEXR2x+89Ff85PVvfeipU29ENpvmxOm3efn1v2NicqhonSiKOOwenHYvVRWNVFU04vdV4Hb6sVjsWMw2jEZzUY3+wSMv883v/OdF9VmkM0lCkWlkxYDBYETTdTRdY/vmhxEFEZvt3mRbqalsobK8gf7BDrI3RDBPnH2H9pZtKI7iaLaay9Lde4FgaKKwTBRFSvxVq5KJEQQBh93DA3ufY+fWR+nqOc/p8wfp7rtAKDxJPBGdE6HXNI1zlw4xPjHAs0/9Mzat3XtPOReS0YzJW7lixxMEAaPBzM6tj7Fl4wP09l/m1LkDdHadIRiaJBYPz9Fe0XWNrp5zzMyM8/hDX2bXtsewWm5tnHyC28Na1kyo5yT6DY6vlk0zeODviQycw9O2D2ugLs/MIyvzE30I+f8TRAlBkhBlY16DwmTLi9zdofPuqF6Hf91DJMZ7yMaLa7izsRm6XvwT1FQM35r7MbrLZht8l/Ze6JpGLptCTYRJhcaIDl7EWbvxni9lu1OUbn+W6UsHCXYeLnIu0TUiAxe48t3/h/pP/S72ilZky/wZ4dtBy6nk0nGy8RDJ6UHCPaepe/y3btnvZDSamJ6Zon+wlzWt65manuT9o+9iMBgIR0K4omHGxkd49c2XKAmUcub8Sb78+V9ibGyY946+w7NPfp5//P43aapvRtc0dE3H6XDhcrqBfLAuGotyqeM8G9Zuzis3KwasVisuh7tQfuVwuDhx+jABXwC/r4TB4QG+9+N/YE3ben7w4rf5l//8jwiGpnnjnVfYv/cRegdubl6+dg+yaKkYmprKiz+a7POyLC0Guq6RS0XRs0kEUUY02uZo43wcYTZZMChGZHnh8j3pFuvuBu4Ozx9gtzl49MGnePTBp4jHY4xPjhKJhIkn48iyjM1qx+8rwe8N3PVJNBia5K2DP+Crn//9Je2n6zpXrp7knfd+PMepMJmstDVtZvf2J2hv2V6IBHzcoOs6vQOXOXD4xTlOhcFgor6mnZ1bHmXjun047Cuf5h8dH2ByeoSWhg2UldRy/MxbJJOxfL2/wTiv0vm9AIPBREvjJi5fPVnUxH2l8yTTM2Oz9yo/Yem6TiaT5uTZA0XHsFmdNNatW7AnY6VgNllZ176T9pZtTE4Pc+7iIS52HGd4tIdwZBpVLTaex6eGeOGn38Bp99DUsAF5FfUdlgJrSQPWkoZVObYiG2hu2EBj3TpC4SnOXzrM+ctHGBzuIhSeJJNNF20/Exrntbe/g83mZMv6/RhWUcjr44DAhkeYuvAWycl+bswW6bksoa7jhLqOL+o4giQjGSxIJitGZynWklpslW3YK9dg9lVhdPiX3QwuGc341z9MfLyb8VM/Rbsp+5eJTNL10p8Q6T9HyeYnC1Sjstkxr5ORb0bNoGWS5NJJ1FSMTGyaxHhetyTUdZxsPETrl/7fj7xjYbC6qX3010mFRkmM9xSXRGkq4d7TXPnOv6Fsx3N4WvdgcARQLI4FHUY9lyOnpgr3NpuMkA5PEBu+QrDzCOGek4gGM7WP/sYt3we7zU5JoIxkf163aHJ6AqvFysZ1W7FabEiiRN9AN6l0gkgkjNfjI5lMkMvl2LpxJ+vaN9FQd4hQOEh5WSXlZZXUVNZRX5vvQ7BYrJSXVjAylp97jUYTZaUVVJRV4/cG8Hvz2lYl/lKcdmchEt7ZfRlN1wgGpykrqSAcCdHZfZndO/azYc1mTp05Os/VgJaOkRg5T2aqG9Fkx1qzHdniQsskEQ0WEIR8c3Qui6iYEQxmcslw/t+yAcniLoxBVzMkBk+TCQ8jW1wYPbUYffXkUlEESUGQDYVjCaKMaLKvSq/MvQa308+GtbuJ3SBYfDO8d0OU9Rb4QGZ0q9VGvbXpgzj1vJBlAzari2BoMt9xj4AkSSi3SQ+n0gnePfQS08FiKrt8GcSjfPbp31gSJds1ytW7SaW62shkUpw48w6DQ51FyyVRYuPaPXzmU7+O31ex6FKdPJWmzmLaUBTFyNq27ZSX1hXq1R/Z/4VZurk8I9n2zQ/f/pyLGtnKo7lhA2WBGiYnhwssZddKyirK6jGZrjX76YQjU1zpOlW0v8ddSnvL1rs2XkmSKA1UUxqoZseWR7l45Sinzr1Ld+8FwtGZoizc2MQAB95/gbKSGpwO78cmIi+KIh53gP17nmHbpge5cvUUJ86+zdXuc8yEJorofKdnxjh87FUqyxqoLG/42Nyj1YCzbiNl259l+P3vzqEeXQr0nIqajKAmI6SDo0T6TsPRH2Fyl+Nds5/ApidwVK+bZQJa+vOyBGop3/k5MtFpgp2H0W5yOLV0krHjLzB14W2c9ZuxV7VjK2vOl0dJMoIg5XVJtByamiEbmyEVGiM9M0J8oof4WHcRNfBHuQTqZribdlD9wC/R9+pfkgqOFK/UNZJTA/S+8heMHvsxrvot2CpaMXsrEQ2mgsF67d7m0gnSkUnSwVGS08PERztJTA2g35Bdvp3oYy6XIxqLMDY+wtTMJJNT41jMFnJajr6BbsYnR/F5ApQESqmvbaa+thGn3UVVRQ3vHXlnlq30Gs2sjiCImE1mBkf6qSivoqykgmgswsjYMDPBacYnx/C655IVZLNZpmcmmQnNMDI2RG11PQFfCY11zaxv34TBaKS+polQeIa+gW58Xj/ReHTeiVG2uLFWbkAy2vLsRyY7yfEOcqkokskOWg4tm0TPqYiKCYOnhtT4FXLpGJLJiaNpP0jXbQFBUjB6ahGNVtT4DDqQnuxCNNiQjNY8i1NORRBlTIFmDEvQg/iwIuCv5Muf/Rcf9DBuiXsjVPgBQxIlVDXDoeOv4HWX5hvHveU03Ib3v3+wk/HJwTklHzVVzTz75K9iMS9NmTKnqahq5gNnkVpJjE0MMDTSPSciW15Wx6ce+YUlORWQL6fJqrcX7AIoDVRjMlmLSs3yDeD3duPTNXjcJTTUrqG77wLRG6ITpy8cZP+eZzAazQiCQC6X48KVYyST14WOFMVIZVk9leWrE4G/HZwOzyyV6haOnnydg0deZnxioIjG+ezF93nwvs8WZV8+TrBY7GzesJ+mhg2cOnuAA4deYGCos6gRvrP7DEMj3ZSVVN+SV15TM0xfXrx661LgbduHeItzfxggiBJVD3yNXDrO8Pv/NIfW9U6RCo4w/N53CHUfp2r/L1Ky+VNIJuuynAtn/Saq7v8FdC1HqPvEnMwFgJqMMH3xHaZntS8ESUE2WRElAzk1g5ZNoalpFhWB+RihfOfnyKUTDB74e1LTQ3PW65pKcrJ/NrNFge71GnVsLpuepSS9cy0lTcsxOTVONBZBkRWGRwZprG+hNFBGb3++h9Dn9dPWvJZwOMTV7g5Ax+3yEvCXoOZURFGkoa4Zm9WOIis01bfy9nuv09XbSYm/lJmZKWaC01jMFgaH+nDYnSiKQnlpBQ57vgw4m83QP9iLzWpnanqSYGiGtpZ19A/2cvHKOTRNo7K8hk3rt9PRdYnOrstUVdRgtdpue43Z0EiBeSnefxw1NonRV4/J30Dk6juICRuCKKM4SpEsrllHqfh5ZEJDiLIRS8UGUlM9yDY/6JCNjqPY/BhL20lP96Impj8WjsWHAZ84FuQjrdeata81Xy/GKRgcvko8PneCum/n08uqi06lEqTSiSXtc69jbGKQYHhyzvKtG+7H6ylbclNxJpsinoguatuyZfTMzIcPMk7c3rqdU+feLXIshkZ6GBy+itPhRZx1ik/dVAblsHtY07r9lnWYdwMed4AH7/ssoijys7e/y8wNPSCpdIL+oQ5qKpsxGpdXh/tRgN3mYvf2JzAYTLz02t8yOt5fWJfOpBge7WZN6zYcds+Cx1CTMS7+3dJKOReL3f/uLQy2hc99r0NTMySnBomPXs3XfRvMK+5YXEN8tIvul/8MBIGy7c/BMtjPBEHE07IbUTIwbHEyc+X9OT0XN0PPZcnGQ3cw8o8HBFGkav/PIypGRg59j+jQ5etikvNB19EyyXmduzuFohhoamilqaG1aPmeHfeza9t9AIX58ZEHnkRVs3l1aFHE7wsUtn/i4U8X/m5ubKOhrhlByFdd1NU2Ulc7l7lp66adhb8tFis7tu5hx9Y9Rds8+6kvkM1mkaTrQqe/9gu/g6ZpRXS2t4JgMKPH4mRDg6BriLIhr3AvGRAQkK0+EgOnEU1W7J7qOY6FKBsxl7STy0TJJUOIigktk0S2+TDIRkBDkI358qlPfOh7Bp84FuSNsOWobEeiM2TU9JzlDfXrlkUHFgpPEYrM3H7DDxHiiTCp1FwGieqqFkzLMCbj8QjTM6MrMbQPBarKG6iqaGJ4rDevuUG+dvrk2XdpadqM0WBmOjhOT/+lwj6CIOLzlNHSuLBS/d2E0WBi68YHuNRxvMixAJicHF4VtfkPGxTFQHvLVjq7zhQ5FgAzwQnS6STcMtahk1utoMSHOOqdCo4RvHqEqQtvE+w4TPYmViDI902IkmGWEWp+6LqWVzFXs+i5W8uYZ2Mz9L7y59gr27BXLa93QRBE3E3bMdi9WPw1TF18h/hoVz4LsUIQDWYsgdoPtdO4HAiiRMXuL2D2VjFy5HnCPafuqDxuPsgWZ75vZZnli/MF3BYTJBIEAVleObNOUYrPec1hueUYJAOyzZfP9JgckMuixqdRnKUIlCGa7AiihMFTjRqbQnGWIpmdpMY7UeylhVIoQZSQ7QFExYJBrCATGsLkbyQTHMg7J0YbgighygZkmx/hY9Bf8WHBJ47FHSCdSaLl5vL32yxLZxrSdZ2RsV7GJwZWYmj3DLLZDKo613C0mG1Ldr50XWc6OEbfYOftN/6IIN8nsoMrV08W0RBf7DhOIhHFoBi5eOUY2RtKzcwmC431a28pcnS34XEHsNlcBa2Wa8iqGfRPQk1APsDhcvkQRamo10JVs2i3M+4FAcXqXvS5dF1Dz6lo2TS6Vvz7lIwWzP4aDHYvisX1oa3Dj492MXL0h4ydeJFMeJIbQ5oGuxdbeQtGdxkGm2e2jt4wf3pyVjdH1/L3K5dOkI2HSYfHSYz3zOojFEe906ExBg98i/av/Oc7UkG3ljZQ/fCv4qjdwPTlg0T6zhEf7yGXirGcEK2omDA6A5h91dgqWnDWbsRe2bbs8X1YIYgSntbd2MqamDz3OsGrR4kOXyE1M3Jbx3EhyGYHJncZlkAd9qp2XA1b73mF5NWAaDBj9FQX/m0qab7+qt7gaFkqNhDvP4HirEAyWEjPDHDjOy1ICiZffeHfij2fpVGc5YBeRLlq9NauxqV8gmXiE8fiDpCnQJ374chmlx5VCkemudpzjqmZlY2cfNCQJBlpno9rNpuZbaJe/KSbSEbp7r3A6FjfCo7w9vigzd7mho2UBKqYmhkrGJwzwTH6hzqx29ycvVis1mu3udmwZs98h/rAoKrqbGai+G6aTNZ7npP7biGXU1FVdU6PldFoRhIlNE0rlCTcDMlgpvbxYoGmayQF80LT0HLZPD1mdIbk9CDR4Stk40EEScbbuhf/+kcwecqQDJb5j7GCiERmMJmtSxIFvBWSU4MMvvstxk++jJosLp10N27Hv/FRnHWbMPuqUcyOJUWWNTUzSyk6RKT/HGMnXiI2fGWOQTp14W3SkUlMrtI7uhbZaMW35n6cdZuIDlwgMnSJxFg3qZkR0pFJ1EQYNRVHz2XQNW02A5NnzZFNVhSrC8XqxuDwYfZWYvbVYCtrwhyoQTYuka1QEDC5y6l55J/NWWWwebCW1M+z09Ihyga8rXuRTXPr+K0lDUgrwJImCCJGVwkVe7+Ed81+wj2niY10kJjsJx0aJxObRk1G0TIptNlnK0oygqwgKiYUsx3Z4sZgc2F0lWL2VmEJ1GKraMXkLls2O9i9hLcOvsbwyCBfeParGI3LvefCgvXEppJmMqERNDWNpWojiLc3SfPfh5UrUE6lkxw58T6dXZcBsJqtrF+7mXXtG1fsHIuBrmtc7rhA30AP69ZsoqpicaK2mqbx09d/TDwe44uf+YVVHuXicFcci1Q6xeTUODPBKRLJxLJLH7yefCPTvQK7zYWiGEimipcPjnTh9ZQu2mhOpRKcm6WfXKpi972OvA6FBaLFJV5jEwM01K3FZFyc0ZLJprnafY6jp94gk03dfoePEJwODy2Nm+gbuFLUa3Gp4xhVFU30DVwpLJMlhYqyOqorm1fk3NlsBllW7tjYGxnrJRiamGM0+71lBVXXDytU9Vod8p05SFPTo4xPDs4hJnC7/IiiSFffeRw2Nz5vObIkE47OYJANeedMNuLc/DSyrGA2WQlHp5mYHKK8tO6WdMO6lkNNRkhMDhDuO8PYiReJDXcQ7j2Dp2UPitVz26hrTsuRTifRNA2DYkCWDai5LOl0EklSMJssJFNxNC2H2WRFVbPIsoJOvoFVFESmgmOUKtUosgFN04hEZzCbrCiKgUw2jUExoqpqXmE4lyWVimM0mOftzcllUoydeJGJM6/NdSpadlH3+D/HVb9l2dFkUTZgdAYwOgM4qtdhcPjpfvFPSM0UC5vmUjHCvacxbXpiWee5GYrFiad1D+6WXWTCk6SCI6TDE2TjoZscCwlRMiAqBiSTLe9UWN0YnH4MNi/iHfRdCYKI2VdF46f/5Ypc00IQZQP+9Q/jX3971r47hSBKmL1VmDyV+LOP5u9rcIxMdAo1GSWXSaLnsuhccywMSIoJ2exAsbkx2NwYXaXIJvucd0rXdaKxKCfPHKF/sJdkKoHZbKG8pII1rRuoKK9a9eu7E7zy+gu8f+QAn37ic3fgWCwMyeTAXLp45szVgKbphCPBgghhb38Xv/LV3/4AHAudMxdO8cY7P8VmcyzasdB1ne+/8I+MjY98PByLZCrJhctnOXL8ID19VwmFgyRTSXK5HMuJA+/ctu+ecixKAtWYTVYiNxnNh469Smvj5kWp5sYTUc5dfJ8D7/+Y8Ym5LBUfdnjcpTjsbiamiq/t9PmDrGndTom/8rYGWTqd5ErXKV4/8D0Gh6+u5nDnxb1A8rl+zR6Onny9yLG42n2O5oZNJFPX2aDMZivr2nZiXCHdgyMnXiOn5airbqeivH5ZmhMzwXEOn3iNkZsyTWazjaqKJpQPuMH8TnH2wntEYiEqZ/thjMsQ/YtEg5w89w5dveeKlhuNZspL6xBFic6us9RUNuNxlTA8MUAwPEUkOsOmtXuZCU8yMTmE31uOsaSGYHCCjq4zuJz+WzoWgiihWN04rW7ss/SaXS/+CaGeE/S/+b8xB2owuctveT2xWIjegcuIopQfb0ktI2N9JJJRqiuaSKZiTE6NEIlOU13ZTCQaxOcpZSY0gdvpx2ZzMjbRj9vpx2Q009t/mXQmSTaboaaqheGxXmqrWhifHMLt8hMMTZBIxCgrrZnXsYgNX2Hq4jtkY8UNzwa7l9qHfx1X/eYVK1ERZQXfmvsZO/Zj0qHxorIyXdeJjXRQskKOxTVci7QbXfemBs+HFYIgIBlMWEvqVyTzous6E1Pj/N23v87x04dnfx9G0ukURoOJL37m5+95xwK4NybAVYTJaOLh/U+wbdMuDh19l//+v/6/H9BIBDat24Lb5aau5oNhc1wprJpjkUjGeevd1/j+C9/m4uUzxBN3LgFfUXZv/Qhrq1pwu/xMTA0XRRkvXjnG6we+x/17nsPpmL8xLpNJMzzaw+kLBzl97l1GxnoBvdB3cGON9YcZZaU1BPyV9PRfKrqmrp5zvPnu8zy477OU+Cvn7bfI5VTGJgY5e/F9Tp55h77BK+i6PtvYJqzYPdJ1fZbGNk02myGTSZHNpslkM4xNDJCahxFkfHKIvsErGBQjimzEYDCiKAYU2bgiEf6bURaopq6mnfHJoUIT9+jEAOcuHbohCyDgdHhZ275z4QMtEecuHaa3/zKlJdWUl9ZSXlpHeWleQd5udyEv0DCnaTki0SB9A1c4e/F9zlx4f46I5JqWbfi95csiOoBrzy1HVs0UnlcmkyabTTM63jdvZmt0vB+n04vRYM4/O8Uw+19jES3xUtDRfZazF97D5fRTVlpLeWktFaV1lPircTm9CzZdappGPBFhYKiT85ePcOb8QYKhYga1htq1lJfVYbHk6SRdTh+SLNPRdRoQiERnSKUTCAhMTY+i5XKUl9ZhNOaj+Q7b4vsuRMWIt+0+Ql3HGQ6NE7x6lODVo5RueQrhFnSzyVScYGiSkkAV4cg0NquTWDyE0WjGYrHT3XeR0bE+0pkkbmcASZQYGetjcPgq2zY9iCwpJJPxfM+apnG15xzr1+ymu/cCk9MjjE8MUFZSw/TMGHabi2w2w/jkEBazDa97bplR8OpRklOD3By88rTswVGzbsVL72STFUtJHaHuE+TSxdn4TGRqRc/1CT48yOVy/N23v86PfvJPPPnIs+zb9QA2q51INMxMaJrK8urbH+QTrDpEUcRqsWEymovYtj6IcbS1rKOtZd0HNoaVwqo5FmfOn+Q7P/g7zp4/WcTLvlRYzFaqKmqorqpj364HV3CEdw6X08fath0Mj/YURZJT6QRvvvs8w6O91Ne04/OW5cXMdJ1kKkEoMsXYWD/DY70Mj/YUDK6Ar4LqymaGR3sZHe/7YC5qhWG3umht2sTVnnNM3tB8nM6kOHTsFcYnh2isW0uJv2qWojdf8xiJzjA6PsDIWC9DI92EI9MAOB1eGmrXEApP09N/cVlj0nWdyelhDh5+mUw2PetIZFBzKrlcFjWXJaeqqLkskWiwQEF8I46ceI0rV08iSQqyJCPLcuFvSVYwKEaMBjOlgSr27Xp6eTfvBsiywqZ1+7hw6Qgzs45FJpPi/KUjhW0MioGm+g14VlBNXNd1guFJpoNjXOk8idPpw+MK4LC7sVmdOBxezCYrBsWIJEnkcirJVIJINEgwNMHE1BATk8Okb3LOfJ4y9u18Cqt1aUQHI6O9HDv9JslUPP/c1EzhWak5FVXNksupRGMhIvMwrL139Cecu3QIWVKQZBn5hmcmS8qsg2ikprKFrRvvX1yZlq4TiQaZmBrmas9ZHHYPblcAl8OL1erA5fBhNtswKHmnM5dTSWeSRKNBguFJJqZGGJ8cLNIhgfz3ZceWhwn4KgpO0OT0CAFfBU6Hj9Gx/rwDYTCTTMXJ5VTGJwcRRRGDwYSqZpkOjlFpXnz0S5QVPK17mDj9KqlUjKnzbxLY8OhtdSxS6QTB4DiSlL+nJpMVt9OP2WTFYrbnBbwQMJosBLzlHDr+CpIkYzJZiSeihCPT9A5cxmH3YLe5GB3vJ51JYjHbkUSZi5ePkkzFqa1uBV0nkYgQmv0m3IhcNkV8rKtIBO4aPK178o3oqyA0qFhc87BK6eQWSVOqZZMkRi6iZ5NYKjYgmVe2PETLpkmOXiAbHcdavbXQCHuvQdd11Og44cs/w1a/G5O/mCo1HJnmUucJgsFJFMVAY91a/L4KunsvMB0cI5NJY7M6WdO2HbfTT1fveXr7L5PNpigrqWVt205kWeHtgz/E5y1jYmoYURTZt+tp1GyWK12nCr+rhto1+fdtmbhy9QIvvfoDNq7byq/+wm9TVlJx/Rpzc3up7k18xNMVHxEI99hzWhXHIhwOcfjYQS5eOVdwKupqGti4ditlpRUYDUa++8O/Z3R8mNrqBh7a/zhGg5FEMs7I6BDnL51hdHwYRVFY176RX/7qb1FeWoHPe299DEVRYseWRwpR2Wz2en9ENBbixJm36Og6jc3qRJmtKc5mMyRTceLxMNkb+im87hLu2/VpWpo28eqb3/7IOBaiKLKubRd9gx0cPvYqyRuoZxPJGOcvHaa3/xI2qxODwYQAZNUsqXSCWCxUJKxnt7nYtfUxtm56kCMnfnZHjsX0zBhvvPv9Gxpmby+4dyPGJgYYuwWDlyTJKLKB5oYNK+JYADTVb6AkUE0oMl3I1oRvMK5MJitbN96PuErN0Dktx0xwnJngODBbkmE0oygGZFFGEEX0WQHDdDpZ9H7fCI+rhMcf+jKN9euXXAY1PjXE2+/9kGQyb0hrS3xuI2O9s9nBuRAEAUmUkSSZrRsfYNO6fUvu/9B1nXBk+obnImA0mmcdLxlRzLNiqWq+B+Fm4chrcNg97N/9DOvbdxf6kNpbtpHTcoiSREvjRgKz4pImkwW75mJN6/bC/nabm3XtO7FYlibSCWD2VReYoKLDHeiL6IkzGkxUVTRjMppxOn2YjGYMSr4cr7ykBovZhqpm8LhLMBrNtDZtQZZlTEYLai7LxnX7MBpMs7S724jFw5T4K/H7ylFkhXgyiiIbsFmdSKKMyWzDZplrfKuJKNlEGH2eYJbZV71qDbW5bHJePQRxkRSYei5LeroXLRXBFGhaccdC11TS032kJq9iKmm5Zx0LgFwyQrTnEMZA4xzHYmJqmI6rp2lv2YrT7sVh95BOJ7nacw6zyUpdTRvnLx3JZ7Yyac5dPER5WR12q4vT5w/icZdQVdHI5asnaRO2UFXRhCgIoOuMTvRztecca1u2MzkzwsWO43jdpdjtrmVdx9sHXyeeiPPsp75QcCog/525+bs3E5zmzPkTXOo4z8TUGKqq4vX42bl1DxvWbsU2K0Z35PhBDhx6k69+/pc5e+EUp84dJ5GM4/eVsG/nA2zZuKOQddU0jYmpcd59/w2udF0ilUri95WwY/NuNq7bisVyvXE/m81w/PRhDh9/j+mZSTxuLw/ue4x81q/YaE1n0hw6eoDjpw8TDM1gtdhY276BPTvux3+DjXa15wrvvPcGa9s2UOIv4+Dht+ju60TXob1lHY89+BSiKPBXf/vfePrxz/Le4bcZHBlg/+6H2LhuC99+/ptEomF2bdvHQ/sfRxAEotEIZy+c5PzlM4xPjJLJpHG5vGzZuJ2tG3fidCzvWS0GXT0dvPLGi9TXNvHAvkewmK/fvx/95J+4cOkMv/aLv0NpIC/Sp+s6YxOjvPXua3T3dpJIxjAZzZSXVbJz2z7Wt+fp4MfGR3j1zZe4cPkMAD5vCU8+8gzr18yli89k0hw8/DbHTx8mHAkR8JXy6ANPFlEMx+JRfvr6jxkeGeQXv/TP8Nygtn7+0hleeeMFtmzYwc5te3n5tR9itzlJZ1Kcv3iapvpW9u1+kPePHuByxwWa6lt49lNfwGJZmtjnqjgW/UO9XOo8Tzqdj6zu2Xk/X3z2q7Q2r8VucyCJEm+/9zpjEyOUBEr5/LNfwWl3ks1micaiDI0M8MrrP+Ynr/+YkbEhuno72LFlD0bjvUd76HWX8uTDP08mk+ZS53FU9ToziK7rRKIzc3owbkZZSQ0P7P0M2zY/hNVix++rQJENCxpmHzY4HV4e3PsZ0qkkJ88dmKNrEYuH55TJ3Ay308/+3c+wZ+eTuJx++gauYDSYSGeW18it5lRSqdUTI8zlVDQtRyo9N2KZTqcYnxxDVbP4vQHs9sVF7a0WO+vbd9E/1EHiJpFAURApDVRRfxu1+KXiVmVKuq6RSsXn1SlZCHXVbTyw9zNsWr8Ps2mJjDTkywuSqcSq/DbykcR8xiqdSS2aBlcQxVtEwXXS6QTpJWhMlJfWct+uT7Nt80NFpZSlgepZB1hAsRqw3mBY26wurBZngf/eZDRTVd7IcnrZJIO50IOQjUze1uk2m2xUVzZTVZE3AgVBKOrxMZkslNzQCyEIAuU3iFfKskJ9TXvh3y6nD5fTV5jI/L4K/FD4t8loydPyzuNA59JxtAXeDcloXpVsBbpOamYULXvzeQWMjsVRPouKGXv9bvScimR2rfgQPyrwuAJUVTQxMtZPOp3E7ytH13UUxUBZSQ1tzVsZHu0hHJlGzWXRdZ3G2nV4PaV09Z5jeLSH8rI6BEGksqyB5saNQD7jNjTSTVfveRRZIRYPI8sK8WRk2Y7FuQunkCWJbZt23Xbbqz1X+MFL3yGdTuPz+snlchw5fpDjJw/xG7/8L9iz4z4UxcDAUB+vvPEiwdAMk1MTeD3538mbB17l5Jmj/B+//YdsXr8NXdcZHO7n69/8b1zpvEhZaQVWi42zF05y/NRhnnny83zq0WexWfPZxJ+9/RO+/fw3yWYzVFXWMjE5xv/8mz9jemaqqOQ4nU7z7R98k5df+yFetw+vx8fI+BCnzx2n4+olvvalX6ckUAbA9PQkBw+/RU/fVWw2O5NTE1jNVsKREANDvaTSKUQB3nnvdYaGB/B6fFy6co6zF06ya9s+ZoJTjI6P0N3bSX1tI/W1TQyNDvD9F/+RSDRCwJfPzJ8+d5xjJ9/n57/4qzz+0NOr0mQOMDUzyaFjB8hmM+zdeT/c0N518fJZ3jzwKl/67Ndg1rfq6bvKn/z5f6R3oIv6miZcTjfhaJjxyTGqKmsLjoXJZKa6spZUOsnRE+9z8cp5Nq/fNsex0HWdH7z0XZ5/4R9RDAZqKusYGRviT//iPzE1c10fKpNJc+7iaS5dOc/nn/0qnhuqYccmRjjw/hs4HS62bNzOuQun6OrppKmhlcGRfo6ePMSZCyeRJJmJyTGOnDhIdVUtu7bdtyR9lFVxLMYnRhkZzTfrVpRV8enHP8u+3Q9huuGBm01mBEFAy+Vw2Jy4nPkJ1O8roaaqjvKySmRZ4Ycvf5cfvvgd/J4ATz/x2dUY7h1BEARqqpr5wrO/zftHf8rhE68RCk+zmAndYrbR3rKdPTueoLFuPTZr3lAoK6nG4fAw/RGhnhUEgbKSWp5+/JcoCVRx6NgrTEwNoWm3jzYripHmho3s2/kUrU2bC4aWz1uGz1vO8GjPag//jqFpGolEHMVgIJPNMD09yamzx/C4vXT1dLB7x35s1sVFljdv2M+BQy/McSwUxcjGtfsWzbK1WDz+0JfxuEs4c+5dxqeWRy4gihKlgWo2rdvH+jW7qa5owmg0r3gfygeFfTufwmyycvr8QYZHe5bFepcXNSxl/ZrdbFq3j5qqltnSQGHOdtf/vnndfP9e+j1Wk1H0WX2exZRr2KwOTLd5nkt51ou5rgVT/7c4j5qM5cX+Vvi1S0wNkJzonePQCIKApXRxZWiCpGBwVdx+w485nE4fmzfsJxSe5HLnCc5dPMy69p1kMiky2TS6rpNKJTCb7VitDlKZJOrs7zEWi1BV3sy1t8dmux7QEUUJi9mOx+Vnw9q9CIDBYMLl9M0/kEVgYmoMk9mCy5m37KamJ/mLb/wJg8N5AcyWpjX86s//Nm6Xh7qaBn75K7+J2WwpzAWnzx3nm9/5OidOH2Zt2/pCxYaqZrnUcZ7f/fU/oKGuGVEUudRxnj/649/nlddfYPP6bUSiYX721sucPneCZ578HA/vfxKDwcDk1DjPv/htfvTSdykvrWDfrgcZHO7n1TdfJpPJ8Etf+Q3WtK5H03IcO3WI//nXfzZLtpOfxy51nuc7z3+Tndv28pXP/RJWq41YPMqbB17lxVeep6qihi9/7pcK9yCbzXD2wkk+9+mv8Nynvojd5iCTzSBLMl63l2BoevbYOX7us7/Izm37+Ff/7neorarnd3/jD+jsvsz/77/9BzquXqK+tomykgp+4Yu/htFowmFzIIgClzsu8K1/+gbHTx9my8Yd90Tviqbl+Mu//jNOnTnKH/zev2P9ms2YTGay2SypdLKo+sZhd7J7+31s2biDTCbDq2+8OO8xu3s7efm1H2IymvmNX/49aqvryWYzvHvoTf7H//oTfN7l6VZpusa+XQ9is9n5r3/xx3T1dPC7v/EHuF1efvf//lXOnD/Btk27PnjHIhSeKbwwrc1raG1aU+RUABgMBgRBJJWeGxmUJIm66gY+98xXOHn2GP1Dvfz0jRfYtmVXIc10L0EUJcpL63jswS+xef1+LnWeoKf/EiNjPcTiEdLpZCGK57Dn6SJrqlporF1HRVk9LqcPRblew7xx7T6qKprIZPJlEjarE7fz9qlrQRCprmzmX/3u/yxabjSY8HnLln19giDyxWd/h6ce/doNy4SiiOntIIoiAV8F9+95lrWtO+joPkN33wWGR3uIRIOkknF0dAyKEbvNhddTSnVlE011G6gsb8DjDmC4IQraVLeOX/uFf1vIOljMtkVfoyAI1Ne0z7lPKw0BMJmtpDNpTp49htVqJRIJU11Vx8BQH8HQNG6Xt+jZ3w4+TyktjZuYDo4Vld6ZTBa2bLx/xa+htqoVr7uEXVsfZXomr50xPjFIMDJJODxDIhkhk82QU7Noeg5FNmAwmLBZnXg9ZZSV1FBb1Up5aS0edwlWi+O2yq23QkvjRv7P3/5vtxeMu0PYbS6U2/QVXEN5aR0P3edly4b7CYUmGRi5yuhYPzOhCULhKWKJcL6HJ5tB03OzvRwmLGY7Xk8ppSXV1FQ2U1neiNddgs3mWhb71koh0n8ONZ3PQslmx22bnSVJvmcog2WTHUmZP2IZGTiPo2Y9kmHlyqG0nMrY8RdJTs9tFhdECWf95lvunwkNE+l4i0wwX1ZpKmnB3rgfxV5sJMT7j5OcuIqtdjvJsSukJq8i6HmxMEfrw8hWT8EB07UcmfAI0a4DZMNjSEYbppIWdK1YZyM5doVo17vYandgqdxQWJ6NTxE8/QPMpe1Ya7cjyvlKAV3XSE/1EO87RiYyCpqKaLRjCjRjq9uFNKuJoesamdBQfrvgAOhgcFdhq9uF4iwvYuTKpeNEu98lNXYFXcth8jVg9M/vjOm6zvBIN+8efhFBENG0HGta8oQugiBw4fIRevovoqoqa1q3U15ax8hoH2+9+300TcdgMFJX04ZY+P5c9zAVWaGmspnhkW4OH38VQRCormimNLB8IzWbVZFluZBFlCQRl9PD1MwkFy+fQ1VVMpn8N9zvDeDzBIoUtxXFwKtvvsTo+DDxRKzIGN274362b96NzZZ3Qhx2J35foKDFEAoHOXDoTQK+AJ99+kv4Z6P7FWVVjE+OcvHyWc5fOsPWjTvp7LpM/0A3+/c8zPYtu/F58u+e31fC93/0jySSfflnlcvx1oFXiSeifP6Zr9DSlM8yappGNBrhp6+/wLmLp3nuqZ/DbDLPPjOorW5g1/Z9tDatWTDA0FjfSk1VPX5fCZIk0VDXTENdnjJdFEWC4XzVh9PhYtP6bUX3yWyy8O6ht5icGiccCd0TjkXfQA9HT7zHru338cTDz2A2Lxzwy5ezmjGZzJhNC2937tJpRsaG+IUv/hqb1m8tOKAet5e//tbybZmykgoa6pooLSnH5XRjMVvzTlxpBQ6bk+mZ6UUFgW/EqswGqXSKZCpfAlIaKCt47DfCYDAiigLRWBRdm2skSJJEVWUN9+16kL/77v+if6CH85fO3JOOBeQ/bE5HvuazrLSG3anHSaeTsyUx+YciiiKyrKAoRkxGC2aTdV7GGIfdjcO+eDaXG8dgMdtomU3vrhQEQaCy/M7pzwRBwG5zYbM6KQ1UsW3Tg6TTSdRctqBgLogisiRfv0ezolk3w2KxU7OM+vFr47BaHCt+nxZCPBFneHSA4dEhnnni88iSRMBfyprW9QyN9BMKBynxL05ESxQlLBZ7kbEnihItjZvxee5MiGv+84mF97qiPF86kMmkUdVMvsk9l0PTtXy5jJ6/t6IoIUkSimLEaDBhMub1CFYiQ2G3uW5Jn/pBQBTFwrjKS+toqF9LOp1vLL/WTK7rWt4Z0vXZeyQiijKKYpi9R5Z8j9EHnMVJTPYzduJFsvE8Vau1rPFDJfSlWJwYHF4ESZkjWDd2/AVKtjyJqJSuyH2+5lSMn3yZbCIyZ72zfjMm162DHZLFja1uJxlXObG+Y2RCI+i5uX03ajJEcuQ86ckuJIsbo6sKTU0S7z9GNjpKyf7fAUFC13Wy0Ummj/0DuXQUc2kbgiCRGDxDNjKKZL1eWqelY6Rn+jCVFDco62qG9HQvir2k0Dei6zqJwdPMnP4+omTEVNKMqJhRE0HU2CRCYR7TSU92EbrwEzQ1jdFTC7pGcvwKmeAA7g3PYfTWgSCgayrBsz8kMXgaU0kLss1HJjxCYvTCgvcr4K/k4f1fAPKaPTabk0QiislkpbWklsa6tciSgsPhwaAY2b75IeKJCJqmYTJacDo8CAh89tO/WZSNEAQRjzvA/j3PkkzFEBAwmSzLZqwDsFisBMMz5HI5JEnCYXfx1S/8CoPDffzlX/9ZIXAIkEgmOHfhFO8fO8DAUB+RSJh4IsbAUB87tuyZY9i1NLVjMBoL77GiKNisduLJfEAgmUoyMjbElg078N4QyZYkiZJZm2x8coxINMzk9DjReJSqilrsN2TObVY7pSXlDI8OAvnI9pWrl4hEwvyb//h/oCjXbZdkKsHw6BC11fUkErGCYwFQWVZFwH/r35zL6UIUBMwmC4Ig4nV78z1vUn4uyal5+yCdTnGp4zzvHn6LvoFuwuEQ8USckdFBmpvaCnbEB42+gR6SqSQbZjMVK4HRsWFSqST1tU1F5V52m5PS0nIikdCyjmu1WDEY8syWkiTjdLhQZAVJlJBleVkZ+FVxLFRVLfQaXGvIuxlWiw1RlAhHQgt6Q1azjbWzIiUzoWmudF7gkfufXI0hrxiuGa1LieZ/3CAIAmazDbN5rqrqRxV2q4Otm3Zy4coZmupbmJgcI5GIYzabMRgWn7FIJuNcuXqqSN1dlhV2bH34jibB20EQBGRJxmZ1wtJbIz42kKR8SYXFvDynd7nQdX3e5uHb7wiamiYVGifUfZyx4y8Q6T9faNj2tOy+wWi89yFIEvbKdqYvHSQdKi4ljY9epfvFP6X5s3+IbHHdkXORDo8z/N53GTvxIqmZkXnvfeW+r8zDFFUMUTFj9NUjmZ2kp/vJpWPzb6jnmaMUewD3uqeQbX7QNSSjjfDl18mEhjB6atDVFImh06jxadzrP42lciMAqfEOgmdfmPe4i4GeTTFz5gcIooJ/768hmZwgiAXdDkHMvyNqIkR84CS6lsO19mmMnnz0ODl6kdDFV0gMn0O2+ZFMdlLjnSSHz2Ot3oKj9RFEgxUtm2D66LfmHYMgCJhN1jm9WYlEFFGQcNjdczIMNqsz/826CQHf3LIzSZJxOb24nN7F3ZTboKaqlr6BbkZGh6iqrEGSJLweH4lkHKPBVHAswpFQvuT7pe9SW1XHpvXb8Xr9ZLMZvv+jf2C+h2S32ef0GAmCUCAtyBNEqMiSPGe7awQVuZxKTsuhqipaTkNRlDlziKwoRaWDqXQKo9HEA/semXe+qa9tnGNIG4zG25J0CKIEglD4TUpFZTf5ZfFEjNfeepm//ce/ojRQxvbNu/H7SmaVp19A03LL6ChbGWiaVnTufCZKx3SLTMX8WPgKVFXNZ94Uw5xnutjsuq7paNrNmVUxX1567d5LUqGktJAFXfT481gVx0KWZWRJJqNlSGfTRQ3N12C35UsiwuEgsVgUn9c/50OvKEoh/ZdKJZmemUsv+Ak+wb0Os8nMQ/sfR5IkMtkMBoORqopaBCGfbbBaFu9gnbt0iOmZsaLad48rwJqWbasx9GWju+8CPX2XaGncuGIq4J9gYWTjIY7/yTJ70HQdPaeSy6bIpWIF48TkLsO//pHbUs3ea/C27WPi9KtzHAtdyzFx5jWS0yPUPPwreNv3Iy6hhCuXSREf72bq/JtMXXibxEQfuUwiX+9xE/wbHsXTsvu2xxQEAQQpb5jfjs1N17FUb0ZxlhfKk0wl7YQuvooancDoqck7ieMdiEYb1uqtiIa8YWPw1GDw1qDGlzeHpqa6UGPTeDZ/HsVZsaBTpsamSE/3YvTUYi5pRphlxTIFmpB7DpGe6SeXjuYdi8kucpk41todyDYfgiAiGsxYqjaRnOhc9NhcTh/3731mQU2dDwrbt+zhrYM/48ChN/jqF35lwe16+q7yxjuvUFfTyD//td+noqwKWZIZGhlYsN7+duWJBsWI2+UhGJohm80UBXejsQjhaJg2+1psVjsOuwOTyUQoHCSdSRVlImZmJguBX0EQKC8pp7f/Kk88/My84n6SJGM0FJPsCAjLcOLnbj82PsJPf/Zj3C4Pv/eb/zc1VfXIcr7J+PDxg0zPTM5znJWDJEqIopSnpb+JdW5mZqqoNDmfoREZmu2nWQm4nG4MisJ0cBJVzd5QUqwzNT1+wz0WkCUlT0aiFmcbEsk40eitiXJWogdtVRwLk9GE2Wwhk80QCgWJxWOFGr9r8PtKUGSFhB7navdlqiqr5y0Lkma94qyaJX5Tw+onWDp0LYeaiiGIMvIyWHk+zJiZGcdisRcah3Vdz9P/puM47fMLGc57nOAEplnxr8VAFMUCtd+1FObNH9/FQNM0jp58nfgNZReCILJt00MFas97Bf2DHZw69y4lgSo++IrXjwF0jdT08prr54NktNL47L/C7Kngw8Zlb/JUULL5SRKT/XOcCy2bJtx7ikvf6sDg8ONq3Ia1tAGTuwLZbMs7UZpGLpsml0mQjc2QnBkmOTlAfKyLdGQSLZNCU9PzOhQAtrJmGj/9L5FMthUvbVOsgYKxDhRogQuN41qOXDKMZLQjKOYbtjMhmRzLdiyykfx9NHqqb3lNWiaOGp8mPd1HrPe6xo6ua+jZJEZ/QyEblksEESQDktHG9XdMQLEtrQlVkuS7niFcDB65/wn+6m/+jH/43t+wY8semhrm18RIZ9IkEnGaG1qpLK8u0Jhe7rzA8OggTfUtSz630+li++Y9vH/0Hd478g4P7HsUyEf9z186TTQaoqGuGZvVTn1tM35vgMPHD7Jv94M01tkL5x8aGSw0b0uixEP3P8Hr77zCK2+8yO/+xh8UvQu5nEoulyvqf1hJZNUssXgMn8dPTVVdgYK3b6Cb7r6ruFaRahbywXCb1c7w6BAzM1N4XPnM1oXLZ+kf6iN7QwC9vWUtJYFSXv7Zj/jS5762In0fbc1rcdidvPnua+zYsgf/rC1x9uJpxidGKS3JtwnIsoLfFyCeiNHdd5Xa6ryK/PjEKBcunyGeWCAruoJYFcfC7fLi9fgIR0KMjg0RDE3PkSivqaorGFnvHn6LvbsfnKN8m1WzTE6N37DXh2uC+6Chz9Z0FyAIaGqWbDyEZLQgzcMgFOo+jrW0EcXqurbTtaPl/752vGvPqcCyspyoxJ3hWtRe1/XZ4QiAnh+ScP3va7hw5Qj1desoK6lBRETXdZKpONF4aFahWL/h8oQFj32p8zjlpXVFFJmrDV3X6eg6zdBId1HNo6IYuG/30x94bf7NSKeTGBQDNsvSBPA+wQcB4fp/BBFHzTrqn/xdXA1bEFZBRX61IYgSpdufIzHZz8jh51GTN/U/6BpqMoqajJKcHJilC56HMnj2+5nvH9LQNY1bFwUIOKrX0vaV/4zZNzeae2cXNfsf2UDRPDjfo8l/AOccYN4od+Ezrl9/zro+9zKvfRhvU26p6zqCKGEpX4elam7jumRyIlu9hW2Zj7lslXR47jZcTg//+vf/I3/w7/45v/q7X2LPjv34vAFGRgY5ff543mEQoMRfSmNdM+8fPYD1r/+M+pr/P3vvHV5Xep33/nY/vaD3Xth7mT6cPppRG/VuWZYcVzmx4yT3Jrm+uddxfJM4cRLHjuMiy5ZlSxqV6b3PcEgOeycIovdycHrZ9f6xQZAgWAASIMgR3+eZIXDOLh/2Ofvb31rrXe/bzKnOk5zuOkkmk74qp/iiSDGfeOwzHDq2lz/849/j/Q/eobSkjGMnDrP/8Ac8fN9j3H3bfa7bc9sabtt6Nz/4yd/y+//p/2T75jsxTJ3X33kZzeNBnu7bEEWRO7bew+MPf5LvP/kdOs6cYOParUiSRN9gD+MTozxy/0f5+Ec+s9iXEnCv56r2tbz+9ov88Z/9IatXrKW7t4vjp46QSExRFJl/cvAsHMchnUnTP9hDKpXg6PFDFAoFzvR0sHvfewQDIcpLKykuKqG+tomVrav5wc/+jj/SC9PqW0ne2/3mDL3tLDTNw7/49v/N7/7er/HVX/kUjz7wUSrLq0mmEgwO97OybQ1f+8K3sG2beGKKodEB0ukU3X1nyOYynOg4SjRaRMAfoqaqlmAgxMZ1W9m2+Q5eePVp/u2//+ds2XQbqVSSl15/hqrK2hlZYL/Pz/bNd/L9J7/DH//ZH3DsxCFUVePQ0X2c7jxBNLI4VL/LYUkCi/LSCirLqunq6aSzu4PB4QE2rts66wG1sm3NDAXkuVd+xmc/+RVWr1g3SzEmNjXB2ztfBdxm73Do1iJlIcjHhhg78AKWkUNSvfgrW5E0P+nBU0Rbt7turBN9yN4genIC2RdkaNeP8USriLZux8wm8Fe14S2uZeDt71G28SMMv/8kiBLhxvWogSJG9z+PGiymZPUOvCXXNzftODanOg9w8vQBSooraapbSe9AByNj/bS3bHDdu8f68HkCGKYrcffB/lexbJttmx6gKFLGzj0vUFXZSCRYxKFjO4nFx5BlmZVtW8jnsxw/9QHlpTU0N66lb/rYmWySyrL66/q3GqbOG+/+hKnE7HLvlg33URRZPKftxYLPF0KWFQpGbvai5RaWBKKsUrr2gYXvKAgIkoLsDeIrbSDcvJlAVRuS6mU5kgWLBVHRaHr8nyJpfgbf+0f01ORF+yAc27yq1pTZJ5OQFA8V2z5B4yO/ihpy6btLde0ue1xBQvQGsAtpHMuYDkTcPhqrcEHFXxTdRatjzgpGrFx8pnfiLGR/KeBgJEbQipsuOQZR9SIqfiRfFH/91ov0mJzbT/KGcMwCtnG+F5GDmf1wUJ4FQeC+ux/mL//7P/Kdv/9f7N77LoZpUlJUyp237eChez9CNBylrKScb3zl1/j7J/+al19/FsuyWL1iHb/8td9g976dJJJTM8GFLMv4vH5XhW1WfCng9Xgxz4qgCAKr2tfw//3e/+Dvn/wO7+56g3QmTW11Pb/yi/+URx/4GNHphbgkSfzil3+VkqJSfvb8j/iHn3yXqooafvkXvs3I6BA/eup7Mxx8vz/Av/pn/w8b1m3hmRd+zN//6K8RBKiqqOH2bffM8l4QJQmvx+0hvNQ3VhBEvF4fiqzMbOP3+WfoWKIo4vP6kBWF8tIKfuGLv4woiby3601ef/tFWptX8oVPf42h4QFOnT6OtMBqiWka7NzzFv/XH/wubuLQwbZtXnj1aV567Vk0zcMXP/0L/Oo3/hkej4cvfe4b+AMBXn79Of7+ye9QXlrBVz7/SySSCZ596cczimeCIHD37ffxV//jB/ztP/wFr739EplMmlAwxMr2tbRNV6+yuQzPvPhj/vSv/gvgNsg7tsPf/+iv+f6T30GWZf7dv/qPPLjDNcH7nV//N1RV1PD8K0/x3X/4cxpqm/k/f+f3OXRkH6+9/eLMNVuzcj2//2/+C9/7wV/y1PM/wqN52HH3Qzz28Cd5+fXnZsRUVM0zI7oCrqeGqmquaeT075rqWbD9j+Asga98PDHFn/7lH/G9H/01juPwja/8Kt/48q9SXDS7xPlb/8e3eOOdlzEMnZqqOv717/w+69dsRhAEEsk4Tz71fb7z/T/DsizKyyr55a/9Jl/67C9e4qy3cCHSQx1MHnuLQM1KUgPH8Vc0E27aRLzzA7RwGeGGDYzsfZpYxy6qbv8s4fp19L72V5RtfBRvcS1DO39EsHYVgap2On78+9Td/4sMvPMPtH3q/0BPTTK679npMraDbRnU3PXF6/r3jY0P0DtwisryRmqqmjhw+G1U1UNzw2reev9phkd62bx+B4nUJCOjffi8ARrrV1Ff087Pnv8LPv/Eb9I3eJr+wU7WrbqNg0fepbF+FbpRYO/BNygpqiTgD5NMT5FMTtLcuIb6mnYOHHmH+tp2WpvWXZe/0zQN3tr5NM+89DckkhMzr6uqxr/57b+kpqr5hlsA9g928upbP6S6spm7bnt8RvFoTh5VEG+4sV8LzqcCGIarCHU5qcHz4TgOhUIeQRSviip3CxfHVOceel7+c5K9h7EK2TlqUVcFUUKUFCTVS7R1O7U7vkaoft2C+lFmHr2Og5mNET/yDFY+SXT9E66nxXQ2XxAEEideIX70Wcp3fBvPeXKshVgPQy/+B0q2f41g853YepbEyVdIdb5D0ebP4at2ZWTzox3EDjyJqHop2vRZPCXN5MdOEzvwI9SiBsIrH0byhMC2mDr8FKnTbxJe9SjhVY8gKl6sQobBZ/4tkj9K+Y5vIyoe3Ar2NP9eduXjzcwk8aPPoU/1E1n7MTxlbdMVCAfHNhEkBUF0q2DZgUNM7PlbAo13EFrxIKLixbF0xt//a3LDxym57WsEG6/cp3ILt3ALNxaWpGIRCUdpbVlJcVEpsakJjp86ytDI4JzA4mOPfoqDR/YyNj7CwFAfv/o7X6OkqAy/P8D4xCjZ6RKcIAhUV9ayeeP2pRjuDYNUOkkqlXT9HFSNcDCMei0LDEFAUFRERUGUZBzbxjYKWHp++t8coqyieALTJX8HUVawCllsI48oqxjZJEY2DraFIIiowXNlNAcQJBEtUomn6PqbO7mZcBHLMsjns9Oyp86MG7esqDPyvuejoOcQJbcJq1DIYZg6hmEgSTJ+fwgrNTWTZRdEkYbadlLp+Ew24+qa0RYO27YoFPIcPbGLV976waygQhAE7tz2GBXll+c8LxdKiitZ1b6NnR+8yOh4PyvbNuP3zVUyaahbiaYtjhzfcsOyLbp7O2eaCnfueYvOrlN882u/Ma/9c7ksz7z4Y6KRYh6+//ElHu3S4+zCebm/n9GWbYQbNzJ57G3GD71CvOsDzHwa2zRwLNOtWpxV1ZpFHZ0OekUJQZQQJRlBUpAUD77SBqJt2ylZ+wC+skbEq1HOcmzMXBwzNY6ZmcDMTGAXshTGOrALaWRfEbK/CBYQrAiKF3/dFjJ9+5k6+DP0iV4QRfT4II6RA/VckKtGqtGKG8n07sPWMyihCozEEGZ2ao4xoqj6iG78NLH9P2T09T/GW7UGUfVNVxcEImseR/ZGkP1F+Bu2oSeGmTr4Ezzl7UieELaepTDZQ7D1Hny1mxAkBW/lKjxlK0idfgsrl0QJlaPHB7ByiUsbIN7CosOyLQr5PPlCDtM0cQBREFEUBY/mQdOWXwZ7qXH2+27blvvfWRrkdBXjcpAlBfkmpIwuJZbM1Wjtqg3ctuVO+gZ6uHP7vXOatwF23PkQr7/1Ii++9iy5aaOzidjYLHtyQRAoK63gvrsfpq155VIN94bAy68/y9/98K8YHRumrXklv/3r/5r1ay5vsHQ5iLKK4gsjKl5kvyuvmBk6TWa4Y0bWUJQ1Sjc8QiExhp6cIFC1gqlT72PlUwSq2xjd9xyZ4Q480SoESZnpvZB9ISJNm5k4/hYIIlro6lwfrwXFRRWMjPVx+Pj7VJQNUl5aS//gabr7TlBV0YgsuR4BXo+fUDCKR/PR03eC092HWb/6TmKxEU53HSGXTzMy3ofPG0SWZFRFo66mjWi4hO6+k0iiRHlpLYPDXew58Bo4Dpq6OIvhXD5DKh1HFEQ30y24fSyWZRFPTnLwyNvs/OBF4omJWfuVl9Xy6P1fvuGUUM5iz/7XeO7l75LPZznTfYTd+1656Hb/+p/9OZUVDRd9z22uNygU8vj9AURRvO6L1VwuSyabcZtPp88dDISwbItsLottWQSDLu1rcLCPJ5/+Pp/75FcpLSmf7uHJMTo2jOM4RCJFSKLIVGIK27ZRFYVQKIJh6CRTrpFmLp9j4Q42ywdXecTAtIw5MqAFPYeAcM2Bo+M42NM+KVdrrihKCqXrHqB03QMYmSmSvUfIjHaRHe+mEB/FymemEyoFHBxESUZUPMieALI/ghYuwxOtxlfeSKCyBTVYcs3+HraRI9v7AcnTb816PXHqNQB8VWsItT+IEipH0vwoofIZatNZCKKCEq5AnJ6PBEFACVVQetvXSZx8ldzwUURviEDDNqjbTH6sY6b5W1R9hKdlXnMjxzDiQ6hF9RRv/RLxw08jeYLAOWpHoPF2ZF+E1Jl3yQ0exsFB8obxVa1FlM9+xgLesnakbV8h3fU++fHT2EYeSfWjFtWhhqtmrpsgKRRv+QLJU6Xkho6iT/XiKV9BdMOnGH/3fyMqC5XqPAfHtrEKGURFc6skizhf2EYBRBFxnnOv4zjYpo4oKTNUGce2cKyzFZxr7yk5m/RKphJkcxl0Q8e2bSRRRNO8BANBfD7/nMRONpehp6+Ld99/gz37dzI0MoBlWQT8IRrqm9iy4TZu23InFeXVeD5EAYZpGRh6Ad3QMYwCpmVQ0PMkkpMkU1MUClkMQ0c3dSxTv2xw0dq8ntamdXgu0rP684oloUKB23g9MNSH1+OlvLTykl/Iickx/v0f/Rv2HtzNVHxyRoEAXH5XRVkVj9z/Ub751V8jEPhwe0M4joOuF/jzv/lvnOg4xq/84j+9psDiamFbJoIoucpJluVyceEiDYHn9POX00TrfANCZ7rycr4u8/lwppsx50vBWcixrwZ7D7zBj57+UzyeacNEScGyTRLJSSZjo+iz+McuAv4wX/3cP2fTunsvqqR2I6Cr9zidZw5fcUEDwL4AAQAASURBVLs7tn0EVfNimSYejwfTtKZNedx5YHC4nwOHP+Dh+x/Ho3nJ5jLkcjnCocjMInM6FkMQBGzHxjQMZMU1+NEN3V1sXWVGac++nby7+03y+ZxrBmjb3HfXQ8STcU53nSSXy7J+zWbaW1by0uvPsnvfu2xYu5XbttxFPp/jyae/T2tzO4lEnAd3fITyskp+8sw/IEkKkVCUHXc9wPjkOK+/8xJ+r5/JqQnuvePBm6ZiYVkmA8NdjI71sW3TgzOvm6bBqc4DqKqH1qZ1WLaFY9uIkoRtudVPUZx7DzqO4z70DR1N9SCKEgU9x2RsBEEQKC6qRFW0D80C5xauDo5tn+eh4VaUbNMAHARJxtbzjB95jWDNSnxlje6cL8rTFSkHBBHbKLga/pICjo1t6Ajy2eq+hW0Z7nPi7PumgSBJpAdPIXv808k2+dyxBMEN/KafMY6pI6peHMsgPXQaX3kDsuZ3ndFTE+Tjo/hLG5E0L7ZtuRWxq3iOOo5DNpfhZMcxnn/1KfYf2sPgUD/ZXJaAP0Bb8wruv+cR7rv7Yaoqamf6FzKZNC+/+Tx//b0/o7PrFJcSJmisb+FbX/sNHrj3UYKB0E1577lrqzzZfJpcLs345BD9g2cYHD7D0EgPk7ERsrnUFasTF8OjD3yJR+//EuHQ0jdF3yxYsoqFIis01l3ZrbmkuIx//2//K089/yPeeu9VYlOufbimeWhqaOWBex7ljm33LMhEbKFwHAfHLGBmY9hGDgER0RNE9kauaHC0mBAEAU3zoKrL++A8X9tduEKG8KwO+3LifHm7Ky363ffnP96FHPtqYFoGieQEYxNzA4iLIRiI8PCOz7Nu9R03bFAB0FS/al6qWZlMms4zJynoOqtXrqPzzEnaWlfRP9RLeWklAX8QSZIwDB1Jkjl64jAdncd54N5HURUNyzZRFBXLtFBVlcnYOKl0kvraJkRRYmCoF93QaWtagc/nX/Dn5+BQU1WHYRh4PV7iySm6+86QSifZsHYzkXCUV954gXWrN/LwfY9jGDrf/NpvEAyEePPdV6gor+K3/sm/5NDR/fz0uR+yef1W1qzcwMP3f5T3dr3JT579IS1N7WzffBfr12zk6Rd+fLWX/OLjdxwcy8DMpbAKGSxDh7ONuaKMqKjImh/ZE5jmyS/w+jgOuVx6TkUtnpykoOdn3I2TyRi5XJpotIzJ2Agej59ouMRtQj3vWIZRoKv3BLl8mkiohJrqZsYnhth78HX8vvAtX5RbAMDMJshPDePYFkqwCMUbIh8fwdJzeIuqUQJRJMUzTXWzyY33ohVVYqRiSB4/giCSGTmDEojiK2vAyCbc330hfOXN6MlxCvFRlEARWqQcPTGKnoqhRSsoxEcoODZ6Koa3tB7ZGyAz2oVVyBCqW4Ol5ylMDWEZBUL167D0PEZ6EqG8EdsyKcRHSA+ewshMoQWK0TMx9NQkWqgUT1HVgoOLQiHPcy//jD/+sz9kKj678T2RjPPBgV0cPnaADw7s4p98/bdYvWIdtmPz1s7X+Ovv/el0UHFpdPd28n//f/+SVDrJ55/46izX5xsdlmWSSseJJ8bp7e+go+sQHZ2HmIgNs3Dbt1uYL67fqvky8Hn9fOFTv8Dnn/gqyVQSXS8QCITwLdi18OrgWDrZwSMkTryInhhCFGW8lasJrXgQreTyjbG2bTM6PsLY+Ai5fBZxWuWgpal9pnRo2Rax2ASDwwMUCjk0zUtFWSVlpeVX5ZacTCUYGOwjlU4iSRIlxWXUVtfPZHCzuQx9Az0E/EHyhTxTU5MIokhJUSkV5VV4FjgxONPUnP7BXmJTEximgSzJRCJF1Nc0oCjqTBl2dGyYVDqJbdt4vT4qyqsoihTPjK23vxvHsZFlhcnYOPlCHo/mpa62gUgoOkvmVdcLDAz1MZWIYZomiuwaJlZX1swsqnVDZ2z6+humgd8XoLaqjmAwPCsoOHR0P9VVriTb4FA/Bb2A3xegrWXlTdEoK0sKxUUV3Ln9I9x396cWjYp1PWDZFpZpIIgisiTPkk88fPwAE5NjNNQ2IQBvvPcqTQ2tHDy8lzu23zOL6nVWQlgUJbweH129neQLOYL+EPlCjkgowoEjeykvraS5sY0P9r/PVDxG32APoWCYhtqmq6LSKLKCJEmuYkY2QyqTZGRsiHhyiuJpTfVgIEhBz89UuM6Ot6qyBkFw6Qi5XJZ8PkdlRTGyJKPICslUAtu28Hq9eDT3v8WA4zhYhSz5yQEyo52k+o+TGe1CT05g6W7vmqT6UUMl+MoaCdasxF/RjLe4dmbhtbATzv7Vo/kYnxjEMApUVzYxERtmYnIIj8dHd98JiqPlhAKRWYEFQP9QJ2/t/Bkr2zbzwYHX+ezHfxVwjSSDgQh+34e7an0L80MuNkCq7xiioiEngoiKB8vIYWYS2HqOUP26OdubhQyJrn2Ubf4ohalhUgPH8JU14i2uoRAfITfRSzw+RtUdxSR7DiHIKlq4jEJ8hFT/MWRvEI9YA7hmibneQyAIqMFizEyMscOv4i2uQc9MMXnsTYpX3uPeRwKkh08TqGpHkGSmOnYhe4OYuST5+DCZkU7MfAYtUo4aLL6oDPzlsO/QHv7z//h/SaWTl9ymoBd45/3X8fsCfPuXfxfTsnjl9edmggq/L0A0WozP60NAoKAXiCdiJJIJHMdG1wv8yV/8Zxrrm7n79vsX+GldfximzlR8jKGRHo6d3MPBI+8yOTXqSkffwpLjhggs4FwmORK+/gxjKxsncex5CpNd7u9ApvcDRNWPGqmeZTR0PlxvgeP89Nkf0NXTiW4U3MDC5+f3fvc/4CmrxLZthoYH+NFT3+PIsUNYtomqarS3rOQTj32O1qb2BWUJk6kET7/wI97d9RbZbAZJkigtKefzT3yVTeu3IQgCQ8MD/NH//PdUlldjWSYjY8Pk8zlqquv47Me/zKb12xZkYuM4Dnv2vcePnv4+U/EYtm0hywrtLSv5tW/8NoqiYlomx08d5qnnf0QsNumaxQiwffOdfPLxz1FZ7jZ3//jp7zM4MkAkFGV0fJhUOkWhkOf+ex7ha5//5kw2JF/I8877r/Pcyz8lkYhjOzaqorJ10+185bO/hCwrGKbBsZOHee6ln3KmpwPLstBUjR13PcRHHvwERdFzpcl/9x//FR975AkKus7R4wdJpuJEoyX83r/8w2UNLDyaj2ikjFR6Ct0oYFnWDFVLkRU8Hj/BQISqika2b3qQ1Su23TTNzrqeZ3xymNHxflLpKcpKamioW4GmehmfHETTfKTTScpKygkGw4CAz+ujp6+LRNLtQ8jkU0zFY8SmJqkPhIiEoni9XkRRRFVUpqYmSadTM0mI6spa2ppXEgyEyBfyxBMxQoHQNBVqcf6uirIqAv4g5aUVVFXWEgqGCUyfL5vPcrLjGA31za4YwnlNqB6Ph+qqes50dxAKRZiIjbNhzWb8vgA9vWdQJDfYLi+ruKbxObZFfmqY2Il3GN3/PImegy4v/DIQJIVQ/VrKN36E4lX34CmuXZAr9YW9tgF/iGDwXKLgQiOtS1EO+vo78Gg+DEOnvLQGXS8QChZRFC2nvLSGkuLK+Y/pQwSrkEGUtXlX0F0Ov44gqVfMgDu2hZVPIsoeBOUm4dE7rqSwEigCHGyzgCRrCNNGp1Y+g5FLIibG8RTXEGneyvCen2KbOoovhCCIJLr2kx48RbhxI+nBU+RjwziW4f6HgydchqhomIUMoqyiBktmmvR9ZY2owWJEUSI71k1+cgAzm5xp/vdXtROoWQGCgGMa4NjoqQmUYAmOY6P4o5i5FI5lYWZTIIDsOd8ocH7Q9QJ//b0/mwkqJFGisqKKyvJqPB4ftmOTTqcYHh1kYmKMD/bv5J1db6CpHg6fOIAgiNRW13PHtnvYsvE2qiqqEQSRqfgkx04dZtcH73Lk+EF0vUA6k+LPv/Pf2LRuG/5pc7obDZZlMhUfp7vvBHsPvsHRk7vJ3qTGyql0nLHxAXL5zBW3FQSB0uIqykprrsPIroxrCixM0yBfyBLwX72/RDaXRlFU5EVusJovHMfBNrLoU32zX7dNzMwEVjaOGL74Qm4qEeOv/u5PGZ8c5ZOPf45V7euwLJOevi6Ki1wKQL6Q5+kXnuTNd17lW1//TdqaV9DV08kzL/6Yf/jx3/Bb/+RfLiiYemvna3z/ye/y6Y+7hjuZTJp//Mnf8l//7D/wR7//vygvdRclsakJRseG+ewnvsxXPvdL9PZ384Of/C2vvPk8bS0rCQXn/5mNjA3xH//7/0NtTT3f/OqvU1FeRSqVcDmcAdelUxIliqIl3LX9PhrrmxFEkRdfe5o33nmZlqb2mcACYN/B3WzffCdf/uw3KI6W8NzLP+Vvvv+/eOCeR2hqaMW2bU6fOcH//Ms/YmXbGr74qa9TXFzKVDyGLEkzLtbDI4P85Ol/IJ6Y4muf/xblZZW8vfM1nnnxJ1SWV3P37fehKOcodK+++QK3bb2bf/KLv4VH8zAyPkwktLytstVVTTz6wJeJTY2QziQo6Hksy0SWFLxeP8XRCmqqWmisW4nXu3Aqz3JBNwqc7DzAm+/+lJ7+U6QzCW7b/BAlxZUossq7u54jEAizomUbx04eIZ1JU1Fexfo1mzjddRK/P4iqqKRSSVRFJZ6YoqaqnmAghN8XYDI2QUVZJfFEjNGxYUqKSwkGwjiO25sFsGHtZrweD5ZlURQtviqjqeJoCWdd2lVFI+gPUlpSjm4UOH7yCEMjg9TXNlIULaaspIKWxnaOnTyMpnlmGrgFQSAcCrNp/TZWr1jLyOgQh4/up7y0ggfufZSx8RF2732PvsEeKsqrqCiruurrblsm2dEuBt75e0b2PoOVn5/LqmMZJLr2k+o/TrL/OLX3fpVAdfu8GlQty2RicpjO7iME/GGKouVkMkliU6NIkkw8OYGqesjlMwwMdzExOUw0fHGxh/KyWgpGgebGNUiiTGlJNdlcCkmUGBrtIRQqpqTo2gKvmwW2ZeBYOqKkUZjsRgmWIXmCCLLmquHpWbe/QFLdxbBtTvP8PThmASM96TZ8i5IbaJgFV+FKUt2fHRtB1nAci8LEGeRAKWqkZtmprfOCAGYuiSDJeEvq0CLlZEe7sDJx/KUNIAiIsoZZSGMbBRR/FKuQJdSwAUGUsQpZvCW1WIWsm8TxRxAVDcdxUAJRvMU1ZMe6EUQJb3ENRiZOdrQbSfWihsuQ/WFERUVUPNiWgRatItxgIaoeFCcEEXt6vnEwC1lE1YueieMprsFf0UJ2vAdJ8+MtqUWQZArJcTzRSsQFJrm6e8+w//AewH0Gr2xfw5c+84ts33InxUWlmKbJ4HAf77z/Bs+8+GM6Ok+y/9AePB4fI6PD1FbV8Utf+VUeffDjc9YE9939MA/c8yj/9U//Azv3vIVlWZw8fZxDR/dzx/Z7FumDXDykM0m6+46z9+AbHDryHonUze2HEpsa45mX/oaOM4e4Em1LFCW2bX6Qr3zmd5bM+XwhuKbAIpNN0tN/krbmDciSgqKoGEYBwzRQFQ1JkskXsjiOjaZ6XVqQZVHQXfqLIIqMTwxSXFSJ7FPQ9TyWbSEg4PH4sCyTTDbl0hA035yy+WLBse2Ll8icy0uNHT1+iI7OE3zza7/Ow/d/dIZitKp97fTuDtlshpdff5a7br+Pjz3yKQAaapvI5bM8+dTfc6LjKLdvvXte47Rtmxde/hnNDa185uNfIhyK4Dg2wWCIb377i+za+y6fmHa9lESJppZWPvvJr+DRPNRU1XGy4xg9/V3EpiYXFFjs3P02o+PD/Of/909paWq/6DaSJLGidTUrWlfPvJbNZjh87ADxeGyWSZpH8/DZT3yZjeu3IokSfl+AH/z07zjTc5qmhlZ0vcDO3W9jGAa/+o1/Sn1t00XPefL0MXoHuvnkY5/l3jsfRBRFSorK+GD/Lg4e3cf6NZtnAjwABPiFL/7yTANa67RJzXKitLiKe+/4+HIPY9ExPNrL2zufJpWOc/vWRzhxau/Me7KsYFkWh4/tZPO6HXzkwU/MfD82rt3K+tWbZyhLxUWltLWcU4OrrqqlssINUkVRpKS4bOZngKrKcxmbqooaKsqrZgyAriYou9T3HWDd6rnCCl/6zNdnv7DS9RGora6ntto1VfzcE1+ZtUkoGL7seeYLx7bJTw7Q9/pfMbz7Z5xtUlX8YTyRKpd3rvlmst6OZWAVsujpGIWpYYxsEtvIM7Lnp9hGjqbHvo2vrPGyGW9BEPH7Q3i9fvoGOigrqSEULCKZjqEortFSKh2nKFJGMBBlKj5GOFREOFx8URpoc+NaRsb66R/sRFO9VFU0utTR8jrOdB9lKj72cxFY2HoOIzWKbRZQw1VY2RjYJnrcwVPagmPqGJkJHDOPp6zdVV8yC0iKDyVc6SrL5eIowVJsS8dMT2DlEsj+YiRfFDM3hZkaRwlVoATLZhqUXV+KGz+wkFQvgZqVRJq3uNK0goAWLuN8U8eKLR+d2d5duFcRqlvjBgsltXiKKmcC5+LVOwBnJvkQql1DsNZ9lgmCSLR5C44rsI7vgnnEV1o/vX6YPnegCG/xuXnIV1KL755z93y4cSPhxg0z59KilUyLty94jtq1910s0+2ZCgbDfOtrvzlL+EFTNdqaV1JdWYvP6+dP/uI/c+jYASRRQhQF7r/3Ee6755FLrgdWtq3hV7/xzzhx6ggTsXEMQ+e93W/eUIGFZZmMTw5x8Mi7vLfnBYZGumZRUm9WVJTVUlpSxYnT+9D1K/dgHjr6Ho/e/yXKSq6/9P+FuKaVum4UGBnrR1N9qKpGWUk1k7ERkqkpiiKlFBdXMhUfY2xiiJqqZjTVw9BIN7ZtU1/bjiwrTMSGCYWKAYfO7iMoikY6k2BV2xaXlxsbwXFsVrVtWZLAQhAERNWLHCjFTI2ee0OUkfxRJG/wkvsODPYiiAJNDa2X7FvIZjOMT47R1nJuEatpHspLK3Ech6GRgXmPVdcLDA4PsOPuh2Z6DARBpKKsinAwzJnzmrC8Xh81VbUz49JUD16vD10voOuXp0VciNNnThANF1128eM4DslUnDPdpxkbHyGby9I30M3E5DiGacwKLCrLq4mEo0jTC4tQyJXCTafdkqVpmXT3nqG0uOySQQXAZGyCydg4R08coqDrgBt8xaYmGB4ZnJEwPosVrWtmHCeXA2elOTPZJNlcmnw+S76QRdfzrpeGqWNZJrZtTcubunrigigiihKiKKLIKqqioaoaquLB4/Hj8wXweYNo6o3TVNfXf4pkKsZ9dz3Btk0PkkxNzXq/oryWQ8fewzD1OYv+K/VBnJ+RuVJ2RpzmOP88wNKzDH/wFCMfPAM4yN4g4aZNRJq3EqxZiaeoeiYzi+PKZhqZKfKxAVIDJ4if2Uui6wBmPsXYwZfwFFXT+MivuRSNS9wzkiTRULuChtrZQXp9TTv1NbPniy0b7rusIpsgCGiqh/vuegLLMpEkCUEQkZBorFtFfe2KK/ob2LZNQc+RySbJ5TPoen56zsujGwVM05jWqrexHeuc6tvZ+0xw3aglSXI9cGQVWVZRFAVF8cz0wWiab0a1ainmEyM1ipEeR/YXnaM/CSJGfAAlWEZ+vBNw3OAgXE1u+DiCpKCG3WqXHCzDzMZwzAKObaLHB5C0IKKsYesZzEyM/NhpAJRg2aKPf6mhRSpQArOrkJerSFqFHNHWbUiq7xw9b07/1vlW1sLs79qFv1+AhVRDLzzXnHMvACdPH8N2bERRpLmxlR13PXjR7fy+ABvWbmHd6o289d6rgEvpXLtqIyVFl5eKX79mE6tWrOWd99/AsixOdZ64qrEuBXSjQE/vCd7e9QyHju0knY4v95AWDZrmpa15A8dOfsDwaM8Vt0+nE3xw4HUef+irSz+4K+CaV+qCIGAYBabiYxiGTv/gaYxpbWBJUohNjdJx5iBej59wqIjh0V5qqpqRZQVZkkkkJ8nlUoSDUU53HWbtytsYGu6mrrqV0fEBxiYG0VQP0hIq4EieEMGWu0mdfhsrF0eQZLSSJnw1GxHVS3MJLdtyH0SXOfbZTMaF+tHC9ETlLCCydqYNWy52TlEUZ0XpkijNUW8QcCmgC9VCMKcf8pfDZGycV958nsPHDhAMhJAlmYnYGPl8bs62Ho931vHO/i0zxSEHLPvK53Qcm3w+R09fF5nMOR5iW/NKVq1cN6cR1uv1Xbeg4qw0bTIVI54YZyoxMaORnUxOkkzH3QAjm5pZABWMPKahY9lnFzxuBk0SJSRJRpRkNEVD8/jcBY7HT8DnctlDgSjBQIRgIEokXEwkVEIoVLRs2tqZbApN81FWWnNR9SpFVjFN/VYz3SLBsS0yI10M7/oxjm0i+0KUb3qc6ju/SKCq7eJa+R4/arAIf0UzRSvupnjVvQy+94+M7nsOM5dk5IOnKFv/CKH6tQtSUrsU5qvIJgjCnO+MIAhIF+xrOzb5XIapxDjxxATJ1BSpTJxUaopEKkY6kyCfz8wE8Pl81tWsty1sy5y+zywcByRRRBCl6UyuiCQpM8G7qmqoqgeP5sPnDeD3BfH5gvi8bkAf8Idn/xcII4nytc01Z4Nty8SxXellJVSOY+kuhUkQsfIJxOkKlKh4Xa+LQBlmIYlj5LELaczMJKInyFmXbMc2sfQsZnIUW3f9WWwjj5lLYus5ZH8x4rWO/TrA7UeYP3yldUs0kuXFwGAftm0jyzIb1my+rKFueWkFjfXNvPmu6ylUU1VHRdmlrQDOQhRFNq7bynu738K2bcYnRi+7/fVCLp/h5On9vP72jznVeQDD1Jd7SIuOlsY1VJTVMjLWe0UpXMPUOXjkHR64+9N4PMvrqbEoJQDDLLjNR5LsZoJsG4/HTyoTZ2xikGwuhT09OUYjZZSX1qIq2syiani0l6Koa6BXU9XC0EiP2+SsaEzFx2htWr+kTpyi6ifYfDeyvxgzM4kgqWjFDWjFjZe96cpKKzBMg+HRQVpbVqIqcyVxff4ARZFiuvs6Z17TDZ3J2DiO41BWMv+yvqZpVJRV0TfQjWkagLuAnZyaIJFKUFfTMGv7xbpmtdUNvPjaswyPDM7QUC5EV08nL772LOtXb+Szn/wKJcVlHDyyl/7BvjnbXmkikySJyvIaOs6cZGx8hLLSi1+jSLiI2uoGHn3gY+y46+FZSVVV1Zalwcw0DcYmBhkd72d0rJ/R8X4mYyNMTo0wFZ8gN0/O+1k4jrv4OTtpZgESF99WUVTCwWKKisopjpRTVFROSVElZSU1lJXWEAkVXzeJWllWXOfwi5RwHcdhfHIIj8ePJM5vCpqKj7P/8Ftkcwu7fudDEAQe2vH5G6qys1iwTYPYyXcoxEcQJIVww0bq7v8GvtL6ee0viCLBmpXU3f8N8rEhYqd2oicnmDz5DoHqFUjqjUGPMUyd2NQYI6O9jE8OMREbYSI2xGRshHhignQmiXkVCwzLtsC2MM9/8Qo9k4Ig4NF8bmAfjBIKFBEKRomES4iGS4lGyyiKlBENl+LzXbryfTEowTLXEdzIg2OjRmsRVT9KqBJRC+CtWIWRHgVBRFIDeMpaEWQVyRtBUDUEQUYJVYAkI2lB1HCVW8GwTSTVhxKpRvJFUILl4Dgo/uJ5Bfm6UWD33peJJ29u/vr1hCIrbFq/Y0koKrH4pCsSIUgzVMtLwe8PEA0XzfweCoXx++f3vawoq3YToY5DJnv1c/BiIZtLc+jYe7z61o/o6T3hGmh+CBEJl1Bb3ULHmYNkrtCE7jg2o+MDdPefYGXr5us0wovjmgILvy9EQ+0KbNuaVu2oRdO8ZLKpGR6sKIgUF1VQWlKFR/MhCiLqeQ/2uuo21zIegRVtLrfapUmpJJKTNNevxnFsMtkEwcDSNNoKgoDsixBsumNB+61ZuZ6aqjqeeeknqIpGY0OLqwI1MsCaFeumJXP93HfPw+zc/Q6b1m+nrqaBgcE+3t75OnU1DbS3ntP6t20bwzQwDAPLMtF1t3QvSW4GSRQlHr7vMf7uh3/Fq2+/xOb1W8nlc/zsuR8SjRSxbfPCxj9f3LH9Hr7/5Hf46+/9KZ947LNEo8Vksxky2QwrWlfh8XjRjQKFQp5AIISqqgwM9bJn306GRwYXfD5V1bht61289vaL/P2P/ppHHvgYoWCYVDqFY9s0N7aiaR7amldQXVnL0ROHaGpopaKsCt3QGRzup6mhZaaxfKnhODbjk8P0DZymf/A0g8NdjIz1MTYtt3m9YBj6NH1wGJjmv/tClJdWU1ZaS0VpLVWVTdTVtFAUKV/SIKO8tAYBOHp8F9FQCaapI0sK2VyaYyf3cPTEbhrqVuC5wK35UohNjfLia9+f+duuBoIgcO8dH79pA4vLuY7bls7U6d0AKL4QJWvum3dQcT58pfWUrL2fVP9R9NQk8dN7qNvxdWD5rpllmcSmxugb6GBg+AxDI90Mj/YxGRsmm8uwXHr0rrN6hlw+w9j4OUqrIIiEAhGikbKZ4KK0uIryslrKS2spjpbPegZeDKLixVPSNPOnSR5XZlfSziVLZP+5RaK3YiUXQgmVz/ysRqpmaFIIApKvaPpH97vkrbyy5wyAYRR4/Z2f0NN/cl7b3wJ4PX5qqlqWJLA4S/cVBIFQKHLZbRVZmcViUBUVRZ7fEtDj8cxQC843MV4O5PIZjhx/n5de+wd6By7vwXGzQxBEWhrXsf/w21cMLAAKeo6DR969uQMLnzdAa9M5vWhBEKiubJr1+9lKxNkJ7HwFKZ8vyNpVt8383t68AYDa6pYZtSlV9Uxb098wyrgzqCyv5kuf+TpPv/AkP3zqe2iaB1mUQBBorGsmEAjh0Tx84iOfIZlM8I8//i4ejxfDMAgGgnz80c9QVupen/7BXt567zW6ezs5cvwgk7Fx/u6Hf8krbzzHnbftYMvG2/H7/Nx/zyMMjQzy2lsv8t7uN3Bsh3whzze/+uvU1TQuyd/Z3NDKt772G7z0+rP8xd/+CaqqIYoiNVV1NDW04PF4qa1uYOPaLezZ9x69/V1omge/L+A2zy4QkiSxbvVGPvfEV3hv11v09nejKCqiKLKqfS11tQ1omoe6mkYee+gTvPLm83z/ye8gy/KMo+8XPvULVJQtrTSlrufpHzrD6a5DdPeeYHC4i9HxgavKmC4FHMcmnYmTzsQ503MMVfVQUlRJdWUjtVUtNNStpL62nWAgsujUh/raFbS3buLgkXcZGe9jeKQXSZJ57uXvMhkbcVUsNj6Af4GZ3J8H2JaBpeeRZA3xvCpoomsf/so2lIt4OTiWRXasGwDJE5ij478QhOrXIWl+SE2SHe+ZoeJcT5ztRxoY6uRU50G6eo8xNNLNxOTwRatgNxIcxyaRipFIxWYW4D5vkJLiSkqKKigprqKyvJ7a6lYqy+vxeS9VWRUuT71f0D07+1g3OtXpFuYHfbq3EMENHC4HURTn9KfNV0HoRlAaAnfhfOLUXl564x/pHehY7uFcFzTUtlMULWdwuOvKdCijQGfXYXK5NN5LzitLj0XpsVjI7/OFqnhoblxDKh3H7wstuJR8PSCKIndsu5eykgq6eztJZVLIkkw0UjSTPZAkicb6Zn7pq7/G8ZOHSWVS+H0BmhtbaW5oO6cMoXmoLK9CkqQ5TdKRcNFMv0FRtIQvf/YXOXL8IOOTY8iyTF1NI2tXbZi5+UtLyvnq5785Iz17dhx33XYfK9rWzHp9fn+nxMc+8hka6psZHO5HLxTweLxUV9XinZb2rKqo4XNPfIUTHcfIZtOEQhGaG9q4c9u9FBeVzHwPHrj3UbZsvJ3i8xrGNE3jd7/9f7FhjRtlC4JAwB/k0x/7IitaVjM8NohhGPi8PhrqmmeyLqqqsmXT7ZSWlnOm+zTpTApFViguKqG2um6W6sw/+YXfpLysCnmeGZrLoVDI0d13kqMndnGm5ygDQ2fIZJNXvOmXG7qeZ2ikm6GRbo6d3ENZSQ211S20Na9nRetmopGyqzKQuxhCwSi3b32UgD/MiY69aJpb1ZqMjVBT1cLGtXfT3Lh2WdzDHcfBtm0SF6FzKIpKMBBZipNimwb5qUFsy8RbVIUgqVh6FiufwTZ11HApoqSSHu4gN96LGiolUNWO4g2SmxpCT8Xwl19ike84GBmXIydKCmqo5OLbzQNqsHimsdXIJK5rH4zjOFi2yemuIxw+9h49fScZHO4mlZ668s43MLK5FH0DKfoGOpAkmVCwiLKSairK6qipaqaxbiVVlY1451nBu4VbAC4w5FzGgVwHWJZFX38HL7/5j/T0neDnxTk7EIhQXdnI6TOHr0ildhyHqcQEfYOnaW/ZeJ1GOBc3XhlgGqIozjTD3ciQZZkVbatZ0bb6kttIkkxdTcOcHojzUVZSzgP3PjqvcxYXlbLjrocu+X44FOG+ux++YAwSq1asndfxL4TLJfawdePtbN14+0W3URSFxvoWGutbZr3e3Ng66/f1a+aW6BRF5VMf/cKccwYDIW7betdlx3ZWTq+teS4V4Hw88sDHLvv+fGCaBr39p9h36C06zhxkaKR7XuY1NyKyuTQ9/SfpH+rk5On97Dv0Fu0tG9mw9i5Ki6sXJcAoKarg9i2P0N6ygWRqCtM0UFWNokg5kXDJsgQVZ6EbeQ4dew/T0BmPDVNaXIWu5wkGo9xz+7V/Vy6EA5iFNOnBU1h6jmTvYYpX3cvUqZ2Y+TSCpKCFSgk3bSQ33ktm+DSObbl0Jm8QK58lM3qGUP1aLnrVBDegsI08Dg7ONdAVHMvk7EPbVSS6foIHA0Od7Nr7CidO72NwuGteMos3G1wTrzGm4mN0dh8hGIhQWlxFVUUjLY1raWtZT3G0ctGC/Fu4hZsdjuMwERvm9Xd/Qmf30Rs+ibeYEASBhrqVBANvzatHs1DIcqrz4K3A4hZu4UaG4ziMTQyy98DrHD6+k4GhM9fURHwj4awG+PjkMN19Jzh6cjfrVt7O5g07iEbKrrkE7vH4qKpopKpiaWh6VwtFVmmsW0nvwCnKS2tpaVxDLD7G2PgAtm1d1GPhmuE4GLkUufEezHyaaMs2zFwSJViCIEro6Ukcy0TxRdAi5fgrmpF9bmLFU1SJnpzANi6+0BYEETVYhJlPYRsFcpP9eIuvjtOdmxyYcepWA8XXhTaTy6V5Z9dz7D/8Fn0DHTdtwL5QWJZJPDFBPDFBT99JjnfspXx/DetX38mWDfcRCV995ekWbuHDgnQmyZ79r3Lo6HtYlnnlHeYJj8dPUaSMgD+E1xvAo3qRJJmpxAQnOvZe+QCXQezEuwx/8BSVt32KorbZCVnHtkj2HWHo/SeJtt5GxebHL1tyaqhpJxAIMzZxZXuCgp6nq+cYtm0vG4VtyQMLx7YoxHrJDR3BSAy7qhSeEFpxI76a9YhacPaDy3GwLYPc8BHyIycxs1MgiMi+CFpJE56yFci+yFIPe9ngWAZGahw93o+ZGsXMxrH1LI6puxY6oowgK0haAMkbRvYXo0aqkYPl83LJnS9sy0Cf7KUw1YeZGsXKJbAtHcHBVR/xhJCDpWhF9ajROkTl5myIvRLy+SzHO/by3u7n6ew+Qio99SHNljgkkpMkkjEGh7voHezg85/8TULBqxNMGB3rZ3Cki6qKRirK5ko97jnwGpriYUXrJjTt4s72S4WzcqY11c0zkoW6USCfz6Ab+SVZSNtGnmTvYSRFI9y4ganOvYCD5PHjiVa6ZnW624gpaT5kTwDFF0FSXPlI2RNAlBUuVT0QJJlA9Uqy472Y2QRTHe9T1Lp9wfwIx7GJnXwXI5sEIFi3+pyPwhKhp/8kr775Q46f2stUYnxJz3UjwzB1xicGGZ8Yoqyk5pYU8y3cAm7wPTDUyTvvP3PNCQefN0BD/Urqq9uprmwkHCrGo/lQFBVZUZFFGUEUOX5yzzUHFp7iaqZOvY+l54i2bJ8l+a2nY4wdfIlkzyFK1tx3xWMVRcuJRkqRJPmKgZVlmUxOuSp5RdHl8ai55ieGbeTJDhwi1fkmAKIWIth0O76aDdimTqZnF6nOd9ATQ9hGztXgllSyAwfJ9h8gsuFTqOEqBFF0uc+FNLGDPyE/cgwzl8CZboQVZBWp7wBaaTPhtvvwlC/MqXbq8FOuIZAzP4qAICr467YQbL0+DpNmLkFu+Di5ocMYiWEsPYNt5NyAwjKnHVFxFwqCiCgpCJKCoHgQVR+SFkIracRbsQJP2YqL69bPA5aeJTtwgEz/AczkKFYh5dIrLB3O8jlFEUFSEGUPkhZADlXgr92Ir3o9kufG64W5WkzEhnl313Ps2f8q45PDN0xT9tLCIZ6YcBXcriFr3zvQwa69L3HXbR+9aGAxNNzN4HAXNdUt1z2wOAtJlKmpaiabSzM00oNH87Jx7T0LMruaNxwHM58hfmYvarjsvPhAQBDEaeKR+38lWES8cw+5iX7KNz+O7I8S79xDeugUYwdfpHzzx/BEK2Y5YouSSnTFnYwdfBEzn2Hi2JtEW7dT1L4wpbjYifeYPPYWVsF9gJesuhdRniujvRiwLIudH7zA2+8/TW9/x3VVULuR4fMGqK5sWjIVxFv48MEwDJ58+h/Ys3/nZbc72XFs5ufjJ4/w53/z3y7pun0+evt7sK3lCXSTqSneef8ZJiavVhFQoL6mlQ1r76a1aR2RcCkBfxifL4ByibmtP1h00dcXAm9JHWWbHmN03zMkeg8RaXSpSY5jk5/oJ3biHUL164i2bLtiAkiWFarKGznZsZ/MdNLncsjlMwwMd968gQWOjZmeIDd8HABB1lAj1Xir15Ht30/i+MvoicFzC2PAMQuYZgEzl8A2C5Te+S0kbxjHNpjc+wMyfXtwzNkPGcfIYxp5rFwcLANB1tCKG+Y9TH2qn9zIcZinwokgqajR2nkf/2phmwXyIydInn4LPdaLlU/iWMald3AccGxs2wQjB/mzXzIBPdaDlZ3CU375foNLIT/eSfLkK+THOjFzU5e+VraFY1tY05+HnhxGn+gmN3SUUPsDeEpbbupOMssy6e47wctv/CMnOvaRzlzCOOJDCo/mY8uG+/Beg8lOMjWJrucveYxwqJi9B99cVg69IAj4fUEaatsZnxyiprIZbYmMhUTFQ9GKOwhUtSIqGoIoo4ZKKV55N6LqAcfBV9aI7Ashe4OUbXoM2yygBIoRFY1Q/TpaPvkvkVQfarAILjTclBWKWrfjr2wlM3yazEgnZ579Y/TkBCVrH0C+QlOwmUszfuhlBt79PpnRLnBsQvXribRsneVQvFgoFLK8/MYPeHf384xPDt3Kzp+H2upWaqtblrUH6RZuLliWyfsfvMMH+9+/7Hbnm8j1D/YyMj48x7z3YjAtc1m8IgxD50zPUQ4cfQfnKpq1K8rrufeOT7CydTPFReX4vMFpo87rsD4RRKrv+gKj+55leOcPZwILM5tg8uS7OEDp+ofnbfZYU9WE1+OfV2BRKOQYGOpi3aqlsSC4Eha9xu2YBcxsnPxoB+meXXOCilmwTXKjJ0h3vUdo5cOkOt+9aFAx6/iWTnb4KEqkCiVShSgtTTbtesDMJUifeY/k6TcxM5NgXwt30MGxLdRo7cJvGsch3fcBieMvocd6Lx/YXAy2hZmdJNO3DzMzSXjVo/hqNy5N5neJoRsFjp7YzXMvf5f+oTM/l1nUNStvo7ys9poqFoahI0kymnrxaoTXE6BQyM1SNbnesG2bsYlBXnzt+3g9fkqKKjl0fCd3bH1k0b+7giii+KMofjcLffYePUt1AuC8B4yn6Fx/hCAIaKFStNA5JbU5xxcEtGgFdff9Iqd+9O+wjQKpvqN0PvWfGNr9Y8KNGwlUtKKGy5CmPxOrkKGQGCM91EGy5yCZ0W6M9CSObSF7Q9Q/+E20cNmiP4STqRjPvvxd9ux/jWQq9iGlFl4dBEGkuWEV1TdYT9It3PgoFPIs5GllWiZmbvH6FZYCmWyS9z94ify0X8d8IUky2zc/xI47P0lNVTMezbss6xFvcQ3lWz/G+MGXSA+dwl/ZRn5qhPEjrxOqXTOvasVZlJfVzdtRW9fzjI7NNSe+XlgS8qyVjZHu3kV+9BTgoIQrUQJlmIUkRnxoduBgWyQ73sBfv4XEseen3xOQ/UWokWocyyA/2YNj5GZ2cYw8+bHT6LE+Nzs+DyihStRwNVY+iaVnYKGL50WGmY2T7Hid5KnXsAuXbwQWJAVR9SFICral4+SzOM7cCUHSAvjrFm6Mkun7gPiRZ9Gn+i8aBMq+KHKoAlH1g21jFVIYyeE543Ysnfz4GZxjLyBIKr7qq1OhWi7kcmn2HHjd9VqYGp1xi/95giRJbN/84DV7WyiKhm7oZC+hYpFMxZBleVn10S3LZHSsf7pxexzLMslmU1iWhSwv/rgWcj2v5tqLskbJmvspxEfpfvFPcGyTQmIUPTVBsvcIkqK51Yezx3ZsbMvENgrYem7Gr0JSvTR/7Lcpar9j0asV6UyCp174K3bve3VembefN5SWVFFfuwKv95bs7C38fMOyTIZGujl6cveC9vNoPh667/Pcvf1xiqLlSEvcI3YpCIIAkkL17Z9j7MCLDO/+KY2P/jqxUztxLIPyTY/PJHnmg9LiqnnThg1TZ3xyGMs2l8UDbknOmBs5DoLLw4+u/xSBxtsQFa/roN2zm/ix57Gy53TJzfQEE7u+i5mZRJAUwqseIdh2v1uNcGzy451M7vsBZmr03D6pMfT40LwDi8jqjxBa8QA4No7j4Jg6tp7GLmQwkmOkOt9Ejy/cJfpqYOkZ0j27SZ542e07uRCSgqe0FV/1OjylrUi+8DSfWgAcHMvETE9QiPWQHzlFbvQUOCaeipVIvoXxcnOjHSROvjY3qBAl/LWbCbXtQAlVug2cggiOg+PYOKYb3CU73qAw3nluP8eiMNFF6szbM8HhzYBsLsW7u5/nmZf+hnQ6vtzDWTa0NW+gpqoZ+RoXlEXRMvKFDB2dh2isWzXLCC+emODw8Z0URctRVe0yR1laiKJEKFTE3oNvAHC8Yy+6nlu2B9G1QhAElECE6ru/iOwP0fPSn6EnJ1zaYj6NNQ+pQl9ZA42PfZuSVfcieQKLWq3I5zM8+/Lfsnv/raDiUqivaaeupvWmrPbewvXHH//B/8Ywr2+SVLtOc3a+kGX3/lcXRJfVVC+PPvAl7r3jE4RCRfOieS01PEVVlG96nIkjr1G08m7GDr5IqHY10db5VyvAdXCPhubXwO04Dtlcinh8guKihfmWLQaW5AnqmAUQREJtOwi17Zil/BRs20Eh1kemZ7fbEOzuQW7kBAD+hm1E1n4cQVIRBAHHcfBUrCDUdi+xfT+cOYeZncJMj+HY1qwmxktBVH2IuGWkc6V3BxwHJTRBdugQXIfAwrHdhXfi+AsXDSq0slYiKx/FU96OIGszOvLnP+Adx0H2F6OVthBq3YGlZymMnUYOVy7ogWTlU6Q63yI/3jkrqBA9QYo3fxFf9TpE1ecGiRfcAI4TIuArRitpJnnyZZIdb7j9HwCORbb/IGq4BtlffMMrRmWzKd5476c8+9J3yRcWVnL9sGHbpgeIhkuveUHZ3LCGxvpVvP7OjxkY6qS9dSN+X4h4YoL9h99iaKSHr3zmtwn4I4sz8KuAKIpUVzax465Pcqb7GJFQMds2PXhTuxILgku5qrrtM4QbNjD0/pOMH3oZPTXXDPB8eItrKd/yMSq2fBRvSZ0rDLGI18E0DV564x95/4MXyGRuBRUXg0fz0VC3gtKrlAm+hZ8/bN6wjevNJLwe06PjOOQLWQ4fu3wz+vkQBIE7tz/GndsfJxy6PjLZ8xmTqGhU3fZpRvc9w+mf/AGOZVKx7ZMLFsUQBIHi4goURZuX5K6uF5iKj394AgsANVqLt2LlHDlZUVLw124kP3ICMzNxbodptajImo8jyuciYveD8aEVNSJ5Qlhnm5UdGyufwtazC1YiOjcewS0CiBKw9JGt4ziYmQlSHW/Oqti4Q5Hw128huvZjKOFquEyDkSAIIEgIooTjKMiKF7khuqA73nEcMn0fkB85Pqu3Q5A0SrZ+FV/thpng7pJjkGSUUAWhFQ9hFbJkenadO76lkxs+iqe83Q2SboCb/EI4jkMun+Gt95/hqef/alZj21JDmA7WBEFAkVWCwShBfxiPx4dH86GpXhzAMAoU9DzpdJyp+DjZXAr7bNVtunq0WKivbaepfjWqeu2BYChYxMM7vgCOw96Db3Ds1AfT9TZX9eaJx3+ZjWvvQVWuc8XigoewJMo01K6gvnYFAswkM67l+3p+z8ByfO/dOdNDsHY1bVXtND32bTLDp0kNnKCQGMXMpwABxRtCK6okVLsWX1kDkuZHkNzK6GKO23Ec9hx4jV17XyaZWnoH7bP3lYAAgoCqaAQCEQL+EH5fCE31IssKkighiCKmaWAYOqapk8tnSaWnSGUSFAo5tzrrOIDj6mZM/7wUqKlqpql+5bLSA2/h5sKlqqtn5yAHB2GR7+erwULnRMsyOdN9jHhi4orbnsWqtq3cse0jFEfLl/3vnQ0BLVJO5bYn6Hvjbyjb8PCCeivORzRciiIrzKeGY5g68eT8r99iYskCCyVUgRK82AcsoBU3IqpeuECSWCtpRAmVzzmWIAiIqg85WHousABsPYutZ24eiVPbQo/1kRk4cMEbAr7qtUTWfBQlUnN1XGxhYY22ZmaS3NAxzExs1uuhFQ/grVx52aDiwvMroUqCTXeQHzs1K2DKT5whP96JVtKEsESSlVcLx3EoFHK8t/t5nnz6T5e8n0IURCRZRlU0ykpqWNG6idrqVqoqGigtrsJzBdWe6VGTL+QYmxhkYLCTvqHTdPeeYGi4C9M0sGzrqs2DBEFg68b7KS6qXJRJWRAEyktr+PJnf4dH7/8SgyPd5PNZgsEIddVtBPzh66fOcRE4joNhFDh+ai+BQJjGupWMTw5zqnM/d21//JroUI6pg+AgSMtH83Kvq4AgqyiBIiKt24m0brvYlhfss7hwHIfuvhO88/4zjCxRM6EoSkiSjKKolBVXU1/bTl1NG1UVDZQUVxEOFl3F5+m4Gb/EOOMTQ4xPDjI2PsjwaA9Do71kskls28K2LCzbuuYAXxRE6mvb3QD3hloULQ1EUfq5+DvBlQpdDGqbZZlYlokDSNPf+ctdw2QqxsBQF1UVDUQjlxZ+WAw4jo1tO4jiXHYDgG1bZLIpNNUzrz4B0zQ4dPS9eZ8/4A+zZeP9NNyA98/ZqkWocQPSe16CtavnxbK5GKLhEuR5rqUMo0AicflK9VJhyQIL2RtB8l5cH1n2Ry9Kj9FKmi55PEFSkLTZAYRt5rEvoyB1o8EqJMn0H5gj4yoHy/A33IZWNFfvfyngOA6FsdNuX8V5kLwR/HWb5poWXgFucFGOt2IF6a7z5O5sCz3Wi5meQI1ULdbwrxmO42CaOgePvsMPn/qfSxpUyLKCzxugrqadTWvvYWXbJsrLaq/6QePzBmiobaeh1vVxcRyHZCrGqc4DHO/Yx4lTe0ll4hhGAXMB3NuykhraWzbO6oW4VgiCgCRIlJXWUFZas2jHvSac7Vt2HCZiw/T0n8Cj+UmmpqYNAicv5UE3b2QHD+I4Nv7aTSDK05VFVyYax4aZZjrn/AFNZ7CcaUlpZ8az5loflLMqtNcZmWySd95/ltNdhxf1uIIgoCgafl+IxvqVbFh9JytaN1EUrUCSFsc13ePxUempp7K8ftbrpmkwOTXKwFAn3X0nONNzjNGxfgqFHKapY5jGggONkuJKmupX4Z1XguHmhiRKbFq/g6IlXuzeKFAUjeLo3ITpQnHs5B6OntyD49hUVzZx+5ZHZhbpZ6vXhUIecJAkGUmUyOZS9PafIhQswnYsZEmZST45joNpGYiihCzJrqSsbaHIquspZlvYto2iqIiihG7kXRq2pMz8LggiiqwwFR9nZLyflsa1KLKC7diYpoEkSsiySr6QI56cJBoumekRsG0bSZZR5NlJTMdxMEydM71H531tVrVtoa15/aLd+0sL4ar5ZKFQybxlqE3TIJWJX9V5rhVLE1gIIqLmvwy3XkDUgi4F6bxFnRq+NLdUEOW5x5v2U7gZ4DgOVj5NbvTEBe8IeEqa8VZcnffEVcG2KEz1YWRml8k8FSuQvFenBiR5w6iRuYtHIzXmeo/cIIHF2Qn4dNcRvvej/7JkpneKohEKRlmzYht3bf8ozY1rliSTIggC4enegK0bHyCfz3Di9H4OHn2PU537SaXj07Kul75PBEFg49q7KS1evM/o7EMrn8+iGwWcS8jKRsLznygXE4Ig4PMG8Xj8mKZBQc8TCZewdtXti6KiYedT5IaOIXlDaCVNOGYBfWoA28ihhKuQtABWLo6o+EBwq6+SrwgrF8fMxsHSkYNlyIESliMgWAzYtsXRE7s5eXr/VVfSLoQgCKiqh/KSGjauu4ftmx6kvKzuutKHZFmhvLSG8tIaNq/fAUAiFaOv/xSnuw5zqvMAE5PD5PUceiGPOQ8FwuqqZhrrVy/xyG8MSLLC/Xd/ihWtm5Z7KDcdVrZuoramjTfe/QmGqZ8LLHAYmxjk3V3P4Tg29XUrWLfqdvy+MLqeYzI2zOj4AI31Kxke7cU0dAxTp6f/FGWlNVRXNNDb38FUYpyG2hUU9ByJ5CTpTILWpnXUVDXzxrs/RVU06mraCfrDHDz2Hn5fkKaG1YyOD3Do6Ltks0mqK5uZnBqhs+swZSXVrGjdxMh4PxMTw6xeuY2hkW4GBs+QysSpKK9j/eo75wTU6UyCsfGBeV0Tr8dPc+NaysuW3ndsueH3Bef9fLJs65qdyq8WSxJYiLKGKHu43ANRlFQERBzOLXjkyykaCcJ0L8Q5OLY1b8O7ZYdtYabHsS6gHkmeIGpJA7Ivct2GYmYmMdPjc66dVtyApF5dxkyUPa4ilaTMkvI102OYuTizsrPLjInYCN978o+WRJlGFCVCwShrV97OYw995aKu00sFQRDwegNsWncPG9bcSWxqjH2H3uTg0XcZnqZvXKyKEQ4Vs7JtC6Hg4jn9GobOqc79vLv7efoGOqb56nO56f/i238yJyN8PeAGZEXcfdtHsW2bgP/K7rMLQX6ii1C0lsSJFyne+hX0WC/5sU604npSnW/jb9iKPtmLEqoABIzEkGsqOngYIzGCp6IdRRDdPoGbFFPxcQ4f37loFChZUigpqWLzunu5546PUxQpc6khjs219Mid61dyrjrjGQ4WsXbV7axddTuO4zA82sPJ0/s50bGPvoHT5PJpcrnMRYMMr8dPfU0b5TdKVe8Wblh09Z2gu+8kLQ1rZvXCObbNRGyE8rIafL4QoUBk1n6BQJixiQEOH9uJ1+vHMPQZ+mtleT17D7xOSXEFWzfez2tvP4lpGjQ3rqGpfjVPvfCXlBRXkUxN8ZXP/g65fIa3dz7F3bd9FF3Psf/wO6xZuZ1sNsmWDfczONzF6Fg/VRWNpNJxRscHqK1qJZ1OoOsFMpkkRUVlbN38AK+9/WPamzfOCixs26an7+S8/W2qKhqoqWpGugbfpZsFPm9g3nOUbZkfrsBCkNQrc+pFac46U7xcr4QgIszpI3Aubb53g8G2dPSpuRG47C9GC1/fB4qZmcS8sHkcAcVfiiBfJS9cEBAkN6C0z3t42noW28hdc0PsYiGfz/LUC3/F8EjPoh/b5w1SV9PKwzu+wLrVty+rbKkoSpQUV/LI/V/krtse59jJD9iz/xV6+k6RTMcwjHOVmjUrt1NZXreoEpc9/Sd58bXvMz45RFVlE0F/+KJZZY+2NE7X84OALClMJIaJJyYQRRFN9VJSXHnNR/ZVrUEraUYZOYGZmUJPDOGv24zkjWDlU5ipCc5NgM6Mq6wga3jKWgjUb13Q+RzHwTYKmNkEsjeIqHqX9X6zbZsTHfvo6DzEYjQ7ezQfbc3refi+L7CybTOWZTE82ksyNbVgDrkrxZjG5z0rp+v2W+UL2UXhoguCQFVFI1UVjey46wkmYyMcPb6L4x17GRzuJp2Jk8mmZqqIFWV1tDSuu9W0fQtXRHP9atpbNuDx+GeL4ogSlWV1vPnuT1nRuom2xvUUCnky2QSmaSBLCl5vkKMn9tDStI6qikaGR3vJZlOk0nEQBAzDIJGcRBQlRNGioOdJpCaRFQ0BgWDwnLmnLKtkskkKeh5V1RBFEXualmvbFqIoYdsWNVXNlJfWksunyeZS5PJpLNsk6IuiKZ7pGXD2/OA4NiNjvfO+JuVldTdBtUJA9oYI1qxEDZZc9VG8Hv+8jWst21qwseBiYYkCC2laJvVyG819SVzootZZKn2OxYdjGRjpsTmvi54gcqD4uo7Fyiex8qlZrwmihJmZJD9++qqPaySHL/q6YxZcWWBpeR+cpmWya9/L7N73yqIfuyhazu1bHuGhHZ8nFIzeEEHUWfh9IbZteoA1K7dz8vR+9ux/lTPdR4knJ9BUL6vathJdBA7w+RgcPkM6m+Rjj/4it215GOUGa94Hl6rTN9DBi69/H10vUFxUQSAQ5tMf/ZVr//zOm/wFUUD2RjBSYzi2gWPpSJ4QjpHHzEy685juSk8Lguj6xSwQjm2R7DnI8J6fEm7cRKhuDf7K1gVLGi4WUuk4Xb3HmJwaueZj+bxBNm/YwWMPuhVAyzIZHu3hRMc+wqESTMsgl0ujal5yufQMf9swCni8fvzeEMlUDMPU8Xr8yJLMrr0vsX7NXS61QJIZm3SlxiPhYvKFHKl0HFXR0FQPBT2PYejIikLAF0ZR5n9NRUGktLiK++7+FPfc8XFGx/o5fPx9TnTsZXR8gEw2SU1VMw117dd8nW7h8nAcB1vPuIlPSQHHwTayCLKGuMhGkEsBvy/kChXIc6WgbcdmfHKISLgEQRA43X2Y4qIKJmLDyJJCPDGJ3xekKFqGqmpUlNUxFR+jq/cY6UyCqooG+gY6OXTsPaqrmpiYHGJwpJvR8X5WtW9B07yUTMuWqoqHFa2bOHpyN35fiBWtmwj4IwR8ITrOHKK+tp2qinoGR7rxGyEKhRzjsSFS6QSx+BjKdN+hKIoUF1XMaUZ2HLf6Mh9IokxJUSWR0PVdQy0UoiQTbd5C9Df+5pqOo6reeScgHNteMqr3lbBEPRbSglWKwO2j+NDCttxegwsgqr5LNrkvFSw9M8dDw7FNJvd+f0nO55g6WKZLk1omOI5DV88xnnnpbxaN7w2u3F9VeQMP7fgcWzc+gMeznBn4y8M3TZNqa17PkRO72HvgdYKBCLXVLciLXF0p6HnCoWIqy+tvyKAC3MAilUmwbdOD5As5Ksvr6e0/ec3VNckbBsdxGxuD5YhaEE9ZiHT3+1j5BJI36go12Ca5kRMIkorkiyCI8sy/C4Vj6owffZ3h3T9l+IOnibZuZ83X/wtqoOiq/46rheM49A920N17/JqPpWk+Nm/YwROPfWummmAYOuMTQ0wlxgmHihkZ7UVRNOpq2jjVeYCpxDiyKGOYBh6vn7amdRw7+QHgSroGAmGOHN9FKBiltqoFvz9EV89xopFSykqq6eo5xshYHz5vEFXVSGcS04GFSlvTeqoqGi45XiM9ga3nUCNV2HoGPTGCt7wNmJ4rKhuprGjgri0P0nHiPQampqiubMLvCwGut5Dj2EhaYEHKMW4VJsPAYB+mZeLz+misn5957I0EIzWK7CsCQcRIjiCq/uleJA+C4p2REMZxq3zyQp6dtk1hsgtR9qKVNuNYBvnx08i+IrSi60PHdM0qUwiihKh4sc08gqTimHmXRSCISKofyRue8/k3N6655HFty6J/8PQMtbN34BSb1t1DfY373dONAgNDZygprnQNUGWFtatuZ/WK7a5GhCBSWd4wM/ftO/gGzQ1rqCxvmFa1Erhr++MASJJEdWUT1ZVNOI4zs9DdvvnB6d8lyktraG9xe2hEUaSyop51q26fM+67b/vo3GvkOExOjc55/WLw+0NEphvCfx4gSfMX83BwFnWtsxAs0achXB03+ENcCnYcC1ufy3cTJfXq6UdXOxaz4JoYXq/z2SaOs7y9MPHEBE+98JckFlHXWZJk2prW89jDX6W9eQPK9fZkuEoE/GFu3/II7S0bMU1jSbI9Pq+rLJbLZW4YGtyFEEWJspJq4okJvB4/Z3qOTvtqXFsd1Fu+YubnYPOdMz+HVz/m+vVMLxg8ZW1oZa0AMzQ0X+XVNfDalkmy11VeEmUVb3ENqn/xemYWAtPU6R/sZOga6YaypLCiZSMfe+TrsyhKHo+PqooGHBwaalcwlRgnnUlgWSbpTIJEYpKmhtU0N67hrfee4nTXYfy+IOvX3IlH82HbNmUl1WxevwNRlDBMnbqaFkbH+0mlppiYHGLbpgcYHull/+G3qa9tY2XbFnr6TjI5NXrZwCI7cID82GlKb/s62aGjxI88S+0n/mDWNoIgIBcS1Ek5Nn3kG7OvXTaGY+qIsmdBgYVt2/T2dfHCa08zGZuktrqOX/nFf3pD3neXQ7prJ6G2+0GSSZx8BW/lavKjp/CUNiN5I9h6DscqgCAh+6KzAwvHwcwlsAtpBMWD5Ali5ZM4RgHJG0ZU/YiSh0Ksx5VAFyUEQUKf6kON1k1XECdcBUpfdOEMinnANnJk+/cjSAreqtXoU/0owXL0xBC5oaPIwTK0aC2i6lvQ5y9JMmtW3kZP30k0zcv61XfOer9QyJHPZygpqqIoUjbz+vnZ7/PlvysrGvD7QkjSxWWBz752/nuuN9O5ba6W2uc4zrz9KwL+EMEL+kk+zBAEcd5UKMdxsJapB3lpqFDC2f/dwgwcB8e8IHoUxGmH2+sbUDmWedOoaS0GLMvi3V3Pcab7GPYl1IkWCkmSaW/ZyCc+8ks01a9aFmWja8X5D5jFRn1NG2e6j3Dy9H6CgQiRcAmKMtcbxaP55j1RLjZEUaK6spHK8np0I4/X4yccLlmy8Zw1tjzvhUVrznZsi3xsCABZ8xOqW7Nsc3A8McngSA+6cfXJC0EQKC2p4tEHvnRFtTJN9TA+MUj/YCeZbBIB0FQvqqIhCAIezUcmm2JouJtwuIRIqASP10/fYCfF0XJs22Z8cphkMka+kEWWNYZGekln4ni9ARRZxaOd7VmZR9BpWzi2jR4fQPLOX77ZKqRxzAKi4kUQRSw9g5VLuotnScGID6KEyhGVi/sAqKqHHXc9TGfXSfy+4A0b0F8WDhSm+l0qtWMhiBJKsBQ1UguSjJmJocf6UIvr0UqaZ+1qGTny46exCxmUUDm2niE/3olj5JG8Ifx1WxBVPzM8bEFwKyL5BDg2RmqUdPcuPKUtaKpvSQILx7YwszFwbNeXq5BG8kbBsVGjdQSb73LXBeLCPjdRFKksnyuNfBbBQIRV7fPv26quvLT0/1LDwaEwz6Zjj+bD6/3wSzSfD1EQgfnNRct1//981I9uEDhcsKidNrFajpHM+VKKMrI3siRGdpIndN2Dp/MxMHSG9/e+hK7Px6/yypAkmbbmDXz04V9YlqDCOVvevIFNpgRBwDANdu9/lb6BDqoqG/F6fHMEGO6764lFVaNa6BhBQJJEvFKA6sqmRekJWBY4DkY2AYCoaHiLlq+ZcXJqZEHNlxeDqmhsXn8f7S0bL/q+1xugpKgSj+bF4/EzlZggnpygKFKOWuZx6RGiTG11C3XVrZzuOsLk1CiiKBEJlbCqbQtj4wP4pxu4HdvG7w8jyyp1Na30D3YSCIRZvWIrsiSjKBolxZUo81hsipq7WLWyU+6icZ6wjRzZwcOIqp+gL4KZnSI/chJv5WokT4h0906CrfehhucGFqIoUl/bSDKVQFEULNO8KZvBHRzM1DiCJLuqQLaNmYtjZCaQvRG3+m0bCKKMY5sI4rnnlduv5OCtWoMSKCHd69LflHA1Rmrkisk0QVZRwhUuDWkJn1eiFkCUNfKjp5D9biOvbRkYyRHyY6eQAyXIgdLrMrenMwm6eo8TT4wDUF5aS31t+/KKajhQ0OeXlFBVD5p6ZcO9DwvO+ovML6gQkZeJfn4rsLhuEOaWNm0bxzbPM8e6XkMR50j9iqqPYOu90/KXiwslXIUgLQ/PPl/I8sa7P2EyNjKjvHOtaKpfxUce+DItjWtBT5ObHMWxDDwlzQiSgp4cQQ1XI4iiK2Np6RQme3AsHVH1oxU3YOWS6FO9LqfWE0IJVc670VZPDGIkRvDVbXKbEG9ADA53Mz4xSDAQJp1N0HHm4EW3u33rI9c9sHAcB13Pc/Tk7unsj4tEKkYyNUVtdet1Hc/iYNpUDxBEEXEe7rZLMoppfvR8NegvDoFopIy7b/voJRdXkXAJkfA5dZV1q26bnkZnu7mfpYRs2/QAtm3PvN/estE16JqWbiw5ryriOA41VW42/PxjNdbNz2tIjdSgT/W7vTLO/DnOSqAUrbgRu5C+yLuXVipxXeQNRFFA0zSqK2qZmJwrFHIzQBAE/HWbQJLJT5yZqSpIWsCdK7UgntIW13w1PoCnpJGzyTlR9uDYJvrUgDvXKh7MTAyrkEIragDbwkiOuKqImUlERcNIDrvb5BLTTd0auZHjCLLmnnMJIEoqsr8IIz2OmZtCjda6jeRmAauQQfSEp9cES3L6WYhNjfLS69/n+Km9ANyx7VGeKPrlZVbrc12j5wNJlBbFd+hmgW1b86Y3iaK4IKGJxcTPzyeyzBAEYdrb43w4OJbhZl6u4wLxrCqGY5+ThRUEAU95O97yD5c6ycmOfRw9uRvdWJxqRUVZHTvufILW5vVIjklm6IhLOZjOoDmOTaZvL8rqcjeb5tgYiSEKY6dd9S8HN7ucGiU7eBhPaYsbdF1UNtnBKmSwCxlE1Yeo+hFEERyHdM9uvNVrQVJm1E5ck7Wo6/RsFnAsE9ssIGkBRMWDY5lY04sWyRNYUrGE5sY18/KGWK5qRS6f4fipD6irOfd9z2SSGNex92gxIYgSWqSc3Hgvjm1jFZZHv9wwdeLTPQ9XC1mSWdm+hbLSSxumXogL+d0Xw4V88kvpwV9rplgJV5Ht24scKMVIXX0FTBDEGRd228hfsk/NcRzGxkcwTIOevjOuatbIEO2tq6763MsFrbTVrZoLEr6qNciBEleyXM8h+VSUULlbzbBtHHP2nC77i1ByZTN9FWq0FgQBx7IRtQAODoKsoIarpisfCqLiRQmW41jGdBDjRStpQrqc9P0iQPKG0SK15EaOQ5WriOkpaSTQsG1Jz3uzYL5JQLfn4OarzF0tCnpu3nRuQRDnKG5dL9wKLK4XROmik5Vt5rEKmetqkCcpXgTFA8Y5jWO3Kc64OXm5l0AyFeOdXc+SSE4uyvGCgSh3bPsIa1Zux6N5yY+fxtKzBOq2IHkjIIrYhTRWLsG59KLjcqctHU/FqvOyYA6yN4q/bovLtb8Ir9+ZDkCsbBwzF8dfuwnZF0Urbphp+HccBys7RXb4KJIawIn14a1YQWHizHQWTkNQVLwVqzASwxjJUcBBCZajFtW7gcoSoKykmrKS+S8Mrzc8mo97bv849bXnAotUeoqh0Wuj8FwJjuPg2AZWZgozO4VVSGHrGRwj7/Y+OTYIIIgKgigjyMp0xjaI5Aki+SIuB/8CqoYgyYTq1pEb78U28uQm+pf077gUcrk0iWRs3uZWF4MsK2xed+8ijur6QtICGKlxfLWbLxlYOI6NkRwh1bUTUfGghKvAcSjEetxFtDeMHCjFsS1yoycQZG2Okt9ZCIKArCgU9Dya6kGWZa7h8i8rfFXnlI/8dVsA5q3YJIgSnrKWme+eILgyz66Bolupkqsjs/aR6zbP/Ow4zrTTPUtGhRJlDbW4AdlX7CaKZBXJG3KDpYuYl/68QlU0cvNQNLIde8YP5ucB6XRi3kpPkigtW+XpVmBxneBKSc5V37ELaczs5HUNLERPEEkLYGXPuYA7lo6Vi+NYxpL0WSwHjp7cQ3ffyYu6TS8UiqyyYc1dbNv4wEyW3cxMIfuLsc0CuZ5dqJFqN8A4H4KEGqnGTE+SGzyM5AnhrVyFYxno8UEyffuRg6VoRfVzgwsHHKOAlU+RHTiIp7QF2Ru5gDbnkB875TYDBkrI9O9H9kUw0uPggOKNoMcHkX3F5EaOY2ZiruRhLoEcLF2ycj+45exYfJx4YnyWId/5aGlae90nP0EQ8Hh81NW0oev5GXdS27YoLbp8o/DVwKXDGW7lKtaLkRjCzMQws1PYhTS2kcU2Ci4t0ramA00ZQZIRJAVR8SF5AohaEMkbdoPCcBVKpBrZX+Rm7WSN0vUPMX74Zcx8mnjXPiq3P4F0nfnH2VyaZCp25Q0vA58vOG/a0Y0GT2krsi9KsO1etOIGuESVQfYX46/d6N7zwtleKQE1Uut6/iheJE8IT3k7Vi6OIGv467ZcNDklCALlpRWY0RIa6ppxHJtUOjX3pD8nuDAxNt8g4exnsJQQFQ+eErcxWiKIEphWO7vwufHzDMEVZJiPa7RlmRd1s/+wIpGKzXs9I8vKvFgDS4FbgcV1giCpqOG5jr5mNo6RHMVzgcLFUkL2RV2t/QvMt/X4IN6q3LKZai0msrkUBw6/TSp9ocP41aG+tp3btjxE6XlZeFH1YmbjAG7DoagiaaFZ+wmCgOSN4q/fQmG8k8JkN2qRW6IXFA3JG0JUPFzsgWamx7HySeRACZLqBgDOhVs6YOYSaMVNyIFiJNWHrWcRZQ3ZV4zkDWFmJqYpUAJqpAbJF0HSgktKhcpkUxw6+i4Hj7xLPDkxZzIUBIFAIEJlef2yZVUcxyYWH6Oz6wi2Y5PLZwgFoty+9ZFFOr4bUOTHOsgNH0OP9boc7+zUJahvMzviWDqO5QZjVi6BkTz3tqj6kQMlKMEytOImvJWrUKO1RJo3U7bhUUb2Pk2y5xATx96kbMMj11U4IZ/Puk6+VwlBEKgoq8PnW1oqylJBK24AIFDvUlp8NRsuup0SKEFpu2/u66HZRpXzoeS4PUMFjOl7LJfLMTwyQDRy/T1MbuEWrhUCAuo8EyK6nqdQWBya882AyamRedN1ZVklvEzGgbcCi+sEQVJQIlUIigfnPL6/lZ1Cj/Vi126aXmAuPeRAKXKgdMZo6CzyYx2u3N11NuxbCnR0HqJ/sHNRqhWhYJRN6+6hsX7VLD6nFq1Dn+onN3wcK59EjdaBAGZ6glTnO4iyiq9uC0ZyGCM+5Pa0CAKIMoIoowTL8FZcOjNrm3n0xBCyNzxdzgdbz1KYOIOZmSQ7cBBf9Xo8Jc3kho9hpkexjRxyoBQrn5xV2ZA9IWx/MWba1WmXfUVLWpnqG+jgnV3PYtsWrU3rOd7xAQFfmKrKRoZHe5mYHGLLxvvxepeuYnIlCIKAzxukqrIRx7GZjI0yOTWCbVvXLDnrOA76VD+pM+9QGDuNHh+cCRSuFbaeQY9l0GO95EZOkBs+gr9+K8Hme6i97+tYepbJ4+/Q/+Z3EQSR4lX3IqnXZ27RjQL5QvbKG14CrlHX9TEr+7DAtm3e2/3WTKY+k0kzNjHKujWblnlkt3ALVwFBIBSMMjZxZQGIfCFLLncxsYMPJ0ZG+yjMU91SUW4FFh96CKKI7I2iRetd6so0HEsnP9FFIdY349C61BBVH2q0BskTnuUGrsf6KcR6kQOlN3XVQtcL7D/yNlPTEnrXAkEQaW/ZyPo1d+H1zNbLljwhfNXrsApplHAFaqgKUQsQXvEQgqIhCJJLgdNCOEHTdTiVvS79KFSJpF0+G6kEyvBVrwfHQQlVIvuLESQZ2V9EZPVHkH0RBElBLap3M+CChBqtRwmUuOZPsuYaMVWscrn5qg/DG3arKFqApSz7j4z1Yhg699zxcTauvYtUeoqiaDl3bH2UXCHLq2/+0M3MLzsZ3DmPo+tmfq/5iJZJunsnqa6dFMbPLFpAcTHYhTS50Q58NZsQJJlAZRsND/8qarCE8UOv0PXC/yB+5gPCjRvxltSjBKKuKecC+qiUQNG8e3Esy8S8BO1tPhCA6BL6q3wYIQhQXFRKMODOJ/lCnmh0eRYUt3AL1wpBECguqqSz+8gVt01nktdUIb2Z4Dg2Q8Pd6POs0KiKStF5xqLXE7cCi+sI0RPEW7N+VmABoE/1ke3bixIqn+0kukQQBAFPaStqpIbceYGFYxVInX4TrbgeJVR10zZxd/Ueo6fv5KL4VlSU1bJx3T2Ul9bMfVNwqUUzzYHTr/lq1s/eLFDiKkJxju8re8NXrAydVSgBZo4NrpylGpk9Hq2sDXBmjq8Ezy3OJNWlGomyB8kXdbdDWFKJ43w+h88boLqikWAgikfzIQgiHo+fstIaWhrXsnv/q2zecB/+ZaK9OI5DLp9hdLwfEJBEiZVtm66JOmQVMiRPvESq+33M1PWR/FQCJXir1zGy91nMbBw9HaOQHMc2dTJDHeQnB5g8/jayL4KknnV0nv9nv/Ybf4zsDV15Q8CyzRlKzlVBEJbt+3CzQhBEVravQZZkMtkMlm1RX9u43MO6hVu4KoiCeEVTzLPIZpNMTVNtb0aT2oVgfHKYidjwvHtKPJr7rF0O3AosriNExYO3vJ10uBojMTjzumPkyfTtRfZFCbTcvaQNtWehhCrwVqxAn+rFyp9r9CuMnyFx/CWi659A8kauKbg4X43jesFxHA4fe5+JyaFrPpYoSrQ0rmVV2xYk6dK3ypUWotfSFDjfazffc1xpu30H9/D2+69RU1XPYw99HL/P/S7atk1X72laGucnR3zWZducVrDwev1ks0kKhRwEo0TCJcQTE5jm0mXz5wNJUmhuWIM2veC2bYuRsT5KS6oWbC5k5VNMHfoJ6Z4PsAvzaJ4VJWR/MWq4CtlXhKgFXMdh28Y2C9h6BjMziZEac916L6p+IhBsvRdBUul67o+xjQK2qWMbBaxpyqVVyJId61nQ33I+7AUECrZtY9nz9264GBRl8R2PP8wQBAFZkhkZHeK1t18kEimipKiU7Zvv/LmS4ryFDwcEQZi31LRlW0zGRkgkJykuWnwPrhsJZ7qPkpxnz6gsK5QUV+DzLk+S5lZgcR0hCCJKqJJg811MHfyxqwIzDTMTI3HyFaxCmmDLPcjBsnkvKh3HwTFyFGJ9iIpnpoHwcjjL/89PnCE7cGimmdSxTTI9e3BMnciax1Ei1QvK4DqWgZEcJTt0BEGU8dVuRAmUXHnHRcJEbJi+wY5r4nmfRVlJNavatxIMLI/XwnKgsb6JEx1HGJ8YwTTP+36aJt//0Xf4v/7FH87rOMFAFN3QmYq7WfuS4kp273uV7r7jeDw+unqPg+PMMqi73rBtm4GhMxw5sYvy6c/6eMdeFFllfHKIdatun/exrEKGqUM/I929G1u/vJqJ5I3gq1mHt2I1crDM9SiRVDeomPYucBwbbNeHxDbyWLk4hYkuciMn0WM9ru4+IAdKCDTejm3Z5Cb6rul6LAYEQbjmz/TnST5yseA4DlPxGJIoMT4+Sj6fY9vmO5Z7WFeNfCHL86/8Hae7DgOuf9DHH/0lopErP0v6Bzt5/Z0fMzLm3g9bNtzP7VsfwTePfi5dz9M/2ElnzxFGx/pJJGOuB5LjujwHAmGKo+VUVTTSUNtONFJ22aTTxWDbNslUjFNnDtLbd5LJqVHy+awraOEPU15WS0vjWupr2+c15gvhOA65XJoTp/fR2X2UidgwhUIOTfVQUlRJc+MaWpvWEw4VIYrSdRV3mA9EUaSuuhU3AXZlquzYeD+j4wMf6sDCtExOdOwllZpfYKGpXqoqmpYtsfBzF1g4jgOWiW3mXIlHM4+RGsPW0xdsZ2NmY+QnuhBlD6KiIcgeRFmblgi8ugy0qHrx1W6gEOsh07P7/DNiZiZJdrxBfqwDb+VqPBUr0aK1iIp3jsSolU9jZiYoxPopTPagT/XiWAbB1h3zCizApcuEWndgpifRp84tSmwjR6ZvH4Wpfnw1692xlDS545h1jRwcIz+dVR2lEOt1lW+m1Yx8lWvwVq6+qut0tejqOcZEbPiaufuiINJYt5KVbVtuuKzfX/ztn1BSVErfQDfxRJzf/fa/RRIlXnnrBfYf3IOmaWzbdAf33f0wQyMDvPT6s/QP9OD1+Lj79vtobV7Je7vfpKa6nk3rtvLCq0/j9/nZvGE7RdESykoryWbPBWYDQ3385Jl/5PW3X0JTPUSjxXzzq79+2etSVdFAVUUDpmlgWW4D975Db/PjZ/4XXo+fqcQEa1fdtqzN27Zjo+sF2prX4/cGOXF6H4V8lobWFcSmRud9HMe2SBx/gXTv5YMKQfEQqN9GoOlOlFA5ohZAnGdVxLEtPKWtBJrudM0Ve/eS6dtHqO1+V+Etn6F0w+KoWV2IhfRbiaK04IXWhTAWoc9loSgUcoxNDFBSXDWnl+pK+732zpNsWX/fvGkHlmXR23+Snv6T3H/3p692yLMgiiJVlTWcOH2MeHKK9Ws2LWvQfq2wLYuBwTOcPL0fcA0t5+vGnM2l6elzry9AbXXrFbX/Tcukf6CDV99+kq6eY2RzKQqFHIZpuEG+M90nKSsoiopH8+HzBqmvaeOR+79IVUXjvJ4T2WyKXfteYfe+V5iIDZPLpTEMHcu2EABJltFUL+/ufo7G2hXsuOsJmhvXoMzzHjRNgzO9x3jpte/TN3iabDaFbhSwbRtRFFEVjQ8Ovk5DbTs77nyCaKRswZXZpYdANFJKSXEFE5PDV9x6eLSXweEu2ls2XtL08mZHb/9J+gZPo8/zHvBoXhpql8/s+EMdWDi2Tfzo0xjx4XOBhJGfcUjGsd1/LRPrQuqCbZLtP0B+7DQIohvVT/8rSAqCoiHKHgRFw1u+En/Dthku++UgCCJKsIxw+4NY+RT5keOzT6tnyI93oscHXGUhxYuoehFUHwIijq27TqRGwTW0MwvYZh7HLCCqPpwFUEsEUcJTsYrw6gzxw09jJM+ZOTmWjhEfIJWZJNO9y9VVV32Iqg8EEcfUsc286whrGa48plnANgszlA3nGikRC4Vt25zpOcZU/NqbtkuKK6erFZFrH9giY2CwD0mU+PhHPoskSaiKSnfvGd7f8w6//Au/ycjoEK++/SJtLSsZGh6gq/s0n3z885SVlhMKhsnls4yNjxAORQCYmBxD18NY1uxM8dngrLS4nI8+8gQvv/4cX/rsL6LIyhWraRXldXzska+jyCqi6HJmP/LAl9i55wUmYsO0t2zknjs+TsAfWYpLNC+IokQwEGbP/lfRNC+J5CSypFBb04qxgPso3fUe6e5d2PlLq5PIgRIi6z6Jr3odkha4qCHi5SBMG2xKniBKsBStuIFg2/0ooTJAQNJ8tH36Xy/omPOFpM1/oS1dY2DhOA6pTPyq979apDJxPjjwBvfd9cSCAgtF0bht8yMEAvPvjRNFkaqKRoqi5VfeeAEIBkI8cM8jmKaB3+e/aXvkFh+Xvw6maXC66xD/8OP/xuh4/yUXb45toesWup4nk0kyyQimqVPQc1e81o7jkEzFePrF77D3wOukMokZpb+ZbQDb0DEMnXQmwVR8jMGRbh578KtsXHf3FWW5LcvkVOcB/v7J/8r4xOAcLr5l2eQsk1w+QyIZY2JyhLtv/+gNlzgTBAFF0WiqXz2vwCKby9DVe5x1q26nvKz2Oozw+sK2LfYdeovxicErbzyNYCBCc+OaK2+4RPhQBxY4NtnBI+iTPa5FvGPPkle9Emwjd0m3UwQRphtgBUF29crnEVi4u8poJU0Urf8kU5JMbvDwnHHbehZbP5s1FtzzCbjjv5wG/gIhyir+ui0IosLUoZ9hJIY4v/x4/jUw5ozDYT6lyuuF0fF+hka6F6Vpu7ysjhWtm264Sfcs2ltXUltdhywrmKZBZ3cHBw9/wJ/99X/FMA001UMqnaS5sZUtG2/j2Zd+QmV5FY8++HFUdXb2y7bty1Z4VFWlvKwSRVGorZ6fFKgiq0TC52gLkiTT3LCGqopGLMtEUVS8Hv81y7peCyRRorFuJZrmRRIlQsEiJmMj9A+doal+1byOUYj1kzz9NmZmgovfCwJKuIKS7b+AVtK8KGprgigjeyNInhBuDxMgSHgiy08FkGUF7VqkbR2HydjF3arPQjcKnOjYx+59L5POJKkqr+fO7Y9TW93C8Ggf7+56lqHRHsLBIh6497NUVzSQTE3xzIvfQVU9jE8OIQgin/3Er1EcrWBgqJMXX/t7OruP0T94mrKSarZueoCWxrUMDJ3h3V3PMTLeh6pobN/0EOtW34GiqHT3nmDP/lfpGzzNFz/1W9RUuV5EU/Exfvr8X+L3hRgd70dTvXz6o79MSXEVmWyKfQff4PDxnVSWN/Dpj/0KAPl8hv2H3+Z012EsyySVSbB1w31sXHcPXo+fvv4Odn7wIlOJMYZGeqirbuPzT/wmwYDbB2fbFqe7ToLjUFlRw66977Hjrodu2Pnr+uLyz6hkeoqfPPe/GRg+g+M4qKqHxrqVrGrfSmlxFZrmwTQNEslJRsb66e47weBwF7qep6VxLeFQ8RUDi2wuxU+f/0t2ffAiBT2PIIiUFFWxbvXt1Fa3EvCHME2DsYlBjp3cQ0/fCXSjwOBwFz97/i/x+4KsWrH1ktUFx3GYmBzmez/6I0bG+jkr5FFSVMnm9fdSW92KoigkkjHO9BzlRMc++odO8/KbPyCfv3ba8GJDlhTamtezZ/+r89ja4VTnAbp6j1FaUv2h+86f6jzIiY69ZHNXNgwE11ywsX71sopgfLgDC1zO/5Jkzs8u7p2zmfmFLbAFSUYrbaF4y5dIhatJnXn3Mg2fjuvgukRreFHW8NduRAmWMnX0WXIDhy8hkbmQcQgIsgfhOpZZu3qPM74ITds+X5CGuhUzGcVM335wbPz1WwDIj53GyiXQylqvi4rXxeDRztHjBFGksrya+rom/vlv/lsEwVWoCviDSJLMgzs+wh3b7uH5V57ilTef55OPfRbTNMkX8liWxdj4MLJ8+alAQEA39JmS+tVAlpUbqgIkCAKq6qE4UkY8GSMSLsbvC1FT3YIyD4URxzJInnrNpRFeIjCT/FGKb/slsrIfybZZTBHnG40bDe5D7VoaBh3HYWik97LbdPee4Mix99m+6SEa6lYgIKB5fOQLOd7d9QylJdXcf8+nOXX6ALv2vswDd38Kx3E4cmIXn/7Yr/DwfV9g196XeOu9p/jMx3+V6somHrj3sxT0PJ947JsUR8vRpg26iqLlPLTjc8iyQseZQ4yM9VFZXk9VZSM11c0EAmH+/sn/MqvCZVkWh4++xy984V/y4L2fZdcHL/Huruf45OPfwuvxs2n9vUiSzKkzB2f2sR2H4ZEeDKPAo/d/iYmpEU6fOURFeT1N9at4a+dTrGzbQnPTGp586s9YtWLLBRlsAVEQOHryMLKsMDDUP++KhW0ZmLkk9rRMsBosvqnlxufi0tfBNA36+k/R1XMcx3Hw+0Lcc/vHePSBL6OpHkRJOqv3h21bWJarehaLj3L81F5am9YRCV9e0tMwdfYdfJOde57HMHRU1cPGtXfz8Ue/QTRcgiQriIKIg4NtWdxz+8d4b/fzvPb2k0wlxhmfHOTlN39ASXElVRUXV/syjALPvfp30wp3DpIks7JtC1/45G9SVFSOLCkzAejtWx+lq+cYz73yXTrOHL4BJL/nQpYVVrZtwePxk5+HA3c8Mc7hY+/TULfyQ+WDk8km2bnnBQaHupjvAtDj8bN6xbZlfT586AOLGxmCKKGEyolu+CS+2o2kOt8mN3BoLi3rykdC9hXhb7odf93GqxvLtB9C2R3fJDd8nOSpN8iNnoAFBmWiJzhNDduOt7wdcQE0imuBZVv09J0gFps/N/5SKCmqZEXLuWqFY+mzytZnVbQWSmdZKoiCSGtzO9s23cHv/cHvIogiTfXN/Ma3/jmHju7jf3/3fyCKIuFQhMce/ATRSDFVlbU888KTvPT6s5iGSUtTOwW9wF9/7095e+frJFMJuno7+ebXfp2m+hZkRWHjuq1867e+yOoV6/jtX7887aa3/xRneo7S3LCG+otwPV964x/xaj62bLz/qhoUFwO2bTM82stPn/vfBAMRHn3gyxw9sZv7735iXpNydugI+bFTOJdyQpVUSm/7BkKokmMHXmNl25ZZzu0fRmiq95pcsx0cRsf7yGST+H1zJW4dxyEWH8XGZvWKrciyOrMwGhrpxnEcKsrqKIqUsXbVbew99DqZXAqfJ4DPF6S9ZQPhUAl1NW28tfNpV1FJVvB5g8iySsAfJuA/lyxIpmK8/8FLDI/2ks2lCQUirGp3EwyKrOLzBpAuMg/4fEHaWzehqR5qqprZc+B1wKVBeTQfHs/c6raiaFRVNlJV2YSianR0HpxZVGVyKTSPj1CwCK/Hj6Z6EcRzinuiKFJX08jQ6CCHju7jrtvunfc1z4310vnUfyLetQ+A9b/yF0Saru45cmPi0gsyy7YYHe+fEQyIhkvZtO6emUrQbLjJBi8Q8IeprmhCFKXLJlrcRuoMz73ydxiG7ioNNqzhC098m3CoaO48I7tN4vff/WmmEuO8/f4zGEaBk6f3c6bnGMVFlXMqgo7jEE9MsGvvyzP3QnlpLZ//5G9QWdlwQa+Ngqp6WNW+hVw+QzqTZHC467JXb7kQDERYs2I7ew++fsVtHcfhwNF3aKhbQTRSekXa2M0Ay7Z4872fcfj4+/Om5gqCQDRcOjNHLReuObAQFC/h1Y8SWvnQeS+CIFx+0VV62zco2f712ceazm6fvTnOv7FlfzEl23+B4m1fPbe9IMDlFneiRPVH/u2SR+SCIF5+HFfaV9LwlLXiKWl2+y4mzpAfP40RH8BMT2IV0m4FQRARZBVR9qL4o8iBUtRoHZ6yVpRw1XRT+dVHqYIgIigefLUb8VWvw8zGyA0dJz/RiR4fwspNuT0qjoMoqwiKF9kbQg5VoIar0EqaUCM1iLIHRJcqthg8X2eacnW5xd5kbJjxyaF5azxfCqIoUVleT8t5/ERBUnCMAonjLwM2jm2jRmtJn3mPQmIQu5Ai3HY/IJLu3QM4WNkEoVUP4ylqZHL/P+JYBvrUAIGmO4msfvSaxvhv/vnvI0nyzLV1HaT9fOVzv8SXPvP16ddEZFlmw9rN/Pc//MvpP0RAkiQEQeDxhz/Jow98lLPZPEkSEUWJr33hW3z5c78EjuM2K06fR5EVfu9f/CG2Y8+rKfT/Z++/w+Q6rzNf9Ldj5VzV1Tl3oxs5JwIgGEBSjBIVKMlWcLavPdEzczx35vjcMOf43LmeZB/PjGecLVuWLFMSRYoZzMg5NdA551BdOexw/tiNRmoAje4GGqTw8uHzoKv2/vZXVTt8a613vW/fQBuHjr2F2+WfM7BIpxOcPP0BzY2bli2w0PUCo2N9bNnwKOMTQxiGPpuVlG+TsTW0HMnuIxQSNwtkBQKrn8ZRuopsLkMyFeeDT36ManNQU9WMIAhUljWSSE5x7uIRdK2AbugoskJFeSOZTJKOrnPU165BUWyMjQ8yFRulpqqZVU3brIrVfQi73XnNwnwhKGh5LrWfYuPaPXO8a2IaBgJzP2MEQbjmujBNc3ZdaVMdSDPPGFEUMc051KeuelZkMklOn/sEE5Nf+Pq/pr3zDG2dZ+aVN7TbnDONpJZK1pzHug6yrKDINkRRnL3XmTNH27HlKd794O95/+Mf4vH4qa9Zcw0txsQkX8izsnENPl/gthXIaz+yjpZLoWXi1t/3uDduuXH176npBZLp+G33EUURUbx9VccwdE6e+XDWRdrnCbJ7x3O3pE8JgoDd7mR18zZa20/RN9iOrmu0XDrGysbN2K5TPzJNg6On9s82tzvsLjau3UNZSe1NjyFJMmuat3Ph0tHZgPx+wuXvYMv6Rzh++r15zS+Xy/Duhz8gFCxh/ZpdSKL0qewzMk0TwzA4dOwNPjr4KvHE5Lz3tducbNu0b9kDq8UHFoIAgnTnzYiSPEPVt/jdgiDOngSGYZDNZXE6rnw5giDAzD53NDdJuYv+wkuDWW8BSURy+nFVbsJVuenOxrAGWorZzHxvIrK7CE9jEY7ah4gnJufdbLjUF3M2m2IyNkZZyc1Nn4ZHe4ktQdO21xOkrmbNNVr6oupEzyUxjDxGNoGRz2CL1OJp3IvHNMmOtZOb6kV2h8HQCW7+GnpmiunzryM7A5iGSWD9F0l2HcQWrl70HBXlxgealXmVuf6SFgQJVb3x2pQkaU4FDVlWbnpTUJT509pS6QR2m5PATZw/I6FSjpx4d3FmaouEJMmEw6W8uf+7AJy7eBjD0GcXn7dCZug8+cnem3hLgBoox7fqc1wO3FTVxoqGDdjtLt776GVqKpsoRKtJZ5IMDHZQVbGCULCYvoF2AOpr12K3Oxkc6kLTChRHK9m84RHe++hlaqtW3RBYmJd7nqwbwbI9UF1O78xvPj+pyLmgaQVOnvmADWt2zZFMEAj4izBNuNh+gpqKJgzTQFVshEMlAIyM9VMcraLl0nGi4Yp5Ba6SJKGqdiZjY7icXhRFRTd0i3Ov2NB1jcHhbiauUgvLF3Jks2l0w2rozeUyqOqtPTisZ1uafD6HrhfIZtPXGnvd5GeLTY/R3LiJDWt243J5b1AJEhAoaAVef/cVUqkU61ZvZOPaLdjtjs8c53wpIUsyFaX1iDMeNmMTg7zzwd8T8EUojlahyMqi+sB0XefkuY9n/3a5vDM0lVtfn4IgUFxUgdcbhBl2b3ffRdKZJNd7qpumyaX2U7N/OxxuVjdvu+0x7HYn5aV1eD0hpuPjd/Kx7glkSaGuZjU1VSvp7D4/r33GJgb58et/ik2109y46ZoE3KcBpmmiaQWOnHiHV9/6qxlq2/zh9YbYufWpZf/My0qFMgyD8YlR4olpSksqcNith+VUbJJX33qZb331V4HLX7al5CTLCghgGiaGoWOaIMvyst08LcnKPPl8jkKhgK5rs9G1ldUQURQVVVFRVdtt57ncJ8TVuJzxSyRjxOITBAPRGem6Kw9cQRBmmtEEFFnFxEQr5K2MuaJg6AaaXkCWFCRZRivk0XQNVbEhSTK5fMaqAKh2RFEim0sjYJWDAXL5DGPjg1xoPXbTwMI0TUZG+4hNL/7m6PUEqK5ouuZ3EFUnemYKUXGC6kLLxDAKOeIX30XPxTFyKUTVhewKW/4jooSgODD0PLLDh6llmG55C1GxowY+O/zPW8EwLOrYzc53WZbRtPyyZsoEQaQ0Ws3Tj3+Dzp7zBP1FNNatv73Ci6GTGb4407A918AigXUvIkjqVVQV6ToFLIFUKm75rQgCsqyiyCqSKNE/0M7wcDe2meDBNE2cDg929XIwceN3Zho6qcFLCJKMPVCKvETGSEYhjz6jpGdVsSQEWUVSbHMmk2RZwecN4XH7SCRjCzqmrmtcaD3OZGyM0HXJDEEQqK1eRTqT5P2Pf8hPMwlKi2vYvf1ZKssb2b3jOT448GOOnnwXjzvAE3tfwu+LEE9MXkNvUWQV11WVFa8nyIq6dfzwtT+mOFrFrq1PU1O1kpqqZj448Ap/9jf/B+FQCWXFNcgzqleHj73N+UtHmJgc4fV3/4aq8hXs2/sVRFHE6wnMuNtbiYDLtK6p2Cg/efMvGJsYJJWO8/0f/xHrVz9EQ9067DbnbEJDEiUcDjeKrKJpBQqFPOcuHuH0+QPousaK+vU8/fg3rqFUed1edmzezdGTBzl74SRDIwPs2r6Xkuhnm353e9z8epYkmbKSWlat2ML5i0fQdY3zF4/QP9jJlg2PsmXDY5REK7GpduQZhbv5wjRNdEOjq8dSfhQEiwZXKOSZnBq97f65XPaauU/HJ9DmSMSYpjmbkACrz6mspPa24wuCQNBfhMfluy8DC0EQcLv97H3o8/T0XkSfp79N/2A73/vRH/LFZ3+d5hWbLfPT+2hddTMYhkE6k+DQsbd4672/u+N+UUtc4nG8nuBdmuH8sayBRSIZ56dv/5hEMs6qprU8/NBjGIbJxdbzNMw4/BqGwXQ8RnvXJQqFArXVDTgdToZHhpiKWRdabXUDxdHSJTt5rMV0nMmpidnXbDY7AV8A+0zwYxgGqXSS0bFhjp48xLGTB2nvusTwyBCpdApJFPF6fPj9QVbUr2T9mk1sXLeN0uKymaba+4Offzvohs6JMx/gcnmpLKu3pPKSU+i6Tl3NajxuP8dPv4/XE6S2aiWpdILWjlOEAsVUlNUzMt5P/0AHpcXV1FavoqP7HL39bayoW091ZRPvf/JDTBM2rt2Dy+nlo0OvIksyKxo2oKoOTp39CFW5dUCmaQVGxgcWLVNp8RPDVMyou1yGVbFIIypOZHcYLTmGFh+2Grort1BIjF6R6r3uHDRNA0GU8Tc/AZLM/aSidTfhcLjI5bNMxcYxDP2arJ+uawyP9mGbpYssF0xyuQwBf4Rdxc/Me69CYpRCrP+mvRW2UC2O4ubZbLsoiDgd7tkFaThUitPp4fDxt3E5PQT9RTjsLlTVjsvpRZZlsrkMiWQMVbVb/ys2BEHE5fLOmUHV0tMc+fdfQPWEaHjx31C8+dkFfB9XYJoGhcQkk5cOMH7hAzJjPZi6huqN4K1eS6h5D65oLbLdfcM57/UECfqjCw4sAFKpOB8fepXnnvz2DZ/XptrZtO5hNq27sY+guKiSlz7/j254PeCP8Fu//Huzf9fXrqW+du0szdKu2Ni94zl2b38W0zQwtDymrtFYt57G2rWAgHDdPWj3jmfZtf0ZS9BCuIp24fLxT3/9P1jj5LM01q2jqdGqQIeCxXz7a78z52d+dM8VT4tQsJjnnvw2AO1d55iMjfH1L/5TSqJVZDJJ/uN/++c8tudLs4GFaZoMjQxy7uJpHt/7NF6Pj3w+y+j4KCVLq2r7KcSt77ked4DPP/0rpDNJ+gc7yOUzTMfHeeeD7/PRoZ9QW7mSjeseprFuPQF/BIfdNe9MeCabmqWymKZBe9dZfvt3X1jQp8hkU+iGNsPwuHJsTdeYjltrFYtC5Jo3HdHl8s3Z73O/wKbaWVG/gbqaNbReJXZwOwwMdfKdv/99nt73DTas2Y3PG56hGN5/AYZpmhQKOUbG+vno0KscOPI6qXnQ8a6FMCtacT9g2SsWhUIel8tNMBACBERRwG638/c/+g47tz1MOpPiyIkD9PZ1UVRUTGv7BTat384Hn7yD2+WmoGmMT47x1GPPYbMtQubwKhQKeV55/Qf87//h386+tnbVRv7Zb/wO27fsplAoMDDUy0/eeJkf/fT7DA0P3JB51YCxiVHGJkZp67jIa2/+kFAwzLNPvsgLz3yZ2qr625bN7wfIksyqpq2cuXAQY8bRs7FuPU6nl/c/+RENtWtorFtPU8NG8vks51oOU1xUybZN+2jrOE08PkFFWT2j4wMEA0XUVK7EbnMyNNpNKFiMIqusqN9IJFzKgSOv4/eF8XvDHD/1PsXRSrZueJR8Ic/5i0duOseJyWEmJ4dns+QLhcPhprys/oYbraS6UDxFyA4/sieCno2jBqvIjbeT6j2GqNgRVRei6rAkQAUBQZSQnUG0xCiCKDN98R1MU0dxR/A1P7GoeX4aEI2UY2Jy+vzHhEPFBP1FiKI0E1T0curcx5SX1i4rF1TTNFo7z2AY+k34/HMjP9GNlpy46fuehj3XqKHZbA62b75iXvfUo1/DNE3Wrdp5DQUUoKF2LTDjPj2Hi/W+h79yy7kZeoFszNJ+Nw3Dcu7WCoBVbRAVG6Io35Y2mZ0cpP1H/56xc/tv8MaZuPABAx/+LRWPfIuynS+hXOdMH/QXURQpp6f/0i2PcSvk8lkOn3iHrRv3URKtXPA4c0HLJJDs7tnvXc+l0bJJ7P5iDEMnOzlIZrwbZ6Qae6CUQiZu+Q/N4bli6gXyyUkUVwBJufZ+bmgFJlsP4QiV4y5tXPB8BcF6LsamxxBFiZGxPiKh0mv8QgRBwOv14XX7OHfhJD6vny0bd+L3LX/28n6HJElUVzbxK9/4Xd796B84fe4T4slJctkMuVyGlrbjtLQdJ+CLsGblDjat20tleQNul+9aGtscuPMF4s1hce9vzNpfLRd7uSoyXyiKumhDy7sNvzfEI7u+QN9gO5nMzb2CrsdkbJTvvvxfaO86x96HXqAkWo3b5b3hnrtcuBxQTCcmudR+kvc+epnOnhYWkny02ew8+chX8d0H1QpY5sAi4A9SUlKOw+ZgVdO62exlTVX97AWbSiUZnxhj7659KIrCsVOHGR4doqykghX1K5maniSemCaTzSxZYDEXRkaHGJ8cI1/Ic/b8Sf77n/9njhw/QL4wv259E5PxyTG+8/0/5fT54/zmL/82WzbsWJLgwpzxttDSUxi5JKZpIEoKkt2LaPcu6iIqFPIkkjGy2RSZTBJBtLKm0kz2XRREcvkMselxJElGVe2zNypRkhEECU3XqK9ZTSoVp6vnAk6nF9MwcdhdrFu9i0PH3iKZnkaSFKs5WBTZtO4Rhsd6SGWSMxnvm1csRif6mYrdvrR8O7hdPmoqm294XVSd+Joen/3bFrToTI7ippuOJco2ghu+TLz1PRzl67AFKimkxskOtyx6nlfDNE20xCimnkcN3D/mQFUVTaxbtZP9H73MwGAnVRUrcDjcxBOTXGo/hSRKPLT1c4tu9F0MRFHE7fLS2nGaweEuQMBmc9xAv7kapmmQn+5Hy8bmHtPmxlGy8rZiDlaT8c23WSiv29Q0shN9ZKcGyU4NkR7tJhcbxtA1FKcPZ6QKZ1E1qi+KpDrmvDfo+Qxdb/xXxs+/PxtUiIodQZQwtBymrpFPTtD77p9h6AWqHvtlJPVKz0coEKW0uHqWt74wWH4Wb733Xb7ywm/O26HdNHQKqWn0fBrZ4UVSHWiZaYxCHlF1ICoqI8dfJbjyYRSnD1FWyE4OYOgaNm+E7NQgExc+QFTsuEoa0bJJspODKC4/stOHlkmgZ5OIig3Z4SEfHyc3PYJsc2OIEoXkBEYhjzIj2SpKMtNdJxcVWFRVrGBgqIujJ9+b6QGS2bf3JRz2K9+JYej0D/TQP9jLmpXrcTmXz9F+uWFizDa9zxeiKBItquArL/wmO7c8xeHjb3Op/SRT02MkU3E0LT+j0vQKR0/tZ8PqXeza/gw1lSux2ea+juB6F3lLZGMxxog29UbRBl23EgeXId9BoCBJ8rJ6Cc0H6kzVYvumfXx48Ce3dVG/GrqucejYm5y/dIRtm/axae3DhEMleFx+1GWgSF1uzE5nEkzHJ+jpu8Sh429xqf3UvJ3lb4RAY+06tm958vab3iMse6jqdroZGh2kb7CH6opa8vkcA0N9JFMJhkYGkCUZn9dHT383TrsDwzDwuD1kMikkaWaxeQ942hNT44yMDXPm/An+6H/+B46eOHgN50+SZOw2O4qiIghQKBRIZ1I3ZNE1XePU2eP8wR////mX/+h32bhuyyL7Q6ygIjvWRqL1fQqJYUxNQ1Qc2KINeOv2oHijC27sTqcTDI30oOsaYxODBPyRGWqSREVpPdGiCs6cP0g+n6O0uBqX0zu7mCgrriGRjDEVG0XT/LicXux2F4Zh4POFyObSDA534fUGcTt9VJWv4NDxt8lkk/i8IaorV3K+5RAul/eWMp0TkyPE4jfPIM8XLoeH8tL6RY8zC1HEUdxMsvswWnwEBBFX1dalGx/ANJg68yPysQHKn/3/3PnupomRTyPICqK0dNr1Toebh7Y9gyKrnDr3CW0zlQFZVigtrmbPjudorFt/24zfXYUgIEsKwyM9fBCfQJIkiosq2bPj+ZvuYuRTFBJjmIW5TRgdxc2IinPZMmKGnme66xTtP/59Jlo+QktPX/O+IKv4qtdRuuPLhJp3o7iDN8x1uvsUU60HMQpZEETcpY14KlYh291kp4ZIDbWRHuuhkI4xcvQn+KrWEVp5peJjszkoLqok4Atf0+x8p8jns5w48yHVlc3s2PIkqnL7JIyh5ZnuOUWi5yyukka81esYO/2WRSMrqcfmjzJ2/n1EmwtPxUps3gixjhPYfBFcxXVkJ/pJj3bjLm3E1DWyqWHifefwVqxGcQeJdRwlM96Ls6gab+VaEoOXyMfHcIQrQYCJiwdIj3QQaNhGoHEHiitAdur27sG3gizJ7NnxLHt23IreJiCJEkMjljtvJBylecXyOe8uJ7RCYcEBrSwrVFc2UVneyFRslHMXj8wqJ03GRslkkmQySQ4cfYOe/ks8+8S3Wb9m102rBFe/LkkS9bVr+fkv//aC5gbg94ZvuF6tfsQZsQTTJD9PaVJgpl9y6Qx37xZ83hC7tj9LV+9FunvvPDmXSEzxzvvf58Dh11m5Ygurm7ZSXlaHy+nF5fRgtzmRZXXJ79umaWKaFuU2nUmSSk8zFRujrfMM5y8eoW+gHX2RKmzhUAlfePbXbhB0WE4se2Cxon4lFy6d4/ipw1SWVRNPTHPh4lkC/hDnW86wdeNOVq5Yy/ufvI1dtVNZXk11hdWY5HJ50A0Dm2q76wsUTStw+twJDh/7hBNnjs4GFQF/kNLicspKKogWleDzBRAEgWQyTndvJwNDffT2d5PNXnHwNk2Ti23n+f6P/pqK8kqikZIFz8s0QUuOMXn8e4iqC2/TE4iqi/xEF6neY5iFLIENX0Kapyv49fD5Qjy8c+6F1kPbngagJFptSdBeFyDZ7U7Wr34IwzAQBKtMW1+75ppSZElxFQLC7GsWTcRAFCVM06R8RjLvZhe81YMzQSq1uJKzIIh43IFbZqsXMqYaKCcYKF+yMZcappYl3X8KW7AKdYnn6feG2Lf3K2zd+DjjE0Pk81mcTg/RSDl2u2vZy9GSaFEgfvHnbu3JcTW05OSsj8lcsEca7qkp5PUwdY3kwEWSAxfnfl/LE2s/Smain0JqipKtX7iB4jN16eCs9Kg9UEzTV/+/eCvXIIiiRe+5+Amdr/8hid6zZGPDjJz4KYGGbYhXLfxLi6spL6tfVGAB1oLgrf3fxe8NsXLFljkV0a6GoeVxBMvAhPRYN850FVp6mrKHvorNb13bzlAF0Q1PIcoqhl7AU7mK1FAbkmLHFa2jUDuFu6wZR6icQnqa7NQQej5NbmoQQ8sTXv0ozohVtfSUNTORGMeYkbl2lzYg2xzEe88RqF/iJMItIAgCoWCEuppG3C7PZ4MCtcDbQyaXuq7J+c4HEkWRULCYh3c+z/bNT9A30Mapsx9zse0EA8NdZLMpBoa6eGP/3xIKFlNXvWrOzL/L5UOS5BlRF4v6HQpEl7RKYLM5UGTFElYxTbKZ1Kxgyu2Qy2UozJN1sZwQRZHS4hr27f0KP3z1fzA+ubBgPZ1JcOzUfo6d2k/AX0RVeSPlZfVEI+X4vWFLQEG1MXkH961CIU8qnQAsA0JNL1Ao5CgU8mRzGVKpacYmBhkc6qKn/xJDIz3kF1yduBYOh5tn9n2DqvKFV0TvBpY9sCgpLuNXv2U120mSRFGkmJde/MY123i9PqorazFMY7bMVxwtvedzff+jtzBME13XZrIPTTy250n27tpHY30zqnIl4jVNS1f85Jmj/Pin3+e9j95mOh6bHSufz3H63HEOHvmIF57+8sIXWaZBqvcYWmqS4m3fxhayHni2UDWGliMzdIH8ZA+O4hspPkuFWy384VploOtvqJJ4vTzqFYrI7cYFSzUqnpyat4HMzWBT7USLypc3g74MKMSHSfUeR7J7ljywACu48vvC+H3hJR97OaBlLLrh3BBQQ9UI4rLfVgEBye7E5i9BtrstGlMhSz4xQT4xQW5qiMEDP8ARqiS06mHEq+gT6dFu9LxVkQk27cJV0jDbuCzKCsGmnRhanpa/+R20bJLUcDuZ8T5cJVeqfdGiCmoqm2lpPU4+P3d1Zz4wMRke6+XHr/8pAE0NG2fVsuZCeqSL6c7jiDYnpqGDaSI7vNdQ02SHh9RQO/ZgKZgm2alB8slJ8qmpa8YydI1CcopcbATD5UNx+Kzq8OSA1UPl8JCbHiEfH5+lRKUGW1F9RWCaaLk02akh6ztPTqK6795i36LylPDSF75x+40/Jbj6WXFZYWk+iMXGyFzj1rw4RoNNtVNfs4aaymZ6+i7x1vvf4/T5T8hm05YRaNc5ykpqb5A1FgQBu81BOFTCyGgfhmEQT0wSmx5fFB3qeoiCSDhUwuBwN2CSyaaIxcYIh26/Rkqmpq/7rm4P0zQopGKkR7vx125c2KQXALvNwZrm7cSmx3lz/3fvyN9hLkzFRpmKjXJqRg7YZnPg94bxeAJ3REvq7W/jw4OvIIoShULOMh5MxkimrOrE1PTYXVE/VBQb2zc/wY4tyy8vez3uhyfgvMx8RFFEZHn1uC9r7ouiyNpVG/mVb/4W27fsnpXJvRqCIGBTbWzb9BD1NY24nB6+/6PvXJMdGBoZ5MSZIzy+93O4XQuUhzQNMsMtVgk01kd+2jLiMXUNIxvHyKfQkveflNxSIZ6YIrkI9ZnLsNuclESrFz3O3YaeS5Gf6kXPTFuLG0/RNaaIpmliajkK8SG0dMxSLhJEZKcfxVuCZLfOs0JqgkJskMzQeQrTQ2SGLsw6vivuKGqwElFWLc56fAQtNYaRzwImos2N6itFdn0GsqJ3CD0zjZGf+0Esqk5k51yOvfcYgogjVE54zWP46zZjD5QgSDJaOk5y8BLj599nuusEqeE2ptoO4a1ag81XNLt7IRWbNUlzRWtvkJUVZRVv1Vq8NeuZbPmYfHKKxEDLNYGFTXVQU7WSkmgVPX0Lb+IGqyrZ09/Kj376JzzxyFdZ3bwNj9s/57aKJ4gtWAamjuoJo7j8OIvrrmmsDjTuIDXSgWR3IYoyRj6LbHejpaZR3AHswTJkhxtT19CyydkEh+z0oXqsPgxBlLEHS9GyCWS7Cz2XQvWE0QIJJNWOXNKAUciiFzLITg+FVOyuBhafNVxelF+GphXmVZUuFHIMj/aRTt+8qrhQSJJMbfUqHt75AqPjA7MysoMzFYy5/FJEUaK5YRMjo5YfQSoVp6X1+Gy1fykgCALVlc0zgYWVbOvsbbltYGEYBmPjg8QTU7fc7nqYhkFqqI3e9/4C/6/+t4VOe0HwuP1s3fgY8cQknxz+KcnU9O13midyuQwjY3137B3R1nmats7TSzaP+UCWFTau3cOz+745K/t/P+G+CCw+baiurOPbX/tVdmzdg/02DeOCIBAMhPnaF7/F6XPHOddy5QQsFPL09ffQN9BLc+OqBc3FxETPJjD1PMnOAze8b4/UI9qXRtP+fkQ8MbUoWcvLsNkclM4zsNAy0wiSgqjcvGnvbsDUCyQ7PyHVcwxBkhAVB6Ldi56++sFgomWmiF/abwUKpolRyFlN99XbcNdsR5Rt6KlJMsMXyI61oWenyY61oyUtg0F7cTOKvwRQMU2dRPsHaMlRTMOwAlYtg6N4Jb5VTy+YYvdphZFPYdxEZlZ2hxFEZYmMKhcOxeWnfM/PU/bQS9c0VQP46zbjrVxN5+t/yOTFT4j3nCEz0X9NYGFo+dm+Ndnpm/Mcl+0uAvVbmWz5GD2XIjPRf8M2VeUrqK9Zw+Bw9yIaE2fmZOj09F/ix6//KRNTw2xcu4dopPIGuWJnuBJHsNxSZpuZtz14bX+Wv34LpqHPVmlKQte+76tZP/tvb+VqvJVXehXsgWJMw5gd3xEqJ9S0a/Z9T+Xqa6meWxYmLXo1slPD6Detki0emfE+jHzm9hveQ4iiRMB/5ZxMZ5L0DrZRX7vmlvv1DbTTN9C2ZFSTueD3hXE5rzxTLxspzgVJktiwdg8Hj75JLp8hmZ7m6Kn3aKhbR9Et+gbvBIIgsrppGweOvA5YjvFnzh1gbfOOW0rJTk2P0TvQSip988V5NjZMou8C5gzVz1+/ddYjR8+mmLx0AC2TQHH58VSuRra50HJp0sMdZKcGEWUVV3Ed9mAZ8b7z2DxhBEUl3n0aX9U6TNMgFx/DESgl3nsWQVbRMnEEUcJfvwXF4b1hTqFAMXsf+vyMkdy7JJJ3Fhh92iGJEutW7eSFz/0Sfl/kvgsq4EFgccew2ew89dizbFq//bZBxWWIokg0UsITjz57TWABVlP4wGDPggMLECy5U5uH4MavXJO9BhBECcl+58o72Wx6xrTu1lUiw9CZnBolkYpRU9lMbHqcdCZBOFQ6r2bLxSKRnFySwEJV7bdsEL8a+ak+tNQEsiuE6i9Dsvtu0Li/G8hNdBO/tB9HySpcNdsQJZXMSAvpnuNIrsuSnwKi7MAWqUNxFyHa3GjpKRJt75PqO4E9Uo/qL0MNVCC7I0h2H8nOT/A2PjpLlxNkFVGxFqSCIKN4S3AUr0RyBTC1AsmugyS7DuEoXYsjen9xO+82jHz6pv4VssN/WzWouw5BxFlUTfHWF24IKqy3RTyVawg27iTec5bM5ACF1PUP5iuLJFFSmIujLio2nFGr183IZ8jHb3S993mDrGraSmvHafoG2hb1sWDGCHOsjzfe/VsGBjvZuulx6mvW3FC9uN21KAgCwiIkNm81/t1Q2Bk58RrxnruXEdUySTKTA3dt/IVAkmSqKlbMmrQmUzHOXjjEqsYtRItuVL8zTZOx8QE+PvxTBoa65n2cQiFPR/d53C4fReGy26o0FrQCvf1t16gQBgPRWUPX6yEIIvU1q1m9cjvHT72HphVo7zzD2+9/j4d3vkBJtOqWcq+5fJbJqRHiiUnKS+pwuW5caAuCQFPDBqKRckbG+skXcrS0HefEmQ/YvP6ROeeWSsc5cfp9OrrO3ZKmM3ridfKJMWSnH0wDb+VacHjAMMgnxkn0taDnU2gZq0Lkr91Eou88ky0fIaoOjEKOzGQ/4VWPMNnyEe7SFSAI9H3w18hPOCmkpsnFRxHrJTpe/U9E1j2BIMmkRzow9QJF65+a8/NGIxXse/gryJLCoeNvzfp4fNahyCprV+3g+ad+kaJw+bIZQ98ODwKLO0R1RQ2bN+yY8d2YPxwOJ2tXbUBVVfL5K3SoRGKa8YkbH8rzhSAI2MK1FKYPAAK24PWa73fO7cvns1zqOMWK+g3XlKPngm7oDI300DfQRk1lM5peIF/I3TNH5UQitgRUKAG73YnH45/X1rIzgJ6ZRkuNY+RTiKoTxV2E7A7dVX59ZugCmCaehodRA+WWtr6vhGTHlUqVRdnw423YO/ua6itFS46R7DqEnpkGf5kVjCp2JJsTQZSR7G7k2eDkCgRRxNt4ZSzL8E+0+noSo/CzFFjM0MzMm8gdinbPrCneckGUFRzhStQ5fsvZbSSLxqN6QmQnBtBzt8hW3yQbJkgyqsfyHjK0wuzC4nrU16yhuXETY+MDlsv4EiCVjnP01H4GhjtZv3o361btpLy0/q7KjS8nprtOMnb6reWexj2FJMlUlNZTHK1iaLh7dkH+03e+w6b1eykKl2G3OTEMnVQ6zvBoH+daDnH6/AEEQUBRbFdVyW6e0c3lM+z/6AcYhkFFWT1F4XKCgSI8Lj92uxNJki1Vn3yGeGKK/sEOjpx4l9ExKxDzuANUVzThsLvmHN+iRDvZ9/CXGR3rp2+gjVQ6zoEjrxObHqepYRPRSPmsJ4ZhGhTyOVKZBPHEJBOTwwwOd6FpBT7/9K/cNLDwuAM8svtFfvDKf0PTCsSmx3n93b8hmZqmrno1fl8YSZLJ5TNMTo3S3nmGIyffJZWOo6r2m/ZBadkEgqTgq1qLq6wJxeGx6LaYiIqN4i3PIYgSw8dfJd57FnfpCpL9Lch2DxWPfIvs1BCDB39AYqAFm68Io5AlNdKFI1RBPhkjOdiCr2YToqxSSMWIrHkMZ7SGkeM/ZfLigTkDi8ufuShSzqO7X8Rmc3Do2JuMjg/yWTagddhdbFz3ME/sfYmyktr72mT5QWBxh1izagOVZdV3XH6SJAm/L4DfF2R0bHj29Vw+RypzZ81T10AQcVVtITNwlti5n+Cp24Xk8GEaOno6ZkmelqxClOfOxPQNtDM61k9By1NWUovH7aet8wzHTr1HMhmjsrwRWVaIJ6ZorFtHPDFJV08LjfXraGk9jq5rs8ov8cQkvX2tKIqN4iLrAh8e7WVouJtcPktZaS3FRZX09rcyFRtD0wpUVzYRCZchLSDTZ5omyXSc1E0WNfOFLMn4PMF5y7Wp/jJUXyn52ACp3mPo+RSy3YfiL8VRshrxLsm+aelxRLsbUXXOLmAFUUb2FM3SmMDE0HLkJnooxIcwcilMXSM32Q2GbjW03hFMcpN9Vl/HDOVOz8xQrPTC7Xf/DME0jZnvb+6Hl6jYl5UGJUgyCCLSPAyyRFlFkBQMvXDNOWGaxrySAoIgIso2BEnCNHSLPjUHPG4/m9fvpafvEq0dp5Ys4aDrGn0D7YxPDNHRdZbVK7ezasUWSqLVt1WOeoD7H4Ig4POFeeShL/Dya39MNpsmmZrm0PG36O67SHGkApt9JrBIxRke7WV8cgi7zcn2zU/Q1nmG3v7WmdFufs4ZhsFkbJSOrnOcOvsRfl+EUCCKx+PHbnchzwQW2VyG6fgEw6O9xBOTmKaJzeZg68bHqK5suqXohyRJ1FSt5Nknvskb+79LV88F0pkkx0+/z8W2E7O+CpKsWD45+RzpdIJYfIJkKoaua5SV1N7Sv0GSZLZt3EdP3yUOH3/H8jUZ7OQnb/4FFWUNBPwRK7DIZZicGmFopAfTNNi0/hGGR3tp65i7Ihbd9CyTFz9huvs0sa5TlGz7PKonjCBIqJ4wNl8RhXQc2eYiFxtGz2cw9AKKO4goq6jeCAigpePYg2VkxvvITg7irVpLLj5GaqiD6MZnECQFxeXHHiy11BTdQfTcrddFl4OLR3Z9gYA/wkeHXqWn79Id+Vx8WuD3hdm2cR97d32eonDZfe898iCwuAOIokRddSPhUNHtN54DsqTg8/ivCSzyhTy53MJVUwRBwBaoxLf6WVLdh5lueXumzG8tcGzhWhzFK+fc1zRNLrQeo5DPES2qQJIkRFFE0/IIWA1CkiQzOjZA32A7DbVriScmOXHmQ9xuPx3d56ipbCaXy8w0EImW1nc2RVVFI7qu0dl9nlw+i6raaWk9jk2xc/LMR/i8IQK+CKIoLVRVEF3XyObS10kL3jlkWSEYmP9vmp/qJzfRZZmOeYux2dxg6CR7j2EL1921wAJTYM7s21WLNaOQJdVzlFTfSWRnANFmKQIhCHdsGgVWlSR+8V1EmwfJ4UUQJQRR/FRony81TEPHNG8emAnzcLS+axAEZLsHLZekkJi0zolbzEXLJtFz6SvnhmkiCAJGIQ9X/7a3CwQEEdBvuV11RTNbNjzK+OQQE5PDN91uIchkU1xoPUbfYDsX206wsnEzzSs2U1JU9ZkJMAL1W+aktd0tWJWo5YdNtbNlw6NMTY9x4MjrTMcnyOez9Pa3XhU0XEEoWMz2TfvYtf1Z0ukEA4Md13hNzQVRlAj4LG8I3dCZmBpmYur252g4WMLGdQ+zZ8dz+L23V7xTZJV1q3dhUx0cOPoGF9uOW8IjqenbNiCrio2iSPkt1dAEQcDrCfD0499AkhROnvmQVDpOMjVNS+uxG7b3+8JsXv8ID+98gQ8P/oTunpY5lRVt/iilO79MariDnrf+B/FoDeE1j4HAnHRCyeZEVGwUUpMYWt6iSBoGssOLI1TOdNdJwMRd2sD4+Q/Q82kkm8uSnBevrFsszO955feF2b7pCYL+Ig4cfZ1zLUeW1PF8OSGKIlUVTWzf9ASb1z9CwB9e9qr4fPAgsLgDeD0+wqEiVHVhDyxRFLHZrq0cGLq+yIWxdUG6q7ageIspxIcs8y5RRrK5UHwlCLcwPotGyhka7iGTSaIoNtwuPxVl9QwO97ByxRY8bj8TV2lGm6aJpuUZnxikKFzOmpU7ABgbH8Tj9lNaXDPjYgyx6XH6hzqQJAW/N8TU1KhVuSipZTo+QSaXwqY6Fnyh5PNZctnF0ytkWSHon7/8n5a1HgSqrxjVX45ocyEIIvnpwRsUdJYSsjtEdvQiRj6FaQYRBBHT0NASI7Pcfj2XItF5AFG24218BMkZANMk3vYBWmoOeT5B4rKx0lxItH9EPj5EZMfnULxRBEkhO9ZBouvgXfuc9y9u/j0BM9/l8gQWgijhCFcQ7zlLeqyH9Gg3zmjNnNtq2RSpkU7yiXFLrnqolXxiAps3THZq0DLGm4FVibjxM5umgaHlMXVtpnpx84ytoqhsXPswQyO9HDz6OunM0jciJ5Ixzpw/QE/fJc5dPExj7TpWNm2lorT+trz5+x1FG58mtGrvPTue7Q7uhXcTgiDg9QZ5Yu9LlEQrudh2kr6BdqZio2Rn7vt2u5OAP0JFWSPNjZtYuWIzfl/YMnJV7beVUrXbHDy6+0uUl9YzMNjJ2KSlkpTJJC1fCMNAFERU1Ybb7SccKKastI66mtU01q7D7wvPi+duUaLsrGreSlGknLbOrXR2n2dgqIuJqWEymQT5Qn52O5fTR8AfIRopp6y0juqKJgL+yC2PIYoSpcXVPPfEt6iuWEFL63EGhjqZjk9QKORRFBWfN0RFWT3NjZtZ1bSVcLCEgC+M3e6ikLwxsBg98Tq5+BiCICLZHNh8tz43ZLsbT/lKJi58SM87/xMjn8XmK8JT1oTqi5BPTKC4g9iDZRj5DKo3gigrmNriqgx2u5NVTVsJBYupqmjiyIl36R9oR/sUV9VdTi9rV+1k++YnaKhZi8MxN93ufsSDwOIOEAqG8XrmVkmZFwRu2NeExdMDZpoR7eEa7OG5FxNz7yawom4DPk+Iju5ztHWewbHShShI6FddkJKsUCjkME3DkqYTBERRtEqOpnlTl1NJkpAldTbgqK5oIhQsJhiIMjjcRUfXWS61n2T96odu2vx2K2TzmSXhbcuyckc+C6q/HDFUg6BcmbNpmriqts42Pd8NOErXkOw6RPziu7hrdyDKdjLDlkys5PBfmYuhg2k5quqZGLnJHrLDF+bs/5AcPhBEMsMtVnVDkhEVB7IriCDKVmViRnrUyGcoJLtJdhxYVhO45YNwgzjCNTBvnbm/mxAlBV/NxhmVpz56P/hLKh/9RZzha3uutFyK8fPvMXHhw1kloJETP0WQFPw1G5lsPUhu+krPVzY2bKkgXQdTK5CbGgLTsM4X560FIgL+CHsfep7J2AjnLhxatO/MzTAdn2A6PkF370XOXTxCTVUzzQ2baKhbh+M+MGVcCGzeWy8oAQqFAp8cfp/WjotsWLOZLRt33IOZ3X2IMz44OzY/xYq6DYxPDpNKT5OfkW1XFRWX00s4WILfH5kVDNm2aR/lZfVohTylJbU37RWUZYWmhg1UVzYxFRu1gopsinw+g6Zps5U8WVaw25x43H6CgSget/+WTdc3gywplESriIRKWbliC1OxURLJGPl8Fk3XZpkCdpsTl8uLzxvC5wmhKPNzhRZFiUi4jN3bn6OpYSOTUyOk00k0Q0OWZJwOD6FglFCgeLYCsm71LoKBYvL5DEUz/R6X4YzWzCrDeSvX4ClvRhBFnEW1VOyxPFMk1Y6/bjN63qqAesqakRT7jCqUgjNSY1GcRInopmeQVAeKO0h0k+UkLzt9YOhUP/kbiIoKgoCrtIHSnS/d0XcrSTJlJbUE/EVUV6zg5NmPOXX2YyYmhzA+RRV2VbFTW72STev2sqppK5Fw6bzMDu8nPAgs7gAuh2veSlCfBhQKOS62n2B0fICp2ChVTi+CIOLzhsjm0nx44BWaGjdRFC7nk0Ov8d7HPySTTWFT7BQXVdLacZqPDr1GIhlDVWz0D3ZyruUQk7FRbDYHtVWrKC+tZWSsn76BdsKhEgL+Ii51nCSRiDExOUIkXL7gh30utzSBhSTK19xMbwc9NUli4DRaagLT1JHsXnzNT6K47y6FwBaowNe8j2TXYaZOvWz5JrgjOMvXk5voBkCyufDUPUSy4xMmT3wfQbKhuMOogXK0G9R/wBaswlm+jsxQC7nJbgRJwV25GVfVVgRVxtvwMLFsnMnTP0SUFCS7F8VfflflL+9XCKJ0y+qa5f2wTIGFrBJZ8wiDB7+Pnk0ycvw1cpNDuCtWYg+UIM7IOKaGO4h1HCc92oUgStiDZWiZBIMHvsf4uf3kp0cpXCU/OXXpABV7fh7xOq10LZci1n4UsOgP9kDJbedYWlzLE3tfIpGM0dl9/qYJiaVAMjVNa8cpevovceHiUcpKamhq3MTKxi2EQsWInwI6wZ1AFEUi4ShHTx6iq7fjMxNYXIYsKxRFyimKzM/Es7K8kcp5uhELgojD7sJRXENp8fwTc4uBLCuEg8WEg8VLPrYgCKiqjbKSWspKam+7fWlxNaXF1XO+56/dNOfrNl8Em88KeEVZxVl0ZX/J5sBTsRJPxY0U7KvHu1rWGSCy5tHZf9v9xdj9C/tunA43TQ0biUYqWd20jfMXD3Pi7EdMTA7f1xReWVapKKtj49qHWdm4mZLiauw256cyGfIgsLgDqKoNRfl0RY63gijKlESr8HlCmBiEAsU47NaJ/PBDn0fXNAL+CF5PgEf3fBFJlJFkBUyDokgFu7Y9A4Klq6zINpwuD5vWP4KmFXC7vAT8ETxuH8VFlWi6htPhxuFwUVnWQC6fpa56FUWRigW7XS9VYCGKIk7H/L0+smNtVgN1ZhrFU0ohMTqr8303IUgKrurtqIFK9GwSQRSR3REEQURLWzQnQbbjqtyM6iu1MkiCiOQMICoOjHzqmsoGgGR346nfgz3ahFHIICAge4oQZn4Te1EjwU0voWfimJhINjeKpwhn6SpE242GUJ9pCOIt5WSNQm7ZKhaIEu6yZkq3f4m+D/4KLT3N+IUPiHUdR7Z7EEQRo5CnkInPVip81esp3fkVptqOMHr6LfLxltnhvFXryE4OkOi/QP9Hf0PF3m9ZXGhBQC/kmLp0kLGz7wCWb4a7tOn2UxRF6mpW8/yTv8APX/sf9PRfwpijGrKUyOUy9A22MzDcRVvXWQ4efZPaqpWsWbmd+pq197QPI5lM8O6Hr9Pd24WiKKxqWsfDDz1GR3cbH3z8DtPxKfz+ILt3PEoqnaS17QLDo0OEgxHGJ8fYsHYLxUUlHDlxgEw2w/R0jLraRp594gtWg3BlHaXF1y68J6cm+OTIB3R2teLx+Ni26SFWNa29YW4Tk2McOX6A8ckxdN0K+BRF4YWnv7xw89YHeIBlgiCIBANFBPxhKsrqWb9mF22dZ7lw6Sid3efvWsV0IXA6PdTXrGFN8zZqqlYSjVTgcno/lQHFZSxZYGGa5gylx7zvO9YXClmR72uJrzuFJEkUF10vT2uh6rpsT1316hu2qa68cTHhdd8oc+n1XOs4O58synyQy2dmubaLgSTJOJ3zf3iaeh5bsAZME3txE0Yudc8WlJLqRIrU3/C64rW4r4IgINncSEVzZevmonsJyM4AsnNueVJBUrCFbsziSfYbZQ8/6xAEYUYJSZkzkDRyyWXLiAmCgOzwULb759DyGYYP/9Dqv0nH0W5oZBTwVq2h4tFfINS0C2/1OlRPiPFz+ymkp/GUNVP52C8yfnY/g4f+gf4Pv0O85wzusiYkxU56vI/pzmPkpkcRRBlHuApv1a2Nyy5DkVWaGjby4rO/xg9e+a/0DbTfE5qCYehMTA4zMTlMb38rZy4cJBopn6libKYkWn3XNeFj8Sne//gdnn3yRYqjpQR81n0xFAizY8tu8lqeDw+8y7mWU7hdHhLJOLIkMzo+gs/rp63jIoZp8MnhD/j6l76N2+XhT/76j9i0ditlpTd6O+TzOS61X6Crp51H9zxFS+s5jp44SEm07Aa5dJfLzarmdXx0cD8V5dUUhaMcOPzBNXSgB3iATxsEQSTgj+D3hakoa2Dj2j2MjQ/Q0nqcts4z9A91LFr8ZSGwqQ4qyupoqF1Hfe0aSoqq8Psjn9oKxfVYksAinUlx8sxRTp09TnlpBZvWb6e8dO4F681w/NRh1q3eiCTJi/5iW9tbiISj+H2BJf2RBG6iyvMAy4J8PndT/e07gShKuBzzz76LNo+V0RdFkl2HKEwP3tcl1vsR8cQkr7zx53zusZ8jdBfoAHcLomJHkNQ5AwvL6Xz5zgNBlHBGKql58jfwVa1j5NTrJPrOo6Vis+/bg2WEV+0lsv5JPBUrkW0uXDYXlY/+IsVbnsPQCsgOL/ZgKTZfEeMtH5Ed72XiwofEOk8gCCJ6ITtb9bAFiine8vxteyyuhqKorGjYwFdf/Cf88LX/QUfXuduq9ywlMtkUA0OdDI300NF9nk8O/ZTSkhpWN2+jqWEjQf/CVP9uB783wN5d+zh97jgdXa08/sjTGIbB4HA/Hx98D8M0uNByBo/Li8vpJhAIocgK0/EYZSUVXGq7gKZpeD0+6mubKApH8Xp89A30zBlYZLIZWttbOHLsAKlUklg8RnFRCal08obAwm5zUFlejSzJ2FQbXrePRDKO9hmU7nyAnz0IgoDb5cPt8lESraKmaiXJ1DTxxCQ9/a10915kaKSb8Ymh2zb8LwSyrBANl1NSXE1l+QpqKpsI+IvwuH04HZ4FszbuVyxJYDE4PEDfQC/7HnmG7t4O3vngdUqjZYyODxONlLJx3VYutV+go6uV8tIqmles5uiJg0zFxtm59WFEUeJvf/AXdPV2sGblenxeP2+99xqSJLH3oX1omsahox+hqCrNjWsoFHIcPXkIh93B+jWbSaaSXGo7T0NdE0XhYl5964d4XB42rt/KyhVrcdjvnVTfA9w76Lq2JA8+SZJx3EFg4arYiCApyO4IuYkunGVrbprxf4C5kUrHudh2gkd2fWG5p3JHEBUngqxC/saHj5aamOmzWD5cDh6KNz9LcMUOtEwCLRNHL+RmmiYDqO4AstM346ptmSBezZm+DGe0jrpn/wlt//B/kE9MoF3VewGgeiNUPPxNQisfvuMEjiKrNNSu5Ztf+Ve8/Nofc/r8gXuuP28Y+myz9+BwFy2txwn4I9RXr2b9mt3UVa+6pcTnncLpdLF31z7Wrd7EqbPHefknf8cv/tyvc+7CKex2B7t2PMLE1MRs74kkyUiSjCzJiJKEaVrMgFhsEk0rYJom4xNj+Lz+OY+nyArBQIiGuiZe+oLVaGu3OwgFbi5U8dD2vZw5f5Kung42rd+O2/kzRnf8lODVN3/IpbbzRItKeOnFb6JctzCdik3w8qvfY3p6il/4ud8g4L/CGsjmMnx08D3cLg87tuy+7bHOnD9Ba8dFvvDMVxbUsH6/QZJk/L4wPm/IEpWpbGbbxsfJ5bNkc2li0+OMjvUxOTVGPDFJPDlFIjlFOm0phWlaHk0voGkagmAFDYpsQ5ZVVNWOx+3D5wni84bw+8IUhcuJRsqx213YbA7sNqdlvvgZZfbAEgUWmUyaQiFPfU0jI6ODDA0P4PcGWLtqEx1drXx0cD+qqrJp/TbKSyv55NAHFEWibFy3hdfe/CFffP7ruN0edm3fi89rVRnWrtzIxbbzHD99hIrSShLJOC8+9zVS6SRtHf0UhYsRBYG2jotksmncLg+nzhxj2+aH8PsCrFm5nhX1K7F9yqUGH+Dm0A190Q2ggiCgKrY7ou9Jdos2Jcg2HCWrZrwAPrs3ibuBbC6zLCXoxUK0exAVJzo3NsLrmWmMQmbZqSMWHc6Jw+a06KkzpneCIFjN5/OcmyjJRNY8js1XwtDhf2C68yRaNoHi9uOrWk9049N4q9Yi38R1+HaQJJnSkmp+7su/TXG0infe/z75Wbfke4uClic2PcZ0fJzB4S6On/mAaMSS016/6iGiRZWLokqZpsnI6BD/6b/9HrIkI4gCG9duxWF3Yrc7+PDgfgaG+hkbH6Gpvvmm4wiArCj8yV/9EclUgqrKGqqraonFp/jjP/vPXLh0DlmWyWTSPPe5L7Jm5QZ6+rr4k7/+IwRBYNvGh3j6iRduPv7MM3VV01pLVl0QPhPUjM8aPjrwLt/++q8RCRcjz7HY97h9bFizmXc/fPOG+6xhGExNTWLo86uuJlNJxsZHlq197G5BmDm3nQ43zpnEomma6KUahYaNaJqGYWjouoauW2sNy3XcuIr6b9GtLo8lCCKSJFn9qDNJAVlRUeT5qXp9VrAkgYU8k1nJZq3yuGkaOJ0uSkvK6enrZGx8hIryasKhIrweH9OJKaqraolGipmOx5BlGZvNjt8XQBQl3vvobeLxKWvbeMxyrfYHCQZCuFxu2joucv7iaXZtfwTD0En0JygK+ykrKaeyvJoLl87h9fhwOd0/Uz/mzxoMQ59tNFw4BCRZuaPzJNl9BMUTRRBEYudfQ3ZH8DXtQ3L87PUdAAwOdfHBgR/f0T6x6XHiyRsX5/c7ZIcf0XaThbRpUIgNoHpL4D6RBxQEAYSFm1BKqgN/zXrcJfXohSwYBoIoISo2JLtrtuqx8PmJBHwRntn3TWqrVvG3P/iPTMZGFzXmYmCaJrlchlwuQ2x6nO7ei7z/8Y9oqF3Lji1PUlez5qbSpbdDJFzEv/itfzsr1+10WEHF4w9/ju1bdiOJIqZp4nA4EQURwzQRBGshKEky61dvore/m2AgzNe/9G18Xj82mw2H3YlNtfMr3/pHFDRLstRus+N2e/F6fHzjpV8ml89Zr9sdt8w6Hzt1iMryalwuN+2drbPJuQfP0fsDw6NDvPnuTzhz4RTf//HfsGXDDh7b8yR//Bd/QDwxjcPu4Odf+iWikRJ8Xj/qVeIEZy+c4qdv/xgwSSTi7N7x6JzHOH7qMO+8/zqZbJp1qzfi9wVoaT3Pv/+D/xfx+DQ//9IvUxIt43/+1R+Sy2XxeQM8/cQLtFw6x9kLpygUcpSVVvLME1+gs7udA0c+oLevC4/bx7e+/msMDPZy8uwxEsk4zz35IutWb1qwN9hS47K08GeNmnSvsSSBRWlJOe3drfz+H/07ykoqaKhrRhTEWUm/mqp6Bob6+e4//AUrGlbS1LiaDw+8y1v7X2NFwypsqo36mkb+7Dv/jYe2PUwmk6Kt4yLBYJiAL2g1TV7OKJsmyVSCoZEBevu7WbNyPSOjw5w5f5KGuiZqquopK61g/4dvMjY2wsb123A6nEvxMR/gPoOxRBWLuTI+t4KWHEeyucmOteGu3kZq4Ax6If0zG1iMTw3z3sc/vKN9TNP8VJoXSU4/knrzDH1uohtn+frPlM+HIMkoLj936xNdzhquW7WT0uJqXn71v3Ps1Pt36Wjzh2HoZLIpMtkUk1MjnDr3EeWl9WzbuI8Na3fj84bmveC+vGApitzYT+R0unA6b1/1cdgdSLI8m2iLhK70gkiSRCg4t9/FzahSc0EraKTSSURRpLe/a/EeS3Mgn8/yf/3Jv/5M0GpuhubGTfzi1/+fC/JnuhUioSK+9MLXOXz8E7711V+luKiEoycOIssSv/Urv01bxyW+870/5bd/699es99UbIrO7nYa6ppYu3I9b+5/dc7xk6kkb7z7E5598kWqK2tRFZUTZ46iyDK/9u1/QlvnJV5764f8i3/0v/Kbv/TbTCdiHD72CSdOH0XTCpSWlPPEI8/wyeEPOHz8Ewr5PKua1rFu1UbGJ8eITU/S09fF5x5/HrvNzj+88l0qyqsoLipd0u9puWD1Wt6dKl82m8Y0DWw2x7wZFuaMz5hpmjcES1cqLks/1yW5sr0eH089+iyP7XkSURQt7pggIEkSTz32PIIgYBgGmlZAlq3qRlPDKgxDR5mJDr/wzFfI5nI4HA6aV6zh8b1PoyhWJlkSJZoaVgHQ0d2GaZr87r/8PU6fO8HE5Biff+bLFLQCkiSjyAq7tu1ly/rtKIr6mZKHvRWs0pyxIEUuw9Cv0CRmxtJ1jUw2hdPhmaUAGKaONIfJ2kLmehmLOakNw1h006cAdxxYIEAhNQ6A7A5bVKhFPIBN0+DdD3/Ay6/+jwWPcTfx27/5X6itar6ph4NpGJSV1vHiM786bx347r6L/N3L/2Upp3lPIDuDVj+NIM7ZqJ0ZbsG/+hlM2f4gy3uHkCSZ4qJKfvHn/i2b1z/Ky6/+MWPjg5jL5A1yNTS9gJYu0Npxms7u87yx/2/ZuvExdm9/llCwZPYeebd/88baJv7VP/7frslELyX2PfI0Hx3cz9DwAM899UU8nrsje5m6Qanss4VUOnFXzltJknA53ciSjMvlxm530N3XSXVFHT5vgLLSCnr7u2/YL51OkstlKSutIFpUSvAmfTbjE6O4XB6CgdCsGbAgCFRX1eH1+ImEo0zFJukf6OUvv/vHqKqNRDJOfU0jAX8Iu91B0B+y3O5NE5fLzYEjH2CaJo/teQpd1znXcopzF0/jdDjxev2fmeqAaZrs//Bltm3eh9vlmzMoNwyDVDqOYej4vHP7XgmCMOe+rR2nOHT8LZ5/6pcoLqqYPeatkC/k6Og6RyIZY+vGx65578Klo6iqnYbatXOOs5jrfkkCi+vLR1dPSFSuLEYuL/KFmVLw9fu7Z/a3fBGupadclnktK65gaHiQH7zyXSrLq9k8E0BcfWxRFJEk1w1z+azAMA1Mw7gmGEil43xy+HWefPSrwJVA4wq3Wph9Ha7wAg3D4OjJ/VSU1VNaXGNRAfJZvvP3v0/AF2HrxscpK6mloOV5+73v8eyT37pqHBPDMGbHAmb+5qpF6LVcRIB0JkEqncDnDc06pS7kd1qKigWCgHiHgYXqLyfR9gGuyk1IrtCSqIUVtMJdUaNYCtzuOxYEEZfTQzRSTjAwP0WddCb+6XygCCKKrwTJ7kXPxG54Oz/ZSyExhs3m5oGC3J3h8j3AbnOyZcNjNNav5+33vs/Hh1+bfRgvN0zToKDlGR3v57W3/5r3P/kxm9fvZe9Dn6e4qBJFtSHcpYwlWM/BuyV5bpomQyOD7Nr+CG6Xh5ZLZ9F13eoJ+Qw+Rz8rqCqv4VzLaTKZNCOjQ5REy9ANnXyhgKZrFAp5VJsNRVWYmKkaxBPTBP03LmyDwRDxRIxEMk4ul7XONdOcTb4JgkA2l+XU2ePUVDXwyK59vPX+a7PrDCupfGU8XdfZunEnj+55ElVRGRoZoKF2Bbt3PkZtdT2SJM2uAT7t6OppIVpUgTLzeaZio+TyOUbGemcauCsYHe/nyIl3cNidNNSup7pyBZlsmuGRHnRdo7SkBqfDM+vInsokiIat5+rqldu50HqMyyaspmkwPjlM/2AHFaX1BAJFxGJjyLKCw+FmcmoUp9M9QxkvkExNk84k8HvDxBNTmCYEZgQ7Uqlp0tkk4xPD2G0OykpqUdWFJ8eWrBY5nwlcvc3128+1/+XGQ+tMNRFECZ/Pz2MPP8ljDz956/1NAwQB0/xsBRemaTI41MXwaC8BX5iaKqvy0917kaqKFbPbpDNJ+gbaSCRiuN0+IuEyNC3PdGIKXS9QWlyDzxNkaKQbp8ODa0YuMpNJ0tJ2Al3TKC+pIxIuRRCgvfMstdWrZsfX9AKjYwOMjvcTDESpKK0jnojRN9CGJEmUl9YhiTLx5BSx6XFEUaSspBZRlDh26n2mYiOUFdeyZuWOBSuv6Ia+aCUZgTunQjnL1uIsu2IyFdry9UXN4dOOokgZO7d8Do8nOO9rzW5z4XJ6bulkfT9CEARUfzmyMzBnYAEmya6DqIFykH62GvbuBOlMcqap1ESW1RljzitZf0EQCPgifPH5X+ehbZ/jjf3f5dTZj8hkU/dcPepmME2DZCrG+5/8iE8Ov87WjY/x+MNfJlpUgc3muKsBxt1AvpDn/MXTiDNTPnTsY6JFpdhCc1OsHmD54HF7Z6nmO7bu4ejJg/zef/pdHHYn3/zar9DR1cr3f/jXdPd28H1RYu+ux6mprOeV1/+eltZzGIbBijlEArxuH/se/hx//+PvkM/nWbNyA2Ul5Tjszlkz3KA/RH1tA3/853/AwFAvdruDaLgYm2pDVVUEBGyqjURiGhM4eeYoR08exOlw8uJzX6OxfiWvvP4DMpk0a1Zt4Ol9L+Bxf/ppxE6Hm7c/+B5lJTXYVDutHac5efZDdm17lh+//qd84yv/gkIhR6GQt5Kqqp1sLsO5lsMMDHWgKDb6BtvZte0Zjpx4l7HJQepr1lAUKgMExOvuJeMTQ/zkrb9k/aqd/N2P/pCf/+I/o6XtOB53gMqyBk6d+4g1zdsxTZPJ2Binzn6M2+2jKFyGqtro6r1AJpskHCphcKSbw8ffpqZqJe2dZ9m94zlqKpsQFihKc9+QHE3TBEMDQUQQJYsblk+jJUYQVAdGJo4tUg8ICKJocdlMw9peEDENHTAtigIChfgoouqwjLwEAVPXLDUUQZyhrcxk0T9lkl+5fJY33/sua1buIDlTThYEEVlW+ejgKzQ1bEDTCnT1XuBcy2GikQr6hztwOT0cP/0+NtWBbuhMTY2ydePjOOwuzl86gt3mwOcNYmJx8VTVjtPlmbl5WRzoV9/6S1au2IxpGgwMdfLehy+zYd0e8jlLCSedjpNIxhgY6mB4tI/a6pUcPv42kVAZYxOD5HIZqipWUCjkUGQbLpcXYZFKK4vmAAvcMX3MKGRnzxs9n55pZv1sGNssBMVFlTc1WrwZAv4I3/rq/0L4U+RhcRlqqArZEyE30Q1z0B1SXYfxNT+J7L65rOe9gsWxtShb95O55/d++IdcaD3GdHycjWse5psv/cs5TSolUaKspJZvfuVfsmvbM+z/+GUutZ0gnU7cV+65BS3HJ0d+yvHT77Fzy+d4eNfniYRKP1WGV20dFzl99gTnW87gdLioqqzB6XR9aub/s4T//X/9T7P/lmWZf/6b/+aGbf63/+X/vOG19Ws23XbsHVv3sGPrnmteu9zoXVVRw+/+q98D4A/+f3960zGe3vcCp84ep6PrEr/wc79OOFTEP7zytySScR7f+zke3/u5285jKVDQ8pjGlXu0xWa5OxW44mgldruTq0s261bvorFuHZ09F0il4gT9UaKRckqLaygrqWFkrJ/+wQ7iiQlE0ZpXMh3HZnOwsnELm9Y9fNPjtXaeoZDP0dV7EVEQGZ0Y5HIS/mqmSC6Xob3zDM2Nm9mx5UkEQZyVwr06sVdTtZKVjZvRdY18IYuma6gLXB/fP4GFXiA/2Y0g21ADFRjZBLmpXrTkOIqvhPxkH4JiR5RtyK4QWjqGnksiO/2INjd6agJDy6G4IwiSgpFPIio2EMDIZygkhhFEBcVbTCExYgUmhoYarPpUZU1tqp3S4hpGRvtoqt8AWAuGspLqa5rhJFHCYXfh9QQsapliIxIuo7y03iqJpePk8hmCgSget3/2O3A5vZQV19DV20JNZfNs81lZSQ2SbI1fKOSZio2xonEj61fvAkDTCmh6gUIhN0NzCmOaJmUltdRVr8Y94MPERFXthIMlaHqBmspmbItobhNFcfEu7+btqT7XI9l1CNVfhqlrxFv3I9pcBNY8j+wK3n7nBwAs7e+KsoblnsaCIKkubKEaMsMXMbI3csX1XJxE634C61/EFJeXRpIvZBkbH0SSZEqiVcs2j+vx7a/9Drl8hv/6p/9mXgGPoqisqF9PTVUzXT0tfHzoVS61nySenCKfz96VJuOFIJvLsP/jlzl0/G0ef/jLPLTtaQK+8Cw94n7G6uZ1OB1OiiLFuF0eMpk0NtvSNh8/wM8Oqitq6Opp58c//XtME+prG6mprL+nc7hw8ShT02Ozf5dEq6ivWbPkwgG6rpPJJsnncyRT03jcfgCU60Q8BNESIkokY6QzSVRFpSRaSX3tGirLGrCpDux2J6IoXdMuoOs62VyKfD5LKhWnoBXwuv001K9n/aqdiJKM0+EmFh8nmZxmOjFFKmX5DsmKQiRciizJ9PRdspK7Wp5sNg1YgYdpmkiitGRr4fsmsNAyU+i5FOmOTwht/hqpvpNIdjdaZhrFV4JpFMhP9WEaOrZAJbmpXoxcEtkTRfWVkp/qtb4cuxdJtlFIDIMgItk9pPpPIjv8ZMfO4a7ZRrL7CPZwDdmxTmR3FMn26VGN0nWN7ZueYHxyiFff+kt+65d/D12HWHyCXD5LPDGJy+nF7fIzMTlMwF9Ec+MmCnoBURCRrjpZDcMgmZomk0mRSMXI5TJzqlhoWoFYfIJCPsd0fGLG5MXB6Fg/45PDqIpKLp+lo/s8bpePmqorJdbrLxAARbERT04xNT2OqtoXfJGLorRokxkTE/0OTc2MfAojnyY73o6v6XGSXYcxtOXR37+fYRg6uXyWfD5n9fvMkd33ugOfSnUYR/FKUn0nyc0RWADE297HWbUZW6j2Hs/sWkzFxjh07C2Ko5X3VWAhCAJ2m/OOf3tVsbGifj21VSvp7W/l8Il3aG0/xWRshFQ6cV/0YYDVR/bKG3/GqXMf8/TjP09j3Tp83vCivDDuBcbGR/B5A7hdHo6ePMim9dtwOh5ULR7gzuH3B/nCsy8t6xzefO/vaGk9Nvv3ru3PUlWxYsmfOdlsirMth9C0AmdbDuF0unE63UiijCCK+Hwhiwmi2AkGo5w6+zEmJutWPUQ0UsHp85/Q3XuR2qqVrFyxBbfLN+utAZDJJrlw6SjZXJoLrcfweUOsaNhI97t/y4Ejb4AATz7yNcpLatn/0T8wFRtDVe0oig23y8fqpm34vEEGh7vx+8KMjg8wMt6PLMn0F1tJaZfTiyTJuF3+RVda75snen6qDy05jqFlwTQx9QKyuwg9mwRAsrmxFzWQjw2g51Po2TiCKCIqdiS7B1F1kpvoRs+VI9ncCIKEWchgGhqmlkdy+JHdIYx8GkEAe3Ezei6BqeXgUxRYpLNJTp79CF3XaKhdhyCIxBMTtLQeR5ZlWlpP0NS4kem45eA6PjFIi2lSU7USjyeAqjpwOgqIooiuF+ju6yCTS9E30E5RpIziSCWyrBIKRGerAelMgnMth7HZHJy/eJR1qx+iJFpNe9c5Dh17k0iojObGjbhdPvoHOxAEgYqyBuw2B153wDq53b5ZI7qS4iq6ei9wtuUQPu8zuOagQMwHoiAu/kFtmujanQUWgmwjH+tHlO1IDh+zpOQHmEVByzM03MOl9pMMjfaQz2W5njakKDZe+Nwv4fctP2XoTqEGK7FH6qxkRyFzw/tGPs3UiR8Q2fUryM57X8nK57OMjg/Q2XOB9u5zCIJAa8dpAIKBIkKB4hnxBp1EcppEcopcPmPxo20OQoFiq09gRqFkaKQbTdeoKK1DEEQMQyeemGI6PkEkXDb7ENS0AtOJSeKJSQxdx2ZzEPBHcDo8S7o4VRSVuprV1FStZGxigFNnP+bcxcOMjPYRT06Rm+N8Ww709rfyp9/5d2xat5fHH/4yZSW1M3SJ+xO9/d243V4kSaK14yKrmtfhdCzMAPEBHuBnBS6Xlx2bn2TH5iu9v6HAFZrv3p1XTCmb6jfOrN0soaHa6lVUVzbNqHpaFe7rKVBul4+tGx9n68bHr3n9uad+gUIhjyzLCIJISbSar3/xn2NizCp4FoXLZrevrrSSvqFgMc2Nc9PibkW/mi/um8BCECRkpx9TL0eQFNRgFdmxDgRAVF1IzgCCpCLZPUh2PwKgZaeRHX7ARJAUJLsHQZQxCllMQ0dLT6EUstYCIGYtABRvEbK7yHJIdPgRPmXZUq87wN6HXkDXNeQZN8dgIMoTe69kBmLTE4xPDrNz29OIgsj4xCA2m4M1zdtvGC/gL2Ltyh3XvOb3hdi9/dkrx/QEeXT3izy6+8WrtvLw7BPfxDAsiVvrYtjLxrUPI4pXVKJKotUABP1X1IJsqp3PPf7zYJqLojItBRXKhDuWrLWFakj3ncBe3ITk8KO4o4jy/WHwc79gZLSXV9/6Szq7z+HxBJmcGrYCTKePVDpOJpeiqX7jfUNhuVMIgoircjPZ0VZy451zyg1nRi4SO/sT/GuetyRq7yHiiSne/+SHdPa0MDzSQyw2xqX2kwDs3Po5Ht75PCCQL+Q5efZDzrUcJpmKYRomkiyzZ8fzbFi7G5tqCSt8fOg1zl08wv/jF/8d0UgFyVScdz74ezp7zvO1F/8pzrJ6NK1Ad99FDh59k/6hDgxdx+n0sGblDjav23tHvg/zhSiKRCMVPPno19i59XO0d57hbMth+gbamJgaIZGYWna/lIKW5/CJd+jtb+WJR7/K6ubtBP1F92UVoKS4jI6uNgaH+xEQblBnfICFwTQM9MwUWmoS0yggSDYkuwfT0NDTMa4EwQKi4kD2RBBEGS01gZFPgSChuCOIdvcsXUXPJigkxzD1ApLdh+q7O/1qejaBlhzD0HLYQjWIin3mM+nomRhaatLyuvGVPXgOzgNzeWdZ65iFrWWUq6SnryiALm9l9L5ZVTvL12NdXNYXYy9qwF5Uf4XzFbB0ey8/oBV3eHZ7BAF7kQt7dMXs9p763VcNHkDxl82O7al7yHq5dM29+GhLDotedPOT0OFwUVpczcBQJ5IkEwpECQWiSz4Py77+ygl8J9WDxVKYrOPd+nuYF0zzjt277ZE67JHa2bWkt/lxHkiLXovu3kuMjPayc+vTbN/8BK+++ReEgsVsXPcwg8PdHD/9Pju2PInL+elVA7GFa3GWracQH8XIJW7cwDSIt30IoopvxSPInug9W6QF/BFeeOqXaO08zRvv/i1bNz3OtplslyUjaF2riqzg84bYtmkf0Ug52XyWN979G97+4PvU167FFrSqFk899nN0913itbf+mi89/xtcaj/B+UtHePLRr1FRZvGmxyeH+OjgT4hNj/PkI18j4Itwse0ER0+8iyIrbN/85KJ6qm4Hj9vPhrV7WLd6FyNjfVxsO8Gl9pMMj/YyOTVCMjW9bIGsaRoMjnTz/R/9ET19rTyy6/OUFtfcdzTAnVsfpru3g6nYJPW1Kx5UK5YApmlQiA+SaPsILTVuUbZtbmyRWjB00kPnrYV7Po3qK0Pxl+Gu3Qm6Rqr/hBWMaDnsRStw12xHsnvQc0mSXQdn6eH26Iq7FlhoyTGSPUdJdnxCyb5/iTqzFjMNjdxkD8nOgxj5NOHt30b0PFAQe4D7KLCwHrjXy9He4iF8/fa3WWB+mhq0Fwubaqexbh2NdeuWeyp3FUsRWJiY6HeY0dRSkxTiw+j5FJgGgmLHEWlAUO9fisO9RjI1jccTYHXzNkqLq3E6PKiKjUiwlJrKZqZioxw69hbVlU2E1E+fMhRY9xR37U7yk72kB05hznUeGRqJS+9iZKbwNOxFDVYi2dw3brcAmFoBo5BGtN9oYiZJMh5PAKfDgyTJM0ION1KyJElmw5rd17w2Nj7Aj177nxQKuVl9eo/bx7NPfIu/+cF/5L2Pf0hbx2maGzezad1eay6mydBID4PD3ezZ8Twb11qqMtFIOSPj/bR2nGJF3XqK70GfhyiKlESrKIlWsXPr5+jtu8TF9pN09bQwOt7P+MQQufyN9LV7gXQmwSeHX2NiapgnH/kadTWr72qwNV/k83myuQyZTBpBEPH7ghw/eYhwMPKZkAJdNpgmppYjfuldjHyawPoXUdxFGIUMpmkgO/14VzxGvPV9cpPdBDd8afb+kJ/qx1W1FcUTJTvWRvziO9iLVyDZPaQHTpOb7CGw+llkb/FdTVjYwrWooRrSA2eveV2UbbgqNiLZPExfeOOuHf8BPn1Y+sDickboQfn0Ae4yRHHxZlGmaVIo5DFMY1YX/HbIDJ0nN9FFPjaIqDrANFA8UdQHgcUsLLMkebaKZbM5yOYy5AtWk3tZcS2Hj78903vx6YXiDuNd8ShaesKSn53Djds0CiR7jpKb6sddsw17USOKJ4rk8N2R3LWh5TFySfRsHD0To5AYw9Ry+FY/zUIrZqZpEouPMzo2QDIVI1/I0dvfRiabuqYRWhBEGmrXsmHtHt5677sUR6t4dPcXUWaoD5eFIAzTIBy6Eig6nR6C/gjtnWdJpu6927JNtdNQt46GunXEk1N0dJ7jUsdJevvbGB7tZSo2xr3uxcgXcpy/eIRUKs5Tj32d1c3bsS/Qy2fJ5pTPEZuOca7lFIV8HlGSOHP+JI/sfvL2Oz/ATWECeiZOevA80T2/geq3+O7SPMxB1UD57L+tYMOclcpP9RzDHm0iFxsgPz2ILVSN7JrbyXl2LqaBnpkmHxucoVcJqIFyFE8UU9coTA+gpaYAA9kdQfWVIkgLMzE1tDyF+DBacgzT0JFsLtRAhSX//wD3LUxDQ0tNINm8CMoyGOTphSzpkS4KqSkkmxN7sBxRVsiM96E4fcgON+mxHvRsCtUbQZRV8okJDD2P6gnjCFci3acSfKIo0VjXzFdf/OY1r9dWNxAKLrzR1Ov2su+RZ1jVdMVcTVFU1qzcsOAxf5YhSzLyAm98V6Og5SkUcrN88ttBy8RwVmxA8RZjjzSQ6j/1M1URmw9cTi+arhFPTAHg94dp6zjD6FgfLqeHWHx8xiDt0w97cRPeFY8RO/cahfjQnP0WmAaF6QFiZ15B8ZdhjzSgBsqRnEEkuxtRcSBIimVIZJqW6IRewChkMAoZ9FwSPR1DS45TSI5SmB5ES02iBirwrfrcgpl4I2N9HDn+DhNTw8gzQcLYxOANv41pmpZctGJDkVUry37N5zQxDWPGFO7aa0EQRMyZ/5YTXneADWt3s37NQ/QPddLafprOnvMMDHUyPNJ7T6sYuq7R1XOB1976KwzDYO2qHdiXUUTE4XASVRTGJkoIBcK4XG5URcH+QG52kTAppCcAUAN35vUzO4KukR25ZPXyqS5MQ6eQGEF2hzHyaUuhcKyD4Pov3DIQ0NMxUn0nKEwPIcg2wERSXSjuIrJjVq+YqRXA1MkMnsfT+Aiqv2xBXl9aYoRUz1GMfApBtiPZ3DP3ugeBxVJAz6cBE1Gx7hlGLokgqwiSgqkXECQVDH3W1sLQctb7ooRp6Jh6HkGQEGQVo2AJJomKHdM0yI13ogarUOQo3GuDPD2XZrrrJIZeQLI5ycfHsQdKGD35Ot6qtTgiVUx3n0JAIDPRBwjouTSy00uiv4Xijc8g+Zee978UkGWZrZt2snXTziUdNxSM8Cvf/K0lHfNnGapqR12CB59hGGQyqXkHFpcXgcCM18rYjEHjA1xGJFyG2+UllY5jGAbVFSs4dfZj9n/8MiVtJ7jQeoxwqBR1mTO1SwFBEHFXb8fUC0y3vEVheoibZcFNQyM/2UN+sgdBtiG7gkiOgKVkJ9ush/hMYGFoWYxcCj2XQE/HMArpuYOWW85NmDEQvbGSAnCu5TDnLx1l55anWLtqB26Xn0PH36K3v/X6mdPWcYajJ99l145n6e69yIcHX+Hpfd/EbnMgipJleCkIxKbHZ/fK5TLEE1M47G4c9vuDry8IIhWl9ZSX1LFt0z46e87T3nmGrt4W+gc6iMXHbz/IEsAwDXr7W3nj3b9BkiTWrto5WwG610hnUnR0tZFMJkgm4yAIGKbxoHF7CTDrwL6A79I0DUsgYrIXV9UWJIcPU9cwdQ17uA5X1Wb0bILh/f8RrXEviqfopmPlY/3kJ3tw1+7EXrQC09As1TdDI9VzDHOmORsEMkMt2CY6UbzRBQUWhpbH1PLIniIc0WYkhx/xU6S+eT9DS8fIxwYQVQe2YBWFxChaehJTy2OPNpKf6kf1laGlxpEcPvTMNHo2jqi6ULxRColRjHwKxVeCJHjQ05MU4iOowWoUdwhEGW7yvJgvFkWFEkQJWbEhSopV+krH0fMZDL2Alp5GEGUEQbIiIV1DVOzINhdaenrZs1cP8OmHTbVjn2cwcCsYhk4mm5q37Km9qGFW0jg73oEaqEB8QIO6BmUlNeze/uysUVBFWQMb1+7h8PG36RtsJ+CNsGfHs7hdvuWd6BJBkGTcdQ8hSDbil94hN9E1Jy3qaphajsL00EwgcnegqnYUWWFwuHvGKE/CZnPMNs2nM0mrh8ITQBQlBoe7uNh2kmwufc04k1NjvPHu31Bd0cSTj3yV8xeP8s4Hf09FWT2b1z+KIAhEIxVEQqWcu3h4JrD00d3bwuBwFytXbCHgv9LYaRgGml7AMHR0Qyev5bEbxlWqJncfgiDgdnlZ07yd5oZNDA530d51js6ec3R2X2B0fOCu+2IYpkFPfyv7P/wH3E4fDXXrlsXrwjAMcrkM5y+eJuAP4vX4aO9sZceW3TjMpXUPFwSBSKgU22d4oRkJl85U7gRkZwDTMCyz31ss/OdCbrKHVO9xS8wmUo8oKZgICJJqNVELkiW3rzgwcim4hXK7nkuBIKJ4SxBEEUG0glg9G7cWnrJttk/MVbXZ2m6BlXjFV4y9pJn8VD/pgVNIDj+OklWI7k+ftPj9BouuNI6QllD95WQGzyFIEnomgRqswCxkyI23o6dj2KKNZEcvYZoWnU6yudBTEyDKiIoDPZekkJogO9qKZPdagcUSYHE9FjN+E7ZQGbLDS2LgIpLNRT4+Zp3EQHqsG1/NBkSHSnZyANM0CDRsQ3H5l2D6D/CzDFW1z7vKcCsYhk4mk5z39rag1YAqOQPI7hCCbENUFjcPnydIdcWKRY1xPSxjw/Fl4ba7XT5WN2+b/dtuc7J90xOUltSQSsXx+8JUlDXcF42rSwVRUi3VFoeXZNdBUr3H5/S4uJcIBqI01q+j5dJxfvLmn2O3O1m7cgerZ6SnG2rX0j/YwcFjb3L+4mEkScHvDV7zu2h6gf0f/QOJVIyvvviP8bgDrGraSm9/Kx8e/AnRokoqyxqIhMvYuulxjhx/hzf3/y2KYiOTTVFRVs/61Q/hdFirnp6+S5y7eIREYoqhkR5kWeEnb/w5DruLbZv2UV5ad08z5YIgoCgqVRUrKC+tZ93qh+jsPk9b1xna2k8zONJNoXD3DDANQ6e9+xwfHHwFj8dPaXHNXTvWzeDz+tm2eRf9g33UVNVRUVZNb183xiIzl3NBkhT27Hye8pK6JR/7XmNoZIBjJw8xMNSHzWZn7aoNrFm5gVCgCFmSEQDJ7sEWrCLe+j6+psdnqw4WleXm97/89CCpnqPIniKc5euQbFbFT5BkbMHKGXpUBC0TwyjkkBz+W85VUh1g6GiJUSSH16qym9Z9S7J5UDxFeBoeRrK50XMJRNluZa8XAEGQsEcasIVqyI22kew+bB3jQWCxaAiiDIJAPj6Ey9QRVQd6egrR5kRSnOArJdn5iSX/qzhAkDC1jNUPKsqIqhPJ4UdSXRTiI2iJsRkxARM9n0ZPT5E3dCSnH1FdmDnmogILSXXiKm3AXdZEcuAiejZFeNVeUiMd5ONjuIobsAdL0VLTaOlp7MEyfDUbUFz+ByXWzwBM0ySTTdI30MHwaC/xGfdvQRBwONyEAlHKS+uJhEtR70I/jarasS0BleZyxeJOIQjiEpmfCTTWrZ9TtWcxiCcmOXDkdc5fOrqk4y4ULpeX5oa5TXk+KxBEEWfpahRPEWqwkkz/abKjrXMrRi3F8eRbX1ded4Dtm58kEiojmZpGllV83itZqdrqVUiSzOBwN5qWJ+CPUFW+guJo1ex2AgJlJTU01K6lrMRyEne7vDz80Odp6zw9S9+xqXaaGzbh9QToH+wgn8/h9QSormwmHLyiXCPLCm6XZcL26J4vXvksCMjzaGq9m5AkiXCwmKC/iBUNG+htbqWt8zTnLx6xPtNdCjDy+SznWg5TEq3C5w0v2DR0saivbWR4dIiRsWFKistQ1aW/b4uiSF31apoaNi752PcSiWScDw8c4KODBxkeHUJVVSYmkmzb9DhVFU2zioWCbMe74hESbR8ydfYniLIN0ebGUbISe7h2zrFNQyPVe4zMwFlsoWoSrVaCwlG2BlugCk/Dw6S6DxE79yqGlsVVsR7Jcev+BcVfjjI9TLLnCOnh89Z40WbskXpcFZvIDF9g+sIbs9QnT91uJFeIZPdR9PQERjZOouNjFF8prooNIEikeo+Tn+qhEB8m0f4htnANjmgTheQ4mcGzGFoeTB3R7ka0LT8VcnSsn0NH30JWlvc+A5a318oVW+54P0GSsQUqkV0hBFHGUbIKLTmGIKkzgYSIPdqM4okg2dw4S1ejZxNIDt8M00KYfW7IDj+Ea1G8URRPBAEBNVg1U9FauDDOggMLyebEW712NkhQvWGCjTtwFtdhCxRTSEyiuPzIDg+56VEMrYDqDiDbFhYBPcD9hXw+S1vnGU6e+ZCegTampkZJpeMUCnkEAdQZ1+2iSDmNdevZtG4vReGyJS3z25YosNB1nUQytvgJLRCCIBAOlRAOlSzpuGMTg1xYpqBiZLSPTDZJcbRqzqbUiclhkqlpSqLVd2XxstyQ3RG8jY9ij9STG+sgO9ZObrwTLTnOYlWIRLsX1V+GLVSNvajxltxtURQJB0sIB+c+t24mTb07dMUgU5Jkdm793HXjShQXVVBcVHHteDYHtVWrqK1addM5lZXUzgYo9ytEUcTnCbK6eRs1Vc00N26mtf0Up89/Qv9gBwUtv+THTCSnOHbqPSrLGlizcseyUKJKomUcOX6AokgJpSUVDwzyboH2rlY+PLCf3v5uwFLWOnbqEB8dfI/a6gYckvVsEkQRe1EjgmyjEB/G1DWLlnJVI7O9qAHFV3xVokDAHqlHsl+rHGctHK33ALTUBIIoY4823nYhKLuCuKo2k5/qw8inQRSR7B5rIVrchGh3W/2CegFRtiPMVFMkuwdBgMD6LyAqdov2K0oziTU/oqygBioRFTuSzRpPsrlRfKWz5n5OdxjVX37L+d0L9PS3Mjk1cl+c002NmxYUWEg292wAIQgCssM/YxQNCAKiYsdR3DS7veKJonii17x/GbIriDTjDXf5O3FEF8+cWHhgodhxFlXP/m3zRrB5LQ6tI1iGI3jFRvxe056SQ21MtnxMZrwPMPHXbyW8ei+S6kDLJhk++gqpkQ4k1UGgYTvBFTsRFnkTn7jwIWPn9qPn7oz6IACIouUcrtiQ7W4UVwDVF8ERKscRrkJ2uBfMdbwbyGRTHD7+Nh988mMGhrvmpAlo6QTpdILh0V66ey/SP9jO43u+THVl05KZQi1VxULTC8TiE0swowe4jMvGZI/u/uKcgUXfQDvHTr/HF57+FULBT6ePxa0gCAKCpGAL1WILVOIoXY2WGKOQGKUQH6aQHJ1pqktgFqy+NEvFQ7B600QZQVatsrXNg2T3ILlCKJ4iZIcfyRVEcYcRbZ774iH5WYXVh+GjqWEjFWX1rGjYwLmLRzhx+n1GxvqXvAdjcKiLk+c+prSkhkiodEnHng/OXzyD0+kiEi6if6CHpvpmVNV2z84xXdf4z//9/2R8fPSujF9SXMGvfuu3sNsX/9wYGuonkZy+4fXO7jZ0TbvqFeteYI/UzwYE1+OyDO3sHqKEo3gljlvcGu90ASgIIoo7PCcdSRBVq3oyRwXl6kXq9XCWrZ3zdVGxI7uWtgK/FMjl0uSu6x9bLpTEqxe87zVB5O2uzdu8fzeu7fvGIG+pkBrpZODj7yI7ffhqN2DqGorTBzML8773/5Lc9CiBhm1omTgjx18FQSDU9NCijpscbmfk+Gto6RtvNLeHAKKIKMmIsg1JdSDZXShOH6onjKu0EX/dZnzV65FsS9tId6fI53OcPPMhP33nO4yNDwDg84ZY2biZirIG3C4vhmkwFRujreM0Xb0txBOTnDj9AZlsii8886tUlNXP2zPiVlBkdVaRZjEPeE3XmJ6+N0owPyuIJ6eYmBpGu0lmN1/I0dl1nlz+0+1jcTsIggCSguorRfGW4DA09GwCPZfE0LKYhRymUQDDwDQNEGbMPAUJQZQQJAVRtll9PKrT0rMX5QfBxD3G5QBjRf0GSqJVNNat4+jJdzl19mOSqYXc8+eGphc433KY5oaNhALRRRuA3ikmpsYRRZHpeIyung40/d6q3RmGwTvvv053b+ddGb+5cTW/8HO/zlJ0dsmyPOfvY7PZH/h4LSHS6QSXOk4TCkQpK7n/3Oof4EZ85n6hqdZDGHqByOpHcJevBNPANHREWSGfmmLo8A9Z9a3fx1u5hkI6Tj4xyfCRHy86sFgcTDB0DEPHKOTQMnG4/KwSBKbajzB25m3cJSso3vQMgaadSLdo+rpbMAyDoZFuXnv7rxgbH5iRbazjc4//PLVVK/F4AiiKDUyTbC7NpnUPc/z0B3x8yHKavXDpGOFgCU8//g2CgTtTx5gLoijicnpx2F2k0gtvULaanG9dsTC0LIX4CJLNbUnp6XlE2U52tBU9n0L1lWGPNiLKNoxClnj7h/iaHgcEjEKaVPdRDC2D7Ajgqtq66ArZpx3ZbArjNqpJnzVcDjJkVxBsXi5ePEP/YC/PPPH55Z7akqFQKHDs1CFyuRx7dz2+3NNZcgiCgM8bYtWKrZQUVdJQu479H71M30DbklUvJqdGOH/pKLVVK4mEy26/wxJiy4YdnDhzhOGRQTau24LTsbyJrPsZtTWNBP0hunraZ1+TJImtG3egqssjG/xZg2kajE8N88PX/hib6qCirIHVzduor1mD1xNY7unddcQTU4xPDJKfRwJOEEUi4TKC/sWvrRaLz1xgkRnvtWhZ/hLE6yLbfGwEPZfGXdpkSeXaXbiK6xg/tx/D0O95dmheME20tNX8nh7tJtF3jtCqh6l67JdRvZF7etMvFHIcOPoGQyM9AAQDRTz52NfZuHYP6nXqPm7Zh8vpxecNkc2m+ejQT0hnkhw58S6rm7fj9QaRlyDz4Hb5cM34JSwUul5gOj6OaRo3pZyZWp7C9BCabMPIJVB8JRiAkU9jC1SSHjqH7A6jeKNkR9vIDJ7HVbYO2R0iN94Fpo6jZPWsosNnEfHEJD39rWQzKfoHO5icGuVsyyH6Btqv2S6dSXLw2Bu4nN5l0+1fboiiSEVZFcHA0sj73S+QJIm6mkb0e5zpvhOYpsGBo2+STE7x6O4vcaH1KJfaTvGVz//mvMeQJIlIuAyPJ0BpcTVvv/99Tp/7eEkqcIZpcKntBBvX7CEcKr2n9/hMNs36NZtRZIWAP2hl3x9gTlSWVfHSi9+wfq/2FnweH8899SLbN+9CWWYRgs8K8vkc7Z1n6R/swDRN+gbauXDpKNFIBY3161m7cjsl0ep5iz6EQ6VUVaxAug/WepXljbfdJpGc4t0Pf0BP/6XbbiuJMiubtvDS5//RUkxvUfjMBRaiYsPQCpiGdsN7kt09YzyVQ1LtlrxWLoOo2O+rHoabwdTypEe7yMXHyIz10vilf4s9WHZPHjymaZJMT3Po2FuYpoksq9RWrWTDmt03BBWXIQgCXk+QLRsfpbPnPG2dZ0gkpzh97hOqKhoJ+CJz7ncncLt8uJ1eFsPItdStUqTSiZv6KpimiZFPkRtuwVG6BtVXTmFGiUF2hzDy6dlzLjN4Fk/NNtKD5/A27kWQZPJT/dhLVlvKC5/RwCKVTnK+5QgtrccYnxxG0wtMTA4jStfexHVdQxQlnnvy23g8/uWZ7HXQNI3Wjov8+KffZyo2STgU4cnHnmPdqo20trfwxruvMDDUj93u4KlHn2Pzhm0oisrb7/0UTSvQ2nGRkbEh1q7awAtPfxm7zcHYxCh/9Xf/k7GxEVSbyr69T7Nn52PEpqd4/+N3OHLiE1bUr+RbX/tVAFKpBO99/BaX2i+Sz+eIJ6bZt/dpy0vA4aSt8xI//unfMzExRlFRMd/4yi8TCoYxDINDxz/mnfdeJ5vLMDY+wqN7nuQrn/8G2VyWw8c+5sMD7wKwcd02HtvzJCYmb7//U3p6O0ln0iRTCZ7e93m2bNiO3e6gt7+bl3/yXcYmRnHYnXz7679GWUkFBa3AwSMf8ua7r2IYBkVFxXzti9+iJFrG6PgI73/8NidOH2Hbpof4wrMvzX6/3X2dvPH2K/T0d6HrOs899UW2bNyxLM7Opglj4wOMjg+gaXk6us4xONK9oLHsNie1VSv50vO/gdcT4ONDr93gAbIQjE8O09XbQn3tmgV5vWi6xuTkBMOjg+Tz1/bAFUdLKS+d2wW6tb2FzRu2U1q8/I22lyGKIl6PD+8S3CtKissQxaW5/6qqjUd3P8mqprUkUwlkWaG4qAS/L/iZvcffa2SyKc5fPIw5Ywyay2cYGetjbGKQrt4LHD7+NlUVK1i/+iEa69bP+ibdDDWVzbzw9C/dFzLn81HKDAaiGKbJ0EjvvCqiuXyWR3d/icgSC8HcKT5zgYW3eh2DB77PdNdJFKcP0zQpJCewBUqw+aN4Klcz8MnfUbn3W+Smhhm/8D7Bpofu3o1AEFG9YcS5TiLTkpUzchnLWFDLMx/FGD2bZKLlIy59///N6m//hxnVhrt7IzNMg56+VuKJSQCcDjfNDZvm5aZbWdZAaXENXT0taHqBts7TpFLxJQksPG7/kpis5XJZxieHbjmWnkuipWZUfWYyHrnJLtIDp3EUN1lGSIU8+al+FE+UzMBpvCsetXwvDINUzxEEScXX9PiipNzuV4SDUfbt/QqbNzzK+5/8iKHhbjas3Y3vahldQcBucxIOlhAtqlgSH5KlwMjoIC//5G9paljNhrVbkCQJv88qtUfCRTy97/MIosiJ00e42Hae8tJKKsqrGJsY5fipw3z+mS9TWlyB0+GcfWD89z//z5SXVPCFZ19CADxuSwXG7XKzbfNOYtOTDAz2zs5B03XOtZwhlU7xxee+Rm9fF6fPHaeirIqSknL++nt/wo7Nu6iva+LAkQ/5u5f/kl/51j/CMHT+7Dv/jX/6679DJpPmL7/7x9RU1SMIAq0dLZw5f5Kvf+kXmIxNcOL0EQ4f/4RN67dy5twJZEXl+ae+SHvnJY6eOEBleRWlJRV853t/wsMP7aM4WsqJM0f487/57/yb3/53ZDJpXnvrRzzz5BcoK6lAFAT8Xut78vsC7Ny6h5GRQUZGB6/5fg8c+gDVZuPrX/oFVEUlFIzcs6xuT98legfa2Lz+ETQtz+vv/A2yrCAKAulsirGJIUKB6ILHF0WJcLCE5578NoIg8MGBV+ZFXbgVDEOnvess69fsuuP7WyqV5PV3XuFvf/Dn5At5pOsC+y89/3W+8dIvz72zCX//o+/g9fiRZZnPP/OV2fN2ueBxe/ni81/jxWe/uuixVNWGYwkaty/D5XJT62pYsvEe4ApM0ySdTtDacfqG9wzDUnJMJGOMjPZy/uIRisJlrFyxhc3rHyEaqbjhvAdLtS4UiM4pKHI90ukEyXQcvzdELp+lUMjj9QTmrI7ohoYoSDddh2l6gdGxfoL+IuzzWDNdht3mpK56JZfaTjA1PXbb7eOJKU6d+5h9D3953se4G/jMBRbBhu1o6TijJ35K77t/CqJE0fonKXvoJWS7m4Yv/Gt63vkTTvzBNxFVO/76rZQ99NLtB14gZLuLFV/6XTzlzXO+b2JajZuGTiE1RWqkk3jPWSYvHSA7OXBT915TLzB56QDdb/0xdc//i7s2/9njGQbdvRdm/7bZHJSXze+GKssqkXAZDoebRHKK4dFeEskYhmEsWlLR7fLjWoLAIp/PMDLaR3XFzRUwJLsPV9U2tOQEhdgAiBKqrxS5dA258S5MvUBusgNbpA7ZE0aye9ASY8ieiOXWbfeS7j+FlppE8Sw+qLrfoCg2QsFiAv4ievsvocgy61btJBq5VpJUEEWkmQbk+yGzZ5omU9OTdPd28k9+/XfwuL2zGTKAqekp3v3gDQaG+pmYHCPgD7Jj6+7Z96sra2ioayYauSLhous6Hx3Yz/f//KcE/CFM05wdU5YVQoEwoUCIwaG+a+aiKAr1NY2sbl6H2+3h/KWzJNNJeno7MU2DFQ0rqamqx+lw8c//za/xC1//dRAERkaHqK6sJZlM4PMF8Hp8ZHNZWttbeGv/q7R3XkLTNTStQFlJxcyxVBrrm1nVtAa7zc65i6dJZ9IMDQ9w6twJ2rvacDqcpDOpWUqMoqjU1zTyvZf/iqf3vcDuHY/OKuyoiko4GMHnC5BOX2s4WVtdzw9f+z6x6Sme3vcCXo/vnsmp5nIZ4olJy+Vb1xmfGKKkuIpQsISR0V50XVu0z87l6uxzT/4CsekJTpz5AF2/sWp+J+jtb2VyapTqiqY7uk7GJ0d5491XeP5zX2L3zkeRrvuefV7/TffdvnU3zStWW8cTBOxLoLq3WIiiRCgQprb6wQL+ZwmaVqC779JtDV7zhRz52CjT8XH6B9vxeUNEQiVzBhaXkUjGLFNcQSAcLEE3NCYmh/G4/LhcXtKZJN19l8jns9hUO7l8FtM0EQQBw9CZmBrBNE38vjC6rnHi9AeEQsXUVq1CVWwMj/ZhtznweUMYhkFffxtDIz047K47CiwEQaC2ejV+f2RegUUun+HMuY95bPcXl0Wu+jI+c4GFpDooWv8UoeZdGFoBEJBsTqSZCNUVraPhC7+DUcghiAKSzTXraHlXIIjY/EU4whW33Mw0TTANPJWrKVr/FFp6mokLH9L34V+THu2y6vfX76MXGDjwfYo2Po234ua68UsB0zSYnLpyYiuyStA/v8WxIAj4PEHsNieJ5BS6rpFIxawoX1wcx97j9uF2LT6jlstnGRnrv/VGooTiKcLIpcjH+pEcPgTJhhqqoZAYIT/RQ7r/FN6VTyC7woBJqu84ireI7EibJf4l25Cciw+E7meIokhZSR2qasfl9N6UKnc/Qdct8QSnc8bddmYhl0wm+ODjdzAx+c1f/uecOH2Ui23nrwk8PG7fDXr/pmmQy+XweHyz481ncWhTbTidLmRZRpZlTExMw0DTCsiygjxzHKfTSS6XwcTEpqg899QX+Se/80uUFFdQEi2joXYF+XweQRDYvmU3v/FL/wwAURBwOl3k8zlsNhtOhxNJkpFlZTb4sTJzPv7xr/1LiqNW87AkWdk4h93B1774bbZv2cX+D9/kwwP7+c1f/udUVdzal2Ljuq1Ultdw7NRh/q//8fs8ve8F9u5+Aqfj9pnDpYRpmphYylsl0Sq6ey9aZnRLFOC6XT6+/Pxv0NvfyshY3+13uAVSqThDI91ksptwOtzz3i+Xy5FKp3j2yRcJBcN3FJRoWoEPD+5neHSITWu3UFZSgXIfmIk9wPLDNE2mYqO88saf8e2v/eu7frx8IUtrx0nm6/tjGAZul4+AP4J8m969/R/9A/lCjnCwmGi4gkz2/2bvvcPkOs/77PvU6b1u79iCRW8ESALspCiKFCWq0bIl23Fk54vt5Euxk3yJnWo7cWzHju1EtmxLlmT1SokSi1hBkATR+2ILtvfd6fWU748ZLLDAAtgGAiBx48IFzJlT3pk55X3a70mTzaXJF7J0tm1nYLibZCqGrms01LUzG5sgk02VCsZNk0w2yYnT++ls247fG2Z6drzU4NaEE6ffIpNNMzDUxQO7n+JM92EQBAaHu2lrXnpTyOrKJgK+KP2DpzGMqwueGIbO+OQQQyPdi6rhuF685wwLBAFJtSJdKe9fFFGdN5+aQMlDJCGJEpJiRba5qNz5FN7mbXT/4A+ZOb13we69WjbJ0MtfpOPn//t1HZ9pQjqTnHstiuKSLG9VtSLJF063bDaFoesrPgNlWcXl9KGq1hWlH+Tz2atOBCSrC2f9jpKak0m50FsoeTEkGXfbgwiCiDXSiqBYAAFbRSfWcHu5oVHpIhckBUF87z+omxo6aazruGWkAZ0ON26Xl7fe2cuu7bvRNA3d0MkVcmSzGTweHwF/iLHJEaZm5lf0lK7d+fuTZZk1zW389GfP8MEHP4xhGOQL+UWkYSxsgNTXNjEzO834xCiV0Wpe3/cy7a3rkCS5nDKQ4vEPfIz79zyCJMkoiloqMA6EeSvxOrlclpqqOnL57NxzWij/maO8vLKiBtM0GBsfpa2lE0VRiMVnS6uYBkW9wNq2DbhdHr71/X+gu7frmoZFvpDH5wvw8P2PkUolGB4dIpNJvWuGxXmP49TM6JxIg98X5fW3fsymzruYnBldleOcb3b5xAd+mb/56n9F05bfcd3EZHikl2RydkmGhapaCAUjjI4PEwwsLTK6981X2Lntbqora/mHb/0dmUwKq8V6U0QWb3Pj8XqCfPxdKg4uFgv0nDu+pG2a6juJhKqveb7KsoLN6qSmsoXxyUFGJwZwOb3YbU6SqTiFQo7Wpo2MTQwgCiIW1UahmJ8zroaGe5iYGqJQ2IDd4cbl9BKN1KIoKv2DXUiSgtXqIF/Ml/o57f4ouVx6Wd+DIqvU17bR1X2IRGr2mutnsilOdR24bVjc5nIEQUBQLDgqmmn92L/n9Nd+h9muNy8vSjcNpk6+Sj4+iWUVahauziWegwWiKFfj4kvdXOK2V9ynIOD3RfC4A3N9NZZDUSswMztGPp9dsOmeIIgIF3lBhEv/LXdMFaSLjAah1OisZHwoc+N9PyCJIqYgXNERfL4QTSh3D33XWOC0EwSB6soannri5/j7r3+Bv/jrP6IiWslHH3+a7Zt30d7aybd+8FVe2fsCldEqIsHo3JglUcQQxfkT9NJe+e1//p/40//zB/zDN/8Ou93OE49+nA8+9GF6z3Xz+S/+Kb19XSTTSf7D7/0rHrr3g6xfuxFJkuZC2AJCKVJQLl79xac/x5e/8QX+7K/+BwF/kF//lX+NRbVQKOSJJ+J86Wt/zbe+/1VsNjufePLT3L/nA2zesJ2p6Ql+9/f/NcVigZamdj724U9TEamcdywEkORSVMJqsfIvf/3f8zdf/gu+/I0vYBgGTz3xNE88+jFS6RT/8Q9+m4mpcSyqhbVt69m66Q4Ajp44xJe/8dec7TmNbhhMTE3w2CMfYfP6bTz7wg/4yYs/pFDI43Q4+eVP/z943O+eg+dszxGmpkfxegKIoogkSsiyjM1qp662lZnY+KodSxBEtm26nxdf+xY9fUubGF3KxNQQqUyCa1WAFAoFXnjlx+X/5wn4AvzO7/0r7r/nEaoqalCVC/eupvo1tLZ0LLgfp9PJ1PQkhmGQzWcZHh2iWCwSDkVvaGrFbeZzPrpommZJtrscicMsB98EAVEQEcXVub+apsn+Qy/y+ls/olDI8du/+ZdAafJ/qusdXt77PaxWBzOz4zQ1rOPBPR/D6wkyOnaOvW8/OxfB83pCfPyJ/4eGuo6rnk+maZBMxRge7V/0GCVJor6unYDv2g1XJUlGlkoRYItqo6VhHf2DXaU0qmAVUzOjvLH/WdwuP9VVzQyP9TE82otFtaFpBTLZJKWmQ5R6cglw7NSb7Nj8AK0tmznVdQBJkvG4AtRWr+HFV75JOpuks33Hoj/PeQRBoKG2DafTuyjDIp/Pcrb3KA/d+8kbNt+47oZFKcXHxDQ0TEPHNPTS6/LE8nwupyCIpTbx5/++TyZg10IQRKz+auru+yWy04NkJy+/0PRClulTr1F5x0eu4zjAYb+QclTywOZwLDINqVjMo12Uc2yzOlZN3jcUqMTnCa3IsABIpZMMj/bRWL/wQ3e5vB/P5d7+U5zpPkhr82aa6i9P0/vxC19GVazcueMD886rG4WqWrhzxx52bd9Nyfq4EDm4564H2XPn/J4M59/7+JOfPr/2Zftsqm/hT37vry7bX0NdE//t3/8J5alAKW5Qfu9zn/3NOWOstrqef/VP//1cGtWGzi2sX7t53v5MTF5940VUVeWbX3wW0zA5fuowX/j7v+CBex7F4/bysQ//HE898fT5kc8d6zc+91sXxlTbxL/95/957lhtLWv5g9/935y3xM6v53K6+eP/+nlMzPInvrC/dR0b+f3f+bMFP9dTTzzNU49/6rIxvFt0tt/Bnl2PY7e7Lky+EPjVz5Y+c2Pd6l7zkiTx4D0fp/fcyVLjw2UyMT1COpOYy+++Erl8lj/7/B/OW2aaJs/85LuXrfuJJ3/+ioZFJFhB97kzDAyfI+gPcfTkIaqi1QQD4fedYXE+LTCXX1ok/Hx64fU4x03TRNOKZPNZDhx6m4NH3ubI8QOMjg+TSMYpFAr4fQFqquq46457ueeuBwmHFidMYLPar5r2tnXjfVRXNvHXf/+fLx4RqXSCVDrOx54oyTW/deB5TnUdYOe2hzl6ch9Oh5t/8sv/jZdf/y6yrBAKXVvJUtM1evtPYJqLl62uiNRTEa5bVJT84Xs/yXm3YF1NqYN5Z/sdCOUGpds3P8C2TfeVz3mBcLCqfM8rbdPWUkppOq8mes+uD6MbGpIo01jXUa6LKr2/ofNO1nXcgbCgA2px1Fa1XFPx6jyaXmRsYoBYYhqf5/Iu6+8G182wME0TUyuiFdJkxs8R732HRP9R0uN95BMT6LkUCCKSxYFic2EP1eGoXIOnfhOehlKHaUm1lnT/F4Gha+i5VFlZ6QKK3YtwSf7zrYYgCPjaduGp20B+dgxDmy8faOoaif6j19mwEAn4L3gCilqB6djYohrdmaZJLDFFLleSYRRFCZfTe9XiqqUQ9FfgXYULKJ1J0D/UteqGxfuR4ZEeDh19laC/ckHDQtOKHDm+l43r7nx3DYsr3AbO3x+udJ+48nJxwV1ebX9Xq7e4ePml6y20nWmYFIpFJFEkkYiTL+Q4N9BLJFJx0f4Wjhwt9VgLbbfYz3Xeq7dSisUC2VwWVbUsWqr2vFdSFKXLxnFhvKv7fBAEgfXtO3Ha3STTsWXvJ5WKkU7HMQzjqvdLt8vDs998HWC+026JbN64nc0bty9vsO8xDMPgm9//Cv/lD//dkrb7y//599x1x55F91ZYyngSqQQ/fv67fO1bX6Ln3MJNGUfGhhgZG+KtA3v5n3/+Xxa1b0EQ+F+/99c8eO+jV3y/9O/lxqUiK4SDVVRE6kgkZ7DbXGTLaT+CIKLpRXK5NKZposgq4iKi1LquMzjcs6ixn6e2qoVQcHHy+wt9jouvr9I+5q9zsVEgCPOvRUEQkC/KVrj0Wl1pSrDT6SUSrqGv/xSF4rUN3Vwuw8BQ13vLsDC0IsXUDDNn3mD0ze8Q7z+CcYUvQ9MKaOlZslMDTJ96DQDFFSDUeR/R7U/grGpHsbmueczsxDm6vvNfmTm9d97yjf/kC/jW7ES4RXK9r4QgiPjW7GDmzBsUkpcYFoZOZnxpF+FSEUWR5obOubqCfD7L8EgvLQ3rr7mtrheZnB4hmy3VaISDVbicvlWLWHg9AXzeMJIkr0iJJZ1JMDjUhWEapQnIbZZNNpfGZnXiu0KBfzBQSSodR9NWppzzrnM+5YCbIxIlCAJ77ryfA4ff4nf/4LeQRJFopJJf+rlfu9FDuy4cP3WUf/j233LPXQ/y6IMfXtQ2jfVraVzAuL3eqKqV9tZtvH3w+RXtJ5mOU9TySNLi6lGKxQLTs1NUROZ37TYMg3RZretGS8jeZmkYhkHfQA//+/N/yMuvP7dgFOV82pNhGKuWarwYBFG8pFja5Hyks6VxPS/t/S5//40/JBioYG3btkU5kgxdY2j47KLHIIoSldH6RQvKXA/0QqZcQ3l9olXVlU3YbI5FGRb5QpaR0V42rN216uNYDKs62zZNE72QIdF3mMFX/56ZU69fFkFYDMXkNCP7vsnk8Z/R8Mg/pWb3z1372Fce1JKPf7Piqu0sqVslL3nDNMjHJ64ZLl8JgiBSU7UGryc0p5Bw8sw77Nz28DV7EQyO9DA61j+XCtVU31lSYlklRFEiFKjA5fQSi08tez+FQo6xyUHS6cSiw463WRjDMMrqO1fwYIsimlZ8Vx+AK8XQNbRsAqOYR1StiKKMXshimgaSxY6paXM1UKKsIts91934EAQBl9PN7/zW71/X49wsWK1WopHKVWmWdr0RBJE1TetXbFikUnGKxcKitPcBevt7+M///bf5yl/9YN7yfCHH93/8TTRN47NPf25FY3q/oKoWnA4Xuq6jl+WKDUN/1+9bw6OD/OGf/Rf2vvUyxeKFOZXVYsXnDeByuHB7fKiKSiqdIBafJZlKkEjE0ReIagiCgCTJqIqCoqhYVAsWy5Ull0tFy5PMxiZL2QozY1gstms2mkul4/i9YbZvfoBQoAKLakPXtatGc0zTRNOLDI+du/YXU8bvDRMKVqOsUDZ6JWSGDqF6a1C9VSCsfp+qykgDNquDeGL6muvmCzlGxs5d1znh1Vg1w8I0TbRsgsnDzzHw0t+SHuteeEVBQJTVUopTufbiSsaHbHHgjDav1hBveVR36IqRF72QxTT06xaZEQQBm83BXTs+yI+e+yKaVqCv/ySHj73O5vV7UJTL5d3MsizbO4dfYni0FwCr1cGGzjtxuVa3cDMcrMbjDqzIsABIpmYZHD5LR+u2VRrZ+xO73Um+kGVmdhy9tn1eKFjTioyOncNmcyDfQpHEfGycyWMvoOdSOCtbMQ2dxMAxMAzs0SZysyOlugJJBkGi9r5fvOUjpTcb7Ws6aV/TeaOHsSgEQVgVZZZMJoG2CAfd3GTXNCmVNs6f/BqGQSqdWpFS1fsJUSzVGj39sV8kkYyTTCZIJOOk0gny+Ty5fI7R8WGy2ZV3Wr8a2Vyp6eX+g2/MMyr83gC777yfjzz2SdZ1bMJqLU3ydV1jZGyYV994kR/+5Nuc7jpB/qLu61arjerKWupqGqgIVxKNVFERrbrmdfXavh8yNTuGw+7muZe/TmPdWrZs2IPD5iLoL6VeSqKMx+VHkmWKxTy5fIaJqeHyJNfA4/Jz3+6PUhltuOqx0ukEqSWkEIaDVQs2uQwFKkhUXFCs83vDCIJYKnrPpzAKaRBERNWBKKtomVkoKz1KVg+mXkAvpMupUwJiuTWBkUuW5luyimRxYWg5LIEGJJsXBBGjkEXPlzzApqEj230Iklzev4EgyoiKDaOYnWs1gCAgKjZAKI3LNErjUh0IokhFpHbRSpxascDU9Og1jbjrxeo89UwTLZtk/MAz9L/wV+Rm5nddRRCQbR4s7iCqO4TVG0G2uTEMDS2bJB8bpZhOUEhOU0yXv3hZwVndhqdp6bq/71Vki/PKHZtNE1PX4DpOZFRFZee2hzlyYi8DQ11Mz47z7AtfRpYUGuracdjdcydxvpAjkZzh4JFX2H/wRdKZBJIks2nd3dTXtKFcQ2d6qUTDNfi9YfoHz6xoP/HEND19x2lfs2XBPMzbLI5ouBZJlDh07DU87iBBfxRJkilqBUbGznHkxF5qq9dgtb67fQxWgqHlsLhDqDVrcUSaSI2cwRFuxOKrIDPeg6EV8a/ZieLwMH7gRyxWf/1KFAp5xifHmJmdQtd1nA4XVZW12G32uZTEnr4uCsUCbS1rEUURXdeZnp1ifGKUuppG3C43iWScyalxbDYHmUyKRCqBqqhEw5X4vP55+cBne07jcZfqn8Ynx8hmMyiKSktTK1aLbS7VIplKMDI6RCaXQZEVQsEw4WB03r7y+RyTUxPMxKbLfThkPG4f0XDFXMM9KIkmjIwOkc6kME0Ti8VKKBghHIzMW6e7t4tisYBqsVAZqSIUvHwikc1mGJ8cJRafxTRN3C4PlRXVc2MH6Oo5jdPhxDRNJqcmMEwDt9NNZUU1dtvq9jQK+KLliczyC7iLWvGa+vXnC41PnjlGd2+pqdjbB/bOe398coz+gR42rtu67LG8nxAEkXUdG1nXsXHecsM0yOWy9A/08Z//8N9y6Oj+6zqOQ0ffYf/BN+fS2AAcdgefefpz/MIn/hGWS+SAJUmmpqqOT37kM2zo3Myf/OXv88bbr84ZmtFwBf/4M7/OBx54fNGTTkEQeOLRX17wvfbWrbS3ls4ph8PNjq0PATAydo7xyUF2bn2YdR13kM2l+fp3/4yZ2YmrGhamaVy7p9QlhIJVC9Z7fvRDvzrPGLNYbKiKimloJLtfQc9nEBUr1vAaFHeEVN+bGMUMgijjatxFMTVJeuAgiqcCUbFhi6yhmJoiN3EWDAPFU4G9ah2F2BDxkz/B3Xo/tmgH+aleEj2vobgj6JkYtspOVG8Vya6XEWQLgqQgO/wUYsMIgoieTyPIKtZgA5LNR3b8NEYujuqvw1GzGcnqxuMJ4rC7FnU/MTHJ5tLEkzMLGlzXm1WZherFXKmZ28tfusyokFQb9kgTgY7dBNfuwVnVhnRJ6oyez5Ae72XmzD5mz75JZrwX09CJbnkcUVrkiX/FN258HvSqcbWTSRCuu3dUEESCgQo+/IFf5uvf+zPGJ4foH+riy9/6n6zr2ElDbRsupw/DMJiZHePU2YN09x4jk02WjY8O7rvrIwT8q3+i+31RIqGaFfezSKXj9A2cInU7HWpF1FavYWPnXfzstW8zOnaO6spmbDYHyVSMnr7jWK0Odm175KZQhFos9lADWjZJov8o+dgYgiCSnR5ktvttotufRCtkSQ6eAMDijS5bAQSgWCxy8Oh+fvzc9zg30Itu6DjsDj70yEe5f/cjc438fviTb/Py3hf44//6eRrqmognZvnKN77AkeMH+Tf/73/C7ergxOmjfPEfPk91ZS3pTIqhkQEMXWfXjj08+dgnqIxWzx33T/7y92lr6cBud3Ds5GEmpycQRYnf/w//i8qK6nJKxAw/+Mm3eH3fS+TyWWRZobW5g6eeeJo1Te1Aqfjy2MnDPPPT7zA43E+xWESSJdZ1bOITT/78XPfvYrHAj5//Pq+98SKpdIqiVsTpdPHgnkf56JyKFIxPjPKlr/0V5wZ6yBfyfPbpz/GxJ+anyGayGfa+9TLP/exHjI6XFOK8Hh+PPfwku3fdj81aMsj+6M//C6FgFIuq0tffTTaXw+l08ZHHPsmD9zy6aqISgiBgtdqxWR1lecrloS3CsABIZ9J87Ttforuvi9HxYf7oL37vwlgAWVHZvH4rO7beueyx3KYkRGC3OfD7g1jU65t6YxgGr7/5MsNj83ss7dq+h4898XOXGRUXI0kSrc1r+eRHfoGu7tNMTpcklc8N9PLavpfYuG4rNVV1123ssqwgSwrTs2P0nDtBPDGN3ebE6bh6g1jDNJmcXrzCoyRJBPxRXAv0J3O7/Atuo2WnyU/1Etnz61B20phaHkfNZoxihtxUL4X4CKYJktWJu3kPompDL6QpDBzEGmzCXrV+bn5pi3aQG+8qy8qXlomSiq/zMQrxYeInf4qp5VC81biadpEb7yJ++jms4VZkuw8tM4tkcWLqRRR3FMnqopgYp5gYRc8mkKxuJFEi6K9AUdRFzXEKxRwzM+O3pmFhGjqpoVOMvPH1Uofoi3duc+Nvv4ua3Z/GXbce8Qpeaslix13biatmLVV3fYKpoy+QGjmLv+3GFJ7crGjZRCkqsQCSakN8F9IuFFmlo20bH370V3jupa8xPNZHLD7Fa/t+yGv7frjgNg67i6b6Th6695PU1bSuWtH2xUiSRG11Cz5PaEUdb03TZHJ6hN7+kzes8Om9gM3qYOe2h1FVK8dO7mN0/By6oaPIKo31a9m17RGaGtbdkDDtctELGRSHH0/DJmK9hxBEEVdNJxZfJVo2jqkVcNasxeIOM7LvmxdJsi6d/qE+vvKNv8Fms/O5z/4GHo+XHz//ff7uHz5PXU0ja9vWI0kSn/25X+XE6aN8/ot/yr/8p/8fbx/cx963XuEXf+5XaW2+oG42MjpIPp/jYx/+NHXV9byx/zVefOUnREIVPP6Bj6JeNEF67c2X2bJxB08/9Yv4fQH6B3sJh0qKcMVigdf2/Yyvf+dL/Pwn/hGbN2zn3EAv3/vR1/nm977Cb/7qb+N0OElnUrzwyrNMTI3z2ad/lWikkqnpCXT9QndzgKmZSb7w93/OYw9/hIfvewzDNBgeHcLnmT9JaKxv4b//x//N3rde5m+/+n8W/M5OnD7C1779JWqq6/iNz/1rrBYrP3nxGf76S39OKBhhQ+cW5HJDwZ+9+hM+8qFP8c//yb8jm8vwtW9/ka9882/YtukOAv7VKwAVKHlJV2JjaxDfAAC5i0lEQVRY6IZ+TQ+lIAj4vH7+6//3xxw9cZD/9X9+n9/5rf8+732bzY7P45v3W9/m5iaRjHFuoId0+kJzNUEQ+NAjH8XpcF4zf15RFBrrW9i0fivPvfSjueXHTx3mdNeJ62pYBP1R6mvbOX32AFPTI4iiRGf7HVRE66+6nWkazMxOXHWdi3HYPXjcgSU9S8xiDlF1XPBIGxr56X4yQ4eQbV609BSy3V9OWbIjlp3hpq6BIJbTXa9+DNkRKDt8VUy9gKEVkCyuue1NrViSoJUVRElBkBS0bIzsyDG0zGypRYNWmHftBwMVqIplUYZFsVggnlhZavhyWfFMtJCcYeLIc8x2zw8HShYHofUPUHvfL+GoaFmkBJiAYnMT3f4kpmlclwnorUwuPo6xQPdtBBHLIprCrBYW1caWDffg84Z568BznBs4zWx8ikw2iaYVERDKRW8e/L4IzQ3r2LHlASqjDde1E3NtTSsBf2RFhgXAzOwE3b3H6Gzbfst0jr4Zcbv83HPnE2zesIeZmXEKxTx2m4NgoBKrxX5TqCotBS2XIjPRRzE9iyPSgGSxI8oWPPUbmD37NtZADcXUDIXkNP72u1aUSnfg0JvMxqZ56vGn2bl9N6Io4vMGeW3fSxw48hbNjWuw2xx43T4+99nf5D/999/ma9/+IgeOvM3ObXfz4D3zZSNV1cLmDdt5+L7HSh25gxG6uk9x8swx7rrjHqKRyrl1TdPgE09+mrqaRgRBoLmxde69bC7Lj1/4Pq0tHXziyV9AlmXqqhuYnpni2Re+T19/N+s6NmIYpc70iqwAJn6vn8a65suiAZqml7qEyzKGYVBX20hrc8dl54YgCMiyjNVqWzCiYJom+w+8gYnB4498lM0bSpKpVRU1vHNoH6/ve5nWpg6czpJohMfl5Vd/8Z/hsDsoFgskEnH++C9/j6GRwVU1LBCEFdcRSZK06HNJkiQi4Uq2bLyDimjVoiV5b3NzMjI2XO56fyGt0uFw0tSwZtETaZ/XT2P9/FrV0bFhRsaGMAzjuvUnEUWJtpZNtLVsWtqGZXn6xeJxB/BcITJxJSS7DxDIjp1GEJVSNCIbQ5AtKJ6KyyT9zyOqdiTVTjE5DqKEpDqQHAH0bAwtM0shPopkdZf6b1x8CxNlVE8luYkucuOn0dLTqIHLjTqzmMVAQLJ5EESZYnK+geXzhhb9u2t6kUQqtshvZHVZ0R3P0Iskh04ycfin89N0BBFv0xaq7voUzoqWJacjlfTQl2ZUvB9UoVJDp9EL2cuWC6KEI3z1YqjVRlFU1jRtoLa6mf7BLgZHepidHSefzyKIInabi1CggtrqVqKR2muqR6wG4UAVkVANZ3uOUlyGGtl5Mtkk/YOnmZoeIRKuXcURvv8QBBGn3Y2qWBBFqaRjfos22rJ6o1jc5UnnJVrskS0L678vl7GJEZLpBAePvs3kTOnhous6mUyawaFSahG20r1yw7otPHjvo3zxa39FQ10Tn/roZy/zSjsdToL+0NykPBAIEfAHGRsfIZWe701vbmjFbnMsaPhpWpGevi6aGtbwvR9/AyhN6kt5/Ukmp0rpFm6Xhzt37OG7z3ydr33nS7Q0trK2fQMb1m6e12ytIlLJE48+xZv7X6e37+xcTntn+4YledaLxSITUxP4PH68F0U7Av4Q4VCUcwM9FM7nWgsC9XVNOMqRE1GUcLs86LpGJpteaPfLxzQXVXh9NVTFgigt/ppRyyo/3/nh1/B6vHg9fnxePz6PH4/bi9Vqu6WM+kIhx9ETh/jWD766ov1EQhXs2LLrlorYJJMJCoX5k9ygP4xFtSz6N7Ra7fh98/sZ5PI54olZCoU8VuvVVR3fbUzTJJ6YWfT6LqcX5xLTlkXVgbNxJ4XZQQTZguqtQvXXoGVm0HNJFHcE2RkqRRQucgyIkoI12k5uspvC7BCyI4BocaKlp5EdfjB09GwMyeZB9dcCAqJqx1bRgcVfh5aeKRkfFieuhl1ouRiSxYUo2xAUC5LVhWkYFJPjCKKM6q1Csjjnju9xBy+R9r0ymlZcUgH8arIiw6KYmmXm1GvkZubnw1l9FYQ3PoKrpuO9VeNwA9GLeWI9B9Bzlz/4BEnGXb/hXR+TIAjYrE7aWjbPdaK8kSiKSm31GtyufUzPjq1oX8NjfZw4s59QsPqWnQjfaLK5NIPD3QwOnyWZilFT1Uxby2asFgcDw2dx2F0EfJFbKip0RfGEVUY3DFKpFCdOH2VoZGBu+cZ1W2huXIMsl74z0zRLjacUFYvFgsViRV+gW60giPMmp+e7Yp/f/mKsVtsVz3kTKBQKjI+Psu/tV+e9t2vbbnzekudQFEXu2Ho3kVAFb76zlyMnDnL42EG6t5zhI49/ikg5tUqWZT7zyX9MZ9sG3j74Bq+/9Qqv7XuJTzz581ds1rXwuExM0yg1LLzEuy+JUrlG4SKvr/3yIu2SktKiD7nIcZW6Yq8ERVGXFL2XJBFFURkZG6J/sBeb1Y7d7sBusyNLMu2t69jQeePv14slnUnzkxd/yE9eXDjVdrHcueMe1nVsvKUMi3whf1mvH1VZWsNfURAWjPJpZQndmw0Tk3Qmsej1HXbXkuXrBUHAFm3HFm2ft1z1VF5hiwsorjCKa36huGz3Ya9cN2+ZxV+KSMg2L+7mPQC4mubXN6lUszDrFlzqdvoWHQHVdY1MJoVp6BjF/JwUOoAoWxCvozTvsp/opmmQmx1l6uQr85YLkoy3eRu+NXcsuvB6NXivF28n+o+QGDi6YKNB2erE07jlBozqcs5PVM5PTFLpJJhgs9lXrSjyajTVryPgj67YsIjFpzjTfYj1a3fNSekthZ5zZ+kf6EVVLTQ1rKEicu0b1nkmpyfo6+9mdnYGj9tDR9t63K6rF7zdbOTyGY6e2Mcrb3yPialhUuk42zfdX1KCstjZf+hFrBYb99390WsW870fCfpD1FTV8fEPf/oyFR+L1YbtIjWtg0fe5tnnf8BTjz/NsZOH+eb3vsKvfvY359UyZLJpZmdn5lIf4okY8XgMr8eHw+FksciSTENdE5XRav75r/2by9RoLt6XLMu0NLXR1LCG+3Y/xLe+/1V+9tpP2bZ555xhAaU0rZ3bd7N9y52cOH2Uv/jCH/Hlb3xhSYaFIisE/CFGx0dIpuJzyxPJOFMzE6zr2DQvhWAlhfWL5Xwj0fwKxCQAVMWKtATDwuvx8+lP/DIzM1P0D/Zx+uwJevu7mZoaJ51JI0rSLWVYrBa34kxAUZTLnpvpTHpRxfznKWpFMpnLJXEtFsuCMvE3GtOETDZ17RXL2GxObLbF38NuZex216Idcbqhk8tnMIp5MhPnyM0MYxo6iCJWXxXu2uvXNHTZhoVRyJEaPk12an4+u8UTwde8Datv8ROp21yd7NQgI298g9zs6OVvCiLepq3YAleyfN89NE1jeHSARDJBfW0jdpuDmdlpJEmeC7cmknF0XcfldCPLMrOxUsjT4/aSyWZw2B3k8llUxVIOicaw2+zYbIuTJY1GaqirWcPAUBe5/PL1xQ1D59zgGbq6DxPYFl1y6sCZrpMMjQ4QCVUwOTXOfbsf5uSZY1hUCxXRKmKxWRLJGIqi0lDfjM9zIUfUMAymZ6Y4efooa5rbS9KGg33MzE7R1LCGQiFPPBEjmUyUtvX6OXzsHQzDIBKumFe0e6MYHunlzXd+giJbePjeT/HO4Zfm3pMkGVmSOXXmHXZufeS2YbEAGzq3sP/gPo6dPEJFtJqAL0gun2NopJ+17RvmZknjk6N84e//gnUdG/mFT/5j9u1/lS997a9oa+ngkQcen+sgn8mkOXL8IG8d2EtlpIoDR95maHSAh+794Lxz71pYLVbu3/0IP3rue5w4fZTmxlZEUWR6Zgow6Wgtedpi8VkGhs4hCAJ+b6CsauWci7ScZ2hkgOHRQYL+EA67E6vFitPhuqw3gGma6LpGPp9H13QKhQKFQgFZlhFFEVEU2bR+K0dOHOSVN17EolpRVZXX33yZVDrFji133pCUj5nZcYwVeoUdDjeKvHjv4szsFN/90TewWmyIYqnGY01TO51t63G7vTfF/eE2iyMYCM9zEABMz04RS8xSWbG4aHoqnWRsYn5Wid1mx+PylmugbjZMcgtkZlwJq2rDeo0mve8V7DbHoqOXhq6Tz2dBFEEQKGbipaJxQycvjGLWXF7Ltlos27AoZpPEeg9cJoFqjzTgqulEuJ0+sipkJgcYfu3LTJ98FWOB+grJ4qDqzk/eFD0XilqRnnPdjI0PEw5GsFltTE6NoygqwUCI2alpzvaewaJaaF/TycTUWEk33+Ojs20Db77zGnt2PcDxU0epr2lkbGKE6ZlJRFFkx5a7rtoZ9DyKrNLZtoMTp99mZAmdOxdiemacE6f309K4gVBw6YayrusUtQJ2m4NDx96hp68Lm9XOidNHsVlt2O1ODEMnn8+zc/vdc9tFQlHWtW/AMHQ62zfi8fgYGDpH/2Afs/HZkpa/rOB2e3nptefY0LmF3nPdiIJIPp+/KSYOQyM9ZLJp7t/9FFs27GFg+Oy898PBKt45/NKK88/fq7S2dPDoQ0/w+r6X+OI/fB5FUUq2hCBQU1WPz+OnqBX56jf/llh8ht/+Z7+Lz+tn1/Y9nO46wbe+/1Xqa5vmJvoupxvTNPjxc9+jUMgzNTtFS1Mbd2y9a9FGO5SiCw/e+yiTU+P84NlvldKmBAEQWNu+ntaWtSiUIiTvHNrHqa4TyJKMIAgk0wl277qf6ouUaGZmp/nxc98jl8+VHpimSS6f5VMf/czcOql0kjf3v86BI28xNDJA/2Avz7/0IwaHztHS1Mpdd9xHJBxlQ+cWHrrnUd48sJf/+8U/RZIkkskEjz30JJvWb33XJ1GmaTIyfm5F+xAEEa87sKT0nUw2w5v7Xyvdd/0hmhtbaWtZS21NPQFf8JZKBYJS2ordVkrlWgkej++WS2utjFQRDVciy/JcSlQul+WtA3tpqm+55rVrmibjE6McPXFo/n6jNVREq2/OWhuTeb0nroWi3JyRl+uBRb1ymuqlGKZBoZhDUqzYww1gGGSnBzFNA4vn+krQLtuw0HMpkgPH5y0TJAV7uAFb6PpJmF2J91TxtmlSSE4T6z3A5LEXmT7xCsUrFOGENzyIp2HTXJ70ldS0TNOgUCzMKTZdDxRZxmax4XZ5cLs8iKJEvpCnUMijaxqCIDIbmyaTSVNf24QoSExOjTM5PUF7y1rOdJ/i7jvupX+wF4/by1sH9mK1WJEkiVw+uyjDAqCpvpPKaAMTk8NoC6loLRJdL3K6+yDHT73J3TsfW3TRFABCqYjyTNcJnnri59j71isE/SE8bh9j48MIokhH6zomp8YZGbt6M6DRsWGyuSwVkSr6B/tAgI2dW1jXsZE/+F//kW2bdzIzO01jXTNrmtqW/XlXk0wuhcVixX+FGgpRlNB1DXOFTeRuFIZenOvQej2MeqvFyj13PUh1RS09/WfJZNKoqoVwMEowECoLXAi0NDSzqXPznHKT2+XhYx/+NE1H3sZ2kYfe7nCyZeMOmhtbGZ8cw2F30NG2nrrq+nnHfeqJp7HbHFdMjxJFkWi4kl/45K9w9OQhpqYmQAC3y0tzw5q5ybvX42fb5p0E/CEy2XRJgz0QpqNtPaHghfzkmqo67tv9MJNT4+QLeWxWGzVV9axfu/miY0q4nG4qo9VURqvZvvmCDLTX45+LgrhdHh554HHqa5sYGOqbi+Bt6NyC2+2dm0R94sM/jyzLnD57kEw2hdViJ5eP88mPPM1sfJgz3YcI+KNoWhGfJ0QyHadYzFMs5pmYGiYYqCQcrGRsYpB4fIpIuJZwsOoytZZSA8P5z8ilYrc5sNvdS6qxCPhD/Mpnfp1YvFScWyjk6Rvo5mzvKbK5LOs6NnHH1rtWNK53E7vNwb13P8SeO+9f0X5CwQhWy63l2XY4nGxct5X9h/YxPnEhY+F7z3yDjZ1b2Lhuy1VTY6ZnJvnZq89xtudC41hBEGhvXUvLRWpvNxv6FWT1L0VAQBIXr5p2qyOK0lwU+lqYpjH3PUqqFYu/Ai2fRpQVbKHa62pULsuwMA2DYjpGdnp+GpTi8GIP1iFbbp1uujcSs9wt2yjm0HJJCskZcrOjZMZ7SY92kRw+TXZy4IrSZ86qdmrv+yUEWWV8cpCu7sO4XD4qInVEL1Ez0nWDTCaJKIrXzbCQZQWr1UoylWQmNo3X7WN6ZpJ4PEZFtHrO4zQ0OkAun53LG+7r70HXdcKBMC+//jyDw/1sWr8Nr8fH9PQkFdGqRRsVUEodaF+zhe6+48Tikyv6TLOxCQ4df5362jYa6pYSCRDK+eUtHDjyFvW1DZzqOoEgiETCFcSTMSyqBVEUrzm5npwa59jJQ9htdjRdQ5ZlLBYr0kUTqpNnjmK1WOm8pEvsjcKiWtE0jWzu8lxZ0zQZnRgo54vejKH4a1OMj5Kb6MJetQ7FtfreH1PXsAgmnW2drFu7sFyjLMvcv3EthdkL9+FSP5d6ai8xGEzTwOcLcu/dD131uNd6H0rGRTgU5YE9H7jiOnabnXUdm1jXcXWpSZ/Xz547H7jqOnabnR1b71xUYzeP23vNde/b/TDFYoEf/vTvqIzWMzk9TD6fpbO9HavVTj6f5fCx1/F7w9isDianhkkkZ9D0ItlsispoPWMTg/QPnil3tB5ix5YH8HnnF3TqhsaZnsPXHPPV8HpCc439FouqqNRW1WO12BgdH2Jg6By957rL0V+BUODdb5i1ElTVQkdrJ489/JEbPZQbwu5d9/Havp8xPTOFppUcZT19XfzZ5/+Qp554mt0778Xl8sw7RwrFAj19Xfzoue/xo+e+O09AoKaqjp3bdi+p7u/dxMRcfFG5IJSUm27GyMt1QBCEcr8ygau404Fy+mj5ezS0IvnYOLnZUWSbE9nhRba5b65UKEMvkpsdwSjOn/AqDh8W39ILXVeDm7V4W89n6P3xn6Eu0BUSE0xTxygbF3ouTTETp5CYophNwFUuLluwlsZHfwNHtBnd0Bka7kY3dIL+CuxWJ/HENGe6D6GqVqoqGtF1jcHhHqoqGnA6PAyOdDM+MTjnaYsnZkimZgmHaqipbKKr5wipdJxwqJrKSD3HTr0JQHPDOnzeK+u819U0YLM5sFntyLLC2rb1ZHNZPG4vsqzQ0bae2up6vB4fhm6wcf021jS3o6oqd+64h9nYNJFIJdFQBXffcS8zsWmcDteS5WrXdezkzXeeI56Yukz1ZimUvI7HOHz8dYLBKlyLrAfY0LkJRVFx2B30njtLTVU9AX8Iu92Jw+5A13W85WZV4dDlPUh8viAbO7fg9fhxOpzYbHZEUUSSZCRRJBgIIQoij3/gKfbtf42PP/nzuF0e3nzn9cs0y28E0XAdkihx4PDLuBweisU8iqySSsXp6z/FsZP7aGlcj912uTrPjcQ0DPR8siQZaHUj2TyYehEtPYsgych2L4IoI1ndaKkp9HwapSxIoudTaKlpZGcQUS0Z0XpmFtM0MLU8irsCMNGzcYxitrSebME0dPRsHD2fQrJ7ERUrhZkBiokJZIcPi78WUbWjpWfQsglkhw/J6kYQRGRHgMSZF2HtlSf5F3266/a93YoUtQKRUDXpbJJYbIrZ+CQ7Wx5henaM46fewunwoOs6hWIOwzSorVrD0EgPs/Ep4vEpDNMg4I1QKOYX1JbvHyhJVq+EcKgah31pNUgTk2P8yf/5PdwuL263B4/Ly90778XlcuO0u6itqV/RmG7z7lJVUcNHH/8UQ8P99PZ3lxySmLx1YC8TU2M8/9KPqK2ux+cLIEsy6UyasfFh+gZ6ONtzhlj8gnSr3xfgkQce58477rlp04cEBERRRNevXaBumgaGoWOa5vvGuCjdxxd3Lz8/9zGKOYqpGYqpGfKxMSTVjj1Ux/WSNFhexEIrLFhIrNg9WDzhBbZ4/2LqRWZOvbaq+3RWttLwgX+Kv/0uEEoXYTRSx/Tptxkc6cbWtIGJqeFSKkCoBrvNRT6fwTB00pkE45NDDAx2oRs6p7sPIQgCHpcfnzdMz7nj5PMZZmMTVFU24fOEOH32ANOzYzhsbt4++AIP3/epK47N7wvi8waAknXdWN8y732H3TGXxgFgdzgQyz0BKqJVRCOVczmEdrtjbtK91JtGwBdhXftORsf7SaXj197gKmSyKd4+9CIVkTq2brx3USlRVRU1c/8/77X1uDcD5rywrc1mJ0Dw0s1x2B1zkpgOhxOfNzDvezvP+rWbmJqeLOudFy7zVN8o6mta2dB5J2+8/Sxf/uYfMT07jiRKTJS9vz5vmB2bH8RuW5pM4PXENA2KiVEyQ0eQnSFMXUOULeQmzqJlY2AaKN4qrMEmZLsXUbmQVqFlYqQH3kG2e8mMHMXdeh+ipDJ79PtYI+1IqhXFFaaYGCc7dgrJ6qQwM4C9dguFmX7yU31Idm9JLlWUKSYnKSbHEEQJ09BLUeLEGEYxR3rgHbwdjyBZXaVoye1GostCFEUEUUQURKwWOz5vhLcOvoCiKNTWtFLUCrx96EV0rYjHHSCdSZSiG4UskVANyeGzjE0OUBGuWzDy9sb+n8x5mJdLVbQBt2sBp9RVcLk8PPrQk5iGQf9QH0WtiChK1Nc2UV/T+K6o891m9RBFkV3bd5NKp/jrL/0Z5wZ65+ST+/q76evvxmF3YivLRBeKRTKZ1IW+LWVCwQgf/uDHeerxpwkFbu55mqpYyC4yHUrXdQxDv6Vky5eLYRjo+uKiOQLCXNqUqFhR3SGE8V4kQUR1BbieOmnLi1gYGoXk5Z0RZasT1bm0Doi3WTyCpBBadx9Vdz2Np3EzoqyWJ5oi0XAtoigxMzvO/oMvEgxUEgxUUBG5UO9itdjQdY1kapZCMY/fF8EnhJiNTeByeqmtbuFs3zEmp0dxOtxURRuwWGy8ffAFHHY3fm8Ejycwtz/TNCnEhkl1v4qtYi326lIvjasZAZcWHl0so3jpxHklHghRlLhj60McObGXdCaJaS5enm8hJiaHeGXvD/B7I7Q0bVjW2IRyketyuFLBliAI7Niyi+nZSSRJJuC73Ei5EdjtLrZvfgCfJ8jx028jiiL5QhZJktiy4R42dt5JXc2am+phYGp5iqkJRNWGNdyCIClo6Wm0XBzVV42eiaOnZ9BdUWSbe962+aluRNWOJdBAMTFOYXYIS6CeYmoK77pmREnB0Apkx0+Tn+pBtDjBNFE8FWiZaSSbG2u4BVG2IsgqktWJqQdQfVWIih0QMHUNLT1DbrwLs/W+RdePtbWs5Z/96m/fcikw1xNJkrlrxwfxugO4nD50XcNmdRBPTKPIKna7i0IhRzqTLKV4WkpN5ZxOLzaLHbvdRdBfURZncF4WUR0Z6+Pw8b0rGqOqWolG6pZsfNusVnweP1/62l8xG5/BYXNQKBb48fPf4967HuLRh57A5XRfe0e3uWlw2J08eM8HCAVCfPeZb/DS68/NU05LZ1KkMwtLtNpsdjZ2buGxRz7CnTv2EApGbm7vvlAqyM4uUhlK04tounZTPUuuF7qulSRjF4EgCHORVFFWsAVrkCx2BEFEcfpvwhoLXae4gBdYVFSk2/UVq44giLjq1lOx7Ql8rTuxBUtGxPk0L8PQ6e47xtj4AIViHq8nhNvl49jJN5mNTRIJ15DNpjnTcxi3y0dL43pkWWF4tJeKSB2SJCOKMqIoIQCVkTpOnT1IIhmjMlpHU0MnB468QrGYp6ZqzbyxGYUUucluFPfNN2kJ+KNs23Qf45ODK45aGIZBT/8JXnvzmbk6lpsBQRBwudy4XDffRMHt8rFu7S4a6jrIZFMYho4sKzgdXhx2903nOTVNEwwDUbEh270AaOlJBEFEsjgxtTx6Nn+ZEh6AoRUQFSuixYkgKXPNiETFiuIsGXt6PgWCiLViLdZgYzk/WAETRNWObL/gmRZkC6JsRVTsCJJMbqoXLRvHGmklN3F2CcHwUh3D+cZ1tykhiuLcNXxeA980zTnp4/PNA/2+yLzXXk9o7rXN6phLNbj4IW2aBj/92ddIJBffPXghIsHqcgPJpV0n0zNTfO9H36AiWsWnP/5LWC02NK3Iya5jHD1xiGAwzP27H17R2G4VTF0rXWeCeFlatGmaGMUcgighLkWY4wbhdLjY0LmFN/e/Ps/RZFEtqKqFdCaNANjtdtwuL1WVNbQ1d7B+7Wba1nQSjVTgsN8K/R6EJaVp5fNZ8vnsZcZ9qTFcFlGxIoiXTnVNTMOgMDuAoFiRrF6KiVEUZwjJevNE0S8lV8guuoeJIIpz2RVaNkk+MYli96Ln02RnhnCEG6+beuvyTDzTwCheLn0qSMotcYHeGghYfVG8jVvxd9yNq7oDq78KyWK7TAFBFEWqKxrxe8NIkoTN6kSUJHyeEIqiYrU6MAwdnzeELMnY7W5CgSryhSwW1QaYKLKKqli4c/ujOOwu/L4IhmlgszqwqFbcLj+SKF3mPbP46wjt/CXEm/BiLHX/fYh3jrxMb99xjBVGLYrFPAeOvIzN5uChez5JMHBj6oluJVTFgt8XmZug3cyIsgXZ7iPZt49iahLVU4U13EwxPkay53UwzVIkQxRJDx0iN9WDoeURFRvWUAupntcpxkfRMjM46reDIJb+nt+/YsXiryV17i2MXALZGcJevRHR4iA7cpz8zDmsoWas4VZkm4fc2CmKiVGcjXciCCKF2QGMXGLu3mvk4qQHD6Elxkl0v4ajdivS+0TP/XpwqQfvWq+vtGz/oZc4fPz1FfevaGroJBhYeoFtIpWgu/c0/+nf/iH1tU1zRlFVZS1j46Oc7T71vjEsMsOHke1+VF8NwqXpaoZGZuAdiskJ/Js+emMGuASSqQR/8YU/4qc/e2YuWrG2bR2/9sv/L5FQBbqhI5ggShJKWUjFYXfhcrqwWJZWo3gjEQCrZfG1d5lsimw2dVnKoGlo6LkEgqhcZliYpkluootifBRbxVoETPTMDEY+hb1q/Yo/Q26iC0ugoXTcVYwMJMsiEotBFEQUWcU0DbKzI0weeQ5BlBEkGVd1O45I06qN61KWaViYGAvkjgqSjLAIw2L4jW8wtv/7aNnkNddVnQGqdj9NeP2DVx/SVcZ6QxFEVHdowfbpAiWrUpQtSBZ7qfjdG8YWrMURbcHqq0ApV++LiuWKoStBEHE4PDgu8rYBWIK2ea8d9gtebavFhml6570PzBVmB/zRed64UPkBd2mqkqDYUH03vjnflXC7/Ny1/VFGx86RziRWvL9sLs3rb/0YSZR58J6P3xIT5htB38Apzg2cpqVxPdWV1+8GtpoIoojircbT/jCYBqJqQ1Qd2KrWYwk1AQJSOSJhDbWguisRJBnR4kIQZVxr7sHUNQRRRLK6AYHAlk9cdAAJ1V+Lx+YB0yx50sr7UtylWiJRtUO5KNvVdDemoSHZPEg2D572h0vXet02ZJsHTLDXbMIaaUVUHbedOjcBQyM9PPPc35FMza5oP3abk8b6tfg8y0htNE1AQJlLlS3dqyVRRFqECt3NiqEV0DOznH/am4DiCmMU82jJcQS5FB0UJBktG0dLT1FMjCHKtlJ0IpegEBtB9VQgWt0gylhCzWTHz1z1uDcDhmHwd1/9v/zwJ99hZmYKE5O17ev5j7/132lpbkeRlZs7vWkJCIKAx+1neLRnUetnsykyl6gPmoZOdvQkppZDsrrJTQxQTIyjZ2NYImuQVAepvjcRVTtqIY1k9yEqdvRCCtPQKMRGyI4eR7J5UZwhCrGhUqRaVBAEEVPLl2vbBKzhZgqzgxSTE9gq1yHKFuJnfoYt3IIl2IRk95aOJVuwV63HNHQyI8cQBAnZ7kNUbXMptKZexBJsuOJnjSdmFl23JYoSFqutNEZvBaF1DyDKKrLNVU6JuslSoa6EIIgIiwjbFhLTpEfPXrE3w8VYPBG0Faax3Ehkq4PWj/0HXDULS5WWml6VPJuCKCJKSinyo6gl63KRP/5ivWnLff9WvWkJgsD2zQ9w4OjLnDi9f8VeRCjdyF7e+z1MTB6+95OXyUzeBs4NnOadwy8R9FfcMoYFCKW6Jcd58YHSMkm1zxVqn78OJIsTyTI/rUC2+y5LjTmfBnV+mSCpCI5g+WilgwiKFaHcWfn8MRFkpItTowQBwTl/OwDZ5gWbdzU+/IooFPMUCjnsNtct14RstRifHOQfvv0njIz1rUiJDqC+tp2qisYl9a84j8vppqqyhr/82z/m4x/+NJFwBclUklf3vsjZ3jM88ejHVjS2G4WWniZ97m0EUaKYnMASasTIximmpjC0HGYxhxqoR/VUkurdh2R1kZ8ZQHFXYOQSJLpfxRJoYObId/Fv+hiiakeyOG64cuRiOHL8AC+//jwzs1NzhuGvfvY3WdPcjvweMiqgdK/zL+GZGk/OkEheYsgLIqqnguz4mZKqX2oSUbFijWwjefYVPGs/iOqrQfVUoHqry5uUrzVBQnYEsPgbKMRHyY6eQLQ4kKxuiolxjHwK1VcDokQxOQ4wZwzkJs/irN+BpDqxVa1HsjhJdu/FFu1AkCRSfW9hi7ZhFNK419yHqRUoxIbIjp3CxERSrl5KMDM7TnGRTWVlWcHl8JVqLWwunBUt5fTb65+CvDzDQhAQFzAgSjnKJrw/nysLI4hYPCFs/qpV2V2hkEeUpHJTmKvfTIrJCWLHf4RpaPg3f7zk5SyT7Hmd5NmX8XR8AEftFqCUj5oePEC67y2KibFSsz1rqajU0/bAXA64nk8TP/UTkt0ltSvJ4sK15h48rfMbGGXHz5A4/QL26o0Igkiy943SBW5x4qjbgqvp7tKNvVzQbGgFEqefJz14CD0zM6/gWnGG8a77EPaqdUv+zqxWO09+8B8zMHSWeGJ6ydsvRC6f4aXXv8vU9ChPfvBXqIjUv28nVAuRy6WRJAm7/eZLkbsWyzHSl7LeYve/mFScm4XJqWGeffEr5HIZ7tj6EG0tW3A6br66n+vF6Hg/X/7GH9LVe2TRqi1XQpJkWps3URmpX9ZvHgyG+eynPsdf//2f8xu/9csYpoEoiDTUtfD0U59h1/bdKxrfjcI0NARZweKvwzR1JIuL3HQvksWFvWItxeQkRi5FLnemJIYQaUPPpxAllWw57cUoZCnEhinEhrCG11z7oDcJR44fZGJqfM5gtdsctLeue88ZFVByUF9N0v5SYvFJYrH5/arOO3FKmJimgWz3INv9GMV8KdIsWxAUK6KsYlw0WTdyiVK0w9AQZRk9U0CQfHPRZBMTQbGU06sEcpPdYJqluYxeRBClciTbgSAq6LlEyelk6HN1ducdU6ZqIKanSQ8cwBJqQgnNV9G8lNHxc+QLuUV9L4qs4naX5mxGMU+s520mj7yAoeUJdt5HeOP1S4dctmGxUMqTaWgYehFxAU3v683N2sditfnOM1+nrWUtne3rF9ROv5i5E9nQLis4NbQcejZeCumViZ9+nsTpF7H4a7DXbwNDp5gYJX3uLbwdF05CUbHiaroLa7CJ3GQ3ye5XMIuXn+wl/f9pYsd+iKjaUTwVWAJ15Ca6iB39IRgG7jX3IZbzwmcPfYtU3z7cbQ+iuMNkR0+T6nsDW6Qd38aPLLtAXBAE6qrX8OA9n+D7z/41xeLiLP5rUSjkOHzsNSamhvjkk7/BmqaN1/xN3i9YrQ5kWUVbpHflNrc2uqETi09xqusAx0+/RcAfZcPaO9m26X6qKxtR3sNpWsdOvsl3nvm/DA6fXXxjr6vQ3LCOtpbNWJbZJVoSJVqa2vjd3/4DYrFZZmLT2O12QoEIdptjrlP5LYkgIsiWUt68IJazooRy1J/yREAsr1pyfpqUJqu2ik4ctZtLE79b7Hycnpkkn7/wjM3ls4yNjxANV950IhgrRRCEJWUBpNJxZuMTFIuFuaJvLRcnM3yE3PipkmR3MQdcXsAPpXlrMTZEqv8dMHVE2YpeSJecoGpJkW/e+C6caOd3gJaaQsvMzJ1zqreS+IlnsVdtwF69ntjxH5bSaqNt5W3L56ggIlldiKqjlH6rXP2aHxk7Rz5/eX3zQsiKgqdcd6IXsoiyBW/zVvKxcRSHD9M0rlvH8mXdYQRRmuf9Po+pFTAKGbiGMpQ9XIe/7S70y/LiDGK976DnM1fY8spcucZiybu6bmRzGfoGetCKRRAE1rauI5vN0jfQja4bNDW04HS4GBoZoK+/G78vSGN9CzarjaGRfgaHB5icGqe5Yc11+Vj5qR4kmwfvxo+guitKF6FpYpr6RdY/pRxwZxjZGQJRJtn96pV3apqYhoZ37aPYqjYgiCJGPs3YK39Kqn8/zoY7EFUbRiFNsuc1HA078XZ+EAQBS7AZPTODXkgjOwNz6SLLQRQlHrr3E5w48zanuw6sOFXhPLqhMzjczZ/91W9z1x0f5OH7PoXPE5pLYXiveZMWS2NdB919xxga6aGhrgNZUq5g41/em+M2ty6GoZPPZxkZ7WNsfIAXX/km0UgdG9buYtP63VSE61AUtZQ2u0BfllsB0yx5QOPJGX722nd4bd8z5Ujoyu8pFouNDZ130lDXvuzvRtOKxOKzBPwhHHYnlRXV82otblUEzqdxlP8VRCy+GvR8ivip50AQcNRuxeKvJX7qOWInnkXPxlA9FdgqO4kdf4bY8WcwDR3/pqfQs1Mkul+lODtE/MzPcDbcgaTenKqWfl8Qi8VKMlWqEzQMg3/x//0an3rqM9y54x6qK2qwWKwL/75C+bsrq2OJkjjXO2q10fMZps/sZfLI8xjFHOFNjxLe+PCSjiUIIlUVV64zuBTTNBke7WNiepiqaGk7yeLG1bwbV9PdF4yJstx7YNunQJBwNu6aW6YG6gn4asvridiiRmniLUqUTVMQBGzRjvLrcq+tqpLEvmnoF5THBBFn452leruyo9HiL6tInjc8ynWppWaHoLgjJYGBq3xP45NDzMxOLDqdW5Etcyp2it2Ns7od2erENIzyuG6yGgtBlFAc3suW64UcWjaF6rp6wVl40wcIb7q8U6xRzLP/Dz9KevTscoZ10zM0PMAf/e//ygce/DD1tY2ksxle3/cz+vp7kCSJrp5TfPChDzMxOUYqneSnP3uGxx/5KFWVdXz9O1+mo7WTE6eOsnn9tusyPtVbQ26qh2TXy7ha9pQL4dTS34vWu3DyC4uKCNmibaj+2lJxvyAgWl2oriiZsRNzspzF1DSmYaB6KuasflG2IDtDaJNnMQqZy3Lal4osKfz8U/+C3/tfv0YyFVvRvi4ll8/wwivfZP+hn/HBB3+BHVsewGp1zCugfDcpTX7MVTOglkpFtJ4tG+7h9Td/xMTkMGvbtuF0eC7zkFRVNKKqyzcYb3PzYhg6BUNnYKiLgaEufvT8l6iMNrK2dStr23ZQU9WM1WJHkmWkcj3ZzTzxNU0DTdfIZJIcObGP51/+OsOjvSvukXMeQRDoWLOVtW3bkRdouLdY+ofO8Z//x7/h3/yz/0jbms6b+jtdCoq3CsVbSim2BBvnveeoKz8Ty/cX77rHS1H6i3oH+Td/AvQilJV6ZFcE/6aPwabFj+H8/dQ0TQzDWNCUNA0DwzDL58XqnNM7tuzi2Re+z/TM5NwYxidH+ZO//H3+5C9//4rbiaKIRbXgdnmJRippX9PJzu13s3HdFrwe/6oXfevFHKrTT2jdfeRmx8oNk8sT80UiCALRcC1Wq51cbnFO5qHRHsbHB+bSBwVBAOEKkRyhPO2d974A0oVnk2kKCCyQbn6ljyGcj0CcN2Kki5ZROufmXlzYj56NUZjuQ7J65gQ8rkRX96EliULYrHai4QuNejF0JIsDd916FLvn5iveFiVlwQ7bWj5FIT2Lnfqrbn/FD3RdPufNE7KQJJnG+hY++qFPAtDX30NX9ymmZ6YQRAFZkpmZLdUAxGKzzMZmKGhFunpO0t7ayZ133MPI6NDqSMct8LV42h8AAVK9b5A69xaWQD3OhjuwVa5DsrqX/fNIFjeiYpvvNZMkMIy5cUhWF4KkUIyPY2h5BEHCKGTQ0tOlIjvryvO1BUEgGqnjI499jq9++08oFvPX3miJxBPTfPXbf8xzL3+du3c+xvaN9+Ny+VAVy3XLhz3/oDEMnaJWRNMK5PNZBofPMjUzturHWwxvvP0sP/jJ35LLpTnZtZ9X9n1/wfX+w7/8ApXRxXunVkomk1pWQeythCCIc+fbzYRhGAyNdDM00s1PX/oabpeflsb1tLdsoalhLd6yPLYsq8hSua/ODZ4Um6aBpmkUinniiWlOnH6b19/8EUOjPasiBHEx4VA1O7Y8QE1l84o+t6Hr6LpOZUXNtVe+hbjqd7LQJHKhZYtIgTJNg3yhQC5X6hlwPkJllI2JQiFPJptmaGSAZPJyYZmu3tN4vX7cLjd2uwNRlBDPRwvE0r+SJGG12lAX2a+ho209H338aeKJOEPD/YuWTjcMg2wuSzaXZXxylCPHD/D17/49LY2t/Pwn/hH373kEj9u7avWBisOLs7KVrGrH0DVEWVlyuo0gCEiSQk1lE2d7jy1qm4nJYQZHeuho2451mSmEl45hpevPW3aF3cl2H86Gndfcv65rnOk5QnKRQkaSJOPzhnGWAwCmoZObHSM1fJrszDCOaBPhjY9ct/vr8iIWsorVXzmXKnMeLZOgkJi8ypbvbwRRmJffarFYaaxvYdvmXbS1dGC12ugf7ONU13Ha13QyPTuFRVGxqlampieZmZ0ikU4sukHKfC6xJAwd85L9iKoD3/oncDXdTWboCKmB/Uy/8zUs/jcI7/41JMvVCnGvYsBJMlzjxiXbfThqt5DqfxvZ4UN2hSlM9VFMTZbqMJTV0eEWBIG7dnyQ/qEuXt/3QzRdW5X9XsrU9Ajffebz/OSFr7Kx807aW7dRX9uK0+5BVS3IkoIsK0uePJmmga7rGIaOpmtoWoGiVqCQzzM5PUzfwCl6+0/SP3hm1QrVl0N1ZRP3331tbXiX03fNdVYL0zT52nf/9KabcK82ToebXds/QEvjhhs9lKuSSM5w4MjLHDjyMlCSuG6s7aChvoPa6jUE/VEUuWRoKLKCJCvIkjyXRrXanJ9AFrUiWrFAoZgnmY4xMHSW46f2carrwOXqM6uE3eZkx+YH2bD2rhV/NofdSXNjKz3nztKxZh2yIpfzwkvc7JGhG002m+WVN17k2z/8BzLpFOlMeq6zdSabplC4et3Yn/zl7839XxAE7DY7dpsDu92Jw+HEYXNQU13HRx77JFs27rjmeEzTJJfLcs+dDzAzO82XvvZ5YvHln4emadDVc4rf++N/T29/Nz//iX9ENBxdnXx7syQCIyoWXJWtKK7AsnYjSTK11a2LNiwMQ+dM90E627fTWLf2PXd+9w+eYXCoa9HOUItqneewEyQZe7geizdKavgUUJ6730yGhShKWNxhFLuXYvrCCV5MzZKbGcE0zXf9h70VirdVRSUcvFCAHAlFqa6q49W9L3L42DtsWreN+romTBPeeOsVEskEFouVNU3tHDt1mJ/+7BnSmRQW1TLvQXElBFFEkBSMYm6+6oFeRM/F5zU5vDhlRnb4cbfei6tlN/FTzzF7+DtkBg/har6amsjKv2dv5wfJTZwh1bMXQSmlQfnWPz6nWrVaSJLMk4/+CtPTo5w4szoStFcim0ux752fsu+dn2JRbdTXtlFf20Y4WEUoUIXHHUBR1LJXS0Qoe7Sg9AA4n85kGDq6rpEv5EgmZ4knp5maHmV0fICx8XOMTw1flwjMcmluWEdzw9IVvK43h4+/fqOHcN3xeUK0Nm+mpfHa695MTM+MMT0zxv7DPwPAarETDdcSjdQRDdcSClbi94ZxOjzIsoIsKUiSVLp2RKn0f0G6KBVCKN0nBcq1YmCWO+4aho5uXDDQda1IUSuQTicYHT/H0GgfA0NdDI10k8mmrj7wFaLIKus7dnHH1oewWlee4+/1+FjfsYkvf/2vuXf3w1REqpAvKvANh6JURFZHpfC9SFEr0jfQw943X17xvkzTLBsmaZiemFs+Oj7Mzm3XVucqakUmp8bZ++bLPPPT73LkxMG5Im5JklBVyxUVIs8/O3RDRysWL3OiZbIZvvHdL+H3+vn4kz+P23V53exS0QsZYt37yUyew+qvwomA6vQveT+yJNPcuJ4XX/02i8066e0/Re+5k9RUNqOqt05DwGuhaUUOHn2V6dnFZx9YLHZqqprnXhtageTwaRL9R1Fsbjz1G+e6bhdSM2hXucdZ/ZWI0tJMhWWrQkkWB87KNcyefWtucSE9S2ayH6OYR3oP/bCrRVVFDZ99+lfnXkuSxOb129iwdjOGYSDLpTzjp5/6LFDKjzx/w/iln/s1NE1Dkhbv4RZlG4ojQHp2gPx4F2I5bzc/O0h++tw8pSjT0CgmxkrhWsVaKjIydGSHH0RxLo+4ZICYmHoRDAOzmCvdwPRy4b4gIUjSZZ0uF0Nm8CBGMUflw/8OxbV4ubmlIggCLqeHTz31z/jbr/w3elahK/diyBeynOk+xJnuQ3PLVNWK2+nDarVjUW2laIasYprmXDRCKxbJ5tOkUjGyufQNq5tYLrquUdQKGIaBJMkosnpbmvc21ySXz3Bu8DTnBk9ftFTAYrHidQfxuoM4nR7sdhd2mwuH3YXVYkdRVCRJLqVTSSVvvW5opRQhQyOfz5LNpsnkUmQySWKJ6ZJkZXyKVDr+rl5fsqzQ2rKJe+/+CBWRulXZ50xsmmd++h3iiRh/9Xd/Wl564Znx0cc/xS988ldW5Vi3uX4UigVOnDrC33z5L9n71stkcyVHoNvlIRyMUBGtpqqyBpfDtcDEr2RAFwoFUukkk9MTTEyOMTk9wWxsek4SOZ1J8+wLP2D92k1s27xrFRzCAorLj8vqwB6qR7YtT25ckmQa69pxOj2kFlkPmc9nOHjsVRrq2mmsW/ueeMaYpkn/0BlOdr1DOnPthtLncTrcNNZ1zO1DFGXcNZ24azrR8+l5Dvep4y8x2/Umei6NoRWQLA5ESUYvZDBNk/af+29LNg6XrTsn25y4a9fNMywwdLJT/WQm+nBVty931+87JEmaJxl3Jfm4pcoEihYH1mg72dETxM88T27iDAgiWjaGoRfn1S2YeoHYsWfQszFkR6kLpakXyU/3Y/HVYavoPL8mWmaW7PAxTC1HITaMqeXJTfYgKK8gylYs/vqrdo+8Elo2jiBK5GfOoaUm55q5iKoT2RlAXIEq1KUIgkg4UM0nnvwNvvqtP+bcwKl3xbi4lEIhx9TM6Lt+3HcDTSsyG59kdLyfyalhCoUcDoeHSKiaikg9TofnPXHzv827iUk+n2V8cpDxycEbPZgVIUkyDXUdPHjPJ1jTtHppa5FQBb/7W39wxffdbu+qHWu1EQSRDZ1bCIcq5pa5ne53NcIiSTJVFTVs33LndTtGOBgm6L+yyI1pmpzuOs6f/dX/4O0Db8wZAhWRKj740Id5/ANP0VjfjLRIT7Ku60xOjfPCK8/yze9/hbM9p+cM6FNdJzjTfYp1azdjs66sPkGUFUTZQnqsh8zkAO7atbhrlx65FgQBm9VJa9PGuVTJxXC25whHTrxBOFiFy+m75VOi0pkke996lpGxvkVvI8sqldEGAv5SMbheyJCfGcEsR6wyk/3Idg/+1lJtR6D9btz1G5g69iKmruNp2IRi95Ae7yY1enZZTuLlGxZWJ+6GjYiKFeOiHgaZ8V4S/UdxVq55Vzr8nefKcrO3lnd3qZimSS6fRS176S5GECWs4Rb8mz5GeugQeiaGoFhxNexEtDjJjp6c6+4rylYcddvITZxGT8+iFUpF0476bTjrtiGXuxFjmuiZWdKDB+aOY420ApAdPVlKQxAlLMEGJIsLS7gFxR1BuKSQTvVWY2qFOT1xPZdEsnnANJk9/J05i1oQ5VKBU/PdOKo3reo5JUkSdTWtfPzD/5Rvfv/P6Rs4dV3Tot5PaLpG/9AZXnrtu3T1HAZAlCS0YgFZVtix5UF273wcnzd827i4zfsOWVaor2njwT0fY137tfPsl4JpGoiSRHVl7bzlhmGQTCWYjc2QzWbw+QJYV0MIZBWRZZnf/50/vfaK1xGnw8kTH3iKJz7w1A0bQzwR43s/+iaHjr4zZ1S4nG5+8ed+jScf+zhOx9IiAZIkEY1U8tTjT6NpRf7iC388J11rmga9584Si81giy7fgDvfF8FZ1Yoj2lx2FC6/Z4pFtbK2bTsHj76y6Ciirmu8uf+nVIRr2bzhnlUp5L5RFAo5Dh59hZNn3l507wooqUG1r9k691rLJkmNdCGW51qF9CzSRZEkiyeMxRNm7O3v4W/dha9lO4Io4Yg2lWSDtaWnWC/7VxdlFXu4AVd1G/G+w3PLc7NjzHbvx992J7ZA9XJ3f5tFYpgGp84cp762Cb/v8kIpUbaAvwHFWUXANV9izF61fu7/gijhrNuKs27rZfuYmBwj6DTnjAZrqJmK+//FNcdmCdRhCSwc3ve0PTjvdbJnL6me1/B0PILsipTy/wwDLTNNqncfyTM/wxpqWbB/ykqQJZmm+rU89fiv8f1n/4buvqNoWnFVj/F+ZHp6lJdf/x5Doz1s3XQf1RVNqKqFdCZBT99x9r79LHa7i907H8dmddzo4d7mNu8aimKhpXE9D+z5GBvW7lr1JlWT0xP8zZf/kicf+wTFYoFQMEJltJrpmUle3vsCXWdPYrc72LZ5F1s2bsduu3393WwcP3WEYycPkctdmFBu27yLe+56YMlGxcVYrTaaGlqpqarj5JkLhdHTs1NkskvvH3YxRrFAMRNDzyYppmNkZ4aweCL4W3cta3+KotLSuB6/L8r0EqL6UzOjvPT6d3G5fLQ1b0JRbj05c00r0tV7hNfe+AHjk8OL3k5AwOMK0NayeW6Z6goSXHf/XHmClkst6HBXnX4S/ccwinlExUohMVFS81yGM3dFLTgt7hDBzvtJDByfC7NgGsR7DzB94hWiO55EvkazvNXiVijevh6YhsHRk4dIJOOEgxGikSokSWJoZACb1UYwEKGn7wz9g31s3rCNYCA870EyNT2BXpYnFAQBl8vN+MQo6UyKqspaJFHi+89+i7t33ks4FMVmsdE30IMsK1REKjEMg9HxYSRRIhSM4PUsXeXHNE0SXS+i+mpxtz0w70GrZeMU4qPkJ7ox8mlYZcMCSt7D5oZ1fPSxz/HjF/6eU10HyC2jSeNtLtA7cJKxiQH27HqcO3d8EPWim/u2TffzD9/5Xxw48gqb1++5bVjc5n2D1WJnbdt2HtjzMVqbN12XVI10JsXPXv0JqXQC04Ta6noevu8xBobP8fq+l2hvXcfU9ATPv/xjfB4/nR03t3rY+5Gevi5GxobmLdu+eSc+79ILoS/FYXfgcMzvCZXP51aukGga6PkshfQsWqYkiyquoMO5IIh4PUG2rN/Ncy9/fUnbdvcd44VXvokiW2iqXzvXkftWQNOK9PSf4PmXv865wTMspWWCoqisad5IOHgh8iRKMiaQmx0lOz0Eho7VX3VZ/Uto/YOMHXiGqROvlBYYOtHtTyBbl94/bEWGhWx342vZgaNiDamhk3PLczPDjB14BmugGt+aO5BuQYvxVsIwDAaH+5mNzXCm5xQhf5ipmUksFitjE2PEE7N09ZyirqYBl8szz7A42XWcmdlpisUCmCbbt9zJucE+zvacoqGumfY1nRw7eZiWxlasFhs902c5eORt7DY7VRU1hIMRXn/zZTra12O3O5ZlWICJqNjQMzFyE2eRbG4EBIxilvzMIPmpXmRnEMm28l4WV0KWFRrq2vnwB38Ft8vP4eOv31C51ludRGIGi8VGVUXTPKMCStKaLY3r6eo5XDrvbnOb9ziCIODzhNi8YQ937/wQtVUt1+9gJqiqhS0b78DvDXDs5CFe3vsCPq+fUDDCZz71j4nFZ/jiP3yec4M9tw2Lm5CZ2SmSycS8ZdFwJZZVEMUpakWKxflReUVWkVaYkipZ7NhDdaVWBIaOlk/PCcYsF5vVwfrOO9m7/1nS6cS1N7iIoyfeAOD+3U/R2rwJVbHc9DUX+XyW7nPHef7lr3PyzAE0fWnZEw6Hmzu2PnTZ59QLWVKjXcS691PMxAl27MYaqJ63ni1YQ90Dv0IxNYuhFVCcPiTVtqzvbEWGhSCI2MMNRLc8Rt/UAHrugmRV4twRBl/+IqZexNeyHfk6Tgrf78iSzKZ1WwkGwvz5F/6IlsZWPvjQk0xMjXHo6H46WteRz+fY0Ln5suZghXye8YlSmLFYLDAxOYbb6aapfg19/T3cfce9RMMV7Nq+G93Q+dlrPyUcjOBxe0kk4/i8ftxuL7t33rfs8QuCiKftQZLdrxE/8WNEixNMA1MvoufTyI4Arqa7Vtx5+1pIkkxNZTOPPfQZAv4obx98gZGxvmX2DXl/IwhiSerwCl6wYjFfkte9ue/zt7nNiikp3HRwx5aH2Lb5flxO73U9niiK1FTV8ZHHPoEkyYiSyBtvvYrD7kAQQFEUQsEIFtVCJnM7MnszomklOeSLKUmRr2y/hmEwMTnGxOT81CKfL4DNtvLsEtPQyE0PkZsdQZRVrIFqlHKTtuUgSTKVkXrWd+xi3/6fLHn7oyfeIJ1JsmfnFBvX3Y3TcX07Ti8X0zRJpmKcOP0Wr+77Id19x5acki1JMs3162ioXUA4SRCx+asQ10hkJgdQHJc7gPVCluTgCYrpWbxN2xBEkezkOayB6iUbiCsyLKAUtQh23kti4BiTR57DLF8MpqExc2YfxUyc9OhZvM3bcESbkW3uOf3c85iGQTE9Q3ZqCL2w+CKVefu4wvJY936K6diKin4tnjCOijUo9pvUOBIEHHYnkiyjKiper5/Dx95B0zWCgTAWi5VMNs2pruPUVjfgcl74HA6HE1VRURSFdAb6B/uYnB7H6/ZhGDom4PcFeefwm9RVN1ARqWJoZACr1UZLYyu6YWBfhRuSs3EnsjNIYWYAvZABU0eUrUgOPxZ/HYqn4to7WQUEQSAYqODeuz5CJFTNvv0/pavnCJns4qXe3mss50bs94XRtCJnug8RDdfi8QQQBRHD0BkZ7+fkmXcIh6pR1Vu3uO42t7kWAX+Ude13sG3z/bQ1b3pXur5bLBacDhfPvvADPG4vh47sZ3DoHNOzU9isNmKxGWRZoVAsLFlp8GbHMAymZiYRBQGPx4ciK+i6Ti6fw2a1XSYUUZL11igWC9jtV0/JNAyD2dgMuq7j9fhQ1euXXmO1WlEVC7mLinaHRwfJ5nK4nMuPAoxPjnLw6H4mJsfnlgmCQG11PW6XdyVDBkr9EnIzwxRSM9hD9asituJyetmx5UFOnz3IbGzi2htcQk/fMeLxKUbG+9m8fjeNde2IonzTGBiFYp7h0V4OHX2VA0deYXTsHOYS0p/O43R4uPeuJxdsACsqFlR3CFGxIDt8KA7vZZ8/1r2f+LnDJAaOYwvWYQvWMLr/B9Te8xnEJRqHK76rCIKALVhD1Z2foJCYItbzDnPTfFMnOXCM7FQ/06dfx1mxBouvAsXuRpCUkke6kEPLJikkJsjOjFBITq10SPMYefPbSIp1RbUWvpYd1N73SzelYSGKIhs7N+P1+rGoFu7f8wi11fV093bhdnuoq25AVS1kmtPo+uWe94a6ZpwOJ4qiks1msFptTE9PlrXgJVRFYfeu+5mZnUSSZbZt3onNasPt9uLzBcpNelZ+gxVEGVu0HVv05pApdjrcbF6/h0ioloNHX+HwsdcYHuu7ogf+vYbd5qSqopHaqhb83jBLbYBYV9NKTVUzh4+9zmxsgnCoBllWyOXSDAydZXxykA/c/3M4b8Jr6jZLR1UsuJxeJEl+31wjV8Nuc7G2bRsbO++io3UbXs+VpUVXG583wO5d9/PG268iCAJOh4sd2+4iFp8ll8vwt1/5PximQTqdoqa6/l0b17uBaZpMTI4xNT3B+rWb8PuCFIsFJqfGqayoRhXVy9bPZjPEErPUXsOwME2T6ZkpRsYGaWtZSzRSed0+RzgUxevxMTZxwbB4de+L3Ll9D47G1iUr6ZmmyeT0BD/8yXd49Y0X59VTVEaraW5Yg+Man/9aaLk06dFuCokpECW0fAp1FYRQSgpqrWzbeB/Pv/L1ZfWZmZoZ5YWXv07/wGnWddxB25qt1Fa3IL2LyqWXUiwWGJ8c5NTZAxw7uY/uvuNkl9mMUxQlNq27m5amjVdYwywV1E8NIFkcpTnxJcR6D+CoaCEz2Y9p6EiKldTwKYxl/Iar4q4QZRV3/QZq7v0spmkQ7zs0r/malkkQ695PrHs/kmpHspYacBi6hl7IYRQyc5GO5XKlaU8hMbmi/QLYI43zOlffTIiixPq1FxQAdm3fjWmaVFXUABe8zZvWbyuvP/+GFA1XEA3PjwYYhnGhey3QvmZtublZ6SLcc+cD5aYrpX1FQiuPJpy/WVzNi7CYdVYTWVaoq1lDwBehobadIyf2cuL020zNjM01DHwvYbXaiYZqqa1eQ211C1UVjVRVNC4rfBzwRbn7jg+hKhZOnz3IidP7MUwDWZIJh6q5766PsGHtne+pDqnvZzzuAHfteIyAL0p33zEGh89e947VNyNul5+mhk461mylo3UbFZG6d90z6nS4eOi+D1JbU08mk6ay3EitUMjT29/DvrdfJZfLsvvO+2ltvjkcOcvFNE0Ghs5xbqAHj9tLQ10zDpuDs7EZstksulvn+KkjpDMpIqEo3YN9TM9OkUolaW3pwO8NcODIW7hdHmqq6ojFZzl28hAW1Up1VS1FrUhv31kC/iDNja3YbDZSqSTJdJLodfxcrc3tVFfWMjYxMrfs8LF3+Mo3/4aPf/jTrGnuQFGuHbkwTZNEMs7xU4d5Ze+LvPz684yMXigKF0WJO++4hzVN7SuX/S4/E1VPqNSGoJBdtXmT0+Fly8Y9nOk+RP/QmWXtQ9M1Tp09MNdwrqVxPY11a6mpasHjXnlR/GIwTYN0Jsng8Fl6+09xtvco/YOnicVX5lAP+it4YM9TV4xACoKEqFgoZuIkB45j6kVU1+UqoqoriFiuiczFx0EQl+pTBFbJsACQLQ78rbsQZZWRN77OzJl9pQ5/l6AXMqVUl8UiCAhLbCf+fmehB9lSbhqXrisIwrymfRcbHavFK3tf4K477kWW5TkvkqZruF0XVKAmp8YZnxxlXcemVT32tXA6Paxfu4vqqiba1mzh5On9nOx6h5nZsVu+/sLl9FIZqaemqoXKigYioWoi4Rq87uCimy8thCiK1Fa34Hb76GzfQSwxja5rWFQrwUAlldEGLKr1pglH32Zl2KwOOlq3Ul/Tysj4OQaHu+kfPEP/0BnGJgaWpMN+qyEIApFQLa0tG2lpWE9tTSsV4Vok6cakWwiCgMvpZtumnfOW220ONnR6aG5Yg67rc5HqW5nZ2Ay957ooFItU2B3IkozFYp2bYJ3//scnRtE0jROnjyKKIl6Pn5dee46PPv40mqYxPjFKLp+jp6+L6Zkp1jS3o6oWNF0jmUowPjmGzWrH6/EhL2JCv1KaG1rZuukOzvaeIZ6YBSCXz/HMT7/L0MgAm9Zvo6WpjWi4Eo/bW8oaMEte8FwhTzwRY3pmkuHRQfr6ezjbc4rec2dJZ+bPyTas3cTD9z1GJLxyM8k0TUTVitNficUTJj3eC4Y+199iJUiSRHVlM7t3fYjv/3iCRGp22fvKZFMcP/UW3b3HqIjUEY3UURVtoCJaTzRcS8AfXZUieSh9J7qhMT0zxtj4AKMT/QyN9DI23s/45CCpdHzFx1BklYfv/SSV0cYrj8PQ0HMpZJsbT+NmrL7Lo23u+o3E+w6RGjnDyL5vYeoanvqNSMtIV17VGbtsdeBfcwcWTxhXTSdTx14kNdqFUVxagw1BlLAGqnHVdOJr2oKncfO1N7rNDaNYLJLOpslkUmhakXAoitViI5NJMz41VpK99YeRZZlEIs7I+BBWi60UmlZU+vp7yJRveKZpEk/E2Lf/NQRBoK1lLXU1DWSyGYZGBuaOmc6k0bQiTqcLrVgkl89htdrQNY3RiRFcTjd+XwB5lYxSURQJ+ivweUI01nWwofNOzvYe5fTZAwyP9FK8SSNal2K1OAgHq6iM1lMRrScSqibgryDoj86lsqwW55VwfJ7Qqu3zNjcGXdfI5TM4rpK6JggCDoeblsb11Ne0sX7tTqamRhibHGRopIehkR5Gx/tJpmK3fMRPEAQCvij1NW3U17VRXdlMdUUjXm/ohqZXXAtJlOY5a2514okYxWKRNU3tNNQ1zS07jyiKVESqONtzGsM0yOaytDa309rSwSt7X0BVFKKRKrq6T5LP55ienaKuppG1beuZmZ1mZGQIm81OLpclnogtU/Vw6TidLj7w4OOcG+jl5b3Pz/WzyGTTvPH2qxw7eZhIKIrH48Nuc8wZUpqmoWlFMtk0yVSS2dg08UTsMgeYKIisW7uJX/jkr7B+7eYF8/KXjkkxOY2eTaI4fORmhkEQsEebV2HfJefFhrV3MTrWz0t7v7vilMtcPkPfwCnODZ7GbnPh84bwuIN43X48niA+TwiPO4DD4cZudWKzOVAVK5IkI0kSoihhGga6oaPrGoVinlwuQzaXIpNJEUtMMRubJBafJJaYJh6fIpaYIpmMLauG4krs2PoQO7Y+eHUnhiAiqXYs7jBWf8WCYkq+pq1Iqq0UsTAMFKevpOqqLr2GdtVDAaJiwVnVhsUbxdeyg+TQCZKDJ0iP9ZCLjaFlEhhaAUEUEWUVUbGg2L0orgAWTxh7qA57qL7UDdBXgdUbRVpELwyLN0L9g5+jYsdHVvsjYfFEShJqVyG4dg82f9VloT9RVrEF665qtRuGUXpfFBGFy4vLoPQgK3XgNBFFad5JVFrHXLZXoHSBCoiiuCwPWyIZ5839r5HKpFBkGb8vyMZ1Wzl4dD+JRIx8IUdn+0aa6lt44ZVnUVULHreHYCCEqqik0klOnD7KA/d8AFEUiSdinDpzDJ83QGW5E6iuaYxNjFIo5Nm8YTuzs9OcG+yloa6J6ZlJMtkM9bWNHDl+EF3XmZqe4K6d91Jf07iqnZ0lSSYUqCTgi9JYt5ZN6+5meLSX3nMn6O0/yfjk4E2TYy6KEm6Xn3CwknCwmnCohnCwCq8niMflx+32Y7XYb0jn61Q6zouvfps9ux5/V/PPb7M8CsU8sfj0VQ2Li1EUlaC/gqC/gqbGdSRTMWLxKRKJGSanRxgZO8f45CBT0yPMxCZummvmatisDkLBKqoqGqirbqUiUkfAX4HfF8ZqsS36/msaBqZeQBAlhBXKcc7t0zTB0EvCKKvccO9mxuf1oek6b7z9CuOTo1RGqzjbc4aTZ47hsLsQJZEjJw7S1XOKxq4WNK2IxWJFEiUMQ2dsYpQDh99kfHKUtW3r8bq9HDjyFsl0AqvFSk9fF/FkDKvFSjqT5kz3KU6cOoKu60RC0etqpDXWt/BLn/41VFXlZ6/9lFTqgoBIMpWY65y9VDxuL3fdcS8f/uDH2bhuC07H6qgtShYHFl8FycGTZA/8CFGx4KpuW7WonSAIeL1Bdm5/hMnpEY6c2Lsq+zVNk3QmQTqTYGikB0EQUFUrdqsTq9WBRbWiKBYURUWWZARRQhSE8vVuYhgGhmmg6yURgKJWoFDIk8ulyGRT5HKZVTUkLqahroNH7vsUdts1miaaBoXUDKmRM2Sn+nFEm7BHmub9NqnRswAE2u9GcfjmaqHfdbnZKyEIAqrTh+LYjLO6jeDaeymkZ9FzKYxioVRPUe7iLEgSkmxFtNiQLXZkuwfZ5kZcoudUtrnwrbnjenycReGINOGINC34XjaX5vjR19i8Yc+C78/GJ5mYHCQUqCIYmF+vcPrsASKhWvy+MP1DZyhqeRpqO+b1BtC0IoeOvcr2zQ8AYBg6uXwW0zRx2K/dpfNs71FUxUp1ZeOyct4LhTypTIqAP4giK0xMjXH81BFi8RlaGtsYHD7H8Mgg0XAlU9MT5At5dm3fM+clqa9tZHCkH8Ms1Xa4XR4C/hA1VbXU15a+U7vdjtvl4eSZowC43R4SiRhne06TTCWw2eyMjY9w4PBbSJLM0HA/oWCEinDlimX0Dh/fy779P5nruXD/7o+WCzIDeD0B6mta6WzbTiw+xeT0CIMjPQyNdDM82kcsPrmsYrOl4nB48HtC+Hxh/N4IAV+EQCCKx+XHbnfhsLlw2N1YrfZ3RZnmWqTSMQ4ceYmtG+9dlGERjdTymU/+FoVi7l0Y3a2Drutkc2mcjgsTfkWxUHWVsPi16O49Rjhcjcvh4djJN2lt2cSR43ux2ZxURuuIJWY4cfotJFGmo3UrHvfluboXo8gqfm8YvzeMaZoUCjlS6TjpTJJMNkkqHWd6ZmzOyIjFp0pGSHJ2yTruq4WqWvF6ggR8EULBKiqjDYQDlbhdfpxOLx6XH4vFuixnjlFIkxk6DIKAq+muK65n6sVyF1zLtQ0QQyPd/w7WyBpkx9V/j5VgUW184slfX5FKnihKVFUs//y8GLfLw+b125iNz+ByunE53bQ2dxAORfF7A7icbta2raO6ooZwKEpFtAqfx4+sKHz8yZ/H4/ayc/vdaMUikXAFFdGqcq8nO3a7g0iognw+h6KoOB0uNF0rSay7PKuWLnMlZEmmo20dv/ZL/4yN67bwkxd+yNETh+YpRS0WURQJB6Ns27yTXdt3s3HdViqj1auqbCVKMrZANZJqQ8umkO0uVOfqnouSKFFd2cT9e54il09zpvvwqu4fSoZGPp8tpW/GV16je72oiNTxkcf+MdFF1HEZxTxaNoGWTVFITCHbXNgjjVxcQGFqRdKjZ4n3voOezyGqFqy+SiKbPrAo5/7FXNfiBUEQkC0OZIsDW7Dmeh7qpkXTNUZG++ZkNTVdI5tNks1lyeZSBP1R8vksUzNj5HJZ8oUcAX8Eq8XO5NQIxWJxrr4hkZwlnY5jGiYVkZI8nGnC4HA3lvIPbxg607PjnOo6gKpaqK9pJxKqpqgVmJ4ZwzRNgv4KVNVCOp1gJjbO0Eg3QX/VZbrZS0GWZDwuL7IsMzU9QTaXQZEUAr4gs/GZUqqTAB98+ElGRod47c2fUVVRTTRSicvpLn/GUu2G1WrF4XDicLjmPEKyrJR12EsPcqfDhcPhpOfcWdxOD3U1jRSKeaoqa2ht7sDlcBEMhFFW4cY5OTXM4eOvUyiUJrUbOndRUj4rXZSqaiUUrCIUrKKhroO1bdtLHpB0kmQ6xtT0CNMzY8QSU8QTM6TScbK5NLlchqJWQNe1cmqIgCRKiKKIKElIkoKqqFhUG1arHYtqx2q14bC7cTm95b8+3E5fKUyrWrGqNiwWGxaLHYvFtmqpYKtNLpelUMyz2K6iDrubzvYd13dQtwD9g2eIhGqwWEqNi7LZNNOzY1RXLuzUuJhYfIpCIUcoWHV1kQRMes+dJBSoZGp2jFYTfN4Qw2N9gIDVYsPnDTM23k9v/0k2rbt70eMXBKF8ftoI+Et53YZhkC9kyeUy5Aule2ChkCOfz5JKx8t/E6QzcdKZBJlsinwuQ75YXq+Qp1DIoWlFdEObiwAbho5hmAgCiKKMXL6mJElGlhVsVkfJ6La7sducOB1u3C4/fl8Ej8tfvuZsc+tZ1MvlSi9FS89gGjp6LoHqr0MQJfRsDC09g+qpQFTtiIoVyeomN9U7943r+TTF1CSipCI7gyCI5Ce7KSbGkR0BLKFGJNWOns9QTJaWSVYXIKBlptFSUxQTY6j+ukX/FstBlhXaWlYnNdnQcuTGz6AGGpAsrsvOSdM0wTTmJEuNYh4jnyo1UC0bWqIoEY1UEikLkAiCgMftpbqqdm4/TocLFph+tLWsBaC1uWPe8vPPHEEQFhQMOR9FfzeQRIn62iaCgTBbNu5gYLCPoycP03eum6GRfqamJ8nmMmRzOUzTQJZlrBYbTqcLnzdANFxBbXUDzQ1rqKttIBKqIBQIY7VeH5lvUVax+irgOmaMqYqFNU0byO/5OPlCjnMDp6/fwW5Sgv4KnvrQr9HatOmyLJeFEFUbqjuEMNaNpFqxuENcWpXtqulAsjpIDhwnGTtJbmSE5OBJgp333lyGxWqSz2eZnB5B1zV83jBu17uT67hiTJNMNkVXz2E627eTzaY4dKzU1dnt8tM/eIb62jamZ8ZIJmOMTw5SWdHA2tZtGIZOb//Jcu5fyfLvGzyNqlo5dOzvefyRX8RmdZIvZDl5Zj8b1u7CME1S6TgTk0P4vGGKxTyFYp7u3qOMTw4CAn5vmMb6tRw98Qa6oTMydg7btUJpl1AsFpiYGiqF/PIFZmMzdPedwWq1UVfdwMbOLex96xW+9+NvUMjn2bl9N5hw6Og7ZTnASXRDJxaf5dW9LzIweI7vPfN1HnngQ9jtToL+MD9+/vskknHuufNB+vp7ePGVn9A/2Mfet15h0/qt1NY08PbBN5AlmfraRgzD4MzZkxw88jaqYuHh+x571/OdZVnB4w7gcQcwTRPDNCjkc+SLOYrFPMViAV0voukahq5jmMZcKhuAgFCK5pVDraIoIopS2eCQkCQJWVKQZQVZVlHK/96IdKbzjE8M8taB55e0zUxsnFRq5YVr1xvTNBka6aa77zhul4+aymYmpkcYGe2lvqYNUZKYnZ0glpimtmYNDbXtHDzyMulMktrqNVRE6tl/+EUUSZ2bkJ3segdJlKmvbZ3nuZ2aGWVwuJt4YppwsIqqikb6h7oYHe+nqX4tToeH19/6EdFwLY11a6mqbOTAkZdxONxUVTSSTM1y4OgrWBQrdTWtTM+ME4tPIcsyNdUtDAx1MTzaR8earVRFGxid6Gd4tI/qyiYaatuxWksPj5rKZl549VsMj/aytm07sqLicvrQimfQ9CJne46QSsdx2N2kV6H4UBRFbFYHNut8uUvTNNH0Us64rhfRtCKaXkQvXzu6Ubp+SgaEUUoxwixPSMvJB6YJQum6EgRxTnhCEEUkUUaSZeTzxoYkoygqqmJFlpeXAhA7/iMUb3Xp4e2vQU/HSPa8huqrJTF2Enf7w4iyimRzz0mgm6aJno2jJSfRUpMo3mqs4Ra09DRaZhZRtYNhoOfTpHrfQHb4yQwcxN32ABg6iTMvYg01kZ/tx1H/7hnfpllK6TKKOUxdQ3EEMIo59EIayeJEVKxo2ThGPoWoOhAkGUG2gKGDICKIMnouiVnIgsVZ6meVGEWyuhEtTvTMLJnRE9gibcjOIKaWQy9mSt8doOfTmFoO0eICTIxiFgwd0eJElC1XH/xVuPh3v1nEJZwOV7mOpJnNG7aTSqfIZjMUCnk0Q8fQdUxMRKH0vJBlGVVVsVps2G12HA4XVst7RyzDotrobNuBrus8+8KXl60UdSsS8Ef56Id+tXRvXuR9SpRkbMEaZJsLQRBR7JcrPQ699lXSY904q9oJrL0HizuEICvI1qXNDeEWMiyGx/r4+nf/FFGUuO/uj7Jt0/I7Pb+bSJJMJFzDO0deAkoRBcM0qIjU4Xb5GBrpJZtN4Xb7qYjUkUzFyOcz5As5/L4IpmnMKwyuCNfS1NDJ0Egv45ND1Ne0URmt59V9Pygdr5xX7/dFqIzUEwnVEEtMcbb3KNOzY+i6TjRcAwIYpkFDbTtFrYBliZX/M7EJvvzN/0mxWGBN01Z8Xj9NDS00NazB7XLjdnnZc+cDJFMJBEHA7wtiUVW2bbqDXD7LQ+KjhIIRBEFg5/a7aWvtxO3y4HC4kCWZLRt3UFNVNxfNqK6s4ZMf+QxFrYDPGyjJAVbU8OmP/zKKXApTC4LAw/d/iHQqiSCKBIPh1fshl4EgCEiChM3mwGZbmUb4zczk9AjPvfz1JW2jG9qqKAVpuRTFTAJJtaHYXKuuIBdPlNLboqEaqiqbSrn0okgmm2RwpBvTMHC7/bS2bOLoiTcoFLIUiwXWdezEbnNy9MRetGIRVbbw5oGfsrZ1O/H4FHfv/BDWSybSyWSMXC5DXXUro+PnsFrsREI1ZLMp+gfPsK5jJxaLjab6TiKhamRJoSJax7mB02hagWMn30TXNHRR5423nyUUrCIcrEbTiwwN9+B0eAgFKqmraS3p2k8NY7c5qYjUoagXJmIWiw27zcn45CABX4REYoYjJ/YyOHyWnnPHSSRnGRrtwe304b5EplHPZyhmYoiyBdnuXnLH1osRBAFFVlBWpbD03UHPp3BH1iBZPSBIZMZOkp8ZwCjmKKYmsSUnsfgu9XgL5W2T5GcHEVUHomxBspU85xZ/HaJqJzt2kvz0ObT0NPmZAayxNoxcAtVTiSXYRHbscs+tXsxRTM0iSDKK3YMor17qi6lr5Cf7KMSHsEba0LIx8tPn0HNxJKsHxRlCS09TTJYiKUYxi+KKoucSSBYniitSrgcxwQS9kEbPJUn178e3/gn0YoZifBRbqKX0WQoZCrODyHY/RjZGYXYIo5BFsntL72djGPkUlmATlsCVm7Odj4QAq9LA7d1EkRX8viB+361dl2YaBmCWDMxlGjtWq50NnXditdp49oWv0NVz+F1JO76R1FQ18+Sjv0J761bUJaoqSooVyXtl9S9H5RqK6dlSTfRoF45oM67qdgg3LHmct4RhoWlFJiaH6O47jt8bJpe7XMb2ZkUQBFTFUvJEl1EkBZfTh8ViR5IkdEPHotpw2j0UiwXyhSymacw1qbv41JElZV7BrSBQrosQ5o4nSwqKoqKoFlTVgmkaeNwBGus7qapoQJEVxieHSKUTWC02VFld0gmq6zrTM2Oc7TmK0+GmtipNOFhBJFxBTdWFfD+f1z+nonF+WTgUxTTNeZK1oWCEUDAy7xhOhxOno3luW7vdcVlnVEmSqIjMf0gH/SECvsC87+M215fzUcRH7n+aSGhxKY/DIz18/yd/s6LjGnqR0Te/w9BrXybYeT81ez6N1b+6aQr5fA7DMPB6g7hdPoZHexkY6kISS43giloBl9NHOFhNvpArFTg73KWmgoLAbGwCrzeMzxMqpSCJIg6nZ8G6EsPUUWQFnzfEyFgfvf0nsducyLJKUSsiihKqYsXl8mG1OkrXha2U920YBrHEFD5vGK87WIomZOKEAhUkUrPMxibxqkHsNme5ANtkbdsOznQforvvGK3Nm3A5vUDpmtmx5QGKWhGH3YVhGOza9gG0Tfdjt7uoqWymvXULimyZl2pn6hqTx16k79k/w9u8g7r7fwn7Mh5KtzKCrCJZXUhWZym90TSxV23AXr0B0zDK6Uvz0dLT5Kf7UVxRME0EWSnXIKoIooIgW0oTYMPAEmzEVtGBW1SQrE7SAwcRJAVRsf3/7f13lGTned+Jf26onDvnNN09M92Tc0AY5EQAJEiCpMQgiVay5LXX9lpr/7xe27s+XluyjkzaMiVREklRDABBgEROM4PB5Jynp3PO1aFy3brh98etrumezj0BA6o+5+BguurWe/O97/O+z/P9wk2dZEPXmGg9RfPP/l885Q1UPfZ7uEtX376dTXfiLJ5CLN4iUqEBlPFu8xjYPCCKaIkQeiqBKNvR4pMYuoqRimNIVm5Og1Qm+khNDpAKDQECks2LZHObqWGYsvOCIIGhoyejoOtY/aVoiUm0+CSyKwfD6gRDw9C1eYOGSN91rv7wXyFZHWz+g79Bsv3qDvrci8RGuml740+J9jfT8NX/jKd8vSk6sALsNgcN9dtxOjy8/cEPuXT1+CdWl3WnWVu/jeee/E1WVTUiL7PPthRy6nfjKqgmOtBMdLCNyfYzDJ19g42/91fYLMtTdvxUBBbReJjuvhb0WzTRu9sYhs5IcIDDJ96ku6+Zj4+/warqdaSzXWYgMLMTHItHuHr9NNfbzhOOTCBbrGi6Sk9/K2OTw4wGByjML2N8YoTDJ96ib6Cdg0deY9vmh7BZ7Vitdj468hqhUJB1a3cR8Odz6epRWtrOU1+7meqKtXR0X2P/xz8nHBln3dqlF74rSoKO7qtouqnkkpebzwN7H0GeQ0Fgrr+XckPcyk1zq5rZWZaP2+WlprJhyYGFRbbccvGjMjlMuPcKseFOlPAo+h1QFvL78ujua+HIyXcoKzbFDUaCA2haCkmyIEvpmhjBHDqorljL4RNvMjTSR0VpLY1rdnD45NvE88NUlNYjpOto5qNvsIPO3uv4ffm4XT6GhnvQDT0zwFCQX8bRk2+zunYzAV8+Zy4cpKevhcqyelbXbuHE2fcpyi8n4MtHEIR0ob4AGLidPjq7mjh57kPKimsYHumlf6iTgryyWc/W6epPoijNMJAyDAOnY3ZOvBIZI9x9mdhwJ86C6hU5tv5qIeAsWcfYhddQo2OIVgfe+odJBjsJtx1Bmewn0n0am78MLRkiOdKCrik4ikzTOtkVID5wmeR4F966fdgL6kiMthFuOwIY+BuewlG8lrEzP0UJDaLFxmasXY2HCXVdIjbcgdWTe0dMXgVRBMmOKFmQbF5kVy5qNIhgsSHKNnQ1gaGrptylw0di6DqpyQFcFVtRo2MoY93oiRDumr2ooSEMNWHWVQgCgiChp+LEB5uwF65GDQ2RHGlFtNiQPYUYWpJ4/yWs/lJEq9Osu5h2vc/HeMsJogMtN4K/LHeVSF+TqRw10omWjLPUOrv5sFis1FQ28JXP/zNKin7B4eNvMBkeW/yHnxJsNgf373qWfXs/S1FB+SxV0NtF94d/TaT/Oo68cpyFNVQ88k2svgKsruWXHXw6AovoJF09n8YcOlPr/KlHfp3HHnwRq8WGLFvICxRnpF2LCyoQRcnsPIgShQXlYBiIkozPk8Pa+q3mSKXVTlF+BQ11W9F0DUEQcTrcOOwuHtv3Ig/d9zmsFhsWiw1BENi87j7W1m3BajXzhRvX7KC2aj0GBjabA4ts5cHdz2XSrKxWO5YlTpMnlRit7Zcyf0uihPNXONXndqHrOolEgqSSIOC/O06fd4PcnCK2bHgQrydnybUet0PmNj7WR2yk65baWAyr1c6mdXtpWL0dSTJrXdbUbSYjz4yQ1jWXefrRr2Gx2nj+yW+iGxpWix1RlHjhGTPYsqbvzeLC+Qtsy4prqCxfg9vtQxKl9P1prstqsbF1wwMoShKr1Wz70Qe+iKZrWK02REGkpKgKAbPWxzAMs+bHl0t5ySokSSYvp9hMMbJYycstZnXd5vQM59Jz0ud7qSmhkYxk4T9U8rZ9BcFyI2CWnAFyt37ZlIKVLAiyFWugjMCmF8wOtGRFECW8tQ9mOuBmYbKA7MrD1/gk6Dqi1QGChL/xKQw1BaJkfgbk7vg6ZlqJgCjfWHcqNkG498od21dBtmLLW5WpAZUcXlyVO9L7KpMYacPiLsDqK0VLhrD6y7EGKsHQzZQsQSSw4Xlzdka24q7ZjWFoeNL9TNHmxL/uGczZCgv2wtXY8mpAsiAIojlDoWvT0u2mXZcLBO/jzceyAcUnSLj3Kqnoyg3u5mLq2fbsE7/Bqup1vPHe9+nsvvapN7AtL6nl6ce+xvq1u3A43He0lrL8oW9gaKo5MyjKpjLrCoOYez6wMAyDcOTTGVhMOVY7pJtTeOQ5/w0w/XEoWaWZ8q+SGZ1PV6oQBGlW0SOQ1l22ZZazyFZk141c5Sl1lqn2l3rxGIZBPBGjrfPykpbPYmIYBoahE4mGiEQj+H2BGfmgU8d/+rm9+fubFUpu9i+Z+/s745Q+nZKiaorSTsNLJRAo4Otf+lfkBlbm+GoYBolgL/HhOxtYmJ1wG3I66BYEYca/pzNV/OxwuGYc+6n7c2r5+Y6Ty+FFQMTt8mGzOuZcl1mYeeMzSZqp1nHzugBEJEh3vux2KfP9dNnhW70+DMMgOTlMdKD5ltr5tCNOM5Myj6mQ+UwwPwRBRrLedA1Y7Oas9dQy6f+LlpntCRYHRjp4mFo20/5N3kap6ATh7jsYWAgCTLuWhamgKH2tWQNlJMe60JUottxqJLt35m8BYVptnyDbbnrmiSBPez9Jlpmyu4KIIC3v2tWSUUJdFzNpXFnuLnoqQXSgGTW+Mg+OhZjq02xo2EN1RQPHz7zH/o9fIRgcQP9UBZICAX8+e7Y/yX27niE/t+SOzVLMWKsgMHDmdYbOvoUaC+Epb6Tqsd/FWTB/vdJ83FOBhdn5MpV0jLTpSCIRpaP7KtFYKLOMklKIL1JnYbXYFjwZhmFkcqTBHHWf3ok3DANdTyuP6PqNB5EgIKZfylPtL+WETz0wp9o0dP3GQ1Qgo+awlDbn+i5z7KYUUgx9xkN6arun1FCm2llU/zgj3Wiej1QqSVvnZcKRCXO9GKTU1KLnwyJbkST5thwrQRAzKkkr7TSbx0pH09UZ7U91uCRJyqjI3C5GRod5+8NfsqauEZfLzZHjBxkc7sft8rB31z5GR4c5efYIJUXlbN6wnebWa7R2XKe8rIotG7Zz+PhBhob72b3jfmqq6nntzZcYGR3ihWe/jN8b4Hs/+gtyc/J4+MEnUVMp3vnwdTNNbc8jlJfeORlKU7lq/pGUqaDKMG5ccxbZSv2qTStboWGgJWPERrpRIsGVtbFMlqsUsxJlmcKCG2lkmY7XHL9d7rPhVrdrUQwDPZUgPtpDcnL49rT5K8StpH4u5fzPWsYwMNQU8dFeEuP9S9/Q28H0gNbqwlHUwJQ090qOw61c6zdjGAYTbWfQlNiyfpfl9mAYBpH+FvMZcQcDO0kyUzcf3/cldm19jI+Pvc7Hx99gIjSKqk5Ju99bCIKAJMp4vQG2bnyIB/c8T1FBxYpNi1dC39GX0RIRVn/x/8bqzmH8+jG63vsOtS/8a6zu5WVY3DOBxVTn43rrefoG2untb6NvoJ2BwS6i06Lb4PggP3z5T/jhy3+yYHv/22//Fzau22sWe82Bqqb4+Pjr/N1Lf4IoSqxbu4t/9rt/DJgd2onJUa41n+HspUN09zYTCo0hShIet5+8nBJqq9exoXEPlWX1i5rKGYaBqqaYCI1y5dpJrlw/SU9fC6HIBKqawuXyUpRfztq6raxv2E1JURUWi23Raa+pznBKVUgm4wyP9HK56SSd3dcYGOokFB5HSSWxyBZcTi95uSXUVDayvmEXFWV12O2uBfO9DcOgo+sqPX2t9PS30jvQRv9AJ5HoRGaZUHicV974Dq+88Z0Ft/UbX/4j7t/1mUVHtU2JyRTh8ARXmk5yuekE3b3XCYUnSKkKTqeHwrxS1tRuYX3DbspKVqXTQpboepsOwKKxEFeun+LchY/o6L6W3ieBnEAhNVWNbN3wILXV63E4XBnJ11tBEAQC/hw2Nm5hYKif0uJydEPn0QefYnh0iA8OvkVleQ1PPPws9bVriURCHD5+gAf2PMyGxi28d+ANdF1jQ+MWPjz4DtVfr+WJhz/DpavnOXzsIPvufwyrzcbTj38WSZJ478CblJdVous6R08e4kuf+9otbf9K0HUzEB2fHGV4tJdEIobXk0Nhfilul39JUnlTszKGppmFn5qKoatE+lsI91y9sa5UklR0AsU+v4usaLEh2VwLrtPQNTQljp5KmnnhVgdS+v42DAND19BVBUNNYRhaWs40LWMqyYiyNTOqutQg2tA1DFVB11KmWoqhm+khgjijzZUG0IaWMtvW1Bvtmxt4Yx2SBUG2LFqfNPXMmToPhq5haCrx0W4mO85lltNVxTwf4fkDP1G2mudj2r07pdiTSt+PosWGbHeZA02ppJmzbxim+63Fbh6bqRk6XUNTEulagqllbOlllv58wNDRVQVdTZlmrlOStYJotilbl3SsptrTEhFzmwQByeq8cT3pOrqmmOde10BPD26IgpmKsIT1ZM6Hrs64R5KTw4w3H8ssp6spUrHJBc+HIFuQba5F1ZTMY6Mseq3euF5nX7e6pqIlIubxBRAELE4fi6kETV3PWjKaVhYCQbIg2ZwzTHUz99W046JrKUavHLhR+2PoKOEx9NT8tSdLeWZoSgJNiZspXhYbks2JIIgZ2WM9lTTPc+Zamn7fWRFkeUn3nXmvpcxaMl3F0NMy5VPtpZ3cRdm64mLozLq0VPr6n+eZkVmXZc7rZepaMTQVPf2MMPQUE22nZgw+pOIhlHBw3mtOECXkOaRRF2Pq+vP78nj2yd/k0Qe/yLnLhzl64i26epszvjef5EzGlNCO1WqjqLCSHZsfYfOGBzLpqneb5OQQeY37cJesRhAECrc/y/CFd2/co8vgngksAJJKgv/67T+86+vVdY1YPJwZIb/eco433vs+zW0XmFFYpJp+GqPBAZpaztA30MGLn/0Digoq5m3bTOUa5/SFg7y7/8cMj/TOWmZiYoSJiRGaWs7y4cevsHfH09y/+1kK8koW7YgnkjEOHX2dIyffoqdv7vxmTVNJJOMEx4e43nqODz56iU3r7+fJh79CRfnqeU3UDEPnW3/1R4TuUiGUkfb8OHfpEG++/3cMDs1Oc5mcTDI5OUpz2wX2H36VnVsfY9/ez1JcuLRUHMPQ6epp5uVf/k+uNZ+Z9X3fQDt9A+2cPPsBm9ffz1OP/DqSJGO12G5JjcwwzJmdWDyGkkygpBSsVhter5+x8SC6riMKAqqmEo1FUDXNdHe1TXVCzFk1BIHPPPl5Tp8/Qf9gL2XF5RiGTllxOY888CQvv/b3rG/YhGCYRcKlReWUFt99c0pd1xkJ9nHg41c5ee5DEokogiCYCkveXB5/+Mts3/wILqd30YdoKjLO2PWjRAZaiA62EBtoJTE+MKMYdfj8Owyff2fBdkr2vEjdC/8GeQGzn8T4AB1vfZuBk69iCxRT/fjvU3rflzF0HTVhFsOOXvqAifYzxIN96KqCbPdg9ebiKV2Lv3YHhZueQFqCL4yuqaixCcJ91wle+YjJznMkgn2oiQiiZMHqzcNduobctffjr92GzV88oyM9H1OdEC0ZRQkHCXddYrztFJH+ZhJjfajxMIahI1kd2Lz5uApX4a/bSaB+F47cUkTLwjKGaiLC2LWPiQy2Eh1oITbYSny0F11NZpYZazrCWNORBbezcOuz1H3uj7D5ZspCJ8b6OPofHkW0OijZ9QL1n/+3xEa76T/6MsPn3kaNh3EW1lC07VkKNj+F1ZOLoaUIdV+m/+hLjDUdQU1GceSWU7T9OQq3PoPNW7BoZ8vQNVKxENHBVoJXDjLRfpb4aA9qIowgiFg9ebhL6shZcx+Buh3YcxY/VrqS4OoP/zUjF9/D4vJT/cQfULbv6+ipJPHRboJXP2Ks6SjR4XZS0QkEwOLOwVVcR17jgwTqd+PIKUVY4LzrqkLwykdEBlsy5yM2YkrcThHqusD5P/+tBfc/b/0j1D7/r3AVzlbyMgwDNR4iOtjG6KUPmWg9RXysDzUeQpAs2Lz5eMoayG14AH/dDmyePMQF6nbiI11c+9G/YbLzAhg6stPPpt/7S7yVG2bMeszaDk1l5NJ+Wl/9/0iM9yOIEnnrHqb6qX+Cp2zNtOVSTLafI9RziehAK9HBFqKD7WjJG89wNR7m2H98bMFjUrzr86z50n9AWKD+sP/4y3S++x2U0Agle79M7XP/AovTh55KEBvpYvDU64w3Hyc+2oWmxJDsHmy+fNxFdeSs3UvO6r2mqdxc+6vraKk4ajxMtL+Z8ZaThHtMwYpUbNx0Zrc6sLgCuIpW4a/ZQm7jPhy55ekAZ+kdVMMw0JU4SjjIeOtJJtpOE+65ghIeRY2FMAwDyebE5ivEmV+Bp2Id/ppteMobkG8e0NE1ooNtTLSdNq/LwVaig22kIuM3ghTg0ncX7u85C6rZ8UevIS1TDv9mHA43e7Y/yZ7tT9Ld08zFa0e5ev00A0PdpFIJUinTI+dOCgQJgogsy8iyFZvVTsBfwOraTaxfu5tVVY3YbHfGtHCpSDY3yYkhkhODiLIVJRxMP9+WH6TeU4GFKAgUFVTMSOExDJ1YPEIkbcQkiRIul2/OuoLpmE7US7+pVFVhYnKUrt5mfvbLP2dgqCuTHiXJFgQE01MipZBKJdENnZrKhoxE41wYhsHE5Cjv7P8R7x/8qTnShoDFasNucyBJFgRMN+6kEkdREoTCY7yz/0cExwZ4+vGvU1ayasFZhcHhbn7+xnfSLsbmxWu12sxC8XSR25QXRiIZQ1VTpFSFU+c+JJGM8rmnf5vKijXzujcW5JXOONYGBolElFDYLL4SRTHtXLtwR8rpcC/6kIvFwrx74Me88d73M9eAxWLDbnOao9uApmskk6Y7byQ6YeZQjg3wmce/QVXFmgWDC8Mw6Olr5Tvf+3cMj04FeKaTsM3mQEoX0atqikQyxokz7xOLhykurFpyYft8qJpKb383F6+cRdNUcnPz8aQ9OxwOB3Wr1mCRrXx05EOqK2tYXduA2+3Fmn4579i2hzfffZW+/m4cNgcet5dUSiE4Porfl0NPXxcXr5zF5/VRkF9EYUERh44eQBRF8vMLF9m6289kKMh7B37KhStHqK/ZQFXFWmw2B+HwONdazvDqW9/FItvYvuWRhdWhdI1Q1yWufP9f3L2NT6MlY6Tikxi6Rmy0m95DP2To1C9JxSZnLJeKBElFgkT7mxk+/y7+mi04HW7me/4YhoGuKoS7L9N76IeMXj4wKz1DTyVQE2Fiwx0Mn3sbd+laKh/9R+SuvR/Z6V14FFvXiA400/PRDwleOTDvKLWqKqixSaKDrQxfeBd7bjmVj/wWBZufxuLyz32/Ggbx4U4u/+0/W/DYLY2F0yEMNUVsuJt4sJeOt77N0Jk3Mt+FOs8TG2pDCQcp3/cNIr1XaXvzvxPqPJ9ZJtJ3jda+ayQnBqh6/PexuHPmTyPVVCIDzfQe+nuGz709owM6RTwZJT7axcjFD3AV1VK+7+vkrX8UqztnSSPEuqoQC3ajxkOMXPiArg/+ithw+6zltLE+EmN9BK8cxF3WQNXjv0duwwNI6bqbm0mFx7j013duQM7QdeJjvXR/+NcMHH9ltrpUKkksETGv1Qvv4q3YQPm+r5vbPM9ov6toFeUPfp1k6E9JBHtRYxO0/vKPWfeb/x2rJ3fu86TrRPqvM3Ds5XSKl4CrqJbiHZ/Fc5OMrhIZp/3tbzPRdnrhnRMylS3zfL28keNUeBRD01ATEYbOvEnr6/8NddoMP4AaHUeNjhPtbyYy0Izs8M0bWCiRIEOn36D/+M+IDXWYBf43oSUiaIkIiWAPwSsH6T7wPcof/Dql9315ySkshq6RDI2Y6zr6ErHR7hkBQGbbY5PmM2OgmZGLH2D1FVDz9D+ldM8XZy6XjNJ/8lV6DnzvphXddM8vcvxNn5PbO3pfUV5PRXk9Tz/2dcbGh2luPUdnz3X6BzsZGx80TQdVBU3X0DQVTdNupExPGXDOtanp2RxJlBAlyTTglGTTrNBix+P2U1JUTUVZHXU1GykprkK+BZ+f203h5ifpPvA9Ri8fQLLaSU4OU3r/ryEv0zwZ7qHAQhAErFYH/9e/+O6Mz2PxCIePv8kv3vlrAPy+fJ585NfYs/3JBduz2RzLqqBXlASXr53g4+NvMDLaT25OEcWFVVSWryYvpwiLbCWWiDI03ENvfyvhyARVFWtwzJN6YRY5R3n/4E9578BPALNosyCvlPpVm6iv3UiOvxBRFJmYHKW1/RJXm88wPNpDKqVw8tyH2B1uPvPY18jLLZk317asZBWNa3Zyrfk0Hrcfvz+f6oq1lBZXkxMowma1o6SSDA51c+X6KVrbL2TqIy5fO0lNZSP5eWW4Xd5Z7YuixD///T+dcSOlUklOnP2QH//8zwBwu3w8+sCLPPLA5xc8vlMqNvORUhX2H/45r7/7fcBAFCXyc4upW7WRNbWbyc0pRhQlQuEx2jouc7X5NIND3SipBOcvH8Zud/Lsk79JcUHlvC+DSHSSv3v5Txge7cvsX1FBBevX7qK+diNup4+kkmBwpJtrzWdo67jE1aZTtHdeRbtFKVOLbGFNXSNr6hpnfZeXe0Mj+v7d+yCtAlRdWZv5PODL4asvfhNNUzO1Jbu335+uBTELu6sra5kSDABoXLMBXTcyf99NWjsu0tnTxKMPfpGH9n5uxmjMww98nu//5L9w9NQ7rKnfii1ngQJuQUB2uPGUNcz4WEslSE4OoyUiAMhOHzZv/oIGYPZAybJGX3QlgRoLERvpouv9v2TwzBuga8gOL6LVjijK5otGVVCTMXQlgbdifboDO/969FSSseZjdLz1bcI9pgiCaLEjO71IFjuCKJnBRyqBGptEUxJE+q5x/aV/T9WT/5iSnZ9fMD1ATyWZbD/H4KnXMDQ1XQRsR7a5zO2WZEDA0FXURBQ1HsLQVBLBHlp/8ScIkoXCrZ+Ze2ZHAMnqmHU+dFUhOTmcKcqU7G5svkKkBUatHbllCxoaGrpKfLSTkYsfMHppP/acUgRRQo2HSEUnUONhRi59gMXlI9R5kUj/dXNWx2JDjYdQY2ZQ2Hf0ZfI3PIq/ZtuMYuPMejSVyc7ztP3yvzHZcdY8H7IV2ekzO/NT50NNosZCaEqM6GArLa/9F5ITQ5Te9xWs3vzF69VUhehACyMX3qfltf+CGg8j2V3m9SSbimG6ljK3PREBXTcDptf/FMnmJKd+t+lxcROibMFT3jij06ZrKkpoOJ1SBpLVic1fuODIryOvHNFy0/1jGMSG2ml66d8z0XoKMBAtdizuwI1jo+umAWBsEi0RYbLjLMnQMEpknOIdz88ezU5TsPkpQr1X6Tv8E7REmInWU/Qd/jFVj/0Owk3XjWEYKJEgw+feIZieCbN6cija/hw5a++bNcshyhbcJfWzOrKxkQ6UUJCpVDlv5QYEcf5r0JFfteAMys0okTG0ZJTBM7+k7fU/RU8p5nVkcyKm16NrCloyjpaMYfMXzphpmdXe5DAjFz8gOtAKGIhWB7LdhZSW1xVE0ZzVUGKkImNmSmhkjO4Df4uuKVQ//vsLzhyBGbBFB9vofP87jF7aj5Y0BzkESUayuZFsDnPbBfO60lMJtEQMXVWwefPwr9o6q01BlHDkluGvmfldcnKQxPggRtprwl1cn+64zn2M7TnFt5TWtRCiIJKXU0TejqfYs+MpUxAkEWVwpIeRYD+ToTHC4TFC4THCkQniiSiplJL2DdIy/SJRNIMJWbZitdpwu3x4PQG87hy83hzycoopLqjA58v7RFKcloqraBV1n/s/iQ13oClxnAVVWN25Kzr+90xgAWZH2emcHR1Zpj3sBEHAZrXPudytMDE5yoEjrzIw2El97SYevv/zrFuzY87pqUQyxtBIL7mBwnmDF8MwaGo5w/sfvQyYQcWqqkaef+ofsbZ+y6yOx7ZND9HcdoE33vs+TS3mqPaJ0+9RXbGG3duemHeaTBJlHnvoRfJzi9m84UFqKhuwWmc/SBpXb2f75ofY//HP+fDQz4hEJzEMnaaWs2xo3IPb1TBH6+YU4nQUxTqjfQEBq8V6y+ejreMy73z4I8BAFEQqyur43NO/w/qGnbOO1ZYND9LRfY033vs+l68dR1VTnL14iIrSegL35c85m2UYBoeO/ZLunmZMJSWB8tJafu3z/zv1qzbOWHY9u9i19XGOnnybdw/8hPGJu1eQulgtx/QZGVmersgizPjb/EzkE4gpABibGMFhd1GdnqmYjtvlo3HNDt7Z/yMUJTFPCyaCKOFftY0df/TajM9DPVdof/PPCF75CIC8xn1UP/WHOPNvX5G6riaJjXTRd+SnDF94F4vTi7tkNd7KDTgLarC4fJl89nBfE9H+6+RteATJMv8MjK6phLov0fG2GVQIooTNX0SgdjuB1XtwFlQj293oqSSx0W7Grx9h7PoxEmP9qPEwne/8OXZfIfkbHpvV+ZpCtjnx127HW76OxOQwdn8R7pJ6PBXrcORVZEbYU9FJQj1XCF7ez2TnBbRkFC0ZpffQD/FXb0EqWjVHMa2Iq7h21vmIDnfQ/uZ/Z/jsWwAEarez6tl/YXbuboHE+AB9R35CbuODlOx+EdnhIXjlAL1HfkoqPEpsqIPeQz8EBHLX3Efxjs9izy1jvPk4PR/9gMRYH7oSZ6zpGJ6yxlmjb4auER1qo+31PzWDCkHE5s3Hv2orOWv24iyqxeLwoKspEmN9jDcfZ6zpCLHRbrRElO6D38Pqzado+3PzdqAz69JUJjsvEB/tQVfiuEvqCdTvJlC7A3tuKYIko4RGmGg9xeil/UQHW9FVhfhIJ4MnX8NVWIMjt+ym8yFg9eax41+9OvO4TQzR/ta3GDhmvn885Q3Ufe5f461cv6zjnwyN0vzz/5QZ+bf5i8hZs5e89Q/jLqpFsrkyKT/Bax8zevkA8dEeEsFe+o78GJs3l7z1j8zpwC6IIpUP/xbRgRbGmg5jaCo9B/4W/6pt5NTvmtGh11MJxq8fo//4z8xaBquDvPUPU7jlmTmDJas7h9Vf/HezPr/243/LwIlXMbQUkt3Npn/8XeQ5TAtXihIaZeTyATrf/nNEyYq3Yj05q/fgLlmNxeUHA5KhYSL9zUT6ruEpb8Q+y4n9Bu7SNfhrt6JEgsg2F+6yNXgrN+IqqsXqzUe2OVATMSID1xk++w7Ba4cyswoj598jb+2D+Go2L7jNifF+Ot//C0YuvG/WliFg8xfiLl2Dr2Yz7qK6TP1LKjZBfKSLUM9VEsEevFWbcM1hginb3ZQ/8FXKH/jqjM+7D3yPrg++ixIy36n1n///4a/dfk84oAuCgMPhprpiLdUVaxdcVtM0NC2VSW/6VfDO0lUFNT6JlK5dS0XGSUXGcRZWz3n/LsQ9FVh8ksTiEXr726hftZEXPvM7rKpaN++ydpuTyrKFX5jJZJy33v8hanraODdQxLNP/CYNq7fNubwoSqyu3cxkeIyx8SEGhrpIKnHOXjxEXc1GSotn37zm70TW1m1lbd3sUYOb8Xpy2LnlUfoG2jl9/gBgplKFw7dXU3q5KKkkb33ww4yylMcT4Pknv8mGxt1zLi+KIjWVDezb+zzBsQF6+lpRlAQXrx5jdd1maipnB0mxeJhjp94llS7cczo8PPfEb84KKqbwuP3s2v4Ek+ExPjj4UkY9LMsSuUn69mZEQUwXH97bjDcfR7RYsfkKKd3zIoXbnsXmnduFNDk5bBZkztPhNwwDJTTCwPFXCHdfBkHAkV9JxcO/RdHWzyDdNEPgKW8gf/0jDJ1+nc73v0NspAs1Hqbrg+/iKV+PI79i7uMrCNgCRVQ+9juoyRg59btm1TFM4V+1ldy199H2+p8SvHIQXVWI9DURHWw127/FFMBbxdA1ZIeHmmf+Ka7CGgCs7gCJiUEGjr+CoaWIj/bgW7WNiod/E/8q8/nqLKxhsusCyclhDC1FuPfqrBQewzBQE1H6j73MZPsZQMAeKKZ839cp2f3FWYGCp2wtuY0PMnrxQzre+19E+q6jJaL0fvwjvBXr8JSvW3R0T1fiJCeH8VVtpOrJPyBn9e6ZnZKiWgK1O/FWbqD9rW+b1wkGY02HKd37JXPW7Q5q2U/H0DX6Dv+IibYzYOhY3DlUPf57lO790qyOoCOvAl/NVjxlDXS88z+Jj3SZqYEX3sNdsgZnQdWc67B6cql+/PdIBHuJDrWhJqK0v/lnOAv+LJMeZGgqkb7r9H7896QiYwiihK9qI8U7Poc9p+ROH4ZlkZwcpuu974AgULL7i1Q++ttzpiMVbn4KLZVETyUWPJ+CKFG4+Wm8lRvxlK7F5i+cdeytHnO2KaduF+1v/w96Dn4PDAMlPErw+pEFAwstlWTw1C8YazqSDirAVVxH+b5vULD5CWT7bCNMMK8NJTKOoSaXNaPzq4IkSZ9IJsCdJNR9ibFrh1HCwRnKWbXP/UtEl39ZbX36w6zbiM+by65tTywYVCyVzp4m2rtM1RqLbKVu1QYaVm9f8DeCIFBfs5HK8tVMTQ22tF9gNNh/24qKCvLLKC2uyYx8R6ITJJKxefMG7wY9vS20dVzGMHREUaK2ej0bGvcs+BtBEKiuWEtt9QamjlVH91UGh7vRtNnHqqXtAuOTI2RmK0pq2dC4d8F1+Dw5rK7dREHB3S9+no/oYCvJ0GhGEWU5aKlE2un0zuP15pBKKXT1NBNNF/6BWdQ9NjFMS/tFcgIFmRqSexU1HkKULJQ/8DVK7/vKvEEFgM1XsGC+vaGpRPqvM3LxfQAsTh8Fm56iaNtzs4KKKUTZQuG2Z8lZe39mmXDvVSbaz2TSCebC4vCSv+FRirc/N29QMYWrsIaCjY9h89+oxYn0N6OlFp5NuhuIsg13yepMUAHmqLmnrOFGB0sQ8FdvwVV8Y7BHsthwF9dlgoPkxKCZFjYdQyc23MHgqV+av7E5yWvcR+neL887+yBKFvI2PEL++kewpN3JowPNy5IxtQeKKHvgq+Su2TvnSKcgiuSs2UvOmr1I6dnXVHSC+Gj3jAL5O01irJ/BM2+mi8AFCjY9Qel9X553dFm2Ocldex/5Gx/LGNRNtJ0h1H15wfeLr2YLZQ98FYvTDxiEui/Tc+B7aOn3UjI8ysDJ1zKqY/bcMoq2P4+veuGR+E8CPZVAiQQp3PYZap7+37DM51osCEhWuzmLsQju0jXkr38Ee07J/OpJgoBkd1O658VMIKMmosSGOxZsOzrYynjzCVIRU6DFFiim+qk/oGjbs1gc8wtrCKKEzZuHPWf+2ZYsny5GLn6I5PBQsudFyvf9RuY/aZF65rnIBhZpBEGgIK+UDQ1zj5Ivl/OXDmeiPpvdycbGvUuq+fD78sjPLcGaTv9KJGIMjfSQTN6el7wkybinFb9rmoaqpj7RwOLi1WOZGQFZktm6cd+SjpXHHaAgrzRT/DsluTuXelNLxyXUtKygKEhsaNwzK3VoLgrySikpqlrG3txZBk68Sqjr4uxO0hKIDXcS7ru6+IK3gYqyenJzijhx9gP2f/xzzl48xIXLRzh9fj9vvf93tHZcZtP6+3E5Z9f23EsIokSgfjd56x++ZWUSNR4meO0wajwMmPnbeeseysiPzocoW8hZvQerOzfzWfDaocwI4+3AVVw/oxOkRMYw5gjQ7zaS1T4jqADzeFhcgUxak2RzYc8pwXJTmpPFnZOpuUnFJmfp1+uqwujl/ajpYnybr4CCLU8tep5FyYJ/1TbsgRuj5eOtJzLndSEEyYK7dC156x5adB2ektUzgsLE+MBtPeeLMXJpP6m0T4woWynd+5VFUz4s7lw8ZQ1Y09dScmKQ2HAHurLwgEbxrhfI3/gYgiRjaCkGTr7K6JWDaMkowSsHGTz1C7N9p5+CTU+Yy94D6TNzYc8poWLfNxZVDLvdCIKA7PTiLDJr8wwtla4zmmcQyjCYbD9DdKhtqgUKtzyDf9X2RZ9JWX71kGxO3MV1uEtW4y6uzfy33DQoyKZCZbDIVgrySvH78m5Le21dNxxPLbKVikVSp6YQBAG324/d7sooPY0E+0kqcRyO5UeOcyHLlhm5+vrNZnp3mY7ua5niaFGUqFokv3EKQRBwubw4nW6S6RfX2PgQsUQE103F6P2DHZl1CKJAddXS1uH15JLjX3jEdy7MtJdRokNtZlGmmsKeU4KrsIZUdILoYBui1Y4ancDqzcNVVEsqOk5suAstGUV2+nAWVGNxeomP9hAP9gBCWq7PMHNdR7vxVW/GMAxCnedxFdUi2d0kxwcyI1UWVwBXSR3K5AgjFz/IFPg58irMYtg79OIrLqjg/l3P8NHRX3LkxFsoqaRZZK7reDwBtmx4gB2bH8m4Vd+rWFwBPOWN2PwrcwifjpqIMNluFgcjpPOYi2sX/lEaZ37VjFmNSO81U8/+NiHZ3QjSjbSnKV3+TxpBsmCdY5ZItFgRrQ6ITmBx+pCdvlkpGVPFxWDWy9xcyKurKcabj0+tCasnZ1ZR+nzYc0qRpwXF0YEW85gtguzw4KvevKQg1eLJRbLdeOarieiKNOVXgmEYTLSfRkvXQFn9BbiKahb5lflMtrgCWH35KOFRMAyS4wMokXEcC8g8SxY7VY/9LtGBZiY7zpOKhej64K/QlDg9H/0dWjKKaLERqN9J8c4XsDju3QGJ3DX3Y3HPrWx1pxEEcUaAraf9ZgRxdkqjlkoSG+5CSc9WWFw+AnU7sbrnmWXJ8itJuPca8WAvqfAYo5cPkJwYQnZ4M8/T3LX3LXtQLRtYpLFa7eQEbr3zAGa6x9Bwd+ZvRUlw/tLHWJaY9tHeeSVTmwFm/Ye6QNrD9PXGExEmJ4NEYpPEEzFTxUBV0HTVdM/WNZpbzy9aNHu30HWd4ZHeTKqXpqtcuHKYa81LGzHp6LpKaprBUTwRnXHsphgfHzYd1DFffvlLzM21251pKV2BxeQxbyY62Eb3h98lf+OjKKEgE62nqHzsd0iM99N/7GVTyQUzX9UeKGG89TSR/iZkhxc1NkmgbieesgaGL7yLlohi9eSRmBjE0DXiY330Hfkpnor1oGv0HX2J8od+A5u3gIETryLIFkSLDUdOKc7CapTIGImxPlKRcWJDHchO3x2dxhZFiTV1W8gJFNLafonhYB9qSsHhcFNeWktd9QYcS5Ag/qSx+gpw5JXd8nYahoGWjExLTRBQJocYOPnakn6fioVIxW4YhZrutUvrZOqqghIZQwkH0ypT8bRpV9oATtNQwkGU0Mi0Df7kgwpIG2TNkZYkCCJT5qeS1TFnwbwgihmxGUNTMabdv1OqW9GBtPePYB7jqbSoxVATYZTQaOZvJRxcMDVtCsnqwFW0aknruNl8zFCVu+YarClx4iNdmX0SgL6jLy2pSDU20jlj9kZNhNGXkCbmyCun6vHf59qP/y1KaIRI33Xa3/oWyfEBEERcRbWU7P7irBmsew1PecMMs77bhWEYqLEJkqFRUtFxtEQUXU2aZoWaZvqwxEPEg33TfzTvoKESHjWLqNPvXmdBNTZf/j07E3S76Oxuo62jBU1Tefzhz2Q+TyQTtHU009ffQ05OHts27VxSewODfbR1thAKT3Lfrn14Pb7Md6YZb5RzF09y/+6Hb/u+3A5iI51Mtp9DkCTUeJjJzvPm8zR9rwfqdmQDi5UiihL2BUZUlkNSiZOaNmUdjYX4yavfWnF7ipLIdIpvxjAMdF2jf7CTzp4mBoa6GBntYzIUJBKdJKkkUJQkmpYyNZl1DV3TZrxkP0kUJYEyLZc7lVL46avfXnF7qVRyVo2FrmsklURmnwWEWTMa8yGJElaLFUmSViQ5K0gyJXtezBivmfrrpryor2pTRqUlNtJNPNiDr2IDeeseov/kq0SH2hEkC4nxQYp3fg5P2Vomuy7ctIb0eUw7nSYnh4n0X6fx6388Y4TbW7me6GArSmiEsgd+fdn7sRIEQaQwv5zC/HunRmW5yHY3ssO3+IKLYeio8fANfwRDZ7LjPJMd51fUnJaMmbrqhjGvN4OaiBDpvUq49xqx4Q4SY31mcBEPm8GFqmCkHbl1Tb1ngonpCIIwv1xmercFyTKPbO3CwWBG1hXAMIgOtHD9pX+/ou3UknGzczfP+ZhClK1YPUudFRc+scA7FR2fMQMTH+2h+eX/uKK2tHQQuxRy1t5H6d4v0fneX2BoKTOoAGzefIp3fJZA/e1JVb6TWH2FmRqT24GhqUSHOwj3XiXaf91U3ZoYQo2H0JIx9FTCdMnWVHRdzQQKi6HGQqjT0oZt/iIk6709g3w7iEYjNLdd48DH780ILHRNY2x8lGOnDiGK4pIDi3giTldPO2++9ypr6xtnBBYAqppiZPTuKUsul7yGB8ipm39fV6Kalg0s0kzX/79Vksn4be22G4Yx21gm/XkiGePk2Q+5cPkIbZ2XZ7lki6KE1WLDIltNEzhJJpmME42F79ro10IklfhtTcMy5hihMQ1uZj5sl2N4J4oykrjCwCLTMRDMEYD0tklWB1ZP7rQlTfPEqelHAcEcbdLVtPGOaSQkSrLpSyBZzOJaY0qhYywdY+hmG1Mji5ljYRo8LtQZvZ1MTI4SHB8iJ1BAwDc7laWl/SKybKGseNUMOel7DVGSF/TGWCqGri0pB38ZLc57/xq6Rny0h8Ezb5gO2f3XM9r0AIIoI1kdpqeF3W12yg2D5OTwDLfmewNh0RHUG/fHMjAM1GkzQLfO/OdjBqJ4y7U6dwPtNqZdGYa+5HeNIMqU7P4CAydeJTHWN/UhzoIqCjY/iTiHj8e9hmSx3zZLNzUeJth0mOHz7zLZdppkaDQzACCIMrLDg2R1YnFZESQLIJAY78/4+yyElkrOUEqTba50G58OUqkUHV2tNLVcIZ6Ik59XyIbGzeTl5DMxOc7FK2cZDQ4jSRa2bd5FUUExkiTRuHYjTqeLg4ffn9Ge0+li+5bdRKJhTp87Ps9aZ1NTVYvL5eLIiYMzPjcMg5a2Jq5ev8T0bAdVU+nt6+bytQtYZAvhSIiS4jI2rduK0+kiEg1z7fplevq7EAWRxrUbqSqvwWK5M+dGsrmQbC5SsUlE2YZosZGKjJGYGDTlrVfQV8gGFncA+aaHn9PhYeumfStur6p8NfY5KvN1XTd9KT56Oa14BLJspaSwkpKiagKBfFwOL1arHYvFiiyZtRVXr5/i9PkDJJJLUzG5k8hpV/MprFYbO7c+vuL2ykpWzZqNECVplrO4pqkLunRPZyG3zcV+mYpOMHj6dZTwKBZXAHug2KyXEJhxw1q9edgDxYR7rpKcHCYx3o+vegvu4jom288xevUQkYEWlLQDvc2bjyjKDJx4BVG2mc8tUcTmzsWZV07/0Z8i2pzYfYUE6nchSBYsTh/hrksMHH8FX/UmXEVLy+9fCZ09TZw5f5AdWx6dM7C4ev0UExMjPP/0P7ptdU13hts4ajztGhIk08DLV7Nlxc3NpSRlGDqJsX463/uLdApdBNJeB56yBhx5ldi8eUgOT0avXJBklHCQ3kN/P6cT9CfKTffJAgstu+npnV1BlHAWVBNYvfIR8ZkDBXMjICxoyHavcPPzzlW4irz1D90YsFgGzoJqrJ751dRuWjOR/uZZRepqIkx0qAObr3Ce3907CIKwos7YzWipBMPn36H7wPeJDbVh6BqSzYWnvBF3cR02fyEWpx/R6kC02MzBJiVG9/6/zRhvLozOjPTeld1GnxjtXa3sP/Quoijg9+WYpnW6jqZrHD52gLGJIE6Hk4HBLoJjI3z+ua/g8/rv6jYawPjEGG+9/xovPPsVADRVpan5Mi+99nc89ejzRCIhuns7sNvsbFq/jQuXz3C95Soej4+R8WFGRod44pFnqSiruqPbGrxyCFdJPY68cgZO/QItFsLiyaV45wvIy1SGuvefcJ9CHHYXsiQzNRbgdLp59onfQFrh9KjFYsPpmJ1nfL3tHO8f/CmTIVO5w+sOsHfXM6yt20JBXhk+bw42m2NWXmw0FuL85cNw9wRG5sVuc84IxGTZyrOP/8aKZ48sFtssUz9JlNLKUWadhAFEY2GsS1C+MAwDNaUsqcZlFukOnWx3I8pWclbvRXZ4sPkKyVv30AyzLtnmwr9qG7LTixoPEcjbibt0LVZ3gPyNjxMbbkcQJUp2voCruA6rJ5fi3V9AjU4gWh2U7/sadl8hssNL0c4XiPY3gyCaBa7pEV1vxQYEUUJTkiSUFBYlOaeZ4u1gbGyI0bEB5qtLcdjdnO0+dE8Et3cDQRBnyPYJkoynfB3VT/4BM+t35qrlmfsz2Ta7RkVLRBk+9zZDZ02ZUEGy4K1YR9GO5/FWrMeeU2rKSN4UVEcH2xg688at7+gnxjIDf4GZZnmihLOwhuon/zDd1lznZOFzIy8gz/lpQ7Y5Z7w37LllVD3++yvKvxdEackj4YlgH53vfscs/DZ/DYZOdLCdviM/wZFTiiPv05tauRzCXZfoP/5zooOtYOjYAsWU7HzBNG4sqMbi8pvnaNo1p4RGGVxi3ZYo2xCnCzYk4ytSG/wkMAyD6y1XGJ8I8s2v/QGF+UXpOk2BiclxPj5+ALvNTkVZNZPhCa5ev8jTjz1/VwMLQRCoX7UGq8XCW++/NuM7TddwOz089ehzxOMx3njvVTq62qitWcPpcyfo7Gqjce1GQqEJevu72L5lNxVlVURjUXRdw+l0EQpN4nA4sVltjI0HGRkdJCcnn4K8QjRNY3wiSCQaoaigGLt98VnScO8VrL481HiIxFg/gbodDJ58jcLNT8G9EFioWgpN05Alecmjwr9KSJJMXm4x3b1mYaCu60iiRE7g9o62HDr6y0zqk9VqZ/eOJ3ny4a/g9cw25JmOpqkrSuu5E0iSTE5OEcGxQXTDLC4XReG2Hyu/L5/egXZzVMMwGB0bIOBffBQtqcSJJSIrnLEQkJ0+8tc/MuNTqyd31ujm6NgImqZTsOa+WZ2TKdm3m8ldM7cPh7u4DndxXebvidA40WiE4qJS8gNFKIpCcGyEaCx6xwKLZCqRDojnzs/0uP3EE9Hb5s9yzyNKyE4fosWGnkpiqAqaEkO2e25beodhmDNkA6d+mUlpcuSVU/7Qb5C37mGkBcQjdFW5a4pD9wbmvSla7ehKAkNT0RIRZLvrtqS+fdqxuAMzaluSE4PmyPgdfJ/rqkL3/r9msvO8uQ0uP/nrH2Xo3FtoyRjjzccZOPkqFY98E9l2exQS71UMXWPs+jFzgMjQQRQp2fmC6ffhzpk3gDUw0JYoSSzbPTNmPZOh4SUpm90LmEXRESwWC/m5pmqjmA56o7EIqqpSUFZEaXEZpcVl7N5+/6zah08SWZbJCeTi9wXQNA2r1YaSUkgk4ySTCQKBXMpKyikrKWfLph2UlVQA0NHVSiweZf3aTZw4c5Q1dWvJzy3k52/8hPpVa4hEI+QG8ujt7+LE6aN4vT6ut1zhoQeeyFgYzIsgosZCTLafxV+zldw195kmpCvo+9yRp8TY+DDXmk9TUlhF3TzOxsvippvo3ig7XphVVeszgUUqlaSj+9pt7SzrukZbx6XMSbfbnNy/6zOLBhWqmiIaC9+SKtTND7VbPR81lQ20d1xGVxV0TaO14zK5OcW32OpMiouqaGo5g6JrGIZOZ/c16mo2LPq7SGQiMyO0XFxFNZTs+vzi64hGOHH6CP2DvWzbvAuHzYHT6aIwv5jWjutMTIwRjoax2+zous6Gxi1cuHyGRDLBtk07cTicnDp7DFVTqamqpa5mTabteCLGuQunuXr9Iju37aW6opbg2AhdPR2sqW/E7XJz/vIZBof6qa1ZTVlJBWcvnCIUnqRxzQZisQhFhaX4/QFOnDrMuoZNHDv1MVarlQ0Nm8nLnVuKVxJlVDWVkUy+mXgimqkb+YeAIAjIdjfOgmoifU1mXczkCImxvnldiZeNYaQli810JkGUcBXVkrv2/gWDCgAlEsxIi/5DQBCEtEJTHeHuS2DoKOEgsZGuGUH5P1QkmxNHfgWx4Q4MTSUe7EUJj2K/DbLL8zF48hcMnnkLDB3RYqNw23OU3fcVEEX6j75EKjLO0Nm3cRbUULj16SUpVH1aURNR4mO9GXEBu7+InDV7sbgDC86KGZpKcnJoSeuwevPMAS5BNM0ihzpIhYMYun7X3N1XiiAIeD0+kskkfQM9lJdWoqopBEHA5/XjcDgoK6ngwb2PYrc7iMdj2O33jjfHXDW9BgYupxu324vX62fPzgfxuL0kk4mM59bY+Cih8CRqvUpvfxelxWUU5BXR3HYNt9vD9s27SSTinDp7nDMXjpOXW0g8EWN942ZKisoW3CZv5YZMUO8pW2um3tndCOLy39HLunp0XSM4NsjIaB99Ax3ouk5KTTEy2k//YGdGCcnl9JBMJhibuFEJH0/E6O1vY3xieFmj5YIozii01XVtTjnRe41N6+/LPPgSiRhnLhxEVVeQTjMPSkohPk3RQZYsFC7BITo4PsjQSM+sYualIggC8vTzYegZc7uVsqFhT6aAV9VSnDjz/i23eTOrqtdlUq50XePClWNLOgYjwQEGh7oXXe5mBEHA5s1fkjusxWJBFEXsNjsFeYWMTQTpG+hBSSVparnCkRMfEYtHGR4Z5PK1Cxw8/D4Wi5XK8ire3f8G4UiI0+ePU12xioBvZmApSxZkWUaWZQrzzSlRm81OIhEnEg0TT8Rpar6Cqql4PX4SiTgXr5zFZrPh8XhpbmtibHwUTdM4fPwgJ84cZnC4n9HgyKzit+n4fbkkkjE6e5pIJGamO0WikzS1nsXvzVux8/Z0uVHAnAVYSbraXUS2u2fUVMSDPYy3nrxt7RuGTioezqQzCLIFqyd3Xhfp6UR6mzLuuytBEMQZaTK6qtxVl+iVBKiibCVnmsqQEh4lePXQ7dyoTwxBEGbMLuhaallO6oIgEqjZhmQxUyg0JcboxQ9u+3ZOMdl1ke6D3zPNCgURT/k6KvZ9A0d+JSW7Po+3cgNgEB/tZuDkq4S7l1JDMJsZKVmGgZa4N1MxNSWenj0wh+2s3nyzk7dAMGXoGvFgD8nxwSWtwwweK7G4zJF8JTLGRPtZUmnDyDuBIEozOqqaEl+RiIwgCKxvMDvL3//xX/Jfv/Uf+emrP2RgqB+3y8OjDz5Nc+s1vvUX/5U//vb/w6GjH5JImwz/+JXv8+NXvs/Q8AB/9YP/waGj+wEYDQ7zgx//Fe/tf5PL1y7ww5f+msvXblZhnM37B97ihy/9DZ1d7fzk5z/gjXd/TiJpitL8+JXv8eOffY/hkUG++4P/mVnXfDjsDnZvv49EIs7//O5/40++/f/w9ge/ZCI0AZizMqaYD8RiUQzDwGq18dUvfpO8nHw+OPg2mq6hqAob123l8Yee4bNPv4jHvfhsTU79Lgo2PUHJni9iDxQjylYq9v3GnVeFSiRivP7u91hdtxmPy0deThHdfc109lzHaffQP9DB5g2mm67b7ctE1vFElAtXjoJhMD45wsaGPRQVVi7JXVmSZJzOGzsWi0cYnxhB1/Ul/f6TYlXVOmoqG2jrvExKVWhqOcex0++yd8fTy9ruqRmJm0cpZEme8ZDRDZ1EIobbNf8FpKSSXGs+Q2vHpWXuzQ1EUcTj8mf+TiTjBMcG0ilMK6uLqK5YQ231ei5dO4Gu67S0X+TjY6+zb+/nbsuxAli9ajM+Ty6xuJnW1NVzncvXTrCxcc+87cXjUdo6r9A3cGcLWm1WG16PD0mSKC4spa+/h3gihqapxGJRYvEY+TkFhKNh9ME+Onva2LppJxVlVbzy+k8wdB273UF97WzTP4vFgtfjIz+3kNLiMkRRQlF82Gx2NFXFbnewffNurjVfpqevk9W1Ddy/+2GaW6/R29dNPBFDSZkzSROhcbp7OsnPKyQvNx95gbSIyvLVFBVU8PHxNwiFglRXNmC3u4hEJrhy/RTXW87x5CO/tmLnbdFim6Guo0SCM3we7kVkh5e8xn0MnXkTNTZJcnKYkYsf4K1Yj6dsaYaNC2FKs94I+g1dQ0slFlUBiwy2Mt5yglR0fMXrFiXLjPSUVHTSNHO8hxFlK/kbH6X/2MukouOkohOMXPwAf81WfNWbPunNuyVM/49p5nrxyLS6haWRv+Ex+o6+ZI6aGwa9h39MYPVeXIXVt3Vblcg4ne/+L2JDHYCBxRWg+sk/yCjSuEvXUPbAV2l59T+Tiowz2XGOgROvYvMXY5tDGGIhLE6PadTJlNBBHzb/vVcQLkryzEBdSSyYqmgYBmoySv+xl5cc0AuCgK96M86CGiYjZ8DQGTz1C7yV68lZveeOpARKNueM4C45MYChpmAFalQlxWU89ehzDAz1o2opPG4vfm8AURTZuXUPxYUlhCMhdEOnML84kwq0af1W6mvXct+uh/D7AuT4zbRkp9PNru33s2n9NlRNxe8NUJC/+LVRt2oNebn57Ny6B6fDhc8bQE7vz+YN21ld28B9ux/C78shx5+LbLGwef12KstMPxaP28vD9z+OKIqIokjD6vX4fQGCY6PohkFuIBe30xwcKisp59jJQ0yGJujsbkPXHmZsfJSrTRdJJOMMjwzisDtYW7+O/R+9g4BAYX4xjWsWz86wuPz4XJtmfDYlh79clhVYaLpGKDzO6lWbsFhsxOIR+ge7TMlI2UrfQDtjE8Pk5840HxsY6qKt4xKiIDIS7CfHX0BuThE22+IFJbJkIcdfgMPuIp6IklTitHZcor3rKrXV65a3t3cRh93FU4/+On/1g/9AUkkwGQryzod/TywWYde2x/F5509ZSiRi9A92cK35DEWFlTTUb5vlui1JMkUF5bR2hACDZDLG6fMH2Lf3s3O2GU9EOXfxYw4cfpXxiZE5l1kKoiiREyjA6fQQi4VJpRQ6e67T1HqOhvptK2rTZnPw5CO/TnvXVSLRSaKxEO/u/zGxeIT7dj6zoGpQMhlnYLiLpuazBPz5NK7ZiXsOjwqP28f2LY/w1gc/RFUVorEQv3znb3A5PdRWz755EskY5y5/zLFT79yVAmOvx0drx3UOHz+I2+Wms7udzu52RoJDSJKEkH7oIJgPq0NHP8RqsbJuzUZzdmSBQnSXy00oMsmBj9+nbtVqevq6OXfxJOMTq3A4nAwM9dPV044oSuTlFDAw1Edndxt+fw4VZVW8f+BNrpVW4LA7WNewiSPHD6IoCmtXz3//5eYU8+Ce50jsj3HizAecuXgIWZJJpRRSqsKOLY+wdeO+JT0D5sLi8mP13UjDivRdJ9R9CXfJ6mUrWNwtBEnGXbqGgk1P0H/0JQwtxUTrKTre/XPKH/w6vqpNC9ZbKJFxQp3niQf7KN7x/MziYwBBxOrKweLOIRUZw1BV4iNdRPqv4yldM2eb0aF2evb/LZMdZ2+pxkJyuLEHbqQvxoY7mew4h7d68wwn4DvHChIyBRFnYQ3FOz5H94G/wdA1wj1X6Hj7f1D+0DcI1O1csHOVik0S7r5EbKSb/A2PYvPNnRb4SSBZHThyKzJ/J8f7mWg5RU79bizTBoYWwp5bStGO5+l87y/QlTixoXaaX/lP1Dz1h4sGXmo8TLjnCoZh4ClvxDLPAIKh6/Qc/B4TLScwdBUEkfIHv0agdnsmBVq02MlZvYfinS/Qvf9v0RIRRi7vx1lYQ+neLy2rA+wqXJXxmNBTSQZOvYa3atM9l/ojO7xY3TkIkmymoo32EB/uwF1UO8vXxTCMjBrU6KWFR8RvxlO6lsCqbUQHWlDjIeLBHjre+hZaMkZe40NI8zyfpwwm48E+LE7fkgM8e6Bkxgzq8Pl3yWl4ELvVsWzhA1mSKS4qpbhottGrw+FkdV3DnL9bWz/3e8vpcLKhcfEMg5upqqihqmJu08b51pWfV0h+nhm0WK1WyksrM9/ZbHaqK2uprpxdV1lSVM5nn3kRgC0bd1BeUolssbBt804Mw1TVlGULq2sbcDqcYIDb7bnrohLLCiwEQcDhcGVqBcbSbsYupwdRNPX1dW32y0lVFQrzy6koq8fl9OB2+ZesXS+KIgF/PnWrNnLxylEMw6C96yqvvP6/2LzhASpK67BZHWiaSjwRJRoLEYtH2Ni4h9ycO5cPuhiCINBQv41nHv8Gr775l+i6xsBQN2998HecvfQRlWWrKSoox2E3lV2SSpxweJyRsQGGR/tM9+zoBI8++CKr56hTEQSBbZsepr3rGrqukUjGeefDHxGJTrJ+7S4CvnwMIBwZp6evlStNJ2lqPUcoFCTgz0dVU7M8L5a6X263n4bV2zl9bj9g0D/Qwc9f/ws6NzZRXbEGu82FpqskErHM+VhTt5niwqp5262tXs/zT3+TH7/y39F1jZFgP+/u/wkXLh+hsmINxQUVOB0eBFFASSYIRyYYTR+riclRItEJ7tv5DKtr534wCILAQ/d9jotXjtLZ04Rh6HR1N/F3P/1j1jfspq5mAy6Xl5SqMBocoLn1PE2tZwmHJwj48lFSCaKx2+lDMJNV1fXkBvKQLRacDieFBcVompqZlfJ5/WiaxobGzfg8fsZXjaEbOl6PD4fDyWef/uK8bZeVVPDEQ59BEEW8Hi8et5fS4nLsdjselxeP20dNVS1ulxuH3YnL5aZh9Tq8Hj8Wi4WSojLsdge7tt1PXk4+xYWlWC3WBYvhZEmmprKRL33un9DT18LgcDdKMoHL5aW0uIbSkhq8npwVzzpanD7cxbVYPLmkwkHUeIjegz9AmRjCX7/LnMqVJNRkHDU2iRIZw5lfhbt0zR0tQF0IQRCwevIo2fUF4qPdjDcfR0tGCV49RGyoHU95I97yddgCRYgWG4amosZCJCYGiQ11EB/tMvPcAyUUbH5iVmAhCAKy00tO/W6Gzr4JGET6muh481uU7HkRb9UGZLsn3SHoZbzlBKOXDxDuvoRocyIjoCbCc3rmLIZsc+EqrsXmKyQ5OYSWjNB//BVSsUly1tyHI7cUUbaiKXHTRTwyhj2nFHfpmkXrP+4UgmAqa5Xs/gLR4XaCVw6ipxKMtxwnPtaLp2wt3ooN2HNKEC12DF1FjYdJTgwTG+kgPtJFMjSCzZtPoG7HPRVYiBY7ruJa7IES09dAiTN8/h10NUFu40M48sqRLDa0VAI1FkKJjGPz5uMuXZMJzAVRonTPl4j0NzNy/l0MXWO8+RjXJgfx12zBW7UJe6AYyWJHVxVTTWZ8kOhQO7HBVpKTQ+StewhnYfW8gcXwxfcYOv1Gxqgtp34npXu/PKPzbN43uRRueYZIXxNjTUdITgwxePqXOPMryW14YMnHxV+3E4vDa/onaSmGz7+HIFkp3PJ0Jv1DU2KkYiHU6CRWTw7ueYLyO4koyXjKGrD5i0gEe9GUGJ0ffBctlSSvcZ9Za4GAEgky2XGegZOvMdF6Ei0ZxxYozhgLLoZkc1C06wWiQ+2MXjmIoaUI9Vyl9Rd/zPC5t/HVbMVZUIXF6cPQddREhMT4ALHhdiJ91xElC5WP/86SAwt36WrsOaVE0kXpE+3naPn5f6Z45wu4imqR7W50NYEaD5OKTAAQqF+aUd0/BKxWK7U1qzOz0IIgYBhG5rOprBGnw0n9qrUzlrubLPsNO30D3W4fhfllHD31LjarnbycIlwuL9daznD52gkkUSI3UERhQQXdvS3mZ5LMrm2P4fUElrzO3EAhu7c9QWfXNUKRcRQlQUv7RfoG2rHZHIiCmHag1tF0FVm2Ulay6hMPLOx2Fw/ueQ5RFHnjve+TSMQIhccIRybo7mnGarVlLgRd19E0lZSqkEopmbxDXZ+/HmXP9qc4dW4/bZ2XMQyd4dFe3vnwR3x8/A0skgUDUwEqqcSJxcKomsr6hl1sbNzLmQsHudK0svxut9PLA7ufpbXtIhOhUVKqQkf3NYZGerDbnIiiiIFZyzClDubz5CwYWFgsVvZsfwrDgJ+/8RckElEi0QnaOifp6W/FarFnip0MXUdNHys1paCnj5W6SO2Oz5vLr3/hn/Od7//fBMcG0HSNnv5WRoIDHDv9LpIkm3nqKYV4PIqqKWxs3Ett9XpOnP3gjgYWTocTR1oSThAEXM4bozrT77kA5kyX0+ma8X1R4cxZwunYbfbM94Ig4HS4CPhvqFLd3JbD4Zzxt6tq5rZM6Wkv9rCyWKwU5JWSEyigIbXNVEeTZKwW87q/lYedIEr4V20nd/VeBs+8AYZOPNhL39GfMnT2rXRKUNoUUFMxNJWKh38LV3EdfIJKdVMdhuon/xBRshC8dhhdiRMdaCU+2kPw6iHTW0IQTf8UTTXrFVIJ9JQCGFgcvnk7/xaXn+LdX2Ci/TTJiSG0ZIxg08eEeq8g290IooRh6OipJGo8jBoPYXH4qHz0twn3XGXkwns33MGXgSBKeMrXkb/xMXo//pHpAj8xyMCJVxm59CGibEu/BG+cj5K9X8KZX/mJBRbmdos4CqpY9fQ/RZStjFx4H11ViA21kwj2MtZ0FNFim3Y+NFPRK5UwU04MA8lix9DvLUkRQRRxFlRTtON5ut7/S1MsIDzK0Jk3CV47fGOfDB1D1zC0FIVbPoM9t3TGjJ/Vk0vtc/8HgigxdOYNDC1FtL+Z+GgPIxc/nPda1ZRE2m0+Mu+1as6WfY/EeD9TKVCrPvPPsbhnz+YLooS7uI6SPV8iOtROcnyAcO81Bk79AntuGa7CuUeMb8bmzaf0/q/Q8da3MXSNVGSMgeOvELx8AEG2IoiieTzS0qXF25/7RAILBIHctfcz3nKC4ckRdDVJpK+Jttf/lO79f4Nkc2LoWvo+jqBERhEEkeLdn8ddVEvzK/9pyaty5lVQ9cTvmUpUTUfQ1SSJsT6SoWHGW08iWRzmcwNA19BVJVMD4sgtm+U5shAWl5+CzU8S6b9OItiLnkoQvHKQUPclJKsj83wyNA0MDVdxfTawuImbA4UpEZSbX6efREAxxbLesE6Hmy88+/uZvy2yldrqdRQVVoABdrsTu81JdflaCvPM/EiXw4PFYmP3tidIJGMIgoDHvfSgAkxvgnVrd/H809/krQ/+3uwUairhyAThdFQ7HbvNeU/IqU7t6769n6WooJIPP3qZptazZm5nMrZgio0gCBQXVVNSXINlnjQXt9vHN77yR/zoZ39GU8uZtARbiOgcueZ2m5Ndmx/m8Ye+jN+XR1dP04r3S5Jk6qo38OJn/5DX3v5rhkd60HWNSHSSSHR24ZfNaie1hMJ1h93FfTufpjC/jPcP/pQrTacwDJ1kMk4yuZAMnkBRQTllJbULptYIgkB15Vp++2v/jp+9/r9obb+IYRjEExHiNzmV2m1Odm16nCce/jVSqSTXWs4uuv23yuyHxdKWXW7bi3233L8XW69Fti7L6XypOHLLKN/3dbRUwhxtU5V0Z3nuAFBTYisajb/diLIFX/Vmaj/7R7jLGhg89UuSEwPp4GHhAlvZ6cNXux3RMvczQRBlfNWbqP3sH9H+1reID3eip5IkxwfmtK1xFa2i4uFvkr/hUUTZynjzsRUFFgA2XwGle7+MloylfTSSaMnovO1pK5ZxnouVv0BFUcJdupra5/4lnvIG+o+9QiLYky5AX1hEQnZ48FVvRnbejXSv5WFxBSje+QJqPEL/8Z+hpzuD80mKqokw6LMLae05JdR97v/EU7qWno9+QHJiEF2JoywiTWr15uMsqJrTyFFLxuh6/y8J913LpOBVP/1PFuzEC7KVQN1OSnd/kY53/xxDVQheOYiroJryfd+YnRo4VxuiRNn9XyUVnaDn4A/A0NGSUeJzXKOCbCE1z7PkbmD15lP56G9jaCqjl/ejKXGU0AhKaISbPVUku4vKR36b0r1fJjHejyhbF712pxBECXfpWuo//28YOPEq/cdfITkxhKGmSEXGSTF/rZQgyctykhcEkfwNj6HGw3R98FckxwfQVWXuGRZBwOpe3HQyy73HsgILUZRm5LsLgoDVaieQHnGa6nDY7U7s9pkPE5fLO6MIe7mdE5fTw94dT1NT2ciFy4e52nyaoeEeovGwOTtgc+Fx+ynML6OibDX5ebPz7j4JzBFiDxsb91BT2UB3XwtXmk7S3nWV4NgAsXgYTdOwWe14PTkU5JVSUVZP/aqNFBdV4XUHsCwwoldaVMPvfuPfm27aFw7S09tCKDyGqqnYbU5yc4qoqWxg07r7qK1Zj8PhRhRMnwib1U5yBRKTgiBgsznYumkf5aW1XLhyhCtNJxkY6iIaDWFgpM+Hj/z0/pSXLu7ybJ5HJw2rt1NRVk9ffxuXr52gresKo6P9xOJhVC2F1eLA6/GbbZfWUVezkdLiGryewKKmd6IoUVu9jn/8m/8vl5tOcP7SYbp7rxOOTiIgkBMooLqygS0bHjDTo5xexiaG8br9yz5OWe4sgiTjLmtg9Rf+Lwo2PWGm9fRcJjk5jK4qSBY7ssOLLacUd3Etgfrds4zhPpkNFxBlC66iVVQ9/rsUbn2GiZaTjLeeJDrQihIeRVNiCKKM7PRiD5TgKq7DX70ZX/UmrN4C5DkMM82mBSSrk/wNj+Eurmfk0oeMXTtEdKgDLRExHdjdAVyFteSu2UNg9R4ceRWIFhuuojpkh4fkxNJUZWatW5RwFa2i9rl/Sd66hxm9/CGhrkskJgbRU0kk2Yrk8KT3ZxW5DQ/Mm8N9VxEEBEnGkVdB+b5vULDxcSZaTzHecpJI/3WU0ChqMoogiOb58BfhLKrFV70JX/Vm7P6iJXVq7zaCKOLILaP6qT8kt+EBRi6+T6jzQjo1KmEW3Ds82PxFuIpWkbfuYeQ5UpamUvjK7v818jc+xljTYfPY9DWhRMbQElEEScbi9GHPKcVVUo+/ZjOe8vXYA0VI1tmBRd+RlzKzdQAFm5+icMvT5qzBPH0DQRCwuHzkb3yccP91Rs6/ixoPM3DqFzgLqinY/NSSaiVkh4fqJ/+QvMZ9DJ5+nVDXRRLjA+hKHNFiR3b6sPuLcJeuJnft/cs86rcPQRRxFa2i/gv/lrwNjzBy8QNCXRdRQqOAgewwnw2B+p0UbHwcZ+EqJJsTLRnFmV9FZKB5yesSJRl7bhkVj3yTwq3PMN58nPHWU0T7r5OMjKHFw6YXj82FzV+Mq6gGX/UWcup34sirXHwF05BtTkp2fh5/9WaGz7/LWMsJ4iNdqLFJBEk2n9nePFzF9fjrsrMVn0YE4/YNGd1xDMMw1Q9UBVVNoaXNzmBq2kdEEkVEScYiWxfM3zYMg1QqmZk1EAQRm9W+JDfmW9l+Uy43haqpGbO2G9svIIoSkiQjS/KS00UMwzDTqFJJNF1DT486CYKAKIhI8tTxuNFeMhlPBxUGdrsLywIP9IXWa56PFKqmoGnz749FtixLNWoqtU1VlTmOlXm+zLYlZMmy7NQawzBQtRRqKoWmq+i6nm5XQpZkZIsVKd2mrusklXhGTnmlxyvLncEwDAwtZZq8aaqZRmgY6eJPIe38K5npOItcJ4auoSnxzPS+IFmQbM47Wpdh6Dq6lsJQUxj6tO0HEEQEUUQQZUTZkg6MljDFnb43p0bdDV3NHBNBEBBEGUG2IkqWTGdM11JoiSiGriHKNlPBZQU1MIZhYOgqekrB0FJznw9RQrRYze2Yti+mlKJOKjqR2X/TuX5mUbuuKmZevqEjiJJ5jm6aFdNSSbRkzDQYEwQsTt+SnKMNQ8dQU+Y50RY4H5JsKtwskHJgGAZaIpIZPRZECdnhWdJ26FoKLRnLyAeLFns6XWR558Q8Hxq6msRQVQxDS++PYG575vqyIkjygvsCYKjKAscmfa9JlnRbc2+rloyZ8rfp34oWG5LNtbT33U33KIKIZHNk0u2WekzQNbS0TPWMa1QQEISpZ4Z5jyyEpiTMWaB0Sq6cdra/Xe8H8/mmmudPS2FMzSqlr0VRtprnTpxKFdZQ42EMXUNIB4/LezcudP3fuH8FyWI+k1boJ2LoOrqaRE8/92bfY+Z1dHOxepZ7n09VYJElS5YsWbJkyZIlS5Z7k3tLYy1LlixZsmTJkiVLliyfSrKBRZYsWbJkyZIlS5YsWW6ZbGCRJUuWLFmyZMmSJUuWWyYbWGTJkiVLlixZsmTJkuWWyQYWWbJkyZIlS5YsWbJkuWWygUWWLFmyZMmSJUuWLFlumWxgkSVLlixZsmTJkiVLllsmG1hkyZIlS5YsWbJkyZLllskGFlmyZMmSJUuWLFmyZLllsoFFlixZsmTJkiVLlixZbpn/P07SdalVEc2kAAAAAElFTkSuQmCC",
      "text/plain": [
       "<Figure size 1000x500 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Generate a word cloud from text (pdf file)\n",
    "# Define a custom color function that returns four specific colors\n",
    "def color_func(word, font_size, position, orientation, random_state=None, **kwargs):\n",
    "    colors = [\"#bc6c25\", \"#dda15e\", \"#606c38\", \"#283618\"]\n",
    "    \n",
    "    # Generate a random color from the list\n",
    "    return colors[np.random.randint(0, len(colors))]  \n",
    "\n",
    "# Generate a word cloud from text (pdf file) with custom colors\n",
    "wordcloud = WordCloud(width=800, height=400, background_color=\"white\", \n",
    "                      color_func=color_func, random_state=39).generate(text)\n",
    "\n",
    "# Display the word cloud using matplotlib\n",
    "plt.figure(figsize=(10, 5))\n",
    "plt.imshow(wordcloud, interpolation=\"bilinear\")\n",
    "plt.axis(\"off\")\n",
    "plt.show()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "c01df165",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<wordcloud.wordcloud.WordCloud at 0x138e5a650>"
      ]
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Save the word cloud image\n",
    "wordcloud.to_file('wordcloud.png')"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
